01780000000000541000450099100020000070000020000270600020000470100020000609100090
00081300053000174210020000701510024000902300053001140350010001674800047001770300
02000224930000600244117000600250085000300256935001000259031000300269032000200272
03600060027404200020028020000020028206500090028412200030029304800140029604800140
03100480024003240490051003480490038003990490037004370490027004740490043005010490
02900544049002300573049002900596049006100625049006300686049007000749049005300819
049008100872049008100953043006801034043006801102043006801170#1#0#i#1#20110401#Br
azilian Journal of Medical and Biological Research#Braz J Med Biol Res#Braz. j. 
med. biol. res#Revista brasileira de pesquisas médicas e biológicas#0100-879X#As
sociação Brasileira de Divulgação Científica#Braz J Med Biol Res#BJMBR#other#nd#
0100-879X#44#4#20114#1#0#20110400#16#^les^hSumario#^lpt^hSumário#^len^hTable of 
Contents#^len^cBJMBR010^tBiochemistry and Molecular Biology#^len^cBJMBR030^tConc
epts and Comments#^len^cBJMBR040^tExperimental Biology#^len^cBJMBR050^tImmunolog
y#^len^cBJMBR060^tNeurosciences and Behavior#^len^cBJMBR070^tPharmacology#^len^c
BJMBR090^tReview#^len^cBJMBR380^tCell Biology#^len^cBJMBR400^tEndocrine Diseases
, Nutrition and Metabolism#^len^cBJMBR430^tCardiovascular, Respiratory and Sport
 Medicine#^len^cBJMBR470^tPsychological Processes, Behavior and Mental Diseases#
^len^cBJMBR540^tSkeletal, Muscle and Nervous Systems#^len^cBJMBR720^tAnalytical,
 Diagnostic an Therapeutic Techniques and Instruments#^len^cBJMBR750^tAnalytica,
 Diagnostic and Therapeutic Techniques and Instruments#^les^tBraz J Med Biol Res
^vvol.44^nno.4^cRibeirão Preto^mabr.^a2011#^lpt^tBraz J Med Biol Res^vvol.44^nno
.4^cRibeirão Preto^mabr.^a2011#^len^tBraz J Med Biol Res^vvol.44^nno.4^cRibeirão
 Preto^mApr.^a2011##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#o#1#1#article#1#20
110411#094456#1001.htm#222##
02682000000000553000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400110014503500100015622400090
01660120043001750100028002180700111002460700066003570831468004230850008018910850
01601899085003401915085003801949085001701987085002902004117000602033072000302039
112000902042111001702051114000902068113001802077891002402095002000902119#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#h#2#1#article#1#co#en#bjmbr#1#3.1#
ILUS#TAB#01#BJMBR030#nd#Braz J Med Biol Res#44#4#20110400#^f268^l275#0100-879X#2
0110311#The fallacy of racial pharmacogenomics^len#^rND^1A01 A02^nS.D.J.^sPena#U
niversidade Federal de Minas Gerais^iA01^1Departamento de Bioquímica e Imunologi
a^cBelo Horizonte^sMG^pBrasil#GENE - Núcleo de Genética Médica^iA02^cBelo Horizo
nte^sMG^pBrasil#^len^aPersonalized pharmacogenomics aims to use individual genot
ypes to direct medical treatment. Unfortunately, the loci relevant for the pharm
acokinetics and especially the pharmacodynamics of most drugs are still unknown.
 Moreover, we still do not understand the role that individual genotypes play in
 modulating the pathogenesis, the clinical course and the susceptibility to drug
s of human diseases which, although appearing homogeneous on the surface, may va
ry from patient to patient. To try to deal with this situation, it has been prop
osed to use interpopulational variability as a reference for drug development an
d prescription, leading to the development of "race-targeted drugs". Given the p
resent limitations of genomic knowledge and of the tools needed to fully impleme
nt it today, some investigators have proposed to use racial criteria as a pallia
tive measure until personalized pharmacogenomics is fully developed. This was th
e rationale for the FDA approval of BiDil for treatment of heart failure in Afri
can Americans. I will evaluate the efficacy and safety of racial pharmacogenomic
s here and conclude that it fails on both counts. Next I shall review the perspe
ctives and the predicted rate of development of clinical genomic studies. The co
nclusion is that "next-generation" genomic sequencing is advancing at a tremendo
us rate and that true personalized pharmacogenomics, based on individual genotyp
ing, should soon become a clinical reality.#^dnd^i1#^tm^len^kDNA^i1#^tm^len^kGen
etic polymorphisms^i1#^tm^len^kHuman genomic variability^i1#^tm^len^kRace^i1#^tm
^len^kPharmacogenomics^i1#other#40#20110111#January 11, 2011#20110214#February 1
4, 2011#S0100-879X2011007500031#1001.htm##
02674000000000541000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400110014503500100015622400090
01660120050001750100028002250700111002530700066003640831475004300850008019050850
01601913085003401929085003801963085001702001085002902018117000602047072000302053
112000902056111002402065114000902089113002502098002000902123#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\1001.htm#S#f#3#1#article#1#co#en#bjmbr#1#3.1#ILUS#TAB#01#
BJMBR030#nd#Braz J Med Biol Res#44#4#20110400#^f268^l275#0100-879X#20110311#<b>T
he fallacy of racial pharmacogenomics</b>^len#^rND^1A01 A02^nS.D.J.^sPena#Univer
sidade Federal de Minas Gerais^iA01^1Departamento de Bioquímica e Imunologia^cBe
lo Horizonte^sMG^pBrasil#GENE - Núcleo de Genética Médica^iA02^cBelo Horizonte^s
MG^pBrasil#^len^aPersonalized pharmacogenomics aims to use individual genotypes 
to direct medical treatment. Unfortunately, the loci relevant for the pharmacoki
netics and especially the pharmacodynamics of most drugs are still unknown. More
over, we still do not understand the role that individual genotypes play in modu
lating the pathogenesis, the clinical course and the susceptibility to drugs of 
human diseases which, although appearing homogeneous on the surface, may vary fr
om patient to patient. To try to deal with this situation, it has been proposed 
to use interpopulational variability as a reference for drug development and pre
scription, leading to the development of "race-targeted drugs<b>"</b>. Given the
 present limitations of genomic knowledge and of the tools needed to fully imple
ment it today, some investigators have proposed to use racial criteria as a pall
iative measure until personalized pharmacogenomics is fully developed. This was 
the rationale for the FDA approval of BiDil for treatment of heart failure in Af
rican Americans. I will evaluate the efficacy and safety of racial pharmacogenom
ics here and conclude that it fails on both counts. Next I shall review the pers
pectives and the predicted rate of development of clinical genomic studies. The 
conclusion is that "next-generation" genomic sequencing is advancing at a tremen
dous rate and that true personalized pharmacogenomics, based on individual genot
yping, should soon become a clinical reality.#^dnd^i1#^tm^len^kDNA^i1#^tm^len^kG
enetic polymorphisms^i1#^tm^len^kHuman genomic variability^i1#^tm^len^kRace^i1#^
tm^len^kPharmacogenomics^i1#other#40#20110111#<i>January 11, 2011</i>#20110214#<
i>February 14, 2011</i>#1001.htm##
02781000000000565000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000300109049000900112
15800030012103000240012403100030014803200020015106500090015301400110016203500100
01732240009001830120043001920100029002350700113002640700068003770831468004450850
00801913085001601921085003401937085003801971085001702009085002902026117000602055
07200030206111200090206411100170207311400090209011300180209900200090211700800890
2126#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#l#4#1#article#1#^mApr.
^a2011#co#en#bjmbr#1#3.1#ilus#tab#01#BJMBR030#nd#Braz. j. med. biol. res#44#4#20
110400#^f268^l275#0100-879X#20110311#The fallacy of racial pharmacogenomics^len#
^rND^1A01 A02^nS. D. J^sPena#^iA01^1Universidade Federal de Minas Gerais^2Depart
amento de Bioquímica e Imunologia^cBelo Horizonte^sMG^pBrasil#^iA02^1GENE - Núcl
eo de Genética Médica^cBelo Horizonte^sMG^pBrasil#^len^aPersonalized pharmacogen
omics aims to use individual genotypes to direct medical treatment. Unfortunatel
y, the loci relevant for the pharmacokinetics and especially the pharmacodynamic
s of most drugs are still unknown. Moreover, we still do not understand the role
 that individual genotypes play in modulating the pathogenesis, the clinical cou
rse and the susceptibility to drugs of human diseases which, although appearing 
homogeneous on the surface, may vary from patient to patient. To try to deal wit
h this situation, it has been proposed to use interpopulational variability as a
 reference for drug development and prescription, leading to the development of 
"race-targeted drugs". Given the present limitations of genomic knowledge and of
 the tools needed to fully implement it today, some investigators have proposed 
to use racial criteria as a palliative measure until personalized pharmacogenomi
cs is fully developed. This was the rationale for the FDA approval of BiDil for 
treatment of heart failure in African Americans. I will evaluate the efficacy an
d safety of racial pharmacogenomics here and conclude that it fails on both coun
ts. Next I shall review the perspectives and the predicted rate of development o
f clinical genomic studies. The conclusion is that "next-generation" genomic seq
uencing is advancing at a tremendous rate and that true personalized pharmacogen
omics, based on individual genotyping, should soon become a clinical reality.#^d
nd^i1#^tm^len^kDNA^i1#^tm^len^kGenetic polymorphisms^i1#^tm^len^kHuman genomic v
ariability^i1#^tm^len^kRace^i1#^tm^len^kPharmacogenomics^i1#other#40#20110111#Ja
nuary 11, 2011#20110214#February 14, 2011#1001.htm#Internet^ihttp://www.scielo.b
r/scielo.php?script=sci_arttext&pid=S0100-879X2011000400001##
00374000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014800071002000900219#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#5#1#article#178#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Vol
ume 44(4) 268-275  </B></font></P>      ^cY#1001.htm##
00369000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014300071002000900214#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#6#2#article#178#<p ALIGN="LEFT"><font si
ze="5" face="Arial"><span lang="EN"><strong>The fallacy of racial pharmacogenomi
cs</strong></span></font></p>      ^cY#1001.htm##
00682000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704045600071002000900527#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#7#3#article#178#<p ALIGN="LEFT"><font fa
ce="Arial"><span lang="EN"><span lang="EN"><font face="Arial, Helvetica, sans-se
rif"><sup><span lang="EN"><font face="Arial, Helvetica, sans-serif"><b><a href="
#Correspondence"><img src="/img/revistas/bjmbr/v44n4/recor.gif" border="0"></a><
/b> <a href="mailto:spena@gene.com.br"><img src="/img/revistas/bjmbr/v44n4/email
-ca.gif" border="0"></a></font></span></sup></font></span> S.D.J. Pena<sup>1,2</
sup></span></font></p>      ^cY#1001.htm##
00481000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704025500071002000900326#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#8#4#article#178#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Departamento de Bi
oqu&iacute;mica e Imunologia, Universidade Federal de Minas Gerais, </font></spa
n><font face="Arial"><span lang="EN">Belo Horizonte, MG, Brasil    ^cY#1001.htm#
#
00402000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704017600071002000900247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#9#5#article#178#<br>  </span></font><fon
t face="Arial"><span lang="EN"><sup>2</sup>GENE - N&uacute;cleo de Gen&eacute;ti
ca M&eacute;dica, Belo Horizonte, MG, Brasil</span></font></p>      ^cY#1001.htm
##
00417000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019000072002000900262#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#10#6#article#178#<P> <font face="Arial, 
Helvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/d
own.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A> 
   ^cY#1001.htm##
00390000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704016300072002000900235#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#11#7#article#178#<BR>   <A HREF="#Text">
<IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSP
ACE=0></A> <A HREF="#Text"><strong>Text</strong></A>    ^cY#1001.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704016800072002000900240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#12#8#article#178#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#1001.htm##
00436000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704020900072002000900281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#13#9#article#178#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#1001.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704021800073002000900291#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#14#10#article#178#<BR>   <A HREF="#Corre
spondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footn
otes</strong></A>  </font>      ^cY#1001.htm##
00265000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003700073002000900110#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#15#11#article#178#<P>  <HR ALIGN=LEFT SI
ZE=2>      ^cY#1001.htm##
00494000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704026600073002000900339#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#16#12#article#178#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      
^cY#1001.htm##
01811000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704158300073002000901656#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#17#13#article#178#<p ALIGN="LEFT"><span 
lang="EN"><font FACE="Arial, Helvetica, sans-serif">Personalized pharmacogenomic
s aims to use individual genotypes to direct medical treatment. Unfortunately, t
he loci relevant for the pharmacokinetics and especially the pharmacodynamics of
 most drugs are still unknown. Moreover, we still do not understand the role tha
t individual genotypes play in modulating the pathogenesis, the clinical course 
and the susceptibility to drugs of human diseases which, although appearing homo
geneous on the surface, may vary from patient to patient. To try to deal with th
is situation, it has been proposed to use interpopulational variability as a ref
erence for drug development and prescription, leading to the development of &quo
t;race-targeted drugs&quot;. Given the present limitations of genomic knowledge 
and of the tools needed to fully implement it today, some investigators have pro
posed to use racial criteria as a palliative measure until personalized pharmaco
genomics is fully developed. This was the rationale for the FDA approval of BiDi
l for treatment of heart failure in African Americans. I will evaluate the effic
acy and safety of racial pharmacogenomics here and conclude that it fails on bot
h counts. Next I shall review the perspectives and the predicted rate of develop
ment of clinical genomic studies. The conclusion is that &quot;next-generation&q
uot; genomic sequencing is advancing at a tremendous rate and that true personal
ized pharmacogenomics, based on individual genotyping, should soon become a clin
ical reality.</font></span></p>      ^cY#1001.htm##
00419000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019100073002000900264#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#18#14#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Key words: DNA; Genetic polymorphisms; Human genomi
c variability; Race; Pharmacogenomics</span></font></p>  <HR ALIGN=LEFT SIZE=2> 
     ^cY#1001.htm##
00542000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031400073002000900387#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#19#15#article#178#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Text" id="Text"></A><FONT color="#00007F" SIZE=4
><B>Text</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A
 HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORD
ER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#1001.htm##
00326000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009800073002000900171#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#20#16#article#178#<p ALIGN="LEFT"><b><fo
nt face="Arial"><span lang="EN">Introduction</span></font></b></p>      ^cY#1001
.htm##
01303000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704107500073002000901148#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#21#17#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">The American astrophysicist Neil deGrasse Tyson&nbs
p;defined the &quot;perimeter of ignorance&quot; as the&nbsp;boundary where scie
ntists face a choice: continue the quest for knowledge or invoke a deity or othe
r supernatural forces (1). He used as an example no less than Isaac Newton himse
lf, whose law of gravity enabled calculation of the force of attraction between 
any two objects. When computing the orbits of the planets around the sun, Newton
 feared that the mutual attraction between them would render the solar system un
stable. He then concluded that God occasionally stepped in to make things right.
 A century later, the French astronomer Pierre-Simon de Laplace created a new ma
thematical tool called perturbation theory and used it to demonstrate that the s
olar system is in fact stable over periods of time much longer than Newton could
 predict.&nbsp;Laplacian science, therefore, no longer needed to postulate the i
nterference of supernatural forces to explain astronomical facts.</span></font><
/p>      ^cY#1001.htm##
00930000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704070200073002000900775#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#22#18#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Newton&rsquo;s appeal to God, however unnecessary, 
may at first sight appear as a humble attitude of a great man. However, Tyson de
monstrates that, on the contrary, it represented presumptuousness on his part: i
f his mathematics was not good enough to explain the phenomenon, then the proble
m was too complicated for any other human mind to figure out, then or anytime in
 the future. By &quot;embracing ignorance&quot; Newton&rsquo;s attitude negative
ly infused a temporary stage of incomplete knowledge with a false permanency, ru
nning counter to the philosophy of open-mindedness and discovery that characteri
zes Science.</span></font></p>      ^cY#1001.htm##
00419000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019100073002000900264#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#23#19#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Pharmacogenetics and pharmacogenomics are likewise 
in a dilemma right at the edge of the perimeter of ignorance.</span></font></p> 
     ^cY#1001.htm##
01228000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704100000073002000901073#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#24#20#article#178#<p ALIGN="LEFT"><span 
lang="EN"><font FACE="Arial, Helvetica, sans-serif">We know that the safety and 
efficacy of drug treatment differs in humans, depending on genes that influence 
pharmacokinetics and pharmacodynamics. Such variability may occur at two differe
nt genetic levels. The first is interpersonal, i.e., the diversity that distingu
ishes one person from all the others in the same population and which is intimat
ely connected to individual identity, uniqueness. The second is the interpopulat
ional level, collective, the diversity that distinguishes different human groups
, including the so-called &quot;races&quot;. (Since there is consensus among ant
hropologists and human geneticists that, from a biological standpoint, human rac
es do not exist (2), I believe that the word &quot;race&quot; should always be m
entioned between quotation marks. However, the excess of quotation marks truncat
es the text and will be omitted in this article for this reason only.)</font></s
pan></p>      ^cY#1001.htm##
01081000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704085300073002000900926#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#25#21#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">For pharmacological agents with well-characterized 
metabolism and mechanisms of action, it would in theory be possible to assess th
e genetic variation in pertinent loci and to use patient genotypes to direct med
ical treatment - the dream of providing the right drug, in the right dosage, to 
the right patient. This is the theoretical underpinning of personalized pharmaco
genomics. Unfortunately, the loci relevant for the pharmacokinetics and especial
ly the pharmacodynamics of most drugs are still unknown. Moreover, we still lack
 comprehension of the role that individual genotypes play in modulating the path
ogenesis, the clinical course and the drug susceptibility of human diseases whic
h, although appearing homogeneous on the surface, may vary from patient to patie
nt.</span></font></p>      ^cY#1001.htm##
00907000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704067900073002000900752#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#26#22#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">To try to deal with this situation it has been prop
osed to use interpopulational variability as a reference for drug development an
d prescription, leading to the development of &quot;race-targeted drugs&quot;, a
s exemplified by the case of BiDil for treatment of heart failure in African Ame
ricans. The rationale for such strategy is that, since we still lack the pharmac
ogenomic knowledge necessary to implement true personalized treatment, we make d
o by using the race or the ethnic-geographic affiliation of a given patient as t
he replacement of the germane individual genotyping at critical loci.</span></fo
nt></p>      ^cY#1001.htm##
00857000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704062900073002000900702#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#27#23#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Therein lies the fallacy of racial pharmacogenomics
 - being predicated on the idea that individual genotyping will be impossible to
 achieve in the near future, it &quot;embraces ignorance&quot;. Moreover, it oft
en does so under false premises. For instance, in the FDA news release entitled 
&quot;FDA Approves BiDil Heart Failure Drug for Black Patients&quot; (3) it is s
tated that this represents &quot;a step toward the promise of personalized medic
ine&quot;. But racial medicine is group medicine - most definitely it is not per
sonalized medicine.</span></font></p>      ^cY#1001.htm##
00856000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704062800073002000900701#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#28#24#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Jones and Goodman (4) report that at a meeting just
 preceding the approval of BiDil, Steve Nissen, chair of the FDA Cardiovascular 
and Renal Drugs Advisory Committee, made the following pronouncement: &quot;...w
e are moving toward the era of genomic-based medicine. There is no question that
 in 10 or 15 years it is going to happen. I know it has been predicted for a lon
g time and has not happened yet but is going to happen, trust me. [...] So what 
we are doing is we are using self-identified race as a surrogate for genomic-bas
ed medicine.&quot;</span></font></p>      ^cY#1001.htm##
01152000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704092400073002000900997#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#29#25#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Thus, the big question is: should we wait for the i
nevitable development of proper personalized pharmacogenomics science or should 
we adopt obviously palliative racial measures as announced by the FDA? Common pr
ecaution indicates that, before we make a decision on this dilemma, we should ev
aluate the efficacy and safety of racial pharmacogenomics, in the same way that 
we evaluate a new pharmacological agent. I start this article by making such ana
lysis and presenting evidence and arguments that reveal the failure of racial ph
armacogenomics on both efficacy and safety counts. I will then conclude with an 
assessment regarding the predicted rate of development of personalized pharmacog
enomics. The good news is that it is advancing at almost warp speed with &quot;n
ext-generation sequencing&quot; and should soon become a clinical reality.</span
></font></p>      ^cY#1001.htm##
00340000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011200073002000900185#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#30#26#article#178#<p ALIGN="LEFT"><b><fo
nt face="Arial"><span lang="EN">The efficacy and safety of racial pharmacogenomi
cs    ^cY#1001.htm##
00266000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003800073002000900111#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#31#27#article#178#<br>  </span></font></
b></p>      ^cY#1001.htm##
00477000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024900073002000900322#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#32#28#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">There is consensus among anthropologists and human 
geneticists that, from a biological standpoint, human races are not biological e
ntities, but social constructs (2,5,6).</span></font></p>      ^cY#1001.htm##
00874000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704064600073002000900719#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#33#29#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">However, a retrospective review of clinical trial p
rotocols and product labeling for 185 new molecular entities approved between 19
95 and 1999 showed that labeling for 45% (84/185) of the products contained some
 statement about race and that in 8% (15/185) of cases race-related differences 
were described (7). Moreover, in 2005 the FDA approved BiDil avowedly &quot;for 
the treatment of heart failure in self-identified black patients&quot; (3). Thus
, from a pharmacological perspective, human races are still being treated as &qu
ot;real&quot; biological categories.</span></font></p>      ^cY#1001.htm##
01545000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704131700073002000901390#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#34#30#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">A peculiar aspect of the literature about &quot;rac
e&quot; is that there does not appear to be a consensus about its exact meaning,
 which is often subjected to ideological manipulation (8). We can actually ident
ify different ways in which the word &quot;race&quot; is used. The first is phen
otypic, generally associated with iconic physical characteristics, more especial
ly skin color, such as Blacks, Whites, etc. &quot;Race&quot; can also assume the
 meaning of &quot;geographic ancestry&quot;, such as Africans, Asians, etc. But 
the rotary machine gun of race spares no one. &quot;Race&quot; has also been use
d, when politically convenient, to denote groups, which have in common religion 
and/or culture, such as the case of the Jewish people, who are not a &quot;race&
quot; in either the phenotypic or geographical sense, and yet were the victims o
f the &quot;racially&quot; perpetrated Nazi holocaust. &quot;Race&quot; can fina
lly be applied even to persons with very vague elements in common, such as the b
izarre American category of &quot;Hispanics&quot;, which covers all Mexicans, Ce
ntral Americans and South Americans, including Portuguese-speaking Brazilians. I
 wish to briefly discuss the first two meanings of race separately.</span></font
></p>      ^cY#1001.htm##
00309000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008100073002000900154#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#35#31#article#178#<p ALIGN="LEFT"><b><fo
nt face="Arial"><span lang="EN">Races as phenotypes    ^cY#1001.htm##
00266000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003800073002000900111#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#36#32#article#178#<br>  </span></font></
b></p>      ^cY#1001.htm##
00791000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704056300073002000900636#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#37#33#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">In the FDA approval of Bidil (3), &quot;Blacks&quot
; were singled out as a racial category because of their skin pigmentation. Howe
ver, we know that skin color is controlled by a handful of genes (9) that are a 
minuscule proportion of the more than 20,000 genes contained in the human genome
. Thus, a person&rsquo;s color, or any other of the iconic racial characteristic
, does not have anything to do with his intelligence, personality, abilities, bl
ood pressure, or prostate health.</span></font></p>      ^cY#1001.htm##
01394000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704116600073002000901239#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#38#34#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">One of the biggest mistakes of racial pharmacogenom
ics is to assume that Africa is homogeneous and all &quot;Blacks&quot; are the s
ame. On the contrary, the variability within Africa is larger than the genetic v
ariability between Africa and Europe (10). One example of this, highlighted by N
g et al. (11), is that of <i>CYP2D6</i>, involved in the metabolism of several d
rugs. The <i>CYP2D6*17</i> allele, which is associated with lower enzyme activit
y, has a frequency of 0.9 in Ethiopia, 0.17 in Tanzania, and 0.34 in Zimbabwe. O
bviously, the expectation of <i>CYP2D6</i> activity of a Black person in America
 would depend on where in Africa his ancestors originated. Africa is still poorl
y studied from the genetic standpoint. However, considering the fact that humank
ind has spent two thirds of it evolutionary history in Africa (12) and also the 
tremendous variety of human geographical environments (forests, savannahs, deser
ts, mountains) on that vast continent, it is expected that allele frequencies at
 several pharmacogenomic loci should vary considerably in different regions.</sp
an></font></p>      ^cY#1001.htm##
01070000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704084200073002000900915#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#39#35#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Phenotypic and geographical racial classifications 
clearly purport to partition human genetic diversity on the basis of very differ
ent criteria. However, in spite of that, they are very often confused. Typical o
f this, and by no means an isolated example, is the case of a recent article of 
the International Warfarin Pharmacogenetics Consortium (13) that studied the pre
dictive power of a genetic polymorphism of the gene <i>VKORC1</i> (SNP rs9923231
, also known as -1639G&gt;A) regarding the dose of the anti-coagulant warfarin f
or &quot;4886 patients of known race&quot;, a sample composed of &quot;1103 Asia
ns, 670 blacks and 3113 white individuals&quot;. The authors thus used a disjoin
t racial classification that mixed phenotypic and geographical criteria.</span><
/font></p>      ^cY#1001.htm##
00696000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704046800073002000900541#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#40#36#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">There is also a tendency to confuse New World popul
ations with their ancestors, which is often convenient, but certainly conceptual
ly wrong. For instance, in the original &quot;mitochondrial Eve&quot; paper, the
 authors used African Americans as if they were Africans (14). Even the more rec
ent and carefully planned HapMap study used groups of Utah Mormons as if they we
re Europeans (15).</span></font></p>      ^cY#1001.htm##
00872000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704064400073002000900717#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#41#37#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">To demonstrate the danger involved in these practic
es, we retrieved from HapMap 3 (16) data about African Yorubas from Ibadan, Nige
ria (YRI - 113 individuals) and European Tuscans from Italy (TSI - 88 individual
s), two populations that differed in continental origin. We also retrieved Ameri
can Blacks from the Southwest USA (ASW - 48 individuals) and American Whites fro
m Utah, USA (CEU - 112 individuals). In all groups we ascertained genotypes at t
he rs9923231 SNP, the same that, according to Limdi et al. (13), explained the g
reatest variance in warfarin dose.</span></font></p>      ^cY#1001.htm##
01249000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704102100073002000901094#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#42#38#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">The frequencies of the C allele of SNP rs9923231 di
ffered considerably between African Yorubans and European Tuscans (geographical 
groups), with a differential (&delta;) of 0.455 (<a href="#Tab1">Table 1</a>). O
n the other hand, the frequencies of American Blacks and Whites (phenotypic grou
ps) were more similar, with a smaller differential (&delta;) of 0.299. The analy
sis of molecular variance of the American color categories (ASW <i>vs</i> CEU) s
howed that 82.6% of the variation occurred within the populations and only 17.4%
 between them, while in the geographical contrast (YRI <i>vs</i> TSI) 54.2% of t
he variation occurred within the populations and 45.8% between them (<a href="#T
ab1">Table 1</a>). This example makes clear the hazards of equating color to geo
graphical ancestry and interchangeably using terms such as White and European on
 one hand, and Black and African on the other, as is often done in racial pharma
cogenomics.</span></font></p>      ^cY#1001.htm##
00601000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704037300073002000900446#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#43#39#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">The racial category &quot;Black&quot; was used by t
he FDA in the BiDil (3) approval as a proxy for a pharmacogenomic genotype. Howe
ver, it is clear that skin color and other iconic racial characteristics are not
 adequately powerful parameters to choose a dosage schedule or a specific medici
ne.</span></font></p>      ^cY#1001.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009000073002000900163#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#44#40#article#178#<p ALIGN="LEFT"><b><fo
nt face="Arial"><span lang="EN">Races as geographical groups    ^cY#1001.htm##
00266000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003800073002000900111#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#45#41#article#178#<br>  </span></font></
b></p>      ^cY#1001.htm##
01122000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704089400073002000900967#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#46#42#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">After World War II and the revelation of the racial
 atrocities of the Nazis, geneticists and anthropologists decided that it was hi
gh time to abandon the typological racial paradigms inherited from the 19th cent
ury &quot;scientific racism&quot; movement and to adopt a model of division of h
umankind into populations. However, in spite of declarations to the contrary suc
h as the one from UNESCO in 1950 (<a target="_blank" href="http://unesdoc.unesco
.org/images/0012/001282/128291eo.pdf">http://unesdoc.unesco.org/images/0012/0012
82/128291eo.pdf</a>, 1949), the concept of human races still survived, although 
in a new statistical plumage. The most accepted position at the time was that of
 Dunn and Dobzhansky (17) who defined races as geographically distinct human pop
ulations that differed in genetic variables.</span></font></p>      ^cY#1001.htm
##
01053000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704082500073002000900898#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#47#43#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">It is curious to note that the idea of geographical
 continental human races dates all the way back to Johann Friedrich&nbsp;Blumenb
ach&nbsp;(1752-1840), who proposed in his book <i>De</i><em> Generis H</em><i>um
a</i><em>ni Varietate Nativa</em>&nbsp;the existence of five human races inhabit
ing different continents: Caucasians (Europe, Middle East, India, and North Afri
ca), Mongoloids (East Asia), Ethiopians (Sub-Saharan Africa), Americans (America
s), and Malays (Oceania) (<a target="_blank" href="http://discovermagazine.com/1
994/nov/thegeometerofrac441">http://discovermagazine.com/1994/nov/thegeometerofr
ac441</a>). Many elements of the classification of Blumenbach still persist, inc
luding the peculiar denomination &quot;Caucasian&quot;.</span></font></p>      ^
cY#1001.htm##
01233000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704100500073002000901078#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#48#44#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">As previously mentioned, the total genetic variatio
n of human populations can be described on two levels: an interpersonal componen
t (within-populations) and an interpopulational component (among-populations). L
ewontin (5) was the first to quantitatively compare these components in an effor
t to evaluate the appropriateness of the division of humankind into distinct rac
es. He compiled the literature on human genetic variation available in 1972, con
sisting of 17 genes, which comprised blood groups, transplantation antigens and 
polymorphisms of serum proteins and soluble enzymes. To a general surprise, he o
bserved that 85.4% of the variance occurred within populations, 8.3% between dif
ferent population of the same continent and only 6.3% between continents (i.e., 
the so-called &quot;continental races&quot;). On these bases, Lewontin concluded
 that the division of humankind into races had no genetic significance (5).</spa
n></font></p>      ^cY#1001.htm##
01015000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704078700073002000900860#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#49#45#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">In 2002 a very influential study was published by R
osenberg et al. (18) using the same general geographical design, but utilizing f
or the first time the reference panel of DNA samples that had been collected by 
the Human Genome Diversity Program and stored at the Fondation Jean Dausset-Cent
re d&rsquo;&Eacute;tudes du Polymorphisme Humain in Paris. This HGDP-CEPH panel 
is a resource of cultured lymphoblastoid cell lines from 1050 individuals in 51 
world populations distributed among Europe, the Middle East, North Africa, Centr
al Asia, East Asia, Sub-Saharan Africa, Oceania, and America (<a target="_blank"
 href="http://www.cephb.fr/en/hgdp/diversity.php">http://www.cephb.fr/en/hgdp/di
versity.php</a>).</span></font></p>      ^cY#1001.htm##
00966000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704073800073002000900811#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#50#46#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">On genotyping a set of 377 autosomal microsatellite
 loci in all the samples, Rosenberg et al. (18) observed a total of 4199 alleles
, 47% of which were present in all populations tested. Only 7% of the alleles we
re present on a single continent, which in the majority of cases was sub-Saharan
 Africa. These results were perfectly compatible with the origin of modern manki
nd in Africa and with a very small degree of genetic differentiation of human co
ntinental populations. Indeed, they found that the within-population variation a
mong the individuals accounted for 93-95% of the total genetic variance, while t
he among-region variation represented only 3.6%.</span></font></p>      ^cY#1001
.htm##
00695000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704046700073002000900540#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#51#47#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Next the authors decided to ascertain the capacity 
of the microsatellites to differentiate human groups. They used a Bayesian clust
ering algorithm that was successful in statistically partitioning human genomic 
variability into five geographical clusters: Sub-Saharan Africa, East Asia, Ocea
nia, America and a fifth set composed of Europe, North Africa, the Middle East, 
and Central Asia.</span></font></p>      ^cY#1001.htm##
00875000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704064700073002000900720#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#52#48#article#178#<p ALIGN="LEFT"> <font
 face="Arial"><span lang="EN"><i>Prima facie</i>, one could recognize here a hom
ology with the five human races defined over one hundred years ago by Blumenbach
. Indeed, authors in both the scientific literature (e.g., Ref. 19,20) and the p
ress (21) claimed that the study of Rosenberg et al. (18) had in fact reestablis
hed the notion of human races on modern post-genomic grounds. However, such view
s are erroneous and cannot withstand close scrutiny. Several lines of evidence i
ndicate methodological and interpretation problems and it is important to unders
tand them to avoid wrong conclusions.</span></font></p>      ^cY#1001.htm##
00663000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043500073002000900508#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#53#49#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">First of all, there is a problem with the populatio
ns sampled in the panel, which is not truly representative of worldwide genetic 
diversity. These were not DNA samples collected in a deliberate way to create a 
panel. Rather, they were initially obtained by independent groups for their own 
research and later grouped as an &quot;international panel&quot;.</span></font><
/p>      ^cY#1001.htm##
00882000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704065400073002000900727#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#54#50#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Secondly, even though the analysis using the cluste
ring algorithm was undertaken without <i>a priori</i> population classification,
 the sampling strategy was clearly population-based. For instance, two of the fi
ve (40%) Amerindian populations present, the Karitiana and the Surui, are geneti
cally close. Both belong to the same Tupi linguistic group and both are from Ron
d&ocirc;nia, Brazil, separated by a distance of only 420 km. Besides, most likel
y these samples contain several related individuals since they were collected fr
om single Karitiana and Surui villages (22).</span></font></p>      ^cY#1001.htm
##
00701000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704047300073002000900546#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#55#51#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Also, the fact that only 127 samples from seven pop
ulations of Africa are available in the panel is grossly inadequate if we consid
er the vastness of the continent and the fact that it harbors the largest amount
 of human genetic diversity on the planet (10). The panel even lacks samples fro
m northeast Africa, from where humans migrated 60,000 years ago to populate the 
rest of the world (12).</span></font></p>      ^cY#1001.htm##
00920000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704069200073002000900765#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#56#52#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Such lack of representativity can create false disc
ontinuities, maximizing the genetic variation between the continental groups and
 artificially creating quantum jumps of allele frequencies between them. The hig
h geographical mobility of humans would lead us to expect gene frequency clines 
rather than geographical discontinuities. Indeed, Serre and Paabo (23) used simu
lation studies to show that if sampling had been done with individuals on a geog
raphical grid, rather than being population-based, the clustering effect would b
e much diminished and the clinical structure of human diversity would be reveale
d.</span></font></p>      ^cY#1001.htm##
00628000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704040000073002000900473#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#57#53#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Third, racial classifications have been based on th
e wrong typological idea that races were very different from each other and very
 internally homogeneous. That is not the picture that emerges from the data of R
osenberg et al. (18), which on the contrary show very heterogeneous clusters bar
ely different from each other.</span></font></p>      ^cY#1001.htm##
01193000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704096500073002000901038#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#58#54#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">This becomes more evident when instead of focusing 
on continental groups one looks at the populations. <a href="#Fig1">Figure 1</a>
 shows an unrooted neighbor-joining tree of all the individuals in the HGDP-CEPH
 panel analyzed with 40 insertion-deletion polymorphisms (24). On the left panel
 of <a href="#Fig1">Figure 1</a> (A) the individuals are color coded according t
o which of five major geographic regions of the globe they originate from. A goo
d, although not perfect, aggregation of individuals can be observed. On the righ
t panel (B) individuals are color coded according to which of the 51 populations
 they come from. Now the impression of order disappears and the colors are shuff
led. Similar trees can be obtained with Rosenberg&rsquo;s original data (25,26).
 As pointed out by Weiss and Long (27), this clearly demonstrates that the way t
he data are interpreted is crucial.</span></font></p>      ^cY#1001.htm##
00734000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704050600073002000900579#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#59#55#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">The study by Rosenberg et al. (18) had a purely geo
graphical structure. It treated the regions as if the enormous variation between
 the San and Yorubas in Sub-Saharan Africa on the one hand, and the small variat
ion between Karitiana and Surui in South America on the other were equivalent. I
n other words, human evolutionary history, especially genealogical relationships
 between continental groups, was not taken into account.</span></font></p>      
^cY#1001.htm##
01369000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704114100073002000901214#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#60#56#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Long et al. (26) showed that the adoption of such a
 model independent of human history has serious consequences, because: i) it und
erestimates diversity within African populations and overestimates diversity wit
hin European and Asia populations; ii) it underestimates diversity between Afric
an populations and overestimates diversity between European and Asian population
s, and iii) it underestimates diversity between Africans and Asians, it underest
imates diversity between Africans and Europeans, and it overestimates diversity 
between Europeans and Asians. Long et al. (26) obtained much better results when
 they tried to accommodate evolutionary history with models containing multiple 
levels of nesting and variable branch length. This is incompatible with a classi
fication of human diversity into races, since the usual genetic and anthropologi
cal racial classifications place continental populations at the same level of cl
assification. Thus, we conclude that the results of Rosenberg et al. (18) do not
 in fact support a racial model of human diversity.</span></font></p>      ^cY#1
001.htm##
00745000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704051700073002000900590#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#61#57#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Treating people, for instance, of the European popu
lation and African population, as separate categories for genetic studies tends 
to contribute to the public perception that the primary difference between these
 ways of defining populations is biological (28). This view confounds several is
sues and obscures the important fact that Europeans and Asians are genealogicall
y related to Africans, having evolved as an offshoot of the latter.</span></font
></p>      ^cY#1001.htm##
00906000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704067800073002000900751#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#62#58#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">I propose that, rather than thinking about populati
ons, ethnicities or races, we should focus on the unique genome of a particular 
individual, which is structured as a mosaic of polymorphic haplotypes with diver
se genealogical histories (29). This shifts the emphasis from populations to per
sons. We should strive to see each individual as having a singular genome and a 
unique life history, rather than try to impose on him/her characteristics of a g
roup or population. Under this model, ideas such as that of human races or &quot
;race-targeted drugs&quot; become meaningless and vanish like smoke.</span></fon
t></p>      ^cY#1001.htm##
00327000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009900073002000900172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#63#59#article#178#<p ALIGN="LEFT"><b><fo
nt face="Arial"><span lang="EN">The safety of racial pharmacogenomics    ^cY#100
1.htm##
00266000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003800073002000900111#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#64#60#article#178#<br>  </span></font></
b></p>      ^cY#1001.htm##
00574000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034600073002000900419#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#65#61#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">The adoption of racial pharmacogenomics by the FDA 
has serious implications that extend much beyond the restricted limits of the me
dical arena. Thus, it has to be evaluated not only scientifically, but also with
in a historical, sociological and philosophical context.</span></font></p>      
^cY#1001.htm##
00704000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704047600073002000900549#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#66#62#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">In the past, the belief that human races had substa
ntial and clearly delimited biological differences contributed to justify discri
mination and was used to oppress and foment injustices, even within the medical 
context. The concept of race is still loaded with ideology and carries within it
 relationships of power and domination (8). It is similar to a banana peel: empt
y, slippery and dangerous.</span></font></p>      ^cY#1001.htm##
00510000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028200073002000900355#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#67#63#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Thus, our final conclusion is that racial pharmaco-
genomics fails on grounds of insufficient benefit/cost ratio: it has much to rec
ommend against it and very little scientific justification in its favor.</span><
/font></p>      ^cY#1001.htm##
00616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038800073002000900461#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#68#64#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">To use racial pharmacogenomics as a palliative meas
ure is tantamount to &quot;embracing ignorance&quot;. It erroneously confers per
sistence and credence to the idea that human races do exist. As pointed out by t
he sociologist Paul Gilroy (30), such persistence is toxic, contaminating and we
akens all society.</span></font></p>      ^cY#1001.htm##
00517000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028900073002000900362#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#69#65#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">The proper course is to wait for the development an
d establishment of real personalized pharmacogenomics, a true science of discove
ry. In the next section, I shall examine how soon we can expect that to happen.<
/span></font></p>      ^cY#1001.htm##
00365000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013700073002000900210#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#70#66#article#178#<p ALIGN="LEFT"><b><fo
nt face="Arial"><span lang="EN">Present and future of personalized pharmacogenom
ics</span></font></b></p>      ^cY#1001.htm##
00513000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028500073002000900358#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#71#67#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">At this point I hope to have made clear the necessi
ty to study individual genomes and not races in personalized pharmacogenomics. I
 propose now to examine the perspectives for the development of this field.</spa
n></font></p>      ^cY#1001.htm##
00575000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034700073002000900420#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#72#68#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Obviously, the present and future of personalized p
harmacogenomics are intimately connected to those of personalized medicine in ge
neral. There, we are experiencing a new genomic revolution impelled by massively
 parallel high-throughput new generation sequencing (31).</span></font></p>     
 ^cY#1001.htm##
00578000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704035000073002000900423#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#73#69#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Today&rsquo;s DNA sequencers are dozens of thousand
s times faster than the ones used in the Human Genome Project (32) (<a href="#Fi
g2">Figure 2A</a>). At the same time the price of sequencing a human genome has 
been dropping exponentially (<a href="#Fig2">Figure 2B</a>).</span></font></p>  
    ^cY#1001.htm##
00660000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043200073002000900505#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#74#70#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">It is possible today to obtain a human genome seque
nce at Illumina for US$14,500 (33). The mythic goal of the one thousand dollar g
enome is in sight and may be achieved as early as 2011 (<a href="#Fig2">Figure 2
B</a>). As a consequence, incorporation of personal genomes into clinical practi
ce has been achieved (34) and is already becoming commonplace.</span></font></p>
      ^cY#1001.htm##
00517000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028900073002000900362#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#75#71#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Moreover, &quot;next-generation&quot; sequencing is
 being challenged by even faster and more effective technologies that already lo
om on the horizon, especially single DNA molecule sequencing and microfluidics.<
/span></font></p>      ^cY#1001.htm##
00971000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704074300073002000900816#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#76#72#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Recently, the 1000 Genomes Project published its fi
rst report, consisting of the whole-genome sequencing of 179 individuals from fo
ur populations, high coverage sequencing of two mother-child-father trios and ex
on-targeted sequencing of 697 individuals (35). Their results indicate that we a
lready have robust protocols for whole genome shotgun sequencing and targeted se
quence data and that there are efficient algorithms to detect individual sequenc
e and structural variants in the complete human genome. A survey made by Nature 
(36) indicates that at least 2700 human genomes have already been sequenced and 
that by the end of 2011 that number may reach 30,000.</span></font></p>      ^cY
#1001.htm##
00555000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704032700073002000900400#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#77#73#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">However, two hurdles will have to be overcome befor
e personalized pharmacogenomics can really take off. The first is that the price
s of sequencing human genomes do not include the necessary bioinformatics interp
retation, which is very complex (37).</span></font></p>      ^cY#1001.htm##
00777000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704054900073002000900622#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#78#74#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">Fortunately, very recently new strategies have star
ted to appear addressing this problem. One good example involves free software t
hat incorporates simple targeted computational algorithms for do-it-yourself scr
eening of specific genes (38). In this fashion, with user-friendly computer prog
rams it may be possible for physicians and scientists to analyze the genome and 
to extract the necessary pharmacogenomic information without the need for bioinf
ormatics expertise.</span></font></p>      ^cY#1001.htm##
00767000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704053900073002000900612#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#79#75#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">This leads us to the second, more formidable, hurdl
e of identifying the proper genome content, i.e., new polymorphisms relevant for
 pharmacogenomics. Up to now, available microarray technology could only study c
ommon variants, which confer relatively small increments in risk. In this fashio
n, only a small proportion of genetic variation in drug handling has been explai
ned so far and the larger part of the pharmacogenomic heritability is still miss
ing (39).</span></font></p>      ^cY#1001.htm##
00891000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704066300073002000900736#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#80#76#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">One promising source for uncovering the still unexp
lained heritability is the investigation of rare, low-penetrance genetic variant
s, a class that ranges from low-frequency polymorphisms (allele frequency &lt;5%
) through subpolymorphic variants (frequency 0.1-1.0%) to very low frequency or 
&lsquo;private&rsquo; variants with frequencies of 0.1% or less (40). If pharmac
ogenomic variation does indeed depend on the phenotypic effect of many rare vari
ants, the missing heritability of drug responses will then largely be explained 
and the information will become clinically available.</span></font></p>      ^cY
#1001.htm##
00664000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704043600073002000900509#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#81#77#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">The wide availability of human whole genome sequenc
ing has removed the technological barriers to the discovery and testing of rare 
predisposition alleles. The next few months will witness a flood of data that sh
ould illuminate the genetics of aspects of pharmacological traits and enhance th
e potential of personal pharmacogenomics for routine clinical use.</span></font>
</p>      ^cY#1001.htm##
00728000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704050000073002000900573#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#82#78#article#178#<p ALIGN="LEFT"><span 
lang="EN"><font FACE="Arial, Helvetica, sans-serif">In summary, human clinical g
enomic knowledge and tools are advancing at enormous speed. Personalized pharmac
ogenomics should soon become a reality in routine clinical practice.</font></spa
n></p>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="
top">      <td><a href="/img/revistas/bjmbr/v44n4/html/1001i01.htm"><img src="/i
mg/revistas/bjmbr/v44n4/1001i01peq.jpg" border="2"></a></td>      <td>    ^cY#10
01.htm##
01352000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704112400073002000901197#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#83#79#article#178#<p ALIGN="LEFT"><span 
lang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1.
 Neighbor-joining trees showing the genetic relationships of 1050 individuals fr
om the HGDP-CEPH panel studied with a panel of 40 insertion-deletion autosomal p
olymorphisms (Ref. 24). This was inspired by an idea of Nievergelt et al. (Ref. 
25). We used a distance matrix (Ref. 24) to construct the neighbor-joining tree 
using the neighbor module of the Phylip v.3.64 program (<a target="_blank" href=
"http://evolution.genetics.washington.edu/phylip.html">http://evolution.genetics
.washington.edu/phylip.html</a>). The branches were colored using the program Hy
perTree v.1.0.0 (<a target="_blank" href="http://www.kinase.com/tools/HyperTree.
html">http://www.kinase.com/tools/HyperTree.html</a>) and the following procedur
e: in <i>Panel A</i> the individuals are color coded according to which of five 
major geographic regions of the globe they originate from and in <i>Panel B</i> 
individuals are color coded according to which of the 51 populations they come f
rom.</font></span></p>      </td>    </tr>  </table>      ^cY#1001.htm##
00568000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034000073002000900413#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#84#80#article#178#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (373 K JPG file)]</fon
t></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="
top">      <td><a href="/img/revistas/bjmbr/v44n4/html/1001i02.htm"><img src="/i
mg/revistas/bjmbr/v44n4/1001i02peq.jpg" border="2"></a></td>      <td>    ^cY#10
01.htm##
01362000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704113400073002000901207#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#85#81#article#178#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN"><a name="Fig2"></a>Figure 2. Graphs showing the fan
tastic progress in the development of rapid and inexpensive human genome next-ge
neration sequencing in the past 10 years. In <i>A</i>, the vertical axis, on a l
ogarithmic scale, shows the efficiency of the DNA sequencers, measured in thousa
nds of base pairs (kilobases) per sequencer per day. The graph was plotted using
 data presented by Venter (Ref. 32). In <i>B</i>, the vertical axis, also on a l
ogarithmic scale, shows the price of sequencing a human genome. The graph was pl
otted using data presented at the following sites (<a target="_blank" href="http
://www.genengnews.com/gen-news-highlights/illumina-cuts-price-for-individual-gen
ome-sequencing-service-by-more-than-half/81243489/">http://www.genengnews.com/ge
n-news-highlights/illumina-cuts-price-for-individual-genome-sequencing-service-b
y-more-than-half/81243489/</a>) (<a target="_blank" href="http://www.technologyr
eview.com/biomedicine/24590/?a=f">http://www.technologyreview.com/biomedicine/24
590/?a=f</a>).</span></font></p>      </td>    </tr>  </table>      ^cY#1001.htm
##
00781000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704055300073002000900626#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#86#82#article#178#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (79 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/1001t01.htm"><img src="/im
g/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td><span lang="EN">
<font face="Arial"><span lang="EN"><a name="Tab1"></a>Table 1. Analysis of singl
e nucleotide polymorphism (SNP) rs9923231 in HapMap 3 (Ref. 16) populations.</sp
an></font></span></td>    </tr>  </table>      ^cY#1001.htm##
00345000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011700073002000900190#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#87#83#article#178#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (82 K JPG file)]</font
></P>      ^cY#1001.htm##
00265000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003700073002000900110#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#88#84#article#178#<P>  <HR ALIGN=LEFT SI
ZE=2>      ^cY#1001.htm##
00544000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031600073002000900389#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#89#85#article#178#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>
References</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif">
<A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BO
RDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#1001.htm##
00551000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704030900075002000900384#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#90#86#article#178#1#<p ALIGN
="LEFT"><font face="Arial"><span lang="EN">1. Tyson NG. The perimeter of ignoran
ce. <a target="_blank" href="http://www.naturalhistorymag.com/universe/211420/th
e-perimeter-of-ignorance">http://www.naturalhistorymag.com/universe/211420/the-p
erimeter-of-ignorance</a>. Accessed January 29, 2011.    ^cY#1001.htm##
00256000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002800073002000900101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#91#87#article#178#</span></font></p>    
  ^cY#1001.htm##
00507000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704026500075002000900340#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#92#88#article#178#2#<p align
="LEFT"><font face="Arial"><span lang="EN">2. American Anthropological Associati
on statement on &quot;Race&quot;. <a target="_blank" href="http://www.aaanet.org
/stmts/racepp.htm">http://www.aaanet.org/stmts/racepp.htm</a>. Accessed January 
29, 2011.    ^cY#1001.htm##
00256000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002800073002000900101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#93#89#article#178#</span></font></p>    
  ^cY#1001.htm##
00515000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027300075002000900348#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#94#90#article#178#3#<p align
="LEFT"><font face="Arial"><span lang="EN">3. <a target="_blank" href="http://ww
w.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108445.htm">http://www.
fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108445.htm</a>. Accessed 
January 29, 2011.    ^cY#1001.htm##
00256000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002800073002000900101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#95#91#article#178#</span></font></p>    
  ^cY#1001.htm##
00542000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704030000075002000900375#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#96#92#article#178#4#<p align
="LEFT"><font face="Arial"><span lang="EN">4. Jones J, Goodman A. BiDil and the 
&quot;fact&quot; of genetic blackness. <a target="_blank" href="http://www.aaane
t.org/press/an/1005/Jones_Goodman.htm">http://www.aaanet.org/press/an/1005/Jones
_Goodman.htm</a>. Accessed January 29, 2011.    ^cY#1001.htm##
00256000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002800073002000900101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#97#93#article#178#</span></font></p>    
  ^cY#1001.htm##
00391000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704014900075002000900224#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#98#94#article#178#5#<p align
="LEFT"><font face="Arial"><span lang="EN">5. Lewontin RC. The apportionment of 
human diversity. <i>J Evol Biol</i> 1972; 6: 381-398.    ^cY#1001.htm##
00256000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002800073002000900101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#99#95#article#178#</span></font></p>    
  ^cY#1001.htm##
00411000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000200074704016800076002000900244#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#100#96#article#178#6#<p alig
n="LEFT"><font face="Arial"><span lang="EN">6. Templeton AR. Human races, a gene
tic and evolutionary perspective. <i>Am Anthropol</i> 1999; 100: 632-650.    ^cY
#1001.htm##
00257000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704002800074002000900102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#101#97#article#178#</span></font></p>   
   ^cY#1001.htm##
00547000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000200074704030400076002000900380#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#102#98#article#178#7#<p alig
n="LEFT"><font face="Arial"><span lang="EN">7. Evelyn B, Toigo T, Banks D, Pohl 
D, Gray K, Robins B, et al. Participation of racial/ethnic groups in clinical tr
ials and race-related labeling: a review of new molecular entities approved 1995
-1999. <i>J Natl Med Assoc</i> 2001; 93: 18S-24S.    ^cY#1001.htm##
00257000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704002800074002000900102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#103#99#article#178#</span></font></p>   
   ^cY#1001.htm##
00545000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704030100077002000900378#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#104#100#article#178#8#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">8. Munanga K. Uma abordagem conceit
ual das no&ccedil;&otilde;es de ra&ccedil;a, racismo, identidade e etnia. In: Br
and&atilde;o AAP (Editor), <i>Cadernos PENESB 5</i>. Niter&oacute;i: Editora da 
Universidade Federal Fluminense; 2004. p 16-34.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#105#101#article#178#</span></font></p>  
    ^cY#1001.htm##
00406000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704016200077002000900239#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#106#102#article#178#9#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">9. Sturm RA. Molecular genetics of 
human pigmentation diversity. <i>Hum Mol Genet</i> 2009; 18: R9-R17.    ^cY#1001
.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#107#103#article#178#</span></font></p>  
    ^cY#1001.htm##
00482000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023700078002000900315#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#108#104#article#178#10#<p al
ign="LEFT"><font face="Arial"><span lang="EN">10. Yu N, Chen FC, Ota S, Jorde LB
, Pamilo P, Patthy L, et al. Larger genetic differences within Africans than bet
ween Africans and Eurasians. <i>Genetics</i> 2002; 161: 269-274.    ^cY#1001.htm
##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#109#105#article#178#</span></font></p>  
    ^cY#1001.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021900078002000900297#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#110#106#article#178#11#<p al
ign="LEFT"><font face="Arial"><span lang="EN">11. Ng PC, Zhao Q, Levy S, Strausb
erg RL, Venter JC. Individual genomes instead of race for personalized medicine.
 <i>Clin Pharmacol Ther</i> 2008; 84: 306-309.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#111#107#article#178#</span></font></p>  
    ^cY#1001.htm##
00468000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704022300078002000900301#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#112#108#article#178#12#<p al
ign="LEFT"><font face="Arial"><span lang="EN">12. Behar DM, Villems R, Soodyall 
H, Blue-Smith J, Pereira L, Metspalu E, et al. The dawn of human matrilineal div
ersity. <i>Am J Hum Genet</i> 2008; 82: 1130-1140.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#113#109#article#178#</span></font></p>  
    ^cY#1001.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704027400078002000900352#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#114#110#article#178#13#<p al
ign="LEFT"><font face="Arial"><span lang="EN">13. Limdi NA, Wadelius M, Cavallar
i L, Eriksson N, Crawford DC, Lee MT, et al. Warfarin pharmacogenetics: a single
 VKORC1 polymorphism is predictive of dose across 3 racial groups. <i>Blood</i> 
2010; 115: 3827-3834.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#115#111#article#178#</span></font></p>  
    ^cY#1001.htm##
00411000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704016600078002000900244#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#116#112#article#178#14#<p al
ign="LEFT"><font face="Arial"><span lang="EN">14. Cann RL, Stoneking M, Wilson A
C. Mitochondrial DNA and human evolution. <i>Nature</i> 1987; 325: 31-36.    ^cY
#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#117#113#article#178#</span></font></p>  
    ^cY#1001.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023200078002000900310#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#118#114#article#178#15#<p al
ign="LEFT"><font face="Arial"><span lang="EN">15. Frazer KA, Ballinger DG, Cox D
R, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map 
of over 3.1 million SNPs. <i>Nature</i> 2007; 449: 851-861.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#119#115#article#178#</span></font></p>  
    ^cY#1001.htm##
00491000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024600078002000900324#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#120#116#article#178#16#<p al
ign="LEFT"><font face="Arial"><span lang="EN">16. <a target="_blank" href="http:
//www.sanger.ac.uk/resources/downloads/human/hapmap3.html">http://www.sanger.ac.
uk/resources/downloads/human/hapmap3.html</a>. Accessed January 29, 2011.    ^cY
#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#121#117#article#178#</span></font></p>  
    ^cY#1001.htm##
00428000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704018300078002000900261#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#122#118#article#178#17#<p al
ign="LEFT"><font face="Arial"><span lang="EN">17. Dunn LC, Dobzhansky T. <i>Here
dity, race, and society</i>. New York: The New American Library of World Literat
ure; 1946.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#123#119#article#178#</span></font></p>  
    ^cY#1001.htm##
00463000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021800078002000900296#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#124#120#article#178#18#<p al
ign="LEFT"><font face="Arial"><span lang="EN">18. Rosenberg NA, Pritchard JK, We
ber JL, Cann HM, Kidd KK, Zhivotovsky LA, et al. Genetic structure of human popu
lations. <i>Science</i> 2002; 298: 2381-2385.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#125#121#article#178#</span></font></p>  
    ^cY#1001.htm##
00505000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026000078002000900338#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#126#122#article#178#19#<p al
ign="LEFT"><font face="Arial"><span lang="EN">19. Burchard EG, Ziv E, Coyle N, G
omez SL, Tang H, Karter AJ, et al. The importance of race and ethnic background 
in biomedical research and clinical practice. <i>N Engl J Med</i> 2003; 348: 117
0-1175.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#127#123#article#178#</span></font></p>  
    ^cY#1001.htm##
00496000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704026600075002000900341#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#128#124#article#178#<p align="LEFT"><fon
t face="Arial"><span lang="EN">20. Mountain JL, Risch N. Assessing genetic contr
ibutions to phenotypic differences among &lsquo;racial&rsquo; and &lsquo;ethnic&
rsquo; groups. <i>Nat Genet</i> 2004; 11 (Suppl): S48-S53.</span></font></p>    
  ^cY#1001.htm##
00410000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704016500078002000900243#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#129#125#article#178#21#<p al
ign="LEFT"><font face="Arial"><span lang="EN">21. Wade N. <i>Before the dawn, re
covering the lost history of our ancestors</i>. New York: Penguin; 2007.    ^cY#
1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#130#126#article#178#</span></font></p>  
    ^cY#1001.htm##
00463000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021800078002000900296#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#131#127#article#178#22#<p al
ign="LEFT"><font face="Arial"><span lang="EN">22. Kidd JR, Black FL, Weiss KM, B
alazs I, Kidd KK. Studies of three Amerindian populations using nuclear DNA poly
morphisms. <i>Hum Biol</i> 1991; 63: 775-794.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#132#128#article#178#</span></font></p>  
    ^cY#1001.htm##
00443000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019800078002000900276#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#133#129#article#178#23#<p al
ign="LEFT"><font face="Arial"><span lang="EN">23. Serre D, Paabo S. Evidence for
 gradients of human genetic diversity within and among continents. <i>Genome Res
</i> 2004; 14: 1679-1685.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#134#130#article#178#</span></font></p>  
    ^cY#1001.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024200078002000900320#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#135#131#article#178#24#<p al
ign="LEFT"><font face="Arial"><span lang="EN">24. Bastos-Rodrigues L, Pimenta JR
, Pena SD. The genetic structure of human populations studied through short inse
rtion-deletion polymorphisms. <i>Ann Hum Genet</i> 2006; 70: 658-665.    ^cY#100
1.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#136#132#article#178#</span></font></p>  
    ^cY#1001.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704017500078002000900253#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#137#133#article#178#25#<p al
ign="LEFT"><font face="Arial"><span lang="EN">25. Nievergelt CM, Libiger O, Scho
rk NJ. Generalized analysis of molecular variance. <i>PLoS Genet</i> 2007; 3: e5
1.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#138#134#article#178#</span></font></p>  
    ^cY#1001.htm##
00428000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704018300078002000900261#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#139#135#article#178#26#<p al
ign="LEFT"><font face="Arial"><span lang="EN">26. Long JC, Li J, Healy ME. Human
 DNA sequences: more variation and less race. <i>Am J Phys Anthropol</i> 2009; 1
39: 23-34.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#140#136#article#178#</span></font></p>  
    ^cY#1001.htm##
00435000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704020500075002000900280#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#141#137#article#178#<p align="LEFT"><fon
t face="Arial"><span lang="EN">27. Weiss KM, Long JC. Non-Darwinian estimation, 
my ancestors, my genes&rsquo; ancestors. <i>Genome Res </i>2009; 19: 703-710.</s
pan></font></p>      ^cY#1001.htm##
00459000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021400078002000900292#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#142#138#article#178#28#<p al
ign="LEFT"><font face="Arial"><span lang="EN">28. Foster MW, Sharp RR. Beyond ra
ce: towards a whole-genome perspective on human populations and genetic variatio
n. <i>Nat Rev Genet</i> 2004; 5: 790-796.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#143#139#article#178#</span></font></p>  
    ^cY#1001.htm##
00381000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704013600078002000900214#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#144#140#article#178#29#<p al
ign="LEFT"><font face="Arial"><span lang="EN">29. Paabo S. The mosaic that is ou
r genome. <i>Nature</i> 2003; 421: 409-412.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#145#141#article#178#</span></font></p>  
    ^cY#1001.htm##
00433000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704018800078002000900266#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#146#142#article#178#30#<p al
ign="LEFT"><font face="Arial"><span lang="EN">30. Gilroy P. <i>Against race - im
agining political culture beyond the color line</i>. Cambridge: Harvard Universi
ty Press; 2000.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#147#143#article#178#</span></font></p>  
    ^cY#1001.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704020600078002000900284#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#148#144#article#178#31#<p al
ign="LEFT"><font face="Arial"><span lang="EN">31. Tucker T, Marra M, Friedman JM
. Massively parallel sequencing: the next big thing in genetic medicine. <i>Am J
 Hum Genet</i> 2009; 85: 142-154.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#149#145#article#178#</span></font></p>  
    ^cY#1001.htm##
00385000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704014000078002000900218#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#150#146#article#178#32#<p al
ign="LEFT"><font face="Arial"><span lang="EN">32. Venter JC. Multiple personal g
enomes await. <i>Nature</i> 2010; 464: 676-677.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#151#147#article#178#</span></font></p>  
    ^cY#1001.htm##
00759000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704051400078002000900592#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#152#148#article#178#33#<p al
ign="LEFT"><font face="Arial"><span lang="EN">33. Genetic Engineering &amp; Biot
echnology News. Illumina cuts price for individual genome sequencing service by 
more than half. <a target="_blank" href="http://www.genengnews.com/gen-news-high
lights/illumina-cuts-price-for-individual-genome-sequencing-service-by-more-than
-half/81243489">http://www.genengnews.com/gen-news-highlights/illumina-cuts-pric
e-for-individual-genome-sequencing-service-by-more-than-half/81243489</a>. Acces
sed January 29, 2011.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#153#149#article#178#</span></font></p>  
    ^cY#1001.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021900078002000900297#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#154#150#article#178#34#<p al
ign="LEFT"><font face="Arial"><span lang="EN">34. Ashley EA, Butte AJ, Wheeler M
T, Chen R, Klein TE, Dewey FE, et al. Clinical assessment incorporating a person
al genome. <i>Lancet</i> 2010; 375: 1525-1535.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#155#151#article#178#</span></font></p>  
    ^cY#1001.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024000078002000900318#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#156#152#article#178#35#<p al
ign="LEFT"><font face="Arial"><span lang="EN">35. Durbin RM, Abecasis GR, Altshu
ler DL, Auton A, Brooks LD, Durbin RM, et al. A map of human genome variation fr
om population-scale sequencing. <i>Nature</i> 2010; 467: 1061-1073.    ^cY#1001.
htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#157#153#article#178#</span></font></p>  
    ^cY#1001.htm##
00382000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704013700078002000900215#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#158#154#article#178#36#<p al
ign="LEFT"><font face="Arial"><span lang="EN">36. Human genome: Genomes by the t
housand. <i>Nature</i> 2010; 467: 1026-1027.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#159#155#article#178#</span></font></p>  
    ^cY#1001.htm##
00391000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704014600078002000900224#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#160#156#article#178#37#<p al
ign="LEFT"><font face="Arial"><span lang="EN">37. Mardis ER. The $1,000 genome, 
the $100,000 analysis? <i>Genome Med</i> 2010; 2: 84.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#161#157#article#178#</span></font></p>  
    ^cY#1001.htm##
00396000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704015100078002000900229#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#162#158#article#178#38#<p al
ign="LEFT"><font face="Arial"><span lang="EN">38. Salzberg SL, Pertea M. Do-it-y
ourself genetic testing. <i>Genome Biol</i> 2010; 11: 404.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#163#159#article#178#</span></font></p>  
    ^cY#1001.htm##
00472000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704022700078002000900305#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#164#160#article#178#39#<p al
ign="LEFT"><font face="Arial"><span lang="EN">39. Manolio TA, Collins FS, Cox NJ
, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability 
of complex diseases. <i>Nature</i> 2009; 461: 747-753.    ^cY#1001.htm##
00258000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002800075002000900103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#165#161#article#178#</span></font></p>  
    ^cY#1001.htm##
00422000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704017700078002000900255#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#p#166#162#article#178#40#<p al
ign="LEFT"><font face="Arial"><span lang="EN">40. Bodmer W, Tomlinson I. Rare ge
netic variants and the risk of cancer. <i>Curr Opin Genet Dev</i> 2010; 20: 262-
267.    ^cY#1001.htm##
00282000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704005200075002000900127#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#167#163#article#178#</span></font></p>  
<HR ALIGN=LEFT SIZE=2>      ^cY#1001.htm##
00565000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704033500075002000900410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#168#164#article#178#<P><font face="Arial
, Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZ
E=4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, 
sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALI
GN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#1001.
htm##
00480000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704025000075002000900325#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#169#165#article#178#<p ALIGN="LEFT"><fon
t face="Arial"><span lang="EN">I am grateful to Fernanda Kehdy for her valuable 
help in the computations involved in <a href="#Tab1">Table 1</a> and <a href="#F
ig1">Figure 1</a>.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#1001.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704033600075002000900411#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#170#166#article#178#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, H
elvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#1001
.htm##
00750000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704052000075002000900595#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#171#167#article#178#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/
recor.gif" border="0"></a> Address for correspondence:</b></font><span lang="EN"
><font face="Arial, Helvetica, sans-serif"> </font></span><font face="Arial"><sp
an lang="EN"> S.D.J. Pena, GENE - N&uacute;cleo de Gen&eacute;tica M&eacute;dica
, Av. Afonso Pena, 3111/9, 30130-909 Belo Horizonte, MG, Brasil. Fax: +55-31-322
7-3792. E-mail: <a href="mailto:spena@gene.com.br">spena@gene.com.br</a></span><
/font></p>      ^cY#1001.htm##
00453000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704022300075002000900298#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#172#168#article#178#<p ALIGN="LEFT"><i><
font face="Arial"><span lang="EN">Received January 11, 2011. Accepted February 1
4, 2011. Available online March 11, 2011. Published April 11, 2011.</span></font
></i></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#1001.htm##
00262000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704003200075002000900107#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#173#169#article#178#<div align="center">
        ^cY#1001.htm##
00428000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704019800075002000900273#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#174#170#article#178#<p><font color="#000
000" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazili
an Journal of Medical and Biological Research is partially financed by</font></e
m><strong>    ^cY#1001.htm##
00254000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704002400075002000900099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#175#171#article#178#<br>                
^cY#1001.htm##
00328000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704009800075002000900173#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#176#172#article#178#<br>    </strong></f
ont></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#10
01.htm##
00386000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704015600075002000900231#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#177#173#article#178#<div align="center">
<a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n
4/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#1001.htm##
00388000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704015800075002000900233#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#178#174#article#178#<div align="center">
<a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v
44n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#1001.htm##
00392000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704016200075002000900237#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#179#175#article#178#<div align="center">
<a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#1001.htm##
00403000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704017300075002000900248#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#180#176#article#178#<div align="center">
<a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/
revistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#1001.ht
m##
00394000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704016400075002000900239#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#181#177#article#178#<div align="center">
<a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmb
r/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#1001.htm##
00401000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704017100075002000900246#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\1001.htm#S#p#182#178#article#178#<div align="center">
<a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v4
4n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#1001.htm#
#
00447000000000205000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720160016000740180031000900620
07600121061002600197865000900223002000900232#v44n4#V:\SciELO\serial\bjmbr\v44n4\
markup\1001.htm#S#c#183#1#article#40#1#^rND^sTyson^nNG#The perimeter of ignoranc
e^len#http://www.naturalhistorymag.com/universe/211420/the-perimeter-of-ignoranc
e#Accessed January 29, 2011#20110400#1001.htm##
00408000000000193000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720170057000740620039001310610
02600170865000900196002000900205#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.
htm#S#c#184#2#article#40#2#American Anthropological Association statement on "Ra
ce"#http://www.aaanet.org/stmts/racepp.htm#Accessed January 29, 2011#20110400#10
01.htm##
00377000000000181000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720620077000740610026001518650
00900177002000900186#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#185#
3#article#40#3#http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/uc
m108445.htm#Accessed January 29, 2011#20110400#1001.htm##
00468000000000217000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720160015000740160017000890180
04600106062005400152061002600206865000900232002000900241#v44n4#V:\SciELO\serial\
bjmbr\v44n4\markup\1001.htm#S#c#186#4#article#40#4#^rND^sJones^nJ#^rND^sGoodman^
nA#BiDil and the "fact" of genetic blackness^len#http://www.aaanet.org/press/an/
1005/Jones_Goodman.htm#Accessed January 29, 2011#20110400#1001.htm##
00444000000000253000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740120041000930300
01200134710000200146065000900148064000500157031000200162014000800164865000900172
002000900181#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#187#5#articl
e#40#5#^rND^sLewontin^nRC#The apportionment of human diversity^len#J Evol Biol#2
#19720000#1972#6#381-398#20110400#1001.htm##
00496000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740120056000940300
01300150065000900163064000500172031000400177014000800181865000900189002000900198
035001000207801001300217#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#
188#6#article#40#6#^rND^sTempleton^nAR#Human races, a genetic and evolutionary p
erspective^len#Am Anthropol#19990000#1999#100#632-650#20110400#1001.htm#0002-729
4#Am Anthropol##
00737000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100015000900100
01500105010001400120010001400134010001600148810000600164012014200170030001700312
06500090032906400050033803100030034301400080034686500090035400200090036303500100
0372801001700382#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#189#7#ar
ticle#40#7#^rND^sEvelyn^nB#^rND^sToigo^nT#^rND^sBanks^nD#^rND^sPohl^nD#^rND^sGra
y^nK#^rND^sRobins^nB#et al#Participation of racial/ethnic groups in clinical tri
als and race-related labeling: a review of new molecular entities approved 1995-
1999^len#J Natl Med Assoc#20010000#2001#93#18S-24S#20110400#1001.htm#0027-9684#J
 Natl Med Assoc##
00564000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740120077000910160
01900168018002200187066000800209062004300217065000900260064000500269014000600274
865000900280002000900289#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#
190#8#article#40#8#^rND^sMunanga^nK#Uma abordagem conceitual das noções de raça,
 racismo, identidade e etnia^lpt#^rED^sBrandão^nAAP#Cadernos PENESB 5^lpt#Niteró
i#Editora da Universidade Federal Fluminense#20040000#2004#16-34#20110400#1001.h
tm##
00491000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740120055000900300
01400145065000900159064000500168031000300173014000700176865000900183002000900192
035001000201801001400211#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#
191#9#article#40#9#^rND^sSturm^nRA#Molecular genetics of human pigmentation dive
rsity^len#Hum Mol Genet#20090000#2009#18#R9-R17#20110400#1001.htm#0964-6906#Hum 
Mol Genet##
00663000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100012000760100015000880100
01300103010001600116010001600132010001600148810000600164012008300170030000900253
06500090026206400050027103100040027601400080028086500090028800200090029703500100
0306801000900316#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#192#10#a
rticle#40#10#^rND^sYu^nN#^rND^sChen^nFC#^rND^sOta^nS#^rND^sJorde^nLB#^rND^sPamil
o^nP#^rND^sPatthy^nL#et al#Larger genetic differences within Africans than betwe
en Africans and Eurasians^len#Genetics#20020000#2002#161#269-274#20110400#1001.h
tm#0016-6731#Genetics##
00627000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100014000890100
01400103010002100117010001700138012006500155030002000220065000900240064000500249
031000300254014000800257865000900265002000900274035001000283801002000293#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#193#11#article#40#11#^rND^sNg^nP
C#^rND^sZhao^nQ#^rND^sLevy^nS#^rND^sStrausberg^nRL#^rND^sVenter^nJC#Individual g
enomes instead of race for personalized medicine^len#Clin Pharmacol Ther#2008000
0#2008#84#306-309#20110400#1001.htm#0009-9236#Clin Pharmacol Ther##
00655000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01800109010002000127010001700147010001800164810000600182012004400188030001500232
06500090024706400050025603100030026101400100026486500090027400200090028303500100
0292801001500302#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#194#12#a
rticle#40#12#^rND^sBehar^nDM#^rND^sVillems^nR#^rND^sSoodyall^nH#^rND^sBlue-Smith
^nJ#^rND^sPereira^nL#^rND^sMetspalu^nE#et al#The dawn of human matrilineal diver
sity^len#Am J Hum Genet#20080000#2008#82#1130-1140#20110400#1001.htm#0002-9297#A
m J Hum Genet##
00697000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01900110010001800129010001900147010001400166810000600180012010500186030000600291
06500090029706400050030603100040031101400100031586500090032500200090033403500100
0343801000600353#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#195#13#a
rticle#40#13#^rND^sLimdi^nNA#^rND^sWadelius^nM#^rND^sCavallari^nL#^rND^sEriksson
^nN#^rND^sCrawford^nDC#^rND^sLee^nMT#et al#Warfarin pharmacogenetics: a single V
KORC1 polymorphism is predictive of dose across 3 racial groups^len#Blood#201000
00#2010#115#3827-3834#20110400#1001.htm#0006-4971#Blood##
00525000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100019000910100
01700110012004200127030000700169065000900176064000500185031000400190014000600194
865000900200002000900209035001000218801000700228#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\1001.htm#S#c#196#14#article#40#14#^rND^sCann^nRL#^rND^sStoneking^nM#^
rND^sWilson^nAC#Mitochondrial DNA and human evolution^len#Nature#19870000#1987#3
25#31-36#20110400#1001.htm#0028-0836#Nature##
00664000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930100
01400113010001600127010001600143010001600159010001300175012007000188030000700258
06500090026506400050027403100040027901400080028386500090029100200090030003500100
0309801000700319#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#197#15#a
rticle#40#15#^rND^sFrazer^nKA#^rND^sBallinger^nDG#^rND^sCox^nDR#^rND^sHinds^nDA#
^rND^sStuve^nLL#^rND^sGibbs^nRA#^rND^set^nal#A second generation human haplotype
 map of over 3: 1 million SNPs^len#Nature#20070000#2007#449#851-861#20110400#100
1.htm#0028-0836#Nature##
00365000000000181000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730620063000760610026001398650
00900165002000900174#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#198#
16#article#40#16#http://www.sanger.ac.uk/resources/downloads/human/hapmap3.html#
Accessed January 29, 2011#20110400#1001.htm##
00471000000000241000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160015000760160020000910180
03200111066000900143062004500152065000900197064000500206865000900211002000900220
#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#199#17#article#40#17#^rN
D^sDunn^nLC#^rND^sDobzhansky^nT#Heredity, race, and society^len#New York#The New
 American Library of World Literature#19460000#1946#20110400#1001.htm##
00643000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100020000960100
01600116010001500132010001500147010002200162810000600184012004300190030000800233
06500090024106400050025003100040025501400100025986500090026900200090027803500100
0287801000800297#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#200#18#a
rticle#40#18#^rND^sRosenberg^nNA#^rND^sPritchard^nJK#^rND^sWeber^nJL#^rND^sCann^
nHM#^rND^sKidd^nKK#^rND^sZhivotovsky^nLA#et al#Genetic structure of human popula
tions^len#Science#20020000#2002#298#2381-2385#20110400#1001.htm#0036-8075#Scienc
e##
00690000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100013000950100
01500108010001600123010001400139010001700153810000600170012009400176030001300270
06500090028306400050029203100040029701400100030186500090031100200090032003500100
0329801001300339#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#201#19#a
rticle#40#19#^rND^sBurchard^nEG#^rND^sZiv^nE#^rND^sCoyle^nN#^rND^sGomez^nSL#^rND
^sTang^nH#^rND^sKarter^nAJ#et al#The importance of race and ethnic background in
 biomedical research and clinical practice^len#N Engl J Med#20030000#2003#348#11
70-1175#20110400#1001.htm#0028-4793#N Engl J Med##
00602000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100015000950120
12100110030001000231065000900241064000500250031000300255014000800258032000800266
865000900274002000900283035001000292801001000302#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\1001.htm#S#c#202#20#article#40#20#^rND^sMountain^nJL#^rND^sRisch^nN#A
ssessing genetic contributions to phenotypic differences among &#8216;racial&#82
17; and &#8216;ethnic&#8217; groups^len#Nat Genet#20040000#2004#11#S48-S53#^sSup
pl#20110400#1001.htm#1061-4036#Nat Genet##
00435000000000229000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160014000760180066000900660
00900156062000800165065000900173064000500182865000900187002000900196#v44n4#V:\Sc
iELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#203#21#article#40#21#^rND^sWade^nN#B
efore the dawn, recovering the lost history of our ancestors^len#New York#Pengui
n#20070000#2007#20110400#1001.htm##
00615000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01600107010001600123010001500139012007600154030000900230065000900239064000500248
031000300253014000800256865000900264002000900273035001000282801000900292#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#204#22#article#40#22#^rND^sKidd^
nJR#^rND^sBlack^nFL#^rND^sWeiss^nKM#^rND^sBalazs^nI#^rND^sKidd^nKK#Studies of th
ree Amerindian populations using nuclear DNA polymorphisms^len#Hum Biol#19910000
#1991#63#775-794#20110400#1001.htm#0018-7143#Hum Biol##
00543000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910120
08200106030001100188065000900199064000500208031000300213014001000216865000900226
002000900235035001000244801001100254#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1
001.htm#S#c#205#23#article#40#23#^rND^sSerre^nD#^rND^sPaabo^nS#Evidence for grad
ients of human genetic diversity within and among continents^len#Genome Res#2004
0000#2004#14#1679-1685#20110400#1001.htm#1088-9051#Genome Res##
00608000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100026000760100018001020100
01500120012010200135030001400237065000900251064000500260031000300265014000800268
865000900276002000900285035001000294801001400304#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\1001.htm#S#c#206#24#article#40#24#^rND^sBastos-Rodrigues^nL#^rND^sPim
enta^nJR#^rND^sPena^nSD#The genetic structure of human populations studied throu
gh short insertion-deletion polymorphisms^len#Ann Hum Genet#20060000#2006#70#658
-665#20110400#1001.htm#0003-4800#Ann Hum Genet##
00507000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100017000970100
01700114012004700131030001100178710000200189065000900191064000500200031000200205
014000400207865000900211002000900220#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1
001.htm#S#c#207#25#article#40#25#^rND^sNievergelt^nCM#^rND^sLibiger^nO#^rND^sSch
ork^nNJ#Generalized analysis of molecular variance^len#PLoS Genet#2#20070000#200
7#3#e51#20110400#1001.htm##
00555000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100012000910100
01600103012005400119030002000173065000900193064000500202031000400207014000600211
865000900217002000900226035001000235801002000245#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\1001.htm#S#c#208#26#article#40#26#^rND^sLong^nJC#^rND^sLi^nJ#^rND^sHe
aly^nME#Human DNA sequences: more variation and less race^len#Am J Phys Anthropo
l#20090000#2009#139#23-34#20110400#1001.htm#0002-9483#Am J Phys Anthropol##
00530000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920120
07000107030001100177065000900188064000500197031000300202014000800205865000900213
002000900222035001000231801001100241#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1
001.htm#S#c#209#27#article#40#27#^rND^sWeiss^nKM#^rND^sLong^nJC#Non-Darwinian es
timation, my ancestors, my genes&#8217; ancestors^len#Genome Res#20090000#2009#1
9#703-710#20110400#1001.htm#1088-9051#Genome Res##
00528000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930120
09500109030001400204710000200218065000900220064000500229031000200234014000800236
865000900244002000900253#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#
210#28#article#40#28#^rND^sFoster^nMW#^rND^sSharp^nRR#Beyond race: towards a who
le-genome perspective on human populations and genetic variation^len#Nat Rev Gen
et#2#20040000#2004#5#790-796#20110400#1001.htm##
00473000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760120034000910300
00700125065002300132064000500155031000400160014000800164865000900172002000900181
035001000190801000700200#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#
211#29#article#40#29#^rND^sPaabo^nS#The mosaic that is our genome^len#Nature#&#8
221;20030000&#8221;#2003#421#409-412#20110400#1001.htm#0028-0836#Nature##
00458000000000229000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160016000760180069000920660
01000161062002500171065000900196064000500205865000900210002000900219#v44n4#V:\Sc
iELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#212#30#article#40#30#^rND^sGilroy^nP
#Against race - imagining political culture beyond the color line^len#Cambridge#
Harvard University Press#20000000#2000#20110400#1001.htm##
00573000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01900107012007400126030001500200065000900215064000500224031000300229014000800232
865000900240002000900249035001000258801001500268#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\1001.htm#S#c#213#31#article#40#31#^rND^sTucker^nT#^rND^sMarra^nM#^rND
^sFriedman^nJM#Massively parallel sequencing: the next big thing in genetic medi
cine^len#Am J Hum Genet#20090000#2009#85#142-154#20110400#1001.htm#0002-9297#Am 
J Hum Genet##
00463000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760120036000930300
00700129065000900136064000500145031000400150014000800154865000900162002000900171
035001000180801000700190#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#
214#32#article#40#32#^rND^sVenter^nJC#Multiple personal genomes await^len#Nature
#20100000#2010#464#676-677#20110400#1001.htm#0028-0836#Nature##
00584000000000205000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730170041000760180083001170620
13400200061002600334865000900360002000900369#v44n4#V:\SciELO\serial\bjmbr\v44n4\
markup\1001.htm#S#c#215#33#article#40#33#Genetic Engineering & Biotechnology New
s#Illumina cuts price for individual genome sequencing service by more than half
^len#http://www.genengnews.com/gen-news-highlights/illumina-cuts-price-for-indiv
idual-genome-sequencing-service-by-more-than-half/81243489#Accessed January 29, 
2011#20110400#1001.htm##
00643000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01800109010001400127010001600141010001600157810000600173012005600179030000700235
06500090024206400050025103100040025601400100026086500090027000200090027903500100
0288801000700298#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#216#34#a
rticle#40#34#^rND^sAshley^nEA#^rND^sButte^nAJ#^rND^sWheeler^nMT#^rND^sChen^nR#^r
ND^sKlein^nTE#^rND^sDewey^nFE#et al#Clinical assessment incorporating a personal
 genome^len#Lancet#20100000#2010#375#1525-1535#20110400#1001.htm#0099-5355#Lance
t##
00671000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
02000112010001500132010001700147010001700164010001300181012006900194030000700263
06500090027006400050027903100040028401400100028886500090029800200090030703500100
0316801000700326#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#217#35#a
rticle#40#35#^rND^sDurbin^nRM#^rND^sAbecasis^nGR#^rND^sAltshuler^nDL#^rND^sAuton
^nA#^rND^sBrooks^nLD#^rND^sDurbin^nRM#^rND^set^nal#A map of human genome variati
on from population-scale sequencing^len#Nature#20100000#2010#467#1061-1073#20110
400#1001.htm#0028-0836#Nature##
00442000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730120042000760300007001180650
00900125064000500134031000400139014001000143865000900153002000900162035001000171
801000700181#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#218#36#artic
le#40#36#Human genome: Genomes by the thousand^len#Nature#20100000#2010#467#1026
-1027#20110400#1001.htm#0028-0836#Nature##
00443000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760120046000930300
01100139710000200150065000900152064000500161031000200166014000300168865000900171
002000900180#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#219#37#artic
le#40#37#^rND^sMardis^nER#The $1,000 genome, the $100,000 analysis?^len#Genome M
ed#2#20100000#2010#2#84#20110400#1001.htm##
00465000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950120
03500111030001200146710000200158065000900160064000500169031000300174014000400177
865000900181002000900190#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#
220#38#article#40#38#^rND^sSalzberg^nSL#^rND^sPertea^nM#Do-it-yourself genetic t
esting^len#Genome Biol#2#20100000#2010#11#404#20110400#1001.htm##
00651000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
01400112010002000126010001900146010001700165810000600182012005700188030000700245
06500090025206400050026103100040026601400080027086500090027800200090028703500100
0296801000700306#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1001.htm#S#c#221#39#a
rticle#40#39#^rND^sManolio^nTA#^rND^sCollins^nFS#^rND^sCox^nNJ#^rND^sGoldstein^n
DB#^rND^sHindorff^nLA#^rND^sHunter^nDJ#et al#Finding the missing heritability of
 complex diseases^len#Nature#20090000#2009#461#747-753#20110400#1001.htm#0028-08
36#Nature##
00531000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920120
04900111030002000160065000900180064000500189031000300194014000800197865000900205
002000900214035001000223801002000233#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\1
001.htm#S#c#222#40#article#40#40#^rND^sBodmer^nW#^rND^sTomlinson^nI#Rare genetic
 variants and the risk of cancer^len#Curr Opin Genet Dev#20100000#2010#20#262-26
7#20110400#1001.htm#0959-437X#Curr Opin Genet Dev##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#o#1#1#article#1#201
10411#094459#445.htm#123##
02922000000000577000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120074001780100027002520100028002790100026003070100023003330100028003560100
02400384070014700408083157600555085000802131085002602139085003202165085005802197
11700060225507200030226111200090226411100130227311400090228611300170229589100240
2312002000802336#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#h#2#1#artic
le#1#sc#en#bjmbr#1#3.1#ILUS#TAB#09#BJMBR060#FAPESP#Braz J Med Biol Res#44#4#2011
0400#^f327^l331#0100-879X#20110225#Effect of neurotrophic factor, MDP, on rats&#
8217; nerve regeneration^len#^rND^1A01^nA.A.^sFornazari#^rND^1A01^nM.R.^sde Reze
nde#^rND^1A01^nR.^sMattar Jr.#^rND^1A01^nR.I.^sTaira#^rND^1A01^nG.B.^sdos Santos
#^rND^1A01^nR.G.^sPaulos#Universidade de São Paulo^iA01^1Hospital das Clínicas^2
Instituto de Ortopedia e Traumatologia^3Laboratório de Microcirurgia^cSão Paulo^
sSP^pBrasil#^len^aOur objective was to determine the immune-modulating effects o
f the neurotrophic factor N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) on media
n nerve regeneration in rats. We used male Wistar rats (120-140 days of age, wei
ghing 250-332 g) and compared the results of three different techniques of nerve
 repair: 1) epineural neurorrhaphy using sutures alone (group S - 10 rats), 2) e
pineural neurorrhaphy using sutures plus fibrin tissue adhesive (FTA; group SF -
 20 rats), and 3) sutures plus FTA, with MDP added to the FTA (group SFM - 20 ra
ts). Functional assessments using the grasp test were performed weekly for 12 we
eks to identify recovery of flexor muscle function in the fingers secondary to m
edian nerve regeneration. Histological analysis was also utilized. The total num
ber and diameter of myelinated fibers were determined in each proximal and dista
l nerve segment. Two indices, reported as percentage, were calculated from these
 parameters, namely, the regeneration index and the diameter change index. By th
e 8th week, superiority of group SFM over group S became apparent in the graspin
g test (P = 0.005). By the 12th week, rats that had received MDP were superior i
n the grasping test compared to both group S (P < 0.001) and group SF (P = 0.001
). Moreover, group SF was better in the grasping test than group S (P = 0.014). 
However, no significant differences between groups were identified by histologic
al analysis. In the present study, rats that had received MDP obtained better fu
nction, in the absence of any significant histological differences.#^dnd^i1#^tm^
len^kGrasping test^i1#^tm^len^kNeurotrophic factor^i1#^tm^len^kN-acetylmuramyl-L
-alanyl-D-isoglutamine (MDP)^i1#other#19#20100515#May 15, 2010#20110203#February
 3, 2011#S0100-879X2011007500021#445.htm##
02910000000000565000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120081001780100027002590100028002860100026003140100023003400100028003630100
02400391070014700415083157900562085000802141085002602149085003202175085005802207
11700060226507200030227111200090227411100200228311400090230311300240231200200080
2336#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#f#3#1#article#1#sc#en#b
jmbr#1#3.1#ILUS#TAB#09#BJMBR060#FAPESP#Braz J Med Biol Res#44#4#20110400#^f327^l
331#0100-879X#20110225#<b>Effect of neurotrophic factor, MDP, on rats&#8217; ner
ve regeneration</b>^len#^rND^1A01^nA.A.^sFornazari#^rND^1A01^nM.R.^sde Rezende#^
rND^1A01^nR.^sMattar Jr.#^rND^1A01^nR.I.^sTaira#^rND^1A01^nG.B.^sdos Santos#^rND
^1A01^nR.G.^sPaulos#Universidade de São Paulo^iA01^1Hospital das Clínicas^2Insti
tuto de Ortopedia e Traumatologia^3Laboratório de Microcirurgia^cSão Paulo^sSP^p
Brasil#^len^aOur objective was to determine the immune-modulating effects of the
 neurotrophic factor N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) on median ner
ve regeneration in rats. We used male Wistar rats (120-140 days of age, weighing
 250-332 g) and compared the results of three different techniques of nerve repa
ir: 1) epineural neurorrhaphy using sutures alone (group S - 10 rats), 2) epineu
ral neurorrhaphy using sutures plus fibrin tissue adhesive (FTA; group SF - 20 r
ats), and 3) sutures plus FTA, with MDP added to the FTA (group SFM - 20 rats). 
Functional assessments using the grasp test were performed weekly for 12 weeks t
o identify recovery of flexor muscle function in the fingers secondary to median
 nerve regeneration. Histological analysis was also utilized. The total number a
nd diameter of myelinated fibers were determined in each proximal and distal ner
ve segment. Two indices, reported as percentage, were calculated from these para
meters, namely, the regeneration index and the diameter change index. By the 8th
 week, superiority of group SFM over group S became apparent in the grasping tes
t (P = 0.005). By the 12th week, rats that had received MDP were superior in the
 grasping test compared to both group S (P &lt; 0.001) and group SF (P = 0.001).
 Moreover, group SF was better in the grasping test than group S (P = 0.014). Ho
wever, no significant differences between groups were identified by histological
 analysis. In the present study, rats that had received MDP obtained better func
tion, in the absence of any significant histological differences.#^dnd^i1#^tm^le
n^kGrasping test^i1#^tm^len^kNeurotrophic factor^i1#^tm^len^kN-acetylmuramyl-L-a
lanyl-D-isoglutamine (MDP)^i1#other#19#20100515#<i>May 15, 2010</i>#20110203#<i>
February 3, 2011</i>#445.htm##
03020000000000589000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762240009001860120074001950100027002690100028002960100028003240100023003520100
02800375010002400403070014900427083157600576085000802152085002602160085003202186
08500580221811700060227607200030228211200090228511100130229411400090230711300170
2316002000802333008008902341#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S
#l#4#1#article#1#^mApr.^a2011#sc#en#bjmbr#1#3.1#ilus#tab#09#BJMBR060#FAPESP#Braz
. j. med. biol. res#44#4#20110400#^f327^l331#0100-879X#20110225#Effect of neurot
rophic factor, MDP, on rats&#8217; nerve regeneration^len#^rND^1A01^nA. A^sForna
zari#^rND^1A01^nM. R^sde Rezende#^rND^1A01^nR^sMattar Júnior#^rND^1A01^nR. I^sTa
ira#^rND^1A01^nG. B^sdos Santos#^rND^1A01^nR. G^sPaulos#^iA01^1Universidade de S
ão Paulo^2Hospital das Clínicas^3Instituto de Ortopedia e Traumatologia. Laborat
ório de Microcirurgia^cSão Paulo^sSP^pBrasil#^len^aOur objective was to determin
e the immune-modulating effects of the neurotrophic factor N-acetylmuramyl-L-ala
nyl-D-isoglutamine (MDP) on median nerve regeneration in rats. We used male Wist
ar rats (120-140 days of age, weighing 250-332 g) and compared the results of th
ree different techniques of nerve repair: 1) epineural neurorrhaphy using suture
s alone (group S - 10 rats), 2) epineural neurorrhaphy using sutures plus fibrin
 tissue adhesive (FTA; group SF - 20 rats), and 3) sutures plus FTA, with MDP ad
ded to the FTA (group SFM - 20 rats). Functional assessments using the grasp tes
t were performed weekly for 12 weeks to identify recovery of flexor muscle funct
ion in the fingers secondary to median nerve regeneration. Histological analysis
 was also utilized. The total number and diameter of myelinated fibers were dete
rmined in each proximal and distal nerve segment. Two indices, reported as perce
ntage, were calculated from these parameters, namely, the regeneration index and
 the diameter change index. By the 8th week, superiority of group SFM over group
 S became apparent in the grasping test (P = 0.005). By the 12th week, rats that
 had received MDP were superior in the grasping test compared to both group S (P
 < 0.001) and group SF (P = 0.001). Moreover, group SF was better in the graspin
g test than group S (P = 0.014). However, no significant differences between gro
ups were identified by histological analysis. In the present study, rats that ha
d received MDP obtained better function, in the absence of any significant histo
logical differences.#^dnd^i1#^tm^len^kGrasping test^i1#^tm^len^kNeurotrophic fac
tor^i1#^tm^len^kN-acetylmuramyl-L-alanyl-D-isoglutamine (MDP)^i1#other#19#201005
15#May 15, 2010#20110203#February 3, 2011#445.htm#Internet^ihttp://www.scielo.br
/scielo.php?script=sci_arttext&pid=S0100-879X2011000400009##
00371000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014700070002000800217#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#5#1#article#100#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 327-331 </B></font></P>      ^cY#445.htm##
00438000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704021400070002000800284#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#6#2#article#100#<p ALIGN="LEFT"><font siz
e="5" face="Arial"><span lang="EN"><strong>Effect of neurotrophic factor, MDP, o
n rats&rsquo; </strong></span><strong><span lang="EN">nerve regeneration</span><
/strong></font></p>      ^cY#445.htm##
00803000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704057900070002000800649#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#7#3#article#100#<p ALIGN="LEFT"><font fac
e="Arial"><span lang="EN"><span lang="EN"><font face="Arial, Helvetica, sans-ser
if"><sup><span lang="EN"><font face="Arial, Helvetica, sans-serif"><b><a href="#
Correspondence"><img src="/img/revistas/bjmbr/v44n4/recor.gif" border="0"></a></
b> <a href="mailto:adrienfornazari@ig.com.br"><img src="/img/revistas/bjmbr/v44n
4/email-ca.gif" border="0"></a></font></span></sup></font></span> A.A. Fornazari
, M.R. de Rezende, R. Mattar Jr., R.I. Taira, </span></font><font face="Arial"><
span lang="EN">G.B. dos Santos and R.G. Paulos</span></font></p>      ^cY#445.ht
m##
00521000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704029700070002000800367#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#8#4#article#100#<p ALIGN="LEFT"><font fac
e="Arial"><span lang="EN">Laborat&oacute;rio de Microcirurgia, Instituto de Orto
pedia e Traumatologia, Hospital das Cl&iacute;nicas, </span></font><font face="A
rial"><span lang="EN">Universidade de S&atilde;o Paulo, S&atilde;o Paulo, SP, Br
asil</span></font></p>      ^cY#445.htm##
00414000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704019000070002000800260#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#9#5#article#100#<P> <font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#445.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#10#6#article#100#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#445.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#11#7#article#100#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#445.htm##
00397000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704017200071002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#12#8#article#100#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#445.htm##
00406000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018100071002000800252#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#13#9#article#100#<BR>   <A HREF="#Discuss
ion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#445
.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#14#10#article#100#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#445.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#15#11#article#100#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#445.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#16#12#article#100#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#445.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#17#13#article#100#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#445.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#18#14#article#100#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#445.htm##
01949000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704172300072002000801795#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#19#15#article#100#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">Our objective was to determin
e the immune-modulating effects of the neurotrophic factor N-acetylmuramyl-L-ala
nyl-D-isoglutamine (MDP) on median nerve regeneration in rats. We used male Wist
ar rats (120-140 days of age, weighing 250-332 g) and compared the results of th
ree different techniques of nerve repair: 1) epineural neurorrhaphy using suture
s alone (group S - 10 rats), 2) epineural neurorrhaphy using sutures plus fibrin
 tissue adhesive (FTA; group SF - 20 rats), and 3) sutures plus FTA, with MDP ad
ded to the FTA (group SFM - 20 rats). Functional assessments using the grasp tes
t were performed weekly for 12 weeks to identify recovery of flexor muscle funct
ion in the fingers secondary to median nerve regeneration. Histological analysis
 was also utilized. The total number and diameter of myelinated fibers were dete
rmined in each proximal and distal nerve segment. Two indices, reported as perce
ntage, were calculated from these parameters, namely, the regeneration index and
 the diameter change index. By the 8th week, superiority</font> <font FACE="Aria
l, Helvetica, sans-serif">of group SFM over group S became apparent in the grasp
ing test (P = 0.005). By the 12th week, rats that had received MDP were superior
 in the grasping test compared to both group S (P &lt; 0.001) and group SF (P = 
0.001). Moreover, group SF was better in the grasping test than group S (P = 0.0
14). However, no significant differences between groups were identified by histo
logical analysis. In the present study, rats that had received MDP obtained bett
er function, in the absence of any significant histological differences.</font><
/span></p>      ^cY#445.htm##
00421000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019500072002000800267#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#20#16#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Key words: Grasping test; Neurotrophic factor; N-ace
tylmuramyl-L-alanyl-D-isoglutamine (MDP)</span></font></p>  <HR ALIGN=LEFT SIZE=
2>      ^cY#445.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#21#17#article#100#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#445.htm##
01456000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704123000072002000801302#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#22#18#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">When peripheral nerve is damaged it undergoes the de
generation process known as Wallerian degeneration. After nerve injury, a local 
inflammatory reaction occurs that involves macrophages. These cells, in turn, ar
e responsible for many of the fundamental events that occur during the regenerat
ive process. Macrophages play a crucial role in processes of Wallerian degenerat
ion and subsequent regeneration of peripheral nerves (1). The use of neurotrophi
c factors has been of special interest to researchers investigating the best way
s to stimulate nerve regeneration. N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP)
 is an immuno-adjuvant that promotes increased macrophage activity (2). When inj
ected into the crushed sciatic nerve, MDP activates macrophages and promotes rec
overy of walking locomotion in rats (3). Some results indicate that locally appl
ied MDP stimulates peripheral nerve regeneration in rats (4). Based on the feasi
bility of using fibrin glue mixed with the neurotrophic factor, we decided to st
udy the immunomodulatory effect of MDP on the process of peripheral nerve regene
ration in a rat experimental model.</span></font></p>  <HR ALIGN=LEFT SIZE=2>   
   ^cY#445.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#23#19#article#100#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#445.htm##
00319000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009300072002000800165#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#24#20#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Animals</span></font></b></p>      ^cY#445.htm##
01008000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704078200072002000800854#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#25#21#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Healthy male Wistar rats between 120 and 140 days of
 age and weighing 250-332 g were used, all without motor deficits. Rats were mai
ntained in cages in groups of 5. The cages were maintained in an acclimatized at
mosphere under hygienic conditions, with food and water provided <i>ad libitum</
i>. The study was approved by the Ethics Committee of Departamento de Ortopedia 
e Traumatologia, Hospital das Cl&iacute;nicas, Universidade de S&atilde;o Paulo 
(USP), Brazil, and was conducted according to the ethical guidelines for animal 
experimentation established by the Brazilian School of Animal Experimentation an
d by the Institute of Laboratory Animal Resources of the U.S. National Academy o
f Sciences.</span></font></p>      ^cY#445.htm##
00318000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009200072002000800164#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#26#22#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Groups</span></font></b></p>      ^cY#445.htm##
00705000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704047900072002000800551#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#27#23#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Rats were anesthetized intraperitoneally (<i>ip</i>)
 with 30 to 40 mg/kg pentobarbital. An incision was made in the prepped and ster
ilized axillary area of the right upper extremity, and the median nerve was iden
tified and dissected. The nerve was transected with micro-scissors 5 mm proximal
 to the medial epicondyle of the humerus and the lesion was immediately repaired
 always by the same surgeon.</span></font></p>      ^cY#445.htm##
01998000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704177200072002000801844#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#28#24#article#100#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">Three groups of rats were use
d: group S (N = 10) was subjected to end-to-end epineural neurorrhaphy without t
ension, using four simple 10-0 mononylon sutures. Group SF (N = 20) was subjecte
d to epineural neurorrhaphy without tension, using two simple sutures plus 0.10 
mL fibrin tissue adhesive (FTA; Tissucol<sup>&reg;</sup>, Immuno AG, Austria). G
roup SFM (N = 20) was subjected to the same procedure as group SF, except that 0
.1 mL neurotrophic factor MDP (Sigma Chemical Co., USA) was added to the FTA. MD
P was maintained at 15&deg;C and diluted in 1 mL saline to a 2-mM concentration.
 After adding an equal volume of FTA, the final concentration of MDP was 1 mM. S
urgery was performed under a light microscope at 12X magnification. After nerve 
repair, the surgical wound was closed with 3.0 mononylon sutures. Rats were excl
uded from analysis for the following reasons: perioperative or post-operative de
ath of the animal, tissue loss in the injured area, autophagy or other significa
nt mutilation in an animal, deep infection at the site of the lesion, and postop
erative loss of more than 10% of preoperative weight. For the three groups, 50 r
ats were used. Six rats were excluded from the SFM group (N = 20). Two weeks pos
toperatively, 3 rats exhibited autophagy in the area of the surgical wound and s
ignificant motor alteration. During the 5th postoperative week, one rat died of 
an idiopathic cause. Two rats failed to exhibit any measurable flexor strength d
uring the grasping test over the entire 12-week postoperative period and, once e
uthanized and examined, both dehiscence of the sutures and tissue loss in the ar
ea of the median nerve lesion were noted.</font></span></p>      ^cY#445.htm##
00331000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010500072002000800177#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#29#25#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Functional analysis</span></font></b></p>      ^c
Y#445.htm##
01200000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704097400072002000801046#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#30#26#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">All rats were submitted to a grasping test for funct
ional evaluation, as classically described (5). For the test, each rat was eleva
ted by the tail and stimulated to grab a metal hook that comprised the apex of a
 metal pyramidal frame. The total frame weighed 700 g and rested on a convention
al digital scale. The left upper extremity of the rat had been previously immobi
lized with adhesive tape. To examine finger flexion, we observed the rat graspin
g the hook while being held. At the same time, a second observer filmed the proc
edure and recorded the weight registered on the scale at the exact moment that t
he rat released the hook. The difference between the weight of the metal frame (
700 g) and the weight registered by the second observer was used to estimate the
 force generated by the muscle flexors of the fingers. When there was flexion of
 the palm or wrist, the data were excluded.</span></font></p>      ^cY#445.htm##
00878000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704065200072002000800724#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#31#27#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Rats were submitted to the grasp test both preoperat
ively and postoperatively. After repair of the nerve injury, each rat underwent 
the grasping test three times every 2 weeks through the 12th week, with the aver
age of each three grouped tests used to represent the mean flexor strength at ea
ch time. These values were compared between the three groups to determine the ra
te and degree of functional recovery. Rats were weighed before each grasp test. 
At the end of the 12th postoperative week, rats were sacrificed by <i>ip</i> inj
ection of a lethal dose of pentobarbital.</span></font></p>      ^cY#445.htm##
00333000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010700072002000800179#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#32#28#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Histological analysis</span></font></b></p>      
^cY#445.htm##
02000000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704177400072002000801846#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#33#29#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Ten rats were chosen at random from each group. The 
nerve segments proximal and distal to the repair were dissected. A 2-cm segment 
of the nerve including the repair region was removed. Two 4-mm long segments wer
e obtained, 4 mm proximal and 4 mm distal to the repair site, and fixed in a sol
ution of 2% osmium tetroxide. Transverse sectioning was performed and 1-&mu;m se
ctions were obtained and stained with 1% toluidine blue. For histological analys
is, each section was photographed using a digital camera (Coolpix; Nikon, Japan)
 coupled to a light microscope, the objective of which had a magnification of 40
 times. One random field of each proximal and distal segment was photographed. E
ach picture captured an area of 36,000 &micro;m<sup>2</sup>. The pictures from t
he proximal and distal segment of each nerve were analyzed using the Sigma Scan 
Pro 5.0 software (SPSS Inc., USA). We obtained the total number and diameter of 
myelinated fibers. Two indices, expressed as a percentage, were calculated from 
these parameters, namely, the regeneration index and the diameter change index. 
The regeneration index was calculated by dividing the total number of regenerate
d axons in the distal segment by the total number of regenerated axons in the pr
oximal segment, resulting in the percentage of axons that crossed the repair sit
e. The diameter change index was calculated by dividing the mean diameter of reg
enerated axons in the distal segment by the mean diameter of regenerated axons i
n the proximal segment (6). These indexes were compared to the results obtained 
in the functional evaluations to determine the extent to which functional recove
ry reflected the histological findings (6).</span></font></p>      ^cY#445.htm##
00332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010600072002000800178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#34#30#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Statistical analysis</span></font></b></p>      ^
cY#445.htm##
00638000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704041200072002000800484#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#35#31#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Data are reported as means &plusmn; standard deviati
on. For the functional test, data were analyzed by two-way repeated measures ana
lysis of variance (ANOVA) followed by the Tukey <i>post hoc</i> test<i>.</i> For
 histological analysis, one-way ANOVA was used with the level of significance se
t at P &lt; 0.05.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#445.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#36#32#article#100#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#445.htm##
00331000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010500072002000800177#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#37#33#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Functional analysis</span></font></b></p>      ^c
Y#445.htm##
00443000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021700072002000800289#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#38#34#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Weight gain was observed in all rats throughout the 
12 weeks, and therefore it was not necessary to exclude any animal due to weight
 loss.</span></font></p>      ^cY#445.htm##
01222000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704099600072002000801068#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#39#35#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a href="#Fig1">Figure 1</a> illustrates the median 
nerve profiles of the three study groups obtained at the time of the first evalu
ation (t0) and at the end of the 6th, 8th, 10th, and 12th weeks after surgery. A
fter surgery, all groups ultimately displayed evidence of increasing median nerv
e function over time. Statistically significant differences were apparent, howev
er, at week 8 (P = 0.019) and week 12 (P &lt; 0.001). <i>Post hoc</i> analysis o
f week 8 data revealed greater grasping strength in group SFM than in group S (P
 = 0.05). At week 12, the grasping strength of group SFM was greater than that o
f both group S (P &lt; 0.001) and group SF (P = 0.001) and, at the same time, th
e strength of group SF was greater than that of group S (P = 0.014). At week 12,
 groups SF and S failed to achieve their respective average values estimated bef
ore surgery (t0). The SFM group showed total functional recovery.</span></font><
/p>      ^cY#445.htm##
00357000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013100072002000800203#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#40#36#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Histological analysis for axonal regeneration</sp
an></font></b></p>      ^cY#445.htm##
00764000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704053800072002000800610#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#41#37#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a href="#Tab1">Table 1</a> presents descriptive sta
tistics for the three study groups. No difference was observed between the param
eters evaluated. The requirement for similar variances between groups was met, j
ustifying the use of ANOVA.</span></font></p>  <HR ALIGN=LEFT SIZE=2>  <table  b
order="0">    <tr align="left" valign="top">      <td><a href="/img/revistas/bjm
br/v44n4/html/445i01.htm"><img src="/img/revistas/bjmbr/v44n4/445i01peq.jpg" bor
der="2"></a></td>      <td>    ^cY#445.htm##
01000000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704077400072002000800846#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#42#38#article#100#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. 
Median nerve profiles during the grasping test in the three study groups. Data a
re reported as means &plusmn; standard deviation. Group S = epineural neurorrhap
hy; group SF = epineural neurorrhaphy plus tissue fibrin adhesive; group SFM = e
pineural neurorrhaphy plus tissue fibrin adhesive and neurotrophic factor. *At w
eek 8, grasping strength was greater in group SFM than in group S (P = 0.05). *A
t week 12, grasping strength was greater in group SFM than in both group S (P &l
t; 0.001) and group SF (P = 0.001). Data were analyzed by two-way repeated measu
res ANOVA followed by the <i>post hoc</i> Tukey test.</font></span></p>      </t
d>    </tr>  </table>      ^cY#445.htm##
00773000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704054700072002000800619#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#43#39#article#100#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (93 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/445t01.htm"><img src="/img/
revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td><span lang="EN"><f
ont face="Arial"><span lang="EN"><a name="Tab1"></a>Table 1. Results of histomor
phometric evaluation after statistical comparison between the groups.</span></fo
nt></span></td>    </tr>  </table>      ^cY#445.htm##
00344000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011800072002000800190#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#44#40#article#100#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (175 K JPG file)]</font
></P>      ^cY#445.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#45#41#article#100#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#445.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#46#42#article#100#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#445.htm##
01170000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704094400072002000801016#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#47#43#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Group SFM was functionally superior to the other two
 groups at weeks 8 and 12 and showed total functional recovery over 12 weeks, al
though histological analysis failed to reveal any significant difference between
 the three groups. Fukuyama et al. (3) compared intrafascicular injection of 50 
&micro;L Ringer solution (Lactec<sup>&reg;</sup> injection, Ohtsuka, Japan) with
 or without MDP at 2 mg/mL into the crushed sciatic nerve of rats. The injection
 was done with a syringe attached with an ultrafine needle (29G) slightly distal
 to the crushed site. In the MDP group, they reported an increase in the axonal 
elongation measured by the pinch test 5 days after the crush operation (P &lt; 0
.05) and increased functional recovery measured by the sciatic nerve functional 
index in walking track analysis, 3 weeks after the operation and injection (P &l
t; 0.01) (3).</span></font></p>      ^cY#445.htm##
01369000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704114300072002000801215#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#48#44#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">In our study, histological analysis failed to confir
m any immunoadjuvant activity of MDP. The discrepancy between the results of the
 functional and histological analysis might be explained by the grasping test be
ing able to assess viable nerve fibers among those still regenerating. Moreover,
 regenerating axons might undergo misdirected growth leading to aberrant muscle 
reinnervation (7,8) and the presence of polyneuronally innervated muscle fibers 
may reduce the efficiency of peripheral nerve regeneration (9). The group with t
he worst results was the suture alone group (S), especially compared to the MDP-
treated group (SFM) at weeks 8 and 12. As some investigators have speculated, ne
urorrhaphy could hinder nerve regeneration in several ways: by escalating the in
flammatory response at the repair point, by causing deviations in the path of th
ose axons otherwise aiming towards the distal segment of the nerve (10), by temp
orarily reducing blood flow through the microcirculation (11), and via the forma
tion of mechanical obstructions such as scar tissue.</span></font></p>      ^cY#
445.htm##
03210000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704298400072002000803056#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#49#45#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The use of neurotrophic substances has been of speci
al interest to those investigating ways by which to optimize nerve regeneration.
 MDP is a minimum structural unit responsible for the immunoadjuvant activities 
of bacterial cell wall peptidoglycans in a variety of species (4). It is known t
hat MDP can be considered a functional lipopolysaccharide (LPS) analogue (12). M
DP is an immuno-adjuvant that promotes increased activity among microglial phago
cytes, Schwann cells and macrophages (2). Wallerian degeneration involves cellul
ar and molecular activities coordinated by a complex network of cytokines that a
lso contribute to macrophage recruitment and activation and, consequently, to ma
crophage-dependent functions like myelin removal by phagocytosis (13). A decreas
ed response of these cells in injured nerves has been associated with decreased 
axonal regeneration (14). However, an intervention can accelerate the regenerati
ve process by introducing inflammatory cells or an enhanced inflammatory respons
e (14). The macrophages rapidly remove myelin debris that contain neurite growth
 inhibitors like myelin-associated glycoprotein. They release cytokines such as 
interleukin -1 (IL-1) and macrophage inflammatory protein-1 (MIP-1), which proba
bly stimulate Schwann cells and other types in the nerves (3) and growth factors
 that facilitate axonal regeneration (14). One of the activation mechanisms of m
acrophages occurs through tumoral necrosis factor-alpha (TNF-&alpha;), which is 
one of the first cytokines synthesized by Schwann cells during the Wallerian deg
eneration process (15). TNF-&alpha; directly stimulates the macrophages (16) and
 induces the production of granulocyte-macrophage colony-stimulating factor (GM-
CSF) by fibroblasts, promoting macrophage activation. MDP is capable of inducing
 the formation of several cytokines like TNF-&alpha; or stimulates cells to prod
uce them (17), indirectly contributing to macrophage activation. Spinal cord cel
ls were induced to proliferate temporarily by the peripheral administration of c
ertain stimulators of the innate immune system, including MDP (18). Toll-like re
ceptor (TLR) and NOD2 ligands are key receptors that allow mammals to detect the
 presence of infection by recognizing specific microorganism-derived biomolecule
s, the so-called pathogen-association molecular patterns (PAMPs). MDP is an NOD2
 ligand. Recognition of PAMPs through TLR and NOD2 receptors appears to link the
 inflammatory and regenerative process. However, other studies have shown that m
yelin fraction-stimulated macrophages release neurotrophic factors that increase
 the survival and neurite regeneration of adult dorsal root ganglion neurons in 
culture (19). Adding MDP or LPS to the culture medium did not enhance neurotroph
ic secretion by macrophages. These observations suggest that myelin may be a spe
cific activator of macrophages in nerve regeneration.</span></font></p>      ^cY
#445.htm##
00796000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704057000072002000800642#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#50#46#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">In summary, using a transected median nerve rat mode
l, we demonstrated enhanced functional recovery twice along the postoperative pe
riod of 12 weeks in rats treated with the combination of suturing, fibrin tissue
 adhesive and the neurotrophic factor MDP compared with rats treated either with
 neurorrhaphy alone or with sutures plus FTA without MDP. Histological analysis,
 however, did not identify any difference by which to explain the enhanced funct
ional recovery.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#445.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#51#47#article#100#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#445.htm##
00399000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704015900074002000800233#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#52#48#article#100#1#<p ALIGN=
"LEFT"><font face="Arial"><span lang="EN">1. Bruck W. The role of macrophages in
 Wallerian degeneration. <i>Brain Pathol</i> 1997; 7: 741-752.    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#53#49#article#100#</span></font></p>     
 ^cY#445.htm##
00468000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704022800074002000800302#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#54#50#article#100#2#<p align=
"LEFT"><font face="Arial"><span lang="EN">2. Parant MA, Parant FJ, Le Contel C, 
Lefrancier P, Chedid L. MDP derivatives and resistance to bacterial infections i
n mice. <i>Adv Exp Med Biol</i> 1992; 319: 175-184.    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#55#51#article#100#</span></font></p>     
 ^cY#445.htm##
00525000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704028500074002000800359#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#56#52#article#100#3#<p align=
"LEFT"><font face="Arial"><span lang="EN">3. Fukuyama R, Takeda H, Fushiki S, Ya
mamoto T. Muramyl dipeptide injected into crushed sciatic nerve, activates macro
phages and promotes recovery of walking locomotion in rats. <i>Restor Neurol Neu
rosci</i> 1998; 13: 213-219.    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#57#53#article#100#</span></font></p>     
 ^cY#445.htm##
00590000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704035000074002000800424#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#58#54#article#100#4#<p align=
"LEFT"><font face="Arial"><span lang="EN">4. Inoe AP, Pereira FC, Stopiglia AJ, 
Da-Silva CF. Pharmacological immunomodulation enhances peripheral nerve regenera
tion. <i>Pesq Vet Bras</i> 2007; 27: 363-369 (<a target="_blank" href="http://ww
w.scielo.br/pdf/pvb/v27n9/v27n9a02.pdf">http://www.scielo.br/pdf/pvb/v27n9/v27n9
a02.pdf</a>).    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#59#55#article#100#</span></font></p>     
 ^cY#445.htm##
00497000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704025700074002000800331#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#60#56#article#100#5#<p align=
"LEFT"><font face="Arial"><span lang="EN">5. Bertelli JA, Mira JC. The grasping 
test: a simple behavioral method for objective quantitative assessment of periph
eral nerve regeneration in the rat. <i>J Neurosci Methods</i> 1995; 58: 151-155.
    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#61#57#article#100#</span></font></p>     
 ^cY#445.htm##
00571000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704033100074002000800405#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#62#58#article#100#6#<p align=
"LEFT"><font face="Arial"><span lang="EN">6. Martins RS, Siqueira MG, Da Silva C
F, Plese JP. Overall assessment of regeneration in peripheral nerve lesion repai
r using fibrin glue, suture, or a combination of the 2 techniques in a rat model
. Which is the ideal choice? <i>Surg Neurol</i> 2005; 64 (Suppl 1): S1-S6.    ^c
Y#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#63#59#article#100#</span></font></p>     
 ^cY#445.htm##
00482000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024200074002000800316#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#64#60#article#100#7#<p align=
"LEFT"><font face="Arial"><span lang="EN">7. Dellon AL, Mackinnon SE. Sciatic ne
rve regeneration in the rat. Validity of walking track assessment in the presenc
e of chronic contractures. <i>Microsurgery</i> 1989; 10: 220-225.    ^cY#445.htm
##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#65#61#article#100#</span></font></p>     
 ^cY#445.htm##
00489000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024900074002000800323#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#66#62#article#100#8#<p align=
"LEFT"><font face="Arial"><span lang="EN">8. Bodine-Fowler SC, Meyer RS, Moskovi
tz A, Abrams R, Botte MJ. Inaccurate projection of rat soleus motoneurons: a com
parison of nerve repair techniques. <i>Muscle Nerve</i> 1997; 20: 29-37.    ^cY#
445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#67#63#article#100#</span></font></p>     
 ^cY#445.htm##
00474000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704023400074002000800308#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#68#64#article#100#9#<p align=
"LEFT"><font face="Arial"><span lang="EN">9. Benfrech E, Alnot JY, Henin D. [An 
experimental study of nerve sutures and grafts of the sciatic nerve in the rat u
sing fibrin glue]. <i>Ann Chir Main</i> 1989; 8: 296-299.    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#69#65#article#100#</span></font></p>     
 ^cY#445.htm##
00443000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704020200075002000800277#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#70#66#article#100#10#<p align
="LEFT"><font face="Arial"><span lang="EN">10. Smahel J, Meyer VE, Bachem U. Glu
eing of peripheral nerves with fibrin: experimental studies. <i>J Reconstr Micro
surg</i> 1987; 3: 211-220.    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#71#67#article#100#</span></font></p>     
 ^cY#445.htm##
00491000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025000075002000800325#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#72#68#article#100#11#<p align
="LEFT"><font face="Arial"><span lang="EN">11. Moy OJ, Peimer CA, Koniuch MP, Ho
ward C, Zielezny Katikaneni PR. Fibrin seal adhesive versus nonabsorbable micros
uture in peripheral nerve repair. <i>J Hand Surg Am</i> 1988; 13: 273-278.    ^c
Y#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#73#69#article#100#</span></font></p>     
 ^cY#445.htm##
00437000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704019600075002000800271#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#74#70#article#100#12#<p align
="LEFT"><font face="Arial"><span lang="EN">12. Hoffmann JA, Kafatos FC, Janeway 
CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. <i>Science</i> 1
999; 284: 1313-1318.    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#75#71#article#100#</span></font></p>     
 ^cY#445.htm##
00419000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704017800075002000800253#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#76#72#article#100#13#<p align
="LEFT"><font face="Arial"><span lang="EN">13. Ramon y Cajal S. <i>Degeneration 
and regeneration of the nervous system</i>. London: Oxford University Press; 192
8.    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#77#73#article#100#</span></font></p>     
 ^cY#445.htm##
00472000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704023100075002000800306#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#78#74#article#100#14#<p align
="LEFT"><font face="Arial"><span lang="EN">14. Kiefer R, Kieseier BC, Stoll G, H
artung HP. The role of macrophages in immune-mediated damage to the peripheral n
ervous system. <i>Prog Neurobiol</i> 2001; 64: 109-127.    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#79#75#article#100#</span></font></p>     
 ^cY#445.htm##
00499000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025800075002000800333#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#80#76#article#100#15#<p align
="LEFT"><font face="Arial"><span lang="EN">15. Shamash S, Reichert F, Rotshenker
 S. The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha,
 interleukin-1alpha, and interleukin-1beta. <i>J Neurosci</i> 2002; 22: 3052-306
0.    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#81#77#article#100#</span></font></p>     
 ^cY#445.htm##
00430000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704018900075002000800264#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#82#78#article#100#16#<p align
="LEFT"><font face="Arial"><span lang="EN">16. Moonis M, Ahmad I, Bachhawat BK. 
Macrophages in host defence - an overview. <i>Indian J Biochem Biophys</i> 1992;
 29: 115-122.    ^cY#445.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#83#79#article#100#</span></font></p>     
 ^cY#445.htm##
00481000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704024000075002000800315#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#84#80#article#100#17#<p align
="LEFT"><font face="Arial"><span lang="EN">17. Wolfert MA, Murray TF, Boons GJ, 
Moore JN. The origin of the synergistic effect of muramyl dipeptide with endotox
in and peptidoglycan. <i>J Biol Chem</i> 2002; 277: 39179-39186.    ^cY#445.htm#
#
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#85#81#article#100#</span></font></p>     
 ^cY#445.htm##
00482000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704024100075002000800316#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#86#82#article#100#18#<p align
="LEFT"><font face="Arial"><span lang="EN">18. Su Y, Zhang Z, Trautmann K, Xu S,
 Schluesener HJ. TLR and NOD2 ligands induce cell proliferation in the rat intac
t spinal cord. <i>J Neuropathol Exp Neurol</i> 2005; 64: 991-997.    ^cY#445.htm
##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#87#83#article#100#</span></font></p>     
 ^cY#445.htm##
00480000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704023900075002000800314#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#p#88#84#article#100#19#<p align
="LEFT"><font face="Arial"><span lang="EN">19. Hikawa N, Takenaka T. Myelin-stim
ulated macrophages release neurotrophic factors for adult dorsal root ganglion n
eurons in culture. <i>Cell Mol Neurobiol</i> 1996; 16: 517-528.    ^cY#445.htm##
00278000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704005200072002000800124#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#89#85#article#100#</span></font></p>  <HR
 ALIGN=LEFT SIZE=2>      ^cY#445.htm##
00561000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033500072002000800407#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#90#86#article#100#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE=4
><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, san
s-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=
BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#445.htm#
#
00595000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704036900072002000800441#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#91#87#article#100#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">Research supported by FAPESP.
</font> <font FACE="Arial, Helvetica, sans-serif">The neurotrophic factor MDP wa
s supplied by the Department of Cellular Biology and Development, Institute of B
iomedical Sciences, USP, S&atilde;o Paulo, SP, Brazil.</font></span></p>  <HR AL
IGN=LEFT SIZE=2>      ^cY#445.htm##
00562000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033600072002000800408#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#92#88#article#100#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, Helv
etica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#445.htm
##
00836000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704061000072002000800682#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#93#89#article#100#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/rec
or.gif" border="0"></a> Address for correspondence:</b></font><span lang="EN"><f
ont face="Arial, Helvetica, sans-serif"> </font></span><span lang="EN"><font fac
e="Arial, Helvetica, sans-serif"> A.A. Fornazari, Laborat&oacute;rio de Microcir
urgia, Instituto de Ortopedia e Traumatologia, HC, USP, Rua Ov&iacute;dio Pires 
de Campos, 333, 05403-010 S&atilde;o Paulo, SP, Brasil. Fax: +55-11-3067-7000. E
-mail: <a href="mailto:adrienfornazari@ig.com.br">adrienfornazari@ig.com.br</a><
/font></span></p>      ^cY#445.htm##
00506000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704028000072002000800352#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#94#90#article#100#<p><font face="Arial, H
elvetica, sans-serif"><i><span lang="EN">Received May 15, 2010. Accepted Februar
y 3, 2011. </span><font face="Arial"><span lang="EN">Available online February 2
5, 2011. Published April 11, 2011.</span></font></i></font></p>  <HR ALIGN=LEFT 
SIZE=2>      ^cY#445.htm##
00258000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003200072002000800104#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#95#91#article#100#<div align="center">   
     ^cY#445.htm##
00424000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019800072002000800270#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#96#92#article#100#<p><font color="#000000
" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilian 
Journal of Medical and Biological Research is partially financed by</font></em><
strong>    ^cY#445.htm##
00250000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002400072002000800096#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#97#93#article#100#<br>                ^cY
#445.htm##
00324000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009800072002000800170#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#98#94#article#100#<br>    </strong></font
></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#445.h
tm##
00382000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704015600072002000800228#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#99#95#article#100#<div align="center"><a 
target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4/c
npq.jpg" border="0"></a></div></td>      <td>    ^cY#445.htm##
00385000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704015800073002000800231#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#100#96#article#100#<div align="center"><a
 target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v44
n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#445.htm##
00389000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704016200073002000800235#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#101#97#article#100#<div align="center"><a
 target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/v
44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#445.htm##
00400000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704017300073002000800246#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#102#98#article#100#<div align="center"><a
 target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/re
vistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#445.htm##
00391000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704016400073002000800237#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#103#99#article#100#<div align="center"><a
 target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#445.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\445.htm#S#p#104#100#article#100#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#445.htm##
00485000000000265000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730120054000880300
01300142065000900155064000500164031000200169014000800171865000900179002000800188
035001000196801001300206#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#c#1
05#1#article#19#1#^rND^sBruck^nW#The role of macrophages in Wallerian degenerati
on^len#Brain Pathol#19970000#1997#7#741-752#20110400#445.htm#1015-6305#Brain Pat
hol##
00630000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100017000900100
01900107010002000126010001600146012006700162030001700229065000900246064000500255
031000400260014000800264865000900272002000800281035001000289801001700299#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#c#106#2#article#19#2#^rND^sParant^n
MA#^rND^sParant^nFJ#^rND^sLe^nContel C#^rND^sLefrancier^nP#^rND^sChedid^nL#MDP d
erivatives and resistance to bacterial infections in mice^len#Adv Exp Med Biol#1
9920000#1992#319#175-184#20110400#445.htm#0065-2598#Adv Exp Med Biol##
00632000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100016000910100
01700107010001800124012013300142030002300275710000200298065000900300064000500309
031000300314014000800317865000900325002000800334#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\445.htm#S#c#107#3#article#19#3#^rND^sFukuyama^nR#^rND^sTakeda^nH#^rND
^sFushiki^nS#^rND^sYamamoto^nT#Muramyl dipeptide injected into crushed sciatic n
erve, activates macrophages and promotes recovery of walking locomotion in rats^
len#Restor Neurol Neurosci#2#19980000#1998#13#213-219#20110400#445.htm##
00629000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100018000880100
02000106010001900126012007600145030001400221710000200235065000900237064000500246
031000300251014000800254061004800262865000900310002000800319#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\445.htm#S#c#108#4#article#19#4#^rND^sInoe^nAP#^rND^sPerei
ra^nFC#^rND^sStopiglia^nAJ#^rND^sDa-Silva^nCF#Pharmacological immunomodulation e
nhances peripheral nerve regeneration^len#Pesq Vet Bras#2#20070000#2007#27#363-3
69#http://www.scielo.br/pdf/pvb/v27n9/v27n9a02.pdf#20110400#445.htm##
00607000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100015000920120
13200107030001900239065000900258064000500267031000300272014000800275865000900283
002000800292035001000300801001900310#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\4
45.htm#S#c#109#5#article#19#5#^rND^sBertelli^nJA#^rND^sMira^nJC#The grasping tes
t: a simple behavioral method for objective quantitative assessment of periphera
l nerve regeneration in the rat^len#J Neurosci Methods#19950000#1995#58#151-155#
20110400#445.htm#0165-0270#J Neurosci Methods##
00717000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100019000910100
01900110010001600129012018000145030001200325065000900337064000500346031000300351
032000400354014000600358865000900364002000800373035001000381801001200391#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#c#110#6#article#19#6#^rND^sMartins^
nRS#^rND^sSiqueira^nMG#^rND^sDa^nSilva CF#^rND^sPlese^nJP#Overall assessment of 
regeneration in peripheral nerve lesion repair using fibrin glue, suture, or a c
ombination of the 2 techniques in a rat model: Which is the ideal choice?^len#Su
rg Neurol#20050000#2005#64#^s1#S1-S6#20110400#445.htm#0090-3019#Surg Neurol##
00586000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100020000900120
12000110030001300230065000900243064000500252031000300257014000800260865000900268
002000800277035001000285801001300295#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\4
45.htm#S#c#111#7#article#19#7#^rND^sDellon^nAL#^rND^sMackinnon^nSE#Sciatic nerve
 regeneration in the rat: Validity of walking track assessment in the presence o
f chronic contractures^len#Microsurgery#19890000#1989#10#220-225#20110400#445.ht
m#0738-1085#Microsurgery##
00647000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100024000730100016000970100
01900113010001600132010001600148012009300164030001300257065000900270064000500279
031000300284014000600287865000900293002000800302035001000310801001300320#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#c#112#8#article#19#8#^rND^sBodine-F
owler^nSC#^rND^sMeyer^nRS#^rND^sMoskovitz^nA#^rND^sAbrams^nR#^rND^sBotte^nMJ#Ina
ccurate projection of rat soleus motoneurons: a comparison of nerve repair techn
iques^len#Muscle Nerve#19970000#1997#20#29-37#20110400#445.htm#0148-639X#Muscle 
nerve##
00597000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100016000910100
01500107012010600122030001400228065000900242064000500251031000200256014000800258
865000900266002000800275035001000283801001400293#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\445.htm#S#c#113#9#article#19#9#^rND^sBenfrech^nE#^rND^sAlnot^nJY#^rND
^sHenin^nD#[An experimental study of nerve sutures and grafts of the sciatic ner
ve in the rat using fibrin glue]^len#Ann Chir Main#19890000#1989#8#296-299#20110
400#445.htm#0753-9053#Ann Chir Main##
00573000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100016000910100
01600107012006700123030002100190065000900211064000500220031000200225014000800227
865000900235002000800244035001000252801002100262#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\445.htm#S#c#114#10#article#19#10#^rND^sSmahel^nJ#^rND^sMeyer^nVE#^rND
^sBachem^nU#Glueing of peripheral nerves with fibrin: experimental studies^len#J
 Reconstr Microsurg#19870000#1987#3#211-220#20110400#445.htm#0743-684X#J Reconst
r Microsurg##
00616000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100017000890100
01800106010001600124010003000140012008500170030001500255710000200270065000900272
064000500281031000300286014000800289865000900297002000800306#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\445.htm#S#c#115#11#article#19#11#^rND^sMoy^nOJ#^rND^sPeim
er^nCA#^rND^sKoniuch^nMP#^rND^sHoward^nC#^rND^sZielezny^nKatikaneni PR#Fibrin se
al adhesive versus nonabsorbable microsuture in peripheral nerve repair^len#J Ha
nd Surg Am#2#19880000#1988#13#273-278#20110400#445.htm##
00572000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100018000940100
01800112010002000130012004900150030000800199065000900207064000500216031000400221
014001000225865000900235002000800244035001000252801000800262#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\445.htm#S#c#116#12#article#19#12#^rND^sHoffmann^nJA#^rND^
sKafatos^nFC#^rND^sJaneway^nCA#^rND^sEzekowitz^nRA#Phylogenetic perspectives in 
innate immunity^len#Science#19990000#1999#284#1313-1318#20110400#445.htm#0036-80
75#Science##
00446000000000229000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720160023000750180056000980660
00700154062002400161065000900185064000500194865000900199002000800208#v44n4#V:\Sc
iELO\serial\bjmbr\v44n4\markup\445.htm#S#c#117#13#article#19#13#^rND^nRamon^sy C
ajal S#Degeneration and regeneration of the nervous system^len#London#Oxford Uni
versity Press#19280000#1928#20110400#445.htm##
00614000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910100
01500110010001800125012008700143030001500230065000900245064000500254031000300259
014000800262865000900270002000800279035001000287801001500297#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\445.htm#S#c#118#14#article#19#14#^rND^sKiefer^nR#^rND^sKi
eseier^nBC#^rND^sStoll^nG#^rND^sHartung^nHP#The role of macrophages in immune-me
diated damage to the peripheral nervous system^len#Prog Neurobiol#20010000#2001#
64#109-127#20110400#445.htm#0301-0082#Prog Neurobiol##
00619000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100018000920100
02000110012012300130030001100253065000900264064000500273031000300278014001000281
865000900291002000800300035001000308801001100318#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\445.htm#S#c#119#15#article#19#15#^rND^sShamash^nS#^rND^sReichert^nF#^
rND^sRotshenker^nS#The cytokine network of Wallerian degeneration: tumor necrosi
s factor-alpha, interleukin-1alpha, and interleukin-1beta^len#J Neurosci#2002000
0#2002#22#3052-3060#20110400#445.htm#0270-6474#J Neurosci##
00564000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100015000910100
02000106012004600126030002500172065000900197064000500206031000300211014000800214
865000900222002000800231035001000239801002500249#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\445.htm#S#c#120#16#article#19#16#^rND^sMoonis^nM#^rND^sAhmad^nI#^rND^
sBachhawat^nBK#Macrophages in host defence - an overview^len#Indian J Biochem Bi
ophys#19920000#1992#29#115-122#20110400#445.htm#0301-1208#Indian J Biochem Bioph
ys##
00620000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100017000930100
01600110010001600126012009500142030001200237065000900249064000500258031000400263
014001200267865000900279002000800288035001000296801001200306#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\445.htm#S#c#121#17#article#19#17#^rND^sWolfert^nMA#^rND^s
Murray^nTF#^rND^sBoons^nGJ#^rND^sMoore^nJN#The origin of the synergistic effect 
of muramyl dipeptide with endotoxin and peptidoglycan^len#J Biol Chem#20020000#2
002#277#39179-39186#20110400#445.htm#0021-9258#J Biol Chem##
00652000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100012000750100015000870100
01900102010001200121010002200133012008100155030002500236065000900261064000500270
031000300275014000800278865000900286002000800295035001000303801002500313#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\445.htm#S#c#122#18#article#19#18#^rND^sSu^nY#
^rND^sZhang^nZ#^rND^sTrautmann^nK#^rND^sXu^nS#^rND^sSchluesener^nHJ#TLR and NOD2
 ligands induce cell proliferation in the rat intact spinal cord^len#J Neuropath
ol Exp Neurol#20050000#2005#64#991-997#20110400#445.htm#0022-3069#J Neuropathol 
Exp Neurol##
00590000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100018000910120
11300109030001900222065000900241064000500250031000300255014000800258865000900266
002000800275035001000283801001900293#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\4
45.htm#S#c#123#19#article#19#19#^rND^sHikawa^nN#^rND^sTakenaka^nT#Myelin-stimula
ted macrophages release neurotrophic factors for adult dorsal root ganglion neur
ons in culture^len#Cell Mol Neurobiol#19960000#1996#16#517-528#20110400#445.htm#
0272-4340#Cell Mol Neurobiol##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#o#1#1#article#1#201
10411#094527#548.htm#204##
04611000000000661000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120112001780100025002900100023003150100025003380100026003630100023003890100
02300412010002300435010002200458070013400480070007300614070012200687083284400809
08500080365308500300366108500310369108500450372208500280376708500280379508500350
38231170006038580720003038641120009038671110014038761140009038901130018038998910
02403917002000803941#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#h#2#1#a
rticle#1#oa#en#bjmbr#1#3.1#ILUS#TAB#13#BJMBR430#FAPESP#Braz J Med Biol Res#44#4#
20110400#^f354^l360#0100-879X#20110304#Relationship between work rate and oxygen
 uptake in mitochondrial myopathy during ramp-incremental exercise^len#^rND^1A01
^nA.C.^sGimenes#^rND^1A01^nJ.A.^sNeder#^rND^1A01^nS.^sDal Corso#^rND^1A01^nC.R.^
sNogueira#^rND^1A01^nL.^sNápolis#^rND^1A03^nM.T.^sMello#^rND^1A02^nA.S.^sBulle#^
rND^1A01^nL.E.^sNery#Universidade Federal de São Paulo^iA01^1Departamento de Med
icina^2Disciplina de Pneumologia^3Setor de Fisiologia Clínica do Exercício#Unive
rsidade Federal de São Paulo^iA02^1Setor de Doenças Neuromusculares#Universidade
 Federal de São Paulo^iA03^1Escola Paulista de Medicina^2Departamento de Psicobi
ologia^cSão Paulo^sSP^pBrasil#^len^aWe determined the response characteristics a
nd functional correlates of the dynamic relationship between the rate (&#916;) o
f oxygen consumption ( <img border=0 width=11 height=13 src="548_files/image001.
gif" v:shapes="_x0000_i1188">O2) and the applied power output (work rate = WR) d
uring ramp-incremental exercise in patients with mitochondrial myopathy (MM). Fo
urteen patients (7 males, age 35.4 ± 10.8 years) with biopsy-proven MM and 10 se
dentary controls (6 males, age 29.0 ± 7.8 years) took a ramp-incremental cycle e
rgometer test for the determination of the <img border=0 width=11 height=13 src=
"548_files/image001.gif" v:shapes="_x0000_i1189">O2 on-exercise mean response ti
me (MRT) and the gas exchange threshold (GET). The &#916;<img border=0 width=11 
height=13 src="548_files/image001.gif" v:shapes="_x0000_i1190">O2/&#916;WR slope
 was calculated up to GET (S1), above GET (S2) and over the entire linear portio
n of the response (S T). Knee muscle endurance was measured by isokinetic dynamo
metry. As expected, peak <img border=0 width=11 height=13 src="548_files/image00
1.gif" v:shapes="_x0000_i1191">O2 and muscle performance were lower in patients 
than controls (P < 0.05). Patients had significantly lower &#916;<img border=0 w
idth=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_i1192">O2/&#916;
WR than controls, especially the S2 component (6.8 ± 1.5 vs 10.3 ± 0.6 mL·min-1·
W-1, respectively; P < 0.001). There were significant relationships between &#91
6;<img border=0 width=11 height=13 src="548_files/image001.gif" v:shapes="_x0000
_i1193">O2/&#916;WR (S T) and muscle endurance, MRT-<img border=0 width=11 heigh
t=13 src="548_files/image001.gif" v:shapes="_x0000_i1194">O2, GET and peak <img 
border=0 width=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_i1195"
>O2 in MM patients (P < 0.05). In fact, all patients with &#916;<img border=0 wi
dth=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_i1196">O2/&#916;W
R below 8 mL·min-1·W-1 had severely reduced peak <img border=0 width=11 height=1
3 src="548_files/image001.gif" v:shapes="_x0000_i1197">O2 values (<60% predicted
). Moreover, patients with higher cardiopulmonary stresses during exercise (e.g.
, higher &#916; ventilation/carbon dioxide output and &#916; heart rate/&#916;<i
mg border=0 width=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_i11
98">O2) had lower &#916;<img border=0 width=11 height=13 src="548_files/image001
.gif" v:shapes="_x0000_i1199">O2/&#916;WR (P < 0.05). In conclusion, a readily a
vailable, effort-independent index of aerobic dysfunction during dynamic exercis
e (&#916;<img border=0 width=11 height=13 src="548_files/image001.gif" v:shapes=
"_x0000_i1200">O2/&#916;WR) is typically reduced in patients with MM, being rela
ted to increased functional impairment and higher cardiopulmonary stress.#^dnd^i
1#^tm^len^kMuscular diseases^i1#^tm^len^kOxygen consumption^i1#^tm^len^kCardiopu
lmonary exercise testing^i1#^tm^len^kSkeletal muscle^i1#^tm^len^kPathophysiology
^i1#^tm^len^kMitochondrial myopathy^i1#other#39#20100624#June 24, 2010#20110216#
February 16, 2011#S0100-879X2011007500023#548.htm##
04907000000000649000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120119001780100025002970100023003220100025003450100026003700100023003960100
02300419010002300442010002200465070013400487070007300621070012200694083314100816
08500080395708500300396508500310399508500450402608500280407108500280409908500350
41271170006041620720003041681120009041711110028041801140009042081130032042170020
00804249#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#f#3#1#article#1#oa#
en#bjmbr#1#3.1#ILUS#TAB#13#BJMBR430#FAPESP#Braz J Med Biol Res#44#4#20110400#^f3
54^l360#0100-879X#20110304#<b>Relationship between work rate and oxygen uptake i
n mitochondrial myopathy during ramp-incremental exercise</b>^len#^rND^1A01^nA.C
.^sGimenes#^rND^1A01^nJ.A.^sNeder#^rND^1A01^nS.^sDal Corso#^rND^1A01^nC.R.^sNogu
eira#^rND^1A01^nL.^sNápolis#^rND^1A03^nM.T.^sMello#^rND^1A02^nA.S.^sBulle#^rND^1
A01^nL.E.^sNery#Universidade Federal de São Paulo^iA01^1Departamento de Medicina
^2Disciplina de Pneumologia^3Setor de Fisiologia Clínica do Exercício#Universida
de Federal de São Paulo^iA02^1Setor de Doenças Neuromusculares#Universidade Fede
ral de São Paulo^iA03^1Escola Paulista de Medicina^2Departamento de Psicobiologi
a^cSão Paulo^sSP^pBrasil#^len^aWe determined the response characteristics and fu
nctional correlates of the dynamic relationship between the rate (&#916;) of oxy
gen consumption ( <img border=0 width=11 height=13 src="548_files/image001.gif" 
v:shapes="_x0000_i1188">O<sub>2</sub>) and the applied power output (work rate =
 WR) during ramp-incremental exercise in patients with mitochondrial myopathy (M
M). Fourteen patients (7 males, age 35.4 ± 10.8 years) with biopsy-proven MM and
 10 sedentary controls (6 males, age 29.0 ± 7.8 years) took a ramp-incremental c
ycle ergometer test for the determination of the <img border=0 width=11 height=1
3 src="548_files/image001.gif" v:shapes="_x0000_i1189">O<sub>2 </sub>on-exercise
 mean response time (MRT) and the gas exchange threshold (GET). The &#916;<img b
order=0 width=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_i1190">
O<sub>2</sub>/&#916;WR slope was calculated up to GET (<i>S<sub>1</sub></i>), ab
ove GET (<i>S<sub>2</sub></i>) and over the entire linear portion of the respons
e (<i>S<sub>T</sub></i>). Knee muscle endurance was measured by isokinetic dynam
ometry. As expected, peak <img border=0 width=11 height=13 src="548_files/image0
01.gif" v:shapes="_x0000_i1191">O<sub>2</sub> and muscle performance were lower 
in patients than controls (P &lt; 0.05). Patients had significantly lower &#916;
<img border=0 width=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_i
1192">O<sub>2</sub>/&#916;WR than controls, especially the <i>S<sub>2</sub></i> 
component (6.8 ± 1.5 <i>vs</i> 10.3 ± 0.6 mL·min<sup>-1</sup>·W<sup>-1</sup>, re
spectively; P &lt; 0.001). There were significant relationships between &#916;<i
mg border=0 width=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_i11
93">O<sub>2</sub>/&#916;WR (<i>S<sub>T</sub></i>) and muscle endurance, MRT-<img
 border=0 width=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_i1194
">O<sub>2</sub>, GET and peak <img border=0 width=11 height=13 src="548_files/im
age001.gif" v:shapes="_x0000_i1195">O<sub>2</sub> in MM patients (P &lt; 0.05). 
In fact, all patients with &#916;<img border=0 width=11 height=13 src="548_files
/image001.gif" v:shapes="_x0000_i1196">O<sub>2</sub>/&#916;WR below 8 mL·min<sup
>-1</sup>·W<sup>-1</sup> had severely reduced peak <img border=0 width=11 height
=13 src="548_files/image001.gif" v:shapes="_x0000_i1197">O<sub>2</sub> values (&
lt;60% predicted). Moreover, patients with higher cardiopulmonary stresses durin
g exercise (e.g., higher &#916; ventilation/carbon dioxide output and &#916; hea
rt rate/&#916;<img border=0 width=11 height=13 src="548_files/image001.gif" v:sh
apes="_x0000_i1198">O<sub>2</sub>) had lower &#916;<img border=0 width=11 height
=13 src="548_files/image001.gif" v:shapes="_x0000_i1199">O<sub>2</sub>/&#916;WR 
(P &lt; 0.05). In conclusion, a readily available, effort-independent index of a
erobic dysfunction during dynamic exercise (&#916;<img border=0 width=11 height=
13 src="548_files/image001.gif" v:shapes="_x0000_i1200">O<sub>2</sub>/&#916;WR) 
is typically reduced in patients with MM, being related to increased functional 
impairment and higher cardiopulmonary stress.#^dnd^i1#^tm^len^kMuscular diseases
^i1#^tm^len^kOxygen consumption^i1#^tm^len^kCardiopulmonary exercise testing^i1#
^tm^len^kSkeletal muscle^i1#^tm^len^kPathophysiology^i1#^tm^len^kMitochondrial m
yopathy^i1#other#39#20100624#<i>June</i><i> 24, 2010</i>#20110216#<i>February</i
><i> 16, 2011</i>#548.htm##
04762000000000673000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762240009001860120112001950100025003070100023003320100024003550100026003790100
02200405010002300427010002300450010002200473070015900495070009800654070012400752
08328510087608500080372708500300373508500310376508500450379608500280384108500280
38690850035038971170006039320720003039381120009039411110014039501140009039641130
01803973002000803991008008903999#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.h
tm#S#l#4#1#article#1#^mApr.^a2011#oa#en#bjmbr#1#3.1#ilus#tab#13#BJMBR430#FAPESP#
Braz. j. med. biol. res#44#4#20110400#^f354^l360#0100-879X#20110304#Relationship
 between work rate and oxygen uptake in mitochondrial myopathy during ramp-incre
mental exercise^len#^rND^1A01^nA. C^sGimenes#^rND^1A01^nJ. A^sNeder#^rND^1A01^nS
^sDal Corso#^rND^1A01^nC. R^sNogueira#^rND^1A01^nL^sNápolis#^rND^1A03^nM. T^sMel
lo#^rND^1A02^nA. S^sBulle#^rND^1A01^nL. E^sNery#^iA01^1Universidade Federal de S
ão Paulo^2Departamento de Medicina^3Disciplina de Pneumologia. Setor de Fisiolog
ia Clínica do Exercício^cSão Paulo^sSP^pBrasil#^iA02^1Universidade Federal de Sã
o Paulo^2Setor de Doenças Neuromusculares^cSão Paulo^sSP^pBrasil#^iA03^1Universi
dade Federal de São Paulo^2Escola Paulista de Medicina^3Departamento de Psicobio
logia^cSão Paulo^sSP^pBrasil#^len^aWe determined the response characteristics an
d functional correlates of the dynamic relationship between the rate (&#916;) of
 oxygen consumption ( <img border=0 width=11 height=13 src="548_files/image001.g
if" v:shapes="_x0000_i1188">O2) and the applied power output (work rate = WR) du
ring ramp-incremental exercise in patients with mitochondrial myopathy (MM). Fou
rteen patients (7 males, age 35.4 ± 10.8 years) with biopsy-proven MM and 10 sed
entary controls (6 males, age 29.0 ± 7.8 years) took a ramp-incremental cycle er
gometer test for the determination of the <img border=0 width=11 height=13 src="
548_files/image001.gif" v:shapes="_x0000_i1189">O2 on-exercise mean response tim
e (MRT) and the gas exchange threshold (GET). The &#916;<img border=0 width=11 h
eight=13 src="548_files/image001.gif" v:shapes="_x0000_i1190">O2/&#916;WR slope 
was calculated up to GET (S1), above GET (S2) and over the entire linear portion
 of the response (S T). Knee muscle endurance was measured by isokinetic dynamom
etry. As expected, peak <img border=0 width=11 height=13 src="548_files/image001
.gif" v:shapes="_x0000_i1191">O2 and muscle performance were lower in patients t
han controls (P < 0.05). Patients had significantly lower &#916;<img border=0 wi
dth=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_i1192">O2/&#916;W
R than controls, especially the S2 component (6.8 ± 1.5 vs 10.3 ± 0.6 mL·min-1·W
-1, respectively; P < 0.001). There were significant relationships between &#916
;<img border=0 width=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_
i1193">O2/&#916;WR (S T) and muscle endurance, MRT-<img border=0 width=11 height
=13 src="548_files/image001.gif" v:shapes="_x0000_i1194">O2, GET and peak <img b
order=0 width=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_i1195">
O2 in MM patients (P < 0.05). In fact, all patients with &#916;<img border=0 wid
th=11 height=13 src="548_files/image001.gif" v:shapes="_x0000_i1196">O2/&#916;WR
 below 8 mL·min-1·W-1 had severely reduced peak <img border=0 width=11 height=13
 src="548_files/image001.gif" v:shapes="_x0000_i1197">O2 values (<60 percent pre
dicted). Moreover, patients with higher cardiopulmonary stresses during exercise
 (e.g., higher &#916; ventilation/carbon dioxide output and &#916; heart rate/&#
916;<img border=0 width=11 height=13 src="548_files/image001.gif" v:shapes="_x00
00_i1198">O2) had lower &#916;<img border=0 width=11 height=13 src="548_files/im
age001.gif" v:shapes="_x0000_i1199">O2/&#916;WR (P < 0.05). In conclusion, a rea
dily available, effort-independent index of aerobic dysfunction during dynamic e
xercise (&#916;<img border=0 width=11 height=13 src="548_files/image001.gif" v:s
hapes="_x0000_i1200">O2/&#916;WR) is typically reduced in patients with MM, bein
g related to increased functional impairment and higher cardiopulmonary stress.#
^dnd^i1#^tm^len^kMuscular diseases^i1#^tm^len^kOxygen consumption^i1#^tm^len^kCa
rdiopulmonary exercise testing^i1#^tm^len^kSkeletal muscle^i1#^tm^len^kPathophys
iology^i1#^tm^len^kMitochondrial myopathy^i1#other#39#20100624#June 24, 2010#201
10216#February 16, 2011#548.htm#Internet^ihttp://www.scielo.br/scielo.php?script
=sci_arttext&pid=S0100-879X2011000400013##
00372000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014800070002000800218#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#5#1#article#161#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 354-360  </B></font></P>      ^cY#548.htm##
00436000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704021200070002000800282#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#6#2#article#161#<p ALIGN="LEFT"><font siz
e="5" face="Arial"><span lang="EN"><strong>Relationship between work rate and ox
ygen uptake in mitochondrial myopathy during ramp-incremental exercise</strong><
/span></font></p>      ^cY#548.htm##
00913000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704068900070002000800759#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#7#3#article#161#<p ALIGN="LEFT"><font fac
e="Arial"><span lang="EN">A.C. Gimenes<sup>1</sup>, J.A. Neder<sup>1</sup>, S. D
al Corso<sup>1</sup>, C.R. Nogueira<sup>1</sup>, L. N&aacute;polis<sup>1</sup>, 
</span></font><font face="Arial"><span lang="EN">M.T. Mello<sup>3</sup>, A.S. Bu
lle<sup>2</sup> and <span lang="EN"><font face="Arial, Helvetica, sans-serif"><s
up><span lang="EN"><font face="Arial, Helvetica, sans-serif"><b><a href="#Corres
pondence"><img src="/img/revistas/bjmbr/v44n4/recor.gif" border="0"></a></b> <a 
href="mailto:lenery@pneumo.epm.br"><img src="/img/revistas/bjmbr/v44n4/email-ca.
gif" border="0"></a></font></span></sup></font></span> L.E. Nery<sup>1</sup></sp
an></font></p>      ^cY#548.htm##
00740000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704051600070002000800586#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#8#4#article#161#<p ALIGN="LEFT"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Setor de Fisiologia
 Cl&iacute;nica do Exerc&iacute;cio, Disciplina de Pneumologia, Departamento de 
Medicina, </font></span><font face="Arial"><span lang="EN"><sup>2</sup>Setor de 
Doen&ccedil;as Neuromusculares, <sup>3</sup>Departamento de Psicobiologia, Escol
a Paulista de Medicina, </span></font><font face="Arial"><span lang="EN">Univers
idade Federal de S&atilde;o Paulo, S&atilde;o Paulo, SP, Brasil</span></font></p
>      ^cY#548.htm##
00414000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704019000070002000800260#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#9#5#article#161#<P> <font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#548.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#10#6#article#161#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#548.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#11#7#article#161#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#548.htm##
00397000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704017200071002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#12#8#article#161#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#548.htm##
00406000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018100071002000800252#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#13#9#article#161#<BR>   <A HREF="#Discuss
ion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#548
.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#14#10#article#161#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#548.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#15#11#article#161#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#548.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#16#12#article#161#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#548.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#17#13#article#161#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#548.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#18#14#article#161#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#548.htm##
04190000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704396400072002000804036#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#19#15#article#161#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">We determined the response ch
aracteristics and functional correlates of the dynamic relationship between the 
rate (&Delta;) of oxygen consumption (<img src="/img/revistas/bjmbr/v44n4/v%20co
m%20ponto.jpg">O<sub>2</sub>) and the applied power output (work rate = WR)</fon
t> <font FACE="Arial, Helvetica, sans-serif">during ramp-incremental exercise in
 patients with mitochondrial myopathy (MM). Fourteen patients (7 males, age 35.4
 &plusmn; 10.8 years) with biopsy-proven MM and 10 sedentary controls (6 males, 
age 29.0 &plusmn; 7.8 years) took a ramp-incremental cycle ergometer test for th
e determination of the <span lang="EN"><font FACE="Arial, Helvetica, sans-serif"
><span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revist
as/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span></font></span>O<sub>2 </sub>on
-exercise mean response time (MRT) and the gas exchange threshold (GET). The &De
lta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/rev
istas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR slo
pe was calculated up to GET (<i>S<sub>1</sub></i>), above GET (<i>S<sub>2</sub><
/i>) and over the entire linear portion of the response (<i>S<sub>T</sub></i>). 
Knee muscle endurance was measured by isokinetic dynamometry. As expected, peak 
<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revista
s/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> and muscle perfor
mance were lower in patients than controls (P &lt; 0.05). Patients had significa
ntly lower &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img
 src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>
/&Delta;WR than controls, especially the <i>S<sub>2</sub></i> component (6.8 &pl
usmn; 1.5 <i>vs</i> 10.3 &plusmn; 0.6 mL&middot;min<sup>-1</sup>&middot;W<sup>-1
</sup>, respectively; P &lt; 0.001). There were significant relationships betwee
n &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/im
g/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;W
R (<i>S<sub>T</sub></i>) and muscle endurance, MRT-<span lang="EN"><font FACE="A
rial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto
.jpg"></font></span>O<sub>2</sub>, GET and peak <span lang="EN"><font FACE="Aria
l, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jp
g"></font></span>O<sub>2</sub> in MM patients (P &lt; 0.05). In fact, all patien
ts with &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img sr
c="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&D
elta;WR below 8 mL&middot;min<sup>-1</sup>&middot;W<sup>-1</sup> had severely re
duced peak <span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/
img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> values
 (&lt;60% predicted). Moreover, patients with higher cardiopulmonary stresses du
ring exercise (e.g., higher &Delta; ventilation/carbon dioxide output and &Delta
; heart rate/&Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><i
mg src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</su
b>) had lower &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><
img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</s
ub>/&Delta;WR (P &lt; 0.05). In conclusion, a readily available, effort-independ
ent index of aerobic dysfunction during dynamic exercise (&Delta;<span lang="EN"
><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v
%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR) is typically reduced 
in patients with MM, being related to increased</font> <font FACE="Arial, Helvet
ica, sans-serif">functional impairment and higher cardiopulmonary stress.</font>
</span></p>      ^cY#548.htm##
00468000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704024200072002000800314#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#20#16#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Key words: Muscular diseases; Oxygen consumption; Ca
rdiopulmonary exercise testing; Skeletal muscle; Pathophysiology; Mitochondrial 
myopath</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#548.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#21#17#article#161#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#548.htm##
01888000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704166200072002000801734#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#22#18#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The rate (&Delta;) of change in oxygen consumption (
<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revista
s/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>) relative to powe
r output (work rate, WR) during ramp-incremental exercise depends on the ability
 of the cardiocirculatory system to deliver, and the muscle capacity to extract,
 O<sub>2</sub> from arterial (capillary) blood (1,2). The &Delta;<span lang="EN"
><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v
%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR relationship is influe
nced by the gas exchange threshold (GET) with most investigators describing a bi
-linear response, i.e., a sub-GET <i>S<sub>1</sub></i> slope flatter than a supr
a-GET <i>S<sub>2</sub></i> slope (3-5). The analysis of the total &Delta;<span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr
/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR slope (<i>S<su
b>T</sub></i>) and its components can provide useful information about the adequ
acy of the aerobic responses to exercise in health and disease. Several studies,
 for instance, have shown that a flatter-than-normal &Delta;<span lang="EN"><fon
t FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20co
m%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR is a sensitive marker of ab
normal O<sub>2</sub> delivery and utilization in a number of systemic pathologic
al conditions ranging from congestive heart failure to systemic lupus erythemato
sus (6-11).</span></font></p>      ^cY#548.htm##
01661000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704143500072002000801507#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#23#19#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Mitochondrial diseases are caused by very diverse ge
netic alterations located either on nuclear DNA or on mitochondrial DNA (mtDNA) 
(12). Mitochondrial myopathy (MM) is the collective term for disease conditions 
in which the diminished rate of cellular O<sub>2</sub> utilization may place a b
urden on several systems in order to enhance O<sub>2 </sub>uptake and delivery (
13-15). In fact, patients with MM commonly present hyperventilatory and hypercir
culatory patterns of response to dynamic exercise (16-20). These abnormalities a
re likely to be related to the fundamental pathophysiological abnormality in MM,
 i.e., impaired O<sub>2</sub> extraction. In this context, although there is a s
ound physiological rationale for the notion that &Delta;<span lang="EN"><font FA
CE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20
ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR would be severely reduced in MM
, and probably related to exercise impairment and to systemic cardiopulmonary st
ress, no previous study has investigated the characteristics and functional corr
elates of &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img 
src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/
&Delta;WR (<i>S<sub>1</sub></i>, <i>S<sub>2</sub></i>, <i>S<sub>T</sub></i>) in 
this patient population.</span></font></p>      ^cY#548.htm##
01465000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704123900072002000801311#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#24#20#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The objective of this study, therefore, was to compa
re the dynamic behavior of &Delta;<span lang="EN"><font FACE="Arial, Helvetica, 
sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></sp
an>O<sub>2</sub>/&Delta;WR during ramp-incremental exercise of patients with MM 
and that of healthy sedentary controls. We hypothesized that patients would pres
ent impaired O<sub>2</sub> utilization (reduced &Delta;<span lang="EN"><font FAC
E="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20p
onto.jpg"></font></span>O<sub>2</sub>/&Delta;WR), which would be significantly r
elated to maximum exercise capacity and selected indexes of functional impairmen
t. In addition, we anticipated that the ventilatory and cardiovascular responses
 to the prevailing metabolic demand (21-23) would be inversely related to &Delta
;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revist
as/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR, sugge
sting that the hyperkinetic cardiopulmonary response would be mechanistically li
nked to impaired muscle bioenergetics in MM.</span></font></p>  <HR ALIGN=LEFT S
IZE=2>      ^cY#548.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#25#21#article#161#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#548.htm##
00328000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010200072002000800174#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#26#22#article#161#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Study population</span></font></b></p>      ^cY#5
48.htm##
01359000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704113300072002000801205#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#27#23#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Fourteen non-smoking patients (7 males aged 20 to 52
 years) with biopsy-proven MM (see below) who had been followed at the Instituti
onal Neuromuscular Division agreed to participate in the study. All consecutive 
patients with the following characteristics were selected: clinical evidence of 
MM in the form of chronic progressive external ophthalmoplegia (13,17): ptosis, 
exercise intolerance, and chronic fatigue. This phenotype is associated with aut
osomal dominant DNA polymerase-gamma and adenine nucleotide translocase mutation
s with consequent deletions in mtDNA (15). There was no clinical or echocardiogr
aphic evidence of cardiomyopathy or impaired cardiac conduction in any patient. 
Subjects with mitochondrial encephalomyopathy, lactic acidosis and strokes, myoc
lonus epilepsy with ragged-red fibers, and other MMs were excluded from the stud
y. In addition, to avoid the confounding effect of physical conditioning on musc
le metabolism in MM (24), we selected patients who had not engaged in any regula
r physical activity in the preceding year.</span></font></p>      ^cY#548.htm##
00850000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704062400072002000800696#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#28#24#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Ten age- and gender-matched healthy volunteers (6 ma
les aged 20 to 46 years) comprised the control group. In order to match patients
 and controls for habitual physical activity, all study participants were requir
ed to present very low daily physical activity scores according to the Baecke qu
estionnaire (total score &lt;6) (25). The experimental protocol was approved by 
the Institutional Ethics Committee. However, muscle biopsies from normal subject
s were not permitted. Written informed consent to participate was obtained from 
each subject.</span></font></p>      ^cY#548.htm##
00324000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009800072002000800170#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#29#25#article#161#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Measurements</span></font></b></p>      ^cY#548.h
tm##
00733000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704050700072002000800579#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#30#26#article#161#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Body composition</i>. Mid-arm circumference was 
measured and skin fold thickness at the bicipital and tricipital levels was obta
ined using a skin fold caliper: arm muscle circumference was derived from these 
readings (cm). Bioelectrical impedance (Quantum BIA-101Q, RJL-101&trade;, USA) w
as used to estimate total body fat-free mass (FFM, kg); FFM index (FFMI) was cal
culated as the ratio of FFM to height in meters squared.</span></font></p>      
^cY#548.htm##
00875000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704064900072002000800721#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#31#27#article#161#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Skeletal muscle biopsies</i>. Percutaneous biops
ies of the right vastus lateralis were obtained from its central region, 10-15 c
m above the patella at mid-thigh level in patients. The biopsies were taken at l
east 3 months before the exercise test. Histopathological evaluation revealed a 
ragged-red fiber pattern in all specimens; abnormally low mitochondrial electron
 transport chain activity (cytochrome c oxidase) was demonstrated histochemicall
y by the method of Seligman et al. (26). Two experienced neuropathologists indep
endently reviewed the muscle biopsies.</span></font></p>      ^cY#548.htm##
00904000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704067800072002000800750#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#32#28#article#161#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif"> <i>Peripheral muscle strengt
h</i>. Isokinetic muscle endurance of the dominant knee extensor (quadriceps) wa
s measured with a computer-based dynamometer (Contrex</font> <font FACE="Arial, 
Helvetica, sans-serif">CE, Switzerland). During the tests, subjects were seated 
upright on the chair of the dynamometer with their back fully supported. The mec
hanical axis of rotation of the lever arm was aligned to the axis of rotation of
 the knee. After a 3-min rest, muscle endurance was determined as the total work
 achieved during 20 consecutive maximal repetitions at 300&ordm;/s.</font></span
></p>      ^cY#548.htm##
03728000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704350200072002000803574#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#33#29#article#161#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Cardiopulmonary exercise testing</i>. The exerci
se tests were carried out on an electromagnetically braked cycle ergometer (CPE 
2000, Medical Graphics Corporation - MGC, USA) with gas exchange and ventilatory
 variables being analyzed breath-by-breath (CardiO<sub>2</sub> System, MGC). The
 power (W) was continuously increased in a linear &quot;ramp&quot; pattern (27) 
(5-15 W/min in patients and 15-25 W/min in healthy subjects) so that the increme
ntal exercise test duration was more than 8 min and less than 12 min in all part
icipants, based on a &quot;symptom-limited interruption&quot;. The following var
iables are reported as means of 15 s: oxygen uptake (<span lang="EN"><font FACE=
"Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20pon
to.jpg"></font></span>O<sub>2</sub>, L/min at standard temperature and pressure 
dry, STPD), carbon dioxide output (<span lang="EN"><font FACE="Arial, Helvetica,
 sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></s
pan>CO<sub>2</sub>, L/min STPD), minute ventilation (<span lang="EN"><font FACE=
"Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20pon
to.jpg"></font></span>E, L/min BTPS), and end-tidal partial pressure for O<sub>2
</sub> and CO<sub>2</sub> (PETO<sub>2 </sub>and PETCO<sub>2</sub>, mmHg). Heart 
rate (HR, bpm) was automatically calculated from the R-R distance of a 12-lead E
CG tracing (CardiO<sub>2</sub> System, MGC). Capillary samples were collected fr
om the ear lobe for blood lactate measurements (mEq/L) at exercise cessation (Ye
llow Springs 2.700 STAT plus, Yellow Springs Instruments, USA). The samples were
 lysed before the measurements and values are reported as absolute values and re
lated to peak WR (lactate/WR ratio). The <span lang="EN"><font FACE="Arial, Helv
etica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></fo
nt></span>O<sub>2</sub> at the estimated lactate threshold was evaluated by the 
gas exchange method (GET), with visual inspection of the inflection point of <sp
an lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/b
jmbr/v44n4/v%20com%20ponto.jpg"></font></span>CO<sub>2</sub> with regard to <spa
n lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bj
mbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> (modified V-slope) an
d by the ventilatory method when <span lang="EN"><font FACE="Arial, Helvetica, s
ans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></spa
n>E/<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/rev
istas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> and PETO<sub>
2</sub> increased while <span lang="EN"><font FACE="Arial, Helvetica, sans-serif
"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>E/<span
 lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjm
br/v44n4/v%20com%20ponto.jpg"></font></span>CO<sub>2</sub> and PETCO<sub>2</sub>
 remained stable (28,29). The average <span lang="EN"><font FACE="Arial, Helveti
ca, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font>
</span>O<sub>2</sub> for the last 15 s was considered to be representative of th
e subject&rsquo;s peak <span lang="EN"><font FACE="Arial, Helvetica, sans-serif"
><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2<
/sub> (29).</span></font></p>      ^cY#548.htm##
01809000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704158300072002000801655#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#34#30#article#161#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">In order to measure the kinet
ics of the initial <span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><im
g src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub
> adjustment during the incremental exercise, the mean response time (MRT) was d
etermined as the time from the onset of the ramp forcing function to the point o
f intersection between the baseline <span lang="EN"><font FACE="Arial, Helvetica
, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></
span>O<sub>2</sub> and a linear backward extrapolation of the <span lang="EN"><f
ont FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20
com%20ponto.jpg"></font></span>O<sub>2</sub> <i>vs</i> time slope (</font><font 
FACE="Arial, Helvetica, sans-serif" COLOR="#000001"><a href="#Fig1">Figure 1</a>
</font><font FACE="Arial, Helvetica, sans-serif">) (30,31). This was performed i
n two ways, using either the region of <span lang="EN"><font FACE="Arial, Helvet
ica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font
></span>O<sub>2</sub> response below the GET, <i>S<sub>1</sub></i> (MRT<sub>1</s
ub>), or the total slope <i>S<sub>T</sub></i> (MRT<sub>T</sub>) (27). The baseli
ne was defined as the average value for <span lang="EN"><font FACE="Arial, Helve
tica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></fon
t></span>O<sub>2</sub> during the last 2 min of unloaded cycling prior to onset 
of the ramp.</font></span></p>      ^cY#548.htm##
01972000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704174600072002000801818#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#35#31#article#161#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Submaximal exercise relationships</i>. As mentio
ned, the &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img s
rc="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&
Delta;WR relationship (mL&middot;min<sup>-1</sup>&middot;W<sup>-1</sup>) was cal
culated to obtain an index of the overall gain of the <span lang="EN"><font FACE
="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20po
nto.jpg"></font></span>O<sub>2</sub> response, i.e., in disease states, reduced 
values would indicate a greater reliance on anaerobic sources of ATP regeneratio
n (1,2). Considering that the GET could distort the linearity of the response (d
ue to an even greater reliance on anaerobic metabolism) (3,5), the &Delta;<span 
lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmb
r/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR slope was det
ermined using linear regression analysis over three segments: <i>S<sub>1</sub></
i>, from the start of <span lang="EN"><font FACE="Arial, Helvetica, sans-serif">
<img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</
sub> increase during exercise to the GET; <i>S<sub>2</sub></i>, from the GET to 
either peak <span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="
/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> or wh
ere <span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/rev
istas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> began to leve
l off, and <i>S<sub>T</sub></i>, over the range of <i>S<sub>1</sub></i> + <i>S<s
ub>2</sub></i>.</span></font></p>      ^cY#548.htm##
01274000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704104800072002000801120#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#36#32#article#161#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Determination of the &Delta;HR/&Delta;<span lang
="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v4
4n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> relationship (beat&middot; 
L<sup>-1</sup>&middot;min<sup>-1</sup>)</i>. Although <span lang="EN"><font FACE
="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20po
nto.jpg"></font></span>O<sub>2</sub> is an appropriate dependent variable, this 
relationship has been traditionally described with HR on the y-axis (22,23). In 
this context, a steeper HR response to a given metabolic demand would imply redu
ced stroke volume and/or low peripheral oxygen extraction (i.e., an inappropriat
e cardiovascular response to incremental exercise). Linearity of the HR response
 throughout the test duration was first investigated for each subject. In the ev
ent of late departures from linearity, we then applied regression analysis only 
to the initial linear phase response.</span></font></p>      ^cY#548.htm##
00967000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704074100072002000800813#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#37#33#article#161#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Determination of the sub-respiratory compensatio
n point (RCP) &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><
img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>E/&Delta;<
span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas
/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>CO<sub>2</sub> relationship</i>.
 For the determination of this index of ventilatory &quot;efficiency&quot; (21-2
3), linear regression analysis was applied only to the individually selected dat
a points below the RCP (i.e., before the development of the characteristic hyper
ventilatory response to the ongoing lactacidemia).</span></font></p>      ^cY#54
8.htm##
00332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010600072002000800178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#38#34#article#161#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Statistical analysis</span></font></b></p>      ^
cY#548.htm##
00833000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704060700072002000800679#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#39#35#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Means and standard deviations (SD) of normally distr
ibuted data (Kolmogorov-Smirnov test) were obtained for patients and controls an
d were compared using an unpaired <i>t</i>-test. Alternatively, the Mann-Whitney
 test was used to assess between-group differences of variables with a non-Gauss
ian distribution. Pearson&rsquo;s product-moment correlation was used to assess 
the degree of association between continuous variables. The probability of a typ
e I error was set at 5% for all tests (P &lt; 0.05).</span></font></p>  <HR ALIG
N=LEFT SIZE=2>      ^cY#548.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#40#36#article#161#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#548.htm##
00322000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009600072002000800168#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#41#37#article#161#<P><b><font face="Arial
"><span lang="EN">Patient characteristics</span></font></b></P>      ^cY#548.htm
##
00827000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704060100072002000800673#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#42#38#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Patients with MM presented decreased total body and 
fat-free mass indexes compared to normal subjects (P &lt; 0.05). Appendicular mu
scle mass, estimated by arm muscle circumference, was reduced in patients (<a hr
ef="#Tab1">Table 1</a>). Muscle endurance capacity (total work) was also signifi
cantly lower in patients than controls (863.4 &plusmn; 274.2 <i>vs</i> 1577.5 &p
lusmn; 450.0 kJ, respectively; P &lt; 0.01). Peripheral muscle performance was r
elated to fat-free mass index in MM patients (R = 0.74; P &lt; 0.001).</span></f
ont></p>      ^cY#548.htm##
00343000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011700072002000800189#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#43#39#article#161#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Metabolic responses to exercise</span></font></b>
</p>      ^cY#548.htm##
01677000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704145100072002000801523#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#44#40#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">There were no significant between-group differences 
in duration of the ramp forcing protocol (8.6 &plusmn; 1.1 <i>vs</i> 8.9 &plusmn
; 1.9 min for patients and controls, respectively; P &gt; 0.05). Peak <span lang
="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v4
4n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> and power (WR) were signifi
cantly lower in patients than controls (<a href="#Tab2">Table 2</a>). The GET wa
s noninvasively identified in all subjects and was lower in patients than contro
ls when analyzed as mL/min and as % of predicted; however, since patients had lo
wer weight, GET in mL&middot;min<sup>-1</sup>&middot;kg<sup>-1</sup> was not sig
nificantly different. Also, patients had a lower capacity to sustain exercise pe
rformance after the GET through peak <span lang="EN"><font FACE="Arial, Helvetic
a, sans-serif"><span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img sr
c="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span></font></span>O<
sub>2</sub>, which was related to symptoms of leg pain and dyspnea. Therefore, t
he GET/<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><span lang="EN"
><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v
%20com%20ponto.jpg"></font></span></font></span>O<sub>2 </sub>peak ratio was hig
her in MM patients compared to controls.</span></font></p>      ^cY#548.htm##
01590000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704136400072002000801436#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#45#41#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The &Delta;<span lang="EN"><font FACE="Arial, Helvet
ica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font
></span>O<sub>2</sub>/&Delta;WR relationship could be described as a bi-linear f
unction in all subjects, with the intersection point between <i>S<sub>1</sub></i
> and <i>S<sub>2</sub></i> corresponding to the GET. Patients with MM presented 
lower <i>S<sub>1</sub></i>, <i>S<sub>2</sub></i> and <i>S<sub>T</sub></i> slopes
 than controls (P &lt; 0.05; <a href="#Tab2">Table 2</a>). However, the between-
group differences were more prominent in the <i>S<sub>2</sub></i> slope compared
 to <i>S<sub>1 </sub></i>and <i>S<sub>T</sub></i> (mean % reduction in MM patien
ts compared to controls = 33.9, 17.8, and 25.2%, respectively). Therefore, the r
atio between the <i>S<sub>2</sub></i> and <i>S<sub>1</sub></i> slopes was signif
icantly lower in patients than controls (0.87 &plusmn; 0.15 <i>vs</i> 1.08 &plus
mn; 0.18, P &lt; 0.01). In addition, on-exercise <span lang="EN"><font FACE="Ari
al, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.j
pg"></font></span>O<sub>2</sub> kinetics (MRT), considering either<i> S<sub>1 </
sub></i>or <i>S<sub>T</sub></i>, was slower in patients than controls (P &lt; 0.
05; <a href="#Tab2">Table 2</a>).</span></font></p>      ^cY#548.htm##
00569000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704034300072002000800415#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#46#42#article#161#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">&Delta;<span lang="EN"><font FACE="Arial, Helveti
ca, sans-serif"><span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img s
rc="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span></font></span>O
<sub>2</sub>/&Delta;WR and functional impairment</span></font></b></p>      ^cY#
548.htm##
02046000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704182000072002000801892#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#47#43#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">As shown in <a href="#Fig2">Figure 2</a>, the overal
l &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/im
g/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;W
R response (i.e., <i>S<sub>T</sub></i>) was significantly related to peak <span 
lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmb
r/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> in MM patients, but not
 in controls. In fact, all patients with &Delta;<span lang="EN"><font FACE="Aria
l, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jp
g"></font></span>O<sub>2</sub>/&Delta;WR below 8 mL&middot;min<sup>-1</sup>&midd
ot;W<sup>-1</sup> had severely reduced peak <span lang="EN"><font FACE="Arial, H
elvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"><
/font></span>O<sub>2</sub> (&lt;60% predicted) (28). Patients with lower &Delta;
<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revista
s/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR present
ed reduced GET (r = 0.73) but higher WR-corrected lactate and MRT<sub>T</sub>-<s
pan lang="EN"><font FACE="Arial, Helvetica, sans-serif"><span lang="EN"><font FA
CE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20
ponto.jpg"></font></span></font></span>O<sub>2</sub> values (r = 0.69 and r = 0.
76, respectively; P &lt; 0.01). Moreover, &Delta;<span lang="EN"><font FACE="Ari
al, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.j
pg"></font></span>O<sub>2</sub>/&Delta;WR was positively related to peripheral m
uscle endurance in MM patients (r = 0.78; P &lt; 0.01) but not in controls (P &g
t; 0.05).</span></font></p>      ^cY#548.htm##
00528000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704030200072002000800374#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#48#44#article#161#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Relationship between &Delta;<span lang="EN"><font
 FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com
%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR and cardiopulmonary response
s in MM</span></font></b></p>      ^cY#548.htm##
02288000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704206200072002000802134#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#49#45#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Patients with MM had increased cardiorespiratory res
ponses to the metabolic demands during progressive exercise compared to healthy 
controls (<a href="#Tab2">Table 2</a>; P &lt; 0.01) as previously described (16-
20). There were significant inverse relationships between &Delta;<span lang="EN"
><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v
%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR (<i>S<sub>1</sub></i>,
 <i>S<sub>2</sub></i> and <i>S<sub>T</sub></i>) and submaximal cardiovascular (&
Delta;HR/&Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img s
rc="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>) 
and ventilatory (&Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif
"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>E/&Delt
a;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revis
tas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>CO<sub>2</sub>) responses in 
patients with MM (P &lt; 0.05). The correlation coefficients, however, were high
er for <i>S<sub>2</sub></i> than <i>S<sub>1</sub></i> and <i>S<sub>T</sub></i> (
<i>S<sub>2</sub></i> = -0.75 and -0.69; <i>S<sub>1</sub> </i>= -0.51 and -0.55; 
<i>S<sub>T</sub> </i>= 0.60 and -0.62, for &Delta;HR/&Delta;<span lang="EN"><fon
t FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20co
m%20ponto.jpg"></font></span>O<sub>2 </sub>and &Delta;<span lang="EN"><font FACE
="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20po
nto.jpg"></font></span>E/&Delta;<span lang="EN"><font FACE="Arial, Helvetica, sa
ns-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span
>CO<sub>2</sub>, respectively).</span></font></p>  <HR ALIGN=LEFT SIZE=2>  <tabl
e  border="0">    <tr align="left" valign="top">      <td><a href="/img/revistas
/bjmbr/v44n4/html/548i01.htm"><img src="/img/revistas/bjmbr/v44n4/548i01peq.jpg"
 border="2"></a></td>      <td>    ^cY#548.htm##
01124000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704089800072002000800970#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#50#46#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig1"></a>Figure 1. Oxygen uptake (<span la
ng="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/
v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>) response to ramp-increme
ntal exercise of a representative normal subject. Mean response time (MRT) of th
e kinetic response is calculated as the time from the onset of the ramp forcing 
function to the point of intersection between the baseline <span lang="EN"><font
 FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com
%20ponto.jpg"></font></span>O<sub>2</sub> and a linear backward extrapolation of
 the <span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/re
vistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> <i>vs</i> ti
me slope (30,31).</span></font></p>      </td>    </tr>  </table>      ^cY#548.h
tm##
00563000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033700072002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#51#47#article#161#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (81 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/548i02.htm"><img src="/img/
revistas/bjmbr/v44n4/548i02peq.jpg" border="2"></a></td>      <td>    ^cY#548.ht
m##
01965000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704173900072002000801811#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#52#48#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig2"></a>Figure 2. Relationship (Pearson&r
squo;s product-moment correlation) between a submaximal metabolic index of exerc
ise functioning (&#8710;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif
"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2
</sub>/&#8710;WR) and peak aerobic capacity (peak <span lang="EN"><font FACE="Ar
ial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.
jpg"></font></span>O<sub>2</sub>) in patients with mitochondrial myopathy (close
d circles) and normal controls (open circles). Note that the lower &#8710;<span 
lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmb
r/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&#8710;WR values were s
ignificantly related to peak <span lang="EN"><font FACE="Arial, Helvetica, sans-
serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<
sub>2 </sub>in patients but not in controls. In addition, a &#8710;<span lang="E
N"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4
/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&#8710;WR below 8 mL&middot;mi
n<sup>-1</sup>&middot;W<sup>-1</sup> was suggestive of severe aerobic impairment
 in MM patients (peak <span lang="EN"><font FACE="Arial, Helvetica, sans-serif">
<img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2 <
/sub>&lt;60% predicted) (29). <span lang="EN"><font FACE="Arial, Helvetica, sans
-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O
<sub>2</sub> = oxygen consumption; WR = work rate (power).</span></font></p>    
  </td>    </tr>  </table>      ^cY#548.htm##
00559000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033300072002000800405#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#53#49#article#161#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (79 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/548t01.htm"><img src="/img/
revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#548.htm##
00448000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704022200072002000800294#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#54#50#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Tab1"></a>Table 1. Resting characteristics 
of patients with mitochondrial myopathy and healthy controls.</span></font></p> 
     </td>    </tr>  </table>      ^cY#548.htm##
00782000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704055600072002000800628#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#55#51#article#161#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (168 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/548t02.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td><span lang="EN"><
font face="Arial"><span lang="EN"><a name="Tab2"></a>Table 2. Cardiopulmonary ex
ercise variables of patients with mitochondrial myopathy and healthy controls.</
span></font></span></td>    </tr>  </table>      ^cY#548.htm##
00344000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011800072002000800190#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#56#52#article#161#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (266 K JPG file)]</font
></P>      ^cY#548.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#57#53#article#161#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#548.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#58#54#article#161#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#548.htm##
01386000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704116000072002000801232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#59#55#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">This study has provided novel evidence that a readil
y available index of &quot;aerobic efficiency&quot; during ramp-incremental cycl
e ergometer exercise (&Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-
serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<
sub>2</sub>/&Delta;WR) is typically reduced in patients with MM, particularly in
 the supra-GET <i>S<sub>2</sub></i> component. The &Delta;<span lang="EN"><font 
FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%
20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR was associated with worsening
 maximal (peak <span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img sr
c="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>, l
actate/WR) and submaximal (<span lang="EN"><font FACE="Arial, Helvetica, sans-se
rif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<su
b>2</sub>GET) markers of aerobic impairment and reduced peripheral muscle perfor
mance. In addition, this index was inversely related to submaximal cardiopulmona
ry stress    ^cY#548.htm##
01182000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704095600072002000801028#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#60#56#article#161#<br>  (&Delta;<span lan
g="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v
44n4/v%20com%20ponto.jpg"></font></span>E/&Delta;<span lang="EN"><font FACE="Ari
al, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.j
pg"></font></span>CO<sub>2</sub> and &Delta;HR/&Delta;<span lang="EN"><font FACE
="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20po
nto.jpg"></font></span>O<sub>2</sub>), suggesting that these systems adopted a h
yperdynamic pattern of response to compensate for an impaired O<sub>2</sub> util
ization. Our data, therefore, indicate that &Delta;<span lang="EN"><font FACE="A
rial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto
.jpg"></font></span>O<sub>2</sub>/&Delta;WR may constitute a useful submaximal, 
effort-independent exercise index for quantification of functional impairment in
 this patient population.</span></font></p>      ^cY#548.htm##
00367000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704014100072002000800213#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#61#57#article#161#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Aerobic impairment and exercise capacity in MM pa
tients</span></font></b></p>      ^cY#548.htm##
02523000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704229700072002000802369#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#62#58#article#161#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">For clinical interpretation o
f &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/im
g/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;W
R during rapid-incremental exercise (ramp), it is important to differentiate bet
ween this index of aerobic metabolism and the <span lang="EN"><font FACE="Arial,
 Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"
></font></span>O<sub>2</sub>-WR relationship in response to constant WR exercise
 (&quot;economy of cycling&quot;), which is largely independent of fitness or ca
rdiocirculatory dysfunction (1,2). Therefore, &Delta;<span lang="EN"><font FACE=
"Arial, Helvetica, sans-serif"><span lang="EN"><font FACE="Arial, Helvetica, san
s-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>
</font></span>O<sub>2</sub>/&Delta;WR does not directly reflect the efficiency o
f muscle contraction, but rather the relative increase in aerobic metabolism as 
power output is increased. In this context, a reduced, but linear, &Delta;<span 
lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmb
r/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR is thought to
 represent decreased O<sub>2</sub> utilization (1,2). Assuming that patients&rsq
uo; ability to increase cardiac output was not impaired (see Study limitations),
</font> <font FACE="Arial, Helvetica, sans-serif">a lower C(a-v)O<sub>2</sub> (i
.e., reduced O<sub>2</sub> extraction) is the most likely explanation for a redu
ced &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/
img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta
;WR as demonstrated by Taivassalo et al. (19) and, more recently, by Grassi et a
l. (32) using near-infrared spectroscopy. Considering that &Delta;<span lang="EN
"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/
v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR was significantly rel
ated to several indicators of aerobic metabolism, this relationship seems to be 
useful to indicate patients in whom O<sub>2</sub> extraction is particularly imp
aired.</font></span></p>      ^cY#548.htm##
01543000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704131700072002000801389#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#63#59#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">In the present study, we found a strong linear relat
ionship between &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"
><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2<
/sub>/&Delta;WR and peak <span lang="EN"><font FACE="Arial, Helvetica, sans-seri
f"><span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revi
stas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span></font></span>O<sub>2</sub> 
in MM patients, but not in controls (<a href="#Fig2">Figure 2</a>). These result
s are consistent with the notion that the decrease in &Delta;<span lang="EN"><fo
nt FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20c
om%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR in disease conditions asso
ciated with impaired O<sub>2</sub> delivery or utilization may be severe enough 
to reduce peak <span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr
/v44n4/v%20com%20ponto.jpg"></font></span></font></span>O<sub>2</sub>. This has 
been previously demonstrated by decreasing arterial O<sub>2</sub> content in hea
lthy subjects (33) and in chronic cardiovascular disease (1,6,10).</span></font>
</p>      ^cY#548.htm##
00591000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704036500072002000800437#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#64#60#article#161#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Determinants of the &Delta;<span lang="EN"><font 
FACE="Arial, Helvetica, sans-serif"><span lang="EN"><font FACE="Arial, Helvetica
, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></
span></font></span>O<sub>2</sub>/&Delta;WR relationship in MM patients</span></f
ont></b></p>      ^cY#548.htm##
02723000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704249700072002000802569#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#65#61#article#161#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">Some previous data have demon
strated that a &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif">
<img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</
sub>/&Delta;WR relationship below the GET (<i>S<sub>1</sub></i>) satisfactorily 
represents the equivalent steady-state <span lang="EN"><font FACE="Arial, Helvet
ica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font
></span>O<sub>2 </sub>response (1,2,5,29), even in conditions associated with re
duced &Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src=
"/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Del
ta;WR (11). For supra-GET exercise, however, the   <span lang="EN"><font FACE="A
rial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto
.jpg"></font></span>O<sub>2</sub> response provides an imprecise estimate of the
 total rate of ATP regeneration, since the increased contribution of the anaerob
ic metabolism would contribute significantly to the overall muscle energetics. P
aradoxically, the observed <span lang="EN"><font FACE="Arial, Helvetica, sans-se
rif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<su
b>2</sub> response is characteristically higher than expected from the sub-GET <
span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas
/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>-WR relationship du
e to the development of an &quot;excessive&quot; <span lang="EN"><font FACE="Ari
al, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.j
pg"></font></span>O<sub>2</sub> response (34). Although the determinants of the 
so-called &quot;slow component&quot; of the <span lang="EN"><font FACE="Arial, H
elvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"><
/font></span>O<sub>2</sub> response remain elusive, much of the extra-<span lang
="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v4
4n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> seems to derive from the ex
ercising muscles (~80%), probably due to progressive recruitment of less efficie
nt type II fibers (4). In fact, the greater increase in <i>S<sub>2 </sub></i>rel
ative to <i>S<sub>1 </sub></i>has been found in subjects with a high percentage 
of type II fibers and at high pedal rates (5).</font></span></p>      ^cY#548.ht
m##
03322000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704309600072002000803168#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#66#62#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">In the present study, we confirm previous observatio
ns that <i>S<sub>2</sub></i> is steeper than <i>S<sub>1</sub></i> in normal subj
ects, probably reflecting the contribution of the <span lang="EN"><font FACE="Ar
ial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.
jpg"></font></span>O<sub>2</sub> slow component (2,3,5,29). This pattern, howeve
r, contrasted with that found in patients with MM who showed a consistently lowe
r         <i>S<sub>2</sub></i>/<i>S<sub>1</sub></i> ratio at the same pedaling r
ate compared to normal subjects. These results were not due to a faster rate of 
work rate incrementation in patients as the ramp duration did not differ between
 patients and controls. Although muscle fiber typing was not performed in the pr
esent study, a selective reduction in the type II fiber population could be rela
ted to this phenomenon and/or MM patients may have an impaired ability to recrui
t these fibers (35,36). Alternatively, the deleterious heteroplasmic mtDNA alter
ations may have equally affected type I and type II fibers (12). In addition, it
 should be recognized that some of the mechanisms involved in the <span lang="EN
"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/
v%20com%20ponto.jpg"></font></span>O<sub>2</sub> slow component might be linked 
to lactate production and/or metabolism. Considering, therefore, that the anaero
bic contribution (and lactate release) to muscle metabolism is increased in thes
e patients since early exercise (16,19), the increase in lactate (and <span lang
="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v4
4n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>) above the GET, compared to
 sub-GET, exercise may have been less abrupt in patients than controls. In this 
context, it is interesting to note that similar findings (lower <i>S<sub>2</sub>
</i>/<i>S<sub>1</sub></i>) were reported in studies involving patients with chro
nic heart failure probably due to impaired O<sub>2</sub> delivery (33,37). We al
so cannot rule out the possibility that the supra-GET exercise was associated wi
th lower rates of ATP regeneration and further decreases in O<sub>2</sub> utiliz
ation. Nevertheless, peak <span lang="EN"><font FACE="Arial, Helvetica, sans-ser
if"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub
>2</sub> was particularly related to<i> S<sub>2</sub></i>, suggesting that the e
nd-exercise <span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="
/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub> respo
nse is strongly influenced by the magnitude of the supra-GET <span lang="EN"><fo
nt FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20c
om%20ponto.jpg"></font></span>O<sub>2</sub> response in patients with reduced &D
elta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/re
vistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR va
lues.</span></font></p>      ^cY#548.htm##
00382000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704015600072002000800228#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#67#63#article#161#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Ventilatory and cardiovascular responses to incre
mental exercise in MM</span></font></b></p>      ^cY#548.htm##
02140000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704191400072002000801986#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#68#64#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The precise etiology of the hyperventilatory and hyp
ercirculatory responses to dynamic exercise in MM patients is unknown. Some inve
stigators have postulated a common mechanism for these adjustments with a descen
ding parallel activation of the respiratory and cardiovascular centers in respon
se to afferent stimulation from metabolically sensitive chemoreceptors in periph
eral skeletal muscles (19,38). Our data showing a strong relationship between &D
elta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/re
vistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR an
d cardiopulmonary stress suggest that these abnormalities can be mechanistically
 linked. Therefore, heightened cardiopulmonary responses could be expected in th
ose patients in whom the intramuscular disturbances were more pronounced and the
 afferent stimuli were higher, i.e., those with lower &Delta;<span lang="EN"><fo
nt FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v%20c
om%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR. This hypothesis, however,
 should be more properly investigated in studies evaluating the responses to int
erventions aimed to improved O<sub>2</sub> utilization in these patients. Nevert
heless, the increased ventilatory and cardiovascular costs combined with lower &
Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><img src="/img/r
evistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O<sub>2</sub>/&Delta;WR (
<i>S<sub>2</sub></i>) seem to indicate that they are not relevant to explain the
 extra-<span lang="EN"><font FACE="Arial, Helvetica, sans-serif"><span lang="EN"
><font FACE="Arial, Helvetica, sans-serif"><img src="/img/revistas/bjmbr/v44n4/v
%20com%20ponto.jpg"></font></span></font></span>O<sub>2</sub> related to heavy e
xercise in MM patients.</span></font></p>      ^cY#548.htm##
00329000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010300072002000800175#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#69#65#article#161#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Study limitations</span></font></b></p>      ^cY#
548.htm##
01221000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704099500072002000801067#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#70#66#article#161#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">In order to accurately measur
e the power output, the patients were evaluated during incremental cycle ergomet
ry. Therefore, our results may not be applicable to body-bearing activities, suc
h as walking or running. In addition, although patients were screened at rest fo
r significant cardiovascular disease, stroke volume was not measured during exer
tion. Consequently, we cannot be sure that our patients were &quot;hypercirculat
ory&quot; as low stroke volume may have limited any increase in cardiac output.<
/font> <font FACE="Arial, Helvetica, sans-serif">Moreover, C(a-v)O<sub>2</sub> w
as not measured and impaired O<sub>2</sub> extraction could only be inferred fro
m noninvasive data. Finally, genetic studies were not performed and we were unab
le to correlate the physiological abnormalities with mtDNA mutation load on skel
etal muscle or the qualitative distribution of type fibers (39).</font></span></
p>      ^cY#548.htm##
00954000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704072800072002000800800#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#71#67#article#161#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">In conclusion, our results indicate that a readily a
vailable, effort-independent submaximal index of aerobic dysfunction during ramp
-incremental exercise (&Delta;<span lang="EN"><font FACE="Arial, Helvetica, sans
-serif"><img src="/img/revistas/bjmbr/v44n4/v%20com%20ponto.jpg"></font></span>O
<sub>2</sub>/&Delta;WR) is severely reduced in patients with MM, being related t
o increased functional impairment and higher HR and ventilatory responses relate
d to metabolism. This relationship, therefore, should be routinely reported in c
ardiopulmonary exercise testing evaluations and clinically valued in this patien
t population.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#548.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#72#68#article#161#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#548.htm##
00469000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704022900074002000800303#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#73#69#article#161#1#<p ALIGN=
"LEFT"><font face="Arial"><span lang="EN">1. Hansen JE, Sue DY, Oren A, Wasserma
n K. Relation of oxygen uptake to work rate in normal men and men with circulato
ry disorders. <i>Am J Cardiol</i> 1987; 59: 669-674.    ^cY#548.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#74#70#article#161#</span></font></p>     
 ^cY#548.htm##
00488000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024800074002000800322#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#75#71#article#161#2#<p align=
"LEFT"><font face="Arial"><span lang="EN">2. Hansen JE, Casaburi R, Cooper DM, W
asserman K. Oxygen uptake as related to work rate increment during cycle ergomet
er exercise. <i>Eur J Appl Physiol Occup Physiol</i> 1988; 57: 140-145.    ^cY#5
48.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#76#72#article#161#</span></font></p>     
 ^cY#548.htm##
00499000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704025900074002000800333#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#77#73#article#161#3#<p align=
"LEFT"><font face="Arial"><span lang="EN">3. Zoladz JA, Duda K, Majerczak J. Oxy
gen uptake does not increase linearly at high power outputs during incremental e
xercise test in humans. <i>Eur J Appl Physiol Occup Physiol</i> 1998; 77: 445-45
1.    ^cY#548.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#78#74#article#161#</span></font></p>     
 ^cY#548.htm##
00485000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024500074002000800319#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#79#75#article#161#4#<p align=
"LEFT"><font face="Arial"><span lang="EN">4. Barstow TJ, Jones AM, Nguyen PH, Ca
saburi R. Influence of muscle fiber type and pedal frequency on oxygen uptake ki
netics of heavy exercise. <i>J Appl Physiol</i> 1996; 81: 1642-1650.    ^cY#548.
htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#80#76#article#161#</span></font></p>     
 ^cY#548.htm##
00487000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024700074002000800321#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#81#77#article#161#5#<p align=
"LEFT"><font face="Arial"><span lang="EN">5. Jones AM, Campbell IT, Pringle JS. 
Influence of muscle fibre type and pedal rate on the VO<sub>2</sub>-work rate sl
ope during ramp exercise. <i>Eur J Appl Physiol</i> 2004; 91: 238-245.    ^cY#54
8.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#82#78#article#161#</span></font></p>     
 ^cY#548.htm##
00426000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704018600074002000800260#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#83#79#article#161#6#<p align=
"LEFT"><font face="Arial"><span lang="EN">6. Itoh H. Oxygen uptake: work rate re
lationship in patients with heart disease. <i>Med Sci Sports Exerc</i> 1992; 37:
 374-380.    ^cY#548.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#84#80#article#161#</span></font></p>     
 ^cY#548.htm##
00485000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024500074002000800319#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#85#81#article#161#7#<p align=
"LEFT"><font face="Arial"><span lang="EN">7. Lewis MI, Belman MJ, Monn SA, Elash
off JD, Koerner SK. The relationship between oxygen consumption and work rate in
 patients with airflow obstruction. <i>Chest</i> 1994; 106: 366-372.    ^cY#548.
htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#86#82#article#161#</span></font></p>     
 ^cY#548.htm##
00511000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027100074002000800345#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#87#83#article#161#8#<p align=
"LEFT"><font face="Arial"><span lang="EN">8. Sakauchi M, Matsumura T, Yamaoka T,
 Koami T, Shibata M, Nakamura M, et al. Reduced muscle uptake of oxygen during e
xercise in patients with systemic lupus erythematosus. <i>J Rheumatol</i> 1995; 
22: 1483-1487.    ^cY#548.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#88#84#article#161#</span></font></p>     
 ^cY#548.htm##
00462000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704022200074002000800296#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#89#85#article#161#9#<p align=
"LEFT"><font face="Arial"><span lang="EN">9. Kimura H, Kawagoe Y, Kaneko N, Fess
ler HE, Hosoda S. Low efficiency of oxygen utilization during exercise in hypert
hyroidism. <i>Chest</i> 1996; 110: 1264-1270.    ^cY#548.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#90#86#article#161#</span></font></p>     
 ^cY#548.htm##
00470000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704022900075002000800304#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#91#87#article#161#10#<p align
="LEFT"><font face="Arial"><span lang="EN">10. Jones S, Elliott PM, Sharma S, Mc
Kenna WJ, Whipp BJ. Cardiopulmonary responses to exercise in patients with hyper
trophic cardiomyopathy. <i>Heart</i> 1998; 80: 60-67.    ^cY#548.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#92#88#article#161#</span></font></p>     
 ^cY#548.htm##
00608000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704036700075002000800442#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#93#89#article#161#11#<p align
="LEFT"><font face="Arial"><span lang="EN">11. Toyofuku M, Takaki H, Sugimachi M
, Kawada T, Goto Y, Sunagawa K. Reduced oxygen uptake increase to work rate incr
ement (DeltaVO<sub>2</sub>/DeltaWR) is predictable by VO<sub>2 </sub>response to
 constant work rate exercise in patients with chronic heart failure. <i>Eur J Ap
pl Physiol</i> 2003; 90: 76-82.    ^cY#548.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#94#90#article#161#</span></font></p>     
 ^cY#548.htm##
00383000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704014200075002000800217#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#95#91#article#161#12#<p align
="LEFT"><font face="Arial"><span lang="EN">12. Edmond JC. Mitochondrial disorder
s. <i>Int Ophthalmol Clin</i> 2009; 49: 27-33.    ^cY#548.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#96#92#article#161#</span></font></p>     
 ^cY#548.htm##
00386000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704014500075002000800220#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#97#93#article#161#13#<p align
="LEFT"><font face="Arial"><span lang="EN">13. DiMauro S. Mitochondrial myopathi
es. <i>Curr Opin Rheumatol</i> 2006; 18: 636-641.    ^cY#548.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#98#94#article#161#</span></font></p>     
 ^cY#548.htm##
00449000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704020800075002000800283#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#99#95#article#161#14#<p align
="LEFT"><font face="Arial"><span lang="EN">14. Siciliano G, Volpi L, Piazza S, R
icci G, Mancuso M, Murri L. Functional diagnostics in mitochondrial diseases. <i
>Biosci Rep</i> 2007; 27: 53-67.    ^cY#548.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#100#96#article#161#</span></font></p>    
  ^cY#548.htm##
00459000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704021700076002000800293#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#101#97#article#161#15#<p alig
n="LEFT"><font face="Arial"><span lang="EN">15. Wong LJ. Comprehensive molecular
 diagnosis of mitochondrial disorders: qualitative and quantitative approach. <i
>Ann N Y Acad Sci</i> 2004; 1011: 246-258.    ^cY#548.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#102#98#article#161#</span></font></p>    
  ^cY#548.htm##
00479000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704023700076002000800313#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#103#99#article#161#16#<p alig
n="LEFT"><font face="Arial"><span lang="EN">16. Dandurand RJ, Matthews PM, Arnol
d DL, Eidelman DH. Mitochondrial disease. Pulmonary function, exercise performan
ce, and blood lactate levels. <i>Chest</i> 1995; 108: 182-189.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#104#100#article#161#</span></font></p>   
   ^cY#548.htm##
00528000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028500077002000800362#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#105#101#article#161#17#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">17. Flaherty KR, Wald J, Weisman IM
, Zeballos RJ, Schork MA, Blaivas M, et al. Unexplained exertional limitation: c
haracterization of patients with a mitochondrial myopathy. <i>Am J Respir Crit C
are Med</i> 2001; 164: 425-432.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#106#102#article#161#</span></font></p>   
   ^cY#548.htm##
00576000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704033300077002000800410#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#107#103#article#161#18#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">18. Haller RG, Lewis SF, Estabrook 
RW, DiMauro S, Servidei S, Foster DW. Exercise intolerance, lactic acidosis, and
 abnormal cardiopulmonary regulation in exercise associated with adult skeletal 
muscle cytochrome c oxidase deficiency. <i>J Clin Invest</i> 1989; 84: 155-161. 
   ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#108#104#article#161#</span></font></p>   
   ^cY#548.htm##
00496000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704025300077002000800330#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#109#105#article#161#19#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">19. Taivassalo T, Jensen TD, Kennaw
ay N, DiMauro S, Vissing J, Haller RG. The spectrum of exercise tolerance in mit
ochondrial myopathies: a study of 40 patients. <i>Brain</i> 2003; 126: 413-423. 
   ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#110#106#article#161#</span></font></p>   
   ^cY#548.htm##
00460000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704021700077002000800294#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#111#107#article#161#20#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">20. Tarnopolsky MA, Raha S. Mitocho
ndrial myopathies: diagnosis, exercise intolerance, and treatment options. <i>Me
d Sci Sports Exerc</i> 2005; 37: 2086-2093.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#112#108#article#161#</span></font></p>   
   ^cY#548.htm##
00458000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704021500077002000800292#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#113#109#article#161#21#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">21. Wasserman K, Whipp BJ, Casaburi
 R, Golden M, Beaver WL. Ventilatory control during exercise in man. <i>Bull Eur
 Physiopathol Respir</i> 1979; 15: 27-51.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#114#110#article#161#</span></font></p>   
   ^cY#548.htm##
00504000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026100077002000800338#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#115#111#article#161#22#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">22. Neder JA, Nery LE, Peres C, Whi
pp BJ. Reference values for dynamic responses to incremental cycle ergometry in 
males and females aged 20 to 80. <i>Am J Respir Crit Care Med</i> 2001; 164: 148
1-1486.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#116#112#article#161#</span></font></p>   
   ^cY#548.htm##
00510000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026700077002000800344#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#117#113#article#161#23#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">23. Fairbarn MS, Blackie SP, McElva
ney NG, Wiggs BR, Pare PD, Pardy RL. Prediction of heart rate and oxygen uptake 
during incremental and maximal exercise in healthy adults. <i>Chest</i> 1994; 10
5: 1365-1369.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#118#114#article#161#</span></font></p>   
   ^cY#548.htm##
00516000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027300077002000800350#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#119#115#article#161#24#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">24. Tartaglia MC, Chen JT, Caramano
s Z, Taivassalo T, Arnold DL, Argov Z. Muscle phosphorus magnetic resonance spec
troscopy oxidative indices correlate with physical activity. <i>Muscle Nerve</i>
 2000; 23: 175-181.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#120#116#article#161#</span></font></p>   
   ^cY#548.htm##
00480000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023700077002000800314#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#121#117#article#161#25#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">25. Baecke JA, Burema J, Frijters J
E. A short questionnaire for the measurement of habitual physical activity in ep
idemiological studies. <i>Am J Clin Nutr</i> 1982; 36: 936-942.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#122#118#article#161#</span></font></p>   
   ^cY#548.htm##
00530000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028700077002000800364#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#123#119#article#161#26#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">26. Seligman AM, Karnovsky MJ, Wass
erkrug HL, Hanker JS. Nondroplet ultrastructural demonstration of cytochrome oxi
dase activity with a polymerizing osmiophilic reagent, diaminobenzidine (DAB). <
i>J Cell Biol</i> 1968; 38: 1-14.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#124#120#article#161#</span></font></p>   
   ^cY#548.htm##
00457000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704021400077002000800291#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#125#121#article#161#27#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">27. Whipp BJ, Davis JA, Torres F, W
asserman K. A test to determine parameters of aerobic function during exercise. 
<i>J Appl Physiol</i> 1981; 50: 217-221.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#126#122#article#161#</span></font></p>   
   ^cY#548.htm##
00446000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704020300077002000800280#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#127#123#article#161#28#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">28. Beaver WL, Wasserman K, Whipp B
J. A new method for detecting anaerobic threshold by gas exchange. <i>J Appl Phy
siol</i> 1986; 60: 2020-2027.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#128#124#article#161#</span></font></p>   
   ^cY#548.htm##
00518000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027500077002000800352#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#129#125#article#161#29#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">29. Neder JA, Nery LE, Castelo A, A
ndreoni S, Lerario MC, Sachs A, et al. Prediction of metabolic and cardiopulmona
ry responses to maximum cycle ergometry: a randomised study. <i>Eur Respir J</i>
 1999; 14: 1304-1313.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#130#126#article#161#</span></font></p>   
   ^cY#548.htm##
00510000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026700077002000800344#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#131#127#article#161#30#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">30. Barstow TJ, Jones AM, Nguyen PH
, Casaburi R. Influence of muscle fibre type and fitness on the oxygen uptake/po
wer output slope during incremental exercise in humans. <i>Exp Physiol</i> 2000;
 85: 109-116.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#132#128#article#161#</span></font></p>   
   ^cY#548.htm##
00437000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704019400077002000800271#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#133#129#article#161#31#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">31. Glantz SA. A method to estimate
 the point at which two lines intersect from noisy data. <i>Am J Physiol</i> 199
0; 259: H1305-H1306.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#134#130#article#161#</span></font></p>   
   ^cY#548.htm##
00535000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029200077002000800369#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#135#131#article#161#32#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">32. Grassi B, Marzorati M, Lanfranc
oni F, Ferri A, Longaretti M, Stucchi A, et al. Impaired oxygen extraction in me
tabolic myopathies: detection and quantification by near-infrared spectroscopy. 
<i>Muscle Nerve</i> 2007; 35: 510-520.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#136#132#article#161#</span></font></p>   
   ^cY#548.htm##
00506000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026300077002000800340#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#137#133#article#161#33#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">33. Ibanez J, Rama R, Riera M, Prat
s MT, Palacios L. Severe hypoxia decreases oxygen uptake relative to intensity d
uring submaximal graded exercise. <i>Eur J Appl Physiol Occup Physiol</i> 1993; 
67: 7-13.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#138#134#article#161#</span></font></p>   
   ^cY#548.htm##
00471000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704022800077002000800305#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#139#135#article#161#34#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">34. Whipp BJ, Mahler M. Dynamics of
 pulmonary gas exchange during exercise. In: West JB (Editor), <i>Pulmonary Gas 
Exchange</i>. New York: Academic Press; 1982. p 36-96.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#140#136#article#161#</span></font></p>   
   ^cY#548.htm##
00486000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024300077002000800320#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#141#137#article#161#35#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">35. Olsen DB, Langkilde AR, Orngree
n MC, Rostrup E, Schwartz M, Vissing J. Muscle structural changes in mitochondri
al myopathy relate to genotype. <i>J Neurol</i> 2003; 250: 1328-1334.    ^cY#548
.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#142#138#article#161#</span></font></p>   
   ^cY#548.htm##
00530000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028700077002000800364#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#143#139#article#161#36#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">36. Enns GM, Hoppel CL, DeArmond SJ
, Schelley S, Bass N, Weisiger K, et al. Relationship of primary mitochondrial r
espiratory chain dysfunction to fiber type abnormalities in skeletal muscle. <i>
Clin Genet</i> 2005; 68: 337-348.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#144#140#article#161#</span></font></p>   
   ^cY#548.htm##
00469000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704022600077002000800303#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#145#141#article#161#37#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">37. Jeppesen TD, Schwartz M, Olsen 
DB, Vissing J. Oxidative capacity correlates with muscle mutation load in mitoch
ondrial myopathy. <i>Ann Neurol</i> 2003; 54: 86-92.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#146#142#article#161#</span></font></p>   
   ^cY#548.htm##
00454000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704021100077002000800288#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#147#143#article#161#38#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">38. Haller RG, Lewis SF, Cook JD, B
lomqvist CG. Hyperkinetic circulation during exercise in neuromuscular disease. 
<i>Neurology</i> 1983; 33: 1283-1287.    ^cY#548.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#148#144#article#161#</span></font></p>   
   ^cY#548.htm##
00477000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023400077002000800311#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#p#149#145#article#161#39#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">39. Jeppesen TD, Quistorff B, Wibra
nd F, Vissing J. 31P-MRS of skeletal muscle is not a sensitive diagnostic test f
or mitochondrial myopathy. <i>J Neurol</i> 2007; 254: 29-37.    ^cY#548.htm##
00280000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704005200074002000800126#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#150#146#article#161#</span></font></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#548.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033500074002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#151#147#article#161#<P><font face="Arial,
 Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE
=4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#548.ht
m##
00526000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704029800074002000800372#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#152#148#article#161#<p ALIGN="LEFT"><font
 face="Arial"><span lang="EN">Research supported by FAPESP. A.C. Gimenes is a Ma
ster&rsquo;s graduate student supported by a CAPES fellowship program. L.E. Nery
 and J.A. Neder are Established Investigators (level II) of CNPq.</span></font><
/p>  <HR ALIGN=LEFT SIZE=2>      ^cY#548.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033600074002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#153#149#article#161#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#548.h
tm##
00662000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704043400074002000800508#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#154#150#article#161#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/r
ecor.gif" border="0"></a> Address for correspondence:</b></font> <font face="Ari
al"><span lang="EN">L.E. Nery, SEFICE, EPM, UNIFESP, Rua Professor Francisco de 
Castro, 54, 04020-050 S&atilde;o Paulo, SP, Brasil. Fax: +55-11-5575-2843. E-mai
l: <a href="mailto:lenery@pneumo.epm.br">lenery@pneumo.epm.br</a></span></font><
/p>      ^cY#548.htm##
00447000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704021900074002000800293#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#155#151#article#161#<p ALIGN="LEFT"><i><f
ont face="Arial"><span lang="EN">Received June 24, 2010. Accepted February 16, 2
011. Available online March 4, 2011. Published April 11, 2011.</span></font></i>
</p>  <HR ALIGN=LEFT SIZE=2>      ^cY#548.htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#156#152#article#161#<div align="center"> 
       ^cY#548.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#157#153#article#161#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#548.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#158#154#article#161#<br>                ^
cY#548.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#159#155#article#161#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#548
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#160#156#article#161#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#548.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#161#157#article#161#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#548.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#162#158#article#161#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#548.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#163#159#article#161#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#548.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#164#160#article#161#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#548.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\548.htm#S#p#165#161#article#161#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#548.htm##
00609000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100014000900100
01400104010001900118012009200137030001300229065000900242064000500251031000300256
014000800259865000900267002000800276035001000284801001300294#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\548.htm#S#c#166#1#article#39#1#^rND^sHansen^nJE#^rND^sSue
^nDY#^rND^sOren^nA#^rND^sWasserman^nK#Relation of oxygen uptake to work rate in 
normal men and men with circulatory disorders^len#Am J Cardiol#19870000#1987#59#
669-674#20110400#548.htm#0002-9149#Am J Cardiol##
00595000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100018000900100
01700108010001900125012008400144030003300228710000200261065000900263064000500272
031000300277014000800280865000900288002000800297#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\548.htm#S#c#167#2#article#39#2#^rND^sHansen^nJE#^rND^sCasaburi^nR#^rN
D^sCooper^nDM#^rND^sWasserman^nK#Oxygen uptake as related to work rate increment
 during cycle ergometer exercise^len#Eur J Appl Physiol Occup Physiol#2#19880000
#1988#57#140-145#20110400#548.htm##
00588000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100014000900100
01900104012011000123030003300233710000200266065000900268064000500277031000300282
014000800285865000900293002000800302#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\5
48.htm#S#c#168#3#article#39#3#^rND^sZoladz^nJA#^rND^sDuda^nK#^rND^sMajerczak^nJ#
Oxygen uptake does not increase linearly at high power outputs during incrementa
l exercise test in humans^len#Eur J Appl Physiol Occup Physiol#2#19980000#1998#7
7#445-451#20110400#548.htm##
00627000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100016000910100
01700107010001800124012009900142030001500241065000900256064000500265031000300270
014001000273865000900283002000800292035001000300801001500310#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\548.htm#S#c#169#4#article#39#4#^rND^sBarstow^nTJ#^rND^sJo
nes^nAM#^rND^sNguyen^nPH#^rND^sCasaburi^nR#Influence of muscle fiber type and pe
dal frequency on oxygen uptake kinetics of heavy exercise^len#J Appl Physiol#199
60000#1996#81#1642-1650#20110400#548.htm#0021-8987#J Appl Physiol##
00604000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100019000890100
01800108012009800126030001900224065000900243064000500252031000300257014000800260
865000900268002000800277035001000285801001900295#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\548.htm#S#c#170#5#article#39#5#^rND^sJones^nAM#^rND^sCampbell^nIT#^rN
D^sPringle^nJS#Influence of muscle fibre type and pedal rate on the VO2-work rat
e slope during ramp exercise^len#Eur J Appl Physiol#20040000#2004#91#238-245#201
10400#548.htm#0301-5548#Eur J Appl Physiol##
00520000000000265000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100014000730120073000870300
02100160065000900181064000500190031000300195014000800198865000900206002000800215
035001000223801002100233#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#1
71#6#article#39#6#^rND^sItoh^nH#Oxygen uptake: work rate relationship in patient
s with heart disease^len#Med Sci Sports Exerc#19920000#1992#37#374-380#20110400#
548.htm#0195-9131#Med Sci Sports Exerc##
00636000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100017000890100
01500106010001900121010001800140012009900158030000600257065000900263064000500272
031000400277014000800281865000900289002000800298035001000306801000600316#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#172#7#article#39#7#^rND^sLewis^nM
I#^rND^sBelman^nMJ#^rND^sMonn^nSA#^rND^sElashoff^nJD#^rND^sKoerner^nSK#The relat
ionship between oxygen consumption and work rate in patients with airflow obstru
ction^len#Chest#19940000#1994#106#366-372#20110400#548.htm#0012-3692#Chest##
00697000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100019000910100
01700110010001500127010001700142010001800159810000600177012009800183030001200281
06500090029306400050030203100030030701400100031086500090032000200080032903500100
0337801001200347#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#173#8#art
icle#39#8#^rND^sSakauchi^nM#^rND^sMatsumura^nT#^rND^sYamaoka^nT#^rND^sKoami^nT#^
rND^sShibata^nM#^rND^sNakamura^nM#et al#Reduced muscle uptake of oxygen during e
xercise in patients with systemic lupus erythematosus^len#J Rheumatol#19950000#1
995#22#1483-1487#20110400#548.htm#0315-162X#J Rheumatol##
00613000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100017000890100
01600106010001800122010001600140012007600156030000600232065000900238064000500247
031000400252014001000256865000900266002000800275035001000283801000600293#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#174#9#article#39#9#^rND^sKimura^n
H#^rND^sKawagoe^nY#^rND^sKaneko^nN#^rND^sFessler^nHE#^rND^sHosoda^nS#Low efficie
ncy of oxygen utilization during exercise in hyperthyroidism^len#Chest#19960000#
1996#110#1264-1270#20110400#548.htm#0012-3692#Chest##
00621000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100018000900100
01600108010001800124010001600142012008700158030000600245065000900251064000500260
031000300265014000600268865000900274002000800283035001000291801000600301#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#175#10#article#39#10#^rND^sJones^
nS#^rND^sElliott^nPM#^rND^sSharma^nS#^rND^sMcKenna^nWJ#^rND^sWhipp^nBJ#Cardiopul
monary responses to exercise in patients with hypertrophic cardiomyopathy^len#He
art#19980000#1998#80#60-67#20110400#548.htm#1355-6037#Heart##
00768000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930100
01900109010001600128010001400144010001800158012017800176030001900354065000900373
06400050038203100030038701400060039086500090039600200080040503500100041380100190
0423#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#176#11#article#39#11#
^rND^sToyofuku^nM#^rND^sTakaki^nH#^rND^sSugimachi^nM#^rND^sKawada^nT#^rND^sGoto^
nY#^rND^sSunagawa^nK#Reduced oxygen uptake increase to work rate increment (Delt
aVO2/DeltaWR) is predictable by VO2 response to constant work rate exercise in p
atients with chronic heart failure^len#Eur J Appl Physiol#20030000#2003#90#76-82
#20110400#548.htm#0301-5548#Eur J Appl Physiol##
00476000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750120028000920300
02000120065000900140064000500149031000300154014000600157865000900163002000800172
035001000180801002000190#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#1
77#12#article#39#12#^rND^sEdmond^nJC#Mitochondrial disorders^len#Int Ophthalmol 
Clin#20090000#2009#49#27-33#20110400#548.htm#0020-8167#Int Ophthalmol Clin##
00479000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750120029000920300
02000121065000900141064000500150031000300155014000800158865000900166002000800175
035001000183801002000193#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#1
78#13#article#39#13#^rND^sDiMauro^nS#Mitochondrial myopathies^len#Curr Opin Rheu
matol#20060000#2006#18#636-641#20110400#548.htm#1040-8711#Curr Opin Rheumatol##
00623000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100015000940100
01600109010001500125010001700140010001500157012005300172030001100225065000900236
06400050024503100030025001400060025386500090025900200080026803500100027680100110
0286#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#179#14#article#39#14#
^rND^sSiciliano^nG#^rND^sVolpi^nL#^rND^sPiazza^nS#^rND^sRicci^nG#^rND^sMancuso^n
M#^rND^sMurri^nL#Functional diagnostics in mitochondrial diseases^len#Biosci Rep
#20070000#2007#27#53-67#20110400#548.htm#0144-8463#Biosci Rep##
00548000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750120104000900300
01700194065000900211064000500220031000500225014000800230865000900238002000800247
035001000255801001700265#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#1
80#15#article#39#15#^rND^sWong^nLJ#Comprehensive molecular diagnosis of mitochon
drial disorders: qualitative and quantitative approach^len#Ann N Y Acad Sci#2004
0000#2004#1011#246-258#20110400#548.htm#0077-8923#Ann N Y Acad Sci##
00611000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100019000950100
01700114010001900131012009400150030000600244065000900250064000500259031000400264
014000800268865000900276002000800285035001000293801000600303#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\548.htm#S#c#181#16#article#39#16#^rND^sDandurand^nRJ#^rND
^sMatthews^nPM#^rND^sArnold^nDL#^rND^sEidelman^nDH#Mitochondrial disease: Pulmon
ary function, exercise performance, and blood lactate levels^len#Chest#19950000#
1995#108#182-189#20110400#548.htm#0012-3692#Chest##
00726000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100014000940100
01800108010001900126010001700145010001700162810000600179012009800185030002600283
06500090030906400050031803100040032301400080032786500090033500200080034403500100
0352801002600362#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#182#17#ar
ticle#39#17#^rND^sFlaherty^nKR#^rND^sWald^nJ#^rND^sWeisman^nIM#^rND^sZeballos^nR
J#^rND^sSchork^nMA#^rND^sBlaivas^nM#et al#Unexplained exertional limitation: cha
racterization of patients with a mitochondrial myopathy^len#Am J Respir Crit Car
e Med#20010000#2001#164#425-432#20110400#548.htm#1073-449X#Am J Respir Crit Care
 Med##
00751000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
02000108010001700128010001800145010001700163012016500180030001400345065000900359
06400050036803100030037301400080037686500090038400200080039303500100040180100140
0411#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#183#18#article#39#18#
^rND^sHaller^nRG#^rND^sLewis^nSF#^rND^sEstabrook^nRW#^rND^sDiMauro^nS#^rND^sServ
idei^nS#^rND^sFoster^nDW#Exercise intolerance, lactic acidosis, and abnormal car
diopulmonary regulation in exercise associated with adult skeletal muscle cytoch
rome c oxidase deficiency^len#J Clin Invest#19890000#1989#84#155-161#20110400#54
8.htm#0021-9738#J Clin Invest##
00663000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100017000950100
01800112010001700130010001700147010001700164012009100181030000600272065000900278
06400050028703100040029201400080029686500090030400200080031303500100032180100060
0331#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#184#19#article#39#19#
^rND^sTaivassalo^nT#^rND^sJensen^nTD#^rND^sKennaway^nN#^rND^sDiMauro^nS#^rND^sVi
ssing^nJ#^rND^sHaller^nRG#The spectrum of exercise tolerance in mitochondrial my
opathies: a study of 40 patients^len#Brain#20030000#2003#126#413-423#20110400#54
8.htm#0006-8950#Brain##
00570000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100022000750100014000970120
08500111030002100196065000900217064000500226031000300231014001000234865000900244
002000800253035001000261801002100271#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\5
48.htm#S#c#185#20#article#39#20#^rND^sTarnopolsky^nMA#^rND^sRaha^nS#Mitochondria
l myopathies: diagnosis, exercise intolerance, and treatment options^len#Med Sci
 Sports Exerc#20050000#2005#37#2086-2093#20110400#548.htm#0195-9131#Med Sci Spor
ts Exerc##
00630000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100016000940100
01800110010001600128010001700144012004700161030002900208065000900237064000500246
031000300251014000600254865000900260002000800269035001000277801002900287#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#186#21#article#39#21#^rND^sWasser
man^nK#^rND^sWhipp^nBJ#^rND^sCasaburi^nR#^rND^sGolden^nM#^rND^sBeaver^nWL#Ventil
atory control during exercise in man^len#Bull Eur Physiopathol Respir#19790000#1
979#15#27-51#20110400#548.htm#0395-3890#Bull Eur Physiopathol Respir##
00655000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100015000910100
01500106010001600121012010900137030002600246065000900272064000500281031000400286
014001000290865000900300002000800309035001000317801002600327#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\548.htm#S#c#187#22#article#39#22#^rND^sNeder^nJA#^rND^sNe
ry^nLE#^rND^sPeres^nC#^rND^sWhipp^nBJ#Reference values for dynamic responses to 
incremental cycle ergometry in males and females aged 20 to 80^len#Am J Respir C
rit Care Med#20010000#2001#164#1481-1486#20110400#548.htm#1073-449X#Am J Respir 
Crit Care Med##
00677000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100018000940100
02000112010001600132010001500148010001600163012010500179030000600284065000900290
06400050029903100040030401400100030886500090031800200080032703500100033580100060
0345#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#188#23#article#39#23#
^rND^sFairbarn^nMS#^rND^sBlackie^nSP#^rND^sMcElvaney^nNG#^rND^sWiggs^nBR#^rND^sP
are^nPD#^rND^sPardy^nRL#Prediction of heart rate and oxygen uptake during increm
ental and maximal exercise in healthy adults^len#Chest#19940000#1994#105#1365-13
69#20110400#548.htm#0012-3692#Chest##
00690000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100015000950100
01900110010002000129010001700149010001500166012010500181030001300286065000900299
06400050030803100030031301400080031686500090032400200080033303500100034180100130
0351#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#189#24#article#39#24#
^rND^sTartaglia^nMC#^rND^sChen^nJT#^rND^sCaramanos^nZ#^rND^sTaivassalo^nT#^rND^s
Arnold^nDL#^rND^sArgov^nZ#Muscle phosphorus magnetic resonance spectroscopy oxid
ative indices correlate with physical activity^len#Muscle Nerve#20000000#2000#23
#175-181#20110400#548.htm#0148-639X#Muscle nerve##
00602000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
01900108012010300127030001500230065000900245064000500254031000300259014000800262
865000900270002000800279035001000287801001500297#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\548.htm#S#c#190#25#article#39#25#^rND^sBaecke^nJA#^rND^sBurema^nJ#^rN
D^sFrijters^nJE#A short questionnaire for the measurement of habitual physical a
ctivity in epidemiological studies^len#Am J Clin Nutr#19820000#1982#36#936-942#2
0110400#548.htm#0002-9165#Am J Clin Nutr##
00667000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100020000940100
02100114010001700135012014000152030001200292065000900304064000500313031000300318
014000500321865000900326002000800335035001000343801001200353#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\548.htm#S#c#191#26#article#39#26#^rND^sSeligman^nAM#^rND^
sKarnovsky^nMJ#^rND^sWasserkrug^nHL#^rND^sHanker^nJS#Nondroplet ultrastructural 
demonstration of cytochrome oxidase activity with a polymerizing osmiophilic rea
gent, diaminobenzidine (DAB)^len#J Cell Biol#19680000#1968#38#1-14#20110400#548.
htm#0021-9525#J Cell Biol##
00597000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100016000910100
01600107010001900123012007100142030001500213065000900228064000500237031000300242
014000800245865000900253002000800262035001000270801001500280#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\548.htm#S#c#192#27#article#39#27#^rND^sWhipp^nBJ#^rND^sDa
vis^nJA#^rND^sTorres^nF#^rND^sWasserman^nK#A test to determine parameters of aer
obic function during exercise^len#J Appl Physiol#19810000#1981#50#217-221#201104
00#548.htm#0021-8987#J Appl Physiol##
00568000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100019000920100
01600111012006700127030001500194065000900209064000500218031000300223014001000226
865000900236002000800245035001000253801001500263#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\548.htm#S#c#193#28#article#39#28#^rND^sBeaver^nWL#^rND^sWasserman^nK#
^rND^sWhipp^nBJ#A new method for detecting anaerobic threshold by gas exchange^l
en#J Appl Physiol#19860000#1986#60#2020-2027#20110400#548.htm#0021-8987#J Appl P
hysiol##
00703000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100015000910100
01700106010001800123010001800141010001500159810000600174012010500180030001300285
06500090029806400050030703100030031201400100031586500090032500200080033403500100
0342801001300352#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#194#29#ar
ticle#39#29#^rND^sNeder^nJA#^rND^sNery^nLE#^rND^sCastelo^nA#^rND^sAndreoni^nS#^r
ND^sLerario^nMC#^rND^sSachs^nA#et al#Prediction of metabolic and cardiopulmonary
 responses to maximum cycle ergometry: a randomised study^len#Eur Respir J#19990
000#1999#14#1304-1313#20110400#548.htm#0903-1936#Eur Respir J##
00647000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930100
01700109010001800126012012500144030001200269065000900281064000500290031000300295
014000800298865000900306002000800315035001000323801001200333#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\548.htm#S#c#195#30#article#39#30#^rND^sBarstow^nTJ#^rND^s
Jones^nAM#^rND^sNguyen^nPH#^rND^sCasaburi^nR#Influence of muscle fibre type and 
fitness on the oxygen uptake/power output slope during incremental exercise in h
umans^len#Exp Physiol#20000000#2000#85#109-116#20110400#548.htm#0958-0670#Exp Ph
ysiol##
00521000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750120080000920300
01300172065000900185064000500194031000400199014001200203865000900215002000800224
035001000232801001300242#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#1
96#31#article#39#31#^rND^sGlantz^nSA#A method to estimate the point at which two
 lines intersect from noisy data^len#Am J Physiol#19900000#1990#259#H1305-H1306#
20110400#548.htm#0002-9513#Am J Physiol##
00720000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910100
02100110010001500131010002000146010001700166810000600183012011500189030001300304
06500090031706400050032603100030033101400080033486500090034200200080035103500100
0359801001300369#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#197#32#ar
ticle#39#32#^rND^sGrassi^nB#^rND^sMarzorati^nM#^rND^sLanfranconi^nF#^rND^sFerri^
nA#^rND^sLongaretti^nM#^rND^sStucchi^nA#et al#Impaired oxygen extraction in meta
bolic myopathies: detection and quantification by near-infrared spectroscopy^len
#Muscle Nerve#20070000#2007#35#510-520#20110400#548.htm#0148-639X#Muscle nerve##
00629000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100014000910100
01500105010001600120010001800136012009900154030003300253710000200286065000900288
064000500297031000300302014000500305865000900310002000800319#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\548.htm#S#c#198#33#article#39#33#^rND^sIbanez^nJ#^rND^sRa
ma^nR#^rND^sRiera^nM#^rND^sPrats^nMT#^rND^sPalacios^nL#Severe hypoxia decreases 
oxygen uptake relative to intensity during submaximal graded exercise^len#Eur J 
Appl Physiol Occup Physiol#2#19930000#1993#67#7-13#20110400#548.htm##
00543000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100016000910120
05500107016001500162018002700177066000900204062001500213065000900228064000500237
014000600242865000900248002000800257#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\5
48.htm#S#c#199#34#article#39#34#^rND^sWhipp^nBJ#^rND^sMahler^nM#Dynamics of pulm
onary gas exchange during exercise^len#^rED^sWest^nJB#Pulmonary Gas Exchange^len
#New York#Academic Press#19820000#1982#36-96#20110400#548.htm##
00656000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100020000910100
01900111010001700130010001800147010001700165012007500182030000900257065000900266
06400050027503100040028001400100028486500090029400200080030303500100031180100090
0321#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#200#35#article#39#35#
^rND^sOlsen^nDB#^rND^sLangkilde^nAR#^rND^sOrngreen^nMC#^rND^sRostrup^nE#^rND^sSc
hwartz^nM#^rND^sVissing^nJ#Muscle structural changes in mitochondrial myopathy r
elate to genotype^len#J Neurol#20030000#2003#250#1328-1334#20110400#548.htm#0340
-5354#J Neurol##
00713000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100017000900100
01900107010001800126010001400144010001800158810000600176012011900182030001100301
06500090031206400050032103100030032601400080032986500090033700200080034603500100
0354801001100364#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\548.htm#S#c#201#36#ar
ticle#39#36#^rND^sEnns^nGM#^rND^sHoppel^nCL#^rND^sDeArmond^nSJ#^rND^sSchelley^nS
#^rND^sBass^nN#^rND^sWeisiger^nK#et al#Relationship of primary mitochondrial res
piratory chain dysfunction to fiber type abnormalities in skeletal muscle^len#Cl
in Genet#20050000#2005#68#337-348#20110400#548.htm#0009-9163#Clin Genet##
00605000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100018000940100
01600112010001700128012008600145030001100231065000900242064000500251031000300256
014000600259865000900265002000800274035001000282801001100292#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\548.htm#S#c#202#37#article#39#37#^rND^sJeppesen^nTD#^rND^
sSchwartz^nM#^rND^sOlsen^nDB#^rND^sVissing^nJ#Oxidative capacity correlates with
 muscle mutation load in mitochondrial myopathy^len#Ann Neurol#20030000#2003#54#
86-92#20110400#548.htm#0364-5134#Ann Neurol##
00589000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
01500108010002000123012007000143030001000213065000900223064000500232031000300237
014001000240865000900250002000800259035001000267801001000277#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\548.htm#S#c#203#38#article#39#38#^rND^sHaller^nRG#^rND^sL
ewis^nSF#^rND^sCook^nJD#^rND^sBlomqvist^nCG#Hyperkinetic circulation during exer
cise in neuromuscular disease^len#Neurology#19830000#1983#33#1283-1287#20110400#
548.htm#0028-3878#Neurology##
00611000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100019000940100
01700113010001700130012009300147030000900240065000900249064000500258031000400263
014000600267865000900273002000800282035001000290801000900300#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\548.htm#S#c#204#39#article#39#39#^rND^sJeppesen^nTD#^rND^
sQuistorff^nB#^rND^sWibrand^nF#^rND^sVissing^nJ#31P-MRS of skeletal muscle is no
t a sensitive diagnostic test for mitochondrial myopathy^len#J Neurol#20070000#2
007#254#29-37#20110400#548.htm#0340-5354#J Neurol##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#o#1#1#article#1#201
10411#094531#594.htm#172##
03427000000000589000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015901201210
01690100033002900100032003230100026003550100027003810100030004080700141004380700
08900579070011100668070010300779083175200882085000802634085005102642085002502693
08500190271808500330273711700060277007200030277611200090277911100140278811400090
2802113001802811002000802829#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S
#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#12#BJMBR750#FAPESP#Braz J Med Biol R
es#44#4#20110400#^f345^l353#0100-879X#Manual and semi-automatic quantification o
f in vivo ¹H-MRS data for the classification of human primary brain tumors^len#^
rND^1A01 A04^nS.^sCuellar-Baena#^rND^1A02 A04^nL.M.T.S.^sMorais#^rND^1A03 A04^nF
.^sCendes#^rND^1A02 A04^nA.V.^sFaria#^rND^1A01 A04^nG.^sCastellano#Universidade 
de Campinas^iA01^1Faculdade de Ciências Médicas^2Instituto de Física Gleb Watagh
in^3Departamento de Raios Cósmicos e Cronologia#Universidade de Campinas^iA02^1F
aculdade de Ciências Médicas^2Departamento de Radiologia#Universidade de Campina
s^iA03^1Faculdade de Ciências Médicas^2Departamento de Neurologia^cCampinas^sSP^
pBrasil#Programa CInAPCe (Cooperação Interinstitucional de Apoio a Pesquisas sob
re o Cérebro)^iA04^cSP^pBrasil#^len^aIn vivo proton magnetic resonance spectrosc
opy (¹H-MRS) is a technique capable of assessing biochemical content and pathway
s in normal and pathological tissue. In the brain, ¹H-MRS complements the inform
ation given by magnetic resonance images. The main goal of the present study was
 to assess the accuracy of ¹H-MRS for the classification of brain tumors in a pi
lot study comparing results obtained by manual and semi-automatic quantification
 of metabolites. In vivo single-voxel ¹H-MRS was performed in 24 control subject
s and 26 patients with brain neoplasms that included meningiomas, high-grade neu
roglial tumors and pilocytic astrocytomas. Seven metabolite groups (lactate, lip
ids, N-acetyl-aspartate, glutamate and glutamine group, total creatine, total ch
oline, myo-inositol) were evaluated in all spectra by two methods: a manual one 
consisting of integration of manually defined peak areas, and the advanced metho
d for accurate, robust and efficient spectral fitting (AMARES), a semi-automatic
 quantification method implemented in the jMRUI software. Statistical methods in
cluded discriminant analysis and the leave-one-out cross-validation method. Both
 manual and semi-automatic analyses detected differences in metabolite content b
etween tumor groups and controls (P < 0.005). The classification accuracy obtain
ed with the manual method was 75% for high-grade neuroglial tumors, 55% for meni
ngiomas and 56% for pilocytic astrocytomas, while for the semi-automatic method 
it was 78, 70, and 98%, respectively. Both methods classified all control subjec
ts correctly. The study demonstrated that ¹H-MRS accurately differentiated norma
l from tumoral brain tissue and confirmed the superiority of the semi-automatic 
quantification method.#^dnd^i1#^tm^len^kProton magnetic resonance spectroscopy^i
1#^tm^len^kBrain tumors^i1#^tm^len^kAMARES^i1#^tm^len^kTumor classification^i1#o
ther#27#20100618#June 18, 2010#20110211#February 11, 2011#594.htm##
03538000000000589000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015901201460
01690100033003150100032003480100026003800100027004060100030004330700141004630700
08900604070011100693070010300804083182400907085000802731085005102739085002502790
08500190281508500330283411700060286707200030287311200090287611100210288511400090
2906113002502915002000802940#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S
#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#12#BJMBR750#FAPESP#Braz J Med Biol R
es#44#4#20110400#^f345^l353#0100-879X#<b>Manual and semi-automatic quantificatio
n of <i>in vivo</i> <sup>1</sup>H-MRS data for the classification of human prima
ry brain tumors</b>^len#^rND^1A01 A04^nS.^sCuellar-Baena#^rND^1A02 A04^nL.M.T.S.
^sMorais#^rND^1A03 A04^nF.^sCendes#^rND^1A02 A04^nA.V.^sFaria#^rND^1A01 A04^nG.^
sCastellano#Universidade de Campinas^iA01^1Faculdade de Ciências Médicas^2Instit
uto de Física Gleb Wataghin^3Departamento de Raios Cósmicos e Cronologia#Univers
idade de Campinas^iA02^1Faculdade de Ciências Médicas^2Departamento de Radiologi
a#Universidade de Campinas^iA03^1Faculdade de Ciências Médicas^2Departamento de 
Neurologia^cCampinas^sSP^pBrasil#Programa CInAPCe (Cooperação Interinstitucional
 de Apoio a Pesquisas sobre o Cérebro)^iA04^cSP^pBrasil#^len^a<i>In vivo</i> pro
ton magnetic resonance spectroscopy (<sup>1</sup>H-MRS) is a technique capable o
f assessing biochemical content and pathways in normal and pathological tissue. 
In the brain, <sup>1</sup>H-MRS complements the information given by magnetic re
sonance images. The main goal of the present study was to assess the accuracy of
 <sup>1</sup>H-MRS for the classification of brain tumors in a pilot study compa
ring results obtained by manual and semi-automatic quantification of metabolites
. <i>In vivo</i> single-voxel <sup>1</sup>H-MRS was performed in 24 control subj
ects and 26 patients with brain neoplasms that included meningiomas, high-grade 
neuroglial tumors and pilocytic astrocytomas. Seven metabolite groups (lactate, 
lipids, N-acetyl-aspartate, glutamate and glutamine group, total creatine, total
 choline, myo-inositol) were evaluated in all spectra by two methods: a manual o
ne consisting of integration of manually defined peak areas, and the advanced me
thod for accurate, robust and efficient spectral fitting (AMARES), a semi-automa
tic quantification method implemented in the jMRUI software. Statistical methods
 included discriminant analysis and the leave-one-out cross-validation method. B
oth manual and semi-automatic analyses detected differences in metabolite conten
t between tumor groups and controls (P &lt; 0.005). The classification accuracy 
obtained with the manual method was 75% for high-grade neuroglial tumors, 55% fo
r meningiomas and 56% for pilocytic astrocytomas, while for the semi-automatic m
ethod it was 78, 70, and 98%, respectively. Both methods classified all control 
subjects correctly. The study demonstrated that <sup>1</sup>H-MRS accurately dif
ferentiated normal from tumoral brain tissue and confirmed the superiority of th
e semi-automatic quantification method.#^dnd^i1#^tm^len^kProton magnetic resonan
ce spectroscopy^i1#^tm^len^kBrain tumors^i1#^tm^len^kAMARES^i1#^tm^len^kTumor cl
assification^i1#other#27#20100618#<i>June 18, 2010</i>#20110211#<i>February 11, 
2011</i>#594.htm##
03636000000000613000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01760120121001860100032003070100034003390100025003730100027003980100029004250700
16500454070011300619070011300732070010500845083178000950085000802730085005102738
08500250278908500190281408500330283311700060286607200030287211200090287511100140
2884114000902898113001802907002000802925008008902933#v44n4#V:\SciELO\serial\bjmb
r\v44n4\markup\594.htm#S#l#4#1#article#1#^mApr.^a2011#oa#en#bjmbr#1#3.1#ilus#tab
#12#BJMBR750#FAPESP#Braz. j. med. biol. res#44#4#20110400#^f345^l353#0100-879X#M
anual and semi-automatic quantification of in vivo ¹H-MRS data for the classific
ation of human primary brain tumors^len#^rND^1A01 A04^nS^sCuellar-Baena#^rND^1A0
2 A04^nL. M. T. S^sMorais#^rND^1A03 A04^nF^sCendes#^rND^1A02 A04^nA. V^sFaria#^r
ND^1A01 A04^nG^sCastellano#^iA01^1Universidade de Campinas^2Faculdade de Ciência
s Médicas^3Instituto de Física Gleb Wataghin. Departamento de Raios Cósmicos e C
ronologia^cCampinas^sSP^pBrasil#^iA02^1Universidade de Campinas^2Faculdade de Ci
ências Médicas^3Departamento de Radiologia^cCampinas^sSP^pBrasil#^iA03^1Universi
dade de Campinas^2Faculdade de Ciências Médicas^3Departamento de Neurologia^cCam
pinas^sSP^pBrasil#^iA04^1Programa CInAPCe (Cooperação Interinstitucional de Apoi
o a Pesquisas sobre o Cérebro)^cSP^pBrasil#^len^aIn vivo proton magnetic resonan
ce spectroscopy (¹H-MRS) is a technique capable of assessing biochemical content
 and pathways in normal and pathological tissue. In the brain, ¹H-MRS complement
s the information given by magnetic resonance images. The main goal of the prese
nt study was to assess the accuracy of ¹H-MRS for the classification of brain tu
mors in a pilot study comparing results obtained by manual and semi-automatic qu
antification of metabolites. In vivo single-voxel ¹H-MRS was performed in 24 con
trol subjects and 26 patients with brain neoplasms that included meningiomas, hi
gh-grade neuroglial tumors and pilocytic astrocytomas. Seven metabolite groups (
lactate, lipids, N-acetyl-aspartate, glutamate and glutamine group, total creati
ne, total choline, myo-inositol) were evaluated in all spectra by two methods: a
 manual one consisting of integration of manually defined peak areas, and the ad
vanced method for accurate, robust and efficient spectral fitting (AMARES), a se
mi-automatic quantification method implemented in the jMRUI software. Statistica
l methods included discriminant analysis and the leave-one-out cross-validation 
method. Both manual and semi-automatic analyses detected differences in metaboli
te content between tumor groups and controls (P < 0.005). The classification acc
uracy obtained with the manual method was 75 percent for high-grade neuroglial t
umors, 55 percent for meningiomas and 56 percent for pilocytic astrocytomas, whi
le for the semi-automatic method it was 78, 70, and 98 percent, respectively. Bo
th methods classified all control subjects correctly. The study demonstrated tha
t ¹H-MRS accurately differentiated normal from tumoral brain tissue and confirme
d the superiority of the semi-automatic quantification method.#^dnd^i1#^tm^len^k
Proton magnetic resonance spectroscopy^i1#^tm^len^kBrain tumors^i1#^tm^len^kAMAR
ES^i1#^tm^len^kTumor classification^i1#other#27#20100618#June 18, 2010#20110211#
February 11, 2011#594.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_a
rttext&pid=S0100-879X2011000400012##
00373000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014900070002000800219#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#5#1#article#141#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 345-353  </B> </font></P>      ^cY#594.htm##
00534000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704031000070002000800380#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#6#2#article#141#<p ALIGN="LEFT"><strong><
font face="Arial"><span lang="EN"><font size="5">Manual and semi-automatic quant
ification of </font></span></font><font size="5" face="Arial"><span lang="EN"><i
>in vivo</i> <sup>1</sup>H-MRS data for the classification of human primary brai
n tumors</span></font></strong></p>      ^cY#594.htm##
00854000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704063000070002000800700#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#7#3#article#141#<p ALIGN="LEFT"><font fac
e="Arial"><span lang="EN">S. Cuellar-Baena<sup>1,4</sup>, L.M.T.S. Morais<sup>2,
4</sup>, F. Cendes<sup>3,4</sup>, A.V. Faria<sup>2,4 </sup></span></font><font f
ace="Arial"><span lang="EN">and <span lang="EN"><font face="Arial, Helvetica, sa
ns-serif"><sup><span lang="EN"><font face="Arial, Helvetica, sans-serif"><b><a h
ref="#Correspondence"><img src="/img/revistas/bjmbr/v44n4/recor.gif" border="0">
</a></b> <a href="mailto:gabriela@ifi.unicamp.br"><img src="/img/revistas/bjmbr/
v44n4/email-ca.gif" border="0"></a></font></span></sup></font></span> G. Castell
ano<sup>1,4</sup></span></font></p>      ^cY#594.htm##
00680000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704045600070002000800526#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#8#4#article#141#<p ALIGN="LEFT"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Departamento de Rai
os C&oacute;smicos e Cronologia, Instituto de F&iacute;sica Gleb Wataghin, </fon
t></span><font face="Arial"><span lang="EN"><sup>2</sup>Departamento de Radiolog
ia, <sup>3</sup>Departamento de Neurologia, Faculdade de Ci&ecirc;ncias M&eacute
;dicas, </span></font><font face="Arial"><span lang="EN">Universidade de Campina
s, Campinas, SP, Brasil    ^cY#594.htm##
00437000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704021300070002000800283#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#9#5#article#141#<br>  </span></font><font
 face="Arial"><span lang="EN"><sup>4</sup>Programa CInAPCe (Coopera&ccedil;&atil
de;o Interinstitucional de Apoio a Pesquisas sobre o C&eacute;rebro), SP, Brasil
</span></font></p>      ^cY#594.htm##
00427000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704020200071002000800273#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#10#6#article#141#<p ALIGN="LEFT"><font fa
ce="Arial, Helvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bj
mbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</s
trong></A>    ^cY#594.htm##
00415000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704019000071002000800261#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#11#7#article#141#<BR>      <A HREF="#Intr
oduction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>  
  ^cY#594.htm##
00415000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704019000071002000800261#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#12#8#article#141#<BR>      <A HREF="#Mate
rial"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>  
  ^cY#594.htm##
00400000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704017500071002000800246#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#13#9#article#141#<BR>      <A HREF="#Resu
lts"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#594.htm##
00410000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018400072002000800256#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#14#10#article#141#<BR>      <A HREF="#Dis
cussion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSP
ACE=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY
#594.htm##
00397000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017100072002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#15#11#article#141#<BR>      <A HREF="#Ref
erences"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSP
ACE=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#594.htm##
00438000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021200072002000800284#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#16#12#article#141#<br>      </strong></A>
<A HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowl
edgments</strong></A>    ^cY#594.htm##
00452000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704022600072002000800298#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#17#13#article#141#<BR>      <A HREF="#Cor
respondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0
 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Foo
tnotes</strong></A>  </font> </p>      ^cY#594.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#18#14#article#141#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#594.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#19#15#article#141#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#594.htm##
02145000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704191900072002000801991#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#20#16#article#141#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><i>In vivo</i> proton magneti
c resonance spectroscopy (<sup>1</sup>H-MRS) is a technique capable of assessing
 biochemical content and pathways in normal and pathological tissue. In the brai
n, <sup>1</sup>H-MRS complements the information given by magnetic resonance ima
ges. The main goal of the present study was to assess the accuracy of <sup>1</su
p>H-MRS for the classification of brain tumors in a pilot study comparing result
s obtained by manual and semi-automatic quantification of metabolites. <i>In viv
o</i> single-voxel <sup>1</sup>H-MRS was performed in 24 control subjects and 26
 patients with brain neoplasms that included meningiomas, high-grade neuroglial 
tumors and pilocytic astrocytomas. Seven metabolite groups (lactate, lipids, N-a
cetyl-aspartate, glutamate and glutamine group, total creatine, total choline, m
yo-inositol) were evaluated in all spectra by two methods: a manual one consisti
ng of integration of manually defined peak areas, and the advanced method for ac
curate, robust and efficient spectral fitting (AMARES), a semi-automatic quantif
ication method implemented in the jMRUI software. Statistical methods included d
iscriminant analysis and the leave-one-out cross-validation method. Both manual 
and semi-automatic analyses detected differences in metabolite content between t
umor groups and controls (P &lt; 0.005). The classification accuracy obtained wi
th the manual method was 75% for high-grade neuroglial tumors, 55% for meningiom
as and 56% for pilocytic astrocytomas, while for the semi-automatic method it wa
s 78, 70, and 98%, respectively. Both methods classified all control subjects co
rrectly. The study demonstrated that <sup>1</sup>H-MRS accurately differentiated
 normal from tumoral brain tissue and confirmed the superiority of the semi-auto
matic quantification method.</font></span></p>      ^cY#594.htm##
00422000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019600072002000800268#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#21#17#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Key words: Proton magnetic resonance spectroscopy; B
rain tumors; AMARES; Tumor classification</span></font></p>  <HR ALIGN=LEFT SIZE
=2>      ^cY#594.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#22#18#article#141#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#594.htm##
01414000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704118800072002000801260#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#23#19#article#141#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><i>In vivo</i> proton magneti
c resonance spectroscopy (<sup>1</sup>H-MRS) is a powerful and promising approac
h to the measurement of biochemical content and pathways in normal and pathologi
cal tissue (1). In the brain, where it is frequently applied, <sup>1</sup>H-MRS 
complements the information provided by magnetic resonance (MR) images (2,3). Qu
antification of the main metabolites detected by MRS at long or short echo times
 can provide quantitative information about these substances, which are involved
 in different processes in the nervous system. In brain tumors, biochemical path
ways such as glycolysis can increase lactate levels, abnormal enzymatic activati
on can increase total choline (i.e., glycerophosphocholine and phosphocholine) l
evels, and neuronal damage can decrease N-acetyl-aspartate (NAA) levels. Also, m
any other known and unknown pathological conditions related to genetic, osmotic,
 nutritional, and energetic stresses change the concentrations of these and othe
r detectable metabolites, such as total creatine (i.e., creatine and phosphocrea
tine) and lipids.</font></span></p>      ^cY#594.htm##
01400000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704117400072002000801246#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#24#20#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Several studies have been conducted to assess the me
tabolic patterns of brain tumors in an attempt to correlate them with the histol
ogy of the tumor, aggressiveness, and clinical outcome (4-12). Some studies have
 compared different kinds of spectral fitting methods, either in the time (13) o
r frequency domain (14). The aim of the present study was to determine the accur
acy of the MRS technique for tumor classification. This was achieved by comparin
g the quantitative data for a control group with that of patients with brain tum
ors from an MRS database. MRS data quantification was performed using two method
s: a manual method and the AMARES (advanced method for accurate, robust and effi
cient spectral fitting) semi-automatic method (15). An additional objective was 
to determine whether the semi-automatic method showed any improvement over the m
anual one. A more accurate measurement of the concentrations of these metabolite
s can contribute to the improvement of diagnosis and of clinical management, and
 expand our knowledge about the metabolism of brain tumors.</span></font></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#594.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#25#21#article#141#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#594.htm##
00320000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009400072002000800166#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#26#22#article#141#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Subjects</span></font></b></p>      ^cY#594.htm##
01287000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704106100072002000801133#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#27#23#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The <sup>1</sup>H-MRS spectral data used in this stu
dy were provided by the Neuroimage Laboratory of the University Hospital, Univer
sity of Campinas (UNICAMP), Campinas, SP, Brazil. They consisted of spectra acqu
ired from 24 normal subjects (control group) and 26 patients with different type
s of primary brain tumors. The study was approved by the Ethics Committee of UNI
CAMP and all subjects gave written informed consent. Subject ages ranged from 14
 to 71 years. The control group was not paired by age to the patient group altho
ugh it is well known that the metabolic pattern of brain tissue is age dependent
. In the present study, only tumor tissue was considered and in this case metabo
lism is much more dependent on the tumor itself. Control subjects ranged in age 
from 19 to 67 years. Magnetic resonance images were used to place the voxel accu
rately within the tumor. Also, given the size of the tumors studied, voxel conta
mination with normal tissue was kept to a minimum.</span></font></p>      ^cY#59
4.htm##
00636000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704041000072002000800482#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#28#24#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Patients underwent surgery or a biopsy for the treat
ment or diagnosis of primary brain tumors. The tissue specimens were processed f
or routine histopathology. Diagnosis was performed on 10-mm thin cryostat sectio
ns after hematoxylin-eosin staining and followed the classification system of th
e World Health Organization (WHO) (16).</span></font></p>      ^cY#594.htm##
00874000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704064800072002000800720#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#29#25#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Patients with tumors were divided into three groups 
according to histological type: group 1: high-grade neuroglial (N = 12); group 2
: meningiomas (N = 7); group 3: pilocytic astrocytoma (N = 7). Group 4 (control)
 consisted of 24 subjects. <a href="#Tab1">Table 1</a> provides further informat
ion about the patients and tumors. Patients were not receiving any treatment (cl
inical or surgical), because the scans reported here were the first step in the 
clinical investigation. <a href="#Fig1">Figure 1</a> shows examples of original 
and fitted spectra from these groups.</span></font></p>      ^cY#594.htm##
00329000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010300072002000800175#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#30#26#article#141#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Scanning protocol</span></font></b></p>      ^cY#
594.htm##
01028000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704080200072002000800874#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#31#27#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">MRS data were acquired at 2.0 T using a head coil in
 an Elscint Prestige Scanner (Haifa, Israel) and a PRESS sequence with repetitio
n time (TR) = 1500 ms, echo time (TE) = 136 ms, 200 repetitions, spectral width 
(SW) = 1000 Hz, and 1024 complex data points. Voxels were localized in the white
 matter for the control subjects, whereas for the patients they were positioned 
inside the tumor volume. All voxels measured 2 x 2 x 2 cm<sup>3</sup>. Common pr
ocedures used in MRS studies, such as automatic shimming, water suppression thro
ugh CHESS pulses and eddy-currents compensation, were performed for all acquisit
ions. T<sub>2</sub>-weighted MR images were also acquired in order to visualize 
the affected area of the brain.</span></font></p>      ^cY#594.htm##
00361000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013500072002000800207#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#32#28#article#141#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Post-processing and quantification of the signals
</span></font></b></p>      ^cY#594.htm##
00878000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704065200072002000800724#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#33#29#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The manual post-processing of spectral signals consi
sted of the use of apodization, varying from 2 to 3 Hz, manual phasing of the sp
ectra, and zero-filling (by a factor of 2). The quantification of metabolites co
nsisted of the integration of peak areas, which was achieved by manually definin
g the center frequency and the initial and final points of each peak. This proce
dure was performed directly on the scanner console by a neuroradiologist, and on
ly the main metabolite resonances were quantified: lipids, lactate, NAA, total c
reatine, choline group, and myo-inositol.</span></font></p>      ^cY#594.htm##
01117000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704089100072002000800963#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#34#30#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Semi-automatic post-processing of spectral signals w
as carried out using the jMRUI software (<a target="_blank" href="http://www.mru
i.uab.es/mrui/mru-Overview.shtml">http://www.mrui.uab.es/mrui/mru-Overview.shtml
</a>). In order to compensate for a small frequency drift of the equipment, the 
first step taken was to phase the residual water peak in all the spectra acquire
d for each scan using a reference signal (acquired without water suppression), t
hen to frequency-align these spectra based on the water peak, and averaging thes
e spectra to obtain a higher signal to noise ratio (SNR) spectrum. Next, the res
idual water signal, centered around 4.68 ppm, was filtered using the Hankel-Lanc
zos singular value decomposition routine (17). Neither zero filling nor apodizat
ion procedures were applied to the data.</span></font></p>      ^cY#594.htm##
00979000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704075300072002000800825#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#35#31#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The metabolite peaks of interest were quantified usi
ng the semi-automatic time-domain quantitation method AMARES (15) implemented in
 the jMRUI software. To improve the quantification process, this method relies o
n prior knowledge entered by the user about the sought resonance peaks (18). The
 frequency ranges shown in <a href="#Tab2">Table 2</a> were used for this purpos
e. They correspond to the metabolite resonances used as markers in the tumor cla
ssification scheme. Ranges were centered on the values reported in Refs. 6 and 1
9. The abbreviated names of the peaks (resonance ranges) were assigned according
 to the metabolite with the largest contribution to that peak.</span></font></p>
      ^cY#594.htm##
00732000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704050600072002000800578#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#36#32#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">A range for the variation of peak line width was als
o entered. It was based on prior information. These were allowed to vary between
 2-14 Hz. No assumptions were made for metabolite peak amplitudes or phases, wit
h the exception of the relative phase of the lactate peak, which was fixed at 18
0 degrees, since this resonance inverts at the echo time used (136 ms). Also, Lo
rentzian line shapes were imposed for spectral fitting.</span></font></p>      ^
cY#594.htm##
00729000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704050300072002000800575#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#37#33#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The AMARES method is a time-domain quantification pr
ocedure used to calculate the amplitudes of the metabolites in noisy MR spectra.
 This method uses the following model function to fit each metabolite peak:</spa
n></font></p>  <table  border="0" align="center">    <tr>      <td><img src="/im
g/revistas/bjmbr/v44n4/594eq1.jpg"></td>      <td><font face="Arial"><span lang=
"EN"><strong>Equation 1</strong></span></font></td>    </tr>  </table>      ^cY#
594.htm##
01116000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704089000072002000800962#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#38#34#article#141#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">where <i>a<sub>k</sub></i> is
 the amplitude, <i>&#1060;<sub>k</sub></i> is the phase, <i>d<sub>k</sub></i> is
 the damping factor, and <i>f<sub>k</sub></i> is the frequency of the <i>k</i>-t
h sinusoid (<i>k</i> = 1,&hellip;,<i>K</i>); <i>t<sub>n</sub></i> = D<i>t</i> + 
<i>t</i><sub>0</sub> with D<i>t</i> as the sampling interval, <i>t</i><sub>0</su
b> is the time between the effective time origin and the first data point to be 
included in the analysis, <i>g<sub>k</sub></i> is a factor that allows choosing 
between Gaussian (<i>g<sub>k</sub></i> = 1) and Lorentzian (<i>g<sub>k</sub></i>
 = 0) line shapes for each peak, and <i>e<sub>n</sub></i> is complex white Gauss
ian noise. <i>&#375;</i> represents the model function, while the actual measure
ments are represented by <i>y</i> (15).</font></span></p>      ^cY#594.htm##
00899000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704067300072002000800745#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#39#35#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The AMARES method provided estimates for the peak fr
equency, amplitude, phase, and line width of the aforementioned resonances (<a h
ref="#Tab2">Table 2</a>). In order to compare the quantitation results for diffe
rent subjects, the peak area of each metabolite was normalized by the sum of all
 peak areas. Although this sum varied among the individuals considered, we expec
ted this variation to be smaller than the variation of the creatine peak, normal
ly used as internal reference in cerebral <sup>1</sup>H-MRS, since the concentra
tion of this metabolite in tumor varies in unpredictable ways.</span></font></p>
      ^cY#594.htm##
00332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010600072002000800178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#40#36#article#141#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Statistical analysis</span></font></b></p>      ^
cY#594.htm##
00594000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704036800072002000800440#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#41#37#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Linear discriminant analysis (LDA) was used to obtai
n a classification model for the groups using combinations of metabolite amounts
 (20,21) and the leave-one-out cross-validation method was applied to assess the
 reliability of the classifier in our small data set.</span></font></p>  <HR ALI
GN=LEFT SIZE=2>      ^cY#594.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#42#38#article#141#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#594.htm##
00324000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009800072002000800170#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#43#39#article#141#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Tumor groups</span></font></b></p>      ^cY#594.h
tm##
01071000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704084500072002000800917#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#44#40#article#141#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Group 1: High-grade neuroglial tumors.</i> This 
group, consisting of 12 subjects, contained the most aggressive parenchymal type
 of tumors: glioblastomas, anaplastic oligoastrocytomas and anaplastic astrocyto
mas. It was characterized by decreased peak amplitudes of NAA and creatine, meta
bolic changes usually correlated to neuronal damage and abnormalities in energy 
metabolism, respectively. The presence of lactate is consistent with tumor aggre
ssiveness. A lipid peak was detected correlating with necrotic tissue, usually p
resent in these tumors (<a href="#Fig1">Figure 1A</a>). The manual method correc
tly classified 75% of the patients for this group, against a 78% correct classif
ication achieved with the AMARES method (see <a href="#Tab3">Table 3</a>).</span
></font></p>      ^cY#594.htm##
00861000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704063500072002000800707#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#45#41#article#141#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Group 2: Non-neuroglial tumors</i>. This group c
ontained extraparenchymal originating tumors. In the present study, it was compo
sed of 7 meningiomas (tumors that arise from the arachnoidal cap cells of the me
ninges). The main characteristic of these spectra was the prominent choline sign
al (<a href="#Fig1">Figure 1B</a>). Peaks that characterize brain tissue, such a
s NAA and creatine, were decreased. The manual method correctly classified 55% o
f the subjects and the AMARES method correctly classified 70% of them (see <a hr
ef="#Tab3">Table 3</a>).</span></font></p>      ^cY#594.htm##
00822000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704059600072002000800668#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#46#42#article#141#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Group 3: Pilocytic astrocytoma</i>. Pilocytic as
trocytoma is a benign neuroglial tumor type, and in this study the corresponding
 group consisted of 7 subjects. Similar to the high-grade neuroglial group, the 
spectra of this group were characterized by a decreased NAA and creatine signal 
and by the presence of lactate (<a href="#Fig1">Figure 1C</a>). For this group, 
the manual method achieved a classification accuracy of 56%, and the AMARES meth
od achieved an accuracy of 98% (see <a href="#Tab3">Table 3</a>).</span></font><
/p>      ^cY#594.htm##
00638000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704041200072002000800484#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#47#43#article#141#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Group 4: Control group</i>. This group was prima
rily characterized by prominent signals of NAA, choline and creatine, and by the
 absence of metabolites such as lactate or lipids (see <a href="#Fig1">Figure 1D
</a>). The control group was correctly identified by both methods in 100% of the
 cases (see <a href="#Tab3">Table 3</a>).</span></font></p>      ^cY#594.htm##
00332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010600072002000800178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#48#44#article#141#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Group classification</span></font></b></p>      ^
cY#594.htm##
01158000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704093200072002000801004#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#49#45#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a href="#Fig2">Figures 2</a> and <a href="#Fig3">3<
/a> show graphs of the mean values of relative concentrations versus tumor group
 (groups 1, 2, 3, where 4 is the control group) for each metabolite group (or fr
equency range) considered. These results are also summarized in <a href="#Tab3">
Table 3</a>. It can be seen that both the manual and semi-automatic analyses sho
wed differences in mean metabolite amounts between tumor groups and controls (P 
&lt; 0.005). The manual analysis showed a greater standard deviation for the mea
surement of choline, creatine and myo-inositol peaks. Also, with this method it 
was not possible to quantify the glutamate/glutamine group: this is one of the l
imitations of the manual method since, due to the post-processing techniques use
d such as apodization, peaks are enlarged and fewer resonances remain detectable
.</span></font></p>      ^cY#594.htm##
00551000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032500072002000800397#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#50#46#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a href="#Tab4">Table 4</a> shows the results of LDA
 (22). As expected, the semi-automatic method achieved a higher classification r
ate for all tumor groups. Also, differentiation between normal and tumoral tissu
e was confirmed with both methods.</span></font></p>      ^cY#594.htm##
01118000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704089200072002000800964#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#51#47#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a href="#Fig4">Figure 4</a> shows the discriminant 
distributions of tumor groups for both methods. The factors 1 and 2 in these gra
phs indicate the main numerical characteristics calculated by LDA that are able 
to discriminate among groups. These graphs show that the semi-automatic method a
chieved the best results for tumor groups, showing less variability within group
s and better separation between groups. In particular, group 3 (pilocytic astroc
ytomas) was well separated from the other tumor types by this method. The manual
 method presented broader and more overlapping distributions.</span></font></p> 
 <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top">  
    <td><a href="/img/revistas/bjmbr/v44n4/html/594i01.htm"><img src="/img/revis
tas/bjmbr/v44n4/594i01peq.jpg" border="2"></a></td>      <td>    ^cY#594.htm##
00874000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704064800072002000800720#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#52#48#article#141#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. 
Typical spectra from the tumor and control groups. Typical <sup>1</sup>H-MRS and
 MRI of patients with <i>A</i>, high-grade neuroglial tumors (group 1); <i>B</i>
, meningioma (non-neuroglial tumors, group 2); <i>C</i>, pilocytic astrocytoma (
group 3), and <i>D</i>, of a control subject (group 4). <sup>1</sup>H-MRS = prot
on magnetic resonance spectroscopy; MRI = magnetic resonance imaging; Cho = chol
ine group; Cre = creatine and phosphocreatine; Lac = lactate; NAA = N-acetyl-asp
artate.</font></span></p>      </td>    </tr>  </table>      ^cY#594.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033800072002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#53#49#article#141#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (204 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/594i02.htm"><img src="/img
/revistas/bjmbr/v44n4/594i02peq.jpg" border="2"></a></td>      <td>    ^cY#594.h
tm##
00560000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033400072002000800406#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#54#50#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig2"></a>Figure 2. Mean relative concentra
tion &plusmn; SD for each tumor group (1 = high-grade neuroglial, 2 = non-neurog
lial, and 3 = pilocytic astrocytoma) and for the control group (4). NAA = N-acet
yl-aspartate.</span></font></p>      </td>    </tr>  </table>      ^cY#594.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033700072002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#55#51#article#141#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (89 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/594i03.htm"><img src="/img/
revistas/bjmbr/v44n4/594i03peq.jpg" border="2"></a></td>      <td>    ^cY#594.ht
m##
00593000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704036700072002000800439#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#56#52#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig3"></a>Figure 3. Mean relative concentra
tion &plusmn; SD for each tumor group (1 = high-grade neuroglial, 2 = non-neurog
lial, and 3 = pilocytic astrocytoma) and for the control group (4). NAA = N-acet
yl-aspartate; Glx = glutamate/glutamine group.</span></font></p>      </td>    <
/tr>  </table>      ^cY#594.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033800072002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#57#53#article#141#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (111 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/594i04.htm"><img src="/img
/revistas/bjmbr/v44n4/594i04peq.jpg" border="2"></a></td>      <td>    ^cY#594.h
tm##
00610000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704038400072002000800456#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#58#54#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig4"></a>Figure 4. Discriminant distributi
ons of tumor groups for the manual (left) and semi-automatic (right) methods. Re
d corresponds to high-grade neuroglial tumors (group 1), blue to non-neuroglial 
tumors (group 2) and green to pilocytic astrocytomas (group 3).</span></font></p
>      </td>    </tr>  </table>      ^cY#594.htm##
00559000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033300072002000800405#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#59#55#article#141#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (84 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/594t01.htm"><img src="/img/
revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#594.htm##
00423000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019700072002000800269#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#60#56#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Tab1"></a>Table 1. Demographic data of cont
rols and patients with brain tumors.</span></font></p>      </td>    </tr>  </ta
ble>      ^cY#594.htm##
00559000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033300072002000800405#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#61#57#article#141#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (52 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/594t02.htm"><img src="/img/
revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#594.htm##
00421000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019500072002000800267#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#62#58#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Tab2"></a>Table 2. Frequency ranges used in
 the AMARES quantification method.</span></font></p>      </td>    </tr>  </tabl
e>      ^cY#594.htm##
00560000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033400072002000800406#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#63#59#article#141#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (128 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/594t03.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#594.htm##
00443000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021700072002000800289#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#64#60#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Tab3"></a>Table 3. Mean quantification resu
lts obtained with the manual and semi-automatic methods.</span></font></p>      
</td>    </tr>  </table>      ^cY#594.htm##
00560000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033400072002000800406#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#65#61#article#141#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (192 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/594t04.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#594.htm##
00378000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704015200072002000800224#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#66#62#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Tab4"></a>Table 4. Classification accuracy 
for different tumor types, and for normal    ^cY#594.htm##
00336000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011000072002000800182#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#67#63#article#141#<br>   versus tumoral t
issue.</span></font><span lang="EN"></span></p>      </td>    </tr>  </table>   
   ^cY#594.htm##
00344000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011800072002000800190#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#68#64#article#141#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (113 K JPG file)]</font
></P>      ^cY#594.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#69#65#article#141#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#594.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#70#66#article#141#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#594.htm##
02082000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704185600072002000801928#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#71#67#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Several factors can interfere with the classificatio
n of brain tumors using 136 ms TE metabolite markers from <i>in vivo</i> <sup>1<
/sup>H-MRS signals. Inherent to the technique are: the low SNR resulting from th
e low-medium magnitude (1-3 Tesla) of the magnetic fields used in clinical appli
cations, together with the low sensitivity of the technique (due to low concentr
ations of the metabolites studied in the human body); magnetic field in homogene
ities arising from a number of different factors (such as eddy currents) that co
ntribute to the uncertainty of the measurements; the residual signals from water
 and fat that modify the baseline. Also, long TE spectra compromise the quantifi
cation of metabolite groups such as glutamate/glutamine, myo-inositol and lipids
 due to their shorter T2 constant. These limitations may have influenced our res
ults independently of the quantification method used. Particularly for the manua
l method, the fact that no filtering of the residual water peak was possible may
 have compromised the quantification of resonances closest to this peak, for exa
mple myo-inositol. Indeed, <a href="#Tab3">Table 3</a> shows a decrease of myo-i
nositol for tumor groups compared to the control group for the manual method, wh
ile it shows an increase of this metabolite for the tumor groups compared to the
 control group for the semi-automatic method. The myo-inositol decrease with the
 manual method was probably due to errors in the setting of peak limits. The man
ual procedure tends to restrict peak limits to what really stands out from the b
aseline, and since the residual water peak was not filtered in this procedure, t
he baseline around the myo-inositol peak was probably increased, reducing the pe
ak limits and consequently the measured area.</span></font></p>      ^cY#594.htm
##
01461000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704123500072002000801307#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#72#68#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">From <a href="#Tab4">Table 4</a>, we see that the re
sults obtained with the manual method for differentiating between normal (contro
l) and tumoral tissue were relatively good (a 92% correct classification as tumo
r or normal). However, the individual tumor classification accuracy was much low
er (75, 55, and 56% for the three tumor groups). This is clearly due to the fact
 that, as can be seen in <a href="#Fig1">Figure 1</a>, normal spectra are quite 
different from spectra obtained from the types of tumor considered, making it ea
sier for the classifier to differentiate between these two types of spectra, whi
le spectra from groups 1 (neuroglial tumors) and 3 (pilocytic astrocytomas) are 
more similar, probably accounting for the lower classification rate. Indeed, we 
found that the more important metabolites that could be used to differentiate am
ong individual tumor groups were lactate/lipids to differentiate between the thr
ee groups with both methods; choline to differentiate between group 2 (non-neuro
glial) and the other groups with the manual method, and creatine to differentiat
e between group 2 and the others with the semi-automatic method.</span></font></
p>      ^cY#594.htm##
00786000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704056000072002000800632#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#73#69#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Also, we agree with Lukas et al. (6) that a limited 
number of patients in each group makes it difficult to build a classifier with a
 high generalization capacity. In addition, noise due to artifacts, as mentioned
 earlier, can reduce the quality of spectral data and consequently impair the ca
lculation of metabolite concentrations, even using a semi-automatic method. This
 partially explains the fact that we have a pronounced overlap between the spect
ra of different tumor groups.</span></font></p>      ^cY#594.htm##
02019000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704179300072002000801865#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#74#70#article#141#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">Even with these limitations, 
using both manual and semi-automatic analyses, we found a metabolic pattern in t
umors and controls that was consistent with recent studies (3,4,6,7,23-27). Tumo
rs showed a reduction in the levels of NAA and creatine and an increase in the l
evels of choline, compared to normal tissue</font><font FACE="Arial, Helvetica, 
sans-serif" COLOR="#0000ff">.</font><font FACE="Arial, Helvetica, sans-serif"> A
lso, some tumor groups showed</font> <font FACE="Arial, Helvetica, sans-serif">t
he presence of lactate and lipid peaks in their spectra, which are not usually s
een in healthy tissue. It is important to note that both methods identified all 
controls correctly, confirming the efficacy of the MRS technique for discriminat
ing between normal and pathological tissue. The most evident difference between 
the manual and semi-automatic analyses was the more specific classification of h
igh-grade tumors obtained with the latter. We attribute this improvement mainly 
to consistency of the AMARES method for the measurement of the creatine and chol
ine peaks. Due to the apodization used in the manual procedure, these peaks ofte
n semi-overlapped, causing a wide variation in the manual determination of peak 
limits. This was confirmed by the higher standard deviations of these measuremen
ts and was particularly true in high-grade neuroglial tumors, where the cell het
erogeneity and the microscopic areas of necrosis can cause a global decrease in 
peak amplitude and damage resolution. Also, in general, the manual method involv
es more sources of error than the semi-automatic one, mainly due to dependency o
n analyst subjectivity, particularly in the phasing procedure.</font></span></p>
      ^cY#594.htm##
00925000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704069900072002000800771#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#75#71#article#141#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">We confirmed that manual and semi-automatic analyses
 of MR spectra are able to differentiate normal from tumoral tissue. The semi-au
tomatic analysis was more accurate in classifying all tumor groups. The semi-aut
omatic method was acceptable to build a model for classifying the tumor types st
udied here by their histological diagnosis and, despite the small number of subj
ects included in the study, the manual and semi-automatic methods were in agreem
ent. We believe that a better classification of brain tumors according to clinic
al parameters will be possible by expanding our sample database.</span></font></
p>  <HR ALIGN=LEFT SIZE=2>      ^cY#594.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#76#72#article#141#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#594.htm##
00515000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027500074002000800349#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#77#73#article#141#1#<p ALIGN=
"LEFT"><font face="Arial"><span lang="EN">1. Preul MC, Caramanos Z, Collins DL, 
Villemure JG, Leblanc R, Olivier A, et al. Accurate, noninvasive diagnosis of hu
man brain tumors by using proton magnetic resonance spectroscopy. <i>Nat Med</i>
 1996; 2: 323-325.    ^cY#594.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#78#74#article#141#</span></font></p>     
 ^cY#594.htm##
00492000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704025200074002000800326#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#79#75#article#141#2#<p align=
"LEFT"><font face="Arial"><span lang="EN">2. Del Sole A, Falini A, Ravasi L, Ott
obrini L, De Marchis D, Bombardieri E, et al. Anatomical and biochemical investi
gation of primary brain tumours. <i>Eur J Nucl Med</i> 2001; 28: 1851-1872.    ^
cY#594.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#80#76#article#141#</span></font></p>     
 ^cY#594.htm##
00568000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704032800074002000800402#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#81#77#article#141#3#<p align=
"LEFT"><font face="Arial"><span lang="EN">3. Nakaiso M, Uno M, Harada M, Kageji 
T, Takimoto O, Nagahiro S. Brain abscess and glioblastoma identified by combined
 proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonanc
e imaging - two case reports. <i>Neurol Med Chir</i> 2002; 42: 346-348.    ^cY#5
94.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#82#78#article#141#</span></font></p>     
 ^cY#594.htm##
00511000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027100074002000800345#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#83#79#article#141#4#<p align=
"LEFT"><font face="Arial"><span lang="EN">4. Lehnhardt FG, Bock C, Rohn G, Ernes
tus RI, Hoehn M. Metabolic differences between primary and recurrent human brain
 tumors: a <sup>1</sup>H NMR spectroscopic investigation. <i>NMR Biomed</i> 2005
; 18: 371-382.    ^cY#594.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#84#80#article#141#</span></font></p>     
 ^cY#594.htm##
00339000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011300072002000800185#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#85#81#article#141#<p align="LEFT"><font f
ace="Arial"><span lang="EN">5. Demaerel P, Johannik K, Van Hecke P, Van Ongeval 
C,    ^cY#594.htm##
00433000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020700072002000800279#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#86#82#article#141#<br>   Verellen S, Marc
hal G, et al. Localized <sup>1</sup>H NMR spectroscopy in fifty cases of newly d
iagnosed intracranial tumors. <i>J Comput Assist Tomogr</i> 1991; 15: 67-76.</sp
an></font></p>      ^cY#594.htm##
00475000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704023500074002000800309#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#87#83#article#141#6#<p align=
"LEFT"><font face="Arial"><span lang="EN">6. Lukas L, Devos A, Suykens JA, Vanha
mme L, Howe FA, Majos C, et al. Brain tumor classification based on long echo pr
oton MRS signals. <i>Artif Intell Med</i> 2004; 31: 73-89.    ^cY#594.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#88#84#article#141#</span></font></p>     
 ^cY#594.htm##
00517000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027700074002000800351#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#89#85#article#141#7#<p align=
"LEFT"><font face="Arial"><span lang="EN">7. Tate AR, Majos C, Moreno A, Howe FA
, Griffiths JR, Arus C. Automated classification of short echo time in <i>in viv
o</i> <sup>1</sup>H brain tumor spectra: a multicenter study. <i>Magn Reson Med<
/i> 2003; 49: 29-36.    ^cY#594.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#90#86#article#141#</span></font></p>     
 ^cY#594.htm##
00539000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704029900074002000800373#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#91#87#article#141#8#<p align=
"LEFT"><font face="Arial"><span lang="EN">8. Majos C, Julia-Sape M, Alonso J, Se
rrallonga M, Aguilera C, Acebes JJ, et al. Brain tumor classification by proton 
MR spectroscopy: comparison of diagnostic accuracy at short and long TE. <i>AJNR
 Am J Neuroradiol</i> 2004; 25: 1696-1704.    ^cY#594.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#92#88#article#141#</span></font></p>     
 ^cY#594.htm##
00531000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704029100074002000800365#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#93#89#article#141#9#<p align=
"LEFT"><font face="Arial"><span lang="EN">9. Simonetti AW, Melssen WJ, Szabo de 
Edelenyi F, van Asten JJ, Heerschap A, Buydens LM. Combination of feature-reduce
d MR spectroscopic and MR imaging data for improved brain tumor classification. 
<i>NMR Biomed</i> 2005; 18: 34-43.    ^cY#594.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#94#90#article#141#</span></font></p>     
 ^cY#594.htm##
00511000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704027000075002000800345#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#95#91#article#141#10#<p align
="LEFT"><font face="Arial"><span lang="EN">10. Sjobakk TE, Johansen R, Bathen TF
, Sonnewald U, Kvistad KA, Lundgren S, et al. Metabolic profiling of human brain
 metastases using<i> in vivo</i> proton MR spectroscopy at 3T. <i>BMC Cancer</i>
 2007; 7: 141.    ^cY#594.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#96#92#article#141#</span></font></p>     
 ^cY#594.htm##
00527000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704028600075002000800361#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#97#93#article#141#11#<p align
="LEFT"><font face="Arial"><span lang="EN">11. Garcia-Gomez JM, Luts J, Julia-Sa
pe M, Krooshof P, Tortajada S, Robledo JV, et al. Multiproject-multicenter evalu
ation of automatic brain tumor classification by magnetic resonance spectroscopy
. <i>MAGMA</i> 2009; 22: 5-18.    ^cY#594.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#98#94#article#141#</span></font></p>     
 ^cY#594.htm##
00495000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025400075002000800329#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#99#95#article#141#12#<p align
="LEFT"><font face="Arial"><span lang="EN">12. Alusta P, Im I, Pearce BA, Beger 
RD, Kretzer RM, Buzatu DA, et al. Improving proton MR spectroscopy of brain tiss
ue for noninvasive diagnostics. <i>J Magn Reson Imaging</i> 2010; 32: 818-829.  
  ^cY#594.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#100#96#article#141#</span></font></p>    
  ^cY#594.htm##
00447000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704020500076002000800281#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#101#97#article#141#13#<p alig
n="LEFT"><font face="Arial"><span lang="EN">13. Vanhamme L, Sundin T, Hecke PV, 
Huffel SV. MR spectroscopy quantitation: a review of time-domain methods. <i>NMR
 Biomed</i> 2001; 14: 233-246.    ^cY#594.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#102#98#article#141#</span></font></p>    
  ^cY#594.htm##
00437000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704019500076002000800271#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#103#99#article#141#14#<p alig
n="LEFT"><font face="Arial"><span lang="EN">14. Mierisova S, Ala-Korpela M. MR s
pectroscopy quantitation: a review of frequency domain methods. <i>NMR Biomed</i
> 2001; 14: 247-259.    ^cY#594.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#104#100#article#141#</span></font></p>   
   ^cY#594.htm##
00488000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024500077002000800322#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#105#101#article#141#15#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">15. Vanhamme L, van den Boogaart A,
 Van Huffel S. Improved method for accurate and efficient quantification of MRS 
data with use of prior knowledge. <i>J Magn Reson</i> 1997; 129: 35-43.    ^cY#5
94.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#106#102#article#141#</span></font></p>   
   ^cY#594.htm##
00491000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024800077002000800325#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#107#103#article#141#16#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">16. Louis DN, Ohgaki H, Wiestler OD
, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours
 of the central nervous system. <i>Acta Neuropathol</i> 2007; 114: 97-109.    ^c
Y#594.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#108#104#article#141#</span></font></p>   
   ^cY#594.htm##
00475000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023200077002000800309#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#109#105#article#141#17#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">17. Laudadio T, Mastronardi N, Vanh
amme L, Van Hecke P, Van Huffel S. Improved Lanczos algorithms for blackbox MRS 
data quantitation. <i>J Magn Reson</i> 2002; 157: 292-297.    ^cY#594.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#110#106#article#141#</span></font></p>   
   ^cY#594.htm##
00557000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704031400077002000800391#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#111#107#article#141#18#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">18. de Graaf AA, Bovee WM. Improved
 quantification of <i>in vivo</i> <sup>1</sup>H NMR spectra by optimization of s
ignal acquisition and processing and by incorporation of prior knowledge into th
e spectral fitting. <i>Magn Reson Med</i> 1990; 15: 305-319.    ^cY#594.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#112#108#article#141#</span></font></p>   
   ^cY#594.htm##
00452000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704020900077002000800286#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#113#109#article#141#19#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">19. Govindaraju V, Young K, Maudsle
y AA. Proton NMR chemical shifts and coupling constants for brain metabolites. <
i>NMR Biomed</i> 2000; 13: 129-153.    ^cY#594.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#114#110#article#141#</span></font></p>   
   ^cY#594.htm##
00398000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704015500077002000800232#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#115#111#article#141#20#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">20. Altman DG. <i>Practical statist
ics for medical research</i>. London: Chapman and Hall; 1991.    ^cY#594.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#116#112#article#141#</span></font></p>   
   ^cY#594.htm##
00409000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704016600077002000800243#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#117#113#article#141#21#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">21. Campbell MJ, Machin D. <i>Medic
al statistics: a commonsense approach</i>. Chichester: John Wiley; 1999.    ^cY#
594.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#118#114#article#141#</span></font></p>   
   ^cY#594.htm##
00413000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704017000077002000800247#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#119#115#article#141#22#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">22. McLachlan GJ. <i>Discriminant a
nalysis and statistical pattern recognition</i>. New York: John Wiley; 1992.    
^cY#594.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#120#116#article#141#</span></font></p>   
   ^cY#594.htm##
00543000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030000077002000800377#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#121#117#article#141#23#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">23. Opstad KS, Ladroue C, Bell BA, 
Griffiths JR, Howe FA. Linear discriminant analysis of brain tumour (1)H MR spec
tra: a comparison of classification using whole spectra versus metabolite quanti
fication. <i>NMR Biomed</i> 2007; 20: 763-770.    ^cY#594.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#122#118#article#141#</span></font></p>   
   ^cY#594.htm##
00515000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027200077002000800349#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#123#119#article#141#24#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">24. Morales H, Kwock L, Castillo M.
 Magnetic resonance imaging and spectroscopy of pilomyxoid astrocytomas: case re
ports and comparison with pilocytic astrocytomas. <i>J Comput Assist Tomogr</i> 
2007; 31: 682-687.    ^cY#594.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#124#120#article#141#</span></font></p>   
   ^cY#594.htm##
00531000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028800077002000800365#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#125#121#article#141#25#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">25. Di Costanzo A, Scarabino T, Tro
jsi F, Giannatempo GM, Popolizio T, Catapano D, et al. Multiparametric 3T MR app
roach to the assessment of cerebral gliomas: tumor extent and malignancy. <i>Neu
roradiology</i> 2006; 48: 622-631.    ^cY#594.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#126#122#article#141#</span></font></p>   
   ^cY#594.htm##
00483000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024000077002000800317#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#127#123#article#141#26#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">26. Cho YD, Choi GH, Lee SP, Kim JK
. <sup>1</sup>H-MRS metabolic patterns for distinguishing between meningiomas an
d other brain tumors. <i>Magn Reson Imaging</i> 2003; 21: 663-672.    ^cY#594.ht
m##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#128#124#article#141#</span></font></p>   
   ^cY#594.htm##
00539000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029600077002000800373#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#p#129#125#article#141#27#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">27. Howe FA, Barton SJ, Cudlip SA, 
Stubbs M, Saunders DE, Murphy M, et al. Metabolic profiles of human brain tumors
 using quantitative <i>in vivo</i> <sup>1</sup>H magnetic resonance spectroscopy
. <i>Magn Reson Med</i> 2003; 49: 223-232.    ^cY#594.htm##
00280000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704005200074002000800126#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#130#126#article#141#</span></font></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#594.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033500074002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#131#127#article#141#<P><font face="Arial,
 Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE
=4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#594.ht
m##
00369000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704014100074002000800215#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#132#128#article#141#<p ALIGN="LEFT"><font
 face="Arial"><span lang="EN">Research supported by FAPESP and CNPq.</span></fon
t></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#594.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033600074002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#133#129#article#141#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#594.h
tm##
00706000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704047800074002000800552#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#134#130#article#141#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/r
ecor.gif" border="0"></a> Address for correspondence:</b></font><font face="Aria
l"><span lang="EN"> G. Castellano, Departamento de Raios C&oacute;smicos e Crono
logia, Instituto de F&iacute;sica Gleb Wataghin, UNICAMP, 13083-970 Campinas, SP
, Brasil. Fax: +55-19-3521-5512. E-mail: <a href="mailto:gabriela@ifi.unicamp.br
">gabriela@ifi.unicamp.br</a></span></font></p>      ^cY#594.htm##
00448000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704022000074002000800294#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#135#131#article#141#<p ALIGN="LEFT"><i><f
ont face="Arial"><span lang="EN">Received June 18, 2010. Accepted February 11, 2
011. Available online March 11, 2011. Published April 11, 2011.</span></font></i
></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#594.htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#136#132#article#141#<div align="center"> 
       ^cY#594.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#137#133#article#141#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#594.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#138#134#article#141#<br>                ^
cY#594.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#139#135#article#141#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#594
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#140#136#article#141#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#594.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#141#137#article#141#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#594.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#142#138#article#141#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#594.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#143#139#article#141#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#594.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#144#140#article#141#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#594.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\594.htm#S#p#145#141#article#141#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#594.htm##
00697000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100019000890100
01800108010002000126010001700146010001700163810000600180012010600186030000800292
06500090030006400050030903100020031401400080031686500090032400200080033303500100
0341801000800351#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#146#1#art
icle#27#1#^rND^sPreul^nMC#^rND^sCaramanos^nZ#^rND^sCollins^nDL#^rND^sVillemure^n
JG#^rND^sLeblanc^nR#^rND^sOlivier^nA#et al#Accurate, noninvasive diagnosis of hu
man brain tumors by using proton magnetic resonance spectroscopy^len#Nat Med#199
60000#1996#2#323-325#20110400#594.htm#1078-8956#Nat Med##
00681000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100016000910100
01600107010001900123010002000142010002100162810000600183012007000189030001500259
06500090027406400050028303100030028801400100029186500090030100200080031003500100
0318801001500328#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#147#2#art
icle#27#2#^rND^sDel^nSole A#^rND^sFalini^nA#^rND^sRavasi^nL#^rND^sOttobrini^nL#^
rND^sDe^nMarchis D#^rND^sBombardieri^nE#et al#Anatomical and biochemical investi
gation of primary brain tumours^len#Eur J Nucl Med#20010000#2001#28#1851-1872#20
110400#594.htm#0340-6997#Eur J Nucl Med##
00747000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100013000900100
01600103010001600119010001800135010001800153012016600171030001600337065000900353
06400050036203100030036701400080037086500090037800200080038703500100039580100160
0405#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#148#3#article#27#3#^r
ND^sNakaiso^nM#^rND^sUno^nM#^rND^sHarada^nM#^rND^sKageji^nT#^rND^sTakimoto^nO#^r
ND^sNagahiro^nS#Brain abscess and glioblastoma identified by combined proton mag
netic resonance spectroscopy and diffusion-weighted magnetic resonance imaging -
 two case reports^len#Neurol Med Chir#20020000#2002#42#346-348#20110400#594.htm#
0470-8105#Neurol Med Chir##
00656000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100020000730100014000930100
01400107010001900121010001500140012011300155030001100268065000900279064000500288
031000300293014000800296865000900304002000800313035001000321801001100331#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#149#4#article#27#4#^rND^sLehnhard
t^nFG#^rND^sBock^nC#^rND^sRohn^nG#^rND^sErnestus^nRI#^rND^sHoehn^nM#Metabolic di
fferences between primary and recurrent human brain tumors: a ¹H NMR spectroscop
ic investigation^len#NMR Biomed#20050000#2005#18#371-382#20110400#594.htm#0952-3
480#NMR Biomed##
00712000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100018000910100
01900109010002100128010001800149010001700167810000600184012008800190030002300278
06500090030106400050031003100030031501400060031886500090032400200080033303500100
0341801002300351#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#150#5#art
icle#27#5#^rND^sDemaerel^nP#^rND^sJohannik^nK#^rND^sVan^nHecke P#^rND^sVan^nOnge
val C#^rND^sVerellen^nS#^rND^sMarchal^nG#et al#Localized ¹H NMR spectroscopy in 
fifty cases of newly diagnosed intracranial tumors^len#J Comput Assist Tomogr#19
910000#1991#15#67-76#20110400#594.htm#0363-8715#J Comput Assist Tomogr##
00666000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100015000880100
01800103010001800121010001500139010001500154810000600169012006900175030001700244
06500090026106400050027003100030027501400060027886500090028400200080029303500100
0301801001700311#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#151#6#art
icle#27#6#^rND^sLukas^nL#^rND^sDevos^nA#^rND^sSuykens^nJA#^rND^sVanhamme^nL#^rND
^sHowe^nFA#^rND^sMajos^nC#et al#Brain tumor classification based on long echo pr
oton MRS signals^len#Artif Intell Med#20040000#2004#31#73-89#20110400#594.htm#09
33-3657#Artif Intell Med##
00677000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100015000880100
01600103010001500119010002000134010001400154012010300168030001500271065000900286
06400050029503100030030001400060030386500090030900200080031803500100032680100150
0336#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#152#7#article#27#7#^r
ND^sTate^nAR#^rND^sMajos^nC#^rND^sMoreno^nA#^rND^sHowe^nFA#^rND^sGriffiths^nJR#^
rND^sArus^nC#Automated classification of short echo time in in vivo ¹H brain tum
or spectra: a multicenter study^len#Magn Reson Med#20030000#2003#49#29-36#201104
00#594.htm#0740-3194#Magn Reson Med##
00735000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100020000880100
01600108010002100124010001800145010001700163810000600180012011300186030002200299
06500090032106400050033003100030033501400100033886500090034800200080035703500100
0365801002200375#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#153#8#art
icle#27#8#^rND^sMajos^nC#^rND^sJulia-Sape^nM#^rND^sAlonso^nJ#^rND^sSerrallonga^n
M#^rND^sAguilera^nC#^rND^sAcebes^nJJ#et al#Brain tumor classification by proton 
MR spectroscopy: comparison of diagnostic accuracy at short and long TE^len#AJNR
 Am J Neuroradiol#20040000#2004#25#1696-1704#20110400#594.htm#0195-6108#AJNR Am 
J Neuroradiol##
00705000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100020000730100018000930100
02700111010002000138010001900158010001800177012011200195030001100307065000900318
06400050032703100030033201400060033586500090034100200080035003500100035880100110
0368#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#154#9#article#27#9#^r
ND^sSimonetti^nAW#^rND^sMelssen^nWJ#^rND^sSzabo^nde Edelenyi F#^rND^svan^nAsten 
JJ#^rND^sHeerschap^nA#^rND^sBuydens^nLM#Combination of feature-reduced MR spectr
oscopic and MR imaging data for improved brain tumor classification^len#NMR Biom
ed#20050000#2005#18#34-43#20110400#594.htm#0952-3480#NMR Biomed##
00658000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100018000930100
01700111010001900128010001800147010001800165810000600183012009300189030001100282
71000020029306500090029506400050030403100020030901400040031186500090031500200080
0324#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#155#10#article#27#10#
^rND^sSjobakk^nTE#^rND^sJohansen^nR#^rND^sBathen^nTF#^rND^sSonnewald^nU#^rND^sKv
istad^nKA#^rND^sLundgren^nS#et al#Metabolic profiling of human brain metastases 
using in vivo proton MR spectroscopy at 3T^len#BMC Cancer#2#20070000#2007#7#141#
20110400#594.htm##
00707000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100023000750100014000980100
02000112010001800132010001900150010001800169810000600187012011500193030000600308
06500090031406400050032303100030032801400050033186500090033600200080034503500100
0353801000600363#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#156#11#ar
ticle#27#11#^rND^sGarcia-Gomez^nJM#^rND^sLuts^nJ#^rND^sJulia-Sape^nM#^rND^sKroos
hof^nP#^rND^sTortajada^nS#^rND^sRobledo^nJV#et al#Multiproject-multicenter evalu
ation of automatic brain tumor classification by magnetic resonance spectroscopy
^len#MAGMA#20090000#2009#22#5-18#20110400#594.htm#0968-5243#MAGMA##
00690000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100012000910100
01700103010001600120010001800136010001700154810000600171012008100177030002100258
06500090027906400050028803100030029301400080029686500090030400200080031303500100
0321801002100331#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#157#12#ar
ticle#27#12#^rND^sAlusta^nP#^rND^sIm^nI#^rND^sPearce^nBA#^rND^sBeger^nRD#^rND^sK
retzer^nRM#^rND^sBuzatu^nDA#et al#Improving proton MR spectroscopy of brain tiss
ue for noninvasive diagnostics^len#J Magn Reson Imaging#20100000#2010#32#818-829
#20110400#594.htm#1053-1807#J Magn Reson Imaging##
00584000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930100
01600109010001700125012006600142030001100208065000900219064000500228031000300233
014000800236865000900244002000800253035001000261801001100271#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\594.htm#S#c#158#13#article#27#13#^rND^sVanhamme^nL#^rND^s
Sundin^nT#^rND^sHecke^nPV#^rND^sHuffel^nSV#MR spectroscopy quantitation: a revie
w of time-domain methods^len#NMR Biomed#20010000#2001#14#233-246#20110400#594.ht
m#0952-3480#NMR Biomed##
00538000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100021000940120
07100115030001100186065000900197064000500206031000300211014000800214865000900222
002000800231035001000239801001100249#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\5
94.htm#S#c#159#14#article#27#14#^rND^sMierisova^nS#^rND^sAla-Korpela^nM#MR spect
roscopy quantitation: a review of frequency domain methods^len#NMR Biomed#200100
00#2001#14#247-259#20110400#594.htm#0952-3480#NMR Biomed##
00608000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100026000930100
02000119012010200139030001300241065000900254064000500263031000400268014000600272
865000900278002000800287035001000295801001300305#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\594.htm#S#c#160#15#article#27#15#^rND^sVanhamme^nL#^rND^svan^nden Boo
gaart A#^rND^sVan^nHuffel S#Improved method for accurate and efficient quantific
ation of MRS data with use of prior knowledge^len#J Magn Reson#19970000#1997#129
#35-43#20110400#594.htm#1090-7807#J Magn Reson##
00643000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100016000910100
01900107010001800126010001700144010001600161810000600177012007300183030001700256
71000020027306500090027506400050028403100040028901400070029386500090030000200080
0309#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#161#16#article#27#16#
^rND^sLouis^nDN#^rND^sOhgaki^nH#^rND^sWiestler^nOD#^rND^sCavenee^nWK#^rND^sBurge
r^nPC#^rND^sJouvet^nA#et al#The 2007 WHO classification of tumours of the centra
l nervous system^len#Acta Neuropathol#2#20070000#2007#114#97-109#20110400#594.ht
m##
00631000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100021000930100
01800114010001900132010002000151012006700171030001300238065000900251064000500260
031000400265014000800269865000900277002000800286035001000294801001300304#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#162#17#article#27#17#^rND^sLaudad
io^nT#^rND^sMastronardi^nN#^rND^sVanhamme^nL#^rND^sVan^nHecke P#^rND^sVan^nHuffe
l S#Improved Lanczos algorithms for blackbox MRS data quantitation^len#J Magn Re
son#20020000#2002#157#292-297#20110400#594.htm#1090-7807#J Magn Reson##
00643000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100016000940120
17300110030001500283065000900298064000500307031000300312014000800315865000900323
002000800332035001000340801001500350#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\5
94.htm#S#c#163#18#article#27#18#^rND^sde^nGraaf AA#^rND^sBovee^nWM#Improved quan
tification of in vivo ¹H NMR spectra by optimization of signal acquisition and p
rocessing and by incorporation of prior knowledge into the spectral fitting^len#
Magn Reson Med#19900000#1990#15#305-319#20110400#594.htm#0740-3194#Magn Reson Me
d##
00570000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100015000960100
01900111012007600130030001100206065000900217064000500226031000300231014000800234
865000900242002000800251035001000259801001100269#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\594.htm#S#c#164#19#article#27#19#^rND^sGovindaraju^nV#^rND^sYoung^nK#
^rND^sMaudsley^nAA#Proton NMR chemical shifts and coupling constants for brain m
etabolites^len#NMR Biomed#20000000#2000#13#129-153#20110400#594.htm#0952-3480#NM
R Biomed##
00423000000000229000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720160017000750180046000920660
00700138062001700145065000900162064000500171865000900176002000800185#v44n4#V:\Sc
iELO\serial\bjmbr\v44n4\markup\594.htm#S#c#165#20#article#27#20#^rND^sAltman^nDG
#Practical statistics for medical research^len#London#Chapman and Hall#19910000#
1991#20110400#594.htm##
00452000000000241000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720160019000750160016000940180
04700110066001100157062001100168065000900179064000500188865000900193002000800202
#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#166#21#article#27#21#^rND
^sCampbell^nMJ#^rND^sMachin^nD#Medical statistics: a commonsense approach^len#Ch
ichester#John Wiley#19990000#1999#20110400#594.htm##
00438000000000229000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720160020000750180062000950660
00900157062001100166065000900177064000500186865000900191002000800200#v44n4#V:\Sc
iELO\serial\bjmbr\v44n4\markup\594.htm#S#c#167#22#article#27#22#^rND^sMcLachlan^
nGJ#Discriminant analysis and statistical pattern recognition^len#New York#John 
Wiley#19920000#1992#20110400#594.htm##
00697000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100017000920100
01500109010002000124010001500144012015000159030001100309065000900320064000500329
031000300334014000800337865000900345002000800354035001000362801001100372#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#168#23#article#27#23#^rND^sOpstad
^nKS#^rND^sLadroue^nC#^rND^sBell^nBA#^rND^sGriffiths^nJR#^rND^sHowe^nFA#Linear d
iscriminant analysis of brain tumour (1)H MR spectra: a comparison of classifica
tion using whole spectra versus metabolite quantification^len#NMR Biomed#2007000
0#2007#20#763-770#20110400#594.htm#0952-3480#NMR Biomed##
00645000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100015000920100
01800107012013200125030002300257065000900280064000500289031000300294014000800297
865000900305002000800314035001000322801002300332#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\594.htm#S#c#169#24#article#27#24#^rND^sMorales^nH#^rND^sKwock^nL#^rND
^sCastillo^nM#Magnetic resonance imaging and spectroscopy of pilomyxoid astrocyt
omas: case reports and comparison with pilocytic astrocytomas^len#J Comput Assis
t Tomogr#20070000#2007#31#682-687#20110400#594.htm#0363-8715#J Comput Assist Tom
ogr##
00718000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100019000960100
01600115010002200131010001900153010001800172810000600190012010200196030001500298
06500090031306400050032203100030032701400080033086500090033800200080034703500100
0355801001500365#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#170#25#ar
ticle#27#25#^rND^sDi^nCostanzo A#^rND^sScarabino^nT#^rND^sTrojsi^nF#^rND^sGianna
tempo^nGM#^rND^sPopolizio^nT#^rND^sCatapano^nD#et al#Multiparametric 3T MR appro
ach to the assessment of cerebral gliomas: tumor extent and malignancy^len#Neuro
radiology#20060000#2006#48#622-631#20110400#594.htm#0028-3940#Neuroradiology##
00616000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100015000890100
01400104010001400118012009200132030001900224065000900243064000500252031000300257
014000800260865000900268002000800277035001000285801001900295#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\594.htm#S#c#171#26#article#27#26#^rND^sCho^nYD#^rND^sChoi
^nGH#^rND^sLee^nSP#^rND^sKim^nJK#¹H-MRS metabolic patterns for distinguishing be
tween meningiomas and other brain tumors^len#Magn Reson Imaging#20030000#2003#21
#663-672#20110400#594.htm#0730-725X#Magn Reson Imaging##
00708000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100017000900100
01700107010001600124010001900140010001600159810000600175012010700181030001500288
06500090030306400050031203100030031701400080032086500090032800200080033703500100
0345801001500355#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\594.htm#S#c#172#27#ar
ticle#27#27#^rND^sHowe^nFA#^rND^sBarton^nSJ#^rND^sCudlip^nSA#^rND^sStubbs^nM#^rN
D^sSaunders^nDE#^rND^sMurphy^nM#et al#Metabolic profiles of human brain tumors u
sing quantitative in vivo ¹H magnetic resonance spectroscopy^len#Magn Reson Med#
20030000#2003#49#223-232#20110400#594.htm#0740-3194#Magn Reson Med##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#o#1#1#article#1#201
10411#094536#673.htm#221##
03560000000000709000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000300107
03000200011003100030013003200020013306500090013501400110014403500100015522400090
01650120147001740100030003210100033003510100031003840100023004150100024004380100
03300462010003300495010003800528070010300566070008700669070008800756070006800844
07001010091207000860101307001140109908313660121308500080257908500270258708500280
26140850030026420850022026720850032026940850034027261170006027600720003027661120
00902769111001502778114000902793113001602802891002402818002000802842#v44n4#V:\Sc
iELO\serial\bjmbr\v44n4\markup\673.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#
TAB#07#BJMBR040#nd#Braz J Med Biol Res#44#4#20110400#^f311^l318#0100-879X#201102
04#Evaluation of the antischistosomal activity of sulfated &#945;-D-glucan from 
the lichen Ramalina celastri free and encapsulated into liposomes^len#^rND^1A01 
A04^nR.V.S.^sAraújo#^rND^1A01 A02^nM.R.^sMelo-Júnior#^rND^1A01 A03^nE.I.C.^sBelt
rão#^rND^1A05^nL.A.^sMello#^rND^1A06^nM.^sIacomini#^rND^1A07^nA.M.A.^sCarneiro-L
eão#^rND^1A01 A03^nL.B.^sCarvalho Jr#^rND^1A01 A03^nN.S.^sSantos-Magalhães#Unive
rsidade Federal de Pernambuco^iA01^1Laboratório de Imunopatologia Keizo-Asami^cR
ecife^sPE^pBrasil#Universidade Federal de Pernambuco^iA02^1Departamento de Patol
ogia^cRecife^sPE^pBrasil#Universidade Federal de Pernambuco^iA03^1Departamento d
e Bioquímica^cRecife^sPE^pBrasil#Associação Caruaruense de Ensino Superior^iA04^
cCaruaru^sPE^pBrasil#Universidade Federal de Minas Gerais^iA05^1Departamento de 
Parasitologia^cBelo Horizonte^sMG^pBrasil#Universidade Federal do Paraná^iA06^1D
epartamento de Bioquímica^cCuritiba^sPR^pBrasil#Universidade Federal Rural de Pe
rnambuco^iA07^1Departamento de Morfologia e Fisiologia Animal^cRecife^sPE^pBrasi
l#^len^aThe antischistosomal activity of the sulfated polysaccharide &#945;-D-gl
ucan (Glu.SO4) extracted from Ramalina celastri was evaluated after encapsulatio
n into liposomes (Glu.SO4-LIPO) in Schistosoma mansoni-infected mice. The effect
 of treatment with Glu.SO4 and Glu.SO4-LIPO (10 mg/kg) on egg elimination, worm 
burden and hepatic granuloma formation was assessed using female albino Swiss mi
ce, 35-40 days of age, weighing 25 ± 2 g, infected with 150 cercariae/animal (Bi
omphalaria glabrata, BH strain). Four groups (N = 10) were studied, two controls
 (empty liposomes and NaCl) and two treated groups (Glu.SO4-LIPO and Glu.SO4) us
ing a single dose. Parasitological analysis revealed that Glu.SO4-LIPO was as ef
ficient as Glu.SO4 in reducing egg elimination and worm burden. Treatment with f
ree Glu.SO4 and Glu.SO4-LIPO induced a statistically significant reduction in th
e number of granulomas (62 and 63%, respectively). Lectin histochemistry showed 
that wheat germ agglutinin intensely stained the egg-granuloma system in all tre
ated groups. On the other hand, peanut agglutinin stained cells in the control g
roups, but not in the treated groups. The present results suggest a correlation 
between the decreasing number of hepatic egg-granulomas and the glycosylation pr
ofile of the egg-granuloma system in animals treated with free Glu.SO4 or Glu.SO
4-LIPO.#^dnd^i1#^tm^len^kPolysaccharide^i1#^tm^len^k&#945;-D-glucan^i1#^tm^len^k
Ramalina celastri^i1#^tm^len^kLiposomes^i1#^tm^len^kSchistosoma mansoni^i1#^tm^l
en^kLectin histochemistry^i1#other#36#20100802#August 2, 2010#20110106#January 6
, 2011#S0100-879X2011007500014#673.htm##
03712000000000697000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000300107
03000200011003100030013003200020013306500090013501400110014403500100015522400090
01650120161001740100030003350100033003650100031003980100023004290100024004520100
03300476010003300509010003800542070010300580070008700683070008800770070006800858
07001010092607000860102707001140111308315260122708500080275308500270276108500280
27880850037028160850022028530850039028750850034029141170006029480720003029541120
00902957111001502966114000902981113001602990002000803006#v44n4#V:\SciELO\serial\
bjmbr\v44n4\markup\673.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#07#BJMBR
040#nd#Braz J Med Biol Res#44#4#20110400#^f311^l318#0100-879X#20110204#<b>Evalua
tion of the antischistosomal activity of sulfated &#945;-D-glucan from the liche
n <i>Ramalina celastri</i> free and encapsulated into liposomes</b>^len#^rND^1A0
1 A04^nR.V.S.^sAraújo#^rND^1A01 A02^nM.R.^sMelo-Júnior#^rND^1A01 A03^nE.I.C.^sBe
ltrão#^rND^1A05^nL.A.^sMello#^rND^1A06^nM.^sIacomini#^rND^1A07^nA.M.A.^sCarneiro
-Leão#^rND^1A01 A03^nL.B.^sCarvalho Jr#^rND^1A01 A03^nN.S.^sSantos-Magalhães#Uni
versidade Federal de Pernambuco^iA01^1Laboratório de Imunopatologia Keizo-Asami^
cRecife^sPE^pBrasil#Universidade Federal de Pernambuco^iA02^1Departamento de Pat
ologia^cRecife^sPE^pBrasil#Universidade Federal de Pernambuco^iA03^1Departamento
 de Bioquímica^cRecife^sPE^pBrasil#Associação Caruaruense de Ensino Superior^iA0
4^cCaruaru^sPE^pBrasil#Universidade Federal de Minas Gerais^iA05^1Departamento d
e Parasitologia^cBelo Horizonte^sMG^pBrasil#Universidade Federal do Paraná^iA06^
1Departamento de Bioquímica^cCuritiba^sPR^pBrasil#Universidade Federal Rural de 
Pernambuco^iA07^1Departamento de Morfologia e Fisiologia Animal^cRecife^sPE^pBra
sil#^len^aThe antischistosomal activity of the sulfated polysaccharide &#945;-D-
glucan (Glu.SO<sub>4</sub>) extracted from <i>Ramalina celastri </i>was evaluate
d after encapsulation into liposomes (Glu.SO<sub>4</sub>-LIPO) in <i>Schistosoma
 mansoni</i>-infected mice. The effect of treatment with Glu.SO<sub>4</sub> and 
Glu.SO<sub>4</sub>-LIPO (10 mg/kg) on egg elimination, worm burden and hepatic g
ranuloma formation was assessed using female albino Swiss mice, 35-40 days of ag
e, weighing 25 ± 2 g, infected with 150 cercariae<i>/</i>animal (<i>Biomphalaria
 glabrata</i>, BH strain). Four groups (N = 10) were studied, two controls (empt
y liposomes and NaCl) and two treated groups (Glu.SO<sub>4</sub>-LIPO and Glu.SO
<sub>4</sub>) using a single dose. Parasitological analysis revealed that Glu.SO
<sub>4</sub>-LIPO was as efficient as Glu.SO<sub>4</sub> in reducing egg elimina
tion and worm burden. Treatment with free Glu.SO<sub>4 </sub>and Glu.SO<sub>4</s
ub>-LIPO induced a statistically significant reduction in the number of granulom
as (62 and 63%, respectively). Lectin histochemistry showed that wheat germ aggl
utinin intensely stained the egg-granuloma system in all treated groups. On the 
other hand, peanut agglutinin stained cells in the control groups, but not in th
e treated groups. The present results suggest a correlation between the decreasi
ng number of hepatic egg-granulomas and the glycosylation profile of the egg-gra
nuloma system in animals treated with free Glu.SO<sub>4 </sub>or Glu.SO<sub>4</s
ub>-LIPO.#^dnd^i1#^tm^len^kPolysaccharide^i1#^tm^len^k&#945;-D-glucan^i1#^tm^len
^k<i>Ramalina celastri</i>^i1#^tm^len^kLiposomes^i1#^tm^len^k<i>Schistosoma mans
oni</i>^i1#^tm^len^kLectin histochemistry^i1#other#36#20100802#August 2, 2010#20
110106#January 6, 2011#673.htm##
03681000000000721000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800030012003000240012303100030014703200020015006500090015201400110016103500100
01722240009001820120147001910100031003380100033003690100032004020100023004340100
02300457010003400480010003700514010003800551070010500589070008900694070009000783
07000700087307001030094307000880104607001160113408313730125008500080262308500270
26310850028026580850030026860850022027160850032027380850034027701170006028040720
00302810112000902813111001502822114000902837113001602846002000802862008008902870
#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#l#4#1#article#1#^mApr.^a201
1#oa#en#bjmbr#1#3.1#ilus#tab#07#BJMBR040#nd#Braz. j. med. biol. res#44#4#2011040
0#^f311^l318#0100-879X#20110204#Evaluation of the antischistosomal activity of s
ulfated &#945;-D-glucan from the lichen Ramalina celastri free and encapsulated 
into liposomes^len#^rND^1A01 A04^nR. V. S^sAraújo#^rND^1A01 A02^nM. R^sMelo-Júni
or#^rND^1A01 A03^nE. I. C^sBeltrão#^rND^1A05^nL. A^sMello#^rND^1A06^nM^sIacomini
#^rND^1A07^nA. M. A^sCarneiro-Leão#^rND^1A01 A03^nL. B^sCarvalho Júnior#^rND^1A0
1 A03^nN. S^sSantos-Magalhães#^iA01^1Universidade Federal de Pernambuco^2Laborat
ório de Imunopatologia Keizo-Asami^cRecife^sPE^pBrasil#^iA02^1Universidade Feder
al de Pernambuco^2Departamento de Patologia^cRecife^sPE^pBrasil#^iA03^1Universid
ade Federal de Pernambuco^2Departamento de Bioquímica^cRecife^sPE^pBrasil#^iA04^
1Associação Caruaruense de Ensino Superior^cCaruaru^sPE^pBrasil#^iA05^1Universid
ade Federal de Minas Gerais^2Departamento de Parasitologia^cBelo Horizonte^sMG^p
Brasil#^iA06^1Universidade Federal do Paraná^2Departamento de Bioquímica^cCuriti
ba^sPR^pBrasil#^iA07^1Universidade Federal Rural de Pernambuco^2Departamento de 
Morfologia e Fisiologia Animal^cRecife^sPE^pBrasil#^len^aThe antischistosomal ac
tivity of the sulfated polysaccharide &#945;-D-glucan (Glu.SO4) extracted from R
amalina celastri was evaluated after encapsulation into liposomes (Glu.SO4-LIPO)
 in Schistosoma mansoni-infected mice. The effect of treatment with Glu.SO4 and 
Glu.SO4-LIPO (10 mg/kg) on egg elimination, worm burden and hepatic granuloma fo
rmation was assessed using female albino Swiss mice, 35-40 days of age, weighing
 25 ± 2 g, infected with 150 cercariae/animal (Biomphalaria glabrata, BH strain)
. Four groups (N = 10) were studied, two controls (empty liposomes and NaCl) and
 two treated groups (Glu.SO4-LIPO and Glu.SO4) using a single dose. Parasitologi
cal analysis revealed that Glu.SO4-LIPO was as efficient as Glu.SO4 in reducing 
egg elimination and worm burden. Treatment with free Glu.SO4 and Glu.SO4-LIPO in
duced a statistically significant reduction in the number of granulomas (62 and 
63 percent, respectively). Lectin histochemistry showed that wheat germ agglutin
in intensely stained the egg-granuloma system in all treated groups. On the othe
r hand, peanut agglutinin stained cells in the control groups, but not in the tr
eated groups. The present results suggest a correlation between the decreasing n
umber of hepatic egg-granulomas and the glycosylation profile of the egg-granulo
ma system in animals treated with free Glu.SO4 or Glu.SO4-LIPO.#^dnd^i1#^tm^len^
kPolysaccharide^i1#^tm^len^k&#945;-D-glucan^i1#^tm^len^kRamalina celastri^i1#^tm
^len^kLiposomes^i1#^tm^len^kSchistosoma mansoni^i1#^tm^len^kLectin histochemistr
y^i1#other#36#20100802#August 2, 2010#20110106#January 6, 2011#673.htm#Internet^
ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000400007#
#
00373000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014900070002000800219#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#5#1#article#181#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 311-318  </B> </font></P>      ^cY#673.htm##
00596000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704037200070002000800442#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#6#2#article#181#<p ALIGN="left"><strong><
font face="Arial, Helvetica, sans-serif"><span lang="EN"><font size="5">Evaluati
on of the antischistosomal activity of sulfated &alpha;-D-glucan from the lichen
 </font></span></font><font size="5" face="Arial, Helvetica, sans-serif"><span l
ang="EN"><i>Ramalina celastri</i> free and encapsulated into liposomes</span></f
ont></strong></p>      ^cY#673.htm##
00992000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704076800070002000800838#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#7#3#article#181#<p ALIGN="left"><font fac
e="Arial"><span lang="EN"><span lang="EN"><font face="Arial, Helvetica, sans-ser
if"><sup><span lang="EN"><font face="Arial, Helvetica, sans-serif"><b><a href="#
Correspondence"><img src="/img/revistas/bjmbr/v44n4/recor.gif" border="0"></a></
b> <a href="mailto:rosangela.vidal@gmail.com"><img src="/img/revistas/bjmbr/v44n
4/email-ca.gif" border="0"></a></font></span></sup></font></span> R.V.S. Ara&uac
ute;jo<sup>1,4</sup>, M.R. Melo-J&uacute;nior<sup>1,2</sup>, E.I.C. Beltr&atilde
;o<sup>1,3</sup>, L.A. Mello<sup>5</sup>, M. Iacomini<sup>6</sup>, </span></font
><font face="Arial"><span lang="EN">A.M.A. Carneiro-Le&atilde;o<sup>7</sup>, L.B
. Carvalho Jr.<sup>1,3</sup> and N.S. Santos-Magalh&atilde;es<sup>1,3</sup></spa
n></font></p>      ^cY#673.htm##
00422000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704019800070002000800268#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#8#4#article#181#<p ALIGN="left"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Laborat&oacute;rio 
de Imunopatologia Keizo-Asami, Universidade Federal de Pernambuco, Recife, PE, B
rasil    ^cY#673.htm##
00382000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704015800070002000800228#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#9#5#article#181#<br>    </font></span><fo
nt face="Arial"><span lang="EN"><sup>2</sup>Departamento de Patologia, Universid
ade Federal de Pernambuco, Recife, PE, Brasil    ^cY#673.htm##
00342000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704011700071002000800188#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#10#6#article#181#<br>    <sup>3</sup>Depa
rtamento de Bioqu&iacute;mica, Universidade Federal de Pernambuco, Recife, PE, B
rasil    ^cY#673.htm##
00329000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704010400071002000800175#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#11#7#article#181#<br>    <sup>4</sup>Asso
cia&ccedil;&atilde;o Caruaruense de Ensino Superior, Caruaru, PE, Brasil    ^cY#
673.htm##
00348000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704012300071002000800194#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#12#8#article#181#<br>    <sup>5</sup>Depa
rtamento de Parasitologia, Universidade Federal de Minas Gerais, Belo Horizonte,
 MG, Brasil    ^cY#673.htm##
00347000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704012200071002000800193#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#13#9#article#181#<br>    <sup>6</sup>Depa
rtamento de Bioqu&iacute;mica, Universidade Federal do Paran&aacute;, Curitiba, 
PR, Brasil    ^cY#673.htm##
00380000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704015400072002000800226#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#14#10#article#181#<br>  <sup>7</sup>Depar
tamento de Morfologia e Fisiologia Animal, Universidade Federal Rural de Pernamb
uco, Recife, PE, Brasil</span></font></p>      ^cY#673.htm##
00416000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019000072002000800262#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#15#11#article#181#<P> <font face="Arial, 
Helvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/d
own.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A> 
   ^cY#673.htm##
00413000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018700072002000800259#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#16#12#article#181#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    
^cY#673.htm##
00413000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018700072002000800259#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#17#13#article#181#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    
^cY#673.htm##
00398000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017200072002000800244#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#18#14#article#181#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#673.htm##
00407000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018100072002000800253#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#19#15#article#181#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#67
3.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#20#16#article#181#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#673.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#21#17#article#181#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#673.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#22#18#article#181#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#673.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#23#19#article#181#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#673.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#24#20#article#181#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#673.htm##
01832000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704160600072002000801678#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#25#21#article#181#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">The antischistosomal activity of the sulfated polysa
ccharide &alpha;-D-glucan (Glu.SO<sub>4</sub>) extracted from <i>Ramalina celast
ri </i>was evaluated after encapsulation into liposomes (Glu.SO<sub>4</sub>-LIPO
) in <i>Schistosoma mansoni</i>-infected mice. The effect of treatment with Glu.
SO<sub>4</sub> and Glu.SO<sub>4</sub>-LIPO (10 mg/kg) on egg elimination, worm b
urden and hepatic granuloma formation was assessed using female albino Swiss mic
e, 35-40 days of age, weighing 25 &plusmn; 2 g, infected with 150 cercariae<i>/<
/i>animal (<i>Biomphalaria glabrata</i>, BH strain). Four groups (N = 10) were s
tudied, two controls (empty liposomes and NaCl) and two treated groups (Glu.SO<s
ub>4</sub>-LIPO and Glu.SO<sub>4</sub>) using a single dose. Parasitological ana
lysis revealed that Glu.SO<sub>4</sub>-LIPO was as efficient as Glu.SO<sub>4</su
b> in reducing egg elimination and worm burden. Treatment with free Glu.SO<sub>4
 </sub>and Glu.SO<sub>4</sub>-LIPO induced a statistically significant reduction
 in the number of granulomas (62 and 63%, respectively). Lectin histochemistry s
howed that wheat germ agglutinin intensely stained the egg-granuloma system in a
ll treated groups. On the other hand, peanut agglutinin stained cells in the con
trol groups, but not in the treated groups. The present results suggest a correl
ation between the decreasing number of hepatic egg-granulomas and the glycosylat
ion profile of the egg-granuloma system in animals treated with free Glu.SO<sub>
4 </sub>or Glu.SO<sub>4</sub>-LIPO.</span></font></p>      ^cY#673.htm##
00463000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704023700072002000800309#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#26#22#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Key words: Polysaccharide; &alpha;-D-glucan; <i>R
amalina celastri</i>; Liposomes;<i> Schistosoma mansoni</i>; Lectin histochemist
ry</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#673.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#27#23#article#181#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#673.htm##
00670000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704044400072002000800516#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#28#24#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Schistosomiasis remains one of the most prevalent
 parasitic infections, involving major economic consequences and affecting many 
public health programs (1). Praziquantel and oxamniquine are currently the drugs
 of choice for the treatment of schistosomiasis (2-4); nevertheless a few report
s have pointed out that some resistance to these drugs has emerged (5-7).</span>
</font></p>      ^cY#673.htm##
00818000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704059200072002000800664#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#29#25#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Parasite egg elimination, granuloma formation, di
sease severity, resistance to reinfection, and drug efficacy have been shown to 
be significantly dependent on the immunological factors of patients infected wit
h <i>Schistosoma</i> (8-10). The prospect of having only a very limited number o
f therapeutic choices available for a disease affecting 200 million people is ra
ther alarming (5). In this scenario, the development of new drugs or novel pharm
aceutical dosage forms of old drugs is of great significance.</span></font></p> 
     ^cY#673.htm##
00735000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704050900072002000800581#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#30#26#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">A series of studies have shown that numerous poly
saccharides, including glucans from diverse biological sources, have immune pote
ntiating activity (11). The immunomodulating effects of glucans involve macropha
ges, T-helper and natural killer cells, T-cell differentiation, the proliferativ
e response of polymorphic nuclear cells, the production of interleukins and inte
rferon, as well as an increase in phagocyte activity (12).</span></font></p>    
  ^cY#673.htm##
01270000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704104400072002000801116#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#31#27#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Lichens are promising sources of &alpha;-glucans,
 which are generally soluble in water and have a linear structure with glycoside
 linkages of the &alpha;-[1.3] and &alpha;-[1.4] type (13). Some cytotoxic effec
ts against HeLa cells have been reported for an &alpha;-D-glucan isolated from t
he lichen <i>Ramalina celastri</i> (14). This polysaccharide, which presents mai
nly &alpha;-[1.3], [1.4] linkages in its structure, has shown cytotoxic effects 
against HeLa cells, phagocytic activity, antitumor effects against sarcoma-180, 
and effects on peritoneal cell exudates. These features suggest a promising role
 of the <i>R. celastri</i> glucan as a biological response modifier (15). Liposo
mes have long been recognized as carriers for <i>in vivo</i> administration of a
ctive substances and drugs (16,17). Market liposome formulations containing amph
otericin B or doxorubicin are successful examples of the application of pharmace
utical nanotechnology to therapy.</span></font></p>      ^cY#673.htm##
00701000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704047500072002000800547#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#32#28#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">The pharmacokinetics of liposomes composed of nat
ural phospholipids and cholesterol is characterized by a high plasma clearance r
ate. These vesicles are rapidly removed from the circulation by macrophages of t
he reticuloendothelial system (16), an important behavior since polysaccharides 
are considered to modify the biological response and to act by improving the cel
ls of the immune system.</span></font></p>      ^cY#673.htm##
01041000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704081500072002000800887#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#33#29#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Furthermore, it has been generally acknowledged t
hat conventional liposomes administered by intravenous injection are rapidly rem
oved from the circulation by macrophages. This property is a great advantage in 
the case of encapsulation of polysaccharides to be used as biological response m
odulators. The administration of glucan-loaded liposomes could enable their spec
ific delivery to the cells of the mononuclear phagocyte system, thereby yielding
 an extremely efficient activation of cellular and humoral immune responses. In 
addition, the antischistosomial drugs praziquantel and oxamniquine encapsulated 
into liposomes have been reported to be greatly effective against experimental <
i>Schistosoma mansoni</i> infection (18,19).</span></font></p>      ^cY#673.htm#
#
00789000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704056300072002000800635#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#34#30#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Lectins are erythrocyte-agglutinating and sugar-s
pecific proteins or glycoproteins, which are particularly useful tools for the i
nvestigation of carbohydrates on cell surfaces (20). In view of their capacity t
o recognize carbohydrates, lectins have been used as histochemical markers for c
ell outer-membrane glycoconjugates, especially for detecting changes that the la
tter undergo in malignancy (21-23), in inflammatory processes (23-25) and in par
asite-host interactions (26,27).</span></font></p>      ^cY#673.htm##
01023000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704079700072002000800869#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#35#31#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Since polysaccharide-based immunomodulators have 
been successful in the treatment of many parasitic infections and in view of the
 effectiveness of drug encapsulation into liposomes, the present study was desig
ned to evaluate the effect of sulfated &alpha;-D-glucan from <i>R. celastri</i> 
encapsulated into liposomes against an experimental model of <i>S. mansoni</i> i
nfection. Qualitative and quantitative analyses of schistosome eggs and worm bur
den were evaluated in infected mice. In addition to histopathology, lectin histo
chemistry analyses of liver and intestine were carried out to substantiate the e
gg-granulomatous reaction after treatment of animals with glucan-loaded liposome
s.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#673.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#36#32#article#181#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#673.htm##
00324000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009800072002000800170#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#37#33#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN"><b>Chemicals</b></span></font></p>      ^cY#673.h
tm##
00795000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704056900072002000800641#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#38#34#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Soya phosphatidylcholine (PC) was obtained from L
ucas Meyer (Germany). Cholesterol (Chol), stearylamine (SA), and lectin wheat ge
rm agglutinin (WGA), peanut agglutinin (PNA), and concanavalin A (Con A) were pu
rchased from Sigma (USA). Chloroform and methanol were obtained from Merck (Germ
any). The polysaccharide &alpha;-D-glucan was isolated from the lichen <i>R. cel
astri</i> (14) and sulfated according to a previously reported protocol (28) and
 is referred to as Glu.SO<sub>4</sub>.</span></font></p>      ^cY#673.htm##
00365000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013900072002000800211#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#39#35#article#181#<p ALIGN="JUSTIFY"><b><
font face="Arial"><span lang="EN">Preparation of Glu.SO<sub>4</sub>-loaded lipos
omes</span></font></b></p>      ^cY#673.htm##
00731000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704050500072002000800577#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#40#36#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Liposome formulations were prepared as previously
 described (16), based on a lipid film formed by evaporation of solvents from an
 organic phospholipid solution. Positive surface-charged liposomes were prepared
 as follows. First lipid constituents, namely PC, Chol and SA (7:2:1, 36 &micro;
mol lipids/10 &micro;L buffered solution), were dissolved in 3:1 chloroform/meth
anol (v/v) under moderate magnetic shaking for 15 min.</span></font></p>      ^c
Y#673.htm##
01192000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704096600072002000801038#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#41#37#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">The organic solvents were then evaporated at redu
ced pressure (40 min at 37 &plusmn; 1&deg;C) with shaking at 120 rpm. Next, the 
dried lipid film was hydrated by the addition of an aqueous phase (10 mL) consis
ting of phosphate-buffered saline, pH 7.4, containing 2.0 mg/mL Glu.SO<sub>4</su
b> and 2% trehalose, leading to multilamellar vesicle formation. The suspension 
was then kept under magnetic shaking (40 min) and sonicated at 200 W (40 cycles/
s) for 250 s, providing small unilamellar vesicles (SUV). Liposomes were then ly
ophilized using a fuel tank self-sealing system (USA) operating at 200 bar for 1
6 h with trehalose as a cryoprotectant. The product was stored in sealed vials a
t 4 &plusmn; 1&deg;C. Liposomes with different properties were prepared by varyi
ng the lipid/buffer ratio (36-42 &micro;mol/10 &micro;L) and Glu.SO<sub>4</sub> 
concentration (1, 1.5 and 2 mg/mL).</span></font></p>      ^cY#673.htm##
00463000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704023700072002000800309#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#42#38#article#181#<p ALIGN="JUSTIFY"><b><
font face="Arial"><span lang="EN">Evaluation of the stability of Glu.SO<sub>4</s
ub>-loaded </span></font></b><b><font face="Arial"><span lang="EN">liposomes (Gl
u.SO<sub>4</sub>-LIPO)</span></font></b></p>      ^cY#673.htm##
00785000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704055900072002000800631#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#43#39#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">The analysis of liposomes was carried out immedia
tely after preparation of the formulations. Many features such as macroscopic an
d microscopic aspects, pH changes and Glu.SO<sub>4</sub> encapsulation ratio wer
e then analyzed. The pH evolution of Glu.SO<sub>4</sub>-LIPO suspensions was obs
erved for samples stored at 4&deg;C for 6 months. Liposomes were submitted to bo
th accelerated and long-term stability tests with the aim of determining the dur
ability of the formulations.</span></font></p>      ^cY#673.htm##
00821000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704059500072002000800667#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#44#40#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">After preparation, liposome suspensions were subm
itted to centrifugation at 1300 <i>g</i> for 1 h (KN-70 centrifuge, Kubota, Japa
n), mechanical stress at 150 strokes/min at 37&deg;C for 48 h (Polytest 20 Biobl
ock Scientific, France) and freeze-thawing cycles (16 h at -18&deg;C and 8 h at 
25 &plusmn; 1&deg;C). The long-term stability of lyophilized liposomes was exami
ned for samples stored at 4 &plusmn; 1&ordm;C. The Glu.SO<sub>4</sub> content in
 liposomes was assessed by the phenol-sulfuric acid method (29).</span></font></
p>      ^cY#673.htm##
00852000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704062600072002000800698#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#45#41#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">A standard calibration curve was constructed with
 D-glucose at concentrations ranging from 8 to 80 &micro;g/mL. The encapsulation
 ratio of Glu.SO<sub>4</sub> into liposomes was determined after ultrafiltration
/ultracentrifugation at 133,570 <i>g</i> for 1 h in ultra-free units (Millipore,
 USA). The Glu.SO<sub>4</sub> concentration in the supernatant was determined as
 described by Fr&eacute;zard and de Melo (18) and the encapsulation ratio was th
en calculated on the basis of the total Glu.SO<sub>4</sub> content in the liposo
me formulation.</span></font></p>      ^cY#673.htm##
00373000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704014700072002000800219#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#46#42#article#181#<p ALIGN="JUSTIFY"><b><
font face="Arial"><span lang="EN">Biological activity of Glu.SO<sub>4</sub>-load
ed liposomes</span></font></b></p>      ^cY#673.htm##
00821000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704059500072002000800667#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#47#43#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Female albino Swiss mice aged 35-40 days and weig
hing 25 &plusmn; 2 g were percutaneously infected with 150 cercariae of <i>S. ma
nsoni</i> (<i>Biomphalaria glabrata</i> (BH) strain, Brazil) shed from mice expe
rimentally infected with the BH strain. The animals were randomly divided into f
our groups of 10 mice each and treated by the intraperitoneal route with a singl
e dose of 10 mg/kg Glu.SO<sub>4</sub> or Glu.SO<sub>4</sub>-LIPO, 24 h after inf
ection. Control groups received 150 mM NaCl and empty liposomes.</span></font></
p>      ^cY#673.htm##
00709000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704048300072002000800555#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#48#44#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">The dose of &alpha;-D-glucan and sulfated glucan 
was selected on the basis of LD50 data for the native polysaccharide, with resul
ts of 3200 and 400 mg/kg, respectively. The test was conducted on males (N = 15 
animals/dose) and females (N = 15 animals/dose) for a treatment period of 30 day
s. The experimental doses were then selected considering the best therapeutic ef
fect and lowest toxic potential.</span></font></p>      ^cY#673.htm##
00933000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704070700072002000800779#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#49#45#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Animal infection was confirmed 36 days after inje
ction by quantitative examination of schistosome eggs in the feces, i.e., counti
ng the number of schistosome eggs per 1 g of feces using the Kato-Katz thick-sme
ar technique (30). Fifty-six days after infection, the animals were anesthetized
 subcutaneously with 10 mg/kg xylazine chloride and 115 mg/kg ketamine chloride,
 sacrificed and submitted to portal hepatic-mesenteric perfusion. Worms were rec
overed and counted using a stereomicroscope and catalogued by sex. Liver and int
estine samples from the animals were collected for histopathological and histoch
emical analyses.</span></font></p>      ^cY#673.htm##
00345000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011900072002000800191#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#50#46#article#181#<p ALIGN="JUSTIFY"><b><
font face="Arial"><span lang="EN">Ethical aspects and statistics</span></font></
b></p>      ^cY#673.htm##
00506000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704028000072002000800352#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#51#47#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">The Animal Ethics Committee of Universidade Feder
al Rural de Pernambuco approved the experimental animal protocol. Parasitologica
l data are summarized in the usual form, namely as means &plusmn; SD.</span></fo
nt></p>      ^cY#673.htm##
00724000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704049800072002000800570#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#52#48#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Data from the different animal groups were submit
ted to analysis of variance (ANOVA). The Tukey test (PRISM<sup>&reg;</sup> 3.0; 
Prism Corporation, USA) was applied at the P = 0.05 level of significance by ass
igning a letter (a, b, c, d) to each group as follows: groups with different let
ters indicate strong evidence for a difference between population means (P = 0.0
5), while the same letters signify P &gt; 0.05.</span></font></p>      ^cY#673.h
tm##
00436000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021000072002000800282#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#53#49#article#181#<p ALIGN="JUSTIFY"><b><
font face="Arial"><span lang="EN">Histopathological analysis of Glu.SO<sub>4</su
b>-loaded </span></font></b><b><font face="Arial"><span lang="EN">liposomes</spa
n></font></b></p>      ^cY#673.htm##
00949000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704072300072002000800795#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#54#50#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Qualitative and quantitative analyses of schistos
ome eggs and of the egg-granuloma reaction were performed in the liver of mice a
fter treatment with Glu.SO<sub>4</sub> and Glu.SO<sub>4</sub>-LIPO. The liver an
d small intestine biopsies were fixed in 10% formalin, routinely processed for h
istology and embedded in paraffin. Slices of tissue samples (4 &micro;m) were pr
epared on slides and treated with 3-amine-propyltriethoxy-silane (Sigma). The sa
mples were then stained with hematoxylin-eosin and Masson trichrome. Histopathol
ogical analysis and egg-granuloma counts were performed using light microscopy (
Olympus BH-2 microscope, Japan).</span></font></p>      ^cY#673.htm##
00769000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704054300072002000800615#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#55#51#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Section images (100X magnification) were captured
 by a digital video camera (Sony, Japan) connected to the microscope and process
ed using the OPTIMAS<sup>&reg;</sup> software version 6.1 (Optimas Corporation, 
USA). Analysis of the number of granulomas per tissue area was carried out in si
x random areas of hepatic tissue. Statistical analysis of the granuloma counts w
as performed by Tukey and Student <i>t</i>-tests (P &lt; 0.05) using the PRISM 3
.0 software.</span></font></p>      ^cY#673.htm##
00364000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013800072002000800210#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#56#52#article#181#<p ALIGN="JUSTIFY"><b><
font face="Arial"><span lang="EN">Lectin histochemistry of the egg-granuloma sys
tem</span></font></b></p>      ^cY#673.htm##
00745000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704051900072002000800591#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#57#53#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Protocols were carried out as described by Beltr&
atilde;o et al. (21). Horseradish peroxidase (HRP)-conjugated WGA, PNA and Con A
 lectin were used to investigate the saccharide profile of the hepatic and intes
tinal schistosome egg-granuloma system after treatment of <i>S. mansoni</i>-infe
cted mice with free and encapsulated sulfated glucan. Tissues were deparaffinize
d in xylene and hydrated through graded alcohol solutions (70-100%).</span></fon
t></p>      ^cY#673.htm##
01317000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704109100072002000801163#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#58#54#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Sections (4 &micro;m) were treated with 0.1% (w/v
) trypsin for 2 min at 37&deg;C, followed by 0.3% (v/v) methanolic hydrogen pero
xide for 2 min at 25&deg;C and incubated with 100 &micro;g/mL conjugated lectins
 (WGA-HRP, PNA-HRP and Con A-HRP) for 2 h at 4&deg;C. Sections were then washed 
twice (5 min) with 10 mM phosphate-buffered saline (PBS), pH 7.2, containing 0.1
5 M NaCl after each step. The peroxidase reaction was visualized using a solutio
n of diaminobenzidine and hydrogen peroxide in PBS. Inhibition assays of lectin-
carbohydrate recognition were performed using the corresponding lectin-specific 
sugar: Nacetyl-glucosamine for WGA, D-galactose for PNA and methyl-a-D-mannoside
 for Con A, at a final concentration of 300 mM. Tissue sections were counterstai
ned with hematoxylin and evaluated by light microscopy (Olympus BH-2, Japan). In
tense brown staining is visualized in the neighborhood of egg-granulomas as a re
sult of the formation of lectin-carbohydrate conjugates.</span></font></p>  <HR 
ALIGN=LEFT SIZE=2>      ^cY#673.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#59#55#article#181#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#673.htm##
00363000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013700072002000800209#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#60#56#article#181#<p ALIGN="JUSTIFY"><b><
font face="Arial"><span lang="EN">Stability of Glu.SO<sub>4</sub>-loaded liposom
es</span></font></b></p>      ^cY#673.htm##
00442000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021600072002000800288#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#61#57#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">The liposomes obtained were classified morphologi
cally as SUV obtained by sonication to reduce their size and were positively cha
rged.</span></font></p>      ^cY#673.htm##
00662000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704043600072002000800508#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#62#58#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Liposome suspensions were submitted to mechanical
 and centrifuge resistance testing and all were found to be stable, except for F
6, which presented precipitation after both tests (<a href="#Tab1">Table 1</a>).
 The most stable formulation was F4 prepared with 36 &micro;mol lipids/10 &micro
;L and 2 mg/mL Glu.SO<sub>4</sub>, which remained stabilized, with no physicoche
mical    ^cY#673.htm##
00520000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704029400072002000800366#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#63#59#article#181#<br>   changes being no
ticed after six freeze-thaw cycles. Furthermore, after redispersion the lyophili
zed F4 formulation presented a macroscopic and microscopic appearance similar to
 that of the suspension form. This preparation was then chosen for further studi
es.</span></font></p>      ^cY#673.htm##
01082000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704085600072002000800928#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#64#60#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">The F4 formulation (suspension form) showed a sli
ght gradual decrease in pH value from 7.4 to 6.5 when stored at 4 &plusmn; 1&deg
;C over a period of 180 days (<a href="#Fig1">Figure 1</a>). This might be a sig
n of slow lipid degradation inducing fatty acid formation. A study by Pontes et 
al. (31) had already shown that the main degradation pathway for a lipid medium 
leads to the formation of fatty acids, interfering with the electrical conductiv
ity and gradually reducing the pH of the preparations. On the other hand, lyophi
lized Glu.SO<sub>4</sub>-LIPO presented no pH changes after redispersion. A Glu.
SO<sub>4</sub> encapsulation ratio of 50% was achieved, which can be considered 
satisfactory for <i>in vivo</i> studies with the Glu.SO<sub>4</sub>-LIPO formula
tion.</span></font></p>      ^cY#673.htm##
00450000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704022400072002000800296#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#65#61#article#181#<p ALIGN="JUSTIFY"><b><
font face="Arial"><span lang="EN">Efficacy of Glu.SO<sub>4</sub>-loaded liposome
s on </span></font></b><b><font face="Arial"><span lang="EN">experimental schist
osomiasis</span></font></b></p>      ^cY#673.htm##
00831000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704060500072002000800677#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#66#62#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN"><a href="#Fig2">Figure 2</a> shows the schistosom
e egg count in feces of treated <i>S. mansoni</i>-infected mice after 56 days of
 infection. Treatment of the animals with Glu.SO<sub>4</sub> produced a signific
ant reduction in <i>S. mansoni</i> infection expressed by an egg elimination of 
90.1% (P = 0.002) in comparison with the untreated control group. However, no si
gnificant difference was observed between groups treated with Glu.SO<sub>4</sub>
 or Glu.SO<sub>4</sub>-LIPO. These data were obtained using a single dose.</span
></font></p>      ^cY#673.htm##
00651000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704042500072002000800497#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#67#63#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Analysis of worms recovered from the portal hepat
ic-mesenteric plexus is shown in <a href="#Tab2">Table 2</a>. A statistically si
gnificant reduction in the number of male and female worms was observed in the a
nimal groups treated with Glu.SO<sub>4</sub> (73 and 71%) and Glu.SO<sub>4</sub>
-LIPO (86 and 91%), respectively, compared to control.</span></font></p>      ^c
Y#673.htm##
00354000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704012800072002000800200#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#68#64#article#181#<p ALIGN="JUSTIFY"><b><
font face="Arial"><span lang="EN">Histopathological analysis of the liver</span>
</font></b></p>      ^cY#673.htm##
00815000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704058900072002000800661#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#69#65#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">The histopathological analysis of the liver of an
imals treated with Glu.SO<sub>4</sub> and Glu.SO<sub>4</sub>-LIPO is shown in <a
 href="#Fig3">Figure 3</a>. The group treated with free polysaccharide showed a 
statistically significant 61% reduction in the number of hepatic granulomas (P =
 0.007336) compared to control. In the polysaccharide-encapsulated group, the re
duction in the number of hepatic granulomas was significantly different from the
 empty liposome group, with a 63% decrease (P = 0.029527).</span></font></p>    
  ^cY#673.htm##
00523000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704029700072002000800369#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#70#66#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">Furthermore, histopathological analysis of the ti
ssue showed various aspects of the stages of evolution of the egg-granuloma syst
em, with extensive areas of necrosis and degenerated eggs being observed in the 
liver.</span></font></p>      ^cY#673.htm##
00372000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704014600072002000800218#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#71#67#article#181#<p ALIGN="JUSTIFY"><b><
font face="Arial"><span lang="EN">Lectin histochemical analysis of the egg-granu
loma system</span></font></b></p>      ^cY#673.htm##
00985000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704075900072002000800831#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#72#68#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">The lectin histochemistry results (<a href="#Tab3
">Table 3</a>) showed that WGA, specific for N-acetyl-glucosamine, bound intense
ly to cells in the egg-granuloma system in both the hepatic and intestinal tissu
e of all experimental animal groups. PNA, which binds specifically to D-galactos
e, produced an intense staining pattern in cells treated with empty liposomes, w
hereas no reactivity was observed in the Glu.SO<sub>4</sub>-LIPO-treated group. 
Con A, which recognizes a-D-mannose and D-glucose residues in cell glycoconjugat
es, stimulated intense cytoplasmic staining in both the liver and intestine egg-
granuloma systems only in the group treated with Glu.SO<sub>4</sub>.</span></fon
t></p>      ^cY#673.htm##
00939000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704071300072002000800785#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#73#69#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN"><a href="#Fig4">Figure 4</a> illustrates the lect
in histochemical staining patterns of the egg-granuloma system in the liver (A) 
and intestine (B) of animals treated with Glu.SO<sub>4</sub>. Commercial lectins
 (WGA, PNA and Con A) conjugated to peroxidase were used. The figure is represen
tative of HRP-PNA, with no reactive staining of intestinal egg-granulomas in ani
mals treated with Glu.SO<sub>4</sub>-LIPO.</span></font></p>  <HR ALIGN=LEFT SIZ
E=2>  <table  border="0">    <tr align="left" valign="top">      <td><a href="/i
mg/revistas/bjmbr/v44n4/html/673i01.htm"><img src="/img/revistas/bjmbr/v44n4/673
i01peq.jpg" border="2"></a></td>      <td>    ^cY#673.htm##
00567000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704034100072002000800413#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#74#70#article#181#<p ALIGN="JUSTIFY"><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 
1. pH evolution of liposome suspensions stored at 4&deg;C. <i>Squares</i>, Sulfa
ted glucan encapsulated into liposomes (Glu.SO<sub>4</sub>-LIPO); <i>triangles</
i>, empty liposomes.</font></span></p>      </td>    </tr>  </table>      ^cY#67
3.htm##
00562000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033600072002000800408#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#75#71#article#181#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/673i02.htm"><img src="/img/r
evistas/bjmbr/v44n4/673i02peq.jpg" border="2"></a></td>      <td>    ^cY#673.htm
##
00770000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704054400072002000800616#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#76#72#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN"><a name="Fig2"></a>Figure 2. Effect of treatments
 against oviposition by <i>Schistosoma mansoni </i>(eggs/g feces after 56 days o
f mouse infection). Glu.SO<sub>4 </sub>= free sulfated glucan; NaCl = 150 mM NaC
l; Glu.SO<sub>4</sub>-LIPO = sulfated glucan encapsulated into liposomes; LIPO =
 empty liposomes. Different letters mean a statistically significant difference 
between groups (P &le; 0.05, Tukey and Student <i>t</i>-tests).</span></font></p
>      </td>    </tr>  </table>      ^cY#673.htm##
00562000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033600072002000800408#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#77#73#article#181#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/673i03.htm"><img src="/img/r
evistas/bjmbr/v44n4/673i03peq.jpg" border="2"></a></td>      <td>    ^cY#673.htm
##
00757000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704053100072002000800603#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#78#74#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN"><a name="Fig3"></a>Figure 3. Histopathological an
alyses (hepatic granulomas) of liver of mice infected with <i>Schistosoma manson
i.</i> Glu.SO<sub>4 </sub>= free sulfated glucan; NaCl = 150 mM NaCl; Glu.SO<sub
>4</sub>-LIPO = sulfated glucan encapsulated into liposomes; LIPO = empty liposo
mes. Different letters mean a statistically significant difference between group
s (P &le; 0.05, Tukey and Student <i>t</i>-tests).</span></font></p>      </td> 
   </tr>  </table>      ^cY#673.htm##
00562000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033600072002000800408#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#79#75#article#181#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/673i04.htm"><img src="/img/r
evistas/bjmbr/v44n4/673i04peq.jpg" border="2"></a></td>      <td>    ^cY#673.htm
##
00686000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704046000072002000800532#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#80#76#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN"><a name="Fig4"></a>Figure 4. Histochemical profil
e of lectin staining in the egg-granuloma system in the liver (A) and intestine 
(B) of animals treated with free sulfated glucan (Glu.SO<sub>4</sub>), which exh
ibited horseradish peroxidase-wheat germ agglutinin and horseradish peroxidase-p
eanut agglutinin lectins, respectively. Magnification 400X.</span></font></p>   
   </td>    </tr>  </table>      ^cY#673.htm##
00558000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033200072002000800404#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#81#77#article#181#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/673t01.htm"><img src="/img/r
evistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#673.htm##
00513000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704028700072002000800359#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#82#78#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN"><a name="Tab1"></a>Table 1. Evaluation of the sho
rt- and long-term stability of sulfated polysaccharide &alpha;-D-glucan encapsul
ated into liposomes (Glu.SO<sub>4</sub>-LIPO).</span></font></p>      </td>    <
/tr>  </table>      ^cY#673.htm##
00558000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033200072002000800404#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#83#79#article#181#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/673t02.htm"><img src="/img/r
evistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#673.htm##
00723000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704049700072002000800569#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#84#80#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span LANG="PT-BR"><a name="Tab2"></a>Table 2.</span> <span LANG=
"EN">Effect of treatment with sulfated polysaccharide &alpha;-D-glucan (Glu.SO<s
ub>4</sub>) and Glu.SO<sub>4</sub> encapsulated into liposomes (Glu.SO<sub>4</su
b>-LIPO) (10 mg/kg,<i> ip</i>, 24 h after infection) on <i>Schistosoma mansoni <
/i>adult worm recovery from infected mice after 56 days of infection.</span></fo
nt><font face="Arial"> </font></p>      </td>    </tr>  </table>      ^cY#673.ht
m##
00946000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704072000072002000800792#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#85#81#article#181#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/673t03.htm"><img src="/img/r
evistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td><span lang="EN"><fo
nt face="Arial"><span LANG="PT-BR"><a name="Tab3"></a>Table 3.</span> <span LANG
="EN">Histochemical profile of lectin staining in the egg-granuloma system in th
e liver and intestine of animals treated with free sulfated glucan (Glu.SO<sub>4
</sub>) and sulfated glucan encapsulated into liposomes (Glu.SO<sub>4</sub>-LIPO
).</span></font></span></td>    </tr>  </table>      ^cY#673.htm##
00342000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011600072002000800188#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#86#82#article#181#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (? K JPG file)]</font><
/P>      ^cY#673.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#87#83#article#181#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#673.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#88#84#article#181#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#673.htm##
00650000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704042400072002000800496#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#89#85#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">In the present study, sulfated glucan from <i>R<s
ub>.</sub> celastri</i> was successfully encapsulated into positively charged li
posomes prepared with PC, Chol, SA (7:2:1) and Glu.SO<sub>4</sub> (2 mg/mL), wit
h an encapsulation efficiency of 50%. The efficacy of Glu.SO<sub>4</sub>-LIPO wa
s tested in experimental <i>S. mansoni</i> infection.</span></font></p>      ^cY
#673.htm##
00732000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704050600072002000800578#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#90#86#article#181#<p ALIGN="JUSTIFY"><fon
t face="Arial"><span lang="EN">The choice of cholesterol and stearylamine (lipid
 laden) is justified by the fact that these compounds increase the rate of encap
sulation, increasing the capture of the drug since the literature (31) shows tha
t the rate of SUV liposome encapsulation is low (30-35%). Our results confirmed 
these data since we obtained an encapsulation rate of 50% of the formulation whe
n we used liposomes loaded with cholesterol and lipids.</span></font></p>      ^
cY#673.htm##
01044000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704081800072002000800890#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#91#87#article#181#<p ALIGN="JUSTIFY"> <fo
nt face="Arial"><span LANG="PT-BR">Glu.SO<sub>4</sub> presented an almost identi
cal efficacy as its liposomal form in the elimination of <i>S. mansoni </i>eggs 
and worm burden and in hepatic granuloma development. </span><span LANG="EN">Des
pite its relatively low encapsulation rate, the efficacy of sulfated glucan was 
improved as a result of encapsulation into liposomes. As a result, liposomes sho
uld be more efficient in activating macrophages, thereby reducing the parasitic 
infection. Furthermore, it should be pointed out that treatment with sulfated gl
ucan, free or encapsulated, induced a remarkable decrease in granuloma developme
nt, which was mainly characterized by an inflammatory reaction of the host again
st the antigens released by parasite eggs (32).</span></font></p>      ^cY#673.h
tm##
00752000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704052600072002000800598#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#92#88#article#181#<p ALIGN="JUSTIFY"><spa
n lang="EN"><font face="Arial">Granulomas are areas of cellular infiltration con
sisting mainly of eosinophils, macrophages, fibroblasts, and lymphocytes. The de
velopment of granulomas around tissue-trapped eggs is the pathogenic feature of 
murine schistosomiasis. Hepatotoxic molecules are released by schistosome eggs, 
including a 31-kDa glycoprotein termed W1 (8). In fact, granulomas may act as se
questers of toxic molecules released by eggs, thus preventing liver damage.</fon
t></span></p>      ^cY#673.htm##
01212000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704098600072002000801058#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#93#89#article#181#<p ALIGN="JUSTIFY"><spa
n lang="EN"><font face="Arial">These findings suggest an immunological activity 
of a-Glu.SO<sub>4</sub>. In fact, it is well known that polysaccharides from bac
teria or yeast are able to stimulate the mononuclear phagocyte system and improv
e host resistance to viral, bacterial and parasitic infections. As reported, a p
olysaccharide such as lentinan, a (1.3)-&szlig;-D-glucan from the cell wall of <
i>Lentinus edodes</i>, presented antitumor activity (33,34). This activity was a
ttributed to the increase in T cells, macrophages, CD4<sup>+</sup>, CD8<sup>+</s
up>, and natural killer cells. Furthermore, lentinan induced an increase in the 
production of interleukin-1 (IL-1) and tumor necrosis factor-&alpha; (TNF-&alpha
;) by monocytes (35). Moreover, schistosomiasis, as is the case with most chroni
c infections, develops a complex tightly regulated host and a balanced immune re
sponse that includes type-1 and type-2 components (32).</font></span></p>      ^
cY#673.htm##
00818000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704059200072002000800664#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#94#90#article#181#<p ALIGN="JUSTIFY"><spa
n lang="EN"><font face="Arial">Animals treated with Glu.SO<sub>4</sub>-LIPO or G
lu.SO<sub>4</sub> exhibited a lectin histochemical profile rather different from
 that of the control groups. The relationship between these results and the hist
opathological findings, which showed that treatment with free or encapsulated Gl
u.SO<sub>4</sub> drastically decreased the number of liver and intestine granulo
mas, suggests that the different glycosylation of components in the egg-granulom
a system may be linked to the decreased number of granulomas.</font></span></p> 
     ^cY#673.htm##
00727000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704050100072002000800573#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#95#91#article#181#<p ALIGN="JUSTIFY"><spa
n lang="EN"><font face="Arial">Insights were provided by lectin histochemistry u
sing HRP-WGA, HRP-PNA and HRP-Con A because different staining patterns were obs
erved in egg-granuloma systems as a function of the treatment and tissues analyz
ed. These findings are related to the carbohydrate profile of cell membrane glyc
oconjugates where glucose, mannose, N-acetyl-glucosamine, and galactose residues
 are distributed differently in the cell membrane.</font></span></p>      ^cY#67
3.htm##
01427000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704120100072002000801273#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#96#92#article#181#<p ALIGN="JUSTIFY"><spa
n lang="EN"><font face="Arial">A number of studies have emphasized the significa
nce of the encapsulation of antischistosomal drugs into liposomes and the action
 of such systems on clinical drugs. Important results have been reported in a st
udy in which mice received subcutaneous prophylactic treatment with free and lip
osome-encapsulated praziquantel before <i>S. mansoni</i> infection (36). The dru
g encapsulated into liposomes had a powerful prophylactic action in the treated 
animals, which had a longer survival and a remarkable reduction of hepatic worms
 compared to the untreated animals. Another study described the encapsulation of
 oxamniquine into conventional liposomes (18). Oxamniquine, a well-known schisto
somicide that acts by inhibiting nucleic synthesis and promoting irreversible al
kylation of schistosomal DNA (2), was encapsulated into conventional liposomes (
LOXA). When the effectiveness of LOXA was tested on experimental<i> S. mansoni</
i> infection a significant reduction in the total number of worms was observed i
n the treated group compared to the control group, which was treated with free o
xamniquine or empty liposomes.</font></span></p>      ^cY#673.htm##
00926000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704070000072002000800772#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#97#93#article#181#<p ALIGN="JUSTIFY"><spa
n lang="EN"><font face="Arial">The maximum effect of LOXA (97% reduction in para
site load) was achieved when the preparation was administered 1 day after infect
ion, although similar results were not achieved with free oxamniquine under simi
lar conditions. The encapsulation of these two antischistosomal drugs was thus b
eneficial for the treatment of experimental schistosomiasis. Although the mode o
f action of most schistosomicidal drugs is still not understood, experimental ev
idence indicates that their capacity to kill adult <i>Schistosoma</i> worms is d
ependent on the immune responsiveness of the host (9), especially regarding praz
iquantel.</font></span></p>      ^cY#673.htm##
00779000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704055300072002000800625#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#98#94#article#181#<p ALIGN="JUSTIFY"><spa
n lang="EN"><font face="Arial">Based on these findings, we may speculate that th
e sulfated glucan from<i> R. celastri</i> has immune potentiating activity and c
ould be used in combined treatment with oxamniquine or praziquantel in order to 
improve the host immune response and the schistosomicidal activity of the drug. 
Indeed, the exact mechanism of action of the sulfated &alpha;-glucan from <i>R. 
celastri</i> remains to be elucidated by further immunological investigations.</
font></span></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#673.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#99#95#article#181#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#673.htm##
00439000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000200073704019800075002000800273#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#100#96#article#181#1#<p ALIGN
="JUSTIFY"><span lang="EN"><font face="Arial">1. Chitsulo L, Engels D, Montresor
 A, Savioli L. The global status of schistosomiasis and its control. <i>Acta Tro
p</i> 2000; 77: 41-51.    ^cY#673.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#101#97#article#181#</font></span></p>    
  ^cY#673.htm##
00431000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000200073704019000075002000800265#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#102#98#article#181#2#<p align
="JUSTIFY"><span lang="EN"><font face="Arial">2. Harder A. Chemotherapeutic appr
oaches to schistosomes: current knowledge and outlook. <i>Parasitol Res</i> 2002
; 88: 395-397.    ^cY#673.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#103#99#article#181#</font></span></p>    
  ^cY#673.htm##
00497000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000200074704025500076002000800331#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#104#100#article#181#3#<p alig
n="JUSTIFY"><span lang="EN"><font face="Arial">3. Hirose Y, Kirinoki M, Matsuda 
H. Efficacy of administration of praziquantel on 2 days 2 weeks apart against <i
>Schistosoma japonicum</i> eggs in mice. <i>Parasitol Int</i> 2003; 52: 141-146.
    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#105#101#article#181#</font></span></p>   
   ^cY#673.htm##
00502000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000200074704026000076002000800336#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#106#102#article#181#4#<p alig
n="JUSTIFY"><span lang="EN"><font face="Arial">4. Pica-Mattoccia L, Cioli D. Sex
- and stage-related sensitivity of <i>Schistosoma mansoni </i>to <i>in vivo</i> 
and <i>in vitro</i> praziquantel treatment. <i>Int J Parasitol</i> 2004; 34: 527
-533.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#107#103#article#181#</font></span></p>   
   ^cY#673.htm##
00429000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000200074704018700076002000800263#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#108#104#article#181#5#<p alig
n="JUSTIFY"><span lang="EN"><font face="Arial">5. Cioli D. Praziquantel: is ther
e real resistance and are there alternatives? <i>Curr Opin Infect Dis</i> 2000; 
13: 659-663.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#109#105#article#181#</font></span></p>   
   ^cY#673.htm##
00568000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000200074704032600076002000800402#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#110#106#article#181#6#<p alig
n="JUSTIFY"><font face="Arial, Helvetica, sans-serif"><span LANG="EN">6. Botros 
S, Pica-Mattoccia L, William S, El-Lakkani N, Cioli D. Effect of praziquantel on
 the immature stages of <i>Schistosoma haematobium</i>. </span><i><span LANG="PT
-BR">Int J Parasitol</span></i><span LANG="PT-BR"> 2005; 35: 1453-1457.    ^cY#6
73.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#111#107#article#181#</span></font></p>   
   ^cY#673.htm##
00564000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000200074704032200076002000800398#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#112#108#article#181#7#<p alig
n="JUSTIFY"> <font face="Arial"><span LANG="PT-BR">7. Coelho PM, Lima e Silva FC
, Nogueira-Machado JA. </span><span LANG="EN">Resistance to oxamniquine of a <i>
Schistosoma mansoni </i>strain isolated from patient submitted to repeated treat
ments. <i>Rev Inst Med Trop S&atilde;o Paulo</i> 1997; 39: 101-106.    ^cY#673.h
tm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#113#109#article#181#</span></font></p>   
   ^cY#673.htm##
00427000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000200074704018500076002000800261#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#114#110#article#181#8#<p alig
n="JUSTIFY"><span lang="EN"><font face="Arial">8. Dunne DW, Hagan P, Abath FG. P
rospects for immunological control of schistosomiasis. <i>Lancet</i> 1995; 345: 
1488-1491.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#115#111#article#181#</font></span></p>   
   ^cY#673.htm##
00451000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000200074704020900076002000800285#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#116#112#article#181#9#<p alig
n="JUSTIFY"><span lang="EN"><font face="Arial">9. Fallon PG, Cooper RO, Probert 
AJ, Doenhoff MJ. Immune-dependent chemotherapy of schistosomiasis. <i>Parasitolo
gy</i> 1992; 105 (Suppl): S41-S48.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#117#113#article#181#</font></span></p>   
   ^cY#673.htm##
00460000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704021700077002000800294#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#118#114#article#181#10#<p ali
gn="JUSTIFY"><span lang="EN"><font face="Arial">10. McCarthy JS, Nutman TB. Pers
pective: prospects for development of vaccines against human helminth infections
. <i>J Infect Dis</i> 1996; 174: 1384-1390.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#119#115#article#181#</font></span></p>   
   ^cY#673.htm##
00489000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024600077002000800323#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#120#116#article#181#11#<p ali
gn="JUSTIFY"><span lang="EN"><font face="Arial">11. Tseng CC, Shang HF, Wang LF,
 Su B, Hsu CC, Kao HY, et al. Antitumor and immunostimulating effects of <i>Anoe
ctochilus formosanus</i> Hayata. <i>Phytomedicine</i> 2006; 13: 366-370.    ^cY#
673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#121#117#article#181#</font></span></p>   
   ^cY#673.htm##
00483000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024000077002000800317#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#122#118#article#181#12#<p ali
gn="JUSTIFY"><span lang="EN"><font face="Arial">12. Popov SV, Popova GY, Ovodova
 RG, Bushneva OA, Ovodov YS. Effects of polysaccharides from <i>Silene vulgaris<
/i> on phagocytes. <i>Int J Immunopharmacol</i> 1999; 21: 617-624.    ^cY#673.ht
m##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#123#119#article#181#</font></span></p>   
   ^cY#673.htm##
00550000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030700077002000800384#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#124#120#article#181#13#<p ali
gn="JUSTIFY"><font face="Arial"><span LANG="EN">13. Stuelp-Campelo PM, Carneiro-
Le&atilde;o AMA, Gorin PAJ, Iacomini M. The glucans of <i>Ramalina celastri</i>:
 relation with chemotypes of other lichens. </span><i><span LANG="PT-BR">Carbohy
 Pol</span></i><span LANG="PT-BR"> 1999; 40: 101-106.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#125#121#article#181#</span></font></p>   
   ^cY#673.htm##
00538000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029500077002000800372#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#126#122#article#181#14#<p ali
gn="JUSTIFY"> <font face="Arial"><span LANG="PT-BR">14. Leao AM, Buchi DF, Iacom
ini M, Gorin PA, Oliveira MB. </span><span LANG="EN">Cytotoxic effect against He
La cells of polysaccharides from the lichen <i>Ramalina celastri</i>. <i>J Submi
crosc Cytol Pathol</i> 1997; 29: 503-509.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#127#123#article#181#</span></font></p>   
   ^cY#673.htm##
00622000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704039400074002000800468#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#128#124#article#181#<p align="JUSTIFY"> <
font face="Arial"><span LANG="EN">15. Stuelp-Campelo PA, Oliveira MBM, Carneiro-
Le&atilde;o AMA, Carbonero ER, Gorin PAJ, Iacomini M. Effect of a soluble &alpha
;-D-glucan from the lichenized fungus <i>Ramalina celastri</i> on macrophage act
ivity. </span><i><span LANG="PT-BR">Int J Immunopharmacol</span></i><span LANG="
PT-BR"> 2002; 2: 691-698.</span></font></p>      ^cY#673.htm##
00526000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028300077002000800360#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#129#125#article#181#16#<p ali
gn="JUSTIFY"> <font face="Arial"><span LANG="PT-BR">16. Andrade CA, Correia MT, 
Coelho LC, Nascimento SC, Santos-Magalhaes NS. </span><span LANG="EN">Antitumor 
activity of <i>Cratylia mollis </i>lectin encapsulated into liposomes. <i>Int J 
Pharm</i> 2004; 278: 435-445.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#130#126#article#181#</span></font></p>   
   ^cY#673.htm##
00426000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704018300077002000800260#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#131#127#article#181#17#<p ali
gn="JUSTIFY"><span lang="EN"><font face="Arial">17. Torchilin VP. Recent advance
s with liposomes as pharmaceutical carriers. <i>Nat Rev Drug Discov</i> 2005; 4:
 145-160.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#132#128#article#181#</font></span></p>   
   ^cY#673.htm##
00522000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027900077002000800356#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#133#129#article#181#18#<p ali
gn="JUSTIFY"><font face="Arial"><span LANG="EN">18. Frezard F, de Melo AL. Evalu
ation of the schistosomicidal efficacy of liposome-entrapped oxamniquine. </span
><i><span LANG="PT-BR">Rev Inst Med Trop S&atilde;o Paulo</span></i><span LANG="
PT-BR"> 1997; 39: 97-100.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#134#130#article#181#</span></font></p>   
   ^cY#673.htm##
00540000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029700077002000800374#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#135#131#article#181#19#<p ali
gn="JUSTIFY"> <font face="Arial"><span LANG="PT-BR">19. Mourao SC, Costa PI, Sal
gado HR, Gremiao MP. </span><span LANG="EN">Improvement of antischistosomal acti
vity of praziquantel by incorporation into phosphatidylcholine-containing liposo
mes. <i>Int J Pharm</i> 2005; 295: 157-162.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#136#132#article#181#</span></font></p>   
   ^cY#673.htm##
00494000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704025100077002000800328#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#137#133#article#181#20#<p ali
gn="JUSTIFY"> <font face="Arial"><span LANG="EN">20. Sharon N, Lis H. History of
 lectins: from hemagglutinins to biological recognition molecules. </span><i><sp
an LANG="PT-BR">Glycobiology</span></i><span LANG="PT-BR"> 2004; 14: 53R-62R.   
 ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#138#134#article#181#</span></font></p>   
   ^cY#673.htm##
00569000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704032600077002000800403#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#139#135#article#181#21#<p ali
gn="JUSTIFY"> <font face="Arial"><span LANG="PT-BR">21. Beltrao EI, Medeiros PL,
 Rodrigues OG, Figueredo-Silva J, Valenca MM, Coelho LC, et al. </span><i><span 
LANG="EN">Parkia pendula</span></i><span LANG="EN"> lectin as histochemistry mar
ker for meningothelial tumour. <i>Eur J Histochem</i> 2003; 47: 139-142.    ^cY#
673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#140#136#article#181#</span></font></p>   
   ^cY#673.htm##
00478000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023500077002000800312#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#141#137#article#181#22#<p ali
gn="JUSTIFY"><span lang="PT-BR"><font face="Arial">22. R&ecirc;go MJBM, Santos L
X, Carvalho Junior LB, Beltr&atilde;o EIC, Sobral APV. Lectin histochemistry of 
mucoepidermoid carcinoma. <i>Oral Oncol</i> 2005; 1: 178-179.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#142#138#article#181#</font></span></p>   
   ^cY#673.htm##
00648000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704040500077002000800482#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#143#139#article#181#23#<p ali
gn="JUSTIFY"><font face="Arial"><span LANG="PT-BR">23. Melo-J&uacute;nior MR, Ar
a&uacute;jo-Filho JLS, Patu VJRM, Machado MCFP, Beltr&atilde;o EIC, Carvalho LB 
Jr. </span><span LANG="EN">Digital image analysis of skin neoplasms evaluated by
 lectin histochemistry: potential marker to biochemical alterations and tumour d
ifferential diagnosis. <i>J Bras Patol Med Labor</i> 2006; 42: 455-460.    ^cY#6
73.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#144#140#article#181#</span></font></p>   
   ^cY#673.htm##
00582000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704033900077002000800416#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#145#141#article#181#24#<p ali
gn="JUSTIFY"> <font face="Arial"><span LANG="EN">24. Wroblewski S, Berenson M, K
opeckova P, Kopecek J. Potential of lectin-N-(2-hydroxypropyl)methacrylamide cop
olymer-drug conjugates for the treatment of pre-cancerous conditions. </span><i>
<span LANG="PT-BR">J Control Release</span></i><span LANG="PT-BR"> 2001; 74: 283
-293.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#146#142#article#181#</span></font></p>   
   ^cY#673.htm##
00554000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704031100077002000800388#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#147#143#article#181#25#<p ali
gn="JUSTIFY"> <font face="Arial"><span LANG="PT-BR">25. Melo-J&uacute;nior MR, T
elles MAS, Albuquerque FB, Pontes Filho NT, Carvalho-Jr LB, Beltr&atilde;o EIC. 
</span><span LANG="EN">Altered lectin-binding sites in normal colon and ulcerati
ve colitis. <i>J Bras Patol Med Lab</i> 2004; 2: 123-125.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#148#144#article#181#</span></font></p>   
   ^cY#673.htm##
00604000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704036100077002000800438#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#149#145#article#181#26#<p ali
gn="JUSTIFY"> <font face="Arial"><span LANG="EN">26. Nyame AK, Leppanen AM, Bogi
tsh BJ, Cummings RD. Antibody responses to the fucosylated LacdiNAc glycan antig
en in <i>Schistosoma mansoni</i>-infected mice and expression of the glycan amon
g schistosomes. </span><i><span LANG="PT-BR">Exp Parasitol</span></i><span LANG=
"PT-BR"> 2000; 96: 202-212.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#150#146#article#181#</span></font></p>   
   ^cY#673.htm##
00573000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704033000077002000800407#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#151#147#article#181#27#<p ali
gn="JUSTIFY"> <font face="Arial"><span LANG="PT-BR">27. Melo-J&uacute;nior MR, C
avalcanti CLB, Pontes-Filho NT, Carvalho-Jr LB, Beltr&atilde;o EIC. </span><span
 LANG="EN">Lectin staining patterns in human gastric mucosae with and without ex
posure to <i>Helicobacter pylori</i>. <i>Braz J Microbiol</i> 2008; 39: 1-7.    
^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#152#148#article#181#</span></font></p>   
   ^cY#673.htm##
00546000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030300077002000800380#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#153#149#article#181#28#<p ali
gn="JUSTIFY"><span lang="EN"><font face="Arial">28. Martinichen-Herrero JC, Carb
onero ER, Gorin PAJ, Iacomini M. Anticoagulant and antithrombotic activity of a 
sulfate obtained from a glucan component of the lichen <i>Parmotrema mantiqueire
nse</i> Hale. <i>Carbohyd Pol</i> 2005; 60: 7-13.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#154#150#article#181#</font></span></p>   
   ^cY#673.htm##
00466000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704022300077002000800300#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#155#151#article#181#29#<p ali
gn="JUSTIFY"><span lang="EN"><font face="Arial">29. Dubois M, Gilles KA, Hamilto
n JK, Rebers PA, Smith F. Colorimetric method for determination of sugars and re
lated substances. <i>Anal Chem</i> 1956; 28: 350.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#156#152#article#181#</font></span></p>   
   ^cY#673.htm##
00559000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704031600077002000800393#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#157#153#article#181#30#<p ali
gn="JUSTIFY"><font face="Arial"><span LANG="EN">30. Katz NA. Simple device for q
uantitative determination of <i>Schistosoma mansoni</i> eggs in faeces examined 
by the thick-smear technique. </span><i><span LANG="PT-BR">Rev Inst Med Trop S&a
tilde;o Paulo</span></i><span LANG="PT-BR"> 1972; 14: 397-400.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#158#154#article#181#</span></font></p>   
   ^cY#673.htm##
00527000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028400077002000800361#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#159#155#article#181#31#<p ali
gn="JUSTIFY"> <font face="Arial"><span LANG="PT-BR">31. Pontes ACO, Caetano MNP,
 Santos-Magalh&atilde;es NS. </span><span LANG="EN">Physico-chemical characteriz
ation and antimicrobial activity of benzathine penicillin G liposomes, STP. <i>P
harm Sci</i> 1999; 9: 419-427.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#160#156#article#181#</span></font></p>   
   ^cY#673.htm##
00469000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704022600077002000800303#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#161#157#article#181#32#<p ali
gn="JUSTIFY"><span lang="EN"><font face="Arial">32. Brunet LR, Dunne DW, Pearce 
EJ. Cytokine interaction and immune responses during <i>Schistosoma mansoni</i> 
infection. <i>Parasitol Today</i> 1998; 14: 422-427.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#162#158#article#181#</font></span></p>   
   ^cY#673.htm##
00520000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027700077002000800354#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#163#159#article#181#33#<p ali
gn="JUSTIFY"><span lang="EN"><font face="Arial">33. Haba S, Hamaoka T, Takatsu K
, Kitagawa M. Selective suppression of T-cell activity in tumor-bearing mice and
 its improvement by lentinan, a potent anti-tumor polysaccharide. <i>Int J Cance
r</i> 1976; 18: 93-104.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#164#160#article#181#</font></span></p>   
   ^cY#673.htm##
00545000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030200077002000800379#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#165#161#article#181#34#<p ali
gn="JUSTIFY"><font face="Arial"><span LANG="EN">34. Hamuro J, Rollinghoff M, Wag
ner H. Beta(1 leads to 3) glucan-mediated augmentation of alloreactive murine cy
totoxic T-lymphocytes <i>in vivo</i>. </span><i><span LANG="PT-BR">Cancer Res</s
pan></i><span LANG="PT-BR"> 1978; 38: 3080-3085.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#166#162#article#181#</span></font></p>   
   ^cY#673.htm##
00607000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704036400077002000800441#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#167#163#article#181#35#<p ali
gn="JUSTIFY"> <font face="Arial"><span LANG="PT-BR">35. Arinaga S, Karimine N, T
akamuku K, Nanbara S, Nagamatsu M, Ueo H, et al. </span><span LANG="EN">Enhanced
 production of interleukin 1 and tumor necrosis factor by peripheral monocytes a
fter lentinan administration in patients with gastric carcinoma. <i>Int J Immuno
pharmacol</i> 1992; 14: 43-47.    ^cY#673.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#168#164#article#181#</span></font></p>   
   ^cY#673.htm##
00479000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023600077002000800313#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#p#169#165#article#181#36#<p ali
gn="JUSTIFY"><span lang="EN"><font face="Arial">36. El-Ridy A, Ghorab M, Ghorab 
MM. Evaluation of the antischistosomal effect of praziquantel in a liposomal del
ivery system in mice. <i>Int J Pharmac</i> 1994; 103: 237-241.    ^cY#673.htm##
00280000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704005200074002000800126#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#170#166#article#181#</font></span></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#673.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033500074002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#171#167#article#181#<P><font face="Arial,
 Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE
=4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#673.ht
m##
00719000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704049100074002000800565#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#172#168#article#181#<p ALIGN="JUSTIFY"><f
ont face="Arial"><span lang="EN">N.S. Santos-Magalh&atilde;es and L.B. Carvalho 
Jr. were recipients of grants from CNPq (#334946-01 and #301735-4, respectively)
. R.V.S. Ara&uacute;jo was supported by CNPq MSc scholarships. Research partiall
y supported by the Brazilian Network of Research on Nanobiotechnology - Nanobiot
ec CNPq/MCT and by the CNPq-PRONEX Research Program (Carbohydrate Structure and 
Properties, UFPR).</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#673.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033600074002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#173#169#article#181#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#673.h
tm##
00663000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704043500074002000800509#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#174#170#article#181#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/r
ecor.gif" border="0"></a> Address for correspondence:</b><span lang="EN"> R.V.S.
 Ara&uacute;jo, Associa&ccedil;&atilde;o Caruaruense de Ensino Superior, Av. Por
tugal, 584, 55016-901 Caruaru, PE, Brasil. Fax: +55-81-2103-2004. E-mail: <a hre
f="mailto:rosangela.vidal@gmail.com">rosangela.vidal@gmail.com</a></span></font>
</p>      ^cY#673.htm##
00485000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704025700074002000800331#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#175#171#article#181#<p><font face="Arial,
 Helvetica, sans-serif">Received August 2, 2010. Accepted January 6, 2011. <i><f
ont face="Arial"><span lang="EN">Available online February 4, 2011. Published Ap
ril 11, 2011.</span></font></i></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#673.
htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#176#172#article#181#<div align="center"> 
       ^cY#673.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#177#173#article#181#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#673.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#178#174#article#181#<br>                ^
cY#673.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#179#175#article#181#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#673
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#180#176#article#181#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#673.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#181#177#article#181#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#673.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#182#178#article#181#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#673.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#183#179#article#181#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#673.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#184#180#article#181#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#673.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\673.htm#S#p#185#181#article#181#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#673.htm##
00572000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100016000910100
01900107010001700126012005700143030001000200065000900210064000500219031000300224
014000600227865000900233002000800242035001000250801001000260#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\673.htm#S#c#186#1#article#36#1#^rND^sChitsulo^nL#^rND^sEn
gels^nD#^rND^sMontresor^nA#^rND^sSavioli^nL#The global status of schistosomiasis
 and its control^len#Acta Trop#20000000#2000#77#41-51#20110400#673.htm#0001-706X
#Acta Trop##
00514000000000265000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730120079000890300
01400168065000900182064000500191031000300196014000800199865000900207002000800216
035001000224801001400234#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#1
87#2#article#36#2#^rND^sHarder^nA#Chemotherapeutic approaches to schistosomes: c
urrent knowledge and outlook^len#Parasitol Res#20020000#2002#88#395-397#20110400
#673.htm#0044-3255#Parasitol Res##
00574000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100018000890100
01700107012011400124030001400238710000200252065000900254064000500263031000300268
014000800271865000900279002000800288#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\6
73.htm#S#c#188#3#article#36#3#^rND^sHirose^nY#^rND^sKirinoki^nM#^rND^sMatsuda^nH
#Efficacy of administration of praziquantel on 2 days 2 weeks apart against Schi
stosoma japonicum eggs in mice^len#Parasitol Int#2#20030000#2003#52#141-146#2011
0400#673.htm##
00583000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100024000730100015000970120
10900112030001600221065000900237064000500246031000300251014000800254865000900262
002000800271035001000279801001600289#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\6
73.htm#S#c#189#4#article#36#4#^rND^sPica-Mattoccia^nL#^rND^sCioli^nD#Sex- and st
age-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquan
tel treatment^len#Int J Parasitol#20040000#2004#34#527-533#20110400#673.htm#0020
-7519#Int J Parasitol##
00478000000000253000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730120071000880300
02100159710000200180065000900182064000500191031000300196014000800199865000900207
002000800216#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#190#5#article
#36#5#^rND^sCioli^nD#Praziquantel: is there real resistance and are there altern
atives?^len#Curr Opin Infect Dis#2#20000000#2000#13#659-663#20110400#673.htm##
00642000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100024000890100
01700113010002000130010001500150012007700165030001600242065000900258064000500267
031000300272014001000275865000900285002000800294035001000302801001600312#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#191#6#article#36#6#^rND^sBotros^n
S#^rND^sPica-Mattoccia^nL#^rND^sWilliam^nS#^rND^sEl-Lakkani^nN#^rND^sCioli^nD#Ef
fect of praziquantel on the immature stages of Schistosoma haematobium^len#Int J
 Parasitol#20050000#2005#35#1453-1457#20110400#673.htm#0020-7519#Int J Parasitol
##
00655000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100023000900100
02700113012011700140030002800257065000900285064000500294031000300299014000800302
865000900310002000800319035001000327801002800337#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\673.htm#S#c#192#7#article#36#7#^rND^sCoelho^nPM#^rND^sLima^ne Silva F
C#^rND^sNogueira-Machado^nJA#Resistance to oxamniquine of a Schistosoma mansoni 
strain isolated from patient submitted to repeated treatments^len#Rev Inst Med T
rop São Paulo#19970000#1997#39#101-106#20110400#673.htm#0036-4665#Rev Inst Med T
rop São Paulo##
00538000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100015000890100
01600104012005900120030000700179065000900186064000500195031000400200014001000204
865000900214002000800223035001000231801000700241#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\673.htm#S#c#193#8#article#36#8#^rND^sDunne^nDW#^rND^sHagan^nP#^rND^sA
bath^nFG#Prospects for immunological control of schistosomiasis^len#Lancet#19950
000#1995#345#1488-1491#20110400#673.htm#0099-5355#Lancet##
00598000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100017000900100
01800107010001900125012005300144030001300197065000900210064000500219031000400224
032000800228014000800236865000900244002000800253035001000261801001300271#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#194#9#article#36#9#^rND^sFallon^n
PG#^rND^sCooper^nRO#^rND^sProbert^nAJ#^rND^sDoenhoff^nMJ#Immune-dependent chemot
herapy of schistosomiasis^len#Parasitology#19920000#1992#105#^sSuppl#S41-S48#201
10400#673.htm#0031-1820#Parasitology##
00559000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100017000940120
08900111030001300200065000900213064000500222031000400227014001000231865000900241
002000800250035001000258801001300268#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\6
73.htm#S#c#195#10#article#36#10#^rND^sMcCarthy^nJS#^rND^sNutman^nTB#Perspective:
 prospects for development of vaccines against human helminth infections^len#J I
nfect Dis#19960000#1996#174#1384-1390#20110400#673.htm#0022-1899#J Infect Dis##
00672000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100016000910100
01500107010001200122010001400134010001400148010001300162012007900175030001400254
06500090026806400050027703100030028201400080028586500090029300200080030203500100
0310801001400320#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#196#11#ar
ticle#36#11#^rND^sTseng^nCC#^rND^sShang^nHF#^rND^sWang^nLF#^rND^sSu^nB#^rND^sHsu
^nCC#^rND^sKao^nHY#^rND^set^nal#Antitumor and immunostimulating effects of Anoec
tochilus formosanus Hayata^len#Phytomedicine#20060000#2006#13#366-370#20110400#6
73.htm#0944-7113#PHYTOMEDICINE##
00638000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100017000910100
01800108010001900126010001700145012006600162030002200228065000900250064000500259
031000300264014000800267865000900275002000800284035001000292801002200302#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#197#12#article#36#12#^rND^sPopov^
nSV#^rND^sPopova^nGY#^rND^sOvodova^nRG#^rND^sBushneva^nOA#^rND^sOvodov^nYS#Effec
ts of polysaccharides from Silene vulgaris on phagocytes^len#Int J Immunopharmac
ol#19990000#1999#21#617-624#20110400#673.htm#0192-0561#Int J Immunopharmacol##
00586000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100025000750100025001000100
01700125010001800142012008000160030001200240710000200252065000900254064000500263
031000300268014000800271865000900279002000800288#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\673.htm#S#c#198#13#article#36#13#^rND^sStuelp-Campelo^nPM#^rND^sCarne
iro-Leão^nAMA#^rND^sGorin^nPAJ#^rND^sIacomini^nM#The glucans of Ramalina celastr
i: relation with chemotypes of other lichens^len#Carbohy Pol#2#19990000#1999#40#
101-106#20110400#673.htm##
00670000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100016000900100
01800106010001600124010001900140012009300159030002600252065000900278064000500287
031000300292014000800295865000900303002000800312035001000320801002600330#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#199#14#article#36#14#^rND^sLeao^n
AM#^rND^sBuchi^nDF#^rND^sIacomini^nM#^rND^sGorin^nPA#^rND^sOliveira^nMB#Cytotoxi
c effect against HeLa cells of polysaccharides from the lichen Ramalina celastri
^len#J Submicrosc Cytol Pathol#19970000#1997#29#503-509#20110400#673.htm#0022-47
82#J Submicrosc Cytol Pathol##
00729000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100025000750100020001000100
02500120010002000145010001700165010001800182012010800200030002200308065000900330
06400050033903100020034401400080034686500090035400200080036303500100037180100220
0381#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#200#15#article#36#15#
^rND^sStuelp-Campelo^nPA#^rND^sOliveira^nMBM#^rND^sCarneiro-Leão^nAMA#^rND^sCarb
onero^nER#^rND^sGorin^nPAJ#^rND^sIacomini^nM#Effect of a soluble &#945;-D-glucan
 from the lichenized fungus Ramalina celastri on macrophage activity^len#Int J I
mmunopharmacol#20020000#2002#2#691-698#20110400#673.htm#0192-0561#Int J Immunoph
armacol##
00644000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100018000930100
01700111010002100128010002700149012007700176030001200253065000900265064000500274
031000400279014000800283865000900291002000800300035001000308801001200318#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#201#16#article#36#16#^rND^sAndrad
e^nCA#^rND^sCorreia^nMT#^rND^sCoelho^nLC#^rND^sNascimento^nSC#^rND^sSantos-Magal
haes^nNS#Antitumor activity of Cratylia mollis lectin encapsulated into liposome
s^len#Int J Pharm#20040000#2004#278#435-445#20110400#673.htm#0378-5173#Int J Pha
rm##
00474000000000253000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750120062000950300
02000157710000200177065000900179064000500188031000200193014000800195865000900203
002000800212#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#202#17#articl
e#36#17#^rND^sTorchilin^nVP#Recent advances with liposomes as pharmaceutical car
riers^len#Nat Rev Drug Discov#2#20050000#2005#4#145-160#20110400#673.htm##
00577000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100018000920120
08200110030002800192065000900220064000500229031000300234014000700237865000900244
002000800253035001000261801002800271#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\6
73.htm#S#c#203#18#article#36#18#^rND^sFrezard^nF#^rND^sde^nMelo AL#Evaluation of
 the schistosomicidal efficacy of liposome-entrapped oxamniquine^len#Rev Inst Me
d Trop São Paulo#19970000#1997#39#97-100#20110400#673.htm#0036-4665#Rev Inst Med
 Trop São Paulo##
00647000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
01800108010001800126012012400144030001200268065000900280064000500289031000400294
014000800298865000900306002000800315035001000323801001200333#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\673.htm#S#c#204#19#article#36#19#^rND^sMourao^nSC#^rND^sC
osta^nPI#^rND^sSalgado^nHR#^rND^sGremiao^nMP#Improvement of antischistosomal act
ivity of praziquantel by incorporation into phosphatidylcholine-containing lipos
omes^len#Int J Pharm#20050000#2005#295#157-162#20110400#673.htm#0378-5173#Int J 
Pharm##
00540000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100013000910120
08000104030001300184065000900197064000500206031000300211014000800214865000900222
002000800231035001000239801001300249#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\6
73.htm#S#c#205#20#article#36#20#^rND^sSharon^nN#^rND^sLis^nH#History of lectins:
 from hemagglutinins to biological recognition molecules^len#Glycobiology#200400
00#2004#14#53R-62R#20110400#673.htm#0959-6658#Glycobiology##
00697000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100019000930100
02000112010002500132010001800157010001700175810000600192012007700198030001600275
06500090029106400050030003100030030501400080030886500090031600200080032503500100
0333801001600343#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#206#21#ar
ticle#36#21#^rND^sBeltrao^nEI#^rND^sMedeiros^nPL#^rND^sRodrigues^nOG#^rND^sFigue
redo-Silva^nJ#^rND^sValenca^nMM#^rND^sCoelho^nLC#et al#Parkia pendula lectin as 
histochemistry marker for meningothelial tumour^len#Eur J Histochem#20030000#200
3#47#139-142#20110400#673.htm#1121-760X#Eur J Histochem##
00613000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100017000920100
02600109010001900135010001800154012005400172030001100226065000900237064000500246
031000200251014000800253865000900261002000800270035001000278801001100288#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#207#22#article#36#22#^rND^sRêgo^n
MJBM#^rND^sSantos^nLX#^rND^sCarvalho^nJunior LB#^rND^sBeltrão^nEIC#^rND^sSobral^
nAPV#Lectin histochemistry of mucoepidermoid carcinoma^len#Oral Oncol#20050000#2
005#1#178-179#20110400#673.htm#1368-8375#Oral oncol##
00739000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100022000750100024000970100
01700121010002000138010001900158010002200177012015900199030002300358710000200381
065000900383064000500392031000300397014000800400865000900408002000800417#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#208#23#article#36#23#^rND^sMelo-J
únior^nMR#^rND^sAraújo-Filho^nJLS#^rND^sPatu^nVJRM#^rND^sMachado^nMCFP#^rND^sBel
trão^nEIC#^rND^sCarvalho^nLB Jr#Digital image analysis of skin neoplasms evaluat
ed by lectin histochemistry: potential marker to biochemical alterations and tum
our differential diagnosis^len#J Bras Patol Med Labor#2#20060000#2006#42#455-460
#20110400#673.htm##
00631000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100018000950100
01900113010001700132012013000149030001800279710000200297065000900299064000500308
031000300313014000800316865000900324002000800333#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\673.htm#S#c#209#24#article#36#24#^rND^sWroblewski^nS#^rND^sBerenson^n
M#^rND^sKopeckova^nP#^rND^sKopecek^nJ#Potential of lectin-N-(2-hydroxypropyl)met
hacrylamide copolymer-drug conjugates for the treatment of pre-cancerous conditi
ons^len#J Control Release#2#20010000#2001#74#283-293#20110400#673.htm##
00651000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100022000750100018000970100
02200115010002300137010002200160010001900182012007200201030002100273710000200294
065000900296064000500305031000200310014000800312865000900320002000800329#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#210#25#article#36#25#^rND^sMelo-J
únior^nMR#^rND^sTelles^nMAS#^rND^sAlbuquerque^nFB#^rND^sPontes^nFilho NT#^rND^sC
arvalho-Jr^nLB#^rND^sBeltrão^nEIC#Altered lectin-binding sites in normal colon a
nd ulcerative colitis^len#J Bras Patol Med Lab#2#20040000#2004#2#123-125#2011040
0#673.htm##
00680000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910100
01800110010001900128012015100147030001400298065000900312064000500321031000300326
014000800329865000900337002000800346035001000354801001400364#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\673.htm#S#c#211#26#article#36#26#^rND^sNyame^nAK#^rND^sLe
ppanen^nAM#^rND^sBogitsh^nBJ#^rND^sCummings^nRD#Antibody responses to the fucosy
lated LacdiNAc glycan antigen in Schistosoma mansoni-infected mice and expressio
n of the glycan among schistosomes^len#Exp Parasitol#20000000#2000#96#202-212#20
110400#673.htm#0014-4894#Exp Parasitol##
00645000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100022000750100022000970100
02300119010002200142010001900164012010300183030001700286710000200303065000900305
064000500314031000300319014000400322865000900326002000800335#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\673.htm#S#c#212#27#article#36#27#^rND^sMelo-Júnior^nMR#^r
ND^sCavalcanti^nCLB#^rND^sPontes-Filho^nNT#^rND^sCarvalho-Jr^nLB#^rND^sBeltrão^n
EIC#Lectin staining patterns in human gastric mucosae with and without exposure 
to Helicobacter pylori^len#Braz J Microbiol#2#20080000#2008#39#1-7#20110400#673.
htm##
00641000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100030000750100020001050100
01700125010001800142012013700160030001300297710000200310065000900312064000500321
031000300326014000500329865000900334002000800343#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\673.htm#S#c#213#28#article#36#28#^rND^sMartinichen-Herrero^nJC#^rND^s
Carbonero^nER#^rND^sGorin^nPAJ#^rND^sIacomini^nM#Anticoagulant and antithromboti
c activity of a sulfate obtained from a glucan component of the lichen Parmotrem
a mantiqueirense Hale^len#Carbohyd Pol#2#20050000#2005#60#7-13#20110400#673.htm#
#
00616000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100017000910100
01900108010001700127010001500144012007500159030001000234065000900244064000500253
031000300258014000400261865000900265002000800274035001000282801001000292#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#214#29#article#36#29#^rND^sDubois
^nM#^rND^sGilles^nKA#^rND^sHamilton^nJK#^rND^sRebers^nPA#^rND^sSmith^nF#Colorime
tric method for determination of sugars and related substances^len#Anal Chem#195
60000#1956#28#350#20110400#673.htm#0003-2700#Anal Chem##
00589000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750120125000900300
02800215065000900243064000500252031000300257014000800260865000900268002000800277
035001000285801002800295#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#2
15#30#article#36#30#^rND^sKatz^nNA#Simple device for quantitative determination 
of Schistosoma mansoni eggs in faeces examined by the thick-smear technique^len#
Rev Inst Med Trop São Paulo#19720000#1972#14#397-400#20110400#673.htm#0036-4665#
Rev Inst Med Trop São Paulo##
00577000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100019000930100
02700112012010700139030001000246710000200256065000900258064000500267031000200272
014000800274865000900282002000800291#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\6
73.htm#S#c#216#31#article#36#31#^rND^sPontes^nACO#^rND^sCaetano^nMNP#^rND^sSanto
s-Magalhães^nNS#Physico-chemical characterization and antimicrobial activity of 
benzathine penicillin G liposomes, STP^len#Pharm Sci#2#19990000#1999#9#419-427#2
0110400#673.htm##
00582000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
01700108012008300125030001600208065000900224064000500233031000300238014000800241
865000900249002000800258035001000266801001600276#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\673.htm#S#c#217#32#article#36#32#^rND^sBrunet^nLR#^rND^sDunne^nDW#^rN
D^sPearce^nEJ#Cytokine interaction and immune responses during Schistosoma manso
ni infection^len#Parasitol Today#19980000#1998#14#422-427#20110400#673.htm#0169-
4758#Parasitol Today##
00655000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100017000890100
01700106010001800123012013500141030001300276065000900289064000500298031000300303
014000700306865000900313002000800322035001000330801001300340#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\673.htm#S#c#218#33#article#36#33#^rND^sHaba^nS#^rND^sHama
oka^nT#^rND^sTakatsu^nK#^rND^sKitagawa^nM#Selective suppression of T-cell activi
ty in tumor-bearing mice and its improvement by lentinan, a potent anti-tumor po
lysaccharide^len#Int J Cancer#19760000#1976#18#93-104#20110400#673.htm#0020-7136
#Int J Cancer##
00601000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100021000910100
01600112012010700128030001100235065000900246064000500255031000300260014001000263
865000900273002000800282035001000290801001100300#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\673.htm#S#c#219#34#article#36#34#^rND^sHamuro^nJ#^rND^sRollinghoff^nM
#^rND^sWagner^nH#Beta(1 leads to 3) glucan-mediated augmentation of alloreactive
 murine cytotoxic T-lymphocytes in vivo^len#Cancer Res#19780000#1978#38#3080-308
5#20110400#673.htm#0008-5472#Cancer res##
00778000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100018000920100
01800110010001700128010001900145010001300164010001300177012015600190030002200346
06500090036806400050037703100030038201400060038586500090039100200080040003500100
0408801002200418#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\673.htm#S#c#220#35#ar
ticle#36#35#^rND^sArinaga^nS#^rND^sKarimine^nN#^rND^sTakamuku^nK#^rND^sNanbara^n
S#^rND^sNagamatsu^nM#^rND^sUeo^nH#^rND^set^nal#Enhanced production of interleuki
n 1 and tumor necrosis factor by peripheral monocytes after lentinan administrat
ion in patients with gastric carcinoma^len#Int J Immunopharmacol#19920000#1992#1
4#43-47#20110400#673.htm#0192-0561#Int J Immunopharmacol##
00563000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
01700108012010100125030001400226710000200240065000900242064000500251031000400256
014000800260865000900268002000800277#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\6
73.htm#S#c#221#36#article#36#36#^rND^sEl-Ridy^nA#^rND^sGhorab^nM#^rND^sGhorab^nM
M#Evaluation of the antischistosomal effect of praziquantel in a liposomal deliv
ery system in mice^len#Int J Pharmac#2#19940000#1994#103#237-241#20110400#673.ht
m##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#o#1#1#article#1#201
10411#094541#705.htm#160##
04091000000000745000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000400086121000300090049000900093158000700102030002000109
03100030012903200020013206500090013401400110014303500100015422400090016401200930
01730100034002660100030003000100033003300100025003630100025003880100028004130100
02000441010004100461010003500502010002300537010002300560010003700583010004500620
07001300066507000760079507000750087107000990094607000760104507000810112107000960
12020700096012980700108013940831643015020850008031450850036031530850031031890850
03303220117000603253072000303259112000903262111001603271114000903287113001703296
891002403313002000803337#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#h#2
#1#article#1#oa#en#bjmbr#1#3.1#TAB#04#BJMBR010#FAPESP#Braz J Med Biol Res#44#4#2
0110400#^f291^l296#0100-879X#20110311#Prevalence of the STK15 F31I polymorphism 
and its relationship with mammographic density^len#^rND^1A01 A05 A08^nJ.^sGiacom
azzi#^rND^1A01 A05 A08^nE.^sAguiar#^rND^1A01 A05 A08^nE.I.^sPalmero#^rND^1A09^nA
.V.^sSchmidt#^rND^1A08^nG.^sSkonieski#^rND^1A08^nD.^sDuarte Filho#^rND^1A06^nH.^
sBock#^rND^1A03 A06 A07^nM.L.^sSaraiva-Pereira#^rND^1A04 A07^nL.^sSchuler-Faccin
i#^rND^1A02^nS.A.^sCamey#^rND^1A08^nM.^sCaleffi#^rND^1A01 A04 A06 A07^nR.^sGiugl
iani#^rND^1A01 A04 A05 A07 A08^nP.^sAshton-Prolla#Universidade Federal do Rio Gr
ande do Sul^iA01^1Programa de Pós Graduação em Medicina: Ciências Médicas^cPorto
 Alegre^sRS^pBrasil#Universidade Federal do Rio Grande do Sul^iA02^1Departamento
 de Estatística#Universidade Federal do Rio Grande do Sul^iA03^1Departamento de 
Bioquímica#Universidade Federal do Rio Grande do Sul^iA04^1Departamento de Genét
ica^cPorto Alegre^sRS^pBrasil#Hospital de Clínicas de Porto Alegre^iA05^1Laborat
ório de Medicina Genômica#Hospital de Clínicas de Porto Alegre^iA06^1Laboratório
 de Identificação Genética#Hospital de Clínicas de Porto Alegre^iA07^1Serviço de
 Genética Médica^cPorto Alegre^sRS^pBrasil#Associação Hospitalar Moinhos de Vent
o^iA08^1Núcleo Mama Porto Alegre^cPorto Alegre^sRS^pBrasil#Universidade Federal 
do Rio Grande do Sul^iA09^1Curso de Graduação em Estatística^cPorto Alegre^sRS^p
Brasil#^len^aSeveral studies have identified the single nucleotide polymorphism 
STK15 F31I as a low-penetrance risk allele for breast cancer, but its prevalence
 and risk association in the Brazilian population have not been determined. The 
goal of this study was to identify the frequency of this polymorphism in the Bra
zilian setting. Considering the high degree of admixture of our population, it i
s of fundamental importance to validate the results already reported in the lite
rature and also to verify the relationship between this variant and breast cance
r risk. A total of 750 women without breast cancer were genotyped using the TaqM
an PCR assay for STK15 F31I polymorphism. Clinical information was obtained from
 review of the medical records and mammographic density from the images obtained
 using the BI-RADS System. The estimated risk of developing cancer was calculate
d according to the Gail model. The genotypic frequencies observed in this study 
were 4.5, 38.7, and 56.6%, respectively, for the STK15 F31I AA, AT and TT genoty
pes. The AT and AA genotypes were encountered significantly more often in premen
opausal women with moderately dense, dense and heterogeneously dense breast tiss
ue (P = 0.023). In addition, the presence of the TT genotype was significantly a
ssociated with age at menarche &#8805;12 years (P = 0.023). High mammographic de
nsity, associated with increased breast cancer risk, was encountered more freque
ntly in premenopausal women with the risk genotypes STK15 F31I AA and AT. The ge
notypic frequencies observed in our Brazilian sample were similar to those descr
ibed in other predominantly European populations.#^dnd^i1#^tm^len^kSTK15 F31I po
lymorphism^i1#^tm^len^kBreast cancer risk^i1#^tm^len^kMammographic density^i1#ot
her#27#20100813#August 13, 2010#20110204#February 4, 2011#S0100-879X201100750002
9#705.htm##
04202000000000733000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000400086121000300090049000900093158000700102030002000109
03100030012903200020013206500090013401400110014303500100015422400090016401201070
01730100034002800100030003140100033003440100025003770100025004020100028004270100
02000455010004100475010003500516010002300551010002300574010003700597010004500634
07001300067907000760080907000750088507000990096007000760105907000810113507000960
12160700096013120700108014080831748015160850008032640850050032720850031033220850
03303353117000603386072000303392112000903395111002303404114000903427113002403436
002000803460#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#f#3#1#article#1
#oa#en#bjmbr#1#3.1#TAB#04#BJMBR010#FAPESP#Braz J Med Biol Res#44#4#20110400#^f29
1^l296#0100-879X#20110311#<b>Prevalence of the <i>STK15 F31I </i>polymorphism an
d its relationship with mammographic density</b>^len#^rND^1A01 A05 A08^nJ.^sGiac
omazzi#^rND^1A01 A05 A08^nE.^sAguiar#^rND^1A01 A05 A08^nE.I.^sPalmero#^rND^1A09^
nA.V.^sSchmidt#^rND^1A08^nG.^sSkonieski#^rND^1A08^nD.^sDuarte Filho#^rND^1A06^nH
.^sBock#^rND^1A03 A06 A07^nM.L.^sSaraiva-Pereira#^rND^1A04 A07^nL.^sSchuler-Facc
ini#^rND^1A02^nS.A.^sCamey#^rND^1A08^nM.^sCaleffi#^rND^1A01 A04 A06 A07^nR.^sGiu
gliani#^rND^1A01 A04 A05 A07 A08^nP.^sAshton-Prolla#Universidade Federal do Rio 
Grande do Sul^iA01^1Programa de Pós Graduação em Medicina: Ciências Médicas^cPor
to Alegre^sRS^pBrasil#Universidade Federal do Rio Grande do Sul^iA02^1Departamen
to de Estatística#Universidade Federal do Rio Grande do Sul^iA03^1Departamento d
e Bioquímica#Universidade Federal do Rio Grande do Sul^iA04^1Departamento de Gen
ética^cPorto Alegre^sRS^pBrasil#Hospital de Clínicas de Porto Alegre^iA05^1Labor
atório de Medicina Genômica#Hospital de Clínicas de Porto Alegre^iA06^1Laboratór
io de Identificação Genética#Hospital de Clínicas de Porto Alegre^iA07^1Serviço 
de Genética Médica^cPorto Alegre^sRS^pBrasil#Associação Hospitalar Moinhos de Ve
nto^iA08^1Núcleo Mama Porto Alegre^cPorto Alegre^sRS^pBrasil#Universidade Federa
l do Rio Grande do Sul^iA09^1Curso de Graduação em Estatística^cPorto Alegre^sRS
^pBrasil#^len^aSeveral studies have identified the single nucleotide polymorphis
m <i>STK15</i> <i>F31I</i> as a low-penetrance risk allele for breast cancer, bu
t its prevalence and risk association in the Brazilian population have not been 
determined. The goal of this study was to identify the frequency of this polymor
phism in the Brazilian setting. Considering the high degree of admixture of our 
population, it is of fundamental importance to validate the results already repo
rted in the literature and also to verify the relationship between this variant 
and breast cancer risk. A total of 750 women without breast cancer were genotype
d using the <i>TaqMan</i> PCR assay for <i>STK15 F31I </i>polymorphism. Clinical
 information was obtained from review of the medical records and mammographic de
nsity from the images obtained using the BI-RADS System. The estimated risk of d
eveloping cancer was calculated according to the Gail model. The genotypic frequ
encies observed in this study were 4.5, 38.7, and 56.6%, respectively, for the <
i>STK15</i> <i>F31I</i> <i>AA, AT </i>and <i>TT</i> genotypes. The <i>AT</i> and
 <i>AA</i> genotypes were encountered significantly more often in premenopausal 
women with moderately dense, dense and heterogeneously dense breast tissue (P = 
0.023). In addition, the presence of the <i>TT</i> genotype was significantly as
sociated with age at menarche &#8805;12 years (P = 0.023). High mammographic den
sity, associated with increased breast cancer risk, was encountered more frequen
tly in premenopausal women with the risk genotypes <i>STK15</i> <i>F31I</i> <i>A
A</i> and <i>AT</i>. The genotypic frequencies observed in our Brazilian sample 
were similar to those described in other predominantly European populations.#^dn
d^i1#^tm^len^k<i>STK15</i> <i>F31I</i> polymorphism^i1#^tm^len^kBreast cancer ri
sk^i1#^tm^len^kMammographic density^i1#other#27#20100813#<i>August 13, 2010</i>#
20110204#<i>February 4, 2011</i>#705.htm##
04305000000000757000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000400099121000300103049000900106158000700115
03000240012203100030014603200020014906500090015101400110016003500100017122400090
01810120093001900100033002830100029003160100033003450100025003780100024004030100
02700427010001900454010004100473010003400514010002300548010002200571010003600593
01000440062907001320067307001040080507001030090907001010101207001040111307001090
12170700098013260700098014240700110015220831650016320850008032820850036032900850
03103326085003303357117000603390072000303396112000903399111001603408114000903424
113001703433002000803450008008903458#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
05.htm#S#l#4#1#article#1#^mApr.^a2011#oa#en#bjmbr#1#3.1#tab#04#BJMBR010#FAPESP#B
raz. j. med. biol. res#44#4#20110400#^f291^l296#0100-879X#20110311#Prevalence of
 the STK15 F31I polymorphism and its relationship with mammographic density^len#
^rND^1A01 A05 A08^nJ^sGiacomazzi#^rND^1A01 A05 A08^nE^sAguiar#^rND^1A01 A05 A08^
nE. I^sPalmero#^rND^1A09^nA. V^sSchmidt#^rND^1A08^nG^sSkonieski#^rND^1A08^nD^sDu
arte Filho#^rND^1A06^nH^sBock#^rND^1A03 A06 A07^nM. L^sSaraiva-Pereira#^rND^1A04
 A07^nL^sSchuler-Faccini#^rND^1A02^nS. A^sCamey#^rND^1A08^nM^sCaleffi#^rND^1A01 
A04 A06 A07^nR^sGiugliani#^rND^1A01 A04 A05 A07 A08^nP^sAshton-Prolla#^iA01^1Uni
versidade Federal do Rio Grande do Sul^2Programa de Pós Graduação em Medicina: C
iências Médicas^cPorto Alegre^sRS^pBrasil#^iA02^1Universidade Federal do Rio Gra
nde do Sul^2Departamento de Estatística^cPorto Alegre^sRS^pBrasil#^iA03^1Univers
idade Federal do Rio Grande do Sul^2Departamento de Bioquímica^cPorto Alegre^sRS
^pBrasil#^iA04^1Universidade Federal do Rio Grande do Sul^2Departamento de Genét
ica^cPorto Alegre^sRS^pBrasil#^iA05^1Hospital de Clínicas de Porto Alegre^2Labor
atório de Medicina Genômica^cPorto Alegre^sRS^pBrasil#^iA06^1Hospital de Clínica
s de Porto Alegre^2Laboratório de Identificação Genética^cPorto Alegre^sRS^pBras
il#^iA07^1Hospital de Clínicas de Porto Alegre^2Serviço de Genética Médica^cPort
o Alegre^sRS^pBrasil#^iA08^1Associação Hospitalar Moinhos de Vento^2Núcleo Mama 
Porto Alegre^cPorto Alegre^sRS^pBrasil#^iA09^1Universidade Federal do Rio Grande
 do Sul^2Curso de Graduação em Estatística^cPorto Alegre^sRS^pBrasil#^len^aSever
al studies have identified the single nucleotide polymorphism STK15 F31I as a lo
w-penetrance risk allele for breast cancer, but its prevalence and risk associat
ion in the Brazilian population have not been determined. The goal of this study
 was to identify the frequency of this polymorphism in the Brazilian setting. Co
nsidering the high degree of admixture of our population, it is of fundamental i
mportance to validate the results already reported in the literature and also to
 verify the relationship between this variant and breast cancer risk. A total of
 750 women without breast cancer were genotyped using the TaqMan PCR assay for S
TK15 F31I polymorphism. Clinical information was obtained from review of the med
ical records and mammographic density from the images obtained using the BI-RADS
 System. The estimated risk of developing cancer was calculated according to the
 Gail model. The genotypic frequencies observed in this study were 4.5, 38.7, an
d 56.6 percent, respectively, for the STK15 F31I AA, AT and TT genotypes. The AT
 and AA genotypes were encountered significantly more often in premenopausal wom
en with moderately dense, dense and heterogeneously dense breast tissue (P = 0.0
23). In addition, the presence of the TT genotype was significantly associated w
ith age at menarche &#8805;12 years (P = 0.023). High mammographic density, asso
ciated with increased breast cancer risk, was encountered more frequently in pre
menopausal women with the risk genotypes STK15 F31I AA and AT. The genotypic fre
quencies observed in our Brazilian sample were similar to those described in oth
er predominantly European populations.#^dnd^i1#^tm^len^kSTK15 F31I polymorphism^
i1#^tm^len^kBreast cancer risk^i1#^tm^len^kMammographic density^i1#other#27#2010
0813#August 13, 2010#20110204#February 4, 2011#705.htm#Internet^ihttp://www.scie
lo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000400004##
00372000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014800070002000800218#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#5#1#article#129#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 291-296  </B></font></P>      ^cY#705.htm##
00447000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704022300070002000800293#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#6#2#article#129#<p ALIGN="LEFT"><font siz
e="5" face="Arial, Helvetica, sans-serif"><span lang="EN"><strong>Prevalence of 
the <i>STK15 F31I </i>polymorphism and its relationship with mammographic densit
y</strong></span></font></p>      ^cY#705.htm##
01207000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704098300070002000801053#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#7#3#article#129#<p ALIGN="LEFT"><font fac
e="Arial, Helvetica, sans-serif"><span lang="EN">J. Giacomazzi<sup>1,5,8</sup>, 
E. Aguiar<sup>1,5,8</sup>, E.I. Palmero<sup>1,5,8</sup>, A.V. Schmidt<sup>9</sup
>, G. Skonieski<sup>8</sup>, </span></font><font face="Arial, Helvetica, sans-se
rif"><span lang="EN">D. Duarte Filho<sup>8</sup>, H. Bock<sup>6</sup>, M.L. Sara
iva-Pereira<sup>3,6,7</sup>, L. Schuler-Faccini<sup>4,7</sup>, </span></font><fo
nt face="Arial, Helvetica, sans-serif"><span lang="EN">S.A. Camey<sup>2</sup>, M
. Caleffi<sup>8</sup>, R. Giugliani<sup>1,4,6,7</sup> and <span lang="EN"><font 
face="Arial, Helvetica, sans-serif"><sup><span lang="EN"><font face="Arial, Helv
etica, sans-serif"><b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v4
4n4/recor.gif" border="0"></a></b> <a href="mailto:pprolla@hcpa.ufrgs.br"><img s
rc="/img/revistas/bjmbr/v44n4/email-ca.gif" border="0"></a></font></span></sup><
/font></span> P. Ashton-Prolla<sup>1,4,5,7,8</sup></span></font></p>      ^cY#70
5.htm##
00476000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704025200070002000800322#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#8#4#article#129#<p ALIGN="LEFT"><font fac
e="Arial, Helvetica, sans-serif"><span lang="EN"><sup>1</sup>Programa de P&oacut
e;s Gradua&ccedil;&atilde;o em Medicina: Ci&ecirc;ncias M&eacute;dicas, Universi
dade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil    ^cY#705.htm##
00489000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704026500070002000800335#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#9#5#article#129#<br>    </span></font><fo
nt face="Arial, Helvetica, sans-serif"><span lang="EN">Departamentos de <sup>2</
sup>Estat&iacute;stica, <sup>3</sup>Bioqu&iacute;mica e <sup>4</sup>Gen&eacute;t
ica, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil    ^cY#
705.htm##
00654000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704042900071002000800500#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#10#6#article#129#<br>    </span></font><f
ont face="Arial, Helvetica, sans-serif"><span lang="EN"><sup>5</sup>Laborat&oacu
te;rio de Medicina Gen&ocirc;mica, <sup>6</sup>Laborat&oacute;rio de Identifica&
ccedil;&atilde;o Gen&eacute;tica e </span></font><font face="Arial, Helvetica, s
ans-serif"><span lang="EN"><sup>7</sup>Servi&ccedil;o de Gen&eacute;tica M&eacut
e;dica, Hospital de Cl&iacute;nicas de Porto Alegre, Porto Alegre, RS, Brasil   
 ^cY#705.htm##
00436000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704021100071002000800282#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#11#7#article#129#<br>    </span></font><f
ont face="Arial, Helvetica, sans-serif"><span lang="EN"><sup>8</sup>N&uacute;cle
o Mama Porto Alegre, Associa&ccedil;&atilde;o Hospitalar Moinhos de Vento, Porto
 Alegre, RS, Brasil    ^cY#705.htm##
00466000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704024100071002000800312#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#12#8#article#129#<br>  </span></font><fon
t face="Arial, Helvetica, sans-serif"><span lang="EN"><sup>9</sup>Curso de Gradu
a&ccedil;&atilde;o em Estat&iacute;stica, Universidade Federal do Rio Grande do 
Sul, Porto Alegre, RS, Brasil</span></font></p>      ^cY#705.htm##
00415000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704019000071002000800261#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#13#9#article#129#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#705.htm##
00413000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018700072002000800259#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#14#10#article#129#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    
^cY#705.htm##
00413000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018700072002000800259#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#15#11#article#129#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    
^cY#705.htm##
00398000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017200072002000800244#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#16#12#article#129#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#705.htm##
00407000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018100072002000800253#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#17#13#article#129#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#70
5.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#18#14#article#129#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#705.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#19#15#article#129#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#705.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#20#16#article#129#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#705.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#21#17#article#129#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#705.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#22#18#article#129#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#705.htm##
02066000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704184000072002000801912#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#23#19#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Several studies have identifi
ed the single nucleotide polymorphism <i>STK15</i> <i>F31I</i> as a low-penetran
ce risk allele for breast cancer, but its prevalence and risk association in the
 Brazilian population have not been determined. The goal of this study was to id
entify the frequency of this polymorphism in the Brazilian setting. Considering 
the high degree of admixture of our population, it is of fundamental importance 
to validate the results already reported in the literature and also to verify th
e relationship between this variant and breast cancer risk. A total of 750 women
 without breast cancer were genotyped using the <i>TaqMan</i> PCR assay for <i>S
TK15 F31I </i>polymorphism. Clinical information was obtained from review of the
 medical records and mammographic density from the images obtained using the BI-
RADS System. The estimated risk of developing cancer was calculated according to
 the Gail model. The genotypic frequencies observed in this study were 4.5, 38.7
, and 56.6%, respectively, for the <i>STK15</i> <i>F31I</i> <i>AA, AT </i>and <i
>TT</i> genotypes. The <i>AT</i> and <i>AA</i> genotypes were encountered signif
icantly more often in premenopausal women with moderately dense, dense and heter
ogeneously dense breast tissue (P = 0.023). In addition, the presence of the <i>
TT</i> genotype was significantly associated with age at menarche &ge;12 years (
P = 0.023). High mammographic density, associated with increased breast cancer r
isk, was encountered more frequently in premenopausal women with the risk genoty
pes <i>STK15</i> <i>F31I</i> <i>AA</i> and <i>AT</i>. The genotypic frequencies 
observed in our Brazilian sample were similar to those described in other predom
inantly European populations.</span></font></p>      ^cY#705.htm##
00442000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021600072002000800288#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#24#20#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Key words: <i>STK15</i> <i>F3
1I</i> polymorphism; Breast cancer risk; Mammographic density</span></font></p> 
 <HR ALIGN=LEFT SIZE=2>      ^cY#705.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#25#21#article#129#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#705.htm##
00607000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704038100072002000800453#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#26#22#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Breast cancer (BC) is a signi
ficant public health problem in South America, being the most common malignancy 
among women. In Brazil, BC incidence and mortality rates continue to rise despit
e significant efforts to establish mammographic screening programs across the co
untry (1).</span></font></p>      ^cY#705.htm##
00693000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704046700072002000800539#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#27#23#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Southern Brazilian states hav
e particularly high incidence rates, in the range of most countries in Europe an
d North America, and this is likely a consequence of life style among women in t
his region (e.g., decreasing number of term pregnancies, significant prevalence 
of overweight and obesity across age groups, increasing use of hormone replaceme
nt therapy) (2).</span></font></p>      ^cY#705.htm##
00604000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704037800072002000800450#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#28#24#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Other factors should also be 
considered, such as the influence of environmental factors and the genetic backg
round of the population. The region has received the highest proportion of Europ
ean immigrants during the last two centuries compared to other regions in Brazil
 (2,3).</span></font></p>      ^cY#705.htm##
00547000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032100072002000800393#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#29#25#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Several genetic polymorphisms
 associated with an increased risk of BC have been identified in genes involved 
in hormone metabolism, carcinogen metabolism as well as in some high penetrance 
genes such as <i>TP53</i> (4).</span></font></p>      ^cY#705.htm##
01220000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704099400072002000801066#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#30#26#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Polymorphisms in the <i>STK15
</i> gene have been recently described and an association with BC risk has been 
proposed. The <i>STK15</i> gene (also known as <i>AURKA, STK6,</i> and <i>BTAK</
i>) encodes <i>Aurora-A</i>, a serine-threonine kinase that acts as a key regula
tor of mitotic chromosome segregation and is particularly involved in the passag
e from the <i>G<sub>2</sub></i> to the <i>M</i> phase of the cell cycle (5,6). D
efects in chromatid segregation cause genetic instability, a condition that is c
learly associated with tumorigenesis (7). Due to its regulatory function in the 
cell cycle, the <i>STK15</i> gene has been suggested to be a potential cancer su
sceptibility gene. A single nucleotide polymorphism (SNP) at nucleotide 91, T&gt
;A, results in the substitution of phenylalanine by isoleucine in codon 31 (<i>F
31I</i>) and affects the function of the <i>STK15</i> gene (6).</span></font></p
>      ^cY#705.htm##
01548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704132200072002000801394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#31#27#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">The first study reporting an 
association of the <i>STK15 F31I </i>polymorphism with BC described a significan
tly increased risk (OR = 1.76, 95%CI = 1.29-2.12) in women with the <i>AA STK15 
F31I</i> genotype (8). A second study reported an increase in BC risk in associa
tion with both the <i>AT STK15 F31I </i>(OR = 1.3, 95%CI = 1.0-1.7) and <i>AA</i
> <i>STK15 F31I </i>genotypes (OR = 1.2, 95%CI = 0.9-1.6) (9). An association be
tween overweight (body mass index, BMI &ge;25) and these genotypes was also desc
ribed (OR = 3.3, 95%CI = 1.4-7.7) for the <i>AT STK15 F31I </i>genotype and for 
the <i>AA STK15 F31I</i> genotype (OR = 4.1, 95%CI = 1.7-9.8). The same authors 
suggested that the association of <i>STK15 </i>genotype, BC risk and increased B
MI could be further modified by factors related to increased endogenous exposure
 to estrogen, including enhanced peripheral metabolism, early menarche, late men
opause, and later age at first childbirth. However, additional studies have repo
rted an association between the <i>AA STK15 F31I </i>genotype and overall BC ris
k in relation to BMI. Results are conflicting, with increased risk being associa
ted with postmenopausal women with and without an increased BMI (9-11).</span></
font></p>      ^cY#705.htm##
00842000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704061600072002000800688#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#32#28#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">No association between the <i
>STK15 F31I </i>polymorphism and mammographic density was identified in the lite
rature. The mammographic density (radiological breast density) is influenced by 
the hormonal changes that occur throughout the life of women and is considered t
o be one of the most important independent risk factor for breast cancer (12). H
ormonal changes reflect persistent differences in cell cycle regulators, signal 
transduction pathways, transcription factors, and other unknown regulatory molec
ules.</span></font></p>      ^cY#705.htm##
00633000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704040700072002000800479#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#33#29#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Thus, the objective of the pr
esent study was to determine the allelic and genotypic frequencies of the <i>STK
15 F31I</i> polymorphism in 750 healthy women and also to investigate the relati
onship of this polymorphism with breast cancer risk factors, including mammograp
hic density.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#705.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#34#30#article#129#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#705.htm##
00371000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704014500072002000800217#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#35#31#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><b><span lang="EN">Study population and data 
collection</span></b></font></p>      ^cY#705.htm##
01199000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704097300072002000801045#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#36#32#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">A consecutive and unselected 
sample of 750 breast cancer-unaffected women (ages 40-69 years) enrolled in a ma
mmography screening program in the city of Porto Alegre (N&uacute;cleo Mama Port
o Alegre - NMPOA Cohort) was recruited for this study during routine mammographi
c visits for 4 months (13,14). Study approval was obtained from the Ethics Commi
ttees of the participating institutions, Hospital de Cl&iacute;nicas de Porto Al
egre and Associa&ccedil;&atilde;o Hospitalar Moinhos de Vento, and all individua
ls recruited for the study gave written informed consent. Demographic and clinic
al information as well as results from mammographic screening were obtained from
 chart review. We also started a prospective DNA collection of all breast cancer
 cases identified within the program and present here preliminary results of the
 analysis of the first 39 cases recruited.</span></font></p>      ^cY#705.htm##
00350000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704012400072002000800196#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#37#33#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><b><span lang="EN">Study variables</span></b>
</font></p>      ^cY#705.htm##
00952000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704072600072002000800798#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#38#34#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Study variables included age 
at recruitment, age at first childbirth, age at menarche and menopause, parity, 
BMI (classified into 4 categories: &lt;18.5; &ge;18.5-24.99; 25-29.99; &ge;30), 
race (white or non-white, assessed by self-classification), results of the mammo
graphic examination and mammographic density (using the BI-RADS and breast densi
ty categories of the American College of Radiology 1998), previous breast biopsi
es, use of hormone replacement therapy (HRT) and/or oral contraceptives, estimat
ed 5-year risk (Gail 5-years) and estimated lifetime risk of developing cancer a
ccording to the Gail model (15,16).</span></font></p>      ^cY#705.htm##
00356000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013000072002000800202#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#39#35#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><b><span lang="EN">Polymorphism analysis</spa
n></b></font></p>      ^cY#705.htm##
00779000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704055300072002000800625#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#40#36#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Genomic DNA was obtained from
 peripheral blood samples using standard methods (17). Genotyping was performed 
using the <i>TaqMan</i> PCR assay for <i>STK15 F31I </i>polymorphism (rs2273535,
 C_25623289_10 Applied Biosystems, USA), with fluorescent minor groove binding p
robes. Analyses were performed using an ABI 7500 real-time PCR system (Applied B
iosystems), and results were analyzed with the Sequence Detection software v 1.4
 (Applied Biosystems).</span></font></p>      ^cY#705.htm##
00355000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704012900072002000800201#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#41#37#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><b><span lang="EN">Statistical analysis</span
></b></font></p>      ^cY#705.htm##
01034000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704080800072002000800880#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#42#38#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">SPSS version 14.0 was used fo
r data handling and statistical analyses. For descriptive analysis, categorical 
variables were described by their absolute and/or relative frequencies and quant
itative variables are reported as means + SD. For analytical statistics, the <i>
t-test</i> for independent variables and ANOVA were used to compare the mean val
ues of the quantitative variables. The existence of an association between categ
orical variables was examined by the chi-square test. The level of significance 
of 0.05 was adopted in all analyses. Comparative analysis of genotypic frequenci
es between this and other studies was done using the WINPEPI package (PEPI-for-W
indows) (18).</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#705.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#43#39#article#129#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#705.htm##
00698000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704047200072002000800544#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#44#40#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Data regarding the BC risk fa
ctors identified in the sample are presented in <a href="#Tab1">Table 1</a>. Mea
n age (&plusmn; SD) at inclusion of the women enrolled in the present study was 
51 &plusmn; 7.6 years, 420 (56.0%) women were postmenopausal, and the mean estim
ated lifetime risk of developing BC in the overall sample using the Gail model w
as 7.8 &plusmn; 3.3%.</span></font></p>      ^cY#705.htm##
00819000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704059300072002000800665#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#45#41#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">The allelic and genotypic fre
quencies of the <i>STK15 F31I</i> polymorphism are presented in <a href="#Tab2">
Table 2</a>. The distribution of genotypes for this polymorphism in the overall 
sample, as well as that of the self-denominated groups of white and non-white wo
men was consistent with Hardy-Weinberg equilibrium (H-W: 3.22, 3.83, 0.02, respe
ctively). There were no significant differences in observed allelic and genotypi
c frequencies between white and non-white women (P &gt; 0.05).</span></font></p>
      ^cY#705.htm##
00745000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704051900072002000800591#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#46#42#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">The <i>STK15 F31I AT</i> and 
<i>AA</i> genotypes were encountered significantly more often in premenopausal w
omen with moderately dense, dense and heterogeneously dense breast tissue (P = 0
.023). In addition, the presence of the <i>STK15 F31I TT</i> genotype was signif
icantly associated with age at menarche &ge;12 years (P = 0.023). No significant
 associations with other breast cancer risk factors were identified.</span></fon
t></p>      ^cY#705.htm##
01160000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704093400072002000801006#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#47#43#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Interestingly, preliminary re
sults of the first 39 BC patients identified within this cohort of 750 women sho
wed that the genotypic frequencies were significantly different between cases an
d controls (especially for the <i>TT</i> and <i>AA</i> genotypes). This differen
ce is striking and in favor of a role of <i>STK15</i> as an independent risk fac
tor for BC as previously suggested by other investigators. Assessment of this po
lymorphism in a larger series of BC patients from the same community is needed, 
however, to confirm these results.</span></font><font face="Arial, Helvetica, sa
ns-serif"><span lang="EN"> </span></font></p>  <HR ALIGN=LEFT SIZE=2>  <table  b
order="0">    <tr align="left" valign="top">      <td><a href="/img/revistas/bjm
br/v44n4/html/705t01.htm"><img src="/img/revistas/bjmbr/v44n4/table.jpg" border=
"2"></a></td>      <td>    ^cY#705.htm##
00443000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021700072002000800289#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#48#44#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN"><a name="Tab1"></a>Table 1. C
linical characteristics of the sample studied (N = 750).</span></font></p>      
</td>    </tr>  </table>      ^cY#705.htm##
00560000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033400072002000800406#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#49#45#article#129#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (168 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/705t02.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#705.htm##
00544000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031800072002000800390#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#50#46#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN"><a name="Tab2"></a>Table 2. G
enotypic and allelic frequencies of the <i>STK15 F31I</i> polymorphism in the ov
erall sample (N = 750), and in white (N = 599) and non-white women (N = 151).</s
pan></font></p>      </td>    </tr>  </table>      ^cY#705.htm##
00864000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704063800072002000800710#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#51#47#article#129#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (110 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/705t03.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td><span lang="EN"><
font face="Arial, Helvetica, sans-serif"><span lang="EN"><a name="Tab3"></a>Tabl
e 3. Genotypic and allelic frequencies of the <i>STK15</i> <i>F31I</i> polymorph
ism in breast cancer-unaffected women in the present study and in other studies.
</span></font></span></td>    </tr>  </table>      ^cY#705.htm##
00344000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011800072002000800190#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#52#48#article#129#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (121 K JPG file)]</font
></P>      ^cY#705.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#53#49#article#129#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#705.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#54#50#article#129#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#705.htm##
00846000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704062000072002000800692#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#55#51#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Several studies have now iden
tified the <i>STK15</i> <i>F31I</i> polymorphism as a low-penetrance risk allele
 for BC, but its association with clinical characteristics or with mammographic 
density in a Brazilian population has not been determined. Compelled by a possib
le association of the <i>STK15</i> <i>F31I</i> polymorphism with these variables
, we performed the present study in a population-based sample of women submitted
 to mammographic screening from a geographic area of Brazil with high BC inciden
ce rates.</span></font></p>      ^cY#705.htm##
01495000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704126900072002000801341#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#56#52#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">The genotypic frequencies enc
ountered in this study were similar to those described in other predominantly Eu
ropean populations (6,11,19,20) and significantly distinct from those observed a
mong Asians (<a href="#Tab3">Table 3</a>). This is not unexpected because, altho
ugh the contemporary Brazilian population is highly admixed, there is a predomin
ance of European alleles, especially in the formation of the genetic pool of Sou
thern Brazil where this study was carried out. Price et al. (22), for instance, 
have estimated that African and European ancestry corresponds to 11 and 71% of t
he alleles in Brazilian individuals and Alves-Silva et al. (23)described a major
 contribution of European alleles to both mitochondrial (66%) and nuclear (79%) 
DNA in populations from Southern Brazil. An interesting observation is that the 
frequency of homozygotes for the <i>STK15 F31I A </i>allele (risk genotype <i>AA
</i>) is 7-fold higher in the Asian (Chinese) populations studied so far than in
 the sample studied here and other European populations. In Chinese women, BC in
cidence rates are significantly lower than those observed in Western countries a
nd in Brazil (24).</span></font></p>      ^cY#705.htm##
00612000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704038600072002000800458#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#57#53#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">In addition, the presence of 
the <i>STK15 F31I TT</i> genotype was significantly associated with age at menar
che &ge;12 years (P = 0.023). No significant association was found between the <
i>STK15 F31I </i>polymorphism and age at menopause, age at first childbirth, BMI
 or use of HRT.</span></font></p>      ^cY#705.htm##
01100000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704087400072002000800946#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#58#54#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">We also investigated a possib
le association between the <i>STK15 F31I </i>polymorphism and indicators of prol
onged estrogen exposure. Breast cancer is a hormone-related tumor, and it is wel
l established that sex hormones increase breast cancer risk (and modify the mamm
ographic density) by increasing proliferation of breast epithelial cells. It has
 also been suggested that loss of function of certain <i>STK15 </i>alleles could
 potentially be enhanced in women with higher exposure, either endogenous or exo
genous, to the mitogenic influence of estrogen (25-27). The <i>STK15 F31I </i>ri
sk genotypes<i> AT</i> and <i>AA</i> were encountered significantly more often i
n premenopausal women with moderately dense, dense and heterogeneously dense bre
ast tissue (P = 0.023).</span></font></p>      ^cY#705.htm##
01600000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704137400072002000801446#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#59#55#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Replication errors and geneti
c damage during cell division, if not corrected, may lead to breast cancer. In e
xperimental studies, overexpression of <i>STK15</i> in non-malignant cultured ce
lls leads to centrosome amplification, chromosome instability, transformation an
d the ability to induce tumors. In addition, amplification and/or overexpression
 of <i>STK15</i> has been reported in cancer cell lines and in several human tum
ors, including breast cancer. Although the functional significance of allele <i>
A</i> of the <i>STK15</i> <i>F31I </i>polymorphism has not been fully determined
, some publications have reported that this allele is associated with accelerate
d growth and proliferation of tumor cells in culture. In the present study, we s
uggest that women with the <i>A</i> allele, associated with increased expression
 of <i>STK15</i>, experience high proliferation of breast epithelial cells and t
his would be the biologic rationale for the observed increase in breast density.
 The increased risk for breast cancer associated with higher breast density coul
d be related to the biologic observation of accelerated cell proliferation and/o
r due to the difficulties in assessing dense breast tissue by conventional scree
ning methods (i.e., mammography) (9,25-27).</span></font></p>      ^cY#705.htm##
01316000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704109000072002000801162#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#60#56#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Since mammographic density di
rectly reflects the status of breast parenchyma and stroma, it is reasonable to 
suggest that increased breast density may be associated with increased breast ca
ncer risk due to an increased number of epithelial cells and/or an increased pro
liferative state of these cells. In this setting, the <i>AT </i>and<i> AA</i> ge
notypes of <i>STK15 </i>polymorphism <i>F31I</i> could be associated with increa
sed breast cancer risk through increased expression of the gene. Multiple factor
s influence the mammographic pattern, including age, reproductive history, hormo
ne levels, and body constitution. In this study, we demonstrate that a genetic p
olymorphism is associated with increased breast density. The genetic determinant
s of breast density are being extensively studied and this is a promising area o
f research, since identification of an &quot;intrinsic&quot; determinant of incr
eased breast density could also potentially be a risk factor for breast cancer.<
/span></font></p>      ^cY#705.htm##
00579000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704035300072002000800425#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#61#57#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">Further investigation of the 
<i>STK15 F31I </i>polymorphism in other populations and especially, in case-cont
rol studies of women with or without breast cancer are necessary to establish wh
ether it has a role as a genetic risk factor for this disease.</span></font></p>
      ^cY#705.htm##
01332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704110600072002000801178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#62#58#article#129#<p ALIGN="LEFT"><font f
ace="Arial, Helvetica, sans-serif"><span lang="EN">We conclude that the genotypi
c frequencies observed in the sample of 750 healthy women from Southern Brazil s
tudied here were similar to those described in other predominantly European popu
lations. High mammographic density was encountered more frequently in premenopau
sal women with the <i>STK15 F31I </i>risk genotypes <i>AA</i> and <i>AT</i>, sug
gesting that this polymorphism has a phenotypic effect and may play an important
 role in breast cancer risk determination. Furthermore, this study adds to curre
nt knowledge that genetic determinants of mammographic density may be useful in 
building multigenic models for predicting breast cancer risk. Finally, if confir
med, the associations between <i>STK15</i> <i>F31I</i> risk genotypes and high m
ammographic density in premenopausal women could have important implications for
 mammographic screening strategies in this and other populations. Additional cas
e-control studies are necessary to confirm the findings described here.</span></
font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#705.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#63#59#article#129#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#705.htm##
00449000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704020900074002000800283#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#64#60#article#129#1#<p ALIGN=
"LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">1. World Health
 Organization Database. [<a target="_blank" href="http://www.who.int/infobase">h
ttp://www.who.int/infobase</a>].    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#65#61#article#129#</span></font></p>     
 ^cY#705.htm##
00468000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704022800074002000800302#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#66#62#article#129#2#<p align=
"LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">2. McPherson K,
 Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk fa
ctors, and genetics. <i>BMJ</i> 2000; 321: 624-628.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#67#63#article#129#</span></font></p>     
 ^cY#705.htm##
00502000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704026200074002000800336#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#68#64#article#129#3#<p align=
"LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">3. Schwartsmann
 G. Breast cancer in South America: challenges to improve early detection and me
dical management of a public health problem. <i>J Clin Oncol</i> 2001; 19: 118S-
124S.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#69#65#article#129#</span></font></p>     
 ^cY#705.htm##
00518000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027800074002000800352#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#70#66#article#129#4#<p align=
"LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">4. Dunning AM, 
Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of ge
netic polymorphisms and breast cancer risk. <i>Cancer Epidemiol Biomarkers Prev<
/i> 1999; 8: 843-854.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#71#67#article#129#</span></font></p>     
 ^cY#705.htm##
00444000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704020400074002000800278#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#72#68#article#129#5#<p align=
"LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">5. Dutertre S, 
Descamps S, Prigent C. On the role of Aurora-A in centrosome function. <i>Oncoge
ne</i> 2002; 21: 6175-6183.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#73#69#article#129#</span></font></p>     
 ^cY#705.htm##
00540000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704030000074002000800374#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#74#70#article#129#6#<p align=
"LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">6. Ewart-Toland
 A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, et al. Identification of
 Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and
 human. <i>Nat Genet</i> 2003; 34: 403-412.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#75#71#article#129#</span></font></p>     
 ^cY#705.htm##
00436000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704019600074002000800270#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#76#72#article#129#7#<p align=
"LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">7. Lengauer C, 
Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. <i>Nature</i> 
1998; 396: 643-649.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#77#73#article#129#</span></font></p>     
 ^cY#705.htm##
00493000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704025300074002000800327#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#78#74#article#129#8#<p align=
"LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">8. Sun T, Miao 
X, Wang J, Tan W, Zhou Y, Yu C, et al. Functional Phe31Ile polymorphism in Auror
a A and risk of breast carcinoma. <i>Carcinogenesis</i> 2004; 25: 2225-2230.    
^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#79#75#article#129#</span></font></p>     
 ^cY#705.htm##
00561000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704032100074002000800395#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#80#76#article#129#9#<p align=
"LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">9. Dai Q, Cai Q
Y, Shu XO, Ewart-Toland A, Wen WQ, Balmain A, et al. Synergistic effects of STK1
5 gene polymorphisms and endogenous estrogen exposure in the risk of breast canc
er. <i>Cancer Epidemiol Biomarkers Prev</i> 2004; 13: 2065-2070.    ^cY#705.htm#
#
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#81#77#article#129#</span></font></p>     
 ^cY#705.htm##
00499000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025800075002000800333#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#82#78#article#129#10#<p align
="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">10. Cox DG, Ha
nkinson SE, Hunter DJ. Polymorphisms of the AURKA (STK15/Aurora Kinase) Gene and
 Breast Cancer Risk (United States). <i>Cancer Causes Control</i> 2006; 17: 81-8
3.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#83#79#article#129#</span></font></p>     
 ^cY#705.htm##
00576000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704033500075002000800410#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#84#80#article#129#11#<p align
="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">11. Egan KM, N
ewcomb PA, Ambrosone CB, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, et al. 
STK15 polymorphism and breast cancer risk in a population-based study. <i>Carcin
ogenesis</i> 2004; 25: 2149-2153. Erratum: <i>Carcinogenesis </i>2005; 26: 701. 
   ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#85#81#article#129#</span></font></p>     
 ^cY#705.htm##
00545000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704030400075002000800379#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#86#82#article#129#12#<p align
="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">12. Chambo D, 
Kemp C, Costa AM, Souza NC, Guerreiro da Silva I. Polymorphism in CYP17, GSTM1 a
nd the progesterone receptor genes and its relationship with mammographic densit
y. <i>Braz J Med Biol Res</i> 2009; 42: 323-329.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#87#83#article#129#</span></font></p>     
 ^cY#705.htm##
00545000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704030400075002000800379#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#88#84#article#129#13#<p align
="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">13. Caleffi M,
 Ashton-Prolla P, Weber B, Zignani JM, Dias EC, Antunes LP, et al. Breast cancer
 screening in 10.000 women of an underserved population in South Brazil: the NMA
MAPOA cohort. <i>J Clin Oncol</i> 2005; 23: 877.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#89#85#article#129#</span></font></p>     
 ^cY#705.htm##
00524000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704028300075002000800358#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#90#86#article#129#14#<p align
="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">14. Smith RA, 
Caleffi M, Albert US, Chen TH, Duffy SW, Franceschi D, et al. Breast cancer in l
imited-resource countries: early detection and access to care. <i>Breast J</i> 2
006; 12 (Suppl 1): S16-S26.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#91#87#article#129#</span></font></p>     
 ^cY#705.htm##
00472000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704023100075002000800306#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#92#88#article#129#15#<p align
="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">15. American C
ollege of Radiology. <i>Illustrated breast imaging reporting and data system (BI
RADS)</i>. Reston: American College of Radiology; 1998.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#93#89#article#129#</span></font></p>     
 ^cY#705.htm##
00561000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704032000075002000800395#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#94#90#article#129#16#<p align
="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">16. Gail MH, B
rinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individual
ized probabilities of developing breast cancer for white females who are being e
xamined annually. <i>J Natl Cancer Inst</i> 1989; 81: 1879-1886.    ^cY#705.htm#
#
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#95#91#article#129#</span></font></p>     
 ^cY#705.htm##
00478000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704023700075002000800312#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#96#92#article#129#17#<p align
="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">17. Miller SA,
 Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from hu
man nucleated cells. <i>Nucleic Acids Res</i> 1988; 16: 1215.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#97#93#article#129#</span></font></p>     
 ^cY#705.htm##
00450000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704020900075002000800284#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#98#94#article#129#18#<p align
="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">18. Abramson J
H. WINPEPI (PEPI-for-Windows): computer programs for epidemiologists. <i>Epidemi
ol Perspect Innov</i> 2004; 1: 6.    ^cY#705.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#99#95#article#129#</span></font></p>     
 ^cY#705.htm##
00553000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704031100076002000800387#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#100#96#article#129#19#<p alig
n="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">19. Fletcher 
O, Johnson N, Palles C, dos Santos Silva I, McCormack V, Whittaker J, et al. Inc
onsistent association between the STK15 F31I genetic polymorphism and breast can
cer risk. <i>J Natl Cancer Inst</i> 2006; 98: 1014-1018.    ^cY#705.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#101#97#article#129#</span></font></p>    
  ^cY#705.htm##
00488000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704024600076002000800322#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#102#98#article#129#20#<p alig
n="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">20. Gu J, Gon
g Y, Huang M, Lu C, Spitz MR, Wu X. Polymorphisms of STK15 (Aurora-A) gene and l
ung cancer risk in Caucasians. <i>Carcinogenesis</i> 2007; 28: 350-355.    ^cY#7
05.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#103#99#article#129#</span></font></p>    
  ^cY#705.htm##
00534000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029100077002000800368#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#104#100#article#129#21#<p ali
gn="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">21. Lo YL, Y
u JC, Chen ST, Yang HC, Fann CS, Mau YC, et al. Breast cancer risk associated wi
th genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK. <i
>Int J Cancer </i>2005; 115: 276-283.    ^cY#705.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#105#101#article#129#</span></font></p>   
   ^cY#705.htm##
00494000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704025100077002000800328#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#106#102#article#129#22#<p ali
gn="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">22. Price AL
, Patterson N, Yu F, Cox DR, Waliszewska A, McDonald GJ, et al. A genomewide adm
ixture map for Latino populations. <i>Am J Hum Genet</i> 2007; 80: 1024-1036.   
 ^cY#705.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#107#103#article#129#</span></font></p>   
   ^cY#705.htm##
00500000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704025700077002000800334#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#108#104#article#129#23#<p ali
gn="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">23. Alves-Si
lva J, da Silva Santos M, Guimaraes PE, Ferreira AC, Bandelt HJ, Pena SD, et al.
 The ancestry of Brazilian mtDNA lineages. <i>Am J Hum Genet</i> 2000; 67: 444-4
61.    ^cY#705.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#109#105#article#129#</span></font></p>   
   ^cY#705.htm##
00513000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027000077002000800347#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#110#106#article#129#24#<p ali
gn="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">24. Tavassol
i FA, Devillee P. <i>World Health Organization. Classification of tumour. Pathol
ogy and genetics of tumours of the breast and female genital organs</i>. Lyon: I
ARC Press; 2003.    ^cY#705.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#111#107#article#129#</span></font></p>   
   ^cY#705.htm##
00519000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027600077002000800353#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#112#108#article#129#25#<p ali
gn="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">25. Persson 
I. Estrogens in the causation of breast, endometrial and ovarian cancers - evide
nce and hypotheses from epidemiological findings. <i>J Steroid Biochem Mol Biol<
/i> 2000; 74: 357-364.    ^cY#705.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#113#109#article#129#</span></font></p>   
   ^cY#705.htm##
00537000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029400077002000800371#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#114#110#article#129#26#<p ali
gn="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">26. Diciocci
o RA, Song H, Waterfall C, Kimura MT, Nagase H, McGuire V, et al. STK15 polymorp
hisms and association with risk of invasive ovarian cancer. <i>Cancer Epidemiol 
Biomarkers Prev</i> 2004; 13: 1589-1594.    ^cY#705.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#115#111#article#129#</span></font></p>   
   ^cY#705.htm##
00508000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026500077002000800342#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#p#116#112#article#129#27#<p ali
gn="LEFT"><font face="Arial, Helvetica, sans-serif"><span lang="EN">27. Tchatcho
u S, Wirtenberger M, Hemminki K, Sutter C, Meindl A, Wappenschmidt B, et al. Aur
ora kinases A and B and familial breast cancer risk. <i>Cancer Lett</i> 2007; 24
7: 266-272.    ^cY#705.htm##
00280000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704005200074002000800126#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#117#113#article#129#</span></font></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#705.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033500074002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#118#114#article#129#<P><font face="Arial,
 Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE
=4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#705.ht
m##
01275000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704104700074002000801121#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#119#115#article#129#<p ALIGN="LEFT"><font
 face="Arial, Helvetica, sans-serif"><span lang="EN">The N&uacute;cleo Mama (NMA
MA) Cohort, from which the patients derive, is maintained by Associa&ccedil;&ati
lde;o Hospitalar Moinhos de Vento in partnership with Instituto da Mama do Rio G
rande do Sul and the Municipal Health Agency from Porto Alegre. The authors are 
indebted to Ademar Bedin J&uacute;nior, F&aacute;vio Marcel Telis Gonzalez, Luci
ano Artico, Bernardete Weber, Karen Barboza de Pereira, and the NMPOA team for t
heir help with the recruitment of the patients included in this study. Research 
supported in part by CNPq (Edital MCT-CNPq/MS-SCTIE-DECIT/CT-Saude #06/2005, pro
tocol #400949/2005-9), Susan G. Komen for the Cure (population-specific grant #P
OP0403033), and Fundo de Incentivo &agrave; Pesquisa do Hospital de Cl&iacute;ni
cas de Porto Alegre (FIPE/HCPA, Brazil, #05-182). P. Ashton-Prolla is the recipi
ent of a Productivity fellowship from CNPq and J. Giacomazzi received a fellowsh
ip from CAPES.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#705.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033600074002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#120#116#article#129#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#705.h
tm##
00970000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704074200074002000800816#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#121#117#article#129#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/r
ecor.gif" border="0"></a> Address for correspondence:</b></font><font face="Aria
l, Helvetica, sans-serif"><span lang="EN"> P. Ashton-Prolla, Departamento de Gen
&eacute;tica, UFRGS e Servi&ccedil;os de Gen&eacute;tica M&eacute;dica e Centro 
de Pesquisa </span></font><font face="Arial, Helvetica, sans-serif"><span lang="
EN">Experimental, Hospital de Cl&iacute;nicas de Porto Alegre, Rua Ramiro Barcel
os, 2350, 90035-903 Porto Alegre, RS, Brasil. </span></font><font face="Arial, H
elvetica, sans-serif"><span lang="EN">Fax: +55-51-3359-8010. E-mail: <a href="ma
ilto:pprolla@hcpa.ufrgs.br">pprolla@hcpa.ufrgs.br</a></span></font></p>      ^cY
#705.htm##
00508000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704028000074002000800354#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#122#118#article#129#<p ALIGN="LEFT"><font
 face="Arial, Helvetica, sans-serif"><span lang="EN">The current affiliation of 
E.I. Palmero is Laborat&oacute;rio de Oncologia Molecular, Hospital de C&acirc;n
cer de Barretos, Funda&ccedil;&atilde;o Pio XVII, Barretos, SP, Brasil.</span></
font></p>      ^cY#705.htm##
00472000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704024400074002000800318#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#123#119#article#129#<p ALIGN="LEFT"><font
 face="Arial, Helvetica, sans-serif"><i><span lang="EN">Received August 13, 2010
. Accepted February 4, 2011. Available online March 11, 2011. Published April 11
, 2011.</span></i></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#705.htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#124#120#article#129#<div align="center"> 
       ^cY#705.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#125#121#article#129#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#705.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#126#122#article#129#<br>                ^
cY#705.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#127#123#article#129#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#705
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#128#124#article#129#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#705.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#129#125#article#129#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#705.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#130#126#article#129#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#705.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#131#127#article#129#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#705.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#132#128#article#129#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#705.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\705.htm#S#p#133#129#article#129#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#705.htm##
00335000000000181000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710170035000730620028001088650
00900136002000800145#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#134#1
#article#27#1#World Health Organization Database#http://www.who.int/infobase#201
10400#705.htm##
00558000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100016000920100
01600108012008300124030000400207065000900211064000500220031000400225014000800229
865000900237002000800246035001000254801000400264#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\705.htm#S#c#135#2#article#27#2#^rND^sMcPherson^nK#^rND^sSteel^nCM#^rN
D^sDixon^nJM#ABC of breast diseases: Breast cancer-epidemiology, risk factors, a
nd genetics^len#BMJ#20000000#2000#321#624-628#20110400#705.htm#0959-8138#BMJ##
00565000000000265000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100022000730120124000950300
01300219065000900232064000500241031000300246014001000249865000900259002000800268
035001000276801001300286#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#1
36#3#article#27#3#^rND^sSchwartsmann^nG#Breast cancer in South America: challeng
es to improve early detection and medical management of a public health problem^
len#J Clin Oncol#20010000#2001#19#118S-124S#20110400#705.htm#0732-183X#J Clin On
col##
00691000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100017000910100
01800108010001600126010001700142010001700159012007200176030003300248065000900281
06400050029003100020029501400080029786500090030500200080031403500100032280100330
0332#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#137#4#article#27#4#^r
ND^sDunning^nAM#^rND^sHealey^nCS#^rND^sPharoah^nPD#^rND^sTeare^nMD#^rND^sPonder^
nBA#^rND^sEaston^nDF#A systematic review of genetic polymorphisms and breast can
cer risk^len#Cancer Epidemiol Biomarkers Prev#19990000#1999#8#843-854#20110400#7
05.htm#1055-9965#Cancer Epidemiol Biomarkers Prev##
00539000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100018000910100
01700109012005100126030000900177065000900186064000500195031000300200014001000203
865000900213002000800222035001000230801000900240#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\705.htm#S#c#138#5#article#27#5#^rND^sDutertre^nS#^rND^sDescamps^nS#^r
ND^sPrigent^nC#On the role of Aurora-A in centrosome function^len#Oncogene#20020
000#2002#21#6175-6183#20110400#705.htm#0950-9232#Oncogene##
00701000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100022000730100020000950100
02000115010001400135010001400149010001400163810000600177012010800183030001000291
06500090030106400050031003100030031501400080031886500090032600200080033503500100
0343801001000353#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#139#6#art
icle#27#6#^rND^sEwart-Toland^nA#^rND^sBriassouli^nP#^rND^sde^nKoning JP#^rND^sMa
o^nJH#^rND^sYuan^nJ#^rND^sChan^nF#et al#Identification of Stk6/STK15 as a candid
ate low-penetrance tumor-susceptibility gene in mouse and human^len#Nat Genet#20
030000#2003#34#403-412#20110400#705.htm#1061-4036#Nat Genet##
00529000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100018000910100
02000109012004300129030000700172065000900179064000500188031000400193014000800197
865000900205002000800214035001000222801000700232#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\705.htm#S#c#140#7#article#27#7#^rND^sLengauer^nC#^rND^sKinzler^nKW#^r
ND^sVogelstein^nB#Genetic instabilities in human cancers^len#Nature#19980000#199
8#396#643-649#20110400#705.htm#0028-0836#Nature##
00659000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100013000730100014000860100
01400100010001300114010001400127010001200141810000600153012007800159030001500237
06500090025206400050026103100030026601400100026986500090027900200080028803500100
0296801001500306#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#141#8#art
icle#27#8#^rND^sSun^nT#^rND^sMiao^nX#^rND^sWang^nJ#^rND^sTan^nW#^rND^sZhou^nY#^r
ND^sYu^nC#et al#Functional Phe31Ile polymorphism in Aurora A and risk of breast 
carcinoma^len#Carcinogenesis#20040000#2004#25#2225-2230#20110400#705.htm#0143-33
34#Carcinogenesis##
00745000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100013000730100014000860100
01400100010002200114010001400136010001700150810000600167012011400173030003300287
06500090032006400050032903100030033401400100033786500090034700200080035603500100
0364801003300374#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#142#9#art
icle#27#9#^rND^sDai^nQ#^rND^sCai^nQY#^rND^sShu^nXO#^rND^sEwart-Toland^nA#^rND^sW
en^nWQ#^rND^sBalmain^nA#et al#Synergistic effects of STK15 gene polymorphisms an
d endogenous estrogen exposure in the risk of breast cancer^len#Cancer Epidemiol
 Biomarkers Prev#20040000#2004#13#2065-2070#20110400#705.htm#1055-9965#Cancer Ep
idemiol Biomarkers Prev##
00607000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100020000890100
01700109012009700126030002200223065000900245064000500254031000300259014000600262
865000900268002000800277035001000285801002200295#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\705.htm#S#c#143#10#article#27#10#^rND^sCox^nDG#^rND^sHankinson^nSE#^r
ND^sHunter^nDJ#Polymorphisms of the AURKA (STK15/Aurora Kinase) Gene and Breast 
Cancer Risk (United States)^len#Cancer Causes Control#20060000#2006#17#81-83#201
10400#705.htm#0957-5243#Cancer Causes Control##
00746000000000349000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100018000900100
02000108010002400128010002400152010001800176810000600194012007400200030001500274
06500090028906400050029803100030030301400100030606100380031686500090035400200080
0363035001000371801001500381#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S
#c#144#11#article#27#11#^rND^sEgan^nKM#^rND^sNewcomb^nPA#^rND^sAmbrosone^nCB#^rN
D^sTrentham-Dietz^nA#^rND^sTitus-Ernstoff^nL#^rND^sHampton^nJM#et al#STK15 polym
orphism and breast cancer risk in a population-based study^len#Carcinogenesis#20
040000#2004#25#2149-2153#Erratum: Carcinogenesis 2005; 26: 701#20110400#705.htm#
0143-3334#Carcinogenesis##
00687000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100014000910100
01600105010001600121010002800137012011600165030002000281065000900301064000500310
031000300315014000800318865000900326002000800335035001000343801002000353#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#145#12#article#27#12#^rND^sChambo
^nD#^rND^sKemp^nC#^rND^sCosta^nAM#^rND^sSouza^nNC#^rND^sGuerreiro^nda Silva I#Po
lymorphism in CYP17, GSTM1 and the progesterone receptor genes and its relations
hip with mammographic density^len#Braz J Med Biol Res#20090000#2009#42#323-329#2
0110400#705.htm#0100-879X#Braz J Med Biol Res##
00708000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100023000920100
01500115010001800130010001500148010001800163810000600181012010900187030001300296
06500090030906400050031803100030032301400040032686500090033000200080033903500100
0347801001300357#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#146#13#ar
ticle#27#13#^rND^sCaleffi^nM#^rND^sAshton-Prolla^nP#^rND^sWeber^nB#^rND^sZignani
^nJM#^rND^sDias^nEC#^rND^sAntunes^nLP#et al#Breast cancer screening in 10000 wom
en of an underserved population in South Brazil: the NMAMAPOA cohort^len#J Clin 
Oncol#20050000#2005#23#877#20110400#705.htm#0732-183X#J Clin Oncol##
00668000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100017000910100
01700108010001500125010001600140010002000156010001300176012008400189030000900273
71000020028206500090028406400050029303100030029803200040030101400080030586500090
0313002000800322#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#147#14#ar
ticle#27#14#^rND^sSmith^nRA#^rND^sCaleffi^nM#^rND^sAlbert^nUS#^rND^sChen^nTH#^rN
D^sDuffy^nSW#^rND^sFranceschi^nD#^rND^set^nal#Breast cancer in limited-resource 
countries: early detection and access to care^len#Breast J#2#20060000#2006#12#^s
1#S16-S26#20110400#705.htm##
00469000000000229000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720170030000750180066001050660
00700171062003000178065000900208064000500217865000900222002000800231#v44n4#V:\Sc
iELO\serial\bjmbr\v44n4\markup\705.htm#S#c#148#15#article#27#15#American College
 of Radiology#Illustrated breast imaging reporting and data system (BIRADS)^len#
Reston#American College of Radiology#19980000#1998#20110400#705.htm##
00731000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100018000900100
01500108010001600123010001600139010001800155810000600173012012200179030001900301
06500090032006400050032903100030033401400100033786500090034700200080035603500100
0364801001900374#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#149#16#ar
ticle#27#16#^rND^sGail^nMH#^rND^sBrinton^nLA#^rND^sByar^nDP#^rND^sCorle^nDK#^rND
^sGreen^nSB#^rND^sSchairer^nC#et al#Projecting individualized probabilities of d
eveloping breast cancer for white females who are being examined annually^len#J 
Natl Cancer Inst#19890000#1989#81#1879-1886#20110400#705.htm#0027-8874#J Natl Ca
ncer Inst##
00582000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
01800108012008100126030001800207065000900225064000500234031000300239014000500242
865000900247002000800256035001000264801001800274#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\705.htm#S#c#150#17#article#27#17#^rND^sMiller^nSA#^rND^sDykes^nDD#^rN
D^sPolesky^nHF#A simple salting out procedure for extracting DNA from human nucl
eated cells^len#Nucleic Acids Res#19880000#1988#16#1215#20110400#705.htm#0305-10
48#Nucleic Acids Res##
00480000000000253000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750120070000940300
02500164710000200189065000900191064000500200031000200205014000200207865000900209
002000800218#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#151#18#articl
e#27#18#^rND^sAbramson^nJH#WINPEPI (PEPI-for-Windows): computer programs for epi
demiologists^len#Epidemiol Perspect Innov#2#20040000#2004#1#6#20110400#705.htm##
00722000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100017000930100
01600110010002600126010001900152010001900171810000600190012009600196030001900292
06500090031106400050032003100030032501400100032886500090033800200080034703500100
0355801001900365#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#152#19#ar
ticle#27#19#^rND^sFletcher^nO#^rND^sJohnson^nN#^rND^sPalles^nC#^rND^sdos^nSantos
 Silva I#^rND^sMcCormack^nV#^rND^sWhittaker^nJ#et al#Inconsistent association be
tween the STK15 F31I genetic polymorphism and breast cancer risk^len#J Natl Canc
er Inst#20060000#2006#98#1014-1018#20110400#705.htm#0027-8874#J Natl Cancer Inst
##
00642000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100012000750100014000870100
01500101010001200116010001600128010001200144012007800156030001500234065000900249
06400050025803100030026301400080026686500090027400200080028303500100029180100150
0301#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#153#20#article#27#20#
^rND^sGu^nJ#^rND^sGong^nY#^rND^sHuang^nM#^rND^sLu^nC#^rND^sSpitz^nMR#^rND^sWu^nX
#Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians^len#C
arcinogenesis#20070000#2007#28#350-355#20110400#705.htm#0143-3334#Carcinogenesis
##
00696000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100013000750100013000880100
01500101010001500116010001500131010001400146810000600160012011300166030001300279
06500090029206400050030103100040030601400080031086500090031800200080032703500100
0335801001300345#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#154#21#ar
ticle#27#21#^rND^sLo^nYL#^rND^sYu^nJC#^rND^sChen^nST#^rND^sYang^nHC#^rND^sFann^n
CS#^rND^sMau^nYC#et al#Breast cancer risk associated with genotypic polymorphism
 of the mitosis-regulating gene Aurora-A/STK15/BTAK^len#Int J Cancer#20050000#20
05#115#276-283#20110400#705.htm#0020-7136#Int J Cancer##
00665000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910100
01200110010001400122010002100136010001900157010001300176012005400189030001500243
06500090025806400050026703100030027201400100027586500090028500200080029403500100
0302801001500312#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#155#22#ar
ticle#27#22#^rND^sPrice^nAL#^rND^sPatterson^nN#^rND^sYu^nF#^rND^sCox^nDR#^rND^sW
aliszewska^nA#^rND^sMcDonald^nGJ#^rND^set^nal#A genomewide admixture map for Lat
ino populations^len#Am J Hum Genet#20070000#2007#80#1024-1036#20110400#705.htm#0
002-9297#Am J Hum Genet##
00664000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100025000960100
02000121010001900141010001800160010001500178810000600193012004500199030001500244
06500090025906400050026803100030027301400080027686500090028400200080029303500100
0301801001500311#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#156#23#ar
ticle#27#23#^rND^sAlves-Silva^nJ#^rND^sda^nSilva Santos M#^rND^sGuimaraes^nPE#^r
ND^sFerreira^nAC#^rND^sBandelt^nHJ#^rND^sPena^nSD#et al#The ancestry of Brazilia
n mtDNA lineages^len#Am J Hum Genet#20000000#2000#67#444-461#20110400#705.htm#00
02-9297#Am J Hum Genet##
00533000000000241000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720160020000750160018000950180
13100113066000500244062001100249065000900260064000500269865000900274002000800283
#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#157#24#article#27#24#^rND
^sTavassoli^nFA#^rND^sDevillee^nP#World Health Organization. Classification of t
umour. Pathology and genetics of tumours of the breast and female genital organs
^len#Lyon#IARC Press#20030000#2003#20110400#705.htm##
00594000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750120130000920300
02700222065000900249064000500258031000300263014000800266865000900274002000800283
035001000291801002700301#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#1
58#25#article#27#25#^rND^sPersson^nI#Estrogens in the causation of breast, endom
etrial and ovarian cancers - evidence and hypotheses from epidemiological findin
gs^len#J Steroid Biochem Mol Biol#20000000#2000#74#357-364#20110400#705.htm#0960
-0760#J Steroid Biochem Mol Biol##
00719000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100014000950100
01900109010001700128010001600145010001700161810000600178012007700184030003300261
06500090029406400050030303100030030801400100031186500090032100200080033003500100
0338801003300348#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#159#26#ar
ticle#27#26#^rND^sDicioccio^nRA#^rND^sSong^nH#^rND^sWaterfall^nC#^rND^sKimura^nM
T#^rND^sNagase^nH#^rND^sMcGuire^nV#et al#STK15 polymorphisms and association wit
h risk of invasive ovarian cancer^len#Cancer Epidemiol Biomarkers Prev#20040000#
2004#13#1589-1594#20110400#705.htm#1055-9965#Cancer Epidemiol Biomarkers Prev##
00669000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100022000940100
01800116010001600134010001600150010002300166810000600189012005900195030001200254
06500090026606400050027503100040028001400080028486500090029200200080030103500100
0309801001200319#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\705.htm#S#c#160#27#ar
ticle#27#27#^rND^sTchatchou^nS#^rND^sWirtenberger^nM#^rND^sHemminki^nK#^rND^sSut
ter^nC#^rND^sMeindl^nA#^rND^sWappenschmidt^nB#et al#Aurora kinases A and B and f
amilial breast cancer risk^len#Cancer Lett#20070000#2007#247#266-272#20110400#70
5.htm#0096-3917#Cancer Lett##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#o#1#1#article#1#201
10411#094558#712.htm#204##
04190000000000841000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120100001780100023002780100029003010100024003300100029003540100022003830100
02400405010002500429010002600454010003400480010002200514010003500536010002300571
01000260059401000340062001000260065401000280068001000290070801000300073701000240
07670100024007910100024008150700106008390700182009450700110011270700109012370700
09401346070014601440083154901586085000803135085002303143085002303166085002703189
08500210321608500190323711700060325607200030326211200090326511100160327411400090
3290113001703299891002403316002000803340#v44n4#V:\SciELO\serial\bjmbr\v44n4\mark
up\712.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#15#BJMBR470#FAPESP#Braz 
J Med Biol Res#44#4#20110400#^f366^l373#0100-879X#20110218#Psychopharmacotherapy
 of panic disorder: 8-week randomized trial with clonazepam and paroxetine^len#^
rND^1A01^nA.E.^sNardi#^rND^1A01 A03^nA.M.^sValença#^rND^1A01^nR.C.^sFreire#^rND^
1A01^nM.D.^sMochcovitch#^rND^1A01^nR.^sAmrein#^rND^1A01^nA.^sSardinha#^rND^1A01^
nM.N.^sLevitan#^rND^1A01^nI.^sNascimento#^rND^1A01 A04^nV.L.^sde-Melo-Neto#^rND^
1A01^nA.L.^sKing#^rND^1A01 A03^nA.C.^sde O. e Silva#^rND^1A01^nA.B.^sVeras#^rND^
1A01 A02^nG.P.^sDias#^rND^1A01 A05^nG.L.^sSoares-Filho#^rND^1A01^nR.T.^sda Costa
#^rND^1A01^nM.A.^sMezzasalma#^rND^1A01^nM.R.^sde Carvalho#^rND^1A01^nA.C.^sde Ce
rqueira#^rND^1A06^nJ.E.^sHallak#^rND^1A06^nJ.A.^sCrippa#^rND^1A01^nM.^sVersiani#
Universidade Federal do Rio de Janeiro^iA01^1Instituto de Psiquiatria^2Laboratór
io de Pânico e Respiração#Universidade Federal do Rio de Janeiro^iA02^1Instituto
 Nacional de Ciência e Tecnologia Translacional em Medicina^2Laboratório de Neur
obiologia da Retina^cRio de Janeiro^sRJ^pBrasil#Universidade Federal Fluminense^
iA03^1Faculdade de Medicina^2Departamento de Psiquiatria^cNiterói^sRJ^pBrasil#Un
iversidade Federal de Alagoas^iA04^1Faculdade de Medicina^2Departamento de Psiqu
iatria^cMaceió^sAL^pBrasil#Hospital Pró-Cardíaco^iA05^1Unidade de Interconsulta 
Psiquiátrica^cRio de Janeiro^sRJ^pBrasil#Universidade de São Paulo^iA06^1Faculda
de de Medicina de Ribeirão Preto^2Departamento de Neurociência e Comportamento^c
Ribeirão Preto^sSP^pBrasil#^len^aThe objective of the present randomized, open-l
abel, naturalistic 8-week study was to compare the efficacy and safety of treatm
ent with clonazepam (N = 63) and paroxetine (N = 57) in patients with panic diso
rder with or without agoraphobia. Efficacy assessment included number of panic a
ttacks and clinician ratings of the global severity of panic disorders with the 
clinical global impression (CGI) improvement (CGI-I) and CGI severity (CGI-S) sc
ales. Most patients were females (69.8 and 68.4% in the clonazepam and paroxetin
e groups, respectively) and age (mean ± SD) was 35.9 ± 9.6 years for the clonaze
pam group and 33.7 ± 8.8 years for the paroxetine group. Treatment with clonazep
am versus paroxetine resulted in fewer weekly panic attacks at week 4 (0.1 vs 0.
5, respectively; P < 0.01), and greater clinical improvements at week 8 (CGI-I: 
1.6 vs 2.9; P = 0.04). Anxiety severity was significantly reduced with clonazepa
m versus paroxetine at weeks 1 and 2, with no difference in panic disorder sever
ity. Patients treated with clonazepam had fewer adverse events than patients tre
ated with paroxetine (73 vs 95%; P = 0.001). The most common adverse events were
 drowsiness/fatigue (57%), memory/concentration difficulties (24%), and sexual d
ysfunction (11%) in the clonazepam group and drowsiness/fatigue (81%), sexual dy
sfunction (70%), and nausea/vomiting (61%) in the paroxetine group. This natural
istic study confirms the efficacy and tolerability of clonazepam and paroxetine 
in the acute treatment of patients with panic disorder.#^dnd^i1#^tm^len^kParoxet
ine^i1#^tm^len^kClonazepam^i1#^tm^len^kPanic disorder^i1#^tm^len^kEfficacy^i1#^t
m^len^kSafety^i1#other#40#20100816#August 16, 2010#20110203#February 3, 2011#S01
00-879X2011007500020#712.htm##
04206000000000829000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120114001780100023002920100029003150100024003440100029003680100022003970100
02400419010002500443010002600468010003400494010002200528010003500550010002300585
01000260060801000340063401000260066801000280069401000290072201000300075101000240
07810100024008050100024008290700106008530700182009590700110011410700109012510700
09401360070014601454083157301600085000803173085002303181085002303204085002703227
08500210325408500190327511700060329407200030330011200090330311100230331211400090
3335113002403344002000803368#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S
#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#15#BJMBR470#FAPESP#Braz J Med Biol R
es#44#4#20110400#^f366^l373#0100-879X#20110218#<b>Psychopharmacotherapy of panic
 disorder</b>: <b>8-week randomized trial with clonazepam and paroxetine</b>^len
#^rND^1A01^nA.E.^sNardi#^rND^1A01 A03^nA.M.^sValença#^rND^1A01^nR.C.^sFreire#^rN
D^1A01^nM.D.^sMochcovitch#^rND^1A01^nR.^sAmrein#^rND^1A01^nA.^sSardinha#^rND^1A0
1^nM.N.^sLevitan#^rND^1A01^nI.^sNascimento#^rND^1A01 A04^nV.L.^sde-Melo-Neto#^rN
D^1A01^nA.L.^sKing#^rND^1A01 A03^nA.C.^sde O. e Silva#^rND^1A01^nA.B.^sVeras#^rN
D^1A01 A02^nG.P.^sDias#^rND^1A01 A05^nG.L.^sSoares-Filho#^rND^1A01^nR.T.^sda Cos
ta#^rND^1A01^nM.A.^sMezzasalma#^rND^1A01^nM.R.^sde Carvalho#^rND^1A01^nA.C.^sde 
Cerqueira#^rND^1A06^nJ.E.^sHallak#^rND^1A06^nJ.A.^sCrippa#^rND^1A01^nM.^sVersian
i#Universidade Federal do Rio de Janeiro^iA01^1Instituto de Psiquiatria^2Laborat
ório de Pânico e Respiração#Universidade Federal do Rio de Janeiro^iA02^1Institu
to Nacional de Ciência e Tecnologia Translacional em Medicina^2Laboratório de Ne
urobiologia da Retina^cRio de Janeiro^sRJ^pBrasil#Universidade Federal Fluminens
e^iA03^1Faculdade de Medicina^2Departamento de Psiquiatria^cNiterói^sRJ^pBrasil#
Universidade Federal de Alagoas^iA04^1Faculdade de Medicina^2Departamento de Psi
quiatria^cMaceió^sAL^pBrasil#Hospital Pró-Cardíaco^iA05^1Unidade de Interconsult
a Psiquiátrica^cRio de Janeiro^sRJ^pBrasil#Universidade de São Paulo^iA06^1Facul
dade de Medicina de Ribeirão Preto^2Departamento de Neurociência e Comportamento
^cRibeirão Preto^sSP^pBrasil#^len^aThe objective of the present randomized, open
-label, naturalistic 8-week study was to compare the efficacy and safety of trea
tment with clonazepam (N = 63) and paroxetine (N = 57) in patients with panic di
sorder with or without agoraphobia. Efficacy assessment included number of panic
 attacks and clinician ratings of the global severity of panic disorders with th
e clinical global impression (CGI) improvement (CGI-I) and CGI severity (CGI-S) 
scales. Most patients were females (69.8 and 68.4% in the clonazepam and paroxet
ine groups, respectively) and age (mean ± SD) was 35.9 ± 9.6 years for the clona
zepam group and 33.7 ± 8.8 years for the paroxetine group. Treatment with clonaz
epam versus paroxetine resulted in fewer weekly panic attacks at week 4 (0.1 <i>
vs</i> 0.5, respectively; P &lt; 0.01), and greater clinical improvements at wee
k 8 (CGI-I: 1.6 <i>vs</i> 2.9; P = 0.04). Anxiety severity was significantly red
uced with clonazepam versus paroxetine at weeks 1 and 2, with no difference in p
anic disorder severity. Patients treated with clonazepam had fewer adverse event
s than patients treated with paroxetine (73 <i>vs</i> 95%; P = 0.001). The most 
common adverse events were drowsiness/fatigue (57%), memory/concentration diffic
ulties (24%), and sexual dysfunction (11%) in the clonazepam group and drowsines
s/fatigue (81%), sexual dysfunction (70%), and nausea/vomiting (61%) in the paro
xetine group. This naturalistic study confirms the efficacy and tolerability of 
clonazepam and paroxetine in the acute treatment of patients with panic disorder
.#^dnd^i1#^tm^len^kParoxetine^i1#^tm^len^kClonazepam^i1#^tm^len^kPanic disorder^
i1#^tm^len^kEfficacy^i1#^tm^len^kSafety^i1#other#40#20100816#<i>August 16, 2010<
/i>#20110203#<i>February 3, 2011</i>#712.htm##
04376000000000853000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762240009001860120100001950100023002950100029003180100024003470100029003710100
02100400010002300421010002500444010002500469010003400494010002200528010003500550
01000230058501000260060801000340063401000260066801000280069401000290072201000300
07510100024007810100024008050100023008290700136008520700184009880700112011720700
11101284070009601395070014801491083160501639085000803244085002303252085002303275
08500270329808500210332508500190334611700060336507200030337111200090337411100160
3383114000903399113001703408002000803425008008903433#v44n4#V:\SciELO\serial\bjmb
r\v44n4\markup\712.htm#S#l#4#1#article#1#^mApr.^a2011#oa#en#bjmbr#1#3.1#ilus#tab
#15#BJMBR470#FAPESP#Braz. j. med. biol. res#44#4#20110400#^f366^l373#0100-879X#2
0110218#Psychopharmacotherapy of panic disorder: 8-week randomized trial with cl
onazepam and paroxetine^len#^rND^1A01^nA. E^sNardi#^rND^1A01 A03^nA. M^sValença#
^rND^1A01^nR. C^sFreire#^rND^1A01^nM. D^sMochcovitch#^rND^1A01^nR^sAmrein#^rND^1
A01^nA^sSardinha#^rND^1A01^nM. N^sLevitan#^rND^1A01^nI^sNascimento#^rND^1A01 A04
^nV. L^sde-Melo-Neto#^rND^1A01^nA. L^sKing#^rND^1A01 A03^nA. C^sde O. e Silva#^r
ND^1A01^nA. B^sVeras#^rND^1A01 A02^nG. P^sDias#^rND^1A01 A05^nG. L^sSoares-Filho
#^rND^1A01^nR. T^sda Costa#^rND^1A01^nM. A^sMezzasalma#^rND^1A01^nM. R^sde Carva
lho#^rND^1A01^nA. C^sde Cerqueira#^rND^1A06^nJ. E^sHallak#^rND^1A06^nJ. A^sCripp
a#^rND^1A01^nM^sVersiani#^iA01^1Universidade Federal do Rio de Janeiro^2Institut
o de Psiquiatria^3Laboratório de Pânico e Respiração^cRio de Janeiro^sRJ^pBrasil
#^iA02^1Universidade Federal do Rio de Janeiro^2Instituto Nacional de Ciência e 
Tecnologia Translacional em Medicina^3Laboratório de Neurobiologia da Retina^cRi
o de Janeiro^sRJ^pBrasil#^iA03^1Universidade Federal Fluminense^2Faculdade de Me
dicina^3Departamento de Psiquiatria^cNiterói^sRJ^pBrasil#^iA04^1Universidade Fed
eral de Alagoas^2Faculdade de Medicina^3Departamento de Psiquiatria^cMaceió^sAL^
pBrasil#^iA05^1Hospital Pró-Cardíaco^2Unidade de Interconsulta Psiquiátrica^cRio
 de Janeiro^sRJ^pBrasil#^iA06^1Universidade de São Paulo^2Faculdade de Medicina 
de Ribeirão Preto^3Departamento de Neurociência e Comportamento^cRibeirão Preto^
sSP^pBrasil#^len^aThe objective of the present randomized, open-label, naturalis
tic 8-week study was to compare the efficacy and safety of treatment with clonaz
epam (N = 63) and paroxetine (N = 57) in patients with panic disorder with or wi
thout agoraphobia. Efficacy assessment included number of panic attacks and clin
ician ratings of the global severity of panic disorders with the clinical global
 impression (CGI) improvement (CGI-I) and CGI severity (CGI-S) scales. Most pati
ents were females (69.8 and 68.4 percent in the clonazepam and paroxetine groups
, respectively) and age (mean ± SD) was 35.9 ± 9.6 years for the clonazepam grou
p and 33.7 ± 8.8 years for the paroxetine group. Treatment with clonazepam versu
s paroxetine resulted in fewer weekly panic attacks at week 4 (0.1 vs 0.5, respe
ctively; P < 0.01), and greater clinical improvements at week 8 (CGI-I: 1.6 vs 2
.9; P = 0.04). Anxiety severity was significantly reduced with clonazepam versus
 paroxetine at weeks 1 and 2, with no difference in panic disorder severity. Pat
ients treated with clonazepam had fewer adverse events than patients treated wit
h paroxetine (73 vs 95 percent; P = 0.001). The most common adverse events were 
drowsiness/fatigue (57 percent), memory/concentration difficulties (24 percent),
 and sexual dysfunction (11 percent) in the clonazepam group and drowsiness/fati
gue (81 percent), sexual dysfunction (70 percent), and nausea/vomiting (61 perce
nt) in the paroxetine group. This naturalistic study confirms the efficacy and t
olerability of clonazepam and paroxetine in the acute treatment of patients with
 panic disorder.#^dnd^i1#^tm^len^kParoxetine^i1#^tm^len^kClonazepam^i1#^tm^len^k
Panic disorder^i1#^tm^len^kEfficacy^i1#^tm^len^kSafety^i1#other#40#20100816#Augu
st 16, 2010#20110203#February 3, 2011#712.htm#Internet^ihttp://www.scielo.br/sci
elo.php?script=sci_arttext&pid=S0100-879X2011000400015##
00372000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014800070002000800218#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#5#1#article#160#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 366-373  </B></font></P>      ^cY#712.htm##
00424000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704020000070002000800270#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#6#2#article#160#<p ALIGN="LEFT"><font siz
e="5" face="Arial"><span lang="EN"><strong>Psychopharmacotherapy of panic disord
er: 8-week randomized trial with clonazepam and paroxetine</strong></span></font
></p>      ^cY#712.htm##
01460000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704123600070002000801306#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#7#3#article#160#<p ALIGN="LEFT"><font fac
e="Arial"><span lang="EN"><span lang="EN"><font face="Arial, Helvetica, sans-ser
if"><sup><span lang="EN"><font face="Arial, Helvetica, sans-serif"><b><a href="#
Correspondence"><img src="/img/revistas/bjmbr/v44n4/recor.gif" border="0"></a></
b> <a href="mailto:antonionardi@terra.com.br"><img src="/img/revistas/bjmbr/v44n
4/email-ca.gif" border="0"></a></font></span></sup></font></span> A.E. Nardi<sup
>1</sup>, A.M. Valen&ccedil;a<sup>1,3</sup>, R.C. Freire<sup>1</sup>, M.D. Mochc
ovitch<sup>1</sup>, R. Amrein<sup>1</sup>, </span></font><font face="Arial"><spa
n lang="EN">A.&nbsp;Sardinha<sup>1</sup>, M.N. Levitan<sup>1</sup>, I. Nasciment
o<sup>1</sup>, V.L. de-Melo-Neto<sup>1,4</sup>, A.L. King<sup>1</sup>, </span></
font><font face="Arial"><span lang="EN">A.C. de O. e Silva<sup>1,3</sup>, A.B. V
eras<sup>1</sup>, G.P. Dias<sup>1,2</sup>, G.L. Soares-Filho<sup>1,5</sup>,</spa
n></font><font face="Arial"><span lang="EN"> R.T. da Costa<sup>1</sup>, M.A. Mez
zasalma<sup>1</sup>, M.R. de Carvalho<sup>1</sup>,&nbsp; A.C.&nbsp;de&nbsp;Cerqu
eira<sup>1</sup>, </span></font><font face="Arial"><span lang="EN">J.E. Hallak<s
up>6</sup>, J.A. Crippa<sup>6</sup> and M. Versiani<sup>1</sup></span></font></p
>      ^cY#712.htm##
00771000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704054700070002000800617#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#8#4#article#160#<p ALIGN="LEFT"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Laborat&oacute;rio 
de P&acirc;nico e Respira&ccedil;&atilde;o, Instituto de Psiquiatria, <sup>2</su
p></font><font FACE="Arial, Helvetica, sans-serif" COLOR="#111111">Laborat&oacut
e;rio de Neurobiologia da Retina, </font></span><font face="Arial"><span lang="E
N">Instituto Nacional de Ci&ecirc;ncia e Tecnologia Translacional em Medicina, <
/span></font><font face="Arial"><span lang="EN">Universidade Federal do Rio de J
aneiro, Rio de Janeiro, RJ, Brasil    ^cY#712.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704018800070002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#9#5#article#160#<br>    </span></font><fo
nt face="Arial"><span lang="EN"><sup>3</sup>Departamento de Psiquiatria, Faculda
de de Medicina, Universidade Federal Fluminense, Niter&oacute;i, RJ, Brasil    ^
cY#712.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#10#6#article#160#<br>    </span></font><f
ont face="Arial"><span lang="EN"><sup>4</sup>Departamento de Psiquiatria, Faculd
ade de Medicina, Universidade Federal de Alagoas, Macei&oacute;, AL, Brasil    ^
cY#712.htm##
00411000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018600071002000800257#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#11#7#article#160#<br>    </span></font><f
ont face="Arial"><span lang="EN"><sup>5</sup>Unidade de Interconsulta Psiqui&aac
ute;trica, Hospital Pr&oacute;-Card&iacute;aco, Rio de Janeiro, RJ, Brasil    ^c
Y#712.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704031100071002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#12#8#article#160#<br>  </span></font><fon
t face="Arial"><span lang="EN"><sup>6</sup>Departamento de Neuroci&ecirc;ncia e 
Comportamento, Faculdade de Medicina de Ribeir&atilde;o Preto, </span></font><fo
nt face="Arial"><span lang="EN">Universidade de S&atilde;o Paulo, Ribeir&atilde;
o Preto, SP, Brasil</span></font></p>      ^cY#712.htm##
00415000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704019000071002000800261#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#13#9#article#160#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#712.htm##
00413000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018700072002000800259#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#14#10#article#160#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    
^cY#712.htm##
00413000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018700072002000800259#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#15#11#article#160#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    
^cY#712.htm##
00398000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017200072002000800244#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#16#12#article#160#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#712.htm##
00407000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018100072002000800253#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#17#13#article#160#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#71
2.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#18#14#article#160#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#712.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#19#15#article#160#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#712.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#20#16#article#160#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#712.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#21#17#article#160#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#712.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#22#18#article#160#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#712.htm##
01892000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704166600072002000801738#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#23#19#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The objective of the present randomized, open-label,
 naturalistic 8-week study was to compare the efficacy and safety of treatment w
ith clonazepam (N = 63) and paroxetine (N = 57) in patients with panic disorder 
with or without agoraphobia. Efficacy assessment included number of panic attack
s and clinician ratings of the global severity of panic disorders with the clini
cal global impression (CGI) improvement (CGI-I) and CGI severity (CGI-S) scales.
 Most patients were females (69.8 and 68.4% in the clonazepam and paroxetine gro
ups, respectively) and age (mean &plusmn; SD) was 35.9 &plusmn; 9.6 years for th
e clonazepam group and 33.7 &plusmn; 8.8 years for the paroxetine group. Treatme
nt with clonazepam versus paroxetine resulted in fewer weekly panic attacks at w
eek 4 (0.1 <i>vs</i> 0.5, respectively; P &lt; 0.01), and greater clinical impro
vements at week 8 (CGI-I: 1.6 <i>vs</i> 2.9; P = 0.04). Anxiety severity was sig
nificantly reduced with clonazepam versus paroxetine at weeks 1 and 2, with no d
ifference in panic disorder severity. Patients treated with clonazepam had fewer
 adverse events than patients treated with paroxetine (73 <i>vs</i> 95%; P = 0.0
01). The most common adverse events were drowsiness/fatigue (57%), memory/concen
tration difficulties (24%), and sexual dysfunction (11%) in the clonazepam group
 and drowsiness/fatigue (81%), sexual dysfunction (70%), and nausea/vomiting (61
%) in the paroxetine group. This naturalistic study confirms the efficacy and to
lerability of clonazepam and paroxetine in the acute treatment of patients with 
panic disorder.</span></font></p>      ^cY#712.htm##
00396000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017000072002000800242#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#24#20#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Key words: Paroxetine; Clonazepam; Panic disorder; E
fficacy; Safety</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#712.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#25#21#article#160#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#712.htm##
00967000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704074100072002000800813#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#26#22#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Panic disorder is a chronic debilitating illness cha
racterized by severe, recurrent, spontaneous panic attacks with autonomic sympto
ms, with a lifetime prevalence rate of 5% (1). Panic disorder, both with and wit
hout agoraphobia, can be profoundly physically and emotionally disabling for aff
ected individuals, and is associated with substantial costs to society (2-5). Th
e disease has several adverse psychological consequences, including poor general
 medical and emotional health, increased risk of alcohol abuse, marital and occu
pational dysfunction, greater use of medication, increased emergency room use, w
ith up to 20% of sufferers attempting suicide (2).</span></font></p>      ^cY#71
2.htm##
00952000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704072600072002000800798#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#27#23#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Pharmacotherapy is effective in the treatment of pan
ic disorder compared with placebo (6-8); however, it is problematic for several 
reasons. Despite pharmacotherapy, 20-40% of patients with panic disorder in clin
ical trials remain symptomatic and this proportion may be higher in the naturali
stic setting (9). In addition, the subtype of panic disorder (respiratory or non
-respiratory) can influence the response to pharmacotherapy and affect outcomes 
(10-12). Furthermore, discontinuation of pharmacotherapy can lead to withdrawal 
symptoms and a significant number of panic disorder patients suffer relapse flow
ing cessation of treatment (13,14).</span></font></p>      ^cY#712.htm##
01131000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704090500072002000800977#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#28#24#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Benzodiazepines (6,8,14) and selective serotonin reu
ptake inhibitors (SSRIs) (8,15) are two drug classes with proven efficacy in tre
ating panic disorder. In a meta-analysis of 53 studies including 7725 patients w
ith panic disorder who received pharmacotherapeutic treatment, the benzodiazepin
es and SSRIs showed comparable efficacy (7). SSRIs have been prescribed for pani
c disorder with or without agoraphobia for over a decade and are recommended as 
first-line treatment for panic disorder on the basis of their favorable safety p
rofile (16). The efficacy and safety profile of the SSRI paroxetine has been dem
onstrated in the treatment of panic disorder in a number of randomized controlle
d trials (17-19). However, the benzodiazepines remain one of the most commonly p
rescribed therapeutic options for panic disorder (20).</span></font></p>      ^c
Y#712.htm##
01031000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704080500072002000800877#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#29#25#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Benzodiazepines are rapidly acting, effective, well 
tolerated and suitable as monotherapy (11,21) or combination therapy (22). Clona
zepam also affects serotonin transmission (23,24) and is the only benzodiazepine
 on the market for which additional serotonergic activity has been shown, an act
ion that may contribute to its ansiolytic effects (23-25). Benzodiazepines and S
SRIs are associated with different adverse event (AE) profiles (6,14). When pati
ents with panic disorder cannot tolerate the AEs associated with a particular dr
ug class, switching to a different drug class can improve the safety outcomes of
 panic disorder (6,26). Accordingly, which drug to prescribe depends largely on 
considerations of AE profiles (6).</span></font></p>      ^cY#712.htm##
01079000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704085300072002000800925#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#30#26#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Although SSRIs and benzodiazepines have been shown t
o have comparable efficacy in the treatment of panic disorder in a meta-analysis
 (7), there have been few direct comparisons in clinical trials. Double-blind, p
lacebo-controlled studies have demonstrated the efficacy and safety of clonazepa
m and of paroxetine individually, but direct comparisons between these drugs hav
e not been made. Therefore, the objective of this study was to compare the effic
acy and safety of 8 weeks of treatment with clonazepam and paroxetine in patient
s with panic disorder in a naturalistic setting, using a randomized, open-label 
study design. Although the open design has its limitations, it permits careful i
ndividual dose adaptation as is done in clinical practice.</span></font></p>  <H
R ALIGN=LEFT SIZE=2>      ^cY#712.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#31#27#article#160#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#712.htm##
00324000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009800072002000800170#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#32#28#article#160#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Study design</span></font></b></p>      ^cY#712.h
tm##
00537000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031100072002000800383#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#33#29#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The study protocol was approved by the Ethics Commit
tee of the Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro, Rio
 de Janeiro, RJ, Brazil. Written informed consent was obtained from all patients
 prior to inclusion.</span></font></p>      ^cY#712.htm##
01657000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704143100072002000801503#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#34#30#article#160#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">This was a naturalistically d
esigned, prospective, randomized, open-label study. For patients on prior anti-p
anic medication a 1-week wash-out period was employed, except for those taking f
luoxetine for whom a 6-week washout period was used. Patients were initially ran
domized to receive either 0.5-2 clonazepam or 10-40 mg/day paroxetine, taken aft
er dinner. The planned starting dose was 0.5-1 mg/day clonazepam and 10 mg/day p
aroxetine. Maintenance doses of 2 mg clonazepam and 40 mg paroxetine were planne
d to be achieved at the end of the second treatment week, but patients were stil
l kept in the study if these doses were not achieved due to AEs. For every 4 pat
ients entering the trial, two were randomly assigned to clonazepam and two to pa
roxetine. Neither the patient nor the treating physician had any influence on th
e drug taken. Treatment was given for 8 weeks and dose adjustment was permitted 
according to the patient&rsquo;s symptoms. Clonazepam and paroxetine were chosen
 for comparison since both are approved for the treatment of panic disorder in B
razil. Generic and branded versions of both drugs are available in Brazil and co
st is generally low, which makes their relative efficacy and safety an important
 factor i</font><font FACE="Arial, Helvetica, sans-serif" COLOR="#06082c">n the 
choice of treatment.</font></span></p>      ^cY#712.htm##
00320000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009400072002000800166#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#35#31#article#160#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Patients</span></font></b></p>      ^cY#712.htm##
01120000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704089400072002000800966#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#36#32#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Patients were evaluated in the Panic and Respiration
 Laboratory of the Institute of Psychiatry, Rio de Janeiro, Brazil. Participants
 were male and female patients aged 18-60 years who met the Diagnostic and Stati
stical Manual of Mental Disorders, Fourth Edition, text revision criteria for pa
nic disorder, with or without agoraphobia, as determined by a structured clinica
l interview. Patients were also required to have at least two panic attacks in t
he week preceding their inclusion in the study. Patients were excluded if they w
ere unable or unwilling to provide written informed consent, did not complete al
l the evaluations before study initiation, or if they were diagnosed with comorb
idities that could affect clinical evaluation including drug abuse, neurological
 disorders, or severe personality disorder.</span></font></p>      ^cY#712.htm##
00328000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010200072002000800174#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#37#33#article#160#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Outcome measures</span></font></b></p>      ^cY#7
12.htm##
01055000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704082900072002000800901#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#38#34#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The rating was performed by independent examiners wh
o were blind to the drugs under study. Demographic and clinical features at base
line were compared between groups. Efficacy parameters were recorded at baseline
 and at weeks 1, 2, 4, and 8. Efficacy assessments included the number of panic 
attack and clinician ratings of the global severity of panic disorder using the 
clinical global impression (CGI) and severity (CGI-S) scale. Scores ranged from 
1 (not at all ill) to 7 (extremely ill). Global change from the baseline assessm
ent was also rated with the CGI improvement (CGI-I) scale. Scores ranged from 1 
(very much improved) to 7 (very much worse). Severity of anxiety was assessed us
ing the Hamilton Anxiety Rating Scale (HAMA) 14-item test.</span></font></p>    
  ^cY#712.htm##
01139000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704091300072002000800985#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#39#35#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Regarding safety parameters, a physical examination 
was performed on day 1 of treatment and at the end of the treatment period or at
 study discontinuation. Blood pressure and heart rate were measured at every vis
it. A 12-lead electrocardiogram and laboratory tests (i.e., hematology, chemistr
y, urinalysis) were obtained at baseline and at week 8. AEs were recorded at bas
eline and at each defined time during treatment by independent examiners who wer
e blind to the study drugs. AE data were collected by asking about spontaneous c
omplaints and by a subsequent systematic inquiry using a list of AEs that were c
ombined with the Benzodiazepine Discontinuation Symptom Scale (27). The severity
 of each AE was also recorded; multiple episodes of the same AE were counted onl
y once, but they were rated at the greatest level of severity.</span></font></p>
      ^cY#712.htm##
00332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010600072002000800178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#40#36#article#160#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Statistical analysis</span></font></b></p>      ^
cY#712.htm##
00850000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704062400072002000800696#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#41#37#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">All patients who took at least one dose were include
d in the final analysis. Patient responses were analyzed based on an intent to t
reat, last value carried forward approach. Appropriate parametric and non-parame
tric tests were employed; the Student <i>t</i>-test for independent samples were
 used for HAMA and for the number of panic attacks. The Cochran-Armitage &chi;<s
up>2</sup> test for linear trends was employed for CGI-I and CGI-S. The statisti
cal analyses were two-tailed and 5% was considered to be significant.</span></fo
nt></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#712.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#42#38#article#160#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#712.htm##
00319000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009300072002000800165#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#43#39#article#160#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Overall</span></font></b></p>      ^cY#712.htm##
01969000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704174300072002000801815#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#44#40#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">A total of 120 patients met the inclusion criteria; 
63 were randomized to receive clonazepam and 57 to receive paroxetine. One patie
nt in the clonazepam group and seven patients in the paroxetine group withdrew c
onsent before the first drug intake. These patients had been included in the ran
domization process but were not considered in the total number of patients. Pati
ent demographics and clinical characteristics were similar for the two groups, w
ith no statistically significant differences between groups for any of the param
eters studied (<a href="#Tab1">Table 1</a>). Most patients were females (69%), w
ere educated at least to high school level (63%), and were employed (66%). Most 
patients included had panic disorder plus agoraphobia (93%) and had not received
 prior therapy (63%). The high proportion of patients suffering from agoraphobia
 was due to patients with a long history of panic disorder and agoraphobia often
 being referred to our institute. Of 44 patients with prior therapy, 1 patient i
n the paroxetine group had failed treatment previously with an SSRI and no patie
nts in the clonazepam group had failed with a benzodiazepine. The mean (&plusmn;
&nbsp;SD) initial dose was 0.97 &plusmn; 0.1 mg/day in the clonazepam group and 
10.5&nbsp;&plusmn; 2.3 mg/day in the paroxetine group. At week 8, the mean dose 
was 1.92 &plusmn; 0.3 mg/day in the clonazepam group and 38.4 &plusmn; 3.7 mg/da
y in the paroxetine group. Two patients who received paroxetine and 1 patient wh
o received clonazepam withdrew from the study at the end of the first month as a
 result of poor efficacy; all other patients participated until the end of the 8
-week study.</span></font></p>      ^cY#712.htm##
00697000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704047100072002000800543#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#45#41#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">A 1-week wash-out period was included to remove prio
r anti-panic medication. Less than 25% of the patients in each group were taking
 anti-panic medication one week before staring the trial (24.6% in the paroxetin
e group and 12.7% in the clonazepam group). There was no significant difference 
in the number of panic attacks, CGI, or AEs reported by these patients at screen
ing and at baseline.</span></font></p>      ^cY#712.htm##
00320000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009400072002000800166#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#46#42#article#160#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Efficacy</span></font></b></p>      ^cY#712.htm##
01322000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704109600072002000801168#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#47#43#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">After initiation of drug treatment there was a drama
tic decrease in the number of weekly panic attacks in both treatment groups, whi
ch persisted over the course of the treatment period (<a href="#Fig1">Figure 1</
a>). At week 4, patients in the clonazepam group had significantly fewer panic a
ttacks (0.1 &plusmn; 0.5 per week) than those in the paroxetine group (0.5 &plus
mn; 0.9 per week; P<i>&nbsp;</i>&lt;&nbsp;0.01; <a href="#Tab2">Table 2</a>). At
 week 8, patients experienced similarly low numbers of panic attacks with clonaz
epam and paroxetine (0.2 &plusmn; 0.6 <i>vs</i> 0.2 &plusmn; 0.4 per week, respe
ctively; P = not significant). The two groups showed a similar average reduction
 of panic attacks over the first 8 weeks of treatment (<a href="#Fig1">Figure 1<
/a>). The proportion of patients who were panic free following treatment is pres
ented in <a href="#Fig2">Figure 2</a>. At week 4, more patients who received clo
nazepam were free of panic attacks (92.06 <i>vs</i> 70.16%, respectively; P = 0.
002).</span></font></p>      ^cY#712.htm##
01876000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704165000072002000801722#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#48#44#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Clonazepam had a faster onset of action than paroxet
ine. When CGI-I was assessed, patients treated with clonazepam had significantly
 greater improvements than those treated with paroxetine at week 1 (2.2 &plusmn;
 0.8 <i>vs</i> 2.7 &plusmn; 1.0; P = 0.003) and week 2 (2.2 &plusmn; 1.0 <i>vs</
i> 2.7&nbsp;&plusmn;&nbsp;1.2; P = 0.006; <a href="#Tab2">Table 2</a>). CGI-I wa
s further reduced over the course of the study, with values of 1.6 &plusmn; 1.0 
for clonazepam and 2.9 &plusmn; 1.2 for paroxetine (P = 0.04) at week 8. At base
line, the severity of panic disorder as measured by CGI-S was borderline signifi
cantly higher in patients randomized to receive clonazepam versus paroxetine (4.
5 &plusmn; 0.5 <i>vs</i> 4.3&nbsp;&plusmn;&nbsp;0.5; P = 0.02; <a href="#Tab2">T
able 2</a>). After 4 weeks of treatment, there was no significant difference bet
ween groups; CGI-S was reduced to 2.0 &plusmn; 1.0 in the clonazepam group and t
o 2.2 &plusmn; 1.3 in the paroxetine group. At week 8, CGI-S was 1.6 &plusmn; 1.
0 in the clonazepam group and 1.9 &plusmn; 1.2 in the paroxetine group (P = not 
significant). In agreement with CGI-I, the severity of anxiety measured by HAMA 
at week 1 was significantly lower in clonazepam-treated patients (10.0 &plusmn; 
3.5) than in paroxetine-treated patients (12.2 &plusmn; 4.2; P = 0.003; <a href=
"#Tab2">Table 2</a>). Significant reductions in the clonazepam group versus the 
paroxetine group were also observed at week 2 (P = 0.03), but not at week 4 or a
t the end of the study (10.5 &plusmn; 3.9 and 10.4 &plusmn; 3.7, respectively).<
/span></font></p>      ^cY#712.htm##
00318000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009200072002000800164#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#49#45#article#160#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Safety</span></font></b></p>      ^cY#712.htm##
00645000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704041900072002000800491#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#50#46#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">No patients withdrew because of AEs. More than 60% o
f patients enrolled in the trial reported AEs at baseline, regardless of the stu
dy group, and these were mainly anxiety, insomnia, headache, shaking/trembling, 
paresthesia, memory/concentration difficulties, nausea/vomiting, sexual dysfunct
ion, and weakness (<a href="#Tab3">Table 3</a>).</span></font></p>      ^cY#712.
htm##
01797000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704157100072002000801643#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#51#47#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Patients treated with clonazepam had significantly f
ewer AEs than patients treated with paroxetine at week 8 (73.0 versus 94.7%, res
pectively; P = 0.001; <a href="#Tab3">Table 3</a>). The most common AEs in the c
lonazepam group were drowsiness/fatigue (57%), memory/concentration difficulties
 (24%), and sexual dysfunction (11%). The vast majority of AEs in clonazepam-tre
ated patients were of mild severity, with moderate severity reported for 6 cases
 of drowsiness/fatigue. The most common AEs in the paroxetine group were drowsin
ess/fatigue (81%), sexual dysfunction (70%), and nausea/vomiting (61%). Although
 most AEs in the paroxetine group were of mild severity, there were several case
s of moderately severe drowsiness/fatigue, sexual dysfunction, nausea/vomiting, 
and appetite/weight change. A severe case of sexual dysfunction was also noted w
ith paroxetine. AEs that occurred significantly more frequently in the paroxetin
e group versus the clonazepam group were drowsiness/fatigue (P = 0.006), sexual 
dysfunction, nausea/vomiting, appetite/weight change, dry mouth, excessive sweat
ing, diarrhea/constipation, and shaking/trembling/tremor (all P &lt; 0.001). The
re were no clinically significant changes in laboratory parameters in either gro
up during the study.</span></font></p>  <HR ALIGN=LEFT SIZE=2>  <table  border="
0">    <tr align="left" valign="top">      <td><a href="/img/revistas/bjmbr/v44n
4/html/712i01.htm"><img src="/img/revistas/bjmbr/v44n4/712i01peq.jpg" border="2"
></a></td>      <td>    ^cY#712.htm##
00528000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704030200072002000800374#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#52#48#article#160#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. 
Number of panic attacks (PA) experienced by patients receiving clonazepam or par
oxetine. *P &lt; 0.05 compared to paroxetine (<i>t</i>-test).</font></span></p> 
     </td>    </tr>  </table>      ^cY#712.htm##
00562000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033600072002000800408#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#53#49#article#160#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/712i02.htm"><img src="/img/r
evistas/bjmbr/v44n4/712i02peq.jpg" border="2"></a></td>      <td>    ^cY#712.htm
##
00526000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704030000072002000800372#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#54#50#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig2"></a>Figure 2. Proportion of patients 
who were free of panic attacks following treatment with clonazepam or paroxetine
. *P &lt; 0.05 compared to paroxetine (Fischer exact test).</span></font></p>   
   </td>    </tr>  </table>      ^cY#712.htm##
00558000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033200072002000800404#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#55#51#article#160#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/712t01.htm"><img src="/img/r
evistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#712.htm##
00422000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019600072002000800268#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#56#52#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Tab1"></a>Table 1. Patient baseline demogra
phics and clinical characteristics.</span></font></p>      </td>    </tr>  </tab
le>      ^cY#712.htm##
00558000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033200072002000800404#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#57#53#article#160#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/712t02.htm"><img src="/img/r
evistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#712.htm##
00433000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020700072002000800279#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#58#54#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Tab2"></a>Table 2. Summary of efficacy vari
ables at baseline and at weeks 1, 2, 4, and 8.</span></font></p>      </td>    <
/tr>  </table>      ^cY#712.htm##
00725000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704049900072002000800571#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#59#55#article#160#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/712t02.htm"><img src="/img/r
evistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td><span lang="EN"><fo
nt face="Arial"><span lang="EN"><a name="Tab3"></a>Table 3. Summary of adverse e
vents (AE) at week 8.</span></font></span></td>    </tr>  </table>      ^cY#712.
htm##
00342000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011600072002000800188#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#60#56#article#160#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (? K JPG file)]</font><
/P>      ^cY#712.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#61#57#article#160#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#712.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#62#58#article#160#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#712.htm##
02148000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704192200072002000801994#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#63#59#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The present investigation confirms earlier studies, 
which have demonstrated the efficacy of clonazepam (11,12,21,28-30) and paroxeti
ne (18,19,31,32) in separate trials in the treatment of panic disorder. The pres
ent study compares clonazepam with paroxetine using a parallel methodology with 
the same team of health providers. There was a small difference in effectiveness
 in favor of clonazepam between the two treatments. As assessed by CGI-I scores,
 clonazepam was associated with significantly greater clinical improvement than 
paroxetine at the end of the 8-week treatment period. Furthermore, clonazepam wa
s associated with a faster response than paroxetine. Although the number of pani
c attacks experienced was similarly reduced in both treatment groups by week 8, 
both CGI-I and HAMA scores were significantly better in clonazepam-treated patie
nts than in paroxetine-treated patients at weeks 1 and 2. The slower onset of ac
tion of paroxetine is consistent with other studies of paroxetine and other SSRI
s, and is often associated with increased agitation and anxiety at the beginning
 of treatment (14,33). Saeki et al. (34) demonstrated that genetic and pharmacok
inetic factors may affect the initial therapeutic response to paroxetine (34). P
lasma concentration of paroxetine, serotonin transporter gene-linked polymorphic
 region (<i>5-HTTLPR</i>) genotype, and co-morbid physical illness were signific
ant factors affecting the initial pharmacotherapeutic effect of paroxetine in Ja
panese patients (34). In contrast to SSRIs, benzodiazepines are associated with 
a rapid onset of action (22,35). An SSRI can take 4-6 weeks to become entirely e
ffective, but a benzodiazepine may be combined with an SSRI at the beginning of 
therapy to overcome this delay, and initial studies have confirmed the suitabili
ty of this approach (16,32,36).</span></font></p>      ^cY#712.htm##
01743000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704151700072002000801589#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#64#60#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">An original methodological feature of this trial was
 the systematic evaluation of AEs prior to as well as during treatment. This all
owed us to differentiate drug-induced AEs from pre-existing drug-independent con
ditions, revealing a completely new picture for some of the reported AEs. Severa
l complaints, typically regarded as AEs, were already frequent before treatment 
and both investigational products were successful not only in reducing the frequ
ency of panic attacks, but also some of the pre-existing panic attack symptoms s
uch as anxiety, paresthesia, insomnia, weakness, headache, and shaking/trembling
. Notably, clonazepam reduced the frequency of nausea/vomiting and memory and co
ncentration difficulties, whereas these events became more frequent under paroxe
tine. Likewise, clonazepam had no effect on preexisting sexual activity, whereas
 paroxetine increased the frequency of sexual dysfunction. Both products were as
sociated with drowsiness and/or fatigue. Whereas paroxetine was associated with 
appetite/weight change, dry mouth, excessive sweating and diarrhea/constipation,
 clonazepam did not have such effects. To summarize, in this short-term investig
ation of safety, almost all patients treated with paroxetine experienced AEs com
pared with three-quarters of patients treated with clonazepam. Furthermore, ther
e were more cases of moderately severe and severe AEs in the paroxetine group ve
rsus the clonazepam group.</span></font></p>      ^cY#712.htm##
01352000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704112600072002000801198#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#65#61#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The AEs reported for clonazepam are typical of those
 expected from a highly potent benzodiazepine, and consistent with the safety pr
ofile of clonazepam observed in other studies (11,22,30). The most frequently re
ported AEs were drowsiness and lapse in memory/concentration. In memory tests, d
elayed recall rather than immediate recall was affected by benzodiazepine treatm
ent, and the effect lasted for a short timeframe after administration (22). The 
AEs observed with paroxetine in the present analysis are consistent with other s
tudies of SSRIs (37). In addition to the drowsiness/fatigue, sexual dysfunction 
and memory impairment that occurred or persisted with both agents, paroxetine tr
eatment was commonly associated with AEs such as nausea/vomiting, dry mouth, exc
essive sweating, diarrhea/constipation and tremor/shaking, which were not experi
enced by any clonazepam-treated patients. In addition, over half of all patients
 who received paroxetine experienced appetite/weight change compared with only o
ne patient treated with clonazepam.</span></font></p>      ^cY#712.htm##
01216000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704099000072002000801062#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#66#62#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">One of the limitations of this study was the open-la
bel design. Although the open design has its limitations, it allows for careful 
individual dose adaptation and was also chosen to permit continuation of the stu
dy with long-term treatment. Our sample also does not permit generalization of t
he results. The trial was conducted at a university research center specialized 
in anxiety and mood disorders. For example, our sample had a high percentage of 
high school or more education, which is different from the general Brazilian pop
ulation. The flexible dose design of the study precludes any dose-response findi
ngs. Patients with panic disorder are especially sensitive to pharmacotherapy at
 the initiation of therapy, and many patients begin on half-doses (14). Clonazep
am was started at 0.5 or 1 mg/day in the present study; however, all patients in
 both groups reached the full dose by 8 weeks of treatment.</span></font></p>   
   ^cY#712.htm##
01844000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704161800072002000801690#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#67#63#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The present acute study cannot address several impor
tant problems that are linked to long-term use of the two drugs. This issue shal
l be addressed in a continuation study lasting 3 years and followed by drug disc
ontinuation. During long-term use, SSRIs may cause weight gain and sexual dysfun
ction, primarily anorgasmia and ejaculatory dysfunction (17,38,39), and benzodia
zepine therapy in panic disorder may lead to abuse or misuse and physical depend
ence, and withdrawal and rebound symptoms when treatment is discontinued (40). P
revious reports indicate a high level of relapse following discontinuation of pa
nic disorder pharmacotherapy (6,13,14). In a study in patients with panic disord
er who received paroxetine for 12 months, 17% of patients experienced one or mor
e panic attacks during the 1-year follow-up period after paroxetine discontinuat
ion (31). The long-term outcomes associated with this study, particularly relaps
e rates, would be of interest. A comparative study of longer duration would also
 prove valuable. Both clonazepam (11) and paroxetine (17,31) have been shown to 
be effective in the treatment of panic disorder over long follow-up periods in s
eparate trials. In a naturalistic 3-year study of 67 patients with panic disorde
r, clonazepam had a sustained therapeutic effect over the entire treatment perio
d (11). Similarly, paroxetine was effective when given over a 2-year period to 5
5 patients with panic disorder, with 0.23 &plusmn; 0.2 panic attacks per week re
corded at the end of the treatment period (31).</span></font></p>      ^cY#712.h
tm##
00621000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704039500072002000800467#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#68#64#article#160#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">To conclude, this naturalistic study confirms the ef
ficacy and tolerability of clonazepam and paroxetine in the acute treatment of p
atients with panic disorder, with greater clinical improvements, faster onset of
 action and a more favorable AE profile observed in clonazepam-treated patients.
</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#712.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#69#65#article#160#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#712.htm##
00420000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704018000074002000800254#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#70#66#article#160#1#<p ALIGN=
"LEFT"><font face="Arial"><span lang="EN">1. Bienvenu OJ. Lifetime prevalence of
 panic disorder is about 5% in the USA. <i>Evid Based Ment Health</i> 2006; 9: 1
14.    ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#71#67#article#160#</span></font></p>     
 ^cY#712.htm##
00429000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704018900074002000800263#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#72#68#article#160#2#<p align=
"LEFT"><font face="Arial"><span lang="EN">2. Hirschfeld RM. Panic disorder: diag
nosis, epidemiology, and clinical course. <i>J Clin Psychiatry</i> 1996; 57 (Sup
pl 10): 3-8.    ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#73#69#article#160#</span></font></p>     
 ^cY#712.htm##
00424000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704018400074002000800258#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#74#70#article#160#3#<p align=
"LEFT"><font face="Arial"><span lang="EN">3. Mendlowicz MV, Stein MB. Quality of
 life in individuals with anxiety disorders. <i>Am J Psychiatry</i> 2000; 157: 6
69-682.    ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#75#71#article#160#</span></font></p>     
 ^cY#712.htm##
00420000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704018000074002000800254#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#76#72#article#160#4#<p align=
"LEFT"><font face="Arial"><span lang="EN">4. Mogotsi M, Kaminer D, Stein DJ. Qua
lity of life in the anxiety disorders. <i>Harv Rev Psychiatry</i> 2000; 8: 273-2
82.    ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#77#73#article#160#</span></font></p>     
 ^cY#712.htm##
00477000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704023700074002000800311#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#78#74#article#160#5#<p align=
"LEFT"><font face="Arial"><span lang="EN">5. Waghorn G, Chant D, White P, Whitef
ord H. Disability, employment and work performance among people with ICD-10 anxi
ety disorders. <i>Aust N Z J Psychiatry</i> 2005; 39: 55-66.    ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#79#75#article#160#</span></font></p>     
 ^cY#712.htm##
00408000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704016800074002000800242#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#80#76#article#160#6#<p align=
"LEFT"><font face="Arial"><span lang="EN">6. Marchesi C. Pharmacological managem
ent of panic disorder. <i>Neuropsychiatr Dis Treat</i> 2008; 4: 93-106.    ^cY#7
12.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#81#77#article#160#</span></font></p>     
 ^cY#712.htm##
00461000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704022100074002000800295#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#82#78#article#160#7#<p align=
"LEFT"><font face="Arial"><span lang="EN">7. Mitte K. A meta-analysis of the eff
icacy of psycho- and pharmacotherapy in panic disorder with and without agorapho
bia. <i>J Affect Disord</i> 2005; 88: 27-45.    ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#83#79#article#160#</span></font></p>     
 ^cY#712.htm##
00404000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704016400074002000800238#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#84#80#article#160#8#<p align=
"LEFT"><font face="Arial"><span lang="EN">8. Pull CB, Damsa C. Pharmacotherapy o
f panic disorder. <i>Neuropsychiatr Dis Treat</i> 2008; 4: 779-795.    ^cY#712.h
tm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#85#81#article#160#</span></font></p>     
 ^cY#712.htm##
00395000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704015500074002000800229#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#86#82#article#160#9#<p align=
"LEFT"><font face="Arial"><span lang="EN">9. Bandelow B, Ruther E. Treatment-res
istant panic disorder. <i>CNS Spectr</i> 2004; 9: 725-739.    ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#87#83#article#160#</span></font></p>     
 ^cY#712.htm##
00546000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704030500075002000800380#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#88#84#article#160#10#<p align
="LEFT"><font face="Arial"><span lang="EN">10. Nardi AE, Nascimento I, Valenca A
M, Lopes FL, Mezzasalma MA, Zin WA, et al. Respiratory panic disorder subtype: a
cute and long-term response to nortriptyline, a noradrenergic tricyclic antidepr
essant. <i>Psychiatry Res</i> 2003; 120: 283-293.    ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#89#85#article#160#</span></font></p>     
 ^cY#712.htm##
00543000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704030200075002000800377#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#90#86#article#160#11#<p align
="LEFT"><font face="Arial"><span lang="EN">11. Nardi AE, Valenca AM, Nascimento 
I, Lopes FL, Mezzasalma MA, Freire RC, et al. A three-year follow-up study of pa
tients with the respiratory subtype of panic disorder after treatment with clona
zepam. <i>Psychiatry Res</i> 2005; 137: 61-70.    ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#91#87#article#160#</span></font></p>     
 ^cY#712.htm##
00494000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025300075002000800328#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#92#88#article#160#12#<p align
="LEFT"><font face="Arial"><span lang="EN">12. Valenca AM, Nardi AE, Mezzasalma 
MA, Nascimento I, Zin WA, Lopes FL, et al. Therapeutic response to benzodiazepin
e in panic disorder subtypes. <i>S&atilde;o Paulo Med J</i> 2003; 121: 77-80.   
 ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#93#89#article#160#</span></font></p>     
 ^cY#712.htm##
00439000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704019800075002000800273#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#94#90#article#160#13#<p align
="LEFT"><font face="Arial"><span lang="EN">13. Ballenger JC. Remission rates in 
patients with anxiety disorders treated with paroxetine. <i>J Clin Psychiatry</i
> 2004; 65: 1696-1707.    ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#95#91#article#160#</span></font></p>     
 ^cY#712.htm##
00458000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704021700075002000800292#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#96#92#article#160#14#<p align
="LEFT"><font face="Arial"><span lang="EN">14. Susman J, Klee B. The role of hig
h-potency benzodiazepines in the treatment of panic disorder. <i>Prim Care Compa
nion J Clin Psychiatry</i> 2005; 7: 5-11.    ^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#97#93#article#160#</span></font></p>     
 ^cY#712.htm##
00493000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025200075002000800327#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#98#94#article#160#15#<p align
="LEFT"><font face="Arial"><span lang="EN">15. Bakker A, van Balkom AJ, van Dyck
 R. Selective serotonin reuptake inhibitors in the treatment of panic disorder a
nd agoraphobia. <i>Int Clin Psychopharmacol</i> 2000; 15 (Suppl 2): S25-S30.    
^cY#712.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#99#95#article#160#</span></font></p>     
 ^cY#712.htm##
00478000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704023600076002000800312#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#100#96#article#160#16#<p alig
n="LEFT"><font face="Arial"><span lang="EN">16. Practice guideline for the treat
ment of patients with panic disorder. Work Group on Panic Disorder. American Psy
chiatric Association. <i>Am J Psychiatry</i> 1998; 155: 1-34.    ^cY#712.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#101#97#article#160#</span></font></p>    
  ^cY#712.htm##
00493000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704025100076002000800327#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#102#98#article#160#17#<p alig
n="LEFT"><font face="Arial"><span lang="EN">17. Dannon PN, Iancu I, Cohen A, Low
engrub K, Grunhaus L, Kotler M. Three year naturalistic outcome study of panic d
isorder patients treated with paroxetine. <i>BMC Psychiatry</i> 2004; 4: 16.    
^cY#712.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#103#99#article#160#</span></font></p>    
  ^cY#712.htm##
00432000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704018900077002000800266#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#104#100#article#160#18#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">18. Pollack MH, Doyle AC. Treatment
 of panic disorder: focus on paroxetine. <i>Psychopharmacol Bull</i> 2003; 37 (S
uppl 1): 53-63.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#105#101#article#160#</span></font></p>   
   ^cY#712.htm##
00488000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024500077002000800322#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#106#102#article#160#19#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">19. Sheehan DV, Burnham DB, Iyengar
 MK, Perera P. Efficacy and tolerability of controlled-release paroxetine in the
 treatment of panic disorder. <i>J Clin Psychiatry</i> 2005; 66: 34-40.    ^cY#7
12.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#107#103#article#160#</span></font></p>   
   ^cY#712.htm##
00536000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029300077002000800370#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#108#104#article#160#20#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">20. Bruce SE, Vasile RG, Goisman RM
, Salzman C, Spencer M, Machan JT, et al. Are benzodiazepines still the medicati
on of choice for patients with panic disorder with or without agoraphobia? <i>Am
 J Psychiatry</i> 2003; 160: 1432-1438.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#109#105#article#160#</span></font></p>   
   ^cY#712.htm##
00579000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704033600077002000800413#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#110#106#article#160#21#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">21. Rosenbaum JF, Moroz G, Bowden C
L. Clonazepam in the treatment of panic disorder with or without agoraphobia: a 
dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Di
sorder Dose-Response Study Group. <i>J Clin Psychopharmacol</i> 1997; 17: 390-40
0.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#111#107#article#160#</span></font></p>   
   ^cY#712.htm##
00450000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704020700077002000800284#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#112#108#article#160#22#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">22. Chouinard G. Issues in the clin
ical use of benzodiazepines: potency, withdrawal, and rebound. <i>J Clin Psychia
try</i> 2004; 65 (Suppl 5): 7-12.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#113#109#article#160#</span></font></p>   
   ^cY#712.htm##
00462000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704021900077002000800296#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#114#110#article#160#23#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">23. Jenner P, Pratt JA, Marsden CD.
 Mechanism of action of clonazepam in myoclonus in relation to effects on GABA a
nd 5-HT. <i>Adv Neurol</i> 1986; 43: 629-643.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#115#111#article#160#</span></font></p>   
   ^cY#712.htm##
00421000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704017800077002000800255#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#116#112#article#160#24#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">24. Moroz G. High-potency benzodiaz
epines: recent clinical results. <i>J Clin Psychiatry</i> 2004; 65 (Suppl 5): 13
-18.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#117#113#article#160#</span></font></p>   
   ^cY#712.htm##
00440000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704019700077002000800274#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#118#114#article#160#25#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">25. Nardi AE, Perna G. Clonazepam i
n the treatment of psychiatric disorders: an update. <i>Int Clin Psychopharmacol
</i> 2006; 21: 131-142.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#119#115#article#160#</span></font></p>   
   ^cY#712.htm##
00465000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704022200077002000800299#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#120#116#article#160#26#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">26. Zamorski MA, Albucher RC. What 
to do when SSRIs fail: eight strategies for optimizing treatment of panic disord
er. <i>Am Fam Physician</i> 2002; 66: 1477-1484.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#121#117#article#160#</span></font></p>   
   ^cY#712.htm##
00527000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028400077002000800361#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#122#118#article#160#27#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">27. Nardi AE, Valen&ccedil;a AM, Fr
eire RC, Amrein R, Sardinha A, Levitan MN, et al. Randomized open naturalistic a
cute treatment of panic disorder with clonazepam or paroxetine. <i>J Clin Psycho
pharmacol</i> 2011 (in press).    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#123#119#article#160#</span></font></p>   
   ^cY#712.htm##
00599000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704035600077002000800433#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#124#120#article#160#28#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">28. Beauclair L, Fontaine R, Annabl
e L, Holobow N, Chouinard G. Clonazepam in the treatment of panic disorder: a do
uble-blind, placebo-controlled trial investigating the correlation between clona
zepam concentrations in plasma and clinical response. <i>J Clin Psychopharmacol<
/i> 1994; 14: 111-118.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#125#121#article#160#</span></font></p>   
   ^cY#712.htm##
00516000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027300077002000800350#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#126#122#article#160#29#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">29. Moroz G, Rosenbaum JF. Efficacy
, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo
-controlled, multicenter study using optimized dosages. <i>J Clin Psychiatry</i>
 1999; 60: 604-612.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#127#123#article#160#</span></font></p>   
   ^cY#712.htm##
00491000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024800077002000800325#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#128#124#article#160#30#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">30. Valenca AM, Nardi AE, Nasciment
o I, Mezzasalma MA, Lopes FL, Zin W. Double-blind clonazepam <i>vs</i> placebo i
n panic disorder treatment. <i>Arq Neuropsiquiatr</i> 2000; 58: 1025-1029.    ^c
Y#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#129#125#article#160#</span></font></p>   
   ^cY#712.htm##
00781000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704053800077002000800615#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#130#126#article#160#31#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">31. Dannon PN, Iancu I, Lowengrub K
, Amiaz R, Grunhaus L, Kotler M. Clonazepam augmentation of paroxetine in the tr
eatment of panic disorder: a one year naturalistic follow-up study. <i>Internet 
J Ment Health</i> 2005; <a target="_blank" href="http://www.ispub.com/journal/th
e_internet_journal_of_mental_health/archive/volume_2_number_2_31.html">http://ww
w.ispub.com/journal/the_internet_journal_of_mental_health/archive/volume_2_numbe
r_2_31.html</a> (Accessed: January 5, 2011).    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#131#127#article#160#</span></font></p>   
   ^cY#712.htm##
00469000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704022600077002000800303#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#132#128#article#160#32#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">32. Dannon PN, Lowengrub K, Iancu I
, Kotler M. Paroxetine in panic disorder: clinical management and long-term foll
ow-up. <i>Expert Rev Neurother</i> 2004; 4: 191-198.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#133#129#article#160#</span></font></p>   
   ^cY#712.htm##
00466000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704022300077002000800300#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#134#130#article#160#33#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">33. American Psychiatric Associatio
n. <i>Practice guidelines for the treatment of psychiatric disorders compendium<
/i>. Arlington: American Psychiatric Press; 2004.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#135#131#article#160#</span></font></p>   
   ^cY#712.htm##
00558000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704031500077002000800392#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#136#132#article#160#34#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">34. Saeki Y, Watanabe T, Ueda M, Sa
ito A, Akiyama K, Inoue Y, et al. Genetic and pharmacokinetic factors affecting 
the initial pharmacotherapeutic effect of paroxetine in Japanese patients with p
anic disorder. <i>Eur J Clin Pharmacol</i> 2009; 65: 685-691.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#137#133#article#160#</span></font></p>   
   ^cY#712.htm##
00561000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704031800077002000800395#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#138#134#article#160#35#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">35. Andersch S, Rosenberg NK, Kulli
ngsjo H, Ottosson JO, Bech P, Bruun-Hansen J, et al. Efficacy and safety of alpr
azolam, imipramine and placebo in treating panic disorder. A Scandinavian multic
enter study. <i>Acta Psychiatr Scand Suppl</i> 1991; 365: 18-27.    ^cY#712.htm#
#
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#139#135#article#160#</span></font></p>   
   ^cY#712.htm##
00536000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029300077002000800370#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#140#136#article#160#36#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">36. Pollack MH, Simon NM, Worthingt
on JJ, Doyle AL, Peters P, Toshkov F, et al. Combined paroxetine and clonazepam 
treatment strategies compared to paroxetine monotherapy for panic disorder. <i>J
 Psychopharmacol</i> 2003; 17: 276-282.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#141#137#article#160#</span></font></p>   
   ^cY#712.htm##
00458000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704021500077002000800292#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#142#138#article#160#37#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">37. Marks DM, Park MH, Ham BJ, Han 
C, Patkar AA, Masand PS, et al. Paroxetine: safety and tolerability issues. <i>E
xpert Opin Drug Saf</i> 2008; 7: 783-794.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#143#139#article#160#</span></font></p>   
   ^cY#712.htm##
00420000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704017700077002000800254#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#144#140#article#160#38#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">38. Masand PS, Gupta S. Selective s
erotonin-reuptake inhibitors: an update. <i>Harv Rev Psychiatry</i> 1999; 7: 69-
84.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#145#141#article#160#</span></font></p>   
   ^cY#712.htm##
00441000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704019800077002000800275#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#146#142#article#160#39#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">39. Rickels K, Schweizer E. Panic d
isorder: long-term pharmacotherapy and discontinuation. <i>J Clin Psychopharmaco
l</i> 1998; 18: 12S-18S.    ^cY#712.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#147#143#article#160#</span></font></p>   
   ^cY#712.htm##
00461000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704021800077002000800295#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#p#148#144#article#160#40#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">40. Salzman C. Benzodiazepine treat
ment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. <i>J P
sychiatr Res</i> 1993; 27 (Suppl 1): 97-110.    ^cY#712.htm##
00280000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704005200074002000800126#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#149#145#article#160#</span></font></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#712.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033500074002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#150#146#article#160#<P><font face="Arial,
 Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE
=4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#712.ht
m##
00904000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704067600074002000800750#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#151#147#article#160#<p ALIGN="LEFT"><font
 face="Arial"><span lang="EN">We thank Hester van Lier, PhD, of Excerpta Medica 
who provided editorial/writing support. Research supported by CNPq and INCT Tran
slational Medicine (CNPq). A.E. Nardi, A.M. Valen&ccedil;a, I. Nascimento, J.A. 
Crippa, and M. Versiani are recipients of CNPq productivity fellowship awards. T
he authors received editorial/writing support solely in the preparation of this 
manuscript funded by F. Hoffmann-La Roche Ltd. The funding source had no role in
 the study design, collection, analysis or interpretation of data, nor in the de
cision to submit the paper for publication.</span></font></p>  <HR ALIGN=LEFT SI
ZE=2>      ^cY#712.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033600074002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#152#148#article#160#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#712.h
tm##
00754000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704052600074002000800600#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#153#149#article#160#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/r
ecor.gif" border="0"></a> Address for correspondence:</b></font> <font face="Ari
al"><span lang="EN">A.E. Nardi, Laborat&oacute;rio de P&acirc;nico e Respira&cce
dil;&atilde;o, Instituto de Psiquiatria, UFRJ, INCT-TM (CNPq), Rua Visconde de P
iraja, 407/702, 22410-003 Rio de Janeiro, RJ, Brasil. Fax: +55-21-2523-6839. E-m
ail: <a href="mailto:antonionardi@terra.com.br">antonionardi@terra.com.br</a></s
pan></font></p>      ^cY#712.htm##
00451000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704022300074002000800297#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#154#150#article#160#<p ALIGN="LEFT"><i><f
ont face="Arial"><span lang="EN">Received August 16, 2010. Accepted February 3, 
2011. Available online February 2, 2011. Published April 11, 2011.</span></font>
</i></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#712.htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#155#151#article#160#<div align="center"> 
       ^cY#712.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#156#152#article#160#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#712.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#157#153#article#160#<br>                ^
cY#712.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#158#154#article#160#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#712
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#159#155#article#160#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#712.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#160#156#article#160#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#712.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#161#157#article#160#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#712.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#162#158#article#160#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#712.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#163#159#article#160#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#712.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\712.htm#S#p#164#160#article#160#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#712.htm##
00473000000000253000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730120065000920300
02300157710000200180065000900182064000500191031000200196014000400198865000900202
002000800211#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#165#1#article
#40#1#^rND^sBienvenu^nOJ#Lifetime prevalence of panic disorder is about 5% in th
e USA^len#Evid Based Ment Health#2#20060000#2006#9#114#20110400#712.htm##
00526000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100021000730120065000940300
01800159065000900177064000500186031000300191032000500194014000400199865000900203
002000800212035001000220801001800230#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
12.htm#S#c#166#2#article#40#2#^rND^sHirschfeld^nRM#Panic disorder: diagnosis, ep
idemiology, and clinical course^len#J Clin Psychiatry#19960000#1996#57#^s10#3-8#
20110400#712.htm#0160-6689#J Clin Psychiatry##
00531000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100021000730100016000940120
05800110030001600168065000900184064000500193031000400198014000800202865000900210
002000800219035001000227801001600237#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
12.htm#S#c#167#3#article#40#3#^rND^sMendlowicz^nMV#^rND^sStein^nMB#Quality of li
fe in individuals with anxiety disorders^len#Am J Psychiatry#20000000#2000#157#6
69-682#20110400#712.htm#0002-953X#Am J Psychiatry##
00549000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100017000900100
01600107012004500123030002000168065000900188064000500197031000200202014000800204
865000900212002000800221035001000229801002000239#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\712.htm#S#c#168#4#article#40#4#^rND^sMogotsi^nM#^rND^sKaminer^nD#^rND
^sStein^nDJ#Quality of life in the anxiety disorders^len#Harv Rev Psychiatry#200
00000#2000#8#273-282#20110400#712.htm#1067-3229#Harv Rev Psychiatry##
00626000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100015000900100
01500105010001900120012009100139030002200230065000900252064000500261031000300266
014000600269865000900275002000800284035001000292801002200302#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\712.htm#S#c#169#5#article#40#5#^rND^sWaghorn^nG#^rND^sCha
nt^nD#^rND^sWhite^nP#^rND^sWhiteford^nH#Disability, employment and work performa
nce among people with ICD-10 anxiety disorders^len#Aust N Z J Psychiatry#2005000
0#2005#39#55-66#20110400#712.htm#0004-8674#Aust N Z J Psychiatry##
00461000000000253000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730120049000910300
02500140710000200165065000900167064000500176031000200181014000700183865000900190
002000800199#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#170#6#article
#40#6#^rND^sMarchesi^nC#Pharmacological management of panic disorder^len#Neurops
ychiatr Dis Treat#2#20080000#2008#4#93-106#20110400#712.htm##
00550000000000265000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730120114000880300
01600202065000900218064000500227031000300232014000600235865000900241002000800250
035001000258801001600268#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#1
71#7#article#40#7#^rND^sMitte^nK#A meta-analysis of the efficacy of psycho- and 
pharmacotherapy in panic disorder with and without agoraphobia^len#J Affect Diso
rd#20050000#2005#88#27-45#20110400#712.htm#0165-0327#J Affect Disord##
00475000000000265000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100015000880120
03800103030002500141710000200166065000900168064000500177031000200182014000800184
865000900192002000800201#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#1
72#8#article#40#8#^rND^sPull^nCB#^rND^sDamsa^nC#Pharmacotherapy of panic disorde
r^len#Neuropsychiatr Dis Treat#2#20080000#2008#4#779-795#20110400#712.htm##
00466000000000265000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100016000910120
03900107030001100146710000200157065000900159064000500168031000200173014000800175
865000900183002000800192#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#1
73#9#article#40#9#^rND^sBandelow^nB#^rND^sRuther^nE#Treatment-resistant panic di
sorder^len#CNS Spectr#2#20040000#2004#9#725-739#20110400#712.htm##
00735000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100020000910100
01800111010001600129010002100145010001400166810000600180012012800186030001500314
06500090032906400050033803100040034301400080034786500090035500200080036403500100
0372801001500382#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#174#10#ar
ticle#40#10#^rND^sNardi^nAE#^rND^sNascimento^nI#^rND^sValenca^nAM#^rND^sLopes^nF
L#^rND^sMezzasalma^nMA#^rND^sZin^nWA#et al#Respiratory panic disorder subtype: a
cute and long-term response to nortriptyline, a noradrenergic tricyclic antidepr
essant^len#Psychiatry Res#20030000#2003#120#283-293#20110400#712.htm#0165-1781#P
sychiatry res##
00732000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100018000910100
02000109010001600129010002100145010001700166810000600183012012400189030001500313
06500090032806400050033703100040034201400060034686500090035200200080036103500100
0369801001500379#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#175#11#ar
ticle#40#11#^rND^sNardi^nAE#^rND^sValenca^nAM#^rND^sNascimento^nI#^rND^sLopes^nF
L#^rND^sMezzasalma^nMA#^rND^sFreire^nRC#et al#A three-year follow-up study of pa
tients with the respiratory subtype of panic disorder after treatment with clona
zepam^len#Psychiatry Res#20050000#2005#137#61-70#20110400#712.htm#0165-1781#Psyc
hiatry res##
00641000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930100
02100109010002000130010001400150010001600164810000600180012007000186030001600256
71000020027206500090027406400050028303100040028801400060029286500090029800200080
0307#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#176#12#article#40#12#
^rND^sValenca^nAM#^rND^sNardi^nAE#^rND^sMezzasalma^nMA#^rND^sNascimento^nI#^rND^
sZin^nWA#^rND^sLopes^nFL#et al#Therapeutic response to benzodiazepine in panic d
isorder subtypes^len#São Paulo Med J#2#20030000#2003#121#77-80#20110400#712.htm#
#
00530000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750120079000950300
01800174065000900192064000500201031000300206014001000209865000900219002000800228
035001000236801001800246#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#1
77#13#article#40#13#^rND^sBallenger^nJC#Remission rates in patients with anxiety
 disorders treated with paroxetine^len#J Clin Psychiatry#20040000#2004#65#1696-1
707#20110400#712.htm#0160-6689#J Clin Psychiatry##
00529000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100014000910120
08000105030003800185710000200223065000900225064000500234031000200239014000500241
865000900246002000800255#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#1
78#14#article#40#14#^rND^sSusman^nJ#^rND^sKlee^nB#The role of high-potency benzo
diazepines in the treatment of panic disorder^len#Prim Care Companion J Clin Psy
chiatry#2#20050000#2005#7#5-11#20110400#712.htm##
00633000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100021000910100
01800112012009500130030002500225065000900250064000500259031000300264032000400267
014000800271865000900279002000800288035001000296801002500306#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\712.htm#S#c#179#15#article#40#15#^rND^sBakker^nA#^rND^sva
n^nBalkom AJ#^rND^svan^nDyck R#Selective serotonin reuptake inhibitors in the tr
eatment of panic disorder and agoraphobia^len#Int Clin Psychopharmacol#20000000#
2000#15#^s2#S25-S30#20110400#712.htm#0268-1315#Int Clin Psychopharmacol##
00566000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100076000750120067001510300
01600218065000900234064000500243031000400248014000500252865000900257002000800266
035001000274801001600284#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#1
80#16#article#40#16#^rND^sPractice^nguideline for the treatment of patients with
 panic disorder#Work Group on Panic Disorder: American Psychiatric Association^l
en#Am J Psychiatry#19980000#1998#155#1-34#20110400#712.htm#0002-953X#Am J Psychi
atry##
00635000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100015000920100
01500107010001900122010001800141010001600159012009300175030001500268710000200283
065000900285064000500294031000200299014000300301865000900304002000800313#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#181#17#article#40#17#^rND^sDannon
^nPN#^rND^sIancu^nI#^rND^sCohen^nA#^rND^sLowengrub^nK#^rND^sGrunhaus^nL#^rND^sKo
tler^nM#Three year naturalistic outcome study of panic disorder patients treated
 with paroxetine^len#BMC Psychiatry#2#20040000#2004#4#16#20110400#712.htm##
00548000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930120
05300109030002100162065000900183064000500192031000300197032000400200014000600204
865000900210002000800219035001000227801002100237#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\712.htm#S#c#182#18#article#40#18#^rND^sPollack^nMH#^rND^sDoyle^nAC#Tr
eatment of panic disorder: focus on paroxetine^len#Psychopharmacol Bull#20030000
#2003#37#^s1#53-63#20110400#712.htm#0048-5764#Psychopharmacol Bull##
00631000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100018000930100
01800111010001600129012009800145030001800243065000900261064000500270031000300275
014000600278865000900284002000800293035001000301801001800311#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\712.htm#S#c#183#19#article#40#19#^rND^sSheehan^nDV#^rND^s
Burnham^nDB#^rND^sIyengar^nMK#^rND^sPerera^nP#Efficacy and tolerability of contr
olled-release paroxetine in the treatment of panic disorder^len#J Clin Psychiatr
y#20050000#2005#66#34-40#20110400#712.htm#0160-6689#J Clin Psychiatry##
00724000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100017000910100
01800108010001700126010001700143010001700160810000600177012011600183030001600299
06500090031506400050032403100040032901400100033386500090034300200080035203500100
0360801001600370#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#184#20#ar
ticle#40#20#^rND^sBruce^nSE#^rND^sVasile^nRG#^rND^sGoisman^nRM#^rND^sSalzman^nC#
^rND^sSpencer^nM#^rND^sMachan^nJT#et al#Are benzodiazepines still the medication
 of choice for patients with panic disorder with or without agoraphobia^len#Am J
 Psychiatry#20030000#2003#160#1432-1438#20110400#712.htm#0002-953X#Am J Psychiat
ry##
00666000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100015000950100
01700110012014100127030007600268710000200344065000900346064000500355031000300360
014000800363865000900371002000800380#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
12.htm#S#c#185#21#article#40#21#^rND^sRosenbaum^nJF#^rND^sMoroz^nG#^rND^sBowden^
nCL#Clonazepam in the treatment of panic disorder with or without agoraphobia: a
 dose-response study of efficacy, safety, and discontinuance^len#Clonazepam Pani
c Disorder Dose-Response Study Group. J Clin Psychopharmacol#2#19970000#1997#17#
390-400#20110400#712.htm##
00545000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750120084000940300
01800178065000900196064000500205031000300210032000400213014000500217865000900222
002000800231035001000239801001800249#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
12.htm#S#c#186#22#article#40#22#^rND^sChouinard^nG#Issues in the clinical use of
 benzodiazepines: potency, withdrawal, and rebound^len#J Clin Psychiatry#2004000
0#2004#65#^s5#7-12#20110400#712.htm#0160-6689#J Clin Psychiatry##
00580000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100016000910100
01800107012009100125030001100216065000900227064000500236031000300241014000800244
865000900252002000800261035001000269801001100279#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\712.htm#S#c#187#23#article#40#23#^rND^sJenner^nP#^rND^sPratt^nJA#^rND
^sMarsden^nCD#Mechanism of action of clonazepam in myoclonus in relation to effe
cts on GABA and 5-HT^len#Adv Neurol#19860000#1986#43#629-643#20110400#712.htm#00
91-3952#Adv Neurol##
00516000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750120058000900300
01800148065000900166064000500175031000300180032000400183014000600187865000900193
002000800202035001000210801001800220#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
12.htm#S#c#188#24#article#40#24#^rND^sMoroz^nG#High-potency benzodiazepines: rec
ent clinical results^len#J Clin Psychiatry#20040000#2004#65#^s5#13-18#20110400#7
12.htm#0160-6689#J Clin Psychiatry##
00554000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100015000910120
06800106030002500174065000900199064000500208031000300213014000800216865000900224
002000800233035001000241801002500251#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
12.htm#S#c#189#25#article#40#25#^rND^sNardi^nAE#^rND^sPerna^nG#Clonazepam in the
 treatment of psychiatric disorders: an update^len#Int Clin Psychopharmacol#2006
0000#2006#21#131-142#20110400#712.htm#0268-1315#Int Clin Psychopharmacol##
00571000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100019000940120
09200113030001700205065000900222064000500231031000300236014001000239865000900249
002000800258035001000266801001700276#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
12.htm#S#c#190#26#article#40#26#^rND^sZamorski^nMA#^rND^sAlbucher^nRC#What to do
 when SSRIs fail: eight strategies for optimizing treatment of panic disorder^le
n#Am Fam Physician#20020000#2002#66#1477-1484#20110400#712.htm#0002-838X#Am Fam 
Physician##
00710000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100018000910100
01700109010001600126010001800142010001800160010001300178012009700191030002300288
06500090031106400050032006100090032586500090033400200080034303500100035180100230
0361#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#191#27#article#40#27#
^rND^sNardi^nAE#^rND^sValença^nAM#^rND^sFreire^nRC#^rND^sAmrein^nR#^rND^sSardinh
a^nA#^rND^sLevitan^nMN#^rND^set^nal#Randomized open naturalistic acute treatment
 of panic disorder with clonazepam or paroxetine^len#J Clin Psychopharmacol#2011
0000#2011#in press#20110400#712.htm#0271-0749#J Clin Psychopharmacol##
00765000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100018000940100
01700112010001700129010001900146012018800165030002300353065000900376064000500385
031000300390014000800393865000900401002000800410035001000418801002300428#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#192#28#article#40#28#^rND^sBeaucl
air^nL#^rND^sFontaine^nR#^rND^sAnnable^nL#^rND^sHolobow^nN#^rND^sChouinard^nG#Cl
onazepam in the treatment of panic disorder: a double-blind, placebo-controlled 
trial investigating the correlation between clonazepam concentrations in plasma 
and clinical response^len#J Clin Psychopharmacol#19940000#1994#14#111-118#201104
00#712.htm#0271-0749#J Clin Psychopharmacol##
00623000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100020000900120
14700110030001800257065000900275064000500284031000300289014000800292865000900300
002000800309035001000317801001800327#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
12.htm#S#c#193#29#article#40#29#^rND^sMoroz^nG#^rND^sRosenbaum^nJF#Efficacy, saf
ety, and gradual discontinuation of clonazepam in panic disorder: a placebo-cont
rolled, multicenter study using optimized dosages^len#J Clin Psychiatry#19990000
#1999#60#604-612#20110400#712.htm#0160-6689#J Clin Psychiatry##
00664000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930100
02000109010002100129010001600150010001300166012006700179030001900246065000900265
06400050027403100030027901400100028286500090029200200080030103500100030980100190
0319#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#194#30#article#40#30#
^rND^sValenca^nAM#^rND^sNardi^nAE#^rND^sNascimento^nI#^rND^sMezzasalma^nMA#^rND^
sLopes^nFL#^rND^sZin^nW#Double-blind clonazepam vs placebo in panic disorder tre
atment^len#Arq Neuropsiquiatr#20000000#2000#58#1025-1029#20110400#712.htm#0004-2
82X#Arq Neuropsiquiatr##
00794000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100015000920100
01900107010001500126010001800141010001600159012011800175030002300293710000200316
065002300318064000500341061012900346865000900475002000800484#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\712.htm#S#c#195#31#article#40#31#^rND^sDannon^nPN#^rND^sI
ancu^nI#^rND^sLowengrub^nK#^rND^sAmiaz^nR#^rND^sGrunhaus^nL#^rND^sKotler^nM#Clon
azepam augmentation of paroxetine in the treatment of panic disorder: a one year
 naturalistic follow-up study^len#Internet J Ment Health#2#&#8221;20050000&#8221
;#2005#http://www.ispub.com/journal/the_internet_journal_of_mental_health/archiv
e/volume_2_number_2_31.html (Accessed: January 5, 2011)#20110400#712.htm##
00574000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100019000920100
01500111010001600126012007800142030002100220710000200241065000900243064000500252
031000200257014000800259865000900267002000800276#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\712.htm#S#c#196#32#article#40#32#^rND^sDannon^nPN#^rND^sLowengrub^nK#
^rND^sIancu^nI#^rND^sKotler^nM#Paroxetine in panic disorder: clinical management
 and long-term follow-up^len#Expert Rev Neurother#2#20040000#2004#4#191-198#2011
0400#712.htm##
00484000000000229000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720170033000750180078001080660
01000186062002700196065000900223064000500232865000900237002000800246#v44n4#V:\Sc
iELO\serial\bjmbr\v44n4\markup\712.htm#S#c#197#33#article#40#33#American Psychia
tric Association#Practice guidelines for the treatment of psychiatric disorders 
compendium^len#Arlington#American Psychiatric Press#20040000#2004#20110400#712.h
tm##
00751000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100018000900100
01400108010001500122010001700137010001500154810000600169012014400175030002100319
06500090034006400050034903100030035401400080035786500090036500200080037403500100
0382801002100392#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#198#34#ar
ticle#40#34#^rND^sSaeki^nY#^rND^sWatanabe^nT#^rND^sUeda^nM#^rND^sSaito^nA#^rND^s
Akiyama^nK#^rND^sInoue^nY#et al#Genetic and pharmacokinetic factors affecting th
e initial pharmacotherapeutic effect of paroxetine in Japanese patients with pan
ic disorder^len#Eur J Clin Pharmacol#20090000#2009#65#685-691#20110400#712.htm#0
031-6970#Eur J Clin Pharmacol##
00760000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100020000930100
02000113010001900133010001400152010002200166810000600188012012300194030002700317
06500090034406400050035303100040035801400060036286500090036800200080037703500100
0385801002700395#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#199#35#ar
ticle#40#35#^rND^sAndersch^nS#^rND^sRosenberg^nNK#^rND^sKullingsjo^nH#^rND^sOtto
sson^nJO#^rND^sBech^nP#^rND^sBruun-Hansen^nJ#et al#Efficacy and safety of alpraz
olam, imipramine and placebo in treating panic disorder: A Scandinavian multicen
ter study^len#Acta Psychiatr Scand Suppl#19910000#1991#365#18-27#20110400#712.ht
m#0065-1591#Acta Psychiatr Scand Suppl##
00726000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930100
02200109010001600131010001600147010001700163810000600180012011400186030001800300
06500090031806400050032703100030033201400080033586500090034300200080035203500100
0360801001800370#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#200#36#ar
ticle#40#36#^rND^sPollack^nMH#^rND^sSimon^nNM#^rND^sWorthington^nJJ#^rND^sDoyle^
nAL#^rND^sPeters^nP#^rND^sToshkov^nF#et al#Combined paroxetine and clonazepam tr
eatment strategies compared to paroxetine monotherapy for panic disorder^len#J P
sychopharmacol#20030000#2003#17#276-282#20110400#712.htm#0269-8811#J Psychopharm
acol##
00610000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100015000910100
01400106010001300120010001700133010001700150810000600167012004700173030002100220
71000020024106500090024306400050025203100020025701400080025986500090026700200080
0276#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\712.htm#S#c#201#37#article#40#37#
^rND^sMarks^nDM#^rND^sPark^nMH#^rND^sHam^nBJ#^rND^sHan^nC#^rND^sPatkar^nAA#^rND^
sMasand^nPS#et al#Paroxetine: safety and tolerability issues^len#Expert Opin Dru
g Saf#2#20080000#2008#7#783-794#20110400#712.htm##
00529000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100015000920120
05500107030002000162065000900182064000500191031000200196014000600198865000900204
002000800213035001000221801002000231#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
12.htm#S#c#202#38#article#40#38#^rND^sMasand^nPS#^rND^sGupta^nS#Selective seroto
nin-reuptake inhibitors: an update^len#Harv Rev Psychiatry#19990000#1999#7#69-84
#20110400#712.htm#1067-3229#Harv Rev Psychiatry##
00553000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100019000920120
06600111030002300177065000900200064000500209031000300214014000800217865000900225
002000800234035001000242801002300252#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
12.htm#S#c#203#39#article#40#39#^rND^sRickels^nK#^rND^sSchweizer^nE#Panic disord
er: long-term pharmacotherapy and discontinuation^len#J Clin Psychopharmacol#199
80000#1998#18#12S-18S#20110400#712.htm#0271-0749#J Clin Psychopharmacol##
00554000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750120097000920300
01600189065000900205064000500214031000300219032000400222014000700226865000900233
002000800242035001000250801001600260#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
12.htm#S#c#204#40#article#40#40#^rND^sSalzman^nC#Benzodiazepine treatment of pan
ic and agoraphobic symptoms: use, dependence, toxicity, abuse^len#J Psychiatr Re
s#19930000#1993#27#^s1#97-110#20110400#712.htm#0022-3956#J Psychiatr Res##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#o#1#1#article#1#201
10411#094609#721.htm#248##
02799000000000649000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000300107
03000200011003100030013003200020013306500090013501400110014403500100015522400090
01650120090001740100035002640100030002990100028003290100022003570100025003790100
02600404070007400430070011000504070006600614070006900680070008900749083109500838
08500080193308500170194108500160195808500230197408500270199708500290202411700060
20530720003020591120009020621110019020711140009020901130018020998910024021170020
00802141#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#h#2#1#article#1#ra#
en#bjmbr#1#3.1#ILUS#TAB#02#BJMBR090#nd#Braz J Med Biol Res#44#4#20110400#^f276^l
282#0100-879X#20110329#The role of the SLAM-SAP signaling pathway in the modulat
ion of CD4+ T cell responses^len#^rND^1A01 A02 A03^nM.L.L.V.^sVilar#^rND^1A02 A0
3^nM.S.^sFrutuoso#^rND^1A01 A04^nS.M.^sArruda#^rND^1A02^nD.M.^sLima#^rND^1A05^nC
.S.^sBezerra#^rND^1A02^nM.M.L.^sPompeu#Escola Bahiana de Medicina e Saúde Públic
a/FDC^iA01^cSalvador^sBA^pBrasil#Universidade Federal do Ceará^iA02^1Faculdade d
e Medicina^2Núcleo de Medicina Tropical^cFortaleza^sCE^pBrasil#Faculdade Christu
s^iA03^1Curso de Medicina^cFortaleza^sCE^pBrasil#FIOCRUZ^iA04^1Centro de Pesquis
a Gonçalo Moniz^cSalvador^sBA^pBrasil#Instituto Federal de Educação, Ciência e T
ecnologia do Ceará^iA05^cFortaleza^sCE^pBrasil#^len^aThe signaling lymphocytic a
ctivation molecule (SLAM), present on the surface of hematopoietic cells, can re
gulate some events of the immune responses. This modulatory action is associated
 with the capacity of SLAM to interact with an intracytoplasmic adapter, such as
 SLAM-associated protein (SAP). SLAM is constitutively expressed in most of thes
e cells, is rapidly induced after antigenic or inflammatory stimuli, and partici
pates in the immunological synapse. Defects in the function of the SLAM-SAP path
way contribute to immunological abnormalities, resulting in autoimmune diseases,
 tumors of the lymphoid tissues and inadequate responses to infectious agents. I
nitially, the role of SLAM was investigated using an anti-SLAM monoclonal antibo
dy (&#945;-SLAM mAb) identified as an agonist of the SLAM-SAP pathway, which cou
ld induce the production of interferon-&#947; and could redirect the immune resp
onse to a T helper 1 (Th1) cell profile. However, in this review we postulate th
at the SLAM-SAP pathway primarily induces a Th2 response and secondarily suppres
ses the Th1 response.#^dnd^i1#^tm^len^kSLAM^i1#^tm^len^kSAP^i1#^tm^len^kIFN-&#94
7;^i1#^tm^len^kImmunoreceptor^i1#^tm^len^kImmunomodulation^i1#other#58#20100918#
September 18, 2010#20110221#February 21, 2011#S0100-879X2011007500038#721.htm##
02795000000000637000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000300107
03000200011003100030013003200020013306500090013501400110014403500100015522400090
01650120108001740100035002820100030003170100028003470100022003750100025003970100
02600422070007400448070011000522070006600632070006900698070008900767083109500856
08500080195108500170195908500160197608500230199208500270201508500290204211700060
2071072000302077112000902080111002602089114000902115113002502124002000802149#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#f#3#1#article#1#ra#en#bjmbr#1#3
.1#ILUS#TAB#02#BJMBR090#nd#Braz J Med Biol Res#44#4#20110400#^f276^l282#0100-879
X#20110329#<b>The role of the SLAM-SAP signaling pathway in the modulation of CD
4<sup>+</sup> T cell responses</b>^len#^rND^1A01 A02 A03^nM.L.L.V.^sVilar#^rND^1
A02 A03^nM.S.^sFrutuoso#^rND^1A01 A04^nS.M.^sArruda#^rND^1A02^nD.M.^sLima#^rND^1
A05^nC.S.^sBezerra#^rND^1A02^nM.M.L.^sPompeu#Escola Bahiana de Medicina e Saúde 
Pública/FDC^iA01^cSalvador^sBA^pBrasil#Universidade Federal do Ceará^iA02^1Facul
dade de Medicina^2Núcleo de Medicina Tropical^cFortaleza^sCE^pBrasil#Faculdade C
hristus^iA03^1Curso de Medicina^cFortaleza^sCE^pBrasil#FIOCRUZ^iA04^1Centro de P
esquisa Gonçalo Moniz^cSalvador^sBA^pBrasil#Instituto Federal de Educação, Ciênc
ia e Tecnologia do Ceará^iA05^cFortaleza^sCE^pBrasil#^len^aThe signaling lymphoc
ytic activation molecule (SLAM), present on the surface of hematopoietic cells, 
can regulate some events of the immune responses. This modulatory action is asso
ciated with the capacity of SLAM to interact with an intracytoplasmic adapter, s
uch as SLAM-associated protein (SAP). SLAM is constitutively expressed in most o
f these cells, is rapidly induced after antigenic or inflammatory stimuli, and p
articipates in the immunological synapse. Defects in the function of the SLAM-SA
P pathway contribute to immunological abnormalities, resulting in autoimmune dis
eases, tumors of the lymphoid tissues and inadequate responses to infectious age
nts. Initially, the role of SLAM was investigated using an anti-SLAM monoclonal 
antibody (&#945;-SLAM mAb) identified as an agonist of the SLAM-SAP pathway, whi
ch could induce the production of interferon-&#947; and could redirect the immun
e response to a T helper 1 (Th1) cell profile. However, in this review we postul
ate that the SLAM-SAP pathway primarily induces a Th2 response and secondarily s
uppresses the Th1 response.#^dnd^i1#^tm^len^kSLAM^i1#^tm^len^kSAP^i1#^tm^len^kIF
N-&#947;^i1#^tm^len^kImmunoreceptor^i1#^tm^len^kImmunomodulation^i1#other#58#201
00918#<i>September 18, 2010</i>#20110221#<i>February 21, 2011</i>#721.htm##
02906000000000661000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800030012003000240012303100030014703200020015006500090015201400110016103500100
01722240009001820120090001910100037002810100030003180100028003480100022003760100
02500398010002700423070007600450070011200526070006800638070007100706070009100777
08310950086808500080196308500170197108500160198808500230200408500270202708500290
20541170006020830720003020891120009020921110019021011140009021201130018021290020
00802147008008902155#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#l#4#1#a
rticle#1#^mApr.^a2011#ra#en#bjmbr#1#3.1#ilus#tab#02#BJMBR090#nd#Braz. j. med. bi
ol. res#44#4#20110400#^f276^l282#0100-879X#20110329#The role of the SLAM-SAP sig
naling pathway in the modulation of CD4+ T cell responses^len#^rND^1A01 A02 A03^
nM. L. L. V^sVilar#^rND^1A02 A03^nM. S^sFrutuoso#^rND^1A01 A04^nS. M^sArruda#^rN
D^1A02^nD. M^sLima#^rND^1A05^nC. S^sBezerra#^rND^1A02^nM. M. L^sPompeu#^iA01^1Es
cola Bahiana de Medicina e Saúde Pública/FDC^cSalvador^sBA^pBrasil#^iA02^1Univer
sidade Federal do Ceará^2Faculdade de Medicina^3Núcleo de Medicina Tropical^cFor
taleza^sCE^pBrasil#^iA03^1Faculdade Christus^2Curso de Medicina^cFortaleza^sCE^p
Brasil#^iA04^1FIOCRUZ^2Centro de Pesquisa Gonçalo Moniz^cSalvador^sBA^pBrasil#^i
A05^1Instituto Federal de Educação, Ciência e Tecnologia do Ceará^cFortaleza^sCE
^pBrasil#^len^aThe signaling lymphocytic activation molecule (SLAM), present on 
the surface of hematopoietic cells, can regulate some events of the immune respo
nses. This modulatory action is associated with the capacity of SLAM to interact
 with an intracytoplasmic adapter, such as SLAM-associated protein (SAP). SLAM i
s constitutively expressed in most of these cells, is rapidly induced after anti
genic or inflammatory stimuli, and participates in the immunological synapse. De
fects in the function of the SLAM-SAP pathway contribute to immunological abnorm
alities, resulting in autoimmune diseases, tumors of the lymphoid tissues and in
adequate responses to infectious agents. Initially, the role of SLAM was investi
gated using an anti-SLAM monoclonal antibody (&#945;-SLAM mAb) identified as an 
agonist of the SLAM-SAP pathway, which could induce the production of interferon
-&#947; and could redirect the immune response to a T helper 1 (Th1) cell profil
e. However, in this review we postulate that the SLAM-SAP pathway primarily indu
ces a Th2 response and secondarily suppresses the Th1 response.#^dnd^i1#^tm^len^
kSLAM^i1#^tm^len^kSAP^i1#^tm^len^kIFN-&#947;^i1#^tm^len^kImmunoreceptor^i1#^tm^l
en^kImmunomodulation^i1#other#58#20100918#September 18, 2010#20110221#February 2
1, 2011#721.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid
=S0100-879X2011000400002##
00373000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014900070002000800219#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#5#1#article#186#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 276-275  </B> </font></P>      ^cY#721.htm##
00425000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704020100070002000800271#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#6#2#article#186#<p ALIGN="LEFT"><font siz
e="5" face="Arial"><span lang="EN"><strong>The role of the SLAM-SAP signaling pa
thway in the modulation of CD4<sup>+</sup> T cell responses</strong></span></fon
t></p>      ^cY#721.htm##
00866000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704064200070002000800712#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#7#3#article#186#<p ALIGN="LEFT"><font fac
e="Arial"><span lang="EN">M.L.L.V. Vilar<sup>1,2,3</sup>, M.S. Frutuoso<sup>2,3<
/sup>, S.M. Arruda<sup>1,4</sup>, D.M. Lima<sup>2</sup>, </span></font><font fac
e="Arial"><span lang="EN">C.S. Bezerra<sup>5</sup> and <span lang="EN"><font fac
e="Arial, Helvetica, sans-serif"><sup><span lang="EN"><font face="Arial, Helveti
ca, sans-serif"><b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v44n4
/recor.gif" border="0"></a></b> <a href="mailto:mpompeu@ufc.br"><img src="/img/r
evistas/bjmbr/v44n4/email-ca.gif" border="0"></a></font></span></sup></font></sp
an> M.M.L. Pompeu<sup>2</sup></span></font></p>      ^cY#721.htm##
00400000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704017600070002000800246#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#8#4#article#186#<p ALIGN="LEFT"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Escola Bahiana de M
edicina e Sa&uacute;de P&uacute;blica/FDC, Salvador, BA, Brasil    ^cY#721.htm##
00419000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704019500070002000800265#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#9#5#article#186#<br>    </font></span><fo
nt face="Arial"><span lang="EN"><sup>2</sup>N&uacute;cleo de Medicina Tropical, 
Faculdade de Medicina, Universidade Federal do Cear&aacute;, Fortaleza, CE, Bras
il    ^cY#721.htm##
00362000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704013700071002000800208#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#10#6#article#186#<br>    </span></font><f
ont face="Arial"><span lang="EN"><sup>3</sup>Curso de Medicina, Faculdade Christ
us, Fortaleza, CE, Brasil    ^cY#721.htm##
00372000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704014700071002000800218#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#11#7#article#186#<br>    </span></font><f
ont face="Arial"><span lang="EN"><sup>4</sup>Centro de Pesquisa Gon&ccedil;alo M
oniz, FIOCRUZ, Salvador, BA, Brasil    ^cY#721.htm##
00430000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704020500071002000800276#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#12#8#article#186#<br>  </span></font><fon
t face="Arial"><span lang="EN"><sup>5</sup>Instituto Federal de Educa&ccedil;&at
ilde;o, Ci&ecirc;ncia e Tecnologia do Cear&aacute;, Fortaleza, CE, Brasil</span>
</font></p>      ^cY#721.htm##
00415000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704019000071002000800261#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#13#9#article#186#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#721.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016400072002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#14#10#article#186#<BR>    <A HREF="#Text"
><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HS
PACE=0></A> <A HREF="#Text"><strong>Text</strong></A>    ^cY#721.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#15#11#article#186#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#721.htm##
00460000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704023400072002000800306#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#16#12#article#186#<br>   </strong></A>   
<A HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspon
dence and Footnotes</strong></A>  </font>      ^cY#721.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#17#13#article#186#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#721.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#18#14#article#186#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#721.htm##
01395000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704116900072002000801241#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#19#15#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The signaling lymphocytic activation molecule (SLAM)
, present on the surface of hematopoietic cells, can regulate some events of the
 immune responses. This modulatory action is associated with the capacity of SLA
M to interact with an intracytoplasmic adapter, such as SLAM-associated protein 
(SAP). SLAM is constitutively expressed in most of these cells, is rapidly induc
ed after antigenic or inflammatory stimuli, and participates in the immunologica
l synapse. Defects in the function of the SLAM-SAP pathway contribute to immunol
ogical abnormalities, resulting in autoimmune diseases, tumors of the lymphoid t
issues and inadequate responses to infectious agents. Initially, the role of SLA
M was investigated using an anti-SLAM monoclonal antibody (&alpha;-SLAM mAb) ide
ntified as an agonist of the SLAM-SAP pathway, which could induce the production
 of interferon-&gamma; and could redirect the immune response to a T helper 1 (T
h1) cell profile. However, in this review we postulate that the SLAM-SAP pathway
 primarily induces a Th2 response and secondarily suppresses the Th1 response.</
span></font></p>      ^cY#721.htm##
00396000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017000072002000800242#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#20#16#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Key words: SLAM; SAP; IFN-&gamma;; Immunoreceptor; I
mmunomodulation</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#721.htm##
00540000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031400072002000800386#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#21#17#article#186#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Text" id="Text"></A><FONT color="#00007F" SIZE=4>
<B>Text</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A 
HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDE
R=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#721.htm##
00324000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009800072002000800170#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#22#18#article#186#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Introduction</span></font></b></p>      ^cY#721.h
tm##
01780000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704155400072002000801626#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#23#19#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The response of the cells of the immune system is co
ntrolled by the equilibrium of signals received by a large number of cell surfac
e receptors, among them the activation receptors, co-stimulatory molecules and i
nhibitory molecules (1,2). Binding of immunoreceptors by their ligands induces a
 tyrosine phosphorylation signal that is essential for cell activation. Although
 immunoreceptors such as the T cell receptor (TCR) and the B cell receptor have 
no intrinsic protein tyrosine kinase activity, they associate with subunits bear
ing immunoreceptor tyrosine-based activation motifs in their intracellular domai
n (3). Signaling through the immunoreceptors alone is not sufficient for the act
ivation of gene transcription. The amplification of the signal is also necessary
. Therefore, co-receptors and co-stimulatory molecules come into play. Evidence 
indicates that receptors of the signaling lymphocytic activation molecule (SLAM)
 family and a group of intracellular adapter proteins, chiefly SLAM-associated p
rotein (SAP) among them, are involved in the modulation of the immune responses 
(2-5). Following the activation of T lymphocytes, the SLAM-SAP signaling pathway
 exerts an important function in inducing the expression of the T helper 2 (Th2)
 cytokine (6), in the production of antibodies, in the generation of memory B ce
lls, in the activation as well as the inhibition of natural killer (NK) cells,&n
bsp;and in the development of natural killer T (NKT) cells (3).</span></font></p
>      ^cY#721.htm##
00351000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704012500072002000800197#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#24#20#article#186#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">The family of receptors related to SLAM</span></f
ont></b></p>      ^cY#721.htm##
00639000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704041300072002000800485#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#25#21#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The SLAM family of receptors is a subgroup of the im
munoglobulin super family, which regulates the function of T cells, B lymphocyte
s, macrophages, and mature dendritic cells (2-7), thereby influencing both the i
nnate and the adaptive immune responses. These families include nine receptors (
3,4,6,8-11) (<a href="#Tab1">Table 1</a>).</span></font></p>      ^cY#721.htm##
00651000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704042500072002000800497#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#26#22#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">All members of the SLAM family have a structure unco
mmon in the extracellular region. It is characterized by a variable Ig-like N-te
rminal domain (V) and a constant type 2 Ig-like C-terminal domain (C2), except f
or CD229 (Ly-9),&nbsp;which has a V-C2 domain, a transmembrane region, and a cyt
oplasmic portion containing tyrosine-based motifs (8).</span></font></p>      ^c
Y#721.htm##
00804000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704057800072002000800650#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#27#23#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The action of the SLAM family of receptors results i
n the phosphorylation of these molecules by protein kinases of the Src family (1
2). These receptors also function as their own ligands, with the exception of 2B
4, which is involved in homotypic and heterotypic cell-cell interactions (8,12).
 Each receptor initiates a signal whose end result will depend on the dispositio
n of the tyrosine motifs in their cytoplasmic domain, their amino acid sequence 
and the types of amino acids they contain (13).</span></font></p>      ^cY#721.h
tm##
00835000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704060900072002000800681#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#28#24#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The genes encoding the receptors related to SLAM are
 located on chromosome 1, at the SLAM locus, in both humans and mice, with the e
xception of CD2, which is located on chromosome 3 (4,14). These receptors have b
een implicated in the physiopathology of autoimmunity. The Sle1b region confers 
a greater susceptibility to systemic lupus erytematosus in mice, and corresponds
 to the region of the gene of the SLAM family (15). Polymorphisms in this partic
ular region have been associated with human systemic lupus erythematosus (16).</
span></font></p>      ^cY#721.htm##
00357000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013100072002000800203#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#29#25#article#186#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">The signaling lymphocytic activation molecule</sp
an></font></b></p>      ^cY#721.htm##
01400000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704117400072002000801246#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#30#26#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The SLAM was initially identified in human cells as 
IPO-3, a cell surface glycoprotein that was expressed in cells of the immune sys
tem (17,18) and was later cloned (A12) and named the SLAM (19). This receptor ha
s a molecular mass of 70 kDa and is made up of 335 amino acids. Its structure in
cludes an extracellular portion containing 202 amino acids, a transmembrane regi
on with 22 amino acids and a cytoplasmic region with 77 amino acids. The cytopla
smic portion has a domain containing three motifs with tyrosine residues Y<sup>2
81</sup>, Y<sup>307</sup>, and Y<sup>327</sup>. The motif that contains tyrosine
 residue Y<sup>281</sup> shows a greater affinity for SAP (20). The tyrosine-bas
ed motifs are constituted by the consensus amino acid sequence TxYxxV/I, where T
 corresponds to threonine, Y to tyrosine, V to valine, I to isoleucine, and x to
 any other amino acid residue (8). SLAM has the capacity to interact in a homoty
pic way at the level of its extracellular domains, but with a low affinity (8,12
), and functions through a bidirectional signaling after SLAM-SLAM binding (19,2
1).</span></font></p>      ^cY#721.htm##
00711000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704048500072002000800557#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#31#27#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Four SLAM isoforms have been identified thus far, al
l originating from the selective elimination of exons - splicing. Two of these a
re composed of 305 amino acids and correspond to the transmembrane extension and
 the other two are cytoplasmic, with one being soluble. The soluble form of SLAM
 is capable of interacting with SLAM expressed on the cell membrane surface, inf
luencing the immune response (18).</span></font></p>      ^cY#721.htm##
01158000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704093200072002000801004#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#32#28#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The expression of SLAM is demonstrated in the cells 
of innate as well as adaptive immunity (1), such as thymocytes, monocytes, macro
phages, dendritic cells, B and T lymphocytes, NK cells, granulocytes, and platel
ets, in both human and murine models (8,17,18). In the majority of these hematop
oietic cells, the expression of SLAM occurs constitutively, being rapidly induce
d in T and B lymphocytes in viral infections, and in dendritic cells by antigeni
c (22) or inflammatory stimuli, such as lipopolysaccharide and interleukin-1&bet
a; (IL-1&beta;) (23), and in macrophages activated by LPS and interferon-&gamma;
 (IFN-&gamma;) (8,19,24). The expression of this molecule was also observed in h
ematopoietic cells of the bone marrow, liver of fetal mice (25), ganglia, spleen
 and tonsils, as well as in a particular subpopulation of endothelial cells (14)
.</span></font></p>      ^cY#721.htm##
00595000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704036900072002000800441#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#33#29#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">SLAM has been considered to be the principal recepto
r of measles virus, contributing to the lymphotropic characteristic of this infe
ctious agent, which induces lymphopenia (26) and immunosuppression (27). Other a
gents, such as morbilliviruses, also utilize this molecule as a receptor (14).</
span></font></p>      ^cY#721.htm##
01334000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704110800072002000801180#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#34#30#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">SLAM promotes the adhesion between T lymphocytes and
 antigen-presenting cells, participating in the formation of the immunological s
ynapse, principally in the co-stimulation dependent on TCR (4,12,19). This co-st
imulator also modulates the production of cytokines by CD4<sup>+</sup> T lymphoc
ytes, macrophages and dendritic cells, where their actions differ depending on t
he type of stimulus (6). An increase in the expression of SLAM has been observed
 in autoimmune diseases such as experimental murine lupus (16) and human multipl
e sclerosis (28). Greater concentrations of soluble forms of SLAM have been dete
cted in the synovial fluid of patients with rheumatoid arthritis (29). There is 
evidence that SLAM causes an amplification of the secretion of Th2 cytokines in 
allergic responses (30). Also, a study evaluating patients with tuberculosis sho
wed that the activation of SLAM induces the phosphorylation of the transcription
 factor cAMP response element-binding protein (CREB) (31) and the production of 
IFN-&gamma; (32).</span></font></p>      ^cY#721.htm##
00349000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704012300072002000800195#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#35#31#article#186#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">The family of adapters related to SAP</span></fon
t></b></p>      ^cY#721.htm##
00835000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704060900072002000800681#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#36#32#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The molecules of adapters related to SAP represents 
a family of cytoplasmic proteins composed of a single Src homology 2 (SH2) domai
n and a small carboxy-terminal region (33). It has been suggested that this carb
oxy-terminal region of SAP can be associated with the stability of this molecule
 (2). These proteins are involved in the pattern of intracellular signaling, pri
ncipally in the regulation of the process of lymphocyte activation (11,34), and 
modulate the activity of various members of the family of SLAM receptors (20).</
span></font></p>      ^cY#721.htm##
00587000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704036100072002000800433#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#37#33#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">This family includes 3 members (3,6,9-11) (<a href="
#Tab2">Table 2</a>). In mice and humans, chromosome 1 harbors the genes encoding
 EAT-2 in the regions 1q22 and ERT, next to the SLAM locus, while the SAP gene i
s located on the long arm of chromosome X, in the Xq25 region (33,35).</span></f
ont></p>      ^cY#721.htm##
00678000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704045200072002000800524#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#38#34#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The expression of SAP, or its mRNA, has been detecte
d in thymocytes, T lymphocytes, NK cells, and NKT lymphocytes, as well as in pla
telets, eosinophils (36-38), and some B lymphocytes (36). Other reports have sho
wn this expression in neuronal cells, proliferative nodules of chronic lymphocyt
ic leukemia (39) and germinal centers of angioimmunoblastic T cell lymphoma (40)
.</span></font></p>      ^cY#721.htm##
00339000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011300072002000800185#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#39#35#article#186#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">The SLAM-associated protein</span></font></b></p>
      ^cY#721.htm##
00842000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704061600072002000800688#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#40#36#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The SAP has a molecular mass of 15 kDa, is composed 
of 128 amino acids, with a single SH2 domain (34) and a carboxy-terminal region 
of 24 to 26 amino acids. The SH2 domain has two binding surfaces; one of the sur
faces interacts with a tyrosine-based motif, i.e., immunoreceptor tyrosine-based
 switch motif (ITSM) (41) in the cytoplasmic portion of SLAM, via the region con
taining an arginine at position 32 (Arg32) (33,35), while the other, with argini
ne at position 78 (Arg78), binds to the SH3 domain of tyrosine phosphokinase (11
,33).</span></font></p>      ^cY#721.htm##
01078000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704085200072002000800924#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#41#37#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The protein adapter related to SAP binds with high a
ffinity, through its SH2 domains, to tyrosine-based motifs located in the cytopl
asmic domains of the receptors of the SLAM family (21,42). SAP is involved in th
e transduction of intracellular signals, interacting with the cytoplasmic tail o
f SLAM through its SH2 domain and thereby blocking the binding of proteins with 
this region, independent of phosphorylation (2,4,5,43). In addition, SAP promote
s the recruitment and enzymatic activation of protein tyrosine kinase Fyn T, ind
ucing the phosphorylation of the cytoplasmic domain of SLAM and allowing the pro
pagation of events of the signaling cascade (20,42). In neural cells, SAP exerts
 its role through the recruitment of protein kinases related to tropomyosin (39)
.</span></font></p>      ^cY#721.htm##
00596000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704037000072002000800442#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#42#38#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The engagement of SAP in the signaling pathway throu
gh SLAM influences the immune response, resulting in the production of IL-4, for
mation of germinal centers, activation of human NK cells, development of NKT lym
phocytes, and activation of the regulator of CD8<sup>+</sup> T lymphocytes (6).<
/span></font></p>      ^cY#721.htm##
00646000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704042000072002000800492#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#43#39#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Mutations or deletions of the SH2D1A gene lead to an
 X-linked lymphoproliferative syndrome (4,33,35,44), a primary immunodeficiency 
characterized by an elevated susceptibility to infection by Epstein-Barr virus (
33), with a high risk for the development of fulminant infectious mononucleosis,
 B cell lymphoma and dysgammaglobulinemia (4,24).</span></font></p>      ^cY#721
.htm##
00599000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704037300072002000800445#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#44#40#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The deletion of the gene that encodes SAP, depending
 on the immune system cells involved, can result in a reduction of Th2 cytokines
, the cytotoxicity of NK and CD8<sup>+</sup> cells, the formation of the germina
l centers, and the production of T lymphocyte-dependent antibodies (5,6,36,45,46
).</span></font></p>      ^cY#721.htm##
01145000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704091900072002000800991#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#45#41#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">SAP<sup>-/-</sup> mice show a deficiency in antitumo
r immunity and immune responses to viral infection, and can even display a tende
ncy towards hypogammaglobulinemia (5,47). These animals fail to adequately contr
ol infections due to the development of defects in cell-mediated immunity such a
s the increase in the proliferation of antigen-specific CD4<sup>+</sup> and CD8<
sup>+</sup> lymphocytes. After a stimulus with lymphocytic choriomeningitis viru
s, <i>Leishmania major </i>or <i>Toxoplasma gondii</i>, these mice display a cyt
okine response of the Th1 phenotype. Despite surviving the acute infection by ly
mphocytic choriomeningitis virus, these animals show high mortality due to the l
ack of an intense and prolonged Th1 response, as is generally demonstrable in th
e spleen and liver cells of animals infected with these agents (48).</span></fon
t></p>      ^cY#721.htm##
00342000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011600072002000800188#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#46#42#article#186#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">The SLAM-SAP signaling pathway</span></font></b><
/p>      ^cY#721.htm##
00434000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020800072002000800280#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#47#43#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">TCR activation induces SLAM expression on the membra
ne of immune response cells and SLAM amplifies the TCR signaling trigger (9).</s
pan></font></p>      ^cY#721.htm##
01613000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704138700072002000801459#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#48#44#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The interaction between SLAM and SAP occurs through 
the SH2 domain of SAP centered on arginine 32 (Arg32), which binds to ITSM, pres
ent in the cytoplasmic portion of SLAM. This binding does not depend on the phos
phorylation of Y281, suggesting that SAP is constitutively associated with SLAM.
 SAP acts as a natural inhibitor, competing with other proteins containing the S
H2 domain, such as tyrosine phosphatase (SHP-2), by binding to the same ITSM in 
SLAM (33). After binding to SLAM, SAP undergoes a conformational change and then
 binds to and activates Fyn T (49) through another binding surface in the SH2 do
main containing arginine at position 78 (Arg78), forming a multiprotein complex.
 Upon recruiting Fyn T for SLAM, SAP phosphorylates the cytoplasmic portion of S
LAM-ITSM, initiating cytoplasmic signal transduction (7,42). Thus, the phosphory
lated site in the SLAM serves as the base for the SH2 domain of inositol-contain
ing phosphatase (SHIP), which then phosphorylates and binds to the adapters of d
ocking protein (Dok)-1 and Dok-2. The phosphorylated Dok-2 binds to the SH2 doma
in of Ras GTPase activating protein (RasGAP) (20). The overall result of this pa
thway activation is the increasing production of IL-4 and suppression of IFN-&ga
mma; production (6,9,21) (<a href="#Fig1">Figure 1</a>).</span></font></p>      
^cY#721.htm##
01109000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704088300072002000800955#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#49#45#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The SLAM-SAP signaling pathway can also modulate the
 immune response through the TCR interaction, while SAP regulates the activation
 of protein kinase C-teta, B cell lymphoma 10, NF-&kappa;B, and GATA-3 (6,50) (<
a href="#Fig1">Figure 1</a>). The transcription factor GATA-3 acts as positive r
egulator of the genes of Th2 cytokines, increasing IL-4, IL-5 and IL-13 producti
on. On the other hand, GATA-3 also suppresses IFN-&gamma; genomic programs (51) 
and at the same time inhibits receptor IL-2 expression (6). Simultaneously, IL-1
3 inhibits the IL-12 receptor &beta;&rsquo;-chain synthesis (52). All of these e
vents together impair the Th1 response. Contributing to this idea, a study with 
murine thymoma cells showed that the SLAM-SLAM interaction induced the reduction
 of IFN-&gamma; production (21).</span></font></p>      ^cY#721.htm##
01071000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704084500072002000800917#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#50#46#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">It must be emphasized that the result of the SLAM-SA
P signaling pathway depends on various factors, such as: the antigen receptor, s
timulus intensity, the SLAM redundancy, the mode of induction of expression of S
LAM family of receptors, the type and amount of &alpha;-SLAM antibody used, and 
the substrates involved in the downstream. Models of deficient mice in SLAM fami
ly of receptors (SLAM, Ly108 or Ly9) showed a reduction in the production of Th2
 cytokines, but this alteration was not as marked as in SAP-deficient mice (53,5
4). The probable explanation for this phenomenon is the likelihood of a redundan
t expression of the SLAM family receptors in the same cell, which could contribu
te to overcome or mask the deficiency or absence of the receptor (3,6,31).</span
></font></p>      ^cY#721.htm##
00856000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704063000072002000800702#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#51#47#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Initially, the role of SLAM was investigated using a
nti-SLAM monoclonal antibody (&alpha;-SLAM mAb). Several investigators observed 
that, the TCR stimulation in the presence of &alpha;-SLAM mAb induced an increas
e in IFN-&gamma; production (17,19,21) and cytotoxicity of CD8<sup>+</sup> T lym
phocytes (55). These findings led to the belief that the &alpha;-SLAM mAb was ag
onistic and that its activation regulated the differentiation of T cell, increas
ing the production of IFN-&gamma; and redirecting the immune response toward a T
h1 profile (17,19).</span></font></p>      ^cY#721.htm##
01008000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704078200072002000800854#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#52#48#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">However, it is possible that the &alpha;-SLAM mAb ma
y act by blocking the binding sites of SLAM in its extracellular portion, preven
ting the activation of the signaling pathway (3,6). Another possibility is that 
&alpha;-SLAM mAb was bound to SLAM soluble molecules or to be associated with TC
R molecules due to electric charge affinity, leading to &alpha;-SLAM mAb functio
nal sequestrum, implying in inactivation of SLAM-SAP signaling pathway (9). It w
as also shown that, in the <i>in vitro</i> sensitization of human lymphocytes wi
th <i>Leishmania amazonensis</i>, the anti-SLAM antibody induced an important in
hibition of IL-13 production, with a slight increase in the production of IFN-&g
amma; (56).</span></font></p>      ^cY#721.htm##
00758000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704053200072002000800604#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#53#49#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">These data strengthen the hypothesis that SLAM-SAP s
ignaling pathway is not primarily involved in Th1 differentiation and that block
ing this signaling pathway with the &alpha;-SLAM mAb directly undermines the Th2
 response. Another important contribution to a better understanding of the SLAM-
SAP signaling pathway came from studies with genetically modified mouse models, 
or human cells with mutations of SAP, as in X-linked lymphoproliferative disease
.</span></font></p>      ^cY#721.htm##
01046000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704082000072002000800892#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#54#50#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">It has been reported that CD4<sup>+</sup> T cells of
 mice deficient in SAP, when stimulated <i>in vitro</i>, show an increase in the
 production of IL-2 and IFN-&gamma;, accompanied by a simultaneous reduction in 
the secretion of IL-4 and IL-13 (48,57,58), as well as the reduction in the expr
ession of the transcription factor GATA-3 (57). Other studies have also demonstr
ated that CD4<sup>+</sup> T cells of mice deficient in SLAM show a reduction of 
IL-4 and IL-13 production, with mild increase in the production of IFN-&gamma; (
24,57). The same effect can be seen in Fyn T<sup>-/-</sup> mice stimulated with 
TCR, which show reduction in the phosphorylation of B cell lymphoma 10 and, as a
 consequence, a decrease in IL-4 production (50).</span></font></p>      ^cY#721
.htm##
00769000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704054300072002000800615#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#55#51#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The blocking of the SLAM-SAP signaling pathway simul
ates the effects of the deficiency of both SLAM and SAP since the tyrosine phosp
horylation cascade initiated by this pathway exerts its action only if SLAM and 
SAP are available (21). These results demonstrate the interdependence of SLAM an
d SAP receptors in this signaling pathway and their action in Th2 differentiatio
n. These findings imply that SLAM is primarily involved in promoting Th2-cytokin
e secretion.</span></font></p>      ^cY#721.htm##
01375000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704114900072002000801221#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#56#52#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">In summary, the SLAM receptor plays an important rol
e in the immunological synapse, where it is detected in almost all cells of the 
immune system. Although the results of some studies suggest that SLAM is an indu
cer of IFN-&gamma;, we agree with the interpretation that the SLAM-SAP interplay
 can be an important signaling pathway for inducing the synthesis of Th2 cytokin
es, and exerting a down-modulation of the Th1 immune response. Thus, the defects
 in the SLAM-SAP pathway could potentially contribute to the various immunologic
al abnormalities observed both in humans and in murine models. In addition, adva
nces in knowledge of this signaling pathway may lead to new strategies for the t
reatment and prevention of autoimmune, allergic, neoplastic, and infectious dise
ases.</span></font><span lang="EN"><font face="Arial, Helvetica, sans-serif"> </
font></span></p>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left
" valign="top">      <td><a href="/img/revistas/bjmbr/v44n4/html/721i01.htm"><im
g src="/img/revistas/bjmbr/v44n4/721i01peq.jpg" border="2"></a></td>      <td>  
  ^cY#721.htm##
01111000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704088500072002000800957#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#57#53#article#186#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. 
SLAM-SAP signaling pathway. After T cell receptor (TCR) activation, signaling ly
mphocytic activation molecule (SLAM) binds to SLAM-associated protein (SAP), whi
ch recruits and activates the protein tyrosine kinase Fyn T. Phosphorylated SLAM
 triggers the activation of substrates downstream, such as the SH2 domain of ino
sitol-containing phosphatase (SHIP), Dok (docking protein)-1, Dok-2 and Ras GTPa
se activating protein (RasGAP). Still, the interaction between TCR and the SLAM-
SAP signaling pathway leads the activation of substrates, such as protein kinase
 C-teta (PKC-&theta;), B cell lymphoma 10 (Bcl-10), nuclear factor-&kappa;B (NF-
&kappa;B), and GATA-3. These signaling pathways increase Th2 cytokines such as I
L-4.</font></span></p>      </td>    </tr>  </table>      ^cY#721.htm##
00558000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033200072002000800404#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#58#54#article#186#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/721t01.htm"><img src="/img/r
evistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#721.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#59#55#article#186#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Tab1"></a>Table 1. Expression, ligands and 
effects of the signaling lymphocytic activation molecule (SLAM) family of recept
ors in hemopoietic cells.</span></font></p>      </td>    </tr>  </table>      ^
cY#721.htm##
00860000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704063400072002000800706#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#60#56#article#186#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (? K JPG file)]</font><
/P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/721t02.htm"><img src="/img/r
evistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td><span lang="EN"><fo
nt face="Arial"><span lang="EN"><a name="Tab2"></a>Table 2. Expression of the si
gnaling lymphocytic activation molecule (SLAM) family of receptors and effects o
f the SLAM-associated protein (SAP) family of adaptors on hemopoietic cells.</sp
an></font></span></td>    </tr>  </table>      ^cY#721.htm##
00342000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011600072002000800188#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#61#57#article#186#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (? K JPG file)]</font><
/P>      ^cY#721.htm##
00264000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003800072002000800110#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#62#58#article#186#<P>   <HR ALIGN=LEFT SI
ZE=2>      ^cY#721.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#63#59#article#186#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#721.htm##
00458000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704021800074002000800292#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#64#60#article#186#1#<p ALIGN=
"LEFT"><font face="Arial"><span lang="EN">1. Veillette A, Dong Z, Latour S. Cons
equence of the SLAM-SAP signaling pathway in innate-like and conventional lympho
cytes. <i>Immunity</i> 2007; 27: 698-710.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#65#61#article#186#</span></font></p>     
 ^cY#721.htm##
00413000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704017300074002000800247#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#66#62#article#186#2#<p align=
"LEFT"><font face="Arial"><span lang="EN">2. Latour S, Veillette A. The SAP fami
ly of adaptors in immune regulation. <i>Semin Immunol</i> 2004; 16: 409-419.    
^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#67#63#article#186#</span></font></p>     
 ^cY#721.htm##
00422000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704018200074002000800256#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#68#64#article#186#3#<p align=
"LEFT"><font face="Arial"><span lang="EN">3. Veillette A. Immune regulation by S
LAM family receptors and SAP-related adaptors. <i>Nat Rev Immunol</i> 2006; 6: 5
6-66.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#69#65#article#186#</span></font></p>     
 ^cY#721.htm##
00459000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704021900074002000800293#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#70#66#article#186#4#<p align=
"LEFT"><font face="Arial"><span lang="EN">4. Engel P, Eck MJ, Terhorst C. The SA
P and SLAM families in immune responses and X-linked lymphoproliferative disease
. <i>Nat Rev Immunol</i> 2003; 3: 813-821.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#71#67#article#186#</span></font></p>     
 ^cY#721.htm##
00476000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704023600074002000800310#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#72#68#article#186#5#<p align=
"LEFT"><font face="Arial"><span lang="EN">5. Nichols KE, Ma CS, Cannons JL, Schw
artzberg PL, Tangye SG. Molecular and cellular pathogenesis of X-linked lymphopr
oliferative disease. <i>Immunol Rev</i> 2005; 203: 180-199.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#73#69#article#186#</span></font></p>     
 ^cY#721.htm##
00469000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704022900074002000800303#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#74#70#article#186#6#<p align=
"LEFT"><font face="Arial"><span lang="EN">6. Ma CS, Nichols KE, Tangye SG. Regul
ation of cellular and humoral immune responses by the SLAM and SAP families of m
olecules. <i>Annu Rev Immunol</i> 2007; 25: 337-379.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#75#71#article#186#</span></font></p>     
 ^cY#721.htm##
00457000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704021700074002000800291#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#76#72#article#186#7#<p align=
"LEFT"><font face="Arial"><span lang="EN">7. Chan AY, Westcott JM, Mooney JM, Wa
keland EK, Schatzle JD. The role of SAP and the SLAM family in autoimmunity. <i>
Curr Opin Immunol</i> 2006; 18: 656-664.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#77#73#article#186#</span></font></p>     
 ^cY#721.htm##
00559000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704031900074002000800393#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#78#74#article#186#8#<p align=
"LEFT"><font face="Arial"><span lang="EN">8. Romero X, Zapater N, Calvo M, Kalko
 SG, de la Fuente MA, Tovar V, et al. CD229 (Ly9) lymphocyte cell surface recept
or interacts homophilically through its N-terminal domain and relocalizes to the
 immunological synapse. <i>J Immunol</i> 2005; 174: 7033-7042.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#79#75#article#186#</span></font></p>     
 ^cY#721.htm##
00445000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704020500074002000800279#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#80#76#article#186#9#<p align=
"LEFT"><font face="Arial"><span lang="EN">9. Veillette A, Cruz-Munoz ME, Zhong M
C. SLAM family receptors and SAP-related adaptors: matters arising. <i>Trends Im
munol</i> 2006; 27: 228-234.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#81#77#article#186#</span></font></p>     
 ^cY#721.htm##
00500000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025900075002000800334#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#82#78#article#186#10#<p align
="LEFT"><font face="Arial"><span lang="EN">10. Valdez PA, Wang H, Seshasayee D, 
van Lookeren CM, Gurney A, Lee WP, et al. NTB-A, a new activating receptor in T 
cells that regulates autoimmune disease. <i>J Biol Chem</i> 2004; 279: 18662-186
69.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#83#79#article#186#</span></font></p>     
 ^cY#721.htm##
00498000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025700075002000800332#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#84#80#article#186#11#<p align
="LEFT"><font face="Arial"><span lang="EN">11. Roncagalli R, Taylor JE, Zhang S,
 Shi X, Chen R, Cruz-Munoz ME, et al. Negative regulation of natural killer cell
 function by EAT-2, a SAP-related adaptor. <i>Nat Immunol</i> 2005; 6: 1002-1010
.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#85#81#article#186#</span></font></p>     
 ^cY#721.htm##
00530000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704028900075002000800364#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#86#82#article#186#12#<p align
="LEFT"><font face="Arial"><span lang="EN">12. Mavaddat N, Mason DW, Atkinson PD
, Evans EJ, Gilbert RJ, Stuart DI, et al. Signaling lymphocytic activation molec
ule (CDw150) is homophilic but self-associates with very low affinity. <i>J Biol
 Chem</i> 2000; 275: 28100-28109.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#87#83#article#186#</span></font></p>     
 ^cY#721.htm##
00517000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704027600075002000800351#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#88#84#article#186#13#<p align
="LEFT"><font face="Arial"><span lang="EN">13. Chen R, Relouzat F, Roncagalli R,
 Aoukaty A, Tan R, Latour S, et al. Molecular dissection of 2B4 signaling: impli
cations for signal transduction by SLAM-related receptors. <i>Mol Cell Biol</i> 
2004; 24: 5144-5156.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#89#85#article#186#</span></font></p>     
 ^cY#721.htm##
00428000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704018700075002000800262#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#90#86#article#186#14#<p align
="LEFT"><font face="Arial"><span lang="EN">14. Sidorenko SP, Clark EA. The dual-
function CD150 receptor subfamily: the viral attraction. <i>Nat Immunol</i> 2003
; 4: 19-24.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#91#87#article#186#</span></font></p>     
 ^cY#721.htm##
00499000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025800075002000800333#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#92#88#article#186#15#<p align
="LEFT"><font face="Arial"><span lang="EN">15. Wandstrat AE, Nguyen C, Limaye N,
 Chan AY, Subramanian S, Tian XH, et al. Association of extensive polymorphisms 
in the SLAM/CD2 gene cluster with murine lupus. <i>Immunity</i> 2004; 21: 769-78
0.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#93#89#article#186#</span></font></p>     
 ^cY#721.htm##
00509000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704026800075002000800343#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#94#90#article#186#16#<p align
="LEFT"><font face="Arial"><span lang="EN">16. Shai R, Quismorio FP Jr, Li L, Kw
on OJ, Morrison J, Wallace DJ, et al. Genome-wide screen for systemic lupus eryt
hematosus susceptibility genes in multiplex families. <i>Hum Mol Genet</i> 1999;
 8: 639-644.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#95#91#article#186#</span></font></p>     
 ^cY#721.htm##
00582000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704034100075002000800416#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#96#92#article#186#17#<p align
="LEFT"><font face="Arial"><span lang="EN">17. Castro AG, Hauser TM, Cocks BG, A
brams J, Zurawski S, Churakova T, et al. Molecular and functional characterizati
on of mouse signaling lymphocytic activation molecule (SLAM): differential expre
ssion and responsiveness in Th1 and Th2 cells. <i>J Immunol</i> 1999; 163: 5860-
5870.    ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#97#93#article#186#</span></font></p>     
 ^cY#721.htm##
00575000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704033400075002000800409#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#98#94#article#186#18#<p align
="LEFT"><font face="Arial"><span lang="EN">18. Punnonen J, Cocks BG, Carballido 
JM, Bennett B, Peterson D, Aversa G, et al. Soluble and membrane-bound forms of 
signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig syn
thesis by activated human B lymphocytes. <i>J Exp Med</i> 1997; 185: 993-1004.  
  ^cY#721.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#99#95#article#186#</span></font></p>     
 ^cY#721.htm##
00453000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704021100076002000800287#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#100#96#article#186#19#<p alig
n="LEFT"><font face="Arial"><span lang="EN">19. Cocks BG, Chang CC, Carballido J
M, Yssel H, de Vries JE, Aversa G. A novel receptor involved in T-cell activatio
n. <i>Nature</i> 1995; 376: 260-263.    ^cY#721.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#101#97#article#186#</span></font></p>    
  ^cY#721.htm##
00456000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704021400076002000800290#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#102#98#article#186#20#<p alig
n="LEFT"><font face="Arial"><span lang="EN">20. Chan B, Lanyi A, Song HK, Griesb
ach J, Simarro-Grande M, Poy F, et al. SAP couples Fyn to SLAM immune receptors.
 <i>Nat Cell Biol</i> 2003; 5: 155-160.    ^cY#721.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#103#99#article#186#</span></font></p>    
  ^cY#721.htm##
00513000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027000077002000800347#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#104#100#article#186#21#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">21. Latour S, Gish G, Helgason CD, 
Humphries RK, Pawson T, Veillette A. Regulation of SLAM-mediated signal transduc
tion by SAP, the X-linked lymphoproliferative gene product. <i>Nat Immunol</i> 2
001; 2: 681-690.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#105#101#article#186#</span></font></p>   
   ^cY#721.htm##
00498000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704025500077002000800332#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#106#102#article#186#22#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">22. Nanda N, Andre P, Bao M, Clause
r K, Deguzman F, Howie D, et al. Platelet aggregation induces platelet aggregate
 stability via SLAM family receptor signaling. <i>Blood</i> 2005; 106: 3028-3034
.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#107#103#article#186#</span></font></p>   
   ^cY#721.htm##
00533000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029000077002000800367#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#108#104#article#186#23#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">23. Kruse M, Meinl E, Henning G, Ku
hnt C, Berchtold S, Berger T, et al. Signaling lymphocytic activation molecule i
s expressed on mature CD83+ dendritic cells and is up-regulated by IL-1 beta. <i
>J Immunol</i> 2001; 167: 1989-1995.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#109#105#article#186#</span></font></p>   
   ^cY#721.htm##
00484000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024100077002000800318#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#110#106#article#186#24#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">24. Wang N, Satoskar A, Faubion W, 
Howie D, Okamoto S, Feske S, et al. The cell surface receptor SLAM controls T ce
ll and macrophage functions. <i>J Exp Med</i> 2004; 199: 1255-1264.    ^cY#721.h
tm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#111#107#article#186#</span></font></p>   
   ^cY#721.htm##
00527000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028400077002000800361#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#112#108#article#186#25#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">25. Kiel MJ, Yilmaz OH, Iwashita T,
 Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoi
etic stem and progenitor cells and reveal endothelial niches for stem cells. <i>
Cell</i> 2005; 121: 1109-1121.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#113#109#article#186#</span></font></p>   
   ^cY#721.htm##
00446000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704020300077002000800280#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#114#110#article#186#26#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">26. Schneider-Schaulies S, Schneide
r-Schaulies J. Measles virus-induced immunosuppression. <i>Curr Top Microbiol Im
munol</i> 2009; 330: 243-269.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#115#111#article#186#</span></font></p>   
   ^cY#721.htm##
00424000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704018100077002000800258#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#116#112#article#186#27#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">27. Yanagi Y, Takeda M, Ohno S, Has
higuchi T. Measles virus receptors. <i>Curr Top Microbiol Immunol</i> 2009; 329:
 13-30.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#117#113#article#186#</span></font></p>   
   ^cY#721.htm##
00649000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704040600077002000800483#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#118#114#article#186#28#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">28. Ferrante P, Fusi ML, Saresella 
M, Caputo D, Biasin M, Trabattoni D, et al. Cytokine production and surface mark
er expression in acute and stable multiple sclerosis: altered IL-12 production a
nd augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphoc
ytes in acute multiple sclerosis. <i>J Immunol</i> 1998; 160: 1514-1521.    ^cY#
721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#119#115#article#186#</span></font></p>   
   ^cY#721.htm##
00600000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704035700077002000800434#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#120#116#article#186#29#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">29. Isomaki P, Aversa G, Cocks BG, 
Luukkainen R, Saario R, Toivanen P, et al. Increased expression of signaling lym
phocytic activation molecule in patients with rheumatoid arthritis and its role 
in the regulation of cytokine production in rheumatoid synovium. <i>J Immunol</i
> 1997; 159: 2986-2993.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#121#117#article#186#</span></font></p>   
   ^cY#721.htm##
00473000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023000077002000800307#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#122#118#article#186#30#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">30. Makani SS, Jen KY, Finn PW. New
 costimulatory families: signaling lymphocytic activation molecule in adaptive a
llergic responses. <i>Curr Mol Med</i> 2008; 8: 359-364.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#123#119#article#186#</span></font></p>   
   ^cY#721.htm##
00489000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024600077002000800323#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#124#120#article#186#31#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">31. Detre C, Keszei M, Romero X, Ts
okos GC, Terhorst C. SLAM family receptors and the SLAM-associated protein (SAP)
 modulate T cell functions. <i>Semin Immunopathol</i> 2010; 32: 157-171.    ^cY#
721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#125#121#article#186#</span></font></p>   
   ^cY#721.htm##
00537000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029400077002000800371#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#126#122#article#186#32#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">32. Pasquinelli V, Townsend JC, Jur
ado JO, Alvarez IB, Quiroga MF, Barnes PF, et al. IFN-gamma production during ac
tive tuberculosis is regulated by mechanisms that involve IL-17, SLAM, and CREB.
 <i>J Infect Dis</i> 2009; 199: 661-665.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#127#123#article#186#</span></font></p>   
   ^cY#721.htm##
00510000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026700077002000800344#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#128#124#article#186#33#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">33. Sayos J, Wu C, Morra M, Wang N,
 Zhang X, Allen D, et al. The X-linked lymphoproliferative-disease gene product 
SAP regulates signals induced through the co-receptor SLAM. <i>Nature</i> 1998; 
395: 462-469.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#129#125#article#186#</span></font></p>   
   ^cY#721.htm##
00483000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024000077002000800317#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#130#126#article#186#34#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">34. Calpe S, Wang N, Romero X, Berg
er SB, Lanyi A, Engel P, et al. The SLAM and SAP gene families control innate an
d adaptive immune responses. <i>Adv Immunol</i> 2008; 97: 177-250.    ^cY#721.ht
m##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#131#127#article#186#</span></font></p>   
   ^cY#721.htm##
00532000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028900077002000800366#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#132#128#article#186#35#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">35. Nichols KE, Harkin DP, Levitz S
, Krainer M, Kolquist KA, Genovese C, et al. Inactivating mutations in an SH2 do
main-encoding gene in X-linked lymphoproliferative syndrome. <i>Proc Natl Acad S
ci U S A</i> 1998; 95: 13765-13770.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#133#129#article#186#</span></font></p>   
   ^cY#721.htm##
00491000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024800077002000800325#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#134#130#article#186#36#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">36. Morra M, Barrington RA, Abadia-
Molina AC, Okamoto S, Julien A, Gullo C, et al. Defective B cell responses in th
e absence of SH2D1A. <i>Proc Natl Acad Sci U S A</i> 2005; 102: 4819-4823.    ^c
Y#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#135#131#article#186#</span></font></p>   
   ^cY#721.htm##
00500000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704025700077002000800334#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#136#132#article#186#37#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">37. Nagy N, Mattsson K, Maeda A, Li
u A, Szekely L, Klein E. The X-linked lymphoproliferative disease gene product S
AP is expressed in activated T and NK cells. <i>Immunol Lett</i> 2002; 82: 141-1
47.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#137#133#article#186#</span></font></p>   
   ^cY#721.htm##
00586000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704034300077002000800420#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#138#134#article#186#38#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">38. Shinozaki K, Kanegane H, Matsuk
ura H, Sumazaki R, Tsuchida M, Makita M, et al. Activation-dependent T cell expr
ession of the X-linked lymphoproliferative disease gene product SLAM-associated 
protein and its assessment for patient detection. <i>Int Immunol</i> 2002; 14: 1
215-1223.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#139#135#article#186#</span></font></p>   
   ^cY#721.htm##
00475000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023200077002000800309#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#140#136#article#186#39#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">39. Lo KY, Chin WH, Ng YP, Cheng AW
, Cheung ZH, Ip NY. SLAM-associated protein as a potential negative regulator in
 Trk signaling. <i>J Biol Chem</i> 2005; 280: 41744-41752.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#141#137#article#186#</span></font></p>   
   ^cY#721.htm##
00549000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030600077002000800383#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#142#138#article#186#40#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">40. Roncador G, Garcia Verdes-Monte
negro JF, Tedoldi S, Paterson JC, Klapper W, Ballabio E, et al. Expression of tw
o markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell
 lymphoma. <i>Haematologica</i> 2007; 92: 1059-1066.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#143#139#article#186#</span></font></p>   
   ^cY#721.htm##
00521000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027800077002000800355#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#144#140#article#186#41#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">41. Li C, Chung B, Tao J, Iosef C, 
Aoukaty A, Wang Y, et al. The X-linked lymphoproliferative syndrome gene product
 SAP regulates B cell function through the FcgammaRIIB receptor. <i>Cell Signal<
/i> 2008; 20: 1960-1967.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#145#141#article#186#</span></font></p>   
   ^cY#721.htm##
00537000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029400077002000800371#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#146#142#article#186#42#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">42. Latour S, Roncagalli R, Chen R,
 Bakinowski M, Shi X, Schwartzberg PL, et al. Binding of SAP SH2 domain to FynT 
SH3 domain reveals a novel mechanism of receptor signalling in immune regulation
. <i>Nat Cell Biol</i> 2003; 5: 149-154.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#147#143#article#186#</span></font></p>   
   ^cY#721.htm##
00503000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026000077002000800337#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#148#144#article#186#43#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">43. Zhong MC, Veillette A. Control 
of T lymphocyte signaling by Ly108, a signaling lymphocytic activation molecule 
family receptor implicated in autoimmunity. <i>J Biol Chem</i> 2008; 283: 19255-
19264.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#149#145#article#186#</span></font></p>   
   ^cY#721.htm##
00476000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704024800074002000800322#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#150#146#article#186#<p align="LEFT"><font
 face="Arial"><span lang="EN">44. Purtilo DT, Cassel CK, Yang JP, Harper R. X-li
nked recessive progressive combined variable immunodeficiency (Duncan&rsquo;s di
sease). <i>Lancet</i> 1975; 1: 935-940.</span></font></p>      ^cY#721.htm##
00547000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030400077002000800381#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#151#147#article#186#45#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">45. Komori H, Furukawa H, Mori S, I
to MR, Terada M, Zhang MC, et al. A signal adaptor SLAM-associated protein regul
ates spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Faslp
r lupus mice. <i>J Immunol</i> 2006; 176: 395-400.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#152#148#article#186#</span></font></p>   
   ^cY#721.htm##
00448000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704020500077002000800282#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#153#149#article#186#46#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">46. Hron JD, Caplan L, Gerth AJ, Sc
hwartzberg PL, Peng SL. SH2D1A regulates T-dependent humoral autoimmunity. <i>J 
Exp Med</i> 2004; 200: 261-266.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#154#150#article#186#</span></font></p>   
   ^cY#721.htm##
00481000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023800077002000800315#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#155#151#article#186#47#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">47. Chung B, Aoukaty A, Dutz J, Ter
horst C, Tan R. Signaling lymphocytic activation molecule-associated protein con
trols NKT cell functions. <i>J Immunol</i> 2005; 174: 3153-3157.    ^cY#721.htm#
#
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#156#152#article#186#</span></font></p>   
   ^cY#721.htm##
00483000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024000077002000800317#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#157#153#article#186#48#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">48. Wu C, Nguyen KB, Pien GC, Wang 
N, Gullo C, Howie D, et al. SAP controls T cell responses to virus and terminal 
differentiation of TH2 cells. <i>Nat Immunol</i> 2001; 2: 410-414.    ^cY#721.ht
m##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#158#154#article#186#</span></font></p>   
   ^cY#721.htm##
00508000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026500077002000800342#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#159#155#article#186#49#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">49. Chen R, Latour S, Shi X, Veille
tte A. Association between SAP and FynT: Inducible SH3 domain-mediated interacti
on controlled by engagement of the SLAM receptor. <i>Mol Cell Biol</i> 2006; 26:
 5559-5568.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#160#156#article#186#</span></font></p>   
   ^cY#721.htm##
00496000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704025300077002000800330#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#161#157#article#186#50#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">50. Cannons JL, Yu LJ, Hill B, Mija
res LA, Dombroski D, Nichols KE, et al. SAP regulates T(H)2 differentiation and 
PKC-theta-mediated activation of NF-kappaB1. <i>Immunity</i> 2004; 21: 693-706. 
   ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#162#158#article#186#</span></font></p>   
   ^cY#721.htm##
00568000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704032500077002000800402#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#163#159#article#186#51#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">51. Jenner RG, Townsend MJ, Jackson
 I, Sun K, Bouwman RD, Young RA, et al. The transcription factors T-bet and GATA
-3 control alternative pathways of T-cell differentiation through a shared set o
f target genes. <i>Proc Natl Acad Sci U S A</i> 2009; 106: 17876-17881.    ^cY#7
21.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#164#160#article#186#</span></font></p>   
   ^cY#721.htm##
00528000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028500077002000800362#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#165#161#article#186#52#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">52. Bourreau E, Prevot G, Pradinaud
 R, Launois P. Unresponsiveness of specific T cells to IL-12 is associated with 
active cutaneous leishmaniasis owing to <i>Leishmania guyanensis</i>. <i>Scand J
 Immunol</i> 2001; 54: 335-339.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#166#162#article#186#</span></font></p>   
   ^cY#721.htm##
00542000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029900077002000800376#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#167#163#article#186#53#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">53. Graham DB, Bell MP, McCausland 
MM, Huntoon CJ, van Deursen J, Faubion WA, et al. Ly9 (CD229)-deficient mice exh
ibit T cell defects yet do not share several phenotypic characteristics associat
ed with. <i>J Immunol</i> 2006; 176: 291-300.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#168#164#article#186#</span></font></p>   
   ^cY#721.htm##
00573000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704033000077002000800407#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#169#165#article#186#54#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">54. Mooney JM, Klem J, Wulfing C, M
ijares LA, Schwartzberg PL, Bennett M, et al. The murine NK receptor 2B4 (CD244)
 exhibits inhibitory function independent of signaling lymphocytic activation mo
lecule-associated protein expression. <i>J Immunol</i> 2004; 173: 3953-3961.    
^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#170#166#article#186#</span></font></p>   
   ^cY#721.htm##
00509000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026600077002000800343#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#171#167#article#186#55#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">55. Henning G, Kraft MS, Derfuss T,
 Pirzer R, de Saint-Basile G, Aversa G, et al. Signaling lymphocytic activation 
molecule (SLAM) regulates T cellular cytotoxicity. <i>Eur J Immunol</i> 2001; 31
: 2741-2750.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#172#168#article#186#</span></font></p>   
   ^cY#721.htm##
00775000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704054700074002000800621#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#173#169#article#186#<p align="LEFT"><font
 face="Arial"><span lang="EN">56. Vilar M. Modula&ccedil;&atilde;o da resposta i
munol&oacute;gica <i>in vitro</i> &agrave; <i>Leishmania amazonensis</i> em indi
v&iacute;duos baixos produtores de IFN-&gamma;. [PhD thesis]. Salvador: Escola B
ahiana de Medicina e Sa&uacute;de P&uacute;blica, EBMSP/FBDC/FIOCRUZ; 2009. [<a 
target="_blank" href="http://capesdw.capes.gov.br/capesdw/resumo.html?idtese=200
91228008014002P6">http://capesdw.capes.gov.br/capesdw/resumo.html?idtese=2009122
8008014002P6</a>].</span></font></p>      ^cY#721.htm##
00533000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029000077002000800367#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#174#170#article#186#57#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">57. Davidson D, Shi X, Zhang S, Wan
g H, Nemer M, Ono N, et al. Genetic evidence linking SAP, the X-linked lymphopro
liferative gene product, to Src-related kinase FynT in T(H)2 cytokine regulation
. <i>Immunity</i> 2004; 21: 707-717.    ^cY#721.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#175#171#article#186#</span></font></p>   
   ^cY#721.htm##
00559000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704031600077002000800393#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#p#176#172#article#186#58#<p ali
gn="LEFT"><font face="Arial"><span lang="EN">58. Czar MJ, Kersh EN, Mijares LA, 
Lanier G, Lewis J, Yap G, et al. Altered lymphocyte responses and cytokine produ
ction in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/
DSHP/SAP. <i>Proc Natl Acad Sci U S A</i> 2001; 98: 7449-7454.    ^cY#721.htm##
00280000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704005200074002000800126#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#177#173#article#186#</span></font></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#721.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033600074002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#178#174#article#186#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#721.h
tm##
00792000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704056400074002000800638#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#179#175#article#186#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/r
ecor.gif" border="0"></a> Address for correspondence:</b></font><span lang="EN">
<font face="Arial, Helvetica, sans-serif"> </font></span><font face="Arial"><spa
n lang="EN"> M.M.L. Pompeu, Departamento de Patologia e Medicina Legal, Faculdad
e de Medicina, Universidade Federal do Cear&aacute;, Rua Monsenhor Furtado, s/n,
 60441-750 Fortaleza, CE, Brasil. Fax: +55-85-3366-8304. E-mail: <a href="mailto
:mpompeu@ufc.br">mpompeu@ufc.br</a></span></font></p>      ^cY#721.htm##
00453000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704022500074002000800299#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#180#176#article#186#<p ALIGN="LEFT"><i><f
ont face="Arial"><span lang="EN">Received September 18, 2010. Accepted February 
21, 2011. Available online March 25, 2011. Published April 11, 2011.</span></fon
t></i></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#721.htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#181#177#article#186#<div align="center"> 
       ^cY#721.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#182#178#article#186#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#721.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#183#179#article#186#<br>                ^
cY#721.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#184#180#article#186#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#721
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#185#181#article#186#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#721.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#186#182#article#186#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#721.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#187#183#article#186#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#721.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#188#184#article#186#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#721.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#189#185#article#186#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#721.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\721.htm#S#p#190#186#article#186#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#721.htm##
00576000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100014000920100
01600106012009400122030000900216065000900225064000500234031000300239014000800242
865000900250002000800259035001000267801000900277#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\721.htm#S#c#191#1#article#58#1#^rND^sVeillette^nA#^rND^sDong^nZ#^rND^
sLatour^nS#Consequence of the SLAM-SAP signaling pathway in innate-like and conv
entional lymphocytes^len#Immunity#20070000#2007#27#698-710#20110400#721.htm#1074
-7613#Immunity##
00518000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100019000890120
05200108030001400160065000900174064000500183031000300188014000800191865000900199
002000800208035001000216801001400226#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
21.htm#S#c#192#2#article#58#2#^rND^sLatour^nS#^rND^sVeillette^nA#The SAP family 
of adaptors in immune regulation^len#Semin Immunol#20040000#2004#16#409-419#2011
0400#721.htm#1044-5323#Semin Immunol##
00475000000000253000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730120072000920300
01600164710000200180065000900182064000500191031000200196014000600198865000900204
002000800213#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#193#3#article
#58#3#^rND^sVeillette^nA#Immune regulation by SLAM family receptors and SAP-rela
ted adaptors^len#Nat Rev Immunol#2#20060000#2006#6#56-66#20110400#721.htm##
00548000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100014000880100
01800102012009100120030001600211710000200227065000900229064000500238031000200243
014000800245865000900253002000800262#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
21.htm#S#c#194#4#article#58#4#^rND^sEngel^nP#^rND^sEck^nMJ#^rND^sTerhorst^nC#The
 SAP and SLAM families in immune responses and X-linked lymphoproliferative dise
ase^len#Nat Rev Immunol#2#20030000#2003#3#813-821#20110400#721.htm##
00633000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100013000910100
01800104010002300122010001700145012008000162030001200242065000900254064000500263
031000400268014000800272865000900280002000800289035001000297801001200307#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#195#5#article#58#5#^rND^sNichols^
nKE#^rND^sMa^nCS#^rND^sCannons^nJL#^rND^sSchwartzberg^nPL#^rND^sTangye^nSG#Molec
ular and cellular pathogenesis of X-linked lymphoproliferative disease^len#Immun
ol Rev#20050000#2005#203#180-199#20110400#721.htm#0105-2896#Immunol Rev##
00595000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100013000730100018000860100
01700104012009800121030001700219065000900236064000500245031000300250014000800253
865000900261002000800270035001000278801001700288#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\721.htm#S#c#196#6#article#58#6#^rND^sMa^nCS#^rND^sNichols^nKE#^rND^sT
angye^nSG#Regulation of cellular and humoral immune responses by the SLAM and SA
P families of molecules^len#Annu Rev Immunol#20070000#2007#25#337-379#20110400#7
21.htm#0732-0582#Annu Rev Immunol##
00620000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100019000880100
01700107010001900124010001900143012005600162030001800218065000900236064000500245
031000300250014000800253865000900261002000800270035001000278801001800288#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#197#7#article#58#7#^rND^sChan^nAY
#^rND^sWestcott^nJM#^rND^sMooney^nJM#^rND^sWakeland^nEK#^rND^sSchatzle^nJD#The r
ole of SAP and the SLAM family in autoimmunity^len#Curr Opin Immunol#20060000#20
06#18#656-664#20110400#721.htm#0952-7915#Curr Opin Immunol##
00743000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100017000890100
01500106010001600121010002300137010001500160810000600175012014900181030001000330
06500090034006400050034903100040035401400100035886500090036800200080037703500100
0385801001000395#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#198#8#art
icle#58#8#^rND^sRomero^nX#^rND^sZapater^nN#^rND^sCalvo^nM#^rND^sKalko^nSG#^rND^s
de^nla Fuente MA#^rND^sTovar^nV#et al#CD229 (Ly9) lymphocyte cell surface recept
or interacts homophilically through its N-terminal domain and relocalizes to the
 immunological synapse^len#J Immunol#20050000#2005#174#7033-7042#20110400#721.ht
m#0022-1767#J Immunol##
00534000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100021000920100
01600113012006800129030001500197710000200212065000900214064000500223031000300228
014000800231865000900239002000800248#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
21.htm#S#c#199#9#article#58#9#^rND^sVeillette^nA#^rND^sCruz-Munoz^nME#^rND^sZhon
g^nMC#SLAM family receptors and SAP-related adaptors: matters arising^len#Trends
 Immunol#2#20060000#2006#27#228-234#20110400#721.htm##
00686000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100014000920100
02000106010002300126010001600149010001400165810000600179012008200185030001200267
06500090027906400050028803100040029301400120029786500090030900200080031803500100
0326801001200336#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#200#10#ar
ticle#58#10#^rND^sValdez^nPA#^rND^sWang^nH#^rND^sSeshasayee^nD#^rND^svan^nLooker
en CM#^rND^sGurney^nA#^rND^sLee^nWP#et al#NTB-A, a new activating receptor in T 
cells that regulates autoimmune disease^len#J Biol Chem#20040000#2004#279#18662-
18669#20110400#721.htm#0021-9258#J Biol Chem##
00652000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100017000950100
01500112010001300127010001400140010002100154810000600175012008800181030001200269
71000020028106500090028306400050029203100020029701400100029986500090030900200080
0318#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#201#11#article#58#11#
^rND^sRoncagalli^nR#^rND^sTaylor^nJE#^rND^sZhang^nS#^rND^sShi^nX#^rND^sChen^nR#^
rND^sCruz-Munoz^nME#et al#Negative regulation of natural killer cell function by
 EAT-2, a SAP-related adaptor^len#Nat Immunol#2#20050000#2005#6#1002-1010#201104
00#721.htm##
00716000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930100
01900109010001600128010001800144010001700162810000600179012011200185030001200297
06500090030906400050031803100040032301400120032786500090033900200080034803500100
0356801001200366#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#202#12#ar
ticle#58#12#^rND^sMavaddat^nN#^rND^sMason^nDW#^rND^sAtkinson^nPD#^rND^sEvans^nEJ
#^rND^sGilbert^nRJ#^rND^sStuart^nDI#et al#Signaling lymphocytic activation molec
ule (CDw150) is homophilic but self-associates with very low affinity^len#J Biol
 Chem#20000000#2000#275#28100-28109#20110400#721.htm#0021-9258#J Biol Chem##
00705000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100018000890100
02000107010001700127010001300144010001600157810000600173012010600179030001400285
06500090029906400050030803100030031301400100031686500090032600200080033503500100
0343801001400353#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#203#13#ar
ticle#58#13#^rND^sChen^nR#^rND^sRelouzat^nF#^rND^sRoncagalli^nR#^rND^sAoukaty^nA
#^rND^sTan^nR#^rND^sLatour^nS#et al#Molecular dissection of 2B4 signaling: impli
cations for signal transduction by SLAM-related receptors^len#Mol Cell Biol#2004
0000#2004#24#5144-5156#20110400#721.htm#0270-7306#Mol Cell Biol##
00499000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100016000950120
06900111030001200180710000200192065000900194064000500203031000200208014000600210
865000900216002000800225#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#2
04#14#article#58#14#^rND^sSidorenko^nSP#^rND^sClark^nEA#The dual-function CD150 
receptor subfamily: the viral attraction^len#Nat Immunol#2#20030000#2003#4#19-24
#20110400#721.htm##
00682000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100016000950100
01600111010001500127010002100142010001500163810000600178012009000184030000900274
06500090028306400050029203100030029701400080030086500090030800200080031703500100
0325801000900335#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#205#15#ar
ticle#58#15#^rND^sWandstrat^nAE#^rND^sNguyen^nC#^rND^sLimaye^nN#^rND^sChan^nAY#^
rND^sSubramanian^nS#^rND^sTian^nXH#et al#Association of extensive polymorphisms 
in the SLAM/CD2 gene cluster with murine lupus^len#Immunity#20040000#2004#21#769
-780#20110400#721.htm#1074-7613#Immunity##
00697000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100023000890100
01200112010001500124010001800139010001800157810000600175012009900181030001400280
06500090029406400050030303100020030801400080031086500090031800200080032703500100
0335801001400345#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#206#16#ar
ticle#58#16#^rND^sShai^nR#^rND^sQuismorio^nFP Jr#^rND^sLi^nL#^rND^sKwon^nOJ#^rND
^sMorrison^nJ#^rND^sWallace^nDJ#et al#Genome-wide screen for systemic lupus eryt
hematosus susceptibility genes in multiplex families^len#Hum Mol Genet#19990000#
1999#8#639-644#20110400#721.htm#0964-6906#Hum Mol Genet##
00766000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100017000920100
01600109010001600125010001800141010001900159810000600178012016900184030001000353
06500090036306400050037203100040037701400100038186500090039100200080040003500100
0408801001000418#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#207#17#ar
ticle#58#17#^rND^sCastro^nAG#^rND^sHauser^nTM#^rND^sCocks^nBG#^rND^sAbrams^nJ#^r
ND^sZurawski^nS#^rND^sChurakova^nT#et al#Molecular and functional characterizati
on of mouse signaling lymphocytic activation molecule (SLAM): differential expre
ssion and responsiveness in Th1 and Th2 cells^len#J Immunol#19990000#1999#163#58
60-5870#20110400#721.htm#0022-1767#J Immunol##
00759000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930100
02100109010001700130010001800147010001600165810000600181012016000187030001000347
06500090035706400050036603100040037101400090037586500090038400200080039303500100
0401801001000411#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#208#18#ar
ticle#58#18#^rND^sPunnonen^nJ#^rND^sCocks^nBG#^rND^sCarballido^nJM#^rND^sBennett
^nB#^rND^sPeterson^nD#^rND^sAversa^nG#et al#Soluble and membrane-bound forms of 
signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig syn
thesis by activated human B lymphocytes^len#J Exp Med#19970000#1997#185#993-1004
#20110400#721.htm#0022-1007#J Exp Med##
00622000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100016000910100
02100107010001500128010001900143010001600162012005100178030000700229065000900236
06400050024503100040025001400080025486500090026200200080027103500100027980100070
0289#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#209#19#article#58#19#
^rND^sCocks^nBG#^rND^sChang^nCC#^rND^sCarballido^nJM#^rND^sYssel^nH#^rND^sde^nVr
ies JE#^rND^sAversa^nG#A novel receptor involved in T-cell activation^len#Nature
#19950000#1995#376#260-263#20110400#721.htm#0028-0836#Nature##
00609000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100015000890100
01500104010001900119010002400138010001300162810000600175012004500181030001400226
71000020024006500090024206400050025103100020025601400080025886500090026600200080
0275#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#210#20#article#58#20#
^rND^sChan^nB#^rND^sLanyi^nA#^rND^sSong^nHK#^rND^sGriesbach^nJ#^rND^sSimarro-Gra
nde^nM#^rND^sPoy^nF#et al#SAP couples Fyn to SLAM immune receptors^len#Nat Cell 
Biol#2#20030000#2003#5#155-160#20110400#721.htm##
00654000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100014000910100
01900105010002000124010001600144010001900160012010600179030001200285710000200297
065000900299064000500308031000200313014000800315865000900323002000800332#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#211#21#article#58#21#^rND^sLatour
^nS#^rND^sGish^nG#^rND^sHelgason^nCD#^rND^sHumphries^nRK#^rND^sPawson^nT#^rND^sV
eillette^nA#Regulation of SLAM-mediated signal transduction by SAP, the X-linked
 lymphoproliferative gene product^len#Nat Immunol#2#20010000#2001#2#681-690#2011
0400#721.htm##
00676000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100015000900100
01300105010001700118010001800135010001500153810000600168012009700174030000600271
06500090027706400050028603100040029101400100029586500090030500200080031403500100
0322801000600332#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#212#22#ar
ticle#58#22#^rND^sNanda^nN#^rND^sAndre^nP#^rND^sBao^nM#^rND^sClauser^nK#^rND^sDe
guzman^nF#^rND^sHowie^nD#et al#Platelet aggregation induces platelet aggregate s
tability via SLAM family receptor signaling^len#Blood#20050000#2005#106#3028-303
4#20110400#721.htm#0006-4971#Blood##
00715000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100015000900100
01700105010001500122010001900137010001600156810000600172012012400178030001000302
06500090031206400050032103100040032601400100033086500090034000200080034903500100
0357801001000367#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#213#23#ar
ticle#58#23#^rND^sKruse^nM#^rND^sMeinl^nE#^rND^sHenning^nG#^rND^sKuhnt^nC#^rND^s
Berchtold^nS#^rND^sBerger^nT#et al#Signaling lymphocytic activation molecule is 
expressed on mature CD83+ dendritic cells and is up-regulated by IL-1 beta^len#J
 Immunol#20010000#2001#167#1989-1995#20110400#721.htm#0022-1767#J Immunol##
00666000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100018000890100
01700107010001500124010001700139010001500156810000600171012007600177030001000253
06500090026306400050027203100040027701400100028186500090029100200080030003500100
0308801001000318#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#214#24#ar
ticle#58#24#^rND^sWang^nN#^rND^sSatoskar^nA#^rND^sFaubion^nW#^rND^sHowie^nD#^rND
^sOkamoto^nS#^rND^sFeske^nS#et al#The cell surface receptor SLAM controls T cell
 and macrophage functions^len#J Exp Med#20040000#2004#199#1255-1264#20110400#721
.htm#0022-1007#J Exp Med##
00693000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100017000900100
01800107010001700125010001800142010001900160012012300179030000500302065000900307
06400050031603100040032101400100032586500090033500200080034403500100035280100050
0362#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#215#25#article#58#25#
^rND^sKiel^nMJ#^rND^sYilmaz^nOH#^rND^sIwashita^nT#^rND^sYilmaz^nOH#^rND^sTerhors
t^nC#^rND^sMorrison^nSJ#SLAM family receptors distinguish hematopoietic stem and
 progenitor cells and reveal endothelial niches for stem cells^len#Cell#20050000
#2005#121#1109-1121#20110400#721.htm#0092-8674#Cell##
00562000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100029000750100029001040120
04400133030002700177065000900204064000500213031000400218014000800222865000900230
002000800239035001000247801002700257#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
21.htm#S#c#216#26#article#58#26#^rND^sSchneider-Schaulies^nS#^rND^sSchneider-Sch
aulies^nJ#Measles virus-induced immunosuppression^len#Curr Top Microbiol Immunol
#20090000#2009#330#243-269#20110400#721.htm#0070-217X#Curr Top Microbiol Immunol
##
00576000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100016000910100
01400107010002000121012002800141030002700169065000900196064000500205031000400210
014000600214865000900220002000800229035001000237801002700247#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\721.htm#S#c#217#27#article#58#27#^rND^sYanagi^nY#^rND^sTa
keda^nM#^rND^sOhno^nS#^rND^sHashiguchi^nT#Measles virus receptors^len#Curr Top M
icrobiol Immunol#20090000#2009#329#13-30#20110400#721.htm#0070-217X#Curr Top Mic
robiol Immunol##
00831000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100015000930100
01900108010001600127010001600143010002000159810000600179012023300185030001000418
06500090042806400050043703100040044201400100044686500090045600200080046503500100
0473801001000483#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#218#28#ar
ticle#58#28#^rND^sFerrante^nP#^rND^sFusi^nML#^rND^sSaresella^nM#^rND^sCaputo^nD#
^rND^sBiasin^nM#^rND^sTrabattoni^nD#et al#Cytokine production and surface marker
 expression in acute and stable multiple sclerosis: altered IL-12 production and
 augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocyt
es in acute multiple sclerosis^len#J Immunol#19980000#1998#160#1514-1521#2011040
0#721.htm#0022-1767#J Immunol##
00782000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
01600108010002000124010001600144010001800160810000600178012018500184030001000369
06500090037906400050038803100040039301400100039786500090040700200080041603500100
0424801001000434#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#219#29#ar
ticle#58#29#^rND^sIsomaki^nP#^rND^sAversa^nG#^rND^sCocks^nBG#^rND^sLuukkainen^nR
#^rND^sSaario^nR#^rND^sToivanen^nP#et al#Increased expression of signaling lymph
ocytic activation molecule in patients with rheumatoid arthritis and its role in
 the regulation of cytokine production in rheumatoid synovium^len#J Immunol#1997
0000#1997#159#2986-2993#20110400#721.htm#0022-1767#J Immunol##
00560000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100014000920100
01500106012010500121030001300226710000200239065000900241064000500250031000200255
014000800257865000900265002000800274#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
21.htm#S#c#220#30#article#58#30#^rND^sMakani^nSS#^rND^sJen^nKY#^rND^sFinn^nPW#Ne
w costimulatory families: signaling lymphocytic activation molecule in adaptive 
allergic responses^len#Curr Mol Med#2#20080000#2008#8#359-364#20110400#721.htm##
00612000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100016000900100
01600106010001700122010001800139012009000157030001900247710000200266065000900268
064000500277031000300282014000800285865000900293002000800302#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\721.htm#S#c#221#31#article#58#31#^rND^sDetre^nC#^rND^sKes
zei^nM#^rND^sRomero^nX#^rND^sTsokos^nGC#^rND^sTerhorst^nC#SLAM family receptors 
and the SLAM-associated protein (SAP) modulate T cell functions^len#Semin Immuno
pathol#2#20100000#2010#32#157-171#20110400#721.htm##
00722000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100019000960100
01700115010001800132010001800150010001700168810000600185012011400191030001300305
06500090031806400050032703100040033201400080033686500090034400200080035303500100
0361801001300371#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#222#32#ar
ticle#58#32#^rND^sPasquinelli^nV#^rND^sTownsend^nJC#^rND^sJurado^nJO#^rND^sAlvar
ez^nIB#^rND^sQuiroga^nMF#^rND^sBarnes^nPF#et al#IFN-gamma production during acti
ve tuberculosis is regulated by mechanisms that involve IL-17, SLAM, and CREB^le
n#J Infect Dis#20090000#2009#199#661-665#20110400#721.htm#0022-1899#J Infect Dis
##
00689000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100012000900100
01500102010001400117010001500131010001500146810000600161012011700167030000700284
06500090029106400050030003100040030501400080030986500090031700200080032603500100
0334801000700344#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#223#33#ar
ticle#58#33#^rND^sSayos^nJ#^rND^sWu^nC#^rND^sMorra^nM#^rND^sWang^nN#^rND^sZhang^
nX#^rND^sAllen^nD#et al#The X-linked lymphoproliferative-disease gene product SA
P regulates signals induced through the co-receptor SLAM^len#Nature#19980000#199
8#395#462-469#20110400#721.htm#0028-0836#Nature##
00667000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100014000900100
01600104010001700120010001500137010001500152810000600167012008000173030001200253
06500090026506400050027403100030027901400080028286500090029000200080029903500100
0307801001200317#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#224#34#ar
ticle#58#34#^rND^sCalpe^nS#^rND^sWang^nN#^rND^sRomero^nX#^rND^sBerger^nSB#^rND^s
Lanyi^nA#^rND^sEngel^nP#et al#The SLAM and SAP gene families control innate and 
adaptive immune responses^len#Adv Immunol#20080000#2008#97#177-250#20110400#721.
htm#0065-2776#Adv Immunol##
00729000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100017000930100
01600110010001700126010001900143010001800162810000600180012009900186030002500285
06500090031006400050031903100030032401400120032786500090033900200080034803500100
0356801002500366#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#225#35#ar
ticle#58#35#^rND^sNichols^nKE#^rND^sHarkin^nDP#^rND^sLevitz^nS#^rND^sKrainer^nM#
^rND^sKolquist^nKA#^rND^sGenovese^nC#et al#Inactivating mutations in an SH2 doma
in-encoding gene in X-linked lymphoproliferative syndrome^len#Proc Natl Acad Sci
 U S A#19980000#1998#95#13765-13770#20110400#721.htm#0027-8424#Proc Natl Acad Sc
i U S A##
00688000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100021000900100
02400111010001700135010001600152010001500168810000600183012005600189030002500245
06500090027006400050027903100040028401400100028886500090029800200080030703500100
0315801002500325#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#226#36#ar
ticle#58#36#^rND^sMorra^nM#^rND^sBarrington^nRA#^rND^sAbadia-Molina^nAC#^rND^sOk
amoto^nS#^rND^sJulien^nA#^rND^sGullo^nC#et al#Defective B cell responses in the 
absence of SH2D1A^len#Proc Natl Acad Sci U S A#20050000#2005#102#4819-4823#20110
400#721.htm#0027-8424#Proc Natl Acad Sci U S A##
00674000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100018000890100
01500107010001300122010001700135010001500152012010300167030001300270065000900283
06400050029203100030029701400080030086500090030800200080031703500100032580100130
0335#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#227#37#article#58#37#
^rND^sNagy^nN#^rND^sMattsson^nK#^rND^sMaeda^nA#^rND^sLiu^nA#^rND^sSzekely^nL#^rN
D^sKlein^nE#The X-linked lymphoproliferative disease gene product SAP is express
ed in activated T and NK cells^len#Immunol Lett#20020000#2002#82#141-147#2011040
0#721.htm#0165-2478#Immunol Lett##
00770000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100018000940100
01900112010001800131010001800149010001600167810000600183012016500189030001200354
06500090036606400050037503100030038001400100038386500090039300200080040203500100
0410801001200420#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#228#38#ar
ticle#58#38#^rND^sShinozaki^nK#^rND^sKanegane^nH#^rND^sMatsukura^nH#^rND^sSumaza
ki^nR#^rND^sTsuchida^nM#^rND^sMakita^nM#et al#Activation-dependent T cell expres
sion of the X-linked lymphoproliferative disease gene product SLAM-associated pr
otein and its assessment for patient detection^len#Int Immunol#20020000#2002#14#
1215-1223#20110400#721.htm#0953-8178#Int Immunol##
00648000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100013000750100015000880100
01300103010001600116010001700132010001300149012007900162030001200241065000900253
06400050026203100040026701400120027186500090028300200080029203500100030080100120
0310#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#229#39#article#58#39#
^rND^sLo^nKY#^rND^sChin^nWH#^rND^sNg^nYP#^rND^sCheng^nAW#^rND^sCheung^nZH#^rND^s
Ip^nNY#SLAM-associated protein as a potential negative regulator in Trk signalin
g^len#J Biol Chem#20050000#2005#280#41744-41752#20110400#721.htm#0021-9258#J Bio
l Chem##
00735000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100035000930100
01700128010001900145010001700164010001800181810000600199012011000205030001400315
06500090032906400050033803100030034301400100034686500090035600200080036503500100
0373801001400383#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#230#40#ar
ticle#58#40#^rND^sRoncador^nG#^rND^sGarcia^nVerdes-Montenegro JF#^rND^sTedoldi^n
S#^rND^sPaterson^nJC#^rND^sKlapper^nW#^rND^sBallabio^nE#et al#Expression of two 
markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell l
ymphoma^len#Haematologica#20070000#2007#92#1059-1066#20110400#721.htm#0390-6078#
Haematologica##
00705000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100012000750100015000870100
01300102010001500115010001700130010001400147810000600161012012200167030001200289
06500090030106400050031003100030031501400100031886500090032800200080033703500100
0345801001200355#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#231#41#ar
ticle#58#41#^rND^sLi^nC#^rND^sChung^nB#^rND^sTao^nJ#^rND^sIosef^nC#^rND^sAoukaty
^nA#^rND^sWang^nY#et al#The X-linked lymphoproliferative syndrome gene product S
AP regulates B cell function through the FcgammaRIIB receptor^len#Cell Signal#20
080000#2008#20#1960-1967#20110400#721.htm#0898-6568#Cell Signal##
00689000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100020000910100
01400111010002000125010001300145010002300158810000600181012011900187030001400306
71000020032006500090032206400050033103100020033601400080033886500090034600200080
0355#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#232#42#article#58#42#
^rND^sLatour^nS#^rND^sRoncagalli^nR#^rND^sChen^nR#^rND^sBakinowski^nM#^rND^sShi^
nX#^rND^sSchwartzberg^nPL#et al#Binding of SAP SH2 domain to FynT SH3 domain rev
eals a novel mechanism of receptor signalling in immune regulation^len#Nat Cell 
Biol#2#20030000#2003#5#149-154#20110400#721.htm##
00604000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910120
13500110030001200245065000900257064000500266031000400271014001200275865000900287
002000800296035001000304801001200314#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
21.htm#S#c#233#43#article#58#43#^rND^sZhong^nMC#^rND^sVeillette^nA#Control of T 
lymphocyte signaling by Ly108, a signaling lymphocytic activation molecule famil
y receptor implicated in autoimmunity^len#J Biol Chem#20080000#2008#283#19255-19
264#20110400#721.htm#0021-9258#J Biol Chem##
00603000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100017000930100
01500110010001600125012009500141030000700236065000900243064000500252031000200257
014000800259865000900267002000800276035001000284801000700294#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\721.htm#S#c#234#44#article#58#44#^rND^sPurtilo^nDT#^rND^s
Cassel^nCK#^rND^sYang^nJP#^rND^sHarper^nR#X-linked recessive progressive combine
d variable immunodeficiency (Duncan&#8217;s disease)^len#Lancet#19750000#1975#1#
935-940#20110400#721.htm#0099-5355#Lancet##
00729000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100018000910100
01400109010001400123010001600137010001600153810000600169012014300175030001000318
06500090032806400050033703100040034201400080034686500090035400200080036303500100
0371801001000381#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#235#45#ar
ticle#58#45#^rND^sKomori^nH#^rND^sFurukawa^nH#^rND^sMori^nS#^rND^sIto^nMR#^rND^s
Terada^nM#^rND^sZhang^nMC#et al#A signal adaptor SLAM-associated protein regulat
es spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Faslpr 
lupus mice^len#J Immunol#20060000#2006#176#395-400#20110400#721.htm#0022-1767#J 
Immunol##
00601000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100016000900100
01600106010002300122010001500145012005400160030001000214065000900224064000500233
031000400238014000800242865000900250002000800259035001000267801001000277#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#236#46#article#58#46#^rND^sHron^n
JD#^rND^sCaplan^nL#^rND^sGerth^nAJ#^rND^sSchwartzberg^nPL#^rND^sPeng^nSL#SH2D1A 
regulates T-dependent humoral autoimmunity^len#J Exp Med#20040000#2004#200#261-2
66#20110400#721.htm#0022-1007#J Exp Med##
00634000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100017000900100
01400107010001800121010001300139012009300152030001000245065000900255064000500264
031000400269014001000273865000900283002000800292035001000300801001000310#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#237#47#article#58#47#^rND^sChung^
nB#^rND^sAoukaty^nA#^rND^sDutz^nJ#^rND^sTerhorst^nC#^rND^sTan^nR#Signaling lymph
ocytic activation molecule-associated protein controls NKT cell functions^len#J 
Immunol#20050000#2005#174#3153-3157#20110400#721.htm#0022-1767#J Immunol##
00635000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100012000750100017000870100
01500104010001400119010001500133010001500148810000600163012008500169030001200254
71000020026606500090026806400050027703100020028201400080028486500090029200200080
0301#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#238#48#article#58#48#
^rND^sWu^nC#^rND^sNguyen^nKB#^rND^sPien^nGC#^rND^sWang^nN#^rND^sGullo^nC#^rND^sH
owie^nD#et al#SAP controls T cell responses to virus and terminal differentiatio
n of TH2 cells^len#Nat Immunol#2#20010000#2001#2#410-414#20110400#721.htm##
00647000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100016000890100
01300105010001900118012012600137030001400263065000900277064000500286031000300291
014001000294865000900304002000800313035001000321801001400331#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\721.htm#S#c#239#49#article#58#49#^rND^sChen^nR#^rND^sLato
ur^nS#^rND^sShi^nX#^rND^sVeillette^nA#Association between SAP and FynT: Inducibl
e SH3 domain-mediated interaction controlled by engagement of the SLAM receptor^
len#Mol Cell Biol#20060000#2006#26#5559-5568#20110400#721.htm#0270-7306#Mol Cell
 Biol##
00677000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100013000930100
01400106010001800120010001900138010001800157810000600175012008800181030000900269
06500090027806400050028703100030029201400080029586500090030300200080031203500100
0320801000900330#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#240#50#ar
ticle#58#50#^rND^sCannons^nJL#^rND^sYu^nLJ#^rND^sHill^nB#^rND^sMijares^nLA#^rND^
sDombroski^nD#^rND^sNichols^nKE#et al#SAP regulates T(H)2 differentiation and PK
C-theta-mediated activation of NF-kappaB1^len#Immunity#20040000#2004#21#693-706#
20110400#721.htm#1074-7613#Immunity##
00765000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100019000920100
01700111010001300128010001800141010001600159810000600175012013900181030002500320
06500090034506400050035403100040035901400120036386500090037500200080038403500100
0392801002500402#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#241#51#ar
ticle#58#51#^rND^sJenner^nRG#^rND^sTownsend^nMJ#^rND^sJackson^nI#^rND^sSun^nK#^r
ND^sBouwman^nRD#^rND^sYoung^nRA#et al#The transcription factors T-bet and GATA-3
 control alternative pathways of T-cell differentiation through a shared set of 
target genes^len#Proc Natl Acad Sci U S A#20090000#2009#106#17876-17881#20110400
#721.htm#0027-8424#Proc Natl Acad Sci U S A##
00662000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930100
01900109010001700128012013100145030001600276065000900292064000500301031000300306
014000800309865000900317002000800326035001000334801001600344#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\721.htm#S#c#242#52#article#58#52#^rND^sBourreau^nE#^rND^s
Prevot^nG#^rND^sPradinaud^nR#^rND^sLaunois^nP#Unresponsiveness of specific T cel
ls to IL-12 is associated with active cutaneous leishmaniasis owing to Leishmani
a guyanensis^len#Scand J Immunol#20010000#2001#54#335-339#20110400#721.htm#0300-
9475#Scand J Immunol##
00724000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100015000920100
02100107010001800128010002100146010001800167810000600185012012200191030001000313
06500090032306400050033203100040033701400080034186500090034900200080035803500100
0366801001000376#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#243#53#ar
ticle#58#53#^rND^sGraham^nDB#^rND^sBell^nMP#^rND^sMcCausland^nMM#^rND^sHuntoon^n
CJ#^rND^svan^nDeursen J#^rND^sFaubion^nWA#et al#Ly9 (CD229)-deficient mice exhib
it T cell defects yet do not share several phenotypic characteristics associated
 with^len#J Immunol#20060000#2006#176#291-300#20110400#721.htm#0022-1767#J Immun
ol##
00755000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100014000920100
01700106010001800123010002300141010001700164810000600181012015500187030001000342
06500090035206400050036103100040036601400100037086500090038000200080038903500100
0397801001000407#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#244#54#ar
ticle#58#54#^rND^sMooney^nJM#^rND^sKlem^nJ#^rND^sWulfing^nC#^rND^sMijares^nLA#^r
ND^sSchwartzberg^nPL#^rND^sBennett^nM#et al#The murine NK receptor 2B4 (CD244) e
xhibits inhibitory function independent of signaling lymphocytic activation mole
cule-associated protein expression^len#J Immunol#20040000#2004#173#3953-3961#201
10400#721.htm#0022-1767#J Immunol##
00695000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
01700108010001600125010002500141010001600166810000600182012008700188030001400275
06500090028906400050029803100030030301400100030686500090031600200080032503500100
0333801001400343#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#245#55#ar
ticle#58#55#^rND^sHenning^nG#^rND^sKraft^nMS#^rND^sDerfuss^nT#^rND^sPirzer^nR#^r
ND^sde^nSaint-Basile G#^rND^sAversa^nG#et al#Signaling lymphocytic activation mo
lecule (SLAM) regulates T cellular cytotoxicity^len#Eur J Immunol#20010000#2001#
31#2741-2750#20110400#721.htm#0014-2980#Eur J Immunol##
00651000000000253000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720160015000750180118000900510
01100208046000900219050006300228045000900291044000500300062007500305865000900380
002000800389#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#246#56#articl
e#58#56#^rND^sVilar^nM#Modulação da resposta imunológica in vitro à Leishmania a
mazonensis em indivíduos baixos produtores de IFN-&#947;^lpt#PhD thesis#Salvador
#Escola Bahiana de Medicina e Saúde Pública^dEBMSP/FBDC/FIOCRUZ#20090000#2009#ht
tp://capesdw.capes.gov.br/capesdw/resumo.html?idtese=20091228008014002P6#2011040
0#721.htm##
00714000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100013000930100
01500106010001400121010001500135010001300150810000600163012013700169030000900306
06500090031506400050032403100030032901400080033286500090034000200080034903500100
0357801000900367#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#247#57#ar
ticle#58#57#^rND^sDavidson^nD#^rND^sShi^nX#^rND^sZhang^nS#^rND^sWang^nH#^rND^sNe
mer^nM#^rND^sOno^nN#et al#Genetic evidence linking SAP, the X-linked lymphoproli
ferative gene product, to Src-related kinase FynT in T(H)2 cytokine regulation^l
en#Immunity#20040000#2004#21#707-717#20110400#721.htm#1074-7613#Immunity##
00756000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100016000900100
01800106010001600124010001500140010001300155810000600168012014000174030002500314
06500090033906400050034803100030035301400100035686500090036600200080037503500100
0383801002500393#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\721.htm#S#c#248#58#ar
ticle#58#58#^rND^sCzar^nMJ#^rND^sKersh^nEN#^rND^sMijares^nLA#^rND^sLanier^nG#^rN
D^sLewis^nJ#^rND^sYap^nG#et al#Altered lymphocyte responses and cytokine product
ion in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DS
HP/SAP^len#Proc Natl Acad Sci U S A#20010000#2001#98#7449-7454#20110400#721.htm#
0027-8424#Proc Natl Acad Sci U S A##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#o#1#1#article#1#201
10411#094616#789.htm#207##
03438000000000685000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120136001780100022003140100025003360100024003610100024003850100023004090100
02300432010002200455010002200477010002600499070018100525070014600706070009500852
07001160094708314360106308500080249908500230250708500270253008500240255708500340
25810850027026150850016026421170006026580720003026641120009026671110017026761140
00902693113001802702891002402720002000802744#v44n4#V:\SciELO\serial\bjmbr\v44n4\
markup\789.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#08#BJMBR050#FAPESP#B
raz J Med Biol Res#44#4#20110400#^f319^l326#0100-879X#20110304#Evidence for eosi
nophil recruitment, leukotriene B4 production and mast cell hyperplasia followin
g Toxocara canis infection in rats^len#^rND^1A01^nD.^sCarlos#^rND^1A01^nE.R.^sMa
chado#^rND^1A01^nL.^sDe Paula#^rND^1A04^nA.^sSá-Nunes#^rND^1A01^nC.A.^sSorgi#^rN
D^1A02^nM.C.^sJamur#^rND^1A02^nC.^sOliver#^rND^1A03^nW.T.^sLima#^rND^1A01^nL.H.^
sFaccioli#Universidade de São Paulo^iA01^1Faculdade de Ciências Farmacêuticas de
 Ribeirão Preto^2Toxicológicas e Bromatológicas^3Departamento de Análises Clínic
as^cRibeirão Preto^sSP^pBrasil#Universidade de São Paulo^iA02^1Faculdade de Medi
cina de Ribeirão Preto^2Departamento de Biologia Molecular e Celular^cRibeirão P
reto^sSP^pBrasil#Universidade de São Paulo^iA03^1Instituto de Ciências Biomédica
s^2Departamento de Farmacologia#Universidade de São Paulo^iA04^1Instituto de Ciê
ncias Biomédicas^2Departamento de Imunologia^cSão Paulo^sSP^pBrasil#^len^aIt is 
well known that eosinophilia is a key pathogenetic component of toxocariasis. Th
e objective of the present study was to determine if there is an association bet
ween peritoneal and blood eosinophil influx, mast cell hyperplasia and leukotrie
ne B4 (LTB4) production after Toxocara canis infection. Oral inoculation of 56-d
ay-old Wistar rats (N = 5-7 per group) with 1000 embryonated eggs containing thi
rd-stage (L3) T. canis larvae led to a robust accumulation of total leukocytes i
n blood beginning on day 3 and peaking on day 18, mainly characterized by eosino
phils and accompanied by higher serum LTB4 levels. At that time, we also noted i
ncreased eosinophil numbers in the peritoneal cavity. In addition, we observed i
ncreased peritoneal mast cell number in the peritoneal cavity, which correlated 
with the time course of eosinophilia during toxocariasis. We also demonstrated t
hat mast cell hyperplasia in the intestines and lungs began soon after the T. ca
nis larvae migrated to these compartments, reaching maximal levels on day 24, wh
ich correlated with the complete elimination of the parasite. Therefore, mast ce
lls appear to be involved in peritoneal and blood eosinophil infiltration throug
h an LTB4-dependent mechanism following T. canis infection in rats. Our data als
o demonstrate a tight association between larval migratory stages and intestinal
 and pulmonary mast cell hyperplasia in the toxocariasis model.#^dnd^i1#^tm^len^
kMast cells^i1#^tm^len^kLeukotriene B4^i1#^tm^len^kEosinophils^i1#^tm^len^kEosin
ophil peroxidase^i1#^tm^len^kToxocara canis^i1#^tm^len^kRat^i1#other#40#20101010
#October 10, 2010#20110216#February 16, 2011#S0100-879X2011007500027#789.htm##
03531000000000673000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120161001780100022003390100025003610100024003860100024004100100023004340100
02300457010002200480010002200502010002600524070018100550070014600731070009500877
07001160097208315080108808500080259608500230260408500380262708500240266508500340
26890850034027230850016027571170006027730720003027791120009027821110024027911140
00902815113002502824002000802849#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.h
tm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#08#BJMBR050#FAPESP#Braz J Med Bi
ol Res#44#4#20110400#^f319^l326#0100-879X#20110304#<b>Evidence for eosinophil re
cruitment, leukotriene B<sub>4</sub> production and mast cell hyperplasia follow
ing <i>Toxocara canis</i> infection in rats</b>^len#^rND^1A01^nD.^sCarlos#^rND^1
A01^nE.R.^sMachado#^rND^1A01^nL.^sDe Paula#^rND^1A04^nA.^sSá-Nunes#^rND^1A01^nC.
A.^sSorgi#^rND^1A02^nM.C.^sJamur#^rND^1A02^nC.^sOliver#^rND^1A03^nW.T.^sLima#^rN
D^1A01^nL.H.^sFaccioli#Universidade de São Paulo^iA01^1Faculdade de Ciências Far
macêuticas de Ribeirão Preto^2Toxicológicas e Bromatológicas^3Departamento de An
álises Clínicas^cRibeirão Preto^sSP^pBrasil#Universidade de São Paulo^iA02^1Facu
ldade de Medicina de Ribeirão Preto^2Departamento de Biologia Molecular e Celula
r^cRibeirão Preto^sSP^pBrasil#Universidade de São Paulo^iA03^1Instituto de Ciênc
ias Biomédicas^2Departamento de Farmacologia#Universidade de São Paulo^iA04^1Ins
tituto de Ciências Biomédicas^2Departamento de Imunologia^cSão Paulo^sSP^pBrasil
#^len^aIt is well known that eosinophilia is a key pathogenetic component of tox
ocariasis. The objective of the present study was to determine if there is an as
sociation between peritoneal and blood eosinophil influx, mast cell hyperplasia 
and leukotriene B<sub>4</sub> (LTB<sub>4</sub>) production after <i>Toxocara can
is</i> infection. Oral inoculation of 56-day-old Wistar rats (N = 5-7 per group)
 with 1000 embryonated eggs containing third-stage (L3) <i>T. canis </i>larvae l
ed to a robust accumulation of total leukocytes in blood beginning on day 3 and 
peaking on day 18, mainly characterized by eosinophils and accompanied by higher
 serum LTB<sub>4</sub> levels. At that time, we also noted increased eosinophil 
numbers in the peritoneal cavity. In addition, we observed increased peritoneal 
mast cell number in the peritoneal cavity, which correlated with the time course
 of eosinophilia during toxocariasis. We also demonstrated that mast cell hyperp
lasia in the intestines and lungs began soon after the <i>T. canis</i> larvae mi
grated to these compartments, reaching maximal levels on day 24, which correlate
d with the complete elimination of the parasite. Therefore, mast cells appear to
 be involved in peritoneal and blood eosinophil infiltration through an LTB<sub>
4</sub>-dependent mechanism following <i>T. canis</i> infection in rats. Our dat
a also demonstrate a tight association between larval migratory stages and intes
tinal and pulmonary mast cell hyperplasia in the toxocariasis model.#^dnd^i1#^tm
^len^kMast cells^i1#^tm^len^kLeukotriene B<sub>4</sub>^i1#^tm^len^kEosinophils^i
1#^tm^len^kEosinophil peroxidase^i1#^tm^len^k<i>Toxocara canis</i>^i1#^tm^len^kR
at^i1#other#40#20101010#<i>October 10, 2010</i>#20110216#<i>February 16, 2011</i
>#789.htm##
03564000000000697000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762240009001860120136001950100021003310100025003520100023003770100023004000100
02300423010002300446010002100469010002200490010002600512070018300538070014800721
07001250086907001180099408314360111208500080254808500230255608500270257908500240
26060850034026300850027026640850016026911170006027070720003027131120009027161110
01702725114000902742113001802751002000802769008008902777#v44n4#V:\SciELO\serial\
bjmbr\v44n4\markup\789.htm#S#l#4#1#article#1#^mApr.^a2011#oa#en#bjmbr#1#3.1#ilus
#tab#08#BJMBR050#FAPESP#Braz. j. med. biol. res#44#4#20110400#^f319^l326#0100-87
9X#20110304#Evidence for eosinophil recruitment, leukotriene B4 production and m
ast cell hyperplasia following Toxocara canis infection in rats^len#^rND^1A01^nD
^sCarlos#^rND^1A01^nE. R^sMachado#^rND^1A01^nL^sDe Paula#^rND^1A04^nA^sSá-Nunes#
^rND^1A01^nC. A^sSorgi#^rND^1A02^nM. C^sJamur#^rND^1A02^nC^sOliver#^rND^1A03^nW.
 T^sLima#^rND^1A01^nL. H^sFaccioli#^iA01^1Universidade de São Paulo^2Faculdade d
e Ciências Farmacêuticas de Ribeirão Preto^3Toxicológicas e Bromatológicas. Depa
rtamento de Análises Clínicas^cRibeirão Preto^sSP^pBrasil#^iA02^1Universidade de
 São Paulo^2Faculdade de Medicina de Ribeirão Preto^3Departamento de Biologia Mo
lecular e Celular^cRibeirão Preto^sSP^pBrasil#^iA03^1Universidade de São Paulo^2
Instituto de Ciências Biomédicas^3Departamento de Farmacologia^cRibeirão Preto^s
SP^pBrasil#^iA04^1Universidade de São Paulo^2Instituto de Ciências Biomédicas^3D
epartamento de Imunologia^cSão Paulo^sSP^pBrasil#^len^aIt is well known that eos
inophilia is a key pathogenetic component of toxocariasis. The objective of the 
present study was to determine if there is an association between peritoneal and
 blood eosinophil influx, mast cell hyperplasia and leukotriene B4 (LTB4) produc
tion after Toxocara canis infection. Oral inoculation of 56-day-old Wistar rats 
(N = 5-7 per group) with 1000 embryonated eggs containing third-stage (L3) T. ca
nis larvae led to a robust accumulation of total leukocytes in blood beginning o
n day 3 and peaking on day 18, mainly characterized by eosinophils and accompani
ed by higher serum LTB4 levels. At that time, we also noted increased eosinophil
 numbers in the peritoneal cavity. In addition, we observed increased peritoneal
 mast cell number in the peritoneal cavity, which correlated with the time cours
e of eosinophilia during toxocariasis. We also demonstrated that mast cell hyper
plasia in the intestines and lungs began soon after the T. canis larvae migrated
 to these compartments, reaching maximal levels on day 24, which correlated with
 the complete elimination of the parasite. Therefore, mast cells appear to be in
volved in peritoneal and blood eosinophil infiltration through an LTB4-dependent
 mechanism following T. canis infection in rats. Our data also demonstrate a tig
ht association between larval migratory stages and intestinal and pulmonary mast
 cell hyperplasia in the toxocariasis model.#^dnd^i1#^tm^len^kMast cells^i1#^tm^
len^kLeukotriene B4^i1#^tm^len^kEosinophils^i1#^tm^len^kEosinophil peroxidase^i1
#^tm^len^kToxocara canis^i1#^tm^len^kRat^i1#other#40#20101010#October 10, 2010#2
0110216#February 16, 2011#789.htm#Internet^ihttp://www.scielo.br/scielo.php?scri
pt=sci_arttext&pid=S0100-879X2011000400008##
00371000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014700070002000800217#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#5#1#article#163#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 319-326</B> </font></P>      ^cY#789.htm##
00549000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704032500070002000800395#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#6#2#article#163#<p ALIGN="left"><strong><
font face="Arial"><span lang="EN"><font size="5">Evidence for eosinophil recruit
ment, leukotriene </font></span></font><font size="5" face="Arial"><span lang="E
N">B<sub>4</sub> production and mast cell hyperplasia following <i>Toxocara cani
s</i> infection in rats</span></font></strong></p>      ^cY#789.htm##
00936000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704071200070002000800782#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#7#3#article#163#<p ALIGN="left"><font fac
e="Arial"><span lang="EN">D. Carlos<sup>1</sup>, E.R. Machado<sup>1</sup>, L. De
 Paula<sup>1</sup>, A. S&aacute;-Nunes<sup>4</sup>, C.A. Sorgi<sup>1</sup>, </sp
an></font><font face="Arial"><span lang="EN">M.C. Jamur<sup>2</sup>, C. Oliver<s
up>2</sup>, W.T. Lima<sup>3</sup> and <span lang="EN"><font face="Arial, Helveti
ca, sans-serif"><sup><span lang="EN"><font face="Arial, Helvetica, sans-serif"><
b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v44n4/recor.gif" borde
r="0"></a></b> <a href="mailto:faccioli@fcfrp.usp.br"><img src="/img/revistas/bj
mbr/v44n4/email-ca.gif" border="0"></a></font></span></sup></font></span> L.H. F
accioli<sup>1</sup></span></font></p>      ^cY#789.htm##
00603000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704037900070002000800449#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#8#4#article#163#<p ALIGN="left"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Departamento de An&
aacute;lises Cl&iacute;nicas, Toxicol&oacute;gicas e Bromatol&oacute;gicas, </fo
nt></span><font face="Arial"><span lang="EN">Faculdade de Ci&ecirc;ncias Farmac&
ecirc;uticas de Ribeir&atilde;o Preto, Universidade de S&atilde;o Paulo, Ribeir&
atilde;o Preto, SP, Brasil    ^cY#789.htm##
00511000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704028700070002000800357#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#9#5#article#163#<br>    </span></font><fo
nt face="Arial"><span lang="EN"><sup>2</sup>Departamento de Biologia Molecular e
 Celular, Faculdade de Medicina de Ribeir&atilde;o Preto, </span></font><font fa
ce="Arial"><span lang="EN">Universidade de S&atilde;o Paulo, Ribeir&atilde;o Pre
to, SP, Brasil    ^cY#789.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704032300071002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#10#6#article#163#<br>  </span></font><fon
t face="Arial"><span lang="EN"><sup>3</sup>Departamento de Farmacologia, <sup>4<
/sup>Departamento de Imunologia, Instituto de Ci&ecirc;ncias Biom&eacute;dicas, 
</span></font><font face="Arial"><span lang="EN">Universidade de S&atilde;o Paul
o, S&atilde;o Paulo, SP, Brasil</span></font></p>      ^cY#789.htm##
00415000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704019000071002000800261#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#11#7#article#163#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#789.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#12#8#article#163#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#789.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#13#9#article#163#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#789.htm##
00398000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017200072002000800244#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#14#10#article#163#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#789.htm##
00407000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018100072002000800253#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#15#11#article#163#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#78
9.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#16#12#article#163#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#789.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#17#13#article#163#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#789.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#18#14#article#163#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#789.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#19#15#article#163#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#789.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#20#16#article#163#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#789.htm##
01806000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704158000072002000801652#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#21#17#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">It is well known that eosinophilia is a key pathogen
etic component of toxocariasis. The objective of the present study was to determ
ine if there is an association between peritoneal and blood eosinophil influx, m
ast cell hyperplasia and leukotriene B<sub>4</sub> (LTB<sub>4</sub>) production 
after <i>Toxocara canis</i> infection. Oral inoculation of 56-day-old Wistar rat
s (N = 5-7 per group) with 1000 embryonated eggs containing third-stage (L3) <i>
T. canis </i>larvae led to a robust accumulation of total leukocytes in blood be
ginning on day 3 and peaking on day 18, mainly characterized by eosinophils and 
accompanied by higher serum LTB<sub>4</sub> levels. At that time, we also noted 
increased eosinophil numbers in the peritoneal cavity. In addition, we observed 
increased peritoneal mast cell number in the peritoneal cavity, which correlated
 with the time course of eosinophilia during toxocariasis. We also demonstrated 
that mast cell hyperplasia in the intestines and lungs began soon after the <i>T
. canis</i> larvae migrated to these compartments, reaching maximal levels on da
y 24, which correlated with the complete elimination of the parasite. Therefore,
 mast cells appear to be involved in peritoneal and blood eosinophil infiltratio
n through an LTB<sub>4</sub>-dependent mechanism following <i>T. canis</i> infec
tion in rats. Our data also demonstrate a tight association between larval migra
tory stages and intestinal and pulmonary mast cell hyperplasia in the toxocarias
is model.</span></font></p>      ^cY#789.htm##
00441000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021500072002000800287#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#22#18#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">Key words: Mast cells; Leukotriene B<sub>4</sub>; Eo
sinophils; Eosinophil peroxidase; <i>Toxocara canis</i>; Rat</span></font></p>  
<HR ALIGN=LEFT SIZE=2>      ^cY#789.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#23#19#article#163#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#789.htm##
01591000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704136500072002000801437#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#24#20#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">Intestinal nematodes cause some of the most prevalen
t parasitic infections in humans. <i>Toxocara canis</i> is an intestinal parasit
e of dogs, and is the etiologic agent of visceral larva migrans syndrome (VLMS).
 In non-compatible hosts such as rodents and humans, VLMS results from the inges
tion of <i>T. canis</i>-embryonated eggs that eclode in the small intestine. Aft
er ingestion, the larvae migrate to other tissues, inducing inflammation in reac
tion to the excretory/secretory products produced by the larvae (1). In general,
 helminthic parasites infect vertebrate hosts and typically promote a Th2-type i
nflammatory response that is marked by eosinophilia, high levels of immunoglobul
in E (IgE) and mast cell hyperplasia (2). Studies from our laboratory have shown
 an accumulation of eosinophils and increased total serum IgE during the course 
of <i>T. canis</i> infection in guinea pigs (3) and Wistar rats (4). Despite the
 presence of elevated levels of circulating IgE during eosinophilic inflammation
 (5,6) and the capacity of mast cell secretory products to promote the traffic o
f leukocytes to the challenge sites (7,8), the relative importance of the IgE-ma
st cell system for the maintenance of the chronic inflammatory response to helmi
nthic infections is controversial.</span></font></p>      ^cY#789.htm##
01726000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704150000072002000801572#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#25#21#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">Mast cells are effector cells that are prominent at 
the interfaces between the immune system and the external environment, such as t
he skin and the gastrointestinal and respiratory tracts. When IgE bound to its h
igh-affinity receptor, Fc&epsilon;RI, is cross-linked with multivalent antigens,
 the activation of mast cells is initiated, resulting in the release of a variet
y of preformed mediators, including &beta;-hexosaminidase and tumor necrosis fac
tor-alpha (TNF-&alpha;); in addition, <i>de novo</i> synthesis of proinflammator
y mediators such as prostaglandin, leukotrienes (LTs) and cytokines occurs (9,10
). LTs are generated by the metabolism of arachidonic acid through the 5-lipoxyg
enase pathway (11). 5-LO expression is generally restricted to myeloid cells, in
 particular neutrophils, eosinophils, monocytes, macrophages, and mast cells (12
,13). Leukotriene B<sub>4</sub> (LTB<sub>4</sub>) was originally discovered as a
n arachidonate metabolite that stimulates neutrophils (14), and has been describ
ed to be a chemoattractant for eosinophils (15,16). It has been shown that IgE-d
riven inflammation may lead to eosinophil accumulation through a mechanism depen
dent on eotaxin, platelet-activating factor and LTs (17). Moreover, it has been 
shown that eosinophil migration to the rat peritoneal cavity is mediated by mast
 cells, which release chemotactic factors such as LTB<sub>4</sub> after stimulat
ion (18).</span></font></p>      ^cY#789.htm##
01301000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704107500072002000801147#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#26#22#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">A previous study showed clearly that the eosinophil 
response induced by <i>T. canis</i> infection was significantly lower in mast ce
ll-deficient W/W<sup>v</sup> mice when compared to normal littermates, suggestin
g that mast cells play a pivotal role in blood eosinophilia during infection wit
h <i>T. canis </i>(19). The present study was undertaken to evaluate the kinetic
s of peripheral blood and tissue eosinophil recruitment, eosinophil peroxidase (
EPO) activity, and the levels of LTB<sub>4</sub> in the serum of <i>T. canis</i>
-infected rats. We also determined if changes in peritoneal mast cell number cor
related with eosinophilia and increased LTB<sub>4</sub> release. In addition, pa
rasitological parameters, such as the number of <i>T. canis</i> larvae in the lu
ngs and intestine as well as the inflammatory consequences of larval migration i
n intestinal and lung mast cell hyperplasia, were also assessed following infect
ion of Wistar rats with <i>T. canis</i>.</span></font></p>  <HR ALIGN=LEFT SIZE=
2>      ^cY#789.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#27#23#article#163#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#789.htm##
00319000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009300072002000800165#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#28#24#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Animals</span></font></b></p>      ^cY#789.htm##
00690000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704046400072002000800536#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#29#25#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">Female Wistar rats (200-250 g) were obtained from th
e animal facility of the School of Pharmaceutical Sciences of Ribeir&atilde;o Pr
eto, University of S&atilde;o Paulo, Brazil. They were maintained under standard
 laboratory conditions, and all experiments were approved and conducted in accor
dance with the guidelines of the Animal Care Committee of the University of S&at
ilde;o Paulo.</span></font></p>      ^cY#789.htm##
00332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010600072002000800178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#30#26#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Infection of animals</span></font></b></p>      ^
cY#789.htm##
00894000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704066800072002000800740#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#31#27#article#163#<p ALIGN="left"> <font 
face="Arial"><span lang="EN"><i>T. canis </i>eggs were obtained according to the
 method of Olson and Schulz (20), modified by Faccioli et al. (3). Briefly, fema
le worms were recovered from young dogs and the eggs were removed from the uteri
, washed and allowed to develop to the infective stage (L3) in shallow dishes co
ntaining 0.5% formalin at 37&deg;C. Before use, the eggs were thoroughly washed 
with saline. Infective doses of 1000 embryonated eggs were prepared in 1 mL sali
ne. Rats were infected with the embryonated eggs by gastric intubation using a m
etal cannula. Controls received 1 mL saline without eggs.</span></font></p>     
 ^cY#789.htm##
00366000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704014000072002000800212#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#32#28#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Collection of peritoneal cavity fluid, blood and 
serum</span></font></b></p>      ^cY#789.htm##
00962000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704073600072002000800808#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#33#29#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">At 3, 6, 18, or 24 days after infection, the animals
 were euthanized with a lethal dose of 2.5% tribromoethanol <i>ip</i> (Acros Org
anics, USA), and blood samples were obtained by cardiac puncture. Peritoneal cel
ls were obtained by injecting rats with 5 mL PBS containing 0.5% sodium citrate.
 The peritoneal wash was gently collected with a Pasteur pipette after laparotom
y and placed in plastic tubes. Total blood or peritoneal cavity fluid cell count
s were performed immediately using a Neubauer chamber. Differential counts were 
obtained using Rosenfeld-stained cytospin preparations. After blood coagulation,
 sera were collected and stored at -20&deg;C.</span></font></p>      ^cY#789.htm
##
00352000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704012600072002000800198#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#34#30#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Detection of LTB<sub>4</sub> in the sera</span></
font></b></p>      ^cY#789.htm##
00920000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704069400072002000800766#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#35#31#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">Quantification of serum LTB<sub>4</sub> was performe
d by enzyme immunoassay (Cayman Chemical, USA) according to the method of Pradel
les et al. (21). Supernatant dilutions were incubated with conjugated eicosanoid
-acetylcholinesterase and with antiserum in 96-well plates precoated with anti-r
abbit immunoglobulin G antibodies. After overnight incubation at 4&deg;C, plates
 were washed and enzyme substrate (Ellman&rsquo;s reagent) was added for 60 to 1
20 min at 25&deg;C. Sample absorbance was determined at 412 nm in a microplate r
eader, and concentrations of eicosanoids were calculated based on a standard cur
ve.</span></font></p>      ^cY#789.htm##
00336000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011000072002000800182#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#36#32#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Histological examination</span></font></b></p>   
   ^cY#789.htm##
01051000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704082500072002000800897#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#37#33#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">For histological examination of the intestine (ileum
) and lungs, fragments of tissue were fixed in buffered formalin, dehydrated, an
d embedded in paraffin. Tissues were sectioned and stained with 0.1% Toluidine b
lue, pH 2.8, for 20 min. For staining of mucosal mast cells, the ileum was fixed
 in Carnoy&rsquo;s fixative and stained with 1% Alcian blue at pH 2.5 for 30 min
. All sections were analyzed, and mast cell numbers were determined using an Oly
mpus BX50 microscope equipped with a Nikon DXM1200 digital camera and the Image-
Pro Plus software (Media Cybernetics, USA). A counting field was superimposed on
 the image obtained with a 40X objective. Each counting point corresponds to a f
ield area of 5000 &micro;m<sup>2</sup> on the section.</span></font></p>      ^c
Y#789.htm##
00342000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011600072002000800188#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#38#34#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Eosinophil peroxidase activity</span></font></b><
/p>      ^cY#789.htm##
01509000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704128300072002000801355#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#39#35#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">EPO activity in the peritoneal cavity fluid was dete
rmined with a colorimetric assay as described by Strath and colleagues (22) with
 slight modifications as follows. In brief, the cell suspensions were recovered 
and centrifuged, and the cells were exposed to Tris-NH<sub>4</sub>Cl buffer (0.1
6 M NH<sub>4</sub>Cl and 0.17 M Tris-HCl; final solution was 9 parts NH<sub>4</s
ub>Cl stock solution and 1 part Tris-solution, pH 7.2) to lyse the erythrocytes.
 The cells were then washed once with PBS, and the cell number was adjusted to 1
0<sup>6</sup> cells/mL. A total of 100 &micro;L was transferred to a 96-well mic
roplate in duplicate. The microplates were then centrifuged at 200 <i>g </i>at 4
&deg;C for 10 min. The supernatants were carefully removed, 100 &micro;L substra
te solution (2.4 mM o-phenylenediamine dihydrochloride in 50 mM Tris-HCl, pH 8.0
, with 6.6 mM H<sub>2</sub>O<sub>2</sub>) was added to each well, and the plates
 were incubated at room temperature for 15 min. This substrate is specific for E
PO and does not recognize myeloperoxidase (23). The reaction was stopped by addi
tion of 50 &micro;L 4 M H<sub>2</sub>SO<sub>4</sub>, and the absorbance of the s
amples was determined at 490 nm.</span></font></p>      ^cY#789.htm##
00330000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010400072002000800176#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#40#36#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Recovery of larvae</span></font></b></p>      ^cY
#789.htm##
00836000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704061000072002000800682#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#41#37#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">Rats were orally infected with 1000 embryonated <i>T
. canis</i> eggs. On days 1, 3, 6, 18, and 24 after inoculation, 3 rats were eut
hanized, and larvae were recovered from the lungs and small intestine by digesti
ng the tissue in 0.5% HCl for 24 h at 37&deg;C. The sedimental liquid was poured
 into a tube and centrifuged for 2 min at 400 <i>g</i>. After centrifugation, 2 
mL of the sediment was collected and mixed thoroughly, and 100 &micro;L of the s
amples was observed with a light microscope to count the number of larvae (24).<
/span></font></p>      ^cY#789.htm##
00332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010600072002000800178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#42#38#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Statistical analyses</span></font></b></p>      ^
cY#789.htm##
00527000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704030100072002000800373#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#43#39#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">Each experiment was performed twice. Data are report
ed as means &plusmn; SEM. Statistical differences were analyzed by the Student <
i>t-</i>test and the level of significance was set at P &lt; 0.05.</span></font>
</p>  <HR ALIGN=LEFT SIZE=2>      ^cY#789.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#44#40#article#163#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#789.htm##
00381000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704015500072002000800227#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#45#41#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Mast cell and eosinophil accumulation after <i>T.
 canis</i> infection</span></font></b></p>      ^cY#789.htm##
01516000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704129000072002000801362#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#46#42#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">During the course of <i>T. canis</i> infection, an i
ntense inflammatory reaction characterized by an increase in the total number of
 leukocytes in the blood and peritoneal cavity was observed (<a href="#Fig1">Fig
ure 1A</a> and <a href="#Fig1">B</a>). Also, we found increased numbers of blood
 eosinophils in <i>T. canis</i>-infected rats from day 3 to day 18, with decreas
ing numbers thereafter (<a href="#Fig1">Figure 1C</a>). A massive infiltration o
f eosinophils into the peritoneal cavity was first noted at 6 days and peaked wi
thin 18 days of infection. This correlated with higher EPO activity in the perit
oneal cavity (<a href="#Fig2">Figure 2A</a> and <a href="#Fig2">B</a>). In infec
ted rats, the peritoneal mast cell number was significantly higher than in contr
ol rats from day 3 to day 24 after infection (<a href="#Fig2">Figure 2C</a>). In
 fact, eosinophil recruitment into the peritoneal cavity occurred in parallel to
 increased peritoneal mast cell accumulation in this compartment (<a href="#Fig2
">Figure 2A</a> and <a href="#Fig2">C</a>). These data show that eosinophil extr
avasation from the blood into the peritoneal cavity is related to alterations in
 mast cell numbers during toxocariasis.</span></font></p>      ^cY#789.htm##
00441000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021500072002000800287#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#47#43#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Increased LTB<sub>4</sub> levels in serum after <
i>T. canis </i></span></font></b><b><font face="Arial"><span lang="EN">infection
</span></font></b></p>      ^cY#789.htm##
00970000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704074400072002000800816#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#48#44#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">The production of LTB<sub>4 </sub>was assessed in th
e serum of <i>T. canis</i>-infected rats and -uninfected rats that received only
 saline (control). Levels of LTB<sub>4</sub> in the serum from <i>T. canis</i>-i
nfected rats were significantly higher on the 3rd, 18th, and 24th days after inf
ection compared to control rats. Although not expected, LTB<sub>4</sub> values f
or controls almost tripled at day 24 (<a href="#Fig3">Figure 3</a>). These resul
ts indicate that release of the LTB<sub>4</sub> chemotactic factor correlates wi
th mast cell accumulation and appears to contribute, at least in part, to eosino
phil recruitment following <i>T. canis</i> infection.</span></font></p>      ^cY
#789.htm##
00402000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017600072002000800248#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#49#45#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Mast cell hyperplasia in the small intestine and 
lungs following <i>T. canis</i> infection</span></font></b></p>      ^cY#789.htm
##
01171000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704094500072002000801017#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#50#46#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">The major site of mast cell accumulation during infe
ction was the small intestine, where mast cell counts per field increased 3-fold
 compared to uninfected rats on the 1st day after infection. Quantification of m
ast cell numbers established that maximal accumulation occurred on the 24th day 
after infection, when a 915-fold increase over uninfected controls was observed 
(<a href="#Tab1">Table 1</a> and <a href="#Fig4">Figure 4B-F</a>). A slight but 
significant increase of the mast cell population was observed on the 1st and 3rd
 days after infection in the lung. On the 6th and 18th days, there was a marked 
increase in the number of mast cells in the lungs of infected rats. A maximum wa
s reached on the 24th day, when mast cell counts per field increased 5-fold comp
ared to uninfected controls (<a href="#Tab2">Table 2</a> and <a href="#Fig4">Fig
ure 4H-L</a>).</span></font></p>      ^cY#789.htm##
00397000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017100072002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#51#47#article#163#<p ALIGN="left"><b><fon
t face="Arial"><span lang="EN">Larval counts in the lungs and small intestines o
f rats infected with <i>T. canis</i></span></font></b></p>      ^cY#789.htm##
01057000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704083100072002000800903#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#52#48#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">In order to determine whether migration of the larva
e was associated with mast cell hyperplasia, we quantified the number of larvae 
recovered from the small intestine and lungs 1, 3, 6, 18, and 24 days after inoc
ulation. The greatest number of larvae was seen 1 day after infection in the sma
ll intestine. After the first day, the number of larvae in this compartment was 
drastically decreased. In the lungs, the number of larvae recovered increased on
ly slightly on days 3, 6, and 18 after infection (<a href="#Fig5">Figure 5</a>).
</span></font></p>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="le
ft" valign="top">      <td><a href="/img/revistas/bjmbr/v44n4/html/789i01.htm"><
img src="/img/revistas/bjmbr/v44n4/789i01peq.jpg" border="2"></a></td>      <td>
    ^cY#789.htm##
00927000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704070100072002000800773#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#53#49#article#163#<p ALIGN="left"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. 
Kinetics of inflammatory cell increase following <i>Toxocara canis</i> infection
. The numbers of blood leukocytes (A), peritoneal cavity fluid leukocytes (B) an
d blood eosinophils (C) were assessed. Samples were collected 3, 6, 18, and 24 d
ays after <i>po</i> inoculation of 1000 infective <i>T. canis</i> eggs (filled b
ars). Control uninfected rats received only 1 mL saline <i>po</i> (open bars). D
ata are reported as means &plusmn; SEM of two independent experiments (N = 8). *
P &lt; 0.05 <i>vs </i>control group (Student <i>t-</i>test).</font></span></p>  
    </td>    </tr>  </table>      ^cY#789.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033800072002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#54#50#article#163#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (133 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/789i02.htm"><img src="/img
/revistas/bjmbr/v44n4/789i02peq.jpg" border="2"></a></td>      <td>    ^cY#789.h
tm##
00951000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704072500072002000800797#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#55#51#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN"><a name="Fig2"></a>Figure 2. Kinetics of inflammator
y cell increase following <i>Toxocara canis</i> infection. The number of periton
eal cavity fluid eosinophils (A), peritoneal cavity fluid eosinophil peroxidase 
(B) and peritoneal cavity fluid mast cells (C) were assessed. Samples were colle
cted 3, 6, 18, and 24 days after <i>po</i> inoculation of 1000 infective <i>T. c
anis</i> eggs (filled bars). Control uninfected rats received only 1 mL saline <
i>po</i> (open bars). Data are reported as means &plusmn; SEM of two independent
 experiments (N = 8). *P &lt; 0.05 <i>vs </i>control group (Student <i>t-</i>tes
t). </span></font></p>      </td>    </tr>  </table>      ^cY#789.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033800072002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#56#52#article#163#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (133 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/789i03.htm"><img src="/img
/revistas/bjmbr/v44n4/789i03peq.jpg" border="2"></a></td>      <td>    ^cY#789.h
tm##
00835000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704060900072002000800681#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#57#53#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN"><a name="Fig3"></a>Figure 3. Kinetics of leukotriene
 B4 (LTB<sub>4</sub>) release into the blood induced by <i>Toxocara canis</i> in
fection. Enzyme immunoassay of serum leukotriene concentration was performed 3, 
6, 18, and 24 days after <i>po </i>inoculation of 1000 <i>T. canis</i> eggs (fil
led bars). Control uninfected rats received only 1 mL saline <i>po</i> (open bar
s). Data are reported as means &plusmn; SEM of at least 4 animals. *P &lt; 0.05 
<i>vs </i>control group (Student <i>t-</i>test).</span></font></p>      </td>   
 </tr>  </table>      ^cY#789.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033700072002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#58#54#article#163#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (56 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/789i04.htm"><img src="/img/
revistas/bjmbr/v44n4/789i04peq.jpg" border="2"></a></td>      <td>    ^cY#789.ht
m##
00888000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704066200072002000800734#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#59#55#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN"><a name="Fig4"></a>Figure 4. Light microscopy analys
is of mast cell hyperplasia in the intestine or lung 1 (B, H), 3 (C, I), 6 (D, J
), 18 (E, K), and 24 (F, L) days after infection, respectively. The analysis was
 conducted on Alcian blue- or Toluidine blue-stained tissue sections from the il
eum and lung of <i>Toxocara canis</i>-infected rats or uninfected rats (A and G)
<i>. </i>Mast cells were readily detected in the intestinal mucosa and pulmonary
 parenchyma after 1 day and progressively increased until day 24. Mast cells are
 indicated by arrows.</span></font></p>      </td>    </tr>  </table>      ^cY#7
89.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033800072002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#60#56#article#163#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (251 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/789i05.htm"><img src="/img
/revistas/bjmbr/v44n4/789i05peq.jpg" border="2"></a></td>      <td>    ^cY#789.h
tm##
00743000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704051700072002000800589#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#61#57#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN"><a name="Fig5"></a>Figure 5. Kinetics of <i>Toxocara
 canis</i>-migrating larvae recovered from lung and intestine. Larvae were recov
ered from the lungs (triangles) and small intestines (inverted triangles) of rat
s inoculated with 1000 infective <i>T. canis</i> eggs. Larval number was counted
 in a pool of 4 animals killed at 1, 3, 6, 18, and 24 days after infection. Data
 are reported as means &plusmn; SEM.</span></font></p>      </td>    </tr>  </ta
ble>      ^cY#789.htm##
00559000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033300072002000800405#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#62#58#article#163#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (69 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/789t01.htm"><img src="/img/
revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#789.htm##
00477000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704025100072002000800323#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#63#59#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN"><a name="Tab1"></a>Table 1. Differences in mast cell
 numbers in the intestinal mucosa from uninfected and <i>Toxocara canis</i>-infe
cted rats.</span></font></p>      </td>    </tr>  </table>      ^cY#789.htm##
00803000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704057700072002000800649#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#64#60#article#163#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (142 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/789t02.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td><span lang="EN"><
font face="Arial"><span lang="EN"><a name="Tab2"></a>Table 2. Differences in mas
t cell numbers in the pulmonary parenchyma from uninfected and <i>Toxocara canis
</i>-infected rats.</span></font></span></td>    </tr>  </table>      ^cY#789.ht
m##
00344000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011800072002000800190#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#65#61#article#163#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (138 K JPG file)]</font
></P>      ^cY#789.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#66#62#article#163#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#789.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#67#63#article#163#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#789.htm##
00867000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704064100072002000800713#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#68#64#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">To gain insight into the mechanisms underlying incre
ased eosinophilia during infection with <i>T. canis</i>, we compared some featur
es of the inflammatory response in infected Wistar rats. Three major effects wer
e observed: 1) increased peripheral blood and tissue eosinophil influx and EPO a
ctivity, 2) significant peritoneal mast cell accumulation and LTB<sub>4</sub> pr
oduction in the serum following <i>T. canis</i> infection, and 3) mast cell hype
rplasia in the lungs and intestinal tissues probably induced by the passage of l
arvae into these compartments.</span></font></p>      ^cY#789.htm##
01788000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704156200072002000801634#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#69#65#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">Increased eosinophilia was observed in the blood and
 peritoneal cavities of rats infected with <i>T. canis</i>. The peritoneal eosin
ophil accumulation reached a peak on day 18 of infection and occurred in paralle
l to a marked increase in the number of mast cells in the peritoneal cavity. Con
sistent with these data, previous findings from our laboratory demonstrated elev
ated serum IgE levels on the 18th day after infection (4). We also evaluated EPO
 activity, a specific marker for eosinophils, and detected higher amounts of EPO
 in the peritoneal exudates of infected rats compared to uninfected rats. Our re
sults also showed that mast cell accumulation in the peritoneal cavity correlate
s with blood eosinophil mobilization and extravasation to the peritoneal cavity 
during toxocariasis. In this context, a study by Nawa et al. (19) reported that 
production of eosinophils and their release from bone marrow into peripheral blo
od was impaired in mast cell-deficient W/W<sup>v</sup> mice compared to their no
rmal littermates after <i>T. canis</i> infection. For instance, the results of t
he present study agree with previous investigations that have shown that IgE-dep
endent mast cell-mediated mechanisms play a crucial role in eosinophilia and in 
the immunological control induced in rats by other nematodes, such as <i>Angiost
rongylus cantonensis </i>(25), <i>Strongyloides venezuelensis </i>(26), <i>Nippo
strongylus brasiliensis </i>(27), and <i>Trichinella spiralis </i>(28).</span></
font></p>      ^cY#789.htm##
02949000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704272300072002000802795#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#70#66#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">It is not clear why eosinophil infiltration persists
 in <i>T. canis</i>-infected mice after the decrease in the number of inciting l
arvae, but the involvement of various eosinophil chemotactic factors has been su
ggested (29). A recent report established a tight correlation between tissue les
ions caused by larval migration and plasma cytokine production. Moreover, the au
thors mentioned eotaxin and RANTES as potential factors responsible for the mark
ed eosinophilic response that is a hallmark of <i>T. canis</i> infection (30). I
n fact, our group described an increased concentration of eotaxin in lung homoge
nates of <i>T. canis</i>-infected mice, which also correlated with eosinophil re
cruitment to this organ (31). Although the <i>in vivo</i> factors responsible fo
r eosinophil accumulation at inflammatory sites of parasitic infections are know
n to be produced by mast cells, only a single study has reported that cultured m
ast cells obtained from mice infected by <i>T. canis</i> released eosinophil che
motactic factors after stimulation with calcium ionophore A23187 or IgE-antigen.
 These investigators also suggested that these factors might be arachidonic acid
 metabolites (32). In agreement with the results of these studies, treatment of 
<i>T. canis-</i>infected rats with a specific LTB<sub>4</sub> receptor antagonis
t significantly reduced eosinophil chemotactic activity in bronchoalveolar fluid
, suggesting that LTB<sub>4</sub> also contributes to the accumulation of eosino
phils in the lungs (33). In another study, treatment of mice infected with the n
ematode <i>S. venezuelensis</i> with the leukotriene inhibitor MK886 significant
ly inhibited the recruitment of eosinophils in the bronchoalveolar space, perito
neal cavity and blood (34). To determine the <i>in vivo</i> relevance of mast ce
ll-derived LTB<sub>4</sub> in eosinophilia, we examined the release of this medi
ator in rats following <i>T. canis</i> infection. We observed increased levels o
f LTB<sub>4</sub> in the serum of infected rats compared to control, with the ma
ximal response occurring 24 days after infection. These data suggest that LTB<su
b>4</sub> released by mast cells is a potent inflammatory mediator probably invo
lved in eosinophil accumulation in blood and maybe in the peritoneal cavity in t
his experimental model. Another study also demonstrated a role for endogenous st
em cell factor production in mediating eosinophil recruitment in an allergic ple
urisy model in mice (35). Moreover, the authors also showed that the effects of 
stem cell factor were dependent on the release of LTB<sub>4</sub>, which was mos
t likely produced by mast cells.</span></font></p>      ^cY#789.htm##
02000000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704177400072002000801846#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#71#67#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">The biological cycle of <i>T. canis</i> has common f
eatures with many nematodes; the larvae penetrate the small intestine, enter the
 circulation and are free to migrate to the liver, lungs and brain (36). Excreto
ry/secretory products released by the larvae interact with molecules expressed o
n the immune system cells, control their activity and induce inflammation in sev
eral tissues (37). We observed that most of the <i>T. canis</i> larvae penetrate
d the intestinal mucosa within 24 h and migrated to the lungs after 72 h of the 
L3 larvae inoculation. In fact, these larvae are metabolically active and inflam
matory mediators are secreted due to activation of the host&rsquo;s immune cells
 by larval products, resulting in an increased influx of leukocytes (38). In our
 study, mast cell hyperplasia was already greater in the small intestine after 1
 day of infection, which coincided with the presence of the <i>T. canis </i>larv
ae in this organ. In addition, we also showed that in <i>T. canis</i>-infected r
ats, L3 larvae were most prevalent in the lungs on the 3rd day, although a secon
d cycle of larval invasion could be detected on the 18th day of infection. Promi
nent mast cell recruitment is a common feature of infections by nematodes in mos
t host species. The timing and degree of mast cell hyperplasia can vary between 
species and with the intensity of infection. Infection with the nematode <i>Tric
hinella spiralis</i> is associated with early and intense recruitment of intesti
nal mast cells (39). However, with other parasites, such as <i>Schistosoma manso
ni</i>, chronic infection causes only a slight increase in mast cell numbers in 
the lungs and small intestine of rats (40).</span></font></p>      ^cY#789.htm##
01207000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704098100072002000801053#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#72#68#article#163#<p ALIGN="left"><font f
ace="Arial"><span lang="EN">The results of the present study suggest that mast c
ells play an essential role in peritoneal and blood eosinophil infiltration and 
in the release of LTB<sub>4 </sub>during infection with <i>T. canis</i> in rats.
 In parallel, mast cell numbers were histologically assessed in the lung and int
estine after staining with Toluidine and Alcian blue, respectively. An important
 correlation was established between mast cell hyperplasia and the time course o
f larval migration into the small intestine and lungs. These data showed that in
fection with <i>T. canis</i> in rats can be considered an alternative model to d
elineate the crucial features of the immune response evoked by <i>T. canis. </i>
In addition, this model may contribute to our understanding of the interplay bet
ween the activation and accumulation of mast cells, LTB<sub>4</sub> production a
nd eosinophil recruitment.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#78
9.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#73#69#article#163#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#789.htm##
00421000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704018100074002000800255#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#74#70#article#163#1#<p ALIGN=
"left"><font face="Arial"><span lang="EN">1. Glickman LT, Schantz PM. Epidemiolo
gy and pathogenesis of zoonotic toxocariasis. <i>Epidemiol Rev</i> 1981; 3: 230-
250.    ^cY#789.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#75#71#article#163#</span></font></p>     
 ^cY#789.htm##
00336000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011000072002000800182#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#76#72#article#163#<p align="left"><font f
ace="Arial"><span lang="EN">2. Maizels RM, Yazdanbakhsh M. Immune regulation by 
   ^cY#789.htm##
00356000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013000072002000800202#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#77#73#article#163#<br>   helminth parasit
es: cellular and molecular mechanisms. <i>Nat Rev Immunol</i> 2003; 3: 733-744.<
/span></font></p>      ^cY#789.htm##
00534000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704029400074002000800368#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#78#74#article#163#3#<p align=
"left"><font face="Arial"><span lang="EN">3. Faccioli LH, Mokwa VF, Silva CL, Ro
cha GM, Araujo JI, Nahori MA, et al. IL-5 drives eosinophils from bone marrow to
 blood and tissues in a guinea-pig model of visceral larva migrans syndrome. <i>
Mediators Inflamm</i> 1996; 5: 24-31.    ^cY#789.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#79#75#article#163#</span></font></p>     
 ^cY#789.htm##
00535000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704029500074002000800369#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#80#76#article#163#4#<p align=
"left"><font face="Arial"><span lang="EN">4. Carlos D, S&aacute;-Nunes A, de Pau
la L, Matias-Peres C, Jamur MC, Oliver C, et al. Histamine modulates mast cell d
egranulation through an indirect mechanism in a model IgE-mediated reaction. <i>
Eur J Immunol</i> 2006; 36: 1494-1503.    ^cY#789.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#81#77#article#163#</span></font></p>     
 ^cY#789.htm##
00493000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704025300074002000800327#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#82#78#article#163#5#<p align=
"left"><font face="Arial"><span lang="EN">5. Elsheikha HM, El-Beshbishi SN, El-S
hazly AM, Hafez AO, Morsy TA. Kinetics of eosinophilia and IgE production in exp
erimental murine toxocariasis. <i>J Egypt Soc Parasitol</i> 2008; 38: 53-64.    
^cY#789.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#83#79#article#163#</span></font></p>     
 ^cY#789.htm##
00548000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704030800074002000800382#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#84#80#article#163#6#<p align=
"left"><font face="Arial"><span lang="EN">6. Machado ER, Carlos D, Louren&ccedil
;o EV, Souza GE, Sorgi CA, Silva EV, et al. Cyclooxygenase-derived mediators reg
ulate the immunological control of <i>Strongyloides venezuelensis </i>infection.
 <i>FEMS Immunol Med Microbiol</i> 2010; 59: 18-32.    ^cY#789.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#85#81#article#163#</span></font></p>     
 ^cY#789.htm##
00430000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704019000074002000800264#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#86#82#article#163#7#<p align=
"left"><font face="Arial"><span lang="EN">7. Stone KD, Prussin C, Metcalfe DD. I
gE, mast cells, basophils, and eosinophils. <i>J Allergy Clin Immunol</i> 2010; 
125: S73-S80.    ^cY#789.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#87#83#article#163#</span></font></p>     
 ^cY#789.htm##
00524000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704029800072002000800370#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#88#84#article#163#<p align="left"><font f
ace="Arial"><span lang="EN">8. Temkin V, Pickholtz D, Levi-Schaffer F. Tumor nec
rosis factors in a murine model of allergic peritonitis: effects on eosinophil a
ccumulation and inflammatory mediators&rsquo; release. <i>Cytokine</i> 2003; 24:
 74-80.</span></font></p>      ^cY#789.htm##
00424000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704018400074002000800258#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#89#85#article#163#9#<p align=
"left"><font face="Arial"><span lang="EN">9. Gordon JR, Burd PR, Galli SJ. Mast 
cells as a source of multifunctional cytokines. <i>Immunol Today</i> 1990; 11: 4
58-464.    ^cY#789.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#90#86#article#163#</span></font></p>     
 ^cY#789.htm##
00388000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704014700075002000800222#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#91#87#article#163#10#<p align
="left"><font face="Arial"><span lang="EN">10. Metcalfe DD, Baram D, Mekori YA. 
Mast cells. <i>Physiol Rev</i> 1997; 77: 1033-1079.    ^cY#789.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#92#88#article#163#</span></font></p>     
 ^cY#789.htm##
00414000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704017300075002000800248#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#93#89#article#163#11#<p align
="left"><font face="Arial"><span lang="EN">11. Funk CD. Prostaglandins and leuko
trienes: advances in eicosanoid biology. <i>Science</i> 2001; 294: 1871-1875.   
 ^cY#789.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#94#90#article#163#</span></font></p>     
 ^cY#789.htm##
00429000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704018800075002000800263#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#95#91#article#163#12#<p align
="left"><font face="Arial"><span lang="EN">12. Werz O. 5-Lipoxygenase: cellular 
biology and molecular pharmacology. <i>Curr Drug Targets Inflamm Allergy</i> 200
2; 1: 23-44.    ^cY#789.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#96#92#article#163#</span></font></p>     
 ^cY#789.htm##
00421000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704018000075002000800255#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#97#93#article#163#13#<p align
="left"><font face="Arial"><span lang="EN">13. Peters-Golden M, Brock TG. 5-Lipo
xygenase and FLAP. <i>Prostaglandins Leukot Essent Fatty Acids</i> 2003; 69: 99-
109.    ^cY#789.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#98#94#article#163#</span></font></p>     
 ^cY#789.htm##
00524000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704028300075002000800358#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#99#95#article#163#14#<p align
="left"><font face="Arial"><span lang="EN">14. Serezani CH, Aronoff DM, Jancar S
, Peters-Golden M. Leukotriene B4 mediates p47phox phosphorylation and membrane 
translocation in polyunsaturated fatty acid-stimulated neutrophils. <i>J Leukoc 
Biol</i> 2005; 78: 976-984.    ^cY#789.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#100#96#article#163#</span></font></p>    
  ^cY#789.htm##
00587000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704034500076002000800421#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#101#97#article#163#15#<p alig
n="left"><font face="Arial"><span lang="EN">15. Cheraim AB, Xavier-Elsas P, de O
liveira SH, Batistella T, Russo M, Gaspar-Elsas MI, et al. Leukotriene B4 is ess
ential for selective eosinophil recruitment following allergen challenge of CD4+
 cells in a model of chronic eosinophilic inflammation. <i>Life Sci</i> 2008; 83
: 214-222.    ^cY#789.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#102#98#article#163#</span></font></p>    
  ^cY#789.htm##
00532000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704029000076002000800366#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#103#99#article#163#16#<p alig
n="left"><font face="Arial"><span lang="EN">16. Miyahara N, Ohnishi H, Miyahara 
S, Takeda K, Matsubara S, Matsuda H, et al. Leukotriene B4 release from mast cel
ls in IgE-mediated airway hyperresponsiveness and inflammation. <i>Am J Respir C
ell Mol Biol</i> 2009; 40: 672-682.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#104#100#article#163#</span></font></p>   
   ^cY#789.htm##
00576000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704033300077002000800410#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#105#101#article#163#17#<p ali
gn="left"><font face="Arial"><span lang="EN">17. Calheiros AS, Aguiar Pires AL, 
Pereira da Silva J, Cordeiro RS, Martins MA, Lima MC. Role of the IgE-mediated s
ystem in eosinophil recruitment triggered by two consecutive cycles of sensitisa
tion and challenge in rats. <i>Int Arch Allergy Immunol</i> 2001; 126: 325-334. 
   ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#106#102#article#163#</span></font></p>   
   ^cY#789.htm##
00525000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028200077002000800359#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#107#103#article#163#18#<p ali
gn="left"><font face="Arial"><span lang="EN">18. Oliveira SH, Costa CH, Ferreira
 SH, Cunha FQ. Sephadex induces eosinophil migration to the rat and mouse perito
neal cavity: involvement of mast cells, LTB4, TNF-alpha, IL-8 and PAF. <i>Inflam
m Res</i> 2002; 51: 144-153.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#108#104#article#163#</span></font></p>   
   ^cY#789.htm##
00446000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704020300077002000800280#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#109#105#article#163#19#<p ali
gn="left"><font face="Arial"><span lang="EN">19. Nawa Y, Owhashi M, Imai J, Abe 
T. Eosinophil response in mast cell-deficient W/WV mice. <i>Int Arch Allergy App
l Immunol</i> 1987; 83: 6-11.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#110#106#article#163#</span></font></p>   
   ^cY#789.htm##
00544000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030100077002000800378#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#111#107#article#163#20#<p ali
gn="left"><font face="Arial"><span lang="EN">20. Olson LJ, Schulz CW. Nematode i
nduced hypersensitivity reactions in guinea pigs: onset of eosinophilia and posi
tive Schultz-Dale reactions following graded infections with <i>Toxocara canis</
i>. <i>Ann N Y Acad Sci</i> 1963; 113: 440-455.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#112#108#article#163#</span></font></p>   
   ^cY#789.htm##
00470000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704022700077002000800304#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#113#109#article#163#21#<p ali
gn="left"><font face="Arial"><span lang="EN">21. Pradelles P, Antoine C, Lellouc
he JP, Maclouf J. Enzyme immunoassays for leukotrienes C4 and E4 using acetylcho
linesterase. <i>Methods Enzymol</i> 1990; 187: 82-89.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#114#110#article#163#</span></font></p>   
   ^cY#789.htm##
00507000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026400077002000800341#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#115#111#article#163#22#<p ali
gn="left"><font face="Arial"><span lang="EN">22. Strath M, Warren DJ, Sanderson 
CJ. Detection of eosinophils using an eosinophil peroxidase assay. Its use as an
 assay for eosinophil differentiation factors. <i>J Immunol Methods</i> 1985; 83
: 209-215.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#116#112#article#163#</span></font></p>   
   ^cY#789.htm##
00588000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704034500077002000800422#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#117#113#article#163#23#<p ali
gn="left"><font face="Arial"><span lang="EN">23. Denzler KL, Borchers MT, Crosby
 JR, Cieslewicz G, Hines EM, Justice JP, et al. Extensive eosinophil degranulati
on and peroxidase-mediated oxidation of airway proteins do not occur in a mouse 
ovalbumin-challenge model of pulmonary inflammation. <i>J Immunol</i> 2001; 167:
 1672-1682.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#118#114#article#163#</span></font></p>   
   ^cY#789.htm##
00429000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704018600077002000800263#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#119#115#article#163#24#<p ali
gn="left"><font face="Arial"><span lang="EN">24. Luo ZJ, Cheng SW, Liao L. A met
hod for isolation and purification of nematode larvae. <i>J Parasitol</i> 1999; 
85: 573-574.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#120#116#article#163#</span></font></p>   
   ^cY#789.htm##
00552000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030900077002000800386#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#121#117#article#163#25#<p ali
gn="left"><font face="Arial"><span lang="EN">25. Serra MF, Barreto EO, Silva JP,
 Azevedo V, Mota EM, Pelajo-Machado M, et al. Kinetics of eosinophil and IgE-mas
t cell changes following infection with <i>Angiostrongylus costaricensis</i> in 
Wistar rats. <i>Parasite Immunol</i> 2003; 25: 169-177.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#122#118#article#163#</span></font></p>   
   ^cY#789.htm##
00547000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030400077002000800381#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#123#119#article#163#26#<p ali
gn="left"><font face="Arial"><span lang="EN">26. Kimura K, Song CH, Rastogi A, D
ranoff G, Galli SJ, Lantz CS. Interleukin-3 and c-Kit/stem cell factor are requi
red for normal eosinophil responses in mice infected with <i>Strongyloides venez
uelensis</i>. <i>Lab Invest</i> 2006; 86: 987-996.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#124#120#article#163#</span></font></p>   
   ^cY#789.htm##
00490000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024700077002000800324#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#125#121#article#163#27#<p ali
gn="left"><font face="Arial"><span lang="EN">27. Watanabe N, Miura K, Fukuda Y. 
Chymase inhibitor ameliorates eosinophilia in mice infected with <i>Nippostrongy
lus brasiliensis</i>. <i>Int Arch Allergy Immunol</i> 2002; 128: 235-239.    ^cY
#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#126#122#article#163#</span></font></p>   
   ^cY#789.htm##
00568000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704032500077002000800402#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#127#123#article#163#28#<p ali
gn="left"><font face="Arial"><span lang="EN">28. Shin K, Watts GF, Oettgen HC, F
riend DS, Pemberton AD, Gurish MF, et al. Mouse mast cell tryptase mMCP-6 is a c
ritical link between adaptive and innate immunity in the chronic phase of <i>Tri
chinella spiralis</i> infection. <i>J Immunol</i> 2008; 180: 4885-4891.    ^cY#7
89.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#128#124#article#163#</span></font></p>   
   ^cY#789.htm##
00473000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023000077002000800307#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#129#125#article#163#29#<p ali
gn="left"><font face="Arial"><span lang="EN">29. Owhashi M, Arita H, Niwa A. Pro
duction of eosinophil chemotactic factor by CD8+ T-cells in <i>Toxocara canis</i
>-infected mice. <i>Parasitol Res</i> 1998; 84: 136-138.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#130#126#article#163#</span></font></p>   
   ^cY#789.htm##
00581000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704033800077002000800415#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#131#127#article#163#30#<p ali
gn="left"><font face="Arial"><span lang="EN">30. Pecinali NR, Gomes RN, Amendoei
ra FC, Bastos AC, Martins MJ, Pegado CS, et al. Influence of murine <i>Toxocara 
canis</i> infection on plasma and bronchoalveolar lavage fluid eosinophil number
s and its correlation with cytokine levels. <i>Vet Parasitol</i> 2005; 134: 121-
130.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#132#128#article#163#</span></font></p>   
   ^cY#789.htm##
00534000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029100077002000800368#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#133#129#article#163#31#<p ali
gn="left"><font face="Arial"><span lang="EN">31. S&aacute;-Nunes A, Rogerio AP, 
Medeiros AI, Fabris VE, Andreu GP, Rivera DG, et al. Modulation of eosinophil ge
neration and migration by <i>Mangifera indica</i> L. extract (Vimang). <i>Int Im
munopharmacol</i> 2006; 6: 1515-1523.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#134#130#article#163#</span></font></p>   
   ^cY#789.htm##
00444000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704020100077002000800278#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#135#131#article#163#32#<p ali
gn="left"><font face="Arial"><span lang="EN">32. Abe T, Nawa Y. Eosinophil chemo
tactic factor released from murine bone marrow derived cultured mast cells. <i>A
rerugi</i> 1990; 39: 69-74.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#136#132#article#163#</span></font></p>   
   ^cY#789.htm##
00524000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028100077002000800358#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#137#133#article#163#33#<p ali
gn="left"><font face="Arial"><span lang="EN">33. Okada K, Fujimoto K, Kubo K, Se
kiguchi M, Sugane K. Eosinophil chemotactic activity in bronchoalveolar lavage f
luid obtained from <i>Toxocara canis</i>-infected rats. <i>Clin Immunol Immunopa
thol</i> 1996; 78: 256-262.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#138#134#article#163#</span></font></p>   
   ^cY#789.htm##
00504000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026100077002000800338#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#139#135#article#163#34#<p ali
gn="left"><font face="Arial"><span lang="EN">34. Machado ER, Ueta MT, Lourenco E
V, Anibal FF, Sorgi CA, Soares EG, et al. Leukotrienes play a role in the contro
l of parasite burden in murine strongyloidiasis. <i>J Immunol</i> 2005; 175: 389
2-3899.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#140#136#article#163#</span></font></p>   
   ^cY#789.htm##
00565000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704032200077002000800399#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#141#137#article#163#35#<p ali
gn="left"><font face="Arial"><span lang="EN">35. Klein A, Talvani A, Silva PM, M
artins MA, Wells TN, Proudfoot A, et al. Stem cell factor-induced leukotriene B4
 production cooperates with eotaxin to mediate the recruitment of eosinophils du
ring allergic pleurisy in mice. <i>J Immunol</i> 2001; 167: 524-531.    ^cY#789.
htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#142#138#article#163#</span></font></p>   
   ^cY#789.htm##
00455000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704021200077002000800289#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#143#139#article#163#36#<p ali
gn="left"><font face="Arial"><span lang="EN">36. Taira K, Permin A, Kapel CM. Es
tablishment and migration pattern of <i>Toxocara canis</i> larvae in chickens. <
i>Parasitol Res</i> 2003; 90: 521-523.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#144#140#article#163#</span></font></p>   
   ^cY#789.htm##
00425000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704018200077002000800259#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#145#141#article#163#37#<p ali
gn="left"><font face="Arial"><span lang="EN">37. Loukas A, Maizels RM. Helminth 
C-type lectins and host-parasite interactions. <i>Parasitol Today</i> 2000; 16: 
333-339.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#146#142#article#163#</span></font></p>   
   ^cY#789.htm##
00505000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026200077002000800339#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#147#143#article#163#38#<p ali
gn="left"><font face="Arial"><span lang="EN">38. Lescano SZ, Queiroz ML, Chieffi
 PP. Larval recovery of <i>Toxocara canis</i> in organs and tissues of experimen
tally infected <i>Rattus norvegicus</i>. <i>Mem Inst Oswaldo Cruz</i> 2004; 99: 
627-628.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#148#144#article#163#</span></font></p>   
   ^cY#789.htm##
00550000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030700077002000800384#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#149#145#article#163#39#<p ali
gn="left"><font face="Arial"><span lang="EN">39. Tuohy M, Lammas DA, Wakelin D, 
Huntley JF, Newlands GF, Miller HR. Functional correlations between mucosal mast
 cell activity and immunity to <i>Trichinella spiralis</i> in high and low respo
nder mice. <i>Parasite Immunol</i> 1990; 12: 675-685.    ^cY#789.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#150#146#article#163#</span></font></p>   
   ^cY#789.htm##
00521000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027800077002000800355#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#p#151#147#article#163#40#<p ali
gn="left"><font face="Arial"><span lang="EN">40. Miller HR, Newlands GF, McKella
r A, Inglis L, Coulson PS, Wilson RA. Hepatic recruitment of mast cells occurs i
n rats but not mice infected with <i>Schistosoma mansoni</i>. <i>Parasite Immuno
l</i> 1994; 16: 145-155.    ^cY#789.htm##
00280000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704005200074002000800126#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#152#148#article#163#</span></font></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#789.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033500074002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#153#149#article#163#<P><font face="Arial,
 Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE
=4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#789.ht
m##
00783000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704055500074002000800629#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#154#150#article#163#<p ALIGN="left"><font
 face="Arial"><span lang="EN">The authors would like to thank Vani Alves Correia
 from the Laborat&oacute;rio de Histologia, Departamento de Biologia Celular e M
olecular e Bioagentes Patog&ecirc;nicos, Faculdade de Medicina de Ribeir&atilde;
o Preto, and Izilda Rodrigues Violante from the Departamento de Cirurgia e Anato
mia, Faculdade de Medicina de Ribeir&atilde;o Preto, for technical assistance wi
th the histological material. Research supported by FAPESP (#01/12145-6) and CNP
q.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#789.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033600074002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#155#151#article#163#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#789.h
tm##
00744000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704051600074002000800590#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#156#152#article#163#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/r
ecor.gif" border="0"></a> Address for correspondence:</b></font> <font face="Ari
al"><span lang="EN">L.H. Faccioli, Departamento de An&aacute;lises Cl&iacute;nic
as, Toxicol&oacute;gicas e Bromatol&oacute;gicas, FCFRP, USP, Av. do Caf&eacute;
, s/n, 14040-903 Ribeir&atilde;o Preto, SP, Brasil. Fax: +55-16-3602-4725. E-mai
l: <a href="mailto:faccioli@fcfrp.usp.br">faccioli@fcfrp.usp.br</a></span></font
></p>      ^cY#789.htm##
00450000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704022200074002000800296#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#157#153#article#163#<p ALIGN="left"><i><f
ont face="Arial"><span lang="EN">Received October 10, 2010. Accepted February 16
, 2011. Available online March 4, 2011. Published April 11, 2011.</span></font><
/i></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#789.htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#158#154#article#163#<div align="center"> 
       ^cY#789.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#159#155#article#163#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#789.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#160#156#article#163#<br>                ^
cY#789.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#161#157#article#163#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#789
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#162#158#article#163#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#789.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#163#159#article#163#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#789.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#164#160#article#163#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#789.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#165#161#article#163#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#789.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#166#162#article#163#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#789.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\789.htm#S#p#167#163#article#163#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#789.htm##
00526000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100018000920120
05900110030001400169065000900183064000500192031000200197014000800199865000900207
002000800216035001000224801001400234#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
89.htm#S#c#168#1#article#40#1#^rND^sGlickman^nLT#^rND^sSchantz^nPM#Epidemiology 
and pathogenesis of zoonotic toxocariasis^len#Epidemiol Rev#19810000#1981#3#230-
250#20110400#789.htm#0193-936X#Epidemiol Rev##
00517000000000265000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100022000910120
07900113030001600192710000200208065000900210064000500219031000200224014000800226
865000900234002000800243#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#1
69#2#article#40#2#^rND^sMaizels^nRM#^rND^sYazdanbakhsh^nM#Immune regulation by h
elminth parasites: cellular and molecular mechanisms^len#Nat Rev Immunol#2#20030
000#2003#3#733-744#20110400#789.htm##
00726000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100016000920100
01600108010001600124010001700140010001700157810000600174012012300180030001800303
06500090032106400050033003100020033501400060033786500090034300200080035203500100
0360801001800370#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#170#3#art
icle#40#3#^rND^sFaccioli^nLH#^rND^sMokwa^nVF#^rND^sSilva^nCL#^rND^sRocha^nGM#^rN
D^sAraujo^nJI#^rND^sNahori^nMA#et al#IL-5 drives eosinophils from bone marrow to
 blood and tissues in a guinea-pig model of visceral larva migrans syndrome^len#
Mediators Inflamm#19960000#1996#5#24-31#20110400#789.htm#0962-9351#Mediators Inf
lamm##
00716000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100018000890100
01800107010002200125010001600147010001600163810000600179012011100185030001400296
06500090031006400050031903100030032401400100032786500090033700200080034603500100
0354801001400364#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#171#4#art
icle#40#4#^rND^sCarlos^nD#^rND^sSá-Nunes^nA#^rND^sde^nPaula L#^rND^sMatias-Peres
^nC#^rND^sJamur^nMC#^rND^sOliver^nC#et al#Histamine modulates mast cell degranul
ation through an indirect mechanism in a model IgE-mediated reaction^len#Eur J I
mmunol#20060000#2006#36#1494-1503#20110400#789.htm#0014-2980#Eur J Immunol##
00660000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100020000730100023000930100
02000116010001600136010001600152012008400168030002200252065000900274064000500283
031000300288014000600291865000900297002000800306035001000314801002200324#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#172#5#article#40#5#^rND^sElsheikh
a^nHM#^rND^sEl-Beshbishi^nSN#^rND^sEl-Shazly^nAM#^rND^sHafez^nAO#^rND^sMorsy^nTA
#Kinetics of eosinophilia and IgE production in experimental murine toxocariasis
^len#J Egypt Soc Parasitol#20080000#2008#38#53-64#20110400#789.htm#0253-5890#J E
gypt Soc Parasitol##
00735000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100016000910100
01900107010001600126010001600142010001600158810000600174012011300180030002700293
06500090032006400050032903100030033401400060033786500090034300200080035203500100
0360801002700370#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#173#6#art
icle#40#6#^rND^sMachado^nER#^rND^sCarlos^nD#^rND^sLourenço^nEV#^rND^sSouza^nGE#^
rND^sSorgi^nCA#^rND^sSilva^nEV#et al#Cyclooxygenase-derived mediators regulate t
he immunological control of Strongyloides venezuelensis infection^len#FEMS Immun
ol Med Microbiol#20100000#2010#59#18-32#20110400#789.htm#0928-8244#FEMS Immunol 
Med Microbiol##
00562000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100017000890100
01900106012004800125030002300173065000900196064000500205031000400210014000800214
865000900222002000800231035001000239801002300249#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\789.htm#S#c#174#7#article#40#7#^rND^sStone^nKD#^rND^sPrussin^nC#^rND^
sMetcalfe^nDD#IgE, mast cells, basophils, and eosinophils^len#J Allergy Clin Imm
unol#20100000#2010#125#S73-S80#20110400#789.htm#0091-6749#J Allergy Clin Immunol
##
00636000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100019000890100
02300108012014700131030000900278065000900287064000500296031000300301014000600304
865000900310002000800319035001000327801000900337#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\789.htm#S#c#175#8#article#40#8#^rND^sTemkin^nV#^rND^sPickholtz^nD#^rN
D^sLevi-Schaffer^nF#Tumor necrosis factors in a murine model of allergic periton
itis: effects on eosinophil accumulation and inflammatory mediators&#8217; relea
se^len#Cytokine#20030000#2003#24#74-80#20110400#789.htm#1043-4666#CYTOKINE##
00547000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100015000900100
01600105012005600121030001400177065000900191064000500200031000300205014000800208
865000900216002000800225035001000233801001400243#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\789.htm#S#c#176#9#article#40#9#^rND^sGordon^nJR#^rND^sBurd^nPR#^rND^s
Galli^nSJ#Mast cells as a source of multifunctional cytokines^len#Immunol Today#
19900000#1990#11#458-464#20110400#789.htm#0167-5699#Immunol Today##
00509000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100015000940100
01700109012001500126030001200141065000900153064000500162031000300167014001000170
865000900180002000800189035001000197801001200207#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\789.htm#S#c#177#10#article#40#10#^rND^sMetcalfe^nDD#^rND^sBaram^nD#^r
ND^sMekori^nYA#Mast cells^len#Physiol Rev#19970000#1997#77#1033-1079#20110400#78
9.htm#0031-9333#Physiol Rev##
00495000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750120068000900300
00800158065000900166064000500175031000400180014001000184865000900194002000800203
035001000211801000800221#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#1
78#11#article#40#11#^rND^sFunk^nCD#Prostaglandins and leukotrienes: advances in 
eicosanoid biology^len#Science#20110000#2001#294#1871-1875#20110400#789.htm#0036
-8075#Science##
00482000000000253000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750120064000890300
03400153710000200187065000900189064000500198031000200203014000600205865000900211
002000800220#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#179#12#articl
e#40#12#^rND^sWerz^nO#5-Lipoxygenase: cellular biology and molecular pharmacolog
y^len#Curr Drug Targets Inflamm Allergy#2#20020000#2002#1#23-44#20110400#789.htm
##
00553000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100023000750100016000980120
02800114030004100142065000900183064000500192031000300197014000700200865000900207
002000800216035001000224801004100234#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
89.htm#S#c#180#13#article#40#13#^rND^sPeters-Golden^nM#^rND^sBrock^nTG#5-Lipoxyg
enase and FLAP^len#Prostaglandins Leukot Essent Fatty Acids#20030000#2003#69#99-
109#20110400#789.htm#0952-3278#Prostaglandins Leukot Essent Fatty Acids##
00665000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100018000940100
01600112010002300128012013200151030001400283065000900297064000500306031000300311
014000800314865000900322002000800331035001000339801001400349#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\789.htm#S#c#181#14#article#40#14#^rND^sSerezani^nCH#^rND^
sAronoff^nDM#^rND^sJancar^nS#^rND^sPeters-Golden^nM#Leukotriene B4 mediates p47p
hox phosphorylation and membrane translocation in polyunsaturated fatty acid-sti
mulated neutrophils^len#J Leukoc Biol#20050000#2005#78#976-984#20110400#789.htm#
0741-5400#J Leukoc Biol##
00769000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100022000930100
02200115010002000137010001500157010002300172810000600195012016000201030000900361
06500090037006400050037903100030038401400080038786500090039500200080040403500100
0412801000900422#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#182#15#ar
ticle#40#15#^rND^sCheraim^nAB#^rND^sXavier-Elsas^nP#^rND^sde^nOliveira SH#^rND^s
Batistella^nT#^rND^sRusso^nM#^rND^sGaspar-Elsas^nMI#et al#Leukotriene B4 is esse
ntial for selective eosinophil recruitment following allergen challenge of CD4+ 
cells in a model of chronic eosinophilic inflammation^len#Life Sci#20080000#2008
#83#214-222#20110400#789.htm#0024-3205#Life sci##
00731000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100017000930100
01800110010001600128010001900144010001700163810000600180012010300186030002600289
06500090031506400050032403100030032901400080033286500090034000200080034903500100
0357801002600367#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#183#16#ar
ticle#40#16#^rND^sMiyahara^nN#^rND^sOhnishi^nH#^rND^sMiyahara^nS#^rND^sTakeda^nK
#^rND^sMatsubara^nS#^rND^sMatsuda^nH#et al#Leukotriene B4 release from mast cell
s in IgE-mediated airway hyperresponsiveness and inflammation^len#Am J Respir Ce
ll Mol Biol#20090000#2009#40#672-682#20110400#789.htm#1044-1549#Am J Respir Cell
 Mol Biol##
00762000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100023000950100
02600118010001900144010001800163010001500181012013700196030002500333065000900358
06400050036703100040037201400080037686500090038400200080039303500100040180100250
0411#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#184#17#article#40#17#
^rND^sCalheiros^nAS#^rND^sAguiar^nPires AL#^rND^sPereira^nda Silva J#^rND^sCorde
iro^nRS#^rND^sMartins^nMA#^rND^sLima^nMC#Role of the IgE-mediated system in eosi
nophil recruitment triggered by two consecutive cycles of sensitisation and chal
lenge in rats^len#Int Arch Allergy Immunol#20010000#2001#126#325-334#20110400#78
9.htm#1018-2438#Int Arch Allergy Immunol##
00662000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100016000940100
01900110010001600129012013900145030001200284065000900296064000500305031000300310
014000800313865000900321002000800330035001000338801001200348#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\789.htm#S#c#185#18#article#40#18#^rND^sOliveira^nSH#^rND^
sCosta^nCH#^rND^sFerreira^nSH#^rND^sCunha^nFQ#Sephadex induces eosinophil migrat
ion to the rat and mouse peritoneal cavity: involvement of mast cells, LTB4, TNF
-alpha, IL-8 and PAF^len#Inflamm Res#20020000#2002#51#144-153#20110400#789.htm#1
023-3830#Inflamm Res##
00601000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100017000890100
01400106010001300120012005700133030003000190065000900220064000500229031000300234
014000500237865000900242002000800251035001000259801003000269#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\789.htm#S#c#186#19#article#40#19#^rND^sNawa^nY#^rND^sOwha
shi^nM#^rND^sImai^nJ#^rND^sAbe^nT#Eosinophil response in mast cell-deficient W/W
V mice^len#Int Arch Allergy Appl Immunol#19870000#1987#83#6-11#20110400#789.htm#
0020-5915#Int Arch Allergy Appl Immunol##
00643000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100017000910120
17000108030001700278065000900295064000500304031000400309014000800313865000900321
002000800330035001000338801001700348#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
89.htm#S#c#187#20#article#40#20#^rND^sOlson^nLJ#^rND^sSchulz^nCW#Nematode induce
d hypersensitivity reactions in guinea pigs: onset of eosinophilia and positive 
Schultz-Dale reactions following graded infections with Toxocara canis^len#Ann N
 Y Acad Sci#19630000#1963#113#440-455#20110400#789.htm#0077-8923#Ann N Y Acad Sc
i##
00611000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100017000940100
02000111010001700131012007800148030001600226065000900242064000500251031000400256
014000600260865000900266002000800275035001000283801001600293#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\789.htm#S#c#188#21#article#40#21#^rND^sPradelles^nP#^rND^
sAntoine^nC#^rND^sLellouche^nJP#^rND^sMaclouf^nJ#Enzyme immunoassays for leukotr
ienes C4 and E4 using acetylcholinesterase^len#Methods Enzymol#19900000#1990#187
#82-89#20110400#789.htm#0076-6879#Methods Enzymol##
00632000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100017000910100
02000108012012600128030001800254065000900272064000500281031000300286014000800289
865000900297002000800306035001000314801001800324#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\789.htm#S#c#189#22#article#40#22#^rND^sStrath^nM#^rND^sWarren^nDJ#^rN
D^sSanderson^nCJ#Detection of eosinophils using an eosinophil peroxidase assay: 
Its use as an assay for eosinophil differentiation factors^len#J Immunol Methods
#19850000#1985#83#209-215#20110400#789.htm#0022-1759#J Immunol Methods##
00770000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100019000930100
01700112010002000129010001600149010001800165810000600183012016800189030001000357
06500090036706400050037603100040038101400100038586500090039500200080040403500100
0412801001000422#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#190#23#ar
ticle#40#23#^rND^sDenzler^nKL#^rND^sBorchers^nMT#^rND^sCrosby^nJR#^rND^sCieslewi
cz^nG#^rND^sHines^nEM#^rND^sJustice^nJP#et al#Extensive eosinophil degranulation
 and peroxidase-mediated oxidation of airway proteins do not occur in a mouse ov
albumin-challenge model of pulmonary inflammation^len#J Immunol#20010000#2001#16
7#1672-1682#20110400#789.htm#0022-1767#J Immunol##
00548000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100016000890100
01400105012006300119030001200182065000900194064000500203031000300208014000800211
865000900219002000800228035001000236801001200246#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\789.htm#S#c#191#24#article#40#24#^rND^sLuo^nZJ#^rND^sCheng^nSW#^rND^s
Liao^nL#A method for isolation and purification of nematode larvae^len#J Parasit
ol#19990000#1999#85#573-574#20110400#789.htm#0022-3395#J Parasitol##
00734000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100018000910100
01600109010001700125010001500142010002400157810000600181012012300187030001700310
06500090032706400050033603100030034101400080034486500090035200200080036103500100
0369801001700379#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#192#25#ar
ticle#40#25#^rND^sSerra^nMF#^rND^sBarreto^nEO#^rND^sSilva^nJP#^rND^sAzevedo^nV#^
rND^sMota^nEM#^rND^sPelajo-Machado^nM#et al#Kinetics of eosinophil and IgE-mast 
cell changes following infection with Angiostrongylus costaricensis in Wistar ra
ts^len#Parasite Immunol#20030000#2003#25#169-177#20110400#789.htm#0141-9838#Para
site Immunol##
00712000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100015000910100
01700106010001700123010001600140010001600156012014000172030001100312065000900323
06400050033203100030033701400080034086500090034800200080035703500100036580100110
0375#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#193#26#article#40#26#
^rND^sKimura^nK#^rND^sSong^nCH#^rND^sRastogi^nA#^rND^sDranoff^nG#^rND^sGalli^nSJ
#^rND^sLantz^nCS#Interleukin-3 and c-Kit/stem cell factor are required for norma
l eosinophil responses in mice infected with Strongyloides venezuelensis^len#Lab
 Invest#20060000#2006#86#987-996#20110400#789.htm#0023-6837#Lab Invest##
00615000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100015000930100
01600108012009800124030002500222065000900247064000500256031000400261014000800265
865000900273002000800282035001000290801002500300#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\789.htm#S#c#194#27#article#40#27#^rND^sWatanabe^nN#^rND^sMiura^nK#^rN
D^sFukuda^nY#Chymase inhibitor ameliorates eosinophilia in mice infected with Ni
ppostrongylus brasiliensis^len#Int Arch Allergy Immunol#20020000#2002#128#235-23
9#20110400#789.htm#1018-2438#Int Arch Allergy Immunol##
00743000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100016000890100
01800105010001700123010002000140010001700160810000600177012014700183030001000330
06500090034006400050034903100040035401400100035886500090036800200080037703500100
0385801001000395#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#195#28#ar
ticle#40#28#^rND^sShin^nK#^rND^sWatts^nGF#^rND^sOettgen^nHC#^rND^sFriend^nDS#^rN
D^sPemberton^nAD#^rND^sGurish^nMF#et al#Mouse mast cell tryptase mMCP-6 is a cri
tical link between adaptive and innate immunity in the chronic phase of Trichine
lla spiralis infection^len#J Immunol#20080000#2008#180#4885-4891#20110400#789.ht
m#0022-1767#J Immunol##
00587000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100015000920100
01400107012009600121030001400217065000900231064000500240031000300245014000800248
865000900256002000800265035001000273801001400283#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\789.htm#S#c#196#29#article#40#29#^rND^sOwhashi^nM#^rND^sArita^nH#^rND
^sNiwa^nA#Production of eosinophil chemotactic factor by CD8+ T-cells in Toxocar
a canis-infected mice^len#Parasitol Res#19980000#1998#84#136-138#20110400#789.ht
m#0044-3255#Parasitol Res##
00760000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100016000940100
02100110010001700131010001800148010001700166810000600183012015200189030001400341
06500090035506400050036403100040036901400080037386500090038100200080039003500100
0398801001400408#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#197#30#ar
ticle#40#30#^rND^sPecinali^nNR#^rND^sGomes^nRN#^rND^sAmendoeira^nFC#^rND^sBastos
^nAC#^rND^sMartins^nMJ#^rND^sPegado^nCS#et al#Influence of murine Toxocara canis
 infection on plasma and bronchoalveolar lavage fluid eosinophil numbers and its
 correlation with cytokine levels^len#Vet Parasitol#20050000#2005#134#121-130#20
110400#789.htm#0304-4017#Vet Parasitol##
00672000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100018000930100
01900111010001700130010001700147010001700164810000600181012009400187030002000281
71000020030106500090030306400050031203100020031701400100031986500090032900200080
0338#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#198#31#article#40#31#
^rND^sSá-Nunes^nA#^rND^sRogerio^nAP#^rND^sMedeiros^nAI#^rND^sFabris^nVE#^rND^sAn
dreu^nGP#^rND^sRivera^nDG#et al#Modulation of eosinophil generation and migratio
n by Mangifera indica L: extract (Vimang)^len#Int Immunopharmacol#2#20060000#200
6#6#1515-1523#20110400#789.htm##
00541000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100013000750100014000880120
09500102030000800197065000900205064000500214031000300219014000600222865000900228
002000800237035001000245801000800255#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
89.htm#S#c#199#32#article#40#32#^rND^sAbe^nT#^rND^sNawa^nY#Eosinophil chemotacti
c factor released from murine bone marrow derived cultured mast cells^len#Arerug
i#19900000#1990#39#69-74#20110400#789.htm#0021-4884#Arerugi##
00686000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100018000900100
01400108010001900122010001600141012011100157030002600268065000900294064000500303
031000300308014000800311865000900319002000800328035001000336801002600346#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#200#33#article#40#33#^rND^sOkada^
nK#^rND^sFujimoto^nK#^rND^sKubo^nK#^rND^sSekiguchi^nM#^rND^sSugane^nK#Eosinophil
 chemotactic activity in bronchoalveolar lavage fluid obtained from Toxocara can
is-infected rats^len#Clin Immunol Immunopathol#19960000#1996#78#256-262#20110400
#789.htm#0090-1229#Clin Immunol Immunopathol##
00686000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100015000930100
01900108010001700127010001600144010001700160810000600177012009000183030001000273
06500090028306400050029203100040029701400100030186500090031100200080032003500100
0328801001000338#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#201#34#ar
ticle#40#34#^rND^sMachado^nER#^rND^sUeta^nMT#^rND^sLourenco^nEV#^rND^sAnibal^nFF
#^rND^sSorgi^nCA#^rND^sSoares^nEG#et al#Leukotrienes play a role in the control 
of parasite burden in murine strongyloidiasis^len#J Immunol#20050000#2005#175#38
92-3899#20110400#789.htm#0022-1767#J Immunol##
00754000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100017000900100
01600107010001800123010001600141010001900157010001300176012015400189030001000343
06500090035306400050036203100040036701400080037186500090037900200080038803500100
0396801001000406#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#202#35#ar
ticle#40#35#^rND^sKlein^nA#^rND^sTalvani^nA#^rND^sSilva^nPM#^rND^sMartins^nMA#^r
ND^sWells^nTN#^rND^sProudfoot^nA#^rND^set^nal#Stem cell factor-induced leukotrie
ne B4 production cooperates with eotaxin to mediate the recruitment of eosinophi
ls during allergic pleurisy in mice^len#J Immunol#20010000#2001#167#524-531#2011
0400#789.htm#0022-1767#J Immunol##
00569000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100016000900100
01600106012007700122030001400199065000900213064000500222031000300227014000800230
865000900238002000800247035001000255801001400265#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\789.htm#S#c#203#36#article#40#36#^rND^sTaira^nK#^rND^sPermin^nA#^rND^
sKapel^nCM#Establishment and migration pattern of Toxocara canis larvae in chick
ens^len#Parasitol Res#20030000#2003#90#521-523#20110400#789.htm#0044-3255#Parasi
tol Res##
00530000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100018000910120
05900109030001600168065000900184064000500193031000300198014000800201865000900209
002000800218035001000226801001600236#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
89.htm#S#c#204#37#article#40#37#^rND^sLoukas^nA#^rND^sMaizels^nRM#Helminth C-typ
e lectins and host-parasite interactions^len#Parasitol Today#20000000#2000#16#33
3-339#20110400#789.htm#0169-4758#Parasitol Today##
00620000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100018000930100
01800111012010500129030002200234065000900256064000500265031000300270014000800273
865000900281002000800290035001000298801002200308#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\789.htm#S#c#205#38#article#40#38#^rND^sLescano^nSZ#^rND^sQueiroz^nML#
^rND^sChieffi^nPP#Larval recovery of Toxocara canis in organs and tissues of exp
erimentally infected Rattus norvegicus^len#Mem Inst Oswaldo Cruz#20040000#2004#9
9#627-628#20110400#789.htm#0074-0276#Mem Inst Oswaldo Cruz##
00721000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100017000900100
01700107010001800124010001900142010001700161012013100178030001700309065000900326
06400050033503100030034001400080034386500090035100200080036003500100036880100170
0378#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#206#39#article#40#39#
^rND^sTuohy^nM#^rND^sLammas^nDA#^rND^sWakelin^nD#^rND^sHuntley^nJF#^rND^sNewland
s^nGF#^rND^sMiller^nHR#Functional correlations between mucosal mast cell activit
y and immunity to Trichinella spiralis in high and low responder mice^len#Parasi
te Immunol#19900000#1990#12#675-685#20110400#789.htm#0141-9838#Parasite Immunol#
#
00692000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100019000920100
01800111010001600129010001800145010001700163012010000180030001700280065000900297
06400050030603100030031101400080031486500090032200200080033103500100033980100170
0349#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\789.htm#S#c#207#40#article#40#40#
^rND^sMiller^nHR#^rND^sNewlands^nGF#^rND^sMcKellar^nA#^rND^sInglis^nL#^rND^sCoul
son^nPS#^rND^sWilson^nRA#Hepatic recruitment of mast cells occurs in rats but no
t mice infected with Schistosoma mansoni^len#Parasite Immunol#19940000#1994#16#1
45-155#20110400#789.htm#0141-9838#Parasite Immunol##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#o#1#1#article#1#201
10411#094620#796.htm#136##
03294000000000613000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120129001780100029003070100025003360100023003610100023003840100030004070700
16300437070011000600070003600710070010500746083160300851085000802454085003602462
08500310249808500210252908500340255011700060258407200030259011200090259311100190
2602114000902621113001802630891002402648002000802672#v44n4#V:\SciELO\serial\bjmb
r\v44n4\markup\796.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#16#BJMBR540#
FAPESP#Braz J Med Biol Res#44#4#20110400#^f374^l380#0100-879X#20110311#A Brazili
an family with hereditary inclusion body myopathy associated with Paget disease 
of bone and frontotemporal dementia^len#^rND^1A01^nR.D.^sFanganiello#^rND^1A02^n
V.E.^sKimonis#^rND^1A03^nC.C.^sCôrte#^rND^1A04^nR.^sNitrini#^rND^1A01^nM.R.^sPas
sos-Bueno#Universidade de São Paulo^iA01^1Instituto de Biociências^2Departamento
 de Genética e Biologia Evolutiva^3Centro de Estudos do Genoma Humano^cSão Paulo
^sSP^pBrasil#University of California^iA02^1Department of Pediatrics^2Division o
f Genetics and Metabolism^cIrvine^sCA^pUSA#CLINORT^iA03^cFortaleza^sCE^pBrasil#U
niversidade de São Paulo^iA04^1Hospital das Clínicas^2Departamento de Neurologia
^cSão Paulo^sSP^pBrasil#^len^aInclusion body myopathy associated with Paget dise
ase and frontotemporal dementia (IBMPFD) is a progressive and usually misdiagnos
ed autosomal dominant disorder. It is clinically characterized by a triad of fea
tures: proximal and distal myopathy, early onset Paget disease of bone (PDB), an
d frontotemporal dementia (FTD). It is caused by missense mutations in the valos
in-containing protein (VCP) gene. We describe here the clinical and molecular fi
ndings of the first Brazilian family identified with IBMPFD. Progressive myopath
y affecting the limb girdles was detected by clinical examination followed by mu
scle biopsy and creatine kinase measurement. PDB was suggested after anatomopath
ological bone examination and FTD was diagnosed by clinical, neuropsychological 
and language evaluations. Brain magnetic resonance revealed severe atrophy of th
e anterior temporal lobes, including the hippocampi. A R93C mutation in VCP was 
detected by direct sequencing screening in subject W (age 62) and in his mother.
 Four more individuals diagnosed with "dementia" were reported in this family. W
e also present a comprehensive genotype-phenotype correlation analysis of mutati
ons in VCP in 182 patients from 29 families described in the literature and show
 that while IBM is a conspicuously penetrant symptom, PDB has a lower penetrance
 when associated with mutations in the AAAD1 domain and FTD has a lower penetran
ce when associated with mutations in the Junction (L1-D1) domain. Furthermore, t
he R93C mutation is likely to be associated with the penetrance of all the clini
cal symptoms of the triad.#^dnd^i1#^tm^len^kFrontotemporal dementia^i1#^tm^len^k
VCP gene mutations^i1#^tm^len^kMyopathy^i1#^tm^len^kPaget disease of bone^i1#oth
er#20#20100921#September 21, 2010#20110221#February 21, 2011#S0100-879X201100750
0028#796.htm##
03279000000000601000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120136001780100029003140100025003430100023003680100023003910100030004140700
16300444070011000607070003600717070010500753083160300858085000802461085003602469
08500310250508500210253608500340255711700060259107200030259711200090260011100260
2609114000902635113002502644002000802669#v44n4#V:\SciELO\serial\bjmbr\v44n4\mark
up\796.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#16#BJMBR540#FAPESP#Braz 
J Med Biol Res#44#4#20110400#^f374^l380#0100-879X#20110311#<b>A Brazilian family
 with hereditary inclusion body myopathy associated with Paget disease of bone a
nd frontotemporal dementia</b>^len#^rND^1A01^nR.D.^sFanganiello#^rND^1A02^nV.E.^
sKimonis#^rND^1A03^nC.C.^sCôrte#^rND^1A04^nR.^sNitrini#^rND^1A01^nM.R.^sPassos-B
ueno#Universidade de São Paulo^iA01^1Instituto de Biociências^2Departamento de G
enética e Biologia Evolutiva^3Centro de Estudos do Genoma Humano^cSão Paulo^sSP^
pBrasil#University of California^iA02^1Department of Pediatrics^2Division of Gen
etics and Metabolism^cIrvine^sCA^pUSA#CLINORT^iA03^cFortaleza^sCE^pBrasil#Univer
sidade de São Paulo^iA04^1Hospital das Clínicas^2Departamento de Neurologia^cSão
 Paulo^sSP^pBrasil#^len^aInclusion body myopathy associated with Paget disease a
nd frontotemporal dementia (IBMPFD) is a progressive and usually misdiagnosed au
tosomal dominant disorder. It is clinically characterized by a triad of features
: proximal and distal myopathy, early onset Paget disease of bone (PDB), and fro
ntotemporal dementia (FTD). It is caused by missense mutations in the valosin-co
ntaining protein (VCP) gene. We describe here the clinical and molecular finding
s of the first Brazilian family identified with IBMPFD. Progressive myopathy aff
ecting the limb girdles was detected by clinical examination followed by muscle 
biopsy and creatine kinase measurement. PDB was suggested after anatomopathologi
cal bone examination and FTD was diagnosed by clinical, neuropsychological and l
anguage evaluations. Brain magnetic resonance revealed severe atrophy of the ant
erior temporal lobes, including the hippocampi. A R93C mutation in VCP was detec
ted by direct sequencing screening in subject W (age 62) and in his mother. Four
 more individuals diagnosed with "dementia" were reported in this family. We als
o present a comprehensive genotype-phenotype correlation analysis of mutations i
n VCP in 182 patients from 29 families described in the literature and show that
 while IBM is a conspicuously penetrant symptom, PDB has a lower penetrance when
 associated with mutations in the AAAD1 domain and FTD has a lower penetrance wh
en associated with mutations in the Junction (L1-D1) domain. Furthermore, the R9
3C mutation is likely to be associated with the penetrance of all the clinical s
ymptoms of the triad.#^dnd^i1#^tm^len^kFrontotemporal dementia^i1#^tm^len^kVCP g
ene mutations^i1#^tm^len^kMyopathy^i1#^tm^len^kPaget disease of bone^i1#other#20
#20100921#<i>September 21, 2010</i>#20110221#<i>February 21, 2011</i>#796.htm##
03395000000000625000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762240009001860120129001950100029003240100025003530100023003780100022004010100
03000423070016500453070011200618070003800730070010700768083160300875085000802478
08500360248608500310252208500210255308500340257411700060260807200030261411200090
2617111001902626114000902645113001802654002000802672008008902680#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#l#4#1#article#1#^mApr.^a2011#oa#en#bjmbr#1#
3.1#ilus#tab#16#BJMBR540#FAPESP#Braz. j. med. biol. res#44#4#20110400#^f374^l380
#0100-879X#20110311#A Brazilian family with hereditary inclusion body myopathy a
ssociated with Paget disease of bone and frontotemporal dementia^len#^rND^1A01^n
R. D^sFanganiello#^rND^1A02^nV. E^sKimonis#^rND^1A03^nC. C^sCôrte#^rND^1A04^nR^s
Nitrini#^rND^1A01^nM. R^sPassos-Bueno#^iA01^1Universidade de São Paulo^2Institut
o de Biociências^3Departamento de Genética e Biologia Evolutiva. Centro de Estud
os do Genoma Humano^cSão Paulo^sSP^pBrasil#^iA02^1University of California^2Depa
rtment of Pediatrics^3Division of Genetics and Metabolism^cIrvine^sCA^pUSA#^iA03
^1CLINORT^cFortaleza^sCE^pBrasil#^iA04^1Universidade de São Paulo^2Hospital das 
Clínicas^3Departamento de Neurologia^cSão Paulo^sSP^pBrasil#^len^aInclusion body
 myopathy associated with Paget disease and frontotemporal dementia (IBMPFD) is 
a progressive and usually misdiagnosed autosomal dominant disorder. It is clinic
ally characterized by a triad of features: proximal and distal myopathy, early o
nset Paget disease of bone (PDB), and frontotemporal dementia (FTD). It is cause
d by missense mutations in the valosin-containing protein (VCP) gene. We describ
e here the clinical and molecular findings of the first Brazilian family identif
ied with IBMPFD. Progressive myopathy affecting the limb girdles was detected by
 clinical examination followed by muscle biopsy and creatine kinase measurement.
 PDB was suggested after anatomopathological bone examination and FTD was diagno
sed by clinical, neuropsychological and language evaluations. Brain magnetic res
onance revealed severe atrophy of the anterior temporal lobes, including the hip
pocampi. A R93C mutation in VCP was detected by direct sequencing screening in s
ubject W (age 62) and in his mother. Four more individuals diagnosed with "demen
tia" were reported in this family. We also present a comprehensive genotype-phen
otype correlation analysis of mutations in VCP in 182 patients from 29 families 
described in the literature and show that while IBM is a conspicuously penetrant
 symptom, PDB has a lower penetrance when associated with mutations in the AAAD1
 domain and FTD has a lower penetrance when associated with mutations in the Jun
ction (L1-D1) domain. Furthermore, the R93C mutation is likely to be associated 
with the penetrance of all the clinical symptoms of the triad.#^dnd^i1#^tm^len^k
Frontotemporal dementia^i1#^tm^len^kVCP gene mutations^i1#^tm^len^kMyopathy^i1#^
tm^len^kPaget disease of bone^i1#other#20#20100921#September 21, 2010#20110221#F
ebruary 21, 2011#796.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_ar
ttext&pid=S0100-879X2011000400016##
00372000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014800070002000800218#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#5#1#article#112#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 374-380  </B></font></P>      ^cY#796.htm##
00453000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704022900070002000800299#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#6#2#article#112#<p ALIGN="LEFT"><strong><
font size="5" face="Arial"><span lang="EN">A Brazilian family with hereditary in
clusion body myopathy associated with Paget disease of bone and frontotemporal d
ementia</span></font></strong></p>      ^cY#796.htm##
00796000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704057200070002000800642#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#7#3#article#112#<p ALIGN="LEFT"><font fac
e="Arial"><span lang="EN">R.D. Fanganiello<sup>1</sup>, V.E. Kimonis<sup>2</sup>
, C.C. C&ocirc;rte<sup>3</sup>, R. Nitrini<sup>4</sup> and <span lang="EN"><font
 face="Arial, Helvetica, sans-serif"><sup><span lang="EN"><font face="Arial, Hel
vetica, sans-serif"><b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v
44n4/recor.gif" border="0"></a></b> <a href="mailto:passos@ib.usp.br"><img src="
/img/revistas/bjmbr/v44n4/email-ca.gif" border="0"></a></font></span></sup></fon
t></span> M.R. Passos-Bueno<sup>1</sup></span></font></p>      ^cY#796.htm##
00551000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704032700070002000800397#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#8#4#article#112#<p ALIGN="LEFT"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Centro de Estudos d
o Genoma Humano, Departamento de Gen&eacute;tica e Biologia Evolutiva, </font></
span><font face="Arial"><span lang="EN">Instituto de Bioci&ecirc;ncias, Universi
dade de S&atilde;o Paulo, S&atilde;o Paulo, SP, Brasil    ^cY#796.htm##
00405000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704018100070002000800251#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#9#5#article#112#<br>    </span></font><fo
nt face="Arial"><span lang="EN"><sup>2</sup>Division of Genetics and Metabolism,
 Department of Pediatrics, University of California, Irvine, CA, USA    ^cY#796.
htm##
00332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704010700071002000800178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#10#6#article#112#<br>    </span></font><f
ont face="Arial"><span lang="EN"><sup>3</sup>CLINORT, Fortaleza, CE, Brasil    ^
cY#796.htm##
00440000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704021500071002000800286#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#11#7#article#112#<br>  </span></font><fon
t face="Arial"><span lang="EN"><sup>4</sup>Departamento de Neurologia, Hospital 
das Cl&iacute;nicas, Universidade de S&atilde;o Paulo, S&atilde;o Paulo, SP, Bra
sil</span></font></p>      ^cY#796.htm##
00415000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704019000071002000800261#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#12#8#article#112#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#796.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#13#9#article#112#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#796.htm##
00413000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018700072002000800259#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#14#10#article#112#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0></A> <A HREF="#Material"><strong>Subjects and Methods</strong></A>    
^cY#796.htm##
00398000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017200072002000800244#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#15#11#article#112#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#796.htm##
00407000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018100072002000800253#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#16#12#article#112#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#79
6.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#17#13#article#112#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#796.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#18#14#article#112#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#796.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#19#15#article#112#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#796.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#20#16#article#112#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#796.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#21#17#article#112#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#796.htm##
01911000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704168500072002000801757#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#22#18#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Inclusion body myopathy associated with Paget diseas
e and frontotemporal dementia (IBMPFD) is a progressive and usually misdiagnosed
 autosomal dominant disorder. It is clinically characterized by a triad of featu
res: proximal and distal myopathy, early onset Paget disease of bone (PDB), and 
frontotemporal dementia (FTD). It is caused by missense mutations in the valosin
-containing protein (VCP) gene. We describe here the clinical and molecular find
ings of the first Brazilian family identified with IBMPFD. Progressive myopathy 
affecting the limb girdles was detected by clinical examination followed by musc
le biopsy and creatine kinase measurement. PDB was suggested after anatomopathol
ogical bone examination and FTD was diagnosed by clinical, neuropsychological an
d language evaluations. Brain magnetic resonance revealed severe atrophy of the 
anterior temporal lobes, including the hippocampi. A R93C mutation in VCP was de
tected by direct sequencing screening in subject W (age 62) and in his mother. F
our more individuals diagnosed with &quot;dementia&quot; were reported in this f
amily. We also present a comprehensive genotype-phenotype correlation analysis o
f mutations in VCP in 182 patients from 29 families described in the literature 
and show that while IBM is a conspicuously penetrant symptom, PDB has a lower pe
netrance when associated with mutations in the AAAD1 domain and FTD has a lower 
penetrance when associated with mutations in the Junction (L1-D1) domain. Furthe
rmore, the R93C mutation is likely to be associated with the penetrance of all t
he clinical symptoms of the triad.</span></font></p>      ^cY#796.htm##
00416000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019000072002000800262#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#23#19#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Key words: Frontotemporal dementia; VCP gene mutatio
ns; Myopathy; Paget disease of bone</span></font></p>  <HR ALIGN=LEFT SIZE=2>   
   ^cY#796.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#24#20#article#112#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#796.htm##
01353000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704112700072002000801199#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#25#21#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Hereditary inclusion body myopathy associated with P
aget disease of bone (PDB) and frontotemporal dementia (FTD; IBMPFD, MIM 167320)
 is a rare, highly penetrant, progressive and ultimately lethal multisystemic di
sorder. It is characterized by a triad of clinical features: 1) proximal and dis
tal muscle weakness due to myopathy; 2) early age of onset of PDB, and 3) FTD (1
,2). Inclusion body myopathy is the most common clinical feature of IBMPFD, occu
rring in about 90% of the patients. The myopathy is of the adult-onset type and 
is characterized by progressive distal and proximal muscle weakness initially in
volving the shoulder and hip girdle muscles. It is accompanied by difficulty to 
raise the arms, inability to properly ambulate or to climb stairs, hand weakness
 and reduction or absence of tendon reflexes, thus resembling limb girdle muscul
ar dystrophy (2,3). In IBMPFD the highest levels of creatine kinase (CK) are typ
ically present at the early stages of the disease. Respiratory and cardiac failu
re may ultimately lead to death (4).</span></font></p>      ^cY#796.htm##
00642000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704041600072002000800488#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#26#22#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">PDB in IBMPFD has a classical distribution, being pr
esent in the spine, pelvis, scapulae, and cranial bones. Other symptoms associat
ed with PDB are long and cranial bone deformations, pathological fractures and s
pine and hip pain. Elevated levels of alkaline phosphatase, urine pydridinoline 
and deoxypydridinoline are also common (1,4).</span></font></p>      ^cY#796.htm
##
00894000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704066800072002000800740#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#27#23#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Progressive FTD associated with IBMPFD is characteri
zed by language and/or behavioral dysfunction due to impaired frontal and tempor
al lobe functions, with preservation of copying, drawing, calculation, and visuo
spatial function together with relative preservation of memory. Problems concern
ing social and personal behavior, apathy, abulia, disinhibition, and absence of 
insight are common (5). Many patients report visual and auditory hallucinations.
 Drastic alterations in the personality such as impairment of social conduct, ap
hasia and emotional blunting have also been reported (4).</span></font></p>     
 ^cY#796.htm##
00433000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020700072002000800279#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#28#24#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Other inconspicuous clinical features are cardiomyop
athy, hepatic fibrosis, sensorimotor axonal neuropathy, and cataracts (6-8).</sp
an></font></p>      ^cY#796.htm##
01065000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704083900072002000800911#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#29#25#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">IBMPFD is inherited as an autosomal-dominant trait. 
It is caused by missense mutations in the valosin-containing protein gene (VCP, 
CDC48, or <i>p97</i>), mapped to chromosome 9p21-p12, a member of the type II AA
A-ATPase (ATPases Associated with a variety of Activities) family (9). VCP plays
 fundamental roles in multiple events within the cell such as membrane fusion, n
uclear envelope reconstruction, endoplasmic reticulum-associated degradation, po
st-mitotic Golgi cisternae reassembly, and ubiquitin-proteasome degradation. Unt
il now 14 mutations in the VCP gene have been described in more than 150 patient
s with IBMPFD, and most of them are clustered in the N-terminal domain. To date 
no correlation between the genotype and phenotype has been observed.</span></fon
t></p>      ^cY#796.htm##
00643000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704041700072002000800489#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#30#26#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">We report the clinical and molecular findings of the
 first Brazilian family identified with IBMPFD and review all the previous mutat
ions in VCP reported in the literature, including the mutation reported here to 
determine if the penetrance of FTD, PDB and myopathy varies according to the loc
ation of the mutation.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#796.ht
m##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#31#27#article#112#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Sub
jects and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#796.htm##
00837000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704061100072002000800683#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#32#28#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The study was approved by the Ethics Committee of th
e Instituto de Biosci&ecirc;ncias, Universidade de S&atilde;o Paulo, Brazil, and
 written informed consent was obtained from all participants. We obtained clinic
al evaluation, review of records, analysis of CK, muscle biopsy, and molecular t
ests for 1 individual (W) and a pedigree diagram for the family (<a href="#Fig1"
>Figure 1</a>). Concerning his deceased mother (N), autopsy was not performed, b
ut a molecular test was obtained since we had isolated her DNA before her death.
</span></font></p>      ^cY#796.htm##
00660000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704043400072002000800506#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#33#29#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Genomic DNA was isolated from venous blood and mutat
ion screening was performed by direct sequencing of PCR products of the coding e
xons of the VCP gene by the Children&rsquo;s Hospital Boston Division of Genetic
s service, Harvard Medical School, USA. The results were confirmed at the Human 
Genome Research Center, University of S&atilde;o Paulo, Brazil.</span></font></p
>      ^cY#796.htm##
00757000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704053100072002000800603#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#34#30#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">A comprehensive literature review of the reports con
taining both clinical and molecular details of the patients was performed. Cases
 containing isolated IBM, PDB, FTD, or combinations of these symptoms were consi
dered. Euler-Venn diagrams comparing the ratio of each symptom in relation to to
tal sample number for mutations occurring in different VCP protein domains (CDC4
8, Linker 1, Junction (L1-D1), and AAAD1) were prepared.</span></font></p>  <HR 
ALIGN=LEFT SIZE=2>      ^cY#796.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#35#31#article#112#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#796.htm##
00339000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011300072002000800185#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#36#32#article#112#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Clinical and molecular data</span></font></b></p>
      ^cY#796.htm##
00613000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704038700072002000800459#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#37#33#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Subject W belongs to a multigenerational family that
 includes 3 deceased individuals with dementia. The patient&rsquo;s mother, N, d
ied at the age of 81 years, with a 20-year history of progressive dementia. We w
ere unable to evaluate these individuals or to have access to detailed clinical 
data about them.</span></font></p>      ^cY#796.htm##
00715000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704048900072002000800561#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#38#34#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Subject W is a 62-year-old university-graduate man w
ith a 7-year history of muscle weakness. Clinical examination revealed muscle we
akness of the shoulders and arms, evident proximal weakness, mild lumbar hyperlo
rdosis, and pain in the lower neck. He still walks unaided but has difficulty to
 get up from bed or a chair. Tendon reflexes are present in both upper and lower
 limbs. Prominent calves were present.</span></font></p>      ^cY#796.htm##
00574000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704034800072002000800420#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#39#35#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">A muscle biopsy of the left quadriceps muscle showed
 irregular fiber size with the presence of slight to moderate atrophic fibers. A
bout 5% of the fibers had nuclear centralization. CK measurements at the age of 
56 years ranged from 284 to 572 U/L (normal &lt;100 U/L).</span></font></p>     
 ^cY#796.htm##
00581000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704035500072002000800427#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#40#36#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Pathological bone examination of four bone fragments
 from the L3 vertebral body performed when the subject was 56 years old presente
d mosaic irregularity of the cement lines in two of them, with intratrabecular s
paces filled with vascular connective tissue, suggestive of PDB.</span></font></
p>      ^cY#796.htm##
01398000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704117200072002000801244#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#41#37#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Mild behavioral disturbances and cognitive decline h
ad started with progressive reduction of initiative and spontaneity, executive d
ysfunction, topographic disorientation, and forgetfulness when he was 56 years o
ld. A neuropsychological evaluation performed three years later revealed impairm
ent of attention and concentration, lack of initiative and mild difficulty on a 
multiple-choice face recognition test. When he was 60 years old his score in the
 Mini-Mental State Examination (MMSE) was 29, a normal score for his educational
 level (10,11). Cerebral magnetic resonance done at the age of 60 showed severe 
atrophy of the anterior temporal lobes, including the hippocampi, with mild diff
use enlargement of the cerebral sulci (<a href="#Fig2">Figure 2A-D</a>). Eightee
n months later, executive dysfunction had increased and difficulties in recogniz
ing friends and well-known people were evident, together with loss of interest i
n hobbies. His MMSE score was still 29, but mild anomia, moderate verbal and non
-verbal semantic impairments, and moderate to severe prosopagnosia were detected
.</span></font></p>      ^cY#796.htm##
00810000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704058400072002000800656#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#42#38#article#112#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">Mutation analysis of the prop
ositus revealed a heterozygous nucleotide transition in exon 3 (c.277C &rarr; T)
 of the VCP gene resulting in an arginine substitution with cysteine in codon 93
 (p.R93C). This substitution is located in the double &psi; barrel of the N-term
inal domain, which could potentially affect the VCP ubiquitin binding domain. Th
is mutation was also identified in the mother (subject N) of the propositus. We 
were not able to test any other member of the family.</font></span></p>      ^cY
#796.htm##
00343000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011700072002000800189#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#43#39#article#112#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Genotype-phenotype correlations</span></font></b>
</p>      ^cY#796.htm##
00899000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704067300072002000800745#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#44#40#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">In order to perform this analysis we considered clin
ical and molecular details of 182 patients from 29 different families described 
in 13 articles (<a href="#Tab1">Table 1</a>). One hundred and sixty-three (89.6%
) of these patients, belonging to 24 families, have mutations in the CDC48 domai
n of VCP, and 90.8% of these mutations are clustered on exon 5. Twelve patients 
from 3 different families were reported with mutations in the Linker 1 domain, w
hereas 4 and 3 patients were reported with a mutation on Junction (L1-D1) and on
 the AAAD1 domain, respectively, each belonging to one family.</span></font></p>
      ^cY#796.htm##
01442000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704121600072002000801288#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#45#41#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The manifestation ratio of each symptom of the triad
 may vary depending on the protein domain affected by the mutation, as pictured 
in the Euler-Venn diagrams (<a href="#Fig3">Figure 3</a>). The genotype-phenotyp
e analysis depending on the protein domain containing the mutation shows that IB
M is the only clinical symptom conspicuously penetrant, with the lowest penetran
ce associated with mutations in the AAAD1 domain (66%) and the highest (100%) as
sociated with mutations in the Linker 1 domain. PDB showed no penetrance associa
ted with mutations in the AAAD1 domain, full penetrance when associated with Jun
ction (L1-D1) domain and penetrance of 36 and 33% when associated with mutations
 in the CDC48 and in the Linker 1 domains, respectively. Last, FTD was absent in
 patients with mutations in the Junction (L1-D1) domain and penetrance varied fr
om 31 to 66% when associated with mutations in the other domains.</span></font><
/p>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="top
">      <td><a href="/img/revistas/bjmbr/v44n4/html/796i01.htm"><img src="/img/r
evistas/bjmbr/v44n4/796i01peq.jpg" border="2"></a></td>      <td>    ^cY#796.htm
##
00592000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704036600072002000800438#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#46#42#article#112#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. 
Pedigree structure of the family studied here. Black symbols identify affected i
ndividuals and the symbols with question marks identify possibly affected indivi
duals. The black arrow indicates the proband.</font></span></p>      </td>    </
tr>  </table>      ^cY#796.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033700072002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#47#43#article#112#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (44 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/796i02.htm"><img src="/img/
revistas/bjmbr/v44n4/796i02peq.jpg" border="2"></a></td>      <td>    ^cY#796.ht
m##
00681000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704045500072002000800527#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#48#44#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig2"></a>Figure 2. Magnetic resonance imag
ing of patient W. Coronal image showing atrophy of anterior temporal lobes (A), 
axial images showing atrophy of the anterior and medial temporal lobes (B) inclu
ding the hippocampi (C), and showing mild enlargement of the sulci (D). Yellow a
rrows point to the areas of interest identified above.</span></font></p>      </
td>    </tr>  </table>      ^cY#796.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033800072002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#49#45#article#112#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (234 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/796i03.htm"><img src="/img
/revistas/bjmbr/v44n4/796i03peq.jpg" border="2"></a></td>      <td>    ^cY#796.h
tm##
01102000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704087600072002000800948#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#50#46#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig3"></a>Figure 3. <i>A</i>, Representatio
n of the <i>VCP</i> gene showing mutations in individuals with Paget disease and
 frontotemporal dementia and relative positions of functional domains in the pro
tein. Asterisks indicate the location of the mutation in the exon-intron structu
re where exons are represented by cylindrical boxes numbered 1-17. The 5&rsquo; 
and the 3&rsquo; untranslated regions are out of the hatched area. <i>B</i>, Eul
er-Venn diagrams in which the area of each circle is in proportion with the rati
o of each symptom in relation to total sample number for mutations occurring in 
different VCP protein domains. VCP = valosin-containing protein; IBM = inclusion
 body myopathy; PDB = Paget disease of bone; FTD = frontotemporal dementia.</spa
n></font></p>      </td>    </tr>  </table>      ^cY#796.htm##
00560000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033400072002000800406#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#51#47#article#112#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (266 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/796t01.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#796.htm##
00502000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027600072002000800348#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#52#48#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Tab1"></a>Table 1. Clinical and molecular f
indings of IBMPFD patients harboring mutations in the valosin-containing protein
 (VCP) gene.</span></font><span lang="EN"></span></p>      </td>    </tr>  </tab
le>      ^cY#796.htm##
00344000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011800072002000800190#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#53#49#article#112#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (116 K JPG file)]</font
></P>      ^cY#796.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#54#50#article#112#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#796.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#55#51#article#112#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#796.htm##
00821000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704059500072002000800667#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#56#52#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Patient W presents mild progressive myopathy affecti
ng mainly the limb girdles, and PDB with the onset of the symptoms approximately
 at the age of 55 years. Mild behavioral disturbances and cognitive impairment s
tarted to develop at the age of 56 years. This caused progressive FTD with featu
res of both the behavioral variant of FTD and of semantic dementia and severe at
rophy of the anterior temporal lobes, one of the characteristic features of sema
ntic dementia (12) previously described in cases of IBMPFD (13).</span></font></
p>      ^cY#796.htm##
00899000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704067300072002000800745#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#57#53#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Therefore, the clinical presentation of this patient
 fulfills the clinical criteria for this condition, which includes the presence 
of at least 2 of the symptoms of the triad and a suspicious family history. It i
s noteworthy that the clinical diagnosis of this patient took several years to b
e established. Indeed, due to its wide phenotypic variability, IBMPFD is frequen
tly misdiagnosed. Amongst the common misdiagnoses are limb-girdle muscular dystr
ophy, amyotrophic lateral sclerosis, Alzheimer&rsquo;s disease, or other types o
f frontotemporal lobar degenerations and muscular dystrophies.</span></font></p>
      ^cY#796.htm##
00675000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704044900072002000800521#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#58#54#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">It should be noted that topographical disorientation
 as observed in this case is an uncommon complaint in FTD. However, since prosop
agnosia and landmark agnosia are frequently associated by both being related to 
the ventral cortical visual processing stream, it is probable that the topograph
ical disorientation manifested by this patient was caused by landmark agnosia.</
span></font></p>      ^cY#796.htm##
00765000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704053900072002000800611#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#59#55#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The best approach to confirm the clinical diagnosis 
of IBMPFD is molecular testing for VCP. Indeed, the screening for mutations in t
he VCP gene in patient W led to the identification of the p.R93C mutation, which
 was also present in his mother. This mutation has been described before in othe
r patients with IBMPFD and compromises an evolutionarily highly conserved argini
ne residue in the VCP N-terminal domain. Therefore, its pathogenicity is unquest
ionable.</span></font></p>      ^cY#796.htm##
01805000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704157900072002000801651#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#60#56#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">It is important to point out that the full-blown phe
notype of IBMPFD involves a triad of clinical features, but each of its individu
al components may have a variable penetrance: generally, inclusion body myopathy
 is present in 80-90% of the affected individuals, PDB is estimated to be presen
t in 43-51% of IBMPFD cases and FTD is usually the latest clinical feature to ma
nifest, at about 51-54 years of age, present in 30% of cases (9). In contrast, t
here are no data showing if the penetrance of each symptom of the triad varies a
ccording to the location of the mutation. Although in the present study it was n
ot possible to apply statistical analysis due to the small number of patients, w
e observed that the penetrance of IBM, FTD and PDB differed among the 4 groups: 
while IBM had a conspicuous penetrance independently of the mutated protein doma
in, FTD had lower penetrance when associated with mutations in the Junction (L1-
D1) domain and PDB had lower penetrance when associated with mutations in the AA
AD1 domain. Since all the mutations may influence VCP binding to adaptor protein
s and in agreement with the findings that VCP mutants R155H and A232E appropriat
ely form a hexamer, it is possible that, depending on the protein domain and on 
the tissue, mutations may enhance association with a specific set of adaptors, f
avoring penetrance of some clinical manifestations in spite of others. Descripti
on of additional new cases will be important to validate these preliminary obser
vations.</span></font></p>      ^cY#796.htm##
00824000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704059800072002000800670#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#61#57#article#112#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">In addition, comparing the clinical features of the 
patient described here to those of the other patients harboring the R93C mutatio
n in the VCP gene described in the literature (6,13) we find a complete penetran
ce of the triad, suggesting that this mutation might be associated with a high p
enetrance of the full major clinical features. Nevertheless, a larger number of 
patients with this same mutation and with a detailed clinical evaluation is need
ed in order to corroborate this hypothesis.</span></font></p>  <HR ALIGN=LEFT SI
ZE=2>      ^cY#796.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#62#58#article#112#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#796.htm##
00503000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704026300074002000800337#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#63#59#article#112#1#<p ALIGN=
"LEFT"><font face="Arial"><span lang="EN">1. Guinto JB, Ritson GP, Taylor JP, Fo
rman MS. Valosin-containing protein and the pathogenesis of frontotemporal demen
tia associated with inclusion body myopathy. <i>Acta Neuropathol</i> 2007; 114: 
55-61.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#64#60#article#112#</span></font></p>     
 ^cY#796.htm##
00618000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704037800074002000800452#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#65#61#article#112#2#<p align=
"LEFT"><font face="Arial"><span lang="EN">2. Kovach MJ, Waggoner B, Leal SM, Gel
ber D, Khardori R, Levenstien MA, et al. Clinical delineation and localization t
o chromosome 9p13.3-p12 of a unique dominant disorder in four families: heredita
ry inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. 
<i>Mol Genet Metab</i> 2001; 74: 458-475.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#66#62#article#112#</span></font></p>     
 ^cY#796.htm##
00482000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024200074002000800316#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#67#63#article#112#3#<p align=
"LEFT"><font face="Arial"><span lang="EN">3. Clark G, White E, White D, Carson J
. Bibliography of diagnostic uses of ultrasound in medicine and biology from 1 J
anuary 1971. No. 15. <i>Ultrasound Med Biol</i> 1978; 4: 363-391.    ^cY#796.htm
##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#68#64#article#112#</span></font></p>     
 ^cY#796.htm##
00510000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027000074002000800344#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#69#65#article#112#4#<p align=
"LEFT"><font face="Arial"><span lang="EN">4. Kimonis VE, Fulchiero E, Vesa J, Wa
tts G. VCP disease associated with myopathy, Paget disease of bone and frontotem
poral dementia: review of a unique disorder. <i>Biochim Biophys Acta</i> 2008; 1
782: 744-748.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#70#66#article#112#</span></font></p>     
 ^cY#796.htm##
00532000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704029200074002000800366#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#71#67#article#112#5#<p align=
"LEFT"><font face="Arial"><span lang="EN">5. Miller BL, Ikonte C, Ponton M, Levy
 M, Boone K, Darby A, et al. A study of the Lund-Manchester research criteria fo
r frontotemporal dementia: clinical and single-photon emission CT correlations. 
<i>Neurology</i> 1997; 48: 937-942.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#72#68#article#112#</span></font></p>     
 ^cY#796.htm##
00503000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704026300074002000800337#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#73#69#article#112#6#<p align=
"LEFT"><font face="Arial"><span lang="EN">6. Guyant-Marechal L, Laquerriere A, D
uyckaerts C, Dumanchin C, Bou J, Dugny F, et al. Valosin-containing protein gene
 mutations: clinical and neuropathologic features. <i>Neurology</i> 2006; 67: 64
4-651.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#74#70#article#112#</span></font></p>     
 ^cY#796.htm##
00515000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027500074002000800349#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#75#71#article#112#7#<p align=
"LEFT"><font face="Arial"><span lang="EN">7. Haubenberger D, Bittner RE, Rauch-S
horny S, Zimprich F, Mannhalter C, Wagner L, et al. Inclusion body myopathy and 
Paget disease is linked to a novel mutation in the VCP gene. <i>Neurology</i> 20
05; 65: 1304-1305.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#76#72#article#112#</span></font></p>     
 ^cY#796.htm##
00480000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024000074002000800314#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#77#73#article#112#8#<p align=
"LEFT"><font face="Arial"><span lang="EN">8. Hubbers CU, Clemen CS, Kesper K, Bo
ddrich A, Hofmann A, Kamarainen O, et al. Pathological consequences of VCP mutat
ions on human striated muscle. <i>Brain</i> 2007; 130: 381-393.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#78#74#article#112#</span></font></p>     
 ^cY#796.htm##
00541000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704030100074002000800375#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#79#75#article#112#9#<p align=
"LEFT"><font face="Arial"><span lang="EN">9. Watts GD, Wymer J, Kovach MJ, Mehta
 SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget dis
ease of bone and frontotemporal dementia is caused by mutant valosin-containing 
protein. <i>Nat Genet</i> 2004; 36: 377-381.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#80#76#article#112#</span></font></p>     
 ^cY#796.htm##
00488000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704024700075002000800322#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#81#77#article#112#10#<p align
="LEFT"><font face="Arial"><span lang="EN">10. Brucki SM, Nitrini R, Caramelli P
, Bertolucci PH, Okamoto IH. [Suggestions for utilization of the Mini-Mental Sta
te Examination in Brazil]. <i>Arq Neuropsiquiatr</i> 2003; 61: 777-781.    ^cY#7
96.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#82#78#article#112#</span></font></p>     
 ^cY#796.htm##
00495000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025400075002000800329#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#83#79#article#112#11#<p align
="LEFT"><font face="Arial"><span lang="EN">11. Folstein MF, Folstein SE, McHugh 
PR. &quot;Mini-Mental State&quot;. A practical method for grading the cognitive 
state of patients for the clinician. <i>J Psychiatr Res</i> 1975; 12: 189-198.  
  ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#84#80#article#112#</span></font></p>     
 ^cY#796.htm##
00528000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704028700075002000800362#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#85#81#article#112#12#<p align
="LEFT"><font face="Arial"><span lang="EN">12. Pereira JM, Williams GB, Acosta-C
abronero J, Pengas G, Spillantini MG, Xuereb JH, et al. Atrophy patterns in hist
ologic <i>vs</i> clinical groupings of frontotemporal lobar degeneration. <i>Neu
rology</i> 2009; 72: 1653-1660.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#86#82#article#112#</span></font></p>     
 ^cY#796.htm##
00537000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704029600075002000800371#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#87#83#article#112#13#<p align
="LEFT"><font face="Arial"><span lang="EN">13. Krause S, Gohringer T, Walter MC,
 Schoser BG, Reilich P, Linn J, et al. Brain imaging and neuropsychology in late
-onset dementia due to a novel mutation (R93C) of valosin-containing protein. <i
>Clin Neuropathol</i> 2007; 26: 232-240.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#88#84#article#112#</span></font></p>     
 ^cY#796.htm##
00519000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704027800075002000800353#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#89#85#article#112#14#<p align
="LEFT"><font face="Arial"><span lang="EN">14. Gidaro T, Modoni A, Sabatelli M, 
Tasca G, Broccolini A, Mirabella M. An Italian family with inclusion-body myopat
hy and frontotemporal dementia due to mutation in the VCP gene. <i>Muscle Nerve<
/i> 2008; 37: 111-114.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#90#86#article#112#</span></font></p>     
 ^cY#796.htm##
00495000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025400075002000800329#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#91#87#article#112#15#<p align
="LEFT"><font face="Arial"><span lang="EN">15. Schroder R, Watts GD, Mehta SG, E
vert BO, Broich P, Fliessbach K, et al. Mutant valosin-containing protein causes
 a novel type of frontotemporal dementia. <i>Ann Neurol</i> 2005; 57: 457-461.  
  ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#92#88#article#112#</span></font></p>     
 ^cY#796.htm##
00606000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704038000072002000800452#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#93#89#article#112#<p align="LEFT"><font f
ace="Arial"><span lang="EN">16. Viassolo V, Previtali SC, Schiatti E, Magnani G,
 Minetti C, Zara F, et al. Inclusion body myopathy, Paget&rsquo;s disease of the
 bone and frontotemporal dementia: recurrence of the VCP R155H mutation in an It
alian family and implications for genetic counselling. <i>Clin Genet</i> 2008; 7
4: 54-60.</span></font></p>      ^cY#796.htm##
00569000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704032800075002000800403#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#94#90#article#112#17#<p align
="LEFT"><font face="Arial"><span lang="EN">17. Djamshidian A, Schaefer J, Hauben
berger D, Stogmann E, Zimprich F, Auff E, et al. A novel mutation in the VCP gen
e (G157R) in a German family with inclusion-body myopathy with Paget disease of 
bone and frontotemporal dementia. <i>Muscle Nerve</i> 2009; 39: 389-391.    ^cY#
796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#95#91#article#112#</span></font></p>     
 ^cY#796.htm##
00505000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704026400075002000800339#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#96#92#article#112#18#<p align
="LEFT"><font face="Arial"><span lang="EN">18. Bersano A, Del Bo R, Lamperti C, 
Ghezzi S, Fagiolari G, Fortunato F, et al. Inclusion body myopathy and frontotem
poral dementia caused by a novel VCP mutation. <i>Neurobiol Aging</i> 2009; 30: 
752-758.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#97#93#article#112#</span></font></p>     
 ^cY#796.htm##
00554000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704031300075002000800388#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#98#94#article#112#19#<p align
="LEFT"><font face="Arial"><span lang="EN">19. Spina S, Van Laar AD, Murrell JR,
 de Courten-Myers G, Hamilton RL, Farlow MR, et al. Frontotemporal dementia asso
ciated with a valosin-containing protein mutation: Report of three families. <i>
FASEB J</i> 2008; 22 (Meeting Abstract Supplement): 58.4.    ^cY#796.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#99#95#article#112#</span></font></p>     
 ^cY#796.htm##
00534000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704029200076002000800368#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#p#100#96#article#112#20#<p alig
n="LEFT"><font face="Arial"><span lang="EN">20. Watts GD, Thomasova D, Ramdeen S
K, Fulchiero EC, Mehta SG, Drachman DA, et al. Novel VCP mutations in inclusion 
body myopathy associated with Paget disease of bone and frontotemporal dementia.
 <i>Clin Genet</i> 2007; 72: 420-426.    ^cY#796.htm##
00279000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704005200073002000800125#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#101#97#article#112#</span></font></p>  <H
R ALIGN=LEFT SIZE=2>      ^cY#796.htm##
00562000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704033500073002000800408#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#102#98#article#112#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE=
4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, sa
ns-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN
=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#796.htm
##
00947000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704072000073002000800793#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#103#99#article#112#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">We are grateful to the family and their physicians 
for their contribution to our study. We are especially grateful to Fabr&iacute;c
io C&ocirc;rte Pinheiro de Sousa (the propositus&rsquo; son) and to Germana Riqu
et Sousa (Fabricio&rsquo;s wife). Without their initial effort this work would n
ot have been possible. We would like to thank Camila Camanzano Ornelas for helpi
ng with the sequencing, Erika Yeh for drawing the representation of the <i>VCP</
i> gene of <a href="#Fig3">Figure 3</a>, and Felipe Augusto Andr&eacute; Ishiy f
or helping prepare <a href="#Tab1">Table 1</a>. Research supported by FAPESP and
 CNPq.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#796.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033600074002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#104#100#article#112#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#796.h
tm##
00809000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704058100074002000800655#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#105#101#article#112#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/r
ecor.gif" border="0"></a> Address for correspondence:</b></font><span lang="EN">
<font face="Arial, Helvetica, sans-serif"> </font></span><font face="Arial"><spa
n lang="EN"> M.R. Passos-Bueno, Centro de Estudos do Genoma Humano, Departamento
 de Gen&eacute;tica e Biologia Evolutiva, IB, USP, Rua do Mat&atilde;o, 277, Sal
a 200, 05508-090 S&atilde;o Paulo, SP, Brasil. Fax: +55-11-3091-7966. E-mail: <a
 href="mailto:passos@ib.usp.br">passos@ib.usp.br</a></span></font></p>      ^cY#
796.htm##
00453000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704022500074002000800299#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#106#102#article#112#<p ALIGN="LEFT"><i><f
ont face="Arial"><span lang="EN">Received September 21, 2010. Accepted February 
21, 2011. Available online March 11, 2011. Published April 11, 2011.</span></fon
t></i></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#796.htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#107#103#article#112#<div align="center"> 
       ^cY#796.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#108#104#article#112#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#796.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#109#105#article#112#<br>                ^
cY#796.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#110#106#article#112#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#796
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#111#107#article#112#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#796.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#112#108#article#112#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#796.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#113#109#article#112#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#796.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#114#110#article#112#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#796.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#115#111#article#112#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#796.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\796.htm#S#p#116#112#article#112#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#796.htm##
00610000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100017000900100
01700107010001700124012011900141030001700260710000200277065000900279064000500288
031000400293014000600297865000900303002000800312#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\796.htm#S#c#117#1#article#20#1#^rND^sGuinto^nJB#^rND^sRitson^nGP#^rND
^sTaylor^nJP#^rND^sForman^nMS#Valosin-containing protein and the pathogenesis of
 frontotemporal dementia associated with inclusion body myopathy^len#Acta Neurop
athol#2#20070000#2007#114#55-61#20110400#796.htm##
00808000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100018000900100
01500108010001600123010001800139010002100157810000600178012020200184030001600386
06500090040206400050041103100030041601400080041986500090042700200080043603500100
0444801001600454#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#118#2#art
icle#20#2#^rND^sKovach^nMJ#^rND^sWaggoner^nB#^rND^sLeal^nSM#^rND^sGelber^nD#^rND
^sKhardori^nR#^rND^sLevenstien^nMA#et al#Clinical delineation and localization t
o chromosome 9p13.3-p12 of a unique dominant disorder in four families: heredita
ry inclusion body myopathy, Paget disease of bone, and frontotemporal dementia^l
en#Mol Genet Metab#20010000#2001#74#458-475#20110400#796.htm#1096-7192#Mol Genet
 Metab##
00589000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100015000880100
01500103010001600118012009800134030002400232710000200256065000900258064000500267
031000200272014000800274865000900282002000800291#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\796.htm#S#c#119#3#article#20#3#^rND^sClark^nG#^rND^sWhite^nE#^rND^sWh
ite^nD#^rND^sCarson^nJ#Bibliography of diagnostic uses of ultrasound in medicine
 and biology from 1 January 1971: No^len#15. Ultrasound Med Biol#2#19780000#1978
#4#363-391#20110400#796.htm##
00658000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100019000910100
01400110010001500124012012100139030002100260065000900281064000500290031000500295
014000800300865000900308002000800317035001000325801002100335#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\796.htm#S#c#120#4#article#20#4#^rND^sKimonis^nVE#^rND^sFu
lchiero^nE#^rND^sVesa^nJ#^rND^sWatts^nG#VCP disease associated with myopathy, Pa
get disease of bone and frontotemporal dementia: review of a unique disorder^len
#Biochim Biophys Acta#20080000#2008#1782#744-748#20110400#796.htm#0006-3002#Bioc
him Biophys Acta##
00716000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100016000900100
01600106010001400122010001500136010001500151810000600166012013400172030001000306
06500090031606400050032503100030033001400080033386500090034100200080035003500100
0358801001000368#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#121#5#art
icle#20#5#^rND^sMiller^nBL#^rND^sIkonte^nC#^rND^sPonton^nM#^rND^sLevy^nM#^rND^sB
oone^nK#^rND^sDarby^nA#et al#A study of the Lund-Manchester research criteria fo
r frontotemporal dementia: clinical and single-photon emission CT correlations^l
en#Neurology#19970000#1997#48#937-942#20110400#796.htm#0028-3878#Neurology##
00687000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100025000730100021000980100
02000119010001900139010001300158010001500171810000600186012008500192030001000277
06500090028706400050029603100030030101400080030486500090031200200080032103500100
0329801001000339#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#122#6#art
icle#20#6#^rND^sGuyant-Marechal^nL#^rND^sLaquerriere^nA#^rND^sDuyckaerts^nC#^rND
^sDumanchin^nC#^rND^sBou^nJ#^rND^sDugny^nF#et al#Valosin-containing protein gene
 mutations: clinical and neuropathologic features^len#Neurology#20060000#2006#67
#644-651#20110400#796.htm#0028-3878#Neurology##
00699000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100022000730100018000950100
02200113010001800135010002000153010001600173810000600189012009200195030001000287
06500090029706400050030603100030031101400100031486500090032400200080033303500100
0341801001000351#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#123#7#art
icle#20#7#^rND^sHaubenberger^nD#^rND^sBittner^nRE#^rND^sRauch-Shorny^nS#^rND^sZi
mprich^nF#^rND^sMannhalter^nC#^rND^sWagner^nL#et al#Inclusion body myopathy and 
Paget disease is linked to a novel mutation in the VCP gene^len#Neurology#200500
00#2005#65#1304-1305#20110400#796.htm#0028-3878#Neurology##
00660000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100017000910100
01600108010001800124010001700142010002000159810000600179012007200185030000600257
06500090026306400050027203100040027701400080028186500090028900200080029803500100
0306801000600316#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#124#8#art
icle#20#8#^rND^sHubbers^nCU#^rND^sClemen^nCS#^rND^sKesper^nK#^rND^sBoddrich^nA#^
rND^sHofmann^nA#^rND^sKamarainen^nO#et al#Pathological consequences of VCP mutat
ions on human striated muscle^len#Brain#20070000#2007#130#381-393#20110400#796.h
tm#0006-8950#Brain##
00725000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100015000890100
01700104010001600121010001400137010001700151810000600168012014100174030001000315
06500090032506400050033403100030033901400080034286500090035000200080035903500100
0367801001000377#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#125#9#art
icle#20#9#^rND^sWatts^nGD#^rND^sWymer^nJ#^rND^sKovach^nMJ#^rND^sMehta^nSG#^rND^s
Mumm^nS#^rND^sDarvish^nD#et al#Inclusion body myopathy associated with Paget dis
ease of bone and frontotemporal dementia is caused by mutant valosin-containing 
protein^len#Nat Genet#20040000#2004#36#377-381#20110400#796.htm#1061-4036#Nat Ge
net##
00652000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100017000920100
01900109010002100128010001800149012008100167030001900248065000900267064000500276
031000300281014000800284865000900292002000800301035001000309801001900319#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#126#10#article#20#10#^rND^sBrucki
^nSM#^rND^sNitrini^nR#^rND^sCaramelli^nP#^rND^sBertolucci^nPH#^rND^sOkamoto^nIH#
[Suggestions for utilization of the Mini-Mental State Examination in Brazil]^len
#Arq Neuropsiquiatr#20030000#2003#61#777-781#20110400#796.htm#0004-282X#Arq Neur
opsiquiatr##
00610000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100019000940100
01700113012010600130030001600236065000900252064000500261031000300266014000800269
865000900277002000800286035001000294801001600304#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\796.htm#S#c#127#11#article#20#11#^rND^sFolstein^nMF#^rND^sFolstein^nS
E#^rND^sMcHugh^nPR#"Mini-Mental State": A practical method for grading the cogni
tive state of patients for the clinician^len#J Psychiatr Res#19750000#1975#12#18
9-198#20110400#796.htm#0022-3956#J Psychiatr Res##
00705000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100019000930100
02600112010001600138010002200154010001700176810000600193012009400199030001000293
06500090030306400050031203100030031701400100032086500090033000200080033903500100
0347801001000357#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#128#12#ar
ticle#20#12#^rND^sPereira^nJM#^rND^sWilliams^nGB#^rND^sAcosta-Cabronero^nJ#^rND^
sPengas^nG#^rND^sSpillantini^nMG#^rND^sXuereb^nJH#et al#Atrophy patterns in hist
ologic vs clinical groupings of frontotemporal lobar degeneration^len#Neurology#
20090000#2009#72#1653-1660#20110400#796.htm#0028-3878#Neurology##
00728000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910100
01700110010001800127010001700145010001400162810000600176012012200182030001700304
06500090032106400050033003100030033501400080033886500090034600200080035503500100
0363801001700373#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#129#13#ar
ticle#20#13#^rND^sKrause^nS#^rND^sGohringer^nT#^rND^sWalter^nMC#^rND^sSchoser^nB
G#^rND^sReilich^nP#^rND^sLinn^nJ#et al#Brain imaging and neuropsychology in late
-onset dementia due to a novel mutation (R93C) of valosin-containing protein^len
#Clin Neuropathol#20070000#2007#26#232-240#20110400#796.htm#0722-5091#Clin Neuro
pathol##
00695000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100016000910100
01900107010001500126010002000141010001900161012011100180030001300291065000900304
06400050031303100030031801400080032186500090032900200080033803500100034680100130
0356#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#130#14#article#20#14#
^rND^sGidaro^nT#^rND^sModoni^nA#^rND^sSabatelli^nM#^rND^sTasca^nG#^rND^sBroccoli
ni^nA#^rND^sMirabella^nM#An Italian family with inclusion-body myopathy and fron
totemporal dementia due to mutation in the VCP gene^len#Muscle Nerve#20080000#20
08#37#111-114#20110400#796.htm#0148-639X#Muscle nerve##
00680000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930100
01600109010001600125010001600141010002000157810000600177012008500183030001100268
06500090027906400050028803100030029301400080029686500090030400200080031303500100
0321801001100331#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#131#15#ar
ticle#20#15#^rND^sSchroder^nR#^rND^sWatts^nGD#^rND^sMehta^nSG#^rND^sEvert^nBO#^r
ND^sBroich^nP#^rND^sFliessbach^nK#et al#Mutant valosin-containing protein causes
 a novel type of frontotemporal dementia^len#Ann Neurol#20050000#2005#57#457-461
#20110400#796.htm#0364-5134#Ann Neurol##
00786000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100020000930100
01800113010001700131010001700148010001400165810000600179012019100185030001100376
06500090038706400050039603100030040101400060040486500090041000200080041903500100
0427801001100437#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#132#16#ar
ticle#20#16#^rND^sViassolo^nV#^rND^sPrevitali^nSC#^rND^sSchiatti^nE#^rND^sMagnan
i^nG#^rND^sMinetti^nC#^rND^sZara^nF#et al#Inclusion body myopathy, Paget&#8217;s
 disease of the bone and frontotemporal dementia: recurrence of the VCP R155H mu
tation in an Italian family and implications for genetic counselling^len#Clin Ge
net#20080000#2008#74#54-60#20110400#796.htm#0009-9163#Clin Genet##
00756000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100018000960100
02200114010001800136010001800154010001400172810000600186012014800192030001300340
06500090035306400050036203100030036701400080037086500090037800200080038703500100
0395801001300405#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#133#17#ar
ticle#20#17#^rND^sDjamshidian^nA#^rND^sSchaefer^nJ#^rND^sHaubenberger^nD#^rND^sS
togmann^nE#^rND^sZimprich^nF#^rND^sAuff^nE#et al#A novel mutation in the VCP gen
e (G157R) in a German family with inclusion-body myopathy with Paget disease of 
bone and frontotemporal dementia^len#Muscle Nerve#20090000#2009#39#389-391#20110
400#796.htm#0148-639X#Muscle nerve##
00695000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
01800108010001600126010001900142010001900161810000600180012008700186030001600273
06500090028906400050029803100030030301400080030686500090031400200080032303500100
0331801001600341#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#134#18#ar
ticle#20#18#^rND^sBersano^nA#^rND^sDel^nBo R#^rND^sLamperti^nC#^rND^sGhezzi^nS#^
rND^sFagiolari^nG#^rND^sFortunato^nF#et al#Inclusion body myopathy and frontotem
poral dementia caused by a novel VCP mutation^len#Neurobiol Aging#20090000#2009#
30#752-758#20110400#796.htm#0197-4580#Neurobiol Aging##
00748000000000349000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100019000900100
01800109010002600127010001900153010001700172810000600189012010800195030000800303
06500090031106400050032003100030032503200300032801400050035886500090036300200080
0372035001000380801000800390#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S
#c#135#19#article#20#19#^rND^sSpina^nS#^rND^sVan Laar^nAD#^rND^sMurrell^nJR#^rND
^sde Courten-Myers^nG#^rND^sHamilton^nRL#^rND^sFarlow^nMR#et al#Frontotemporal d
ementia associated with a valosin-containing protein mutation: Report of three f
amilies^len#FASEB J#20080000#2008#22#^sMeeting Abstract Supplement#58.4#20110400
#796.htm#0892-6638#FASEB j##
00718000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910100
01800110010002000128010001600148010001900164810000600183012011700189030001100306
06500090031706400050032603100030033101400080033486500090034200200080035103500100
0359801001100369#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\796.htm#S#c#136#20#ar
ticle#20#20#^rND^sWatts^nGD#^rND^sThomasova^nD#^rND^sRamdeen^nSK#^rND^sFulchiero
^nEC#^rND^sMehta^nSG#^rND^sDrachman^nDA#et al#Novel VCP mutations in inclusion b
ody myopathy associated with Paget disease of bone and frontotemporal dementia^l
en#Clin Genet#20070000#2007#72#420-426#20110400#796.htm#0009-9163#Clin Genet##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#o#1#1#article#1#201
10411#094626#798.htm#213##
03045000000000541000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120121001780100033002990100026003320700058003580831879004160850008022950850
01902303085003002322085002302352085003202375117000602407072000302413112000902416
111001902425114000902444113001802453891002402471002000802495#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\798.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#11#B
JMBR070#FAPESP#Braz J Med Biol Res#44#4#20110400#^f337^l344#0100-879X#20110401#V
ascular adaptive responses to physical exercise and to stress are affected diffe
rently by nandrolone administration^len#^rND^1A01^nT.^sBruder-Nascimento#^rND^1A
01^nS.^sCordellini#Universidade Estadual Paulista^iA01^cBotucatu^sSP^pBrasil#^le
n^aAndrogenic anabolic steroid, physical exercise and stress induce cardiovascul
ar adaptations including increased endothelial function. The present study inves
tigated the effects of these conditions alone and in combination on the vascular
 responses of male Wistar rats. Exercise was started at 8 weeks of life (60-min 
swimming sessions 5 days per week for 8 weeks, while carrying a 5% body-weight l
oad). One group received nandrolone (5 mg/kg, twice per week for 8 weeks, im). A
cute immobilization stress (2 h) was induced immediately before the experimental
 protocol. Curves for noradrenaline were obtained for thoracic aorta, with and w
ithout endothelium from sedentary and trained rats, submitted or not to stress, 
treated or not with nandrolone. None of the procedures altered the vascular reac
tivity to noradrenaline in denuded aorta. In intact aorta, stress and exercise p
roduced vascular adaptive responses characterized by endothelium-dependent hypor
eactivity to noradrenaline. These conditions in combination did not potentiate t
he vascular adaptive response. Exercise-induced vascular adaptive response was a
bolished by nandrolone. In contrast, the aortal reactivity to noradrenaline of s
edentary rats and the vascular adaptive response to stress of sedentary and trai
ned rats were not affected by nandrolone. Maximum response for 7-10 rats/group (
g): sedentary 3.8 ± 0.2 vs trained 3.0 ± 0.2*; sedentary/stress 2.7 ± 0.2 vs tra
ined/stress 3.1 ± 0.1*; sedentary/nandrolone 3.6 ± 0.1 vs trained/nandrolone 3.8
 ± 0.1; sedentary/stress/nandrolone 3.2 ± 0.1 vs trained/stress/nandrolone 2.5 ±
 0.1*; *P < 0.05 compared to its respective control. Stress and physical exercis
e determine similar vascular adaptive response involving distinct mechanisms as 
indicated by the observation that only the physical exercise-induced adaptive re
sponse was abolished by nandrolone.#^dnd^i1#^tm^len^kStress^i1#^tm^len^kPhysical
 exercise^i1#^tm^len^kNandrolone^i1#^tm^len^kVascular reactivity^i1#other#40#201
00929#September 29, 2010#20110218#February 18, 2011#S0100-879X2011007500043#798.
htm##
03068000000000529000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120128001780100033003060100026003390700058003650831917004230850008023400850
01902348085003002367085002302397085003202420117000602452072000302458112000902461
111002602470114000902496113002502505002000802530#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\798.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#11#BJMBR070#FAPE
SP#Braz J Med Biol Res#44#4#20110400#^f337^l344#0100-879X#20110401#<b>Vascular a
daptive responses to physical exercise and to stress are affected differently by
 nandrolone administration</b>^len#^rND^1A01^nT.^sBruder-Nascimento#^rND^1A01^nS
.^sCordellini#Universidade Estadual Paulista^iA01^cBotucatu^sSP^pBrasil#^len^aAn
drogenic anabolic steroid, physical exercise and stress induce cardiovascular ad
aptations including increased endothelial function. The present study investigat
ed the effects of these conditions alone and in combination on the vascular resp
onses of male Wistar rats. Exercise was started at 8 weeks of life (60-min swimm
ing sessions 5 days per week for 8 weeks, while carrying a 5% body-weight load).
 One group received nandrolone (5 mg/kg, twice per week for 8 weeks, <i>im</i>).
 Acute immobilization stress (2 h) was induced immediately before the experiment
al protocol. Curves for noradrenaline were obtained for thoracic aorta, with and
 without endothelium from sedentary and trained rats, submitted or not to stress
, treated or not with nandrolone. None of the procedures altered the vascular re
activity to noradrenaline in denuded aorta. In intact aorta, stress and exercise
 produced vascular adaptive responses characterized by endothelium-dependent hyp
oreactivity to noradrenaline. These conditions in combination did not potentiate
 the vascular adaptive response. Exercise-induced vascular adaptive response was
 abolished by nandrolone. In contrast, the aortal reactivity to noradrenaline of
 sedentary rats and the vascular adaptive response to stress of sedentary and tr
ained rats were not affected by nandrolone. Maximum response for 7-10 rats/group
 (g): sedentary 3.8 ± 0.2 <i>vs</i> trained 3.0 ± 0.2*; sedentary/stress 2.7 ± 0
.2 <i>vs</i> trained/stress 3.1 ± 0.1*; sedentary/nandrolone 3.6 ± 0.1 <i>vs</i>
 trained/nandrolone 3.8 ± 0.1; sedentary/stress/nandrolone 3.2 ± 0.1 <i>vs</i> t
rained/stress/nandrolone 2.5 ± 0.1*; *P &lt; 0.05 compared to its respective con
trol. Stress and physical exercise determine similar vascular adaptive response 
involving distinct mechanisms as indicated by the observation that only the phys
ical exercise-induced adaptive response was abolished by nandrolone.#^dnd^i1#^tm
^len^kStress^i1#^tm^len^kPhysical exercise^i1#^tm^len^kNandrolone^i1#^tm^len^kVa
scular reactivity^i1#other#40#20100929#<i>September 29, 2010</i>#20110218#<i>Feb
ruary 18, 2011</i>#798.htm##
03146000000000553000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762240009001860120121001950100032003160100025003480700060003730831886004330850
00802319085001902327085003002346085002302376085003202399117000602431072000302437
112000902440111001902449114000902468113001802477002000802495008008902503#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#l#4#1#article#1#^mApr.^a2011#oa#en#
bjmbr#1#3.1#ilus#tab#11#BJMBR070#FAPESP#Braz. j. med. biol. res#44#4#20110400#^f
337^l344#0100-879X#20110401#Vascular adaptive responses to physical exercise and
 to stress are affected differently by nandrolone administration^len#^rND^1A01^n
T^sBruder-Nascimento#^rND^1A01^nS^sCordellini#^iA01^1Universidade Estadual Pauli
sta^cBotucatu^sSP^pBrasil#^len^aAndrogenic anabolic steroid, physical exercise a
nd stress induce cardiovascular adaptations including increased endothelial func
tion. The present study investigated the effects of these conditions alone and i
n combination on the vascular responses of male Wistar rats. Exercise was starte
d at 8 weeks of life (60-min swimming sessions 5 days per week for 8 weeks, whil
e carrying a 5 percent body-weight load). One group received nandrolone (5 mg/kg
, twice per week for 8 weeks, im). Acute immobilization stress (2 h) was induced
 immediately before the experimental protocol. Curves for noradrenaline were obt
ained for thoracic aorta, with and without endothelium from sedentary and traine
d rats, submitted or not to stress, treated or not with nandrolone. None of the 
procedures altered the vascular reactivity to noradrenaline in denuded aorta. In
 intact aorta, stress and exercise produced vascular adaptive responses characte
rized by endothelium-dependent hyporeactivity to noradrenaline. These conditions
 in combination did not potentiate the vascular adaptive response. Exercise-indu
ced vascular adaptive response was abolished by nandrolone. In contrast, the aor
tal reactivity to noradrenaline of sedentary rats and the vascular adaptive resp
onse to stress of sedentary and trained rats were not affected by nandrolone. Ma
ximum response for 7-10 rats/group (g): sedentary 3.8 ± 0.2 vs trained 3.0 ± 0.2
*; sedentary/stress 2.7 ± 0.2 vs trained/stress 3.1 ± 0.1*; sedentary/nandrolone
 3.6 ± 0.1 vs trained/nandrolone 3.8 ± 0.1; sedentary/stress/nandrolone 3.2 ± 0.
1 vs trained/stress/nandrolone 2.5 ± 0.1*; *P < 0.05 compared to its respective 
control. Stress and physical exercise determine similar vascular adaptive respon
se involving distinct mechanisms as indicated by the observation that only the p
hysical exercise-induced adaptive response was abolished by nandrolone.#^dnd^i1#
^tm^len^kStress^i1#^tm^len^kPhysical exercise^i1#^tm^len^kNandrolone^i1#^tm^len^
kVascular reactivity^i1#other#40#20100929#September 29, 2010#20110218#February 1
8, 2011#798.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid
=S0100-879X2011000400011##
00373000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014900070002000800219#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#5#1#article#169#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 337-344  </B> </font></P>      ^cY#798.htm##
00458000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704023400070002000800304#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#6#2#article#169#<p ALIGN="LEFT"><span lan
g="EN"><font size="5" face="Arial, Helvetica, sans-serif"><b>Vascular adaptive r
esponses to physical exercise and to stress are affected differently by nandrolo
ne administration</b></font></span></p>      ^cY#798.htm##
00720000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704049600070002000800566#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#7#3#article#169#<p ALIGN="LEFT"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif">T. Bruder-Nascimento and <span 
lang="EN"><font face="Arial, Helvetica, sans-serif"><sup><span lang="EN"><font f
ace="Arial, Helvetica, sans-serif"><b><a href="#Correspondence"><img src="/img/r
evistas/bjmbr/v44n4/recor.gif" border="0"></a></b> <a href="mailto:cordelli@ibb.
unesp.br"><img src="/img/revistas/bjmbr/v44n4/email-ca.gif" border="0"></a></fon
t></span></sup></font></span> S. Cordellini</font></span></p>      ^cY#798.htm##
00555000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704033100070002000800401#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#8#4#article#169#<p ALIGN="LEFT"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif">Departamento de Farmacologia, I
nstituto de Bioci&ecirc;ncias, </font></span><span lang="EN"><font face="Arial, 
Helvetica, sans-serif">Universidade Estadual Paulista &quot;J&uacute;lio de Mesq
uita Filho&quot;, Botucatu, SP, Brasil</font></span></p>      ^cY#798.htm##
00414000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704019000070002000800260#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#9#5#article#169#<P> <font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#798.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#10#6#article#169#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#798.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#11#7#article#169#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#798.htm##
00397000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704017200071002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#12#8#article#169#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#798.htm##
00406000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018100071002000800252#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#13#9#article#169#<BR>   <A HREF="#Discuss
ion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#798
.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#14#10#article#169#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#798.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#15#11#article#169#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#798.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#16#12#article#169#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#798.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#17#13#article#169#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#798.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#18#14#article#169#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#798.htm##
02294000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704206800072002000802140#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#19#15#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Androgenic anabolic steroid, 
physical exercise and stress induce cardiovascular adaptations including increas
ed endothelial function. The present study investigated the effects of these con
ditions alone and in combination on the vascular responses of male Wistar rats. 
Exercise was started at 8 weeks of life (60-min swimming sessions 5 days per wee
k for 8 weeks, while carrying a 5% body-weight load). One group received nandrol
one (5 mg/kg, twice per week for 8 weeks, <i>im</i>). Acute immobilization stres
s (2 h) was induced immediately before the experimental protocol. Curves for nor
adrenaline were obtained for thoracic aorta, with and without endothelium from s
edentary and trained rats, submitted or not to stress, treated or not with nandr
olone. None of the procedures altered the vascular reactivity to noradrenaline i
n denuded aorta. In intact aorta, stress and exercise produced vascular adaptive
 responses characterized by endothelium-dependent hyporeactivity to noradrenalin
e. These conditions in combination did not potentiate the vascular adaptive resp
onse. Exercise-induced vascular adaptive response was abolished by nandrolone. I
n contrast, the aortal reactivity to noradrenaline of sedentary rats and the vas
cular adaptive response to stress of sedentary and trained rats were not affecte
d by nandrolone. Maximum response for 7-10 rats/group (g): sedentary 3.8 &plusmn
; 0.2 <i>vs</i> trained 3.0 &plusmn; 0.2*; sedentary/stress 2.7 &plusmn; 0.2 <i>
vs</i> trained/stress 3.1 &plusmn; 0.1*; sedentary/nandrolone 3.6 &plusmn; 0.1 <
i>vs</i> trained/nandrolone 3.8 &plusmn; 0.1; sedentary/stress/nandrolone 3.2 &p
lusmn; 0.1 <i>vs</i> trained/stress/nandrolone 2.5 &plusmn; 0.1*; *P &lt; 0.05 c
ompared to its respective control. Stress and physical exercise determine simila
r vascular adaptive response involving distinct mechanisms as indicated by the o
bservation that only the physical exercise-induced adaptive response was abolish
ed by nandrolone.</font></span></p>      ^cY#798.htm##
00421000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019500072002000800267#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#20#16#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Key words: Stress; Physical e
xercise; Nandrolone; Vascular reactivity</font></span></p>  <HR ALIGN=LEFT SIZE=
2>      ^cY#798.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#21#17#article#169#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#798.htm##
00898000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704067200072002000800744#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#22#18#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Regular physical exercise has
 been associated with a reduced incidence of cardiovascular diseases. Endurance 
training of healthy sedentary human subjects results in increased cardiac output
 and stroke volume (1). Chronic exercise is also known to improve the vasodilato
ry mechanisms mediated by endothelium-dependent relaxing factors in the cardiac 
and skeletal muscles, as well as kidney, cutaneous and other vascular beds (2-4)
. Decreased blood pressure induced by exercise training was also reported in hyp
ertensive subjects and spontaneously hypertensive rats (5,6).</font></span></p> 
     ^cY#798.htm##
01561000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704133500072002000801407#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#23#19#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">To potentiate the physiologic
al effects of physical training, many athletes use ergogenic substances. The use
 of anabolic androgenic steroids (AAS) is no longer limited to athletes and body
 builders. Adolescents and adults with no primary interest in sports, but who ar
e interested in weight gain and improvement of their physical appearance have st
arted to abuse AAS. The intake of these steroids has been associated with vascul
ar complications, cardiomyopathy, coronary atherosclerosis, and cardiac hypertro
phy. Furthermore, in several clinical reports, AAS intake was associated with an
 acute myocardial infarct (7,8). It has been reported that treatment with the AA
S nandrolone worsens an animal&rsquo;s endothelial and vascular smooth muscle fu
nction (9-14)</font><font COLOR="#0000ff" face="Arial, Helvetica, sans-serif">. 
</font><font face="Arial, Helvetica, sans-serif">In fact, the endothelial cell p
lays an important role in the cardiovascular system by producing a variety of po
tent vasoactive agents. Changes in endothelial cell function are implicated in a
 variety of pathophysiological processes, such as steroid abuse, and the restora
tion of endothelial function appears to be a promising therapeutic approach (15-
17).</font></span></p>      ^cY#798.htm##
00912000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704068600072002000800758#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#24#20#article#169#<p ALIGN="LEFT"> <span 
lang="EN"><font face="Arial, Helvetica, sans-serif">Stress is another physiologi
cal condition that involves circulatory changes. Although virtually all organs a
re affected by exposure to stressors, the neuroendocrine, cardiovascular, immune
, and gastrointestinal systems are the first to experience functional changes (1
8)</font><font COLOR="#0000ff" face="Arial, Helvetica, sans-serif">.</font><font
 face="Arial, Helvetica, sans-serif"> Similarly to that observed in exercise tra
ining, the stress-induced vascular changes are dependent on both endothelial int
egrity and hyperactivity of the endothelial nitric oxide-system (15,17,19).</fon
t></span></p>      ^cY#798.htm##
00913000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704068700072002000800759#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#25#21#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Despite the reports of vascul
ar reactivity changes related to stress, exercise and abuse of steroids isolated
, the circulatory adaptation to these perturbations in combination requires furt
her investigation. Thus, given the frequent use of AAS by sport athletes and the
 general population as well as the potential health risks of stressful stimuli, 
the objective of the present study was to evaluate the effect of exercise traini
ng, stress and AAS administration alone or in combination on vascular function, 
focusing on the endothelial and smooth muscle cells.</font></span></p>  <HR ALIG
N=LEFT SIZE=2>      ^cY#798.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#26#22#article#169#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#798.htm##
00342000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011600072002000800188#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#27#23#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Animals</font></span></b><
/p>      ^cY#798.htm##
00666000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704044000072002000800512#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#28#24#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Experiments were performed on
 male Wistar rats with 6 weeks of age and 250-270 g body weight at the beginning
 of the experiments. Lights in the animal room were set on a 12:12-h cycle with 
temperature maintained at 22 &plusmn; 1&deg;C. The animals were housed 3 per cag
e and were given regular laboratory chow and water <i>ad libitum</i>.</font></sp
an></p>      ^cY#798.htm##
00592000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704036600072002000800438#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#29#25#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">The experimental procedures w
ere in accordance with the principles and guidelines of the National Council for
 Control of Animal Experimentation and were approved by the Ethics Committee of 
the Instituto de Bioci&ecirc;ncias, UNESP, Botucatu (protocol #67/03-CEEA).</fon
t></span></p>      ^cY#798.htm##
00357000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013100072002000800203#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#30#26#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Body and organ weights</fo
nt></span></b></p>      ^cY#798.htm##
01015000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704078900072002000800861#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#31#27#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">The weights of the body, adre
nals, left ventricle, prostate, testes, and seminal vesicles were measured in se
dentary and trained rats treated or not with nandrolone. The animals were weighe
d weekly throughout the experimental period. Since the weight of the adrenals co
rrelates with stress level, it was employed to assess the efficacy of stress ind
uction. Moreover, since the weights of the prostate, testes and seminal vesicle 
correlate with sex hormone levels, they were employed to assess the efficacy of 
treatment with the exogenous anabolic androgenic steroid nandrolone. Finally, ca
rdiac hypertrophy was assessed by left ventricle weight normalized for body weig
ht (LV weight/BW).</font></span></p>      ^cY#798.htm##
00364000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013800072002000800210#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#32#28#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Measurement of blood press
ure</font></span></b></p>      ^cY#798.htm##
00738000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704051200072002000800584#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#33#29#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Systolic blood pressure was d
etermined in conscious rats using tail-cuff plethysmography (Narco Bio-Systems, 
USA) immediately before starting treatment and weekly until the death of the ani
mal. The rats were prewarmed for 10 to 15 min and placed into a restrainer for b
lood pressure measurement. Three consecutive recordings (~1 min apart) were perf
ormed, and the mean of these three measurements was recorded.</font></span></p> 
     ^cY#798.htm##
00352000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704012600072002000800198#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#34#30#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Adaptation period</font></
span></b></p>      ^cY#798.htm##
01138000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704091200072002000800984#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#35#31#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">To avoid a considerable loss 
of rats and to reduce the animals&rsquo; stress, the rats from the training grou
ps were submitted to a gradual but brief adaptation period. During the first pre
-training week these animals (6 weeks old) were placed exposed to increasing vol
umes of heated water and periods of exposure (28 &plusmn; 1&deg;C; 15-60 min/day
, 5 weekly sessions) within a tank (35 x 17 x 50 cm) in order to adapt to the wa
ter. Subsequently, the rats were submitted to a second pre-training week consist
ing of forced swimming sessions in water at 28 &plusmn; 1&deg;C for 60 min, carr
ying a load strapped to their chests. The workload was gradually increased (1-5%
 of body weight) until the rats could swim for 60 min wearing a chest load weigh
ing 5% of body weight. Thereafter, the workload was constant.</font></span></p> 
     ^cY#798.htm##
00360000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013400072002000800206#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#36#32#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Exercise training program<
/font></span></b></p>      ^cY#798.htm##
00967000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704074100072002000800813#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#37#33#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Exercise training consisted o
f a forced swimming session once a day for a period of 8 weeks (5 days/week). Ra
ts were submitted individually to a forced swimming session in warmed water at 2
8 &plusmn; 1&deg;C for 60 min, carrying a load weighing 5% of body weight strapp
ed to their chests. The sessions were performed between 1:00 and 2:00 pm. During
 the exercise session, the sedentary rats were kept in their home cages. This sw
imming protocol has been characterized previously as being of low to moderate in
tensity and of long duration (20). Forty-eight hours after the last exercise ses
sion, the animals were sacrificed by decapitation.</font></span></p>      ^cY#79
8.htm##
00370000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704014400072002000800216#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#38#34#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Treatment with nandrolone 
decanoate</font></span></b></p>      ^cY#798.htm##
00856000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704063000072002000800702#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#39#35#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Eight-week-old rats were rand
omized into 4 groups (7-10 rats/group): sedentary vehicle-treated (vehicle = cor
n oil: 0.2 mL body weight, twice per week, intramuscularly, for 8 weeks), traine
d vehicle-treated, sedentary nandrolone-treated (nandrolone decanoate, Deca Dura
bolin<sup>&reg;</sup>, Organon do Brasil, Brazil, 5 mg/kg body weight twice a we
ek, intramuscularly, for 8 weeks) (12), and trained nandrolone-treated. This dos
e is comparable to the dose that has been reported to be frequently used by heav
y AAS abusers (21).</font></span></p>      ^cY#798.htm##
00351000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704012500072002000800197#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#40#36#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Stress induction</font></s
pan></b></p>      ^cY#798.htm##
01105000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704087900072002000800951#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#41#37#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Forty-eight hours after the l
ast exercise session, a group of trained rats, treated or not with nandrolone, w
as submitted to a single stress session (Train/St and Train/Nand/St, respectivel
y). Additionally, a group of 16-week-old sedentary rats treated or not with nand
rolone was also submitted to a single stress session (Sed/St and Sed/Nand/St, re
spectively). The stressor agent consisted of immobilization for 2 h in a 5 x 27-
cm metal tube, individually adapted to provide a tight restriction of movements,
 but allowing the animal to breathe normally. This acute stress exposure took pl
ace between 10:00 am and 2:00 pm. During the stress session, the non-stressed ra
ts were kept in their home cage. Immediately after stress exposure the rats were
 sacrificed by decapitation.</font></span></p>      ^cY#798.htm##
00363000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013700072002000800209#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#42#38#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Vascular reactivity protoc
ol</font></span></b></p>      ^cY#798.htm##
01407000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704118100072002000801253#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#43#39#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Immediately after animal sacr
ifice, the descending thoracic aorta was excised and trimmed free of adhering fa
t and connective tissue. Two transverse rings of the same artery, each about 4 m
m in length, were cut and mounted at the optimal length for isometric tension re
cording in organ chambers (17). One ring served as control, while the endotheliu
m was mechanically removed from the other by gently rubbing the luminal surface.
 Briefly, preparations were mounted in organ baths containing 7 mL Krebs-Hensele
it solution of the following composition: 113.0 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl
<sub>2</sub>, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 1.1 mM MgSO<sub>4</sub>, 25.0
 mM NaHCO<sub>3</sub>, 11.0 mM glucose, and 0.11 mM ascorbic acid. The bathing f
luid, kept at 36.0 &plusmn; 0.5<sup>o</sup>C, was saturated with a gas mixture o
f 95% O<sub>2</sub> and 5% CO<sub>2</sub>. The preparations were allowed to equi
librate for at least 1 h under a resting tension of 1.5 g, which is optimal for 
inducing maximum contraction. Tension was recorded with a physiograph (Ugo Basil
e, Italy).</font></span></p>      ^cY#798.htm##
00814000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704058800072002000800660#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#44#40#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Cumulative concentration-effe
ct curves were constructed from the response of the tissue to noradrenaline. At 
the end of the curves, single doses of 1.0 &micro;M acetylcholine or 0.1 mM sodi
um nitroprusside were used to test the integrity of endothelial and smooth muscl
e layers, respectively. Endothelium and smooth muscle were considered to be inta
ct if the acetylcholine and sodium nitroprusside-induced relaxation of the preco
ntracted aorta was greater than 60 and 99%, respectively.</font></span></p>     
 ^cY#798.htm##
00363000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013700072002000800209#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#45#41#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Data analysis and statisti
cs</font></span></b></p>      ^cY#798.htm##
00935000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704070900072002000800781#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#46#42#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">The concentration of vasoacti
ve agents producing a response that was 50% of the maximum (EC<sub>50</sub>) was
 calculated in each experiment. Maximal responses (grams of tension) and blood p
ressure (mmHg), reported as means &plusmn; SEM, and EC<sub>50</sub> values, repo
rted as median with 95% confidence intervals, were compared by multifactorial AN
OVA (SIGMASTAT 2.0). Nandrolone treatment, exercise training and stress were the
 factors in the analysis. A P value less than 0.05 was considered to be statisti
cally significant. The Tukey multiple comparisons test was used to test differen
ces between means.</font></span></p>      ^cY#798.htm##
00354000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704012800072002000800200#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#47#43#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Drugs and solutions</font>
</span></b></p>      ^cY#798.htm##
00621000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704039500072002000800467#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#48#44#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">The following drugs were used
: acetylcholine bromide, noradrenaline bitartrate, sodium nitroprusside (all obt
ained from Sigma, USA) and nandrolone decanoate. All drugs, except nandrolone, w
ere dissolved in Krebs-Henseleit solution. Nandrolone was dissolved in corn oil.
</font></span></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#798.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#49#45#article#169#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#798.htm##
00452000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704022600072002000800298#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#50#46#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Effects of exercise traini
ng associated or not with nandrolone treatment on body and organ weights and blo
od pressure</font></span></b></p>      ^cY#798.htm##
00942000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704071600072002000800788#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#51#47#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">The evolution of body weight 
was similar for all experimental groups [final body weight (g): Sed = 458.3 &plu
smn; 24.5, Train = 426.6 &plusmn; 30.1, Sed/Nand = 439.4 &plusmn; 27.7 and Train
/Nand = 446.3 &plusmn; 25.5, P &gt; 0.05, N = 7-10]. The evolution of blood pres
sure did not differ between sedentary and trained rats, but was significantly in
creased by nandrolone treatment in both groups (&Delta;PA mmHg: Sed 9.7 &plusmn;
 3.1; Train 7.6 &plusmn; 4.6; Sed/Nand 25.4 &plusmn; 8.5*; Train/Nand 24.6 &plus
mn; 6.0*; *P &lt; 0.05 related to the respective group without nandrolone; <a hr
ef="#Fig1">Figure 1</a>).</font></span></p>      ^cY#798.htm##
00895000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704066900072002000800741#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#52#48#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Among the different procedure
s, only exercise training induced cardiac hypertrophy (<a href="#Tab1">Table 1</
a>). The administration of nandrolone induced a further increase in prostate wei
ght and seminal vesicles and a decrease in testicular weight, both in sedentary 
and trained rats (<span lang="EN"><font face="Arial, Helvetica, sans-serif"><a h
ref="#Tab1">Table 1</a></font></span>). Finally, stress exposure induced a decre
ase in adrenal weight in all groups (<span lang="EN"><font face="Arial, Helvetic
a, sans-serif"><a href="#Tab1">Table 1</a></font></span>).</font></span></p>    
  ^cY#798.htm##
00375000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704014900072002000800221#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#53#49#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Vascular responsiveness to
 noradrenaline</font></span></b></p>      ^cY#798.htm##
00721000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704049500072002000800567#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#54#50#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">The exposure to stress and to
 exercise training reduced the maximal responses to noradrenaline (NA) of the in
tact aorta compared to non-stressed sedentary rats. Moreover, the combination of
 these procedures did not potentiate aortal hyporeactivity to the vasoconstricti
on agent (<a href="#Fig2">Figure 2A</a> and <a href="#Fig2">B</a>; <a href="#Tab
2">Tables 2</a> and <a href="#Tab3">3</a>).</font></span></p>       ^cY#798.htm#
#
01139000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704091300072002000800985#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#55#51#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Treatment    with nandrolone 
did not alter the reactivity to NA of the intact aorta from    non-stressed sede
ntary rats, but abolished the aortal hyporeactivity induced    by exercise train
ing (<span lang="EN"><font face="Arial, Helvetica, sans-serif"><a href="#Fig2">F
igure    2</a></font></span>A and C, <a href="#Tab2">Table 2</a>). In contrast, 
the hyporeactivity    to NA induced by stress in both sedentary and trained rats
 was not altered by    nandrolone treatment (<span lang="EN"><font face="Arial, 
Helvetica, sans-serif"><a href="#Fig2">Figure    2B</a></font></span> and <a hre
f="#Fig2">D</a>, <span lang="EN"><font face="Arial, Helvetica, sans-serif"><a hr
ef="#Tab2">Table    2</a></font></span>). None of the experimental procedures pr
ovoked any change    in sensitivity to NA of the intact aorta.</font></span></p>
      ^cY#798.htm##
01131000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704090500072002000800977#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#56#52#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Removal of the endothelium ca
used leftward shifts of the curve and elevated maximum responses to NA that were
 similar in aortas from the different experimental groups. Moreover, none of the
 experimental procedures provoked any change in the reactivity to NA of the denu
ded aorta (<span lang="EN"><font face="Arial, Helvetica, sans-serif"><a href="#F
ig2">Figure 2</a></font></span>, <span lang="EN"><font face="Arial, Helvetica, s
ans-serif"><a href="#Tab2">Tables 2</a> and <a href="#Tab3">3</a></font></span>)
.</font></span><span lang="EN"><font face="Arial, Helvetica, sans-serif"> </font
></span></p>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" va
lign="top">      <td><a href="/img/revistas/bjmbr/v44n4/html/798i01.htm"><img sr
c="/img/revistas/bjmbr/v44n4/798i01peq.jpg" border="2"></a></td>      <td>    ^c
Y#798.htm##
00913000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704068700072002000800759#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#57#53#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. 
Effect of nandrolone on systolic blood pressure of sedentary (Sed) and trained (
Train) rats. Physical training = 60-min swimming session 5 days per week for 8 w
eeks, with a 5% body weight load attached to the chest of rats treated or not wi
th nandrolone decanoate (Nand, Deca Durabolin<sup>&reg;</sup>, 5 mg/kg body weig
ht twice per week for 8 weeks, <i>im</i>). Data are reported as means &plusmn; S
EM for 7-10 animals per group. *P &lt; 0.05 relative to Sed; <sup>+</sup>P &lt; 
0.05 relative to Train (ANOVA and Tukey test).</font></span></p>      </td>    <
/tr>  </table>      ^cY#798.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033700072002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#58#54#article#169#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (83 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/798i02.htm"><img src="/img/
revistas/bjmbr/v44n4/798i02peq.jpg" border="2"></a></td>      <td>    ^cY#798.ht
m##
01194000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704096800072002000801040#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#59#55#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig2"></a>Figure 2. 
Concentration-effect curves for noradrenaline obtained with two rings, one with 
(solid lines) and the other without (dotted lines) endothelium, of the same thor
acic aorta from 16-week-old sedentary (Sed, A and B) and trained rats (Train, C 
and D). Physical training = 60-min swimming session 5 days per week for 8 weeks,
 with a 5% body weight load attached to the chest of rats submitted or not to ac
ute stress (St, immobilization for 2 h) and treated or not with nandrolone decan
oate (Nand, Deca Durabolin<sup>&reg;</sup>, 5 mg/kg body weight twice per week f
or 8 weeks, <i>im</i>). Data are reported as means &plusmn; SEM for 7-10 animals
 per group. *P &lt; 0.05 relative to Sed/St;<sup> #</sup>P &lt; 0.05 relative to
 Sed/Nand/St; <sup>+</sup>P &lt; 0.05 relative to Train/Nand/St (ANOVA and Tukey
 test).</font></span></p>      </td>    </tr>  </table>      ^cY#798.htm##
00560000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033400072002000800406#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#60#56#article#169#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (140 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/798t01.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#798.htm##
00484000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704025800072002000800330#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#61#57#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Tab1"></a>Table 1. E
ffects of physical training, acute stress and nandrolone administration on tissu
e weight of rats.</font></span></p>      </td>    </tr>  </table>      ^cY#798.h
tm##
00560000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033400072002000800406#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#62#58#article#169#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (152 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/798t02.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#798.htm##
00618000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704039200072002000800464#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#63#59#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Tab2"></a>Table 2. M
aximum responses to noradrenaline obtained with two aorta rings, one with and th
e other without endothelium, of the same thoracic aorta from sedentary and train
ed rats, submitted or not to stress and treated or not with nandrolone.</font></
span></p>      </td>    </tr>  </table>      ^cY#798.htm##
00941000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704071500072002000800787#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#64#60#article#169#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (282 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/798t03.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td><span lang="EN"><
span lang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Tab3"></a>Tabl
e 3. EC<sub>50</sub> values for noradrenaline obtained with two rings, one with 
and the other without endothelium, of the same thoracic aorta from sedentary and
 trained rats, submitted or not to stress and treated or not with nandrolone.</f
ont></span></span></td>    </tr>  </table>      ^cY#798.htm##
00344000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011800072002000800190#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#65#61#article#169#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (284 K JPG file)]</font
></P>      ^cY#798.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#66#62#article#169#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#798.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#67#63#article#169#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#798.htm##
00378000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704015200072002000800224#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#68#64#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Effectiveness of the exper
imental protocols</font></span></b></p>      ^cY#798.htm##
00638000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704041200072002000800484#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#69#65#article#169#<p ALIGN="LEFT"> <span 
lang="EN"><font face="Arial, Helvetica, sans-serif">In the present study, exerci
se training produced a negative effect on body weight gain, confirming findings 
in the literature showing that</font> <font face="Arial, Helvetica, sans-serif">
physical exercise counteracts overweight since it reduces the energetic balance 
by increasing energy expenditure (12,22).</font></span></p>      ^cY#798.htm##
00705000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704047900072002000800551#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#70#66#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">The literature also shows tha
t anabolic steroids induce testicular atrophy (23) and increase the weights of t
he prostate and seminal vesicles (24,25). Supporting these findings, in the pres
ent study nandrolone treatment induced gains in seminal vesicle and prostate wei
ght as well as a decrease in testicular weight, confirming the effectiveness of 
the treatment protocol used.</font></span></p>      ^cY#798.htm##
00952000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704072600072002000800798#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#71#67#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Various investigators have us
ed the fresh weight of the adrenal gland, an organ that responds to stress, as i
ndicative of stressogenic conditions. The weight of the adrenal gland may be red
uced or may remain unchanged after exposure to acute stress, but is often increa
sed by chronic stress (26-28). In the present study, the mean fresh weight of th
e adrenal glands was significantly reduced, showing that acute stress was effect
ive in the experimental protocols proposed. In contrast, physical exercise did n
ot alter the adrenal weight, suggesting that the training protocol used did not 
represent a stressogenic condition.</font></span></p>      ^cY#798.htm##
01084000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704085800072002000800930#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#72#68#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">Independently of nandrolone t
reatment, the training protocol produced left ventricular hypertrophy. It is kno
wn that physical exercise is a stimulus for the development of left ventricular 
hypertrophy, which occurs to maintain not only the relative constancy of ventric
ular wall stress but also the adequacy of the stroke volume, so that the resulti
ng structural changes depend on the nature, duration and intensity of exercise (
29). Hypertrophy may represent a physiological and beneficial cardiac adaptation
, usually associated with enhanced heart function (21)</font><font COLOR="#00008
0" face="Arial, Helvetica, sans-serif">.</font><font face="Arial, Helvetica, san
s-serif"> Thus, the data show the effectiveness of the physical exercise protoco
l used.</font></span></p>      ^cY#798.htm##
00413000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018700072002000800259#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#73#69#article#169#<p ALIGN="LEFT"><b><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Impact of different risk f
actors in combination on the cardiovascular response</font></span></b></p>      
^cY#798.htm##
00804000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704057800072002000800650#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#74#70#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">The effects of physical exerc
ise on the blood pressure of normotensive animals and humans have been reported 
to be minimal (20,30). In agreement with these data, the training protocol emplo
yed here did not change the blood pressure of trained rats in a significant mann
er compared to the sedentary group. However, a significant increase in systolic 
blood pressure was observed in both sedentary and trained rats treated with nand
rolone, confirming literature findings (31,32).</font></span></p>      ^cY#798.h
tm##
01488000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704126200072002000801334#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#75#71#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">In the present study, physica
l exercise also produced an adaptive vascular response characterized by aortic h
yporeactivity to noradrenaline, which is dependent on the integrity of endotheli
al cells. This view is supported by the observation that removal of the endothel
ium abolished the decreased response of the aorta to noradrenaline that had been
 induced by the training protocol. A similar hyperactivity of endothelial cells 
was previously reported in conditions that, like physical exercise (33,34), invo
lve prolonged activation of adrenoceptors such as stress, barodenervation, and p
heochromocytoma (15,19,35). In fact, the acute exposure to stress reduced the ao
rtic reactivity to noradrenaline of sedentary rats that was abolished by endothe
lium removal. These findings support published reports showing a decreased react
ivity to vasopressor agents dependent on the integrity of endothelial cells unde
r stress conditions, and confirm earlier findings from our laboratory (15,19,36)
. Although stress and physical exercise alone induced aortic hyporeactivity to n
oradrenaline, the association of the two conditions did not result in a synergis
tic effect.</font></span></p>      ^cY#798.htm##
01899000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704167300072002000801745#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#76#72#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">The literature has shown up-r
egulation in the expression of endothelial nitric oxide synthase (NOS) mRNA in t
he thoracic aortas of rats submitted to 4 to 10 weeks of training (37). These re
sults are consistent with other studies that have reported elevated NOS mRNA lev
els in aortas of exercise-trained dogs, and in coronary resistance vessels of ex
ercise-trained pigs (38,39)</font><font COLOR="#000080" face="Arial, Helvetica, 
sans-serif">.</font><font face="Arial, Helvetica, sans-serif"> The expression of
 inducible NOS and endothelial NOS mRNA was increased in endothelial cells by ch
ronic treadmill training, whereas chronic exercise blunted phenylephrine-induced
 vascular responses, probably by increasing nitric oxide release via inducible N
OS in the rat thoracic aorta (40)</font><font COLOR="#000080" face="Arial, Helve
tica, sans-serif">.</font><font face="Arial, Helvetica, sans-serif"> In this con
text, the training protocol used here may also cause a greater release of nitric
 oxide, which might reduce or antagonize the vasoconstrictor effect of noradrena
line. This could partially explain the hyporeactivity to noradrenaline observed 
in the thoracic aorta isolated from trained rats compared to the sedentary group
. Similarly to exercise, previous data from our laboratory have shown that hyper
activity of the endothelial nitric oxide pathway is responsible for the vascular
 adaptive response to acute stress (15,16,19). However, the mechanisms involved 
in the vascular adaptive responses to physical training and stress have not been
 completely clarified.</font></span></p>      ^cY#798.htm##
01667000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704144100072002000801513#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#77#73#article#169#<p ALIGN="LEFT"> <span 
lang="EN"><font face="Arial, Helvetica, sans-serif">With regard to AAS, treatmen
t with nandrolone did not change the aortic reactivity to noradrenaline of seden
tary rats. Nevertheless, this treatment prevented the vascular adaptive response
 induced by physical exercise. In contrast, nandrolone treatment did not change 
the stress-induced vascular adaptive response in</font> <font face="Arial, Helve
tica, sans-serif">either sedentary or trained rats. In other words, the vascular
 adaptive response to exercise, but not to stress, was shown to be vulnerable to
 the deleterious effects of this anabolic steroid. These data suggest different 
mechanisms for the increased endothelial modulation of vascular responses in phy
sical training and stress. Considering that, in addition to nitric oxide, a majo
r endothelium-relaxing factor, endothelial cells may also produce vasorelaxing f
actors such as prostacyclin and hyperpolarizing factor, one could hypothesize</f
ont> <font face="Arial, Helvetica, sans-serif">that the vascular adaptive respon
ses to stress and physical exercise involve distinct vasorelaxing factors. Howev
er, we cannot exclude the possibility that the vascular adaptive responses to st
ress and physical exercise involve the same vasorelaxing factor, probably the ni
tric oxide that would be produced by an alternative pathway not sensitive to nan
drolone in a stress condition.</font></span></p>      ^cY#798.htm##
01209000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704098300072002000801055#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#78#74#article#169#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif">The present study provides ev
idence that AAS-nandrolone prevents the development of vascular adaptations prom
oted by exercise training without affecting the development of vascular adaptati
ons promoted by stress. If increasing endothelial function is considered to be a
 beneficial adaptation to both physical exercise and stress, it is concluded tha
t nandrolone administration worsens rat endothelial function during exercise tra
ining. In contrast, nandrolone does not represent a risk factor for the vascular
 adaptive response to stress. The understanding that some adverse conditions in 
association may represent additional risk factors for a biological system, while
 others do not, allows us to evaluate which factors in combination would represe
nt the greatest risk for the biological systems and as a consequence could help 
medical advices to patients.</font></span></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#
798.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#79#75#article#169#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#798.htm##
00469000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704022900074002000800303#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#80#76#article#169#1#<p ALIGN=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">1. Wolfe LA, Cu
nningham DA. Effects of chronic exercise on cardiac output and its determinants.
 <i>Can J Physiol Pharmacol</i> 1982; 60: 1089-1097.    ^cY#798.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#81#77#article#169#</font></span></p>     
 ^cY#798.htm##
00514000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027400074002000800348#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#82#78#article#169#2#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">2. De Moraes R,
 Gioseffi G, Nobrega AC, Tibirica E. Effects of exercise training on the vascula
r reactivity of the whole kidney circulation in rabbits. <i>J Appl Physiol</i> 2
004; 97: 683-688.    ^cY#798.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#83#79#article#169#</font></span></p>     
 ^cY#798.htm##
00466000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704022600074002000800300#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#84#80#article#169#3#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">3. Lenasi H, St
rucl M. Effect of regular physical training on cutaneous microvascular reactivit
y. <i>Med Sci Sports Exerc</i> 2004; 36: 606-612.    ^cY#798.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#85#81#article#169#</font></span></p>     
 ^cY#798.htm##
00541000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704030100074002000800375#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#86#82#article#169#4#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">4. Schrage WG, 
Dietz NM, Joyner MJ. Effects of combined inhibition of ATP-sensitive potassium c
hannels, nitric oxide, and prostaglandins on hyperemia during moderate exercise.
 <i>J Appl Physiol</i> 2006; 100: 1506-1512.    ^cY#798.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#87#83#article#169#</font></span></p>     
 ^cY#798.htm##
00520000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704028000074002000800354#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#88#84#article#169#5#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">5. Brum PC, Da 
Silva GJ, Moreira ED, Ida F, Negrao CE, Krieger EM. Exercise training increases 
baroreceptor gain sensitivity in normal and hypertensive rats. <i>Hypertension</
i> 2000; 36: 1018-1022.    ^cY#798.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#89#85#article#169#</font></span></p>     
 ^cY#798.htm##
00592000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704035200074002000800426#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#90#86#article#169#6#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">6. Collier SR, 
Kanaley JA, Carhart R Jr, Frechette V, Tobin MM, Hall AK, et al. Effect of 4 wee
ks of aerobic or resistance exercise training on arterial stiffness, blood flow 
and blood pressure in pre- and stage-1 hypertensives. <i>J Hum Hypertens</i> 200
8; 22: 678-686.    ^cY#798.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#91#87#article#169#</font></span></p>     
 ^cY#798.htm##
00503000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704026300074002000800337#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#92#88#article#169#7#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">7. Fineschi V, 
Baroldi G, Monciotti F, Paglicci RL, Turillazzi E. Anabolic steroid abuse and ca
rdiac sudden death: a pathologic study. <i>Arch Pathol Lab Med</i> 2001; 125: 25
3-255.    ^cY#798.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#93#89#article#169#</font></span></p>     
 ^cY#798.htm##
00539000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704029900074002000800373#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#94#90#article#169#8#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">8. du Toit EF, 
Rossouw E, van Rooyen J, Lochner A. Proposed mechanisms for the anabolic steroid
-induced increase in myocardial susceptibility to ischaemia/reperfusion injury. 
<i>Cardiovasc J S Afr</i> 2005; 16: 21-28.    ^cY#798.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#95#91#article#169#</font></span></p>     
 ^cY#798.htm##
00511000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027100074002000800345#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#96#92#article#169#9#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">9. Ferrer M, En
cabo A, Marin J, Balfagon G. Treatment with the anabolic steroid, nandrolone, re
duces vasoconstrictor responses in rabbit arteries. <i>Eur J Pharmacol</i> 1994;
 258: 103-110.    ^cY#798.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#97#93#article#169#</font></span></p>     
 ^cY#798.htm##
00566000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704032500075002000800400#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#98#94#article#169#10#<p align
="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">10. Ebenbichle
r CF, Sturm W, Ganzer H, Bodner J, Mangweth B, Ritsch A, et al. Flow-mediated, e
ndothelium-dependent vasodilatation is impaired in male body builders taking ana
bolic-androgenic steroids. <i>Atherosclerosis</i> 2001; 158: 483-490.    ^cY#798
.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#99#95#article#169#</font></span></p>     
 ^cY#798.htm##
00525000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704028300076002000800359#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#100#96#article#169#11#<p alig
n="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">11. Sader MA,
 Griffiths KA, McCredie RJ, Handelsman DJ, Celermajer DS. Androgenic anabolic st
eroids and arterial structure and function in male bodybuilders. <i>J Am Coll Ca
rdiol</i> 2001; 37: 224-230.    ^cY#798.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#101#97#article#169#</font></span></p>    
  ^cY#798.htm##
00532000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704029000076002000800366#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#102#98#article#169#12#<p alig
n="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">12. Cunha ST,
 Moura SCJM, Bernardes FC, Tanno PA, Marcondes KF. Vascular sensitivity to pheni
lephrine in rats submitted to anaerobic training and nandrolone treatment. <i>Hy
pertension</i> 2005; 46: 1010-1015.    ^cY#798.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#103#99#article#169#</font></span></p>    
  ^cY#798.htm##
00518000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027500077002000800352#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#104#100#article#169#13#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">13. Lane HA,
 Grace F, Smith JC, Morris K, Cockcroft J, Scanlon MF, et al. Impaired vasoreact
ivity in bodybuilders using androgenic anabolic steroids. <i>Eur J Clin Invest</
i> 2006; 36: 483-488.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#105#101#article#169#</font></span></p>   
   ^cY#798.htm##
00531000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704030300074002000800377#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#106#102#article#169#<p align="LEFT"><span
 lang="EN"><font face="Arial, Helvetica, sans-serif">14. D&rsquo;Ascenzo S, Mill
imaggi D, Di Massimo C, Saccani-Jotti G, Botre F, Carta G, et al. Detrimental ef
fects of anabolic steroids on human endothelial cells. <i>Toxicol Lett</i> 2007;
 169: 129-136.</font></span></p>      ^cY#798.htm##
00553000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704031000077002000800387#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#107#103#article#169#15#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">15. Cordelli
ni S, Vassilieff VS. Decreased endothelium-dependent vasoconstriction to noradre
naline in acute-stressed rats is potentiated by previous chronic stress: nitric 
oxide involvement. <i>Gen Pharmacol</i> 1998; 30: 79-83.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#108#104#article#169#</font></span></p>   
   ^cY#798.htm##
00486000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024300077002000800320#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#109#105#article#169#16#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">16. Cordelli
ni S. Endothelial dysfunction in DOCA-salt hypertension: possible involvement of
 prostaglandin endoperoxides. <i>Gen Pharmacol</i> 1999; 32: 315-320.    ^cY#798
.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#110#106#article#169#</font></span></p>   
   ^cY#798.htm##
00568000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704032500077002000800402#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#111#107#article#169#17#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">17. Cordelli
ni S, Novo R, Lanza JU. Exposure to stress differential vascular adaptive respon
se in spontaneously hypertensive and Wistar rats: Role of nitric oxide, and preh
ypertensive and hypertensive states. <i>Life Sci</i> 2006; 79: 646-653.    ^cY#7
98.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#112#108#article#169#</font></span></p>   
   ^cY#798.htm##
00438000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704019500077002000800272#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#113#109#article#169#18#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">18. Carrasco
 GA, Van de Kar LD. Neuroendocrine pharmacology of stress. <i>Eur J Pharmacol</i
> 2003; 463: 235-272.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#114#110#article#169#</font></span></p>   
   ^cY#798.htm##
00587000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704034400077002000800421#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#115#111#article#169#19#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">19. Navarro-
Oliveira CM, Vassilieff VS, Cordellini S. The sympathetic adrenomedullary system
, but not the hypothalamic-pituitary-adrenal axis, participates in aorta adaptiv
e response to stress: nitric oxide involvement. <i>J Auton Neurosci</i> 2000; 83
: 140-147.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#116#112#article#169#</font></span></p>   
   ^cY#798.htm##
00538000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029500077002000800372#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#117#113#article#169#20#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">20. Medeiros
 A, Oliveira EM, Gianolla R, Casarini DE, Negrao CE, Brum PC. Swimming training 
increases cardiac vagal activity and induces cardiac hypertrophy in rats. <i>Bra
z J Med Biol Res</i> 2004; 37: 1909-1917.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#118#114#article#169#</font></span></p>   
   ^cY#798.htm##
00463000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704022000077002000800297#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#119#115#article#169#21#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">21. Pope HG 
Jr, Katz DL. Affective and psychotic symptoms associated with anabolic steroid u
se. <i>Am J Psychiatry</i> 1988; 145: 487-490.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#120#116#article#169#</font></span></p>   
   ^cY#798.htm##
00481000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023800077002000800315#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#121#117#article#169#22#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">22. Ebal E, 
Cavalie H, Michaux O, Lac G. Effect of a moderate exercise on the regulatory hor
mones of food intake in rats. <i>Appetite</i> 2007; 49: 521-524.    ^cY#798.htm#
#
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#122#118#article#169#</font></span></p>   
   ^cY#798.htm##
00509000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026600077002000800343#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#123#119#article#169#23#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">23. Noorafsh
an A, Karbalay-Doust S, Ardekani FM. High doses of nandrolone decanoate reduce v
olume of testis and length of seminiferous tubules in rats. <i>APMIS</i> 2005; 1
13: 122-125.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#124#120#article#169#</font></span></p>   
   ^cY#798.htm##
00503000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026000077002000800337#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#125#121#article#169#24#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">24. Tseng YT
, Rockhold RW, Hoskins B, Ho IK. Cardiovascular toxicities of nandrolone and coc
aine in spontaneously hypertensive rats. <i>Fundam Appl Toxicol</i> 1994; 22: 11
3-121.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#126#122#article#169#</font></span></p>   
   ^cY#798.htm##
00486000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024300077002000800320#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#127#123#article#169#25#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">25. Qi Z, Si
ngh J, Handelsman DJ. [Effects of 19-nortestosterone on sex accessory gland grow
th in hypogonadal mice]. <i>Zhonghua Nan Ke Xue</i> 2002; 8: 241-243.    ^cY#798
.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#128#124#article#169#</font></span></p>   
   ^cY#798.htm##
00553000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704031000077002000800387#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#129#125#article#169#26#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">26. van Dijk
en HH, de Goeij DC, Sutanto W, Mos J, de Kloet ER, Tilders FJ. Short inescapable
 stress produces long-lasting changes in the brain-pituitary-adrenal axis of adu
lt male rats. <i>Neuroendocrinology</i> 1993; 58: 57-64.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#130#126#article#169#</font></span></p>   
   ^cY#798.htm##
00525000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028200077002000800359#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#131#127#article#169#27#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">27. Pertsova
 SS, Koplik EV, Krause W, Michael N, Oehme P, Sudakov KV. Catecholamines in the 
adrenals of August and Wistar rats with acute emotional stress. <i>Bull Exp Biol
 Med</i> 1997; 123: 562-564.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#132#128#article#169#</font></span></p>   
   ^cY#798.htm##
00554000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704031100077002000800388#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#133#129#article#169#28#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">28. Ricart-J
ane D, Rodriguez-Sureda V, Benavides A, Peinado-Onsurbe J, Lopez-Tejero MD, Llob
era M. Immobilization stress alters intermediate metabolism and circulating lipo
proteins in the rat. <i>Metabolism</i> 2002; 51: 925-931.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#134#130#article#169#</font></span></p>   
   ^cY#798.htm##
00505000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026200077002000800339#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#135#131#article#169#29#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">29. Ghorayeb
e N, Batloni M, Pinto IMF, Dioguardi G. Left ventricular hypertrophy of athletes
. Adaptive physiologic response of the heart. <i>Arq Bras Cardiol</i> 2005; 85: 
191-197.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#136#132#article#169#</font></span></p>   
   ^cY#798.htm##
00503000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026000077002000800337#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#137#133#article#169#30#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">30. Krieger 
EM, Brum PC, Negrao CE. Role of arterial baroreceptor function on cardiovascular
 adjustments to acute and chronic dynamic exercise. <i>Biol Res</i> 1998; 31: 27
3-279.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#138#134#article#169#</font></span></p>   
   ^cY#798.htm##
00522000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027900077002000800356#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#139#135#article#169#31#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">31. Grace F,
 Sculthorpe N, Baker J, Davies B. Blood pressure and rate pressure product respo
nse in males using high-dose anabolic androgenic steroids (AAS). <i>J Sci Med Sp
ort</i> 2003; 6: 307-312.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#140#136#article#169#</font></span></p>   
   ^cY#798.htm##
00519000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027600077002000800353#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#141#137#article#169#32#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">32. Beutel A
, Bergamaschi CT, Campos RR. Effects of chronic anabolic steroid treatment on to
nic and reflex cardiovascular control in male rats. <i>J Steroid Biochem Mol Bio
l</i> 2005; 93: 43-48.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#142#138#article#169#</font></span></p>   
   ^cY#798.htm##
00510000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026700077002000800344#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#143#139#article#169#33#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">33. Scheurin
k AJ, Steffens AB, Bouritius H, Dreteler GH, Bruntink R, Remie R, et al. Adrenal
 and sympathetic catecholamines in exercising rats. <i>Am J Physiol</i> 1989; 25
6: R155-R160.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#144#140#article#169#</font></span></p>   
   ^cY#798.htm##
00476000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023300077002000800310#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#145#141#article#169#34#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">34. Scheurin
k AJ, Steffens AB, Roossien B, Balkan B. Sympathoadrenal function in genetically
 obese Zucker rats. <i>Physiol Behav</i> 1992; 52: 679-685.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#146#142#article#169#</font></span></p>   
   ^cY#798.htm##
00515000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027200077002000800349#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#147#143#article#169#35#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">35. Hiremath
 AN, Hu ZW, Hoffman BB. Desensitization of alpha-adrenergic receptor-mediated sm
ooth muscle contraction: role of the endothelium. <i>J Cardiovasc Pharmacol</i> 
1991; 18: 151-157.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#148#144#article#169#</font></span></p>   
   ^cY#798.htm##
00463000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704022000077002000800297#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#149#145#article#169#36#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">36. Jansakul
 C. Effect of swimming on vascular reactivity to phenylephrine and KCl in male r
ats. <i>Br J Pharmacol</i> 1995; 115: 587-594.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#150#146#article#169#</font></span></p>   
   ^cY#798.htm##
00479000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023600077002000800313#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#151#147#article#169#37#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">37. Delp MD,
 Laughlin MH. Time course of enhanced endothelium-mediated dilation in aorta of 
trained rats. <i>Med Sci Sports Exerc</i> 1997; 29: 1454-1461.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#152#148#article#169#</font></span></p>   
   ^cY#798.htm##
00552000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030900077002000800386#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#153#149#article#169#38#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">38. Sessa WC
, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases c
oronary vascular nitric oxide production and endothelial cell nitric oxide synth
ase gene expression. <i>Circ Res</i> 1994; 74: 349-353.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#154#150#article#169#</font></span></p>   
   ^cY#798.htm##
00527000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704028400077002000800361#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#155#151#article#169#39#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">39. Woodman 
CR, Muller JM, Laughlin MH, Price EM. Induction of nitric oxide synthase mRNA in
 coronary resistance arteries isolated from exercise-trained pigs. <i>Am J Physi
ol</i> 1997; 273: H2575-H2579.    ^cY#798.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#156#152#article#169#</font></span></p>   
   ^cY#798.htm##
00542000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029900077002000800376#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#p#157#153#article#169#40#<p ali
gn="LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">40. Yang AL,
 Tsai SJ, Jiang MJ, Jen CJ, Chen HI. Chronic exercise increases both inducible a
nd endothelial nitric oxide synthase gene expression in endothelial cells of rat
 aorta. <i>J Biomed Sci</i> 2002; 9: 149-155.    ^cY#798.htm##
00280000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704005200074002000800126#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#158#154#article#169#</font></span></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#798.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033500074002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#159#155#article#169#<P><font face="Arial,
 Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE
=4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#798.ht
m##
00397000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016900074002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#160#156#article#169#<p ALIGN="LEFT"><span
 lang="EN"><font face="Arial, Helvetica, sans-serif">Research supported by FAPES
P (#06/57200-8).</font></span></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#798.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033600074002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#161#157#article#169#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#798.h
tm##
00725000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704049700074002000800571#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#162#158#article#169#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/r
ecor.gif" border="0"></a> Address for correspondence:</b></font><span lang="EN">
<font face="Arial, Helvetica, sans-serif"> S. Cordellini, Departamento de Farmac
ologia, Instituto de Bioci&ecirc;ncias, UNESP, Rubi&atilde;o J&uacute;nior, s/n,
 18618-970 Botucatu, SP, Brasil. Fax: +55-14-3815-3744. E-mail: <a href="mailto:
cordelli@ibb.unesp.br">cordelli@ibb.unesp.br</a></font></span></p>      ^cY#798.
htm##
00475000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704024700074002000800321#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#163#159#article#169#<p ALIGN="LEFT"><i><s
pan lang="EN"><font face="Arial, Helvetica, sans-serif">Received September 29, 2
010. Accepted February 18, 2011. Available online April 1, 2011. Published April
 11, 2011.</font></span></i></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#798.htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#164#160#article#169#<div align="center"> 
       ^cY#798.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#165#161#article#169#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#798.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#166#162#article#169#<br>                ^
cY#798.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#167#163#article#169#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#798
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#168#164#article#169#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#798.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#169#165#article#169#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#798.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#170#166#article#169#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#798.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#171#167#article#169#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#798.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#172#168#article#169#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#798.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\798.htm#S#p#173#169#article#169#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#798.htm##
00561000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100021000890120
07100110030002400181065000900205064000500214031000300219014001000222865000900232
002000800241035001000249801002400259#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
98.htm#S#c#174#1#article#40#1#^rND^sWolfe^nLA#^rND^sCunningham^nDA#Effects of ch
ronic exercise on cardiac output and its determinants^len#Can J Physiol Pharmaco
l#19820000#1982#60#1089-1097#20110400#798.htm#0008-4212#Can J Physiol Pharmacol#
#
00633000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100018000920100
01800110010001800128012010300146030001500249065000900264064000500273031000300278
014000800281865000900289002000800298035001000306801001500316#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\798.htm#S#c#175#2#article#40#2#^rND^sDe^nMoraes R#^rND^sG
ioseffi^nG#^rND^sNobrega^nAC#^rND^sTibirica^nE#Effects of exercise training on t
he vascular reactivity of the whole kidney circulation in rabbits^len#J Appl Phy
siol#20040000#2004#97#683-688#20110400#798.htm#0021-8987#J Appl Physiol##
00555000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100016000890120
07800105030002100183065000900204064000500213031000300218014000800221865000900229
002000800238035001000246801002100256#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
98.htm#S#c#176#3#article#40#3#^rND^sLenasi^nH#^rND^sStrucl^nM#Effect of regular 
physical training on cutaneous microvascular reactivity^len#Med Sci Sports Exerc
#20040000#2004#36#606-612#20110400#798.htm#0195-9131#Med Sci Sports Exerc##
00642000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100016000910100
01700107012014300124030001500267065000900282064000500291031000400296014001000300
865000900310002000800319035001000327801001500337#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\798.htm#S#c#177#4#article#40#4#^rND^sSchrage^nWG#^rND^sDietz^nNM#^rND
^sJoyner^nMJ#Effects of combined inhibition of ATP-sensitive potassium channels,
 nitric oxide, and prostaglandins on hyperemia during moderate exercise^len#J Ap
pl Physiol#20060000#2006#100#1506-1512#20110400#798.htm#0021-8987#J Appl Physiol
##
00673000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100019000880100
01800107010001300125010001700138010001800155012009400173030001300267065000900280
06400050028903100030029401400100029786500090030700200080031603500100032480100130
0334#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#178#5#article#40#5#^r
ND^sBrum^nPC#^rND^sDa^nSilva GJ#^rND^sMoreira^nED#^rND^sIda^nF#^rND^sNegrao^nCE#
^rND^sKrieger^nEM#Exercise training increases baroreceptor gain sensitivity in n
ormal and hypertensive rats^len#Hypertension#20000000#2000#36#1018-1022#20110400
#798.htm#0194-911X#Hypertension##
00759000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100018000910100
02000109010001900129010001600148010001500164810000600179012015200185030001600337
06500090035306400050036203100030036701400080037086500090037800200080038703500100
0395801001600405#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#179#6#art
icle#40#6#^rND^sCollier^nSR#^rND^sKanaley^nJA#^rND^sCarhart^nR Jr#^rND^sFrechett
e^nV#^rND^sTobin^nMM#^rND^sHall^nAK#et al#Effect of 4 weeks of aerobic or resist
ance exercise training on arterial stiffness, blood flow and blood pressure in p
re- and stage-1 hypertensives^len#J Hum Hypertens#20080000#2008#22#678-686#20110
400#798.htm#0950-9240#J Hum Hypertens##
00645000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100017000910100
01900108010001900127010002000146012007200166030002000238065000900258064000500267
031000400272014000800276865000900284002000800293035001000301801002000311#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#180#7#article#40#7#^rND^sFineschi
^nV#^rND^sBaroldi^nG#^rND^sMonciotti^nF#^rND^sPaglicci^nRL#^rND^sTurillazzi^nE#A
nabolic steroid abuse and cardiac sudden death: a pathologic study^len#Arch Path
ol Lab Med#20010000#2001#125#253-255#20110400#798.htm#0003-9985#Arch Pathol Lab 
Med##
00623000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100017000910100
02000108010001700128012012700145030001900272710000200291065000900293064000500302
031000300307014000600310865000900316002000800325#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\798.htm#S#c#181#8#article#40#8#^rND^sdu^nToit EF#^rND^sRossouw^nE#^rN
D^svan^nRooyen J#^rND^sLochner^nA#Proposed mechanisms for the anabolic steroid-i
nduced increase in myocardial susceptibility to ischaemia/reperfusion injury^len
#Cardiovasc J S Afr#2#20050000#2005#16#21-28#20110400#798.htm##
00631000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100016000890100
01500105010001800120012010600138030001600244065000900260064000500269031000400274
014000800278865000900286002000800295035001000303801001600313#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\798.htm#S#c#182#9#article#40#9#^rND^sFerrer^nM#^rND^sEnca
bo^nA#^rND^sMarin^nJ#^rND^sBalfagon^nG#Treatment with the anabolic steroid, nand
rolone, reduces vasoconstrictor responses in rabbit arteries^len#Eur J Pharmacol
#19940000#1994#258#103-110#20110400#798.htm#0014-2999#Eur J Pharmacol##
00733000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100022000750100015000970100
01600112010001600128010001800144010001600162810000600178012012600184030001600310
06500090032606400050033503100040034001400080034486500090035200200080036103500100
0369801001600379#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#183#10#ar
ticle#40#10#^rND^sEbenbichler^nCF#^rND^sSturm^nW#^rND^sGanzer^nH#^rND^sBodner^nJ
#^rND^sMangweth^nB#^rND^sRitsch^nA#et al#Flow-mediated, endothelium-dependent va
sodilatation is impaired in male body builders taking anabolic-androgenic steroi
ds^len#Atherosclerosis#20010000#2001#158#483-490#20110400#798.htm#0021-9150#Athe
rosclerosis##
00664000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100020000910100
01900111010002100130010002100151012009000172030001800262065000900280064000500289
031000300294014000800297865000900305002000800314035001000322801001800332#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#184#11#article#40#11#^rND^sSader^
nMA#^rND^sGriffiths^nKA#^rND^sMcCredie^nRJ#^rND^sHandelsman^nDJ#^rND^sCelermajer
^nDS#Androgenic anabolic steroids and arterial structure and function in male bo
dybuilders^len#J Am Coll Cardiol#20010000#2001#37#224-230#20110400#798.htm#0735-
1097#J Am Coll Cardiol##
00666000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100018000910100
02000109010001600129010002000145012010700165030001300272065000900285064000500294
031000300299014001000302865000900312002000800321035001000329801001300339#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#185#12#article#40#12#^rND^sCunha^
nST#^rND^sMoura^nSCJM#^rND^sBernardes^nFC#^rND^sTanno^nPA#^rND^sMarcondes^nKF#Va
scular sensitivity to phenilephrine in rats submitted to anaerobic training and 
nandrolone treatment^len#Hypertension#20050000#2005#46#1010-1015#20110400#798.ht
m#0194-911X#Hypertension##
00685000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100015000900100
01600105010001600121010001900137010001800156810000600174012007900180030001800259
06500090027706400050028603100030029101400080029486500090030200200080031103500100
0319801001800329#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#186#13#ar
ticle#40#13#^rND^sLane^nHA#^rND^sGrace^nF#^rND^sSmith^nJC#^rND^sMorris^nK#^rND^s
Cockcroft^nJ#^rND^sScanlon^nMF#et al#Impaired vasoreactivity in bodybuilders usi
ng androgenic anabolic steroids^len#Eur J Clin Invest#20060000#2006#36#483-488#2
0110400#798.htm#0014-2972#Eur J Clin Invest##
00688000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100025000750100020001000100
02000120010002300140010001500163010001500178810000600193012007200199030001300271
06500090028406400050029303100040029801400080030286500090031000200080031903500100
0327801001300337#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#187#14#ar
ticle#40#14#^rND^sD&#8217;Ascenzo^nS#^rND^sMillimaggi^nD#^rND^sDi^nMassimo C#^rN
D^sSaccani-Jotti^nG#^rND^sBotre^nF#^rND^sCarta^nG#et al#Detrimental effects of a
nabolic steroids on human endothelial cells^len#Toxicol Lett#20070000#2007#169#1
29-136#20110400#798.htm#0378-4274#Toxicol Lett##
00633000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100021000950120
16100116030001400277065000900291064000500300031000300305014000600308865000900314
002000800323035001000331801001400341#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
98.htm#S#c#188#15#article#40#15#^rND^sCordellini^nS#^rND^sVassilieff^nVS#Decreas
ed endothelium-dependent vasoconstriction to noradrenaline in acute-stressed rat
s is potentiated by previous chronic stress: nitric oxide involvement^len#Gen Ph
armacol#19980000#1998#30#79-83#20110400#798.htm#0306-3623#Gen Pharmacol##
00548000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750120107000950300
01400202065000900216064000500225031000300230014000800233865000900241002000800250
035001000258801001400268#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#1
89#16#article#40#16#^rND^sCordellini^nS#Endothelial dysfunction in DOCA-salt hyp
ertension: possible involvement of prostaglandin endoperoxides^len#Gen Pharmacol
#19990000#1999#32#315-320#20110400#798.htm#0306-3623#Gen Pharmacol##
00661000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100014000950100
01600109012017600125030000900301065000900310064000500319031000300324014000800327
865000900335002000800344035001000352801000900362#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\798.htm#S#c#190#17#article#40#17#^rND^sCordellini^nS#^rND^sNovo^nR#^r
ND^sLanza^nJU#Exposure to stress differential vascular adaptive response in spon
taneously hypertensive and Wistar rats: Role of nitric oxide, and prehypertensiv
e and hypertensive states^len#Life Sci#20060000#2006#79#646-653#20110400#798.htm
#0024-3205#Life sci##
00520000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100021000940120
04200115030001600157065000900173064000500182031000400187014000800191865000900199
002000800208035001000216801001600226#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
98.htm#S#c#191#18#article#40#18#^rND^sCarrasco^nGA#^rND^sVan^nde Kar LD#Neuroend
ocrine pharmacology of stress^len#Eur J Pharmacol#20030000#2003#463#235-272#2011
0400#798.htm#0014-2999#Eur J Pharmacol##
00651000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100027000750100021001020100
02000123012016900143030001700312710000200329065000900331064000500340031000300345
014000800348865000900356002000800365#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
98.htm#S#c#192#19#article#40#19#^rND^sNavarro-Oliveira^nCM#^rND^sVassilieff^nVS#
^rND^sCordellini^nS#The sympathetic adrenomedullary system, but not the hypothal
amic-pituitary-adrenal axis, participates in aorta adaptive response to stress: 
nitric oxide involvement^len#J Auton Neurosci#2#20000000#2000#83#140-147#2011040
0#798.htm##
00696000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100019000930100
01800112010001900130010001700149010001500166012009500181030002000276065000900296
06400050030503100030031001400100031386500090032300200080033203500100034080100200
0350#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#193#20#article#40#20#
^rND^sMedeiros^nA#^rND^sOliveira^nEM#^rND^sGianolla^nR#^rND^sCasarini^nDE#^rND^s
Negrao^nCE#^rND^sBrum^nPC#Swimming training increases cardiac vagal activity and
 induces cardiac hypertrophy in rats^len#Braz J Med Biol Res#20040000#2004#37#19
09-1917#20110400#798.htm#0100-879X#Braz J Med Biol Res##
00545000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100015000930120
07400108030001600182065000900198064000500207031000400212014000800216865000900224
002000800233035001000241801001600251#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
98.htm#S#c#194#21#article#40#21#^rND^sPope^nHG Jr#^rND^sKatz^nDL#Affective and p
sychotic symptoms associated with anabolic steroid use^len#Am J Psychiatry#19880
000#1988#145#487-490#20110400#798.htm#0002-953X#Am J Psychiatry##
00592000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100017000890100
01700106010001300123012008400136030000900220065000900229064000500238031000300243
014000800246865000900254002000800263035001000271801000900281#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\798.htm#S#c#195#22#article#40#22#^rND^sEbal^nE#^rND^sCava
lie^nH#^rND^sMichaux^nO#^rND^sLac^nG#Effect of a moderate exercise on the regula
tory hormones of food intake in rats^len#Appetite#20070000#2007#49#521-524#20110
400#798.htm#0195-6663#Appetite##
00599000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100024000950100
01900119012010600138030000600244065000900250064000500259031000400264014000800268
865000900276002000800285035001000293801000600303#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\798.htm#S#c#196#23#article#40#23#^rND^sNoorafshan^nA#^rND^sKarbalay-D
oust^nS#^rND^sArdekani^nFM#High doses of nandrolone decanoate reduce volume of t
estis and length of seminiferous tubules in rats^len#APMIS#20050000#2005#113#122
-125#20110400#798.htm#0903-4641#APMIS##
00625000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910100
01700110010001300127012009100140030002000231065000900251064000500260031000300265
014000800268865000900276002000800285035001000293801002000303#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\798.htm#S#c#197#24#article#40#24#^rND^sTseng^nYT#^rND^sRo
ckhold^nRW#^rND^sHoskins^nB#^rND^sHo^nIK#Cardiovascular toxicities of nandrolone
 and cocaine in spontaneously hypertensive rats^len#Fundam Appl Toxicol#19940000
#1994#22#113-121#20110400#798.htm#0272-0590#Fundam Appl Toxicol##
00550000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100012000750100015000870100
02100102012008600123030002000209710000200229065000900231064000500240031000200245
014000800247865000900255002000800264#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
98.htm#S#c#198#25#article#40#25#^rND^sQi^nZ#^rND^sSingh^nJ#^rND^sHandelsman^nDJ#
[Effects of 19-nortestosterone on sex accessory gland growth in hypogonadal mice
]^len#Zhonghua Nan Ke Xue#2#20020000#2002#8#241-243#20110400#798.htm##
00710000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100019000960100
01700115010001300132010001900145010001800164012011400182030001900296065000900315
06400050032403100030032901400060033286500090033800200080034703500100035580100190
0365#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#199#26#article#40#26#
^rND^svan^nDijken HH#^rND^sde^nGoeij DC#^rND^sSutanto^nW#^rND^sMos^nJ#^rND^sde^n
Kloet ER#^rND^sTilders^nFJ#Short inescapable stress produces long-lasting change
s in the brain-pituitary-adrenal axis of adult male rats^len#Neuroendocrinology#
19930000#1993#58#57-64#20110400#798.htm#0028-3835#Neuroendocrinology##
00681000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100017000940100
01600111010001700127010001500144010001800159012008900177030001800266065000900284
06400050029303100040029801400080030286500090031000200080031903500100032780100180
0337#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#200#27#article#40#27#
^rND^sPertsova^nSS#^rND^sKoplik^nEV#^rND^sKrause^nW#^rND^sMichael^nN#^rND^sOehme
^nP#^rND^sSudakov^nKV#Catecholamines in the adrenals of August and Wistar rats w
ith acute emotional stress^len#Bull Exp Biol Med#19970000#1997#123#562-564#20110
400#798.htm#0007-4888#Bull Exp Biol Med##
00703000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100026000960100
01900122010002500141010002300166010001700189012009700206030001100303065000900314
06400050032303100030032801400080033186500090033900200080034803500100035680100110
0366#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#201#28#article#40#28#
^rND^sRicart-Jane^nD#^rND^sRodriguez-Sureda^nV#^rND^sBenavides^nA#^rND^sPeinado-
Onsurbe^nJ#^rND^sLopez-Tejero^nMD#^rND^sLlobera^nM#Immobilization stress alters 
intermediate metabolism and circulating lipoproteins in the rat^len#Metabolism#2
0020000#2002#51#925-931#20110400#798.htm#0026-0495#Metabolism##
00624000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100017000940100
01700111010001900128012008900147030001700236065000900253064000500262031000300267
014000800270865000900278002000800287035001000295801001700305#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\798.htm#S#c#202#29#article#40#29#^rND^sGhorayebe^nN#^rND^
sBatloni^nM#^rND^sPinto^nIMF#^rND^sDioguardi^nG#Left ventricular hypertrophy of 
athletes: Adaptive physiologic response of the heart^len#Arq Bras Cardiol#200500
00#2005#85#191-197#20110400#798.htm#0066-782X#Arq Bras Cardiol##
00596000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100015000930100
01700108012011100125030000900236065000900245064000500254031000300259014000800262
865000900270002000800279035001000287801000900297#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\798.htm#S#c#203#30#article#40#30#^rND^sKrieger^nEM#^rND^sBrum^nPC#^rN
D^sNegrao^nCE#Role of arterial baroreceptor function on cardiovascular adjustmen
ts to acute and chronic dynamic exercise^len#Biol Res#19980000#1998#31#273-279#2
0110400#798.htm#0716-9760#Biol Res##
00640000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100020000900100
01500110010001600125012011400141030001600255065000900271064000500280031000200285
014000800287865000900295002000800304035001000312801001600322#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\798.htm#S#c#204#31#article#40#31#^rND^sGrace^nF#^rND^sScu
lthorpe^nN#^rND^sBaker^nJ#^rND^sDavies^nB#Blood pressure and rate pressure produ
ct response in males using high-dose anabolic androgenic steroids (AAS)^len#J Sc
i Med Sport#20030000#2003#6#307-312#20110400#798.htm#1440-2440#J Sci Med Sport##
00630000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100022000910100
01700113012010600130030002700236065000900263064000500272031000300277014000600280
865000900286002000800295035001000303801002700313#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\798.htm#S#c#205#32#article#40#32#^rND^sBeutel^nA#^rND^sBergamaschi^nC
T#^rND^sCampos^nRR#Effects of chronic anabolic steroid treatment on tonic and re
flex cardiovascular control in male rats^len#J Steroid Biochem Mol Biol#20050000
#2005#93#43-48#20110400#798.htm#0960-0760#J Steroid Biochem Mol Biol##
00672000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100019000950100
01900114010001900133010001800152010001500170810000600185012006200191030001300253
06500090026606400050027503100040028001400100028486500090029400200080030303500100
0311801001300321#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#206#33#ar
ticle#40#33#^rND^sScheurink^nAJ#^rND^sSteffens^nAB#^rND^sBouritius^nH#^rND^sDret
eler^nGH#^rND^sBruntink^nR#^rND^sRemie^nR#et al#Adrenal and sympathetic catechol
amines in exercising rats^len#Am J Physiol#19890000#1989#256#R155-R160#20110400#
798.htm#0002-9513#Am J Physiol##
00592000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100019000950100
01800114010001600132012006200148030001400210065000900224064000500233031000300238
014000800241865000900249002000800258035001000266801001400276#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\798.htm#S#c#207#34#article#40#34#^rND^sScheurink^nAJ#^rND
^sSteffens^nAB#^rND^sRoossien^nB#^rND^sBalkan^nB#Sympathoadrenal function in gen
etically obese Zucker rats^len#Physiol Behav#19920000#1992#52#679-685#20110400#7
98.htm#0031-9384#Physiol Behav##
00622000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100013000940100
01800107012010900125030002300234065000900257064000500266031000300271014000800274
865000900282002000800291035001000299801002300309#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\798.htm#S#c#208#35#article#40#35#^rND^sHiremath^nAN#^rND^sHu^nZW#^rND
^sHoffman^nBB#Desensitization of alpha-adrenergic receptor-mediated smooth muscl
e contraction: role of the endothelium^len#J Cardiovasc Pharmacol#19910000#1991#
18#151-157#20110400#798.htm#0160-2446#J Cardiovasc Pharmacol##
00526000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750120084000930300
01500177065000900192064000500201031000400206014000800210865000900218002000800227
035001000235801001500245#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#2
09#36#article#40#36#^rND^sJansakul^nC#Effect of swimming on vascular reactivity 
to phenylephrine and KCl in male rats^len#Br J Pharmacol#19950000#1995#115#587-5
94#20110400#798.htm#0007-1188#Br J Pharmacol##
00566000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100019000900120
08300109030002100192065000900213064000500222031000300227014001000230865000900240
002000800249035001000257801002100267#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\7
98.htm#S#c#210#37#article#40#37#^rND^sDelp^nMD#^rND^sLaughlin^nMH#Time course of
 enhanced endothelium-mediated dilation in aorta of trained rats^len#Med Sci Spo
rts Exerc#19970000#1997#29#1454-1461#20110400#798.htm#0195-9131#Med Sci Sports E
xerc##
00681000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910100
01600110010001400126010001700140012014000157030000900297065000900306064000500315
031000300320014000800323865000900331002000800340035001000348801000900358#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#211#38#article#40#38#^rND^sSessa^
nWC#^rND^sPritchard^nK#^rND^sSeyedi^nN#^rND^sWang^nJ#^rND^sHintze^nTH#Chronic ex
ercise in dogs increases coronary vascular nitric oxide production and endotheli
al cell nitric oxide synthase gene expression^len#Circ Res#19940000#1994#74#349-
353#20110400#798.htm#0009-7330#Circ Res##
00642000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100017000930100
01900110010001600129012011200145030001300257065000900270064000500279031000400284
014001200288865000900300002000800309035001000317801001300327#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\798.htm#S#c#212#39#article#40#39#^rND^sWoodman^nCR#^rND^s
Muller^nJM#^rND^sLaughlin^nMH#^rND^sPrice^nEM#Induction of nitric oxide synthase
 mRNA in coronary resistance arteries isolated from exercise-trained pigs^len#Am
 J Physiol#19970000#1997#273#H2575-H2579#20110400#798.htm#0002-9513#Am J Physiol
##
00675000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100015000900100
01600105010001400121010001500135012013400150030001300284065000900297064000500306
031000200311014000800313865000900321002000800330035001000338801001300348#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\798.htm#S#c#213#40#article#40#40#^rND^sYang^n
AL#^rND^sTsai^nSJ#^rND^sJiang^nMJ#^rND^sJen^nCJ#^rND^sChen^nHI#Chronic exercise 
increases both inducible and endothelial nitric oxide synthase gene expression i
n endothelial cells of rat aorta^len#J Biomed Sci#20020000#2002#9#149-155#201104
00#798.htm#1021-7770#J Biomed Sci##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#o#1#1#article#1#201
10411#094643#804.htm#194##
02853000000000541000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400110014003500100015122400090016101201520
01700100023003220100025003450100024003700700111003940831585005050850008020900850
02302098085004002121085002502161085003102186117000602217072000302223112000902226
111001702235114000902252113001802261891002402279002000802303#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\804.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#06#BJMBR
380#nd#Braz J Med Biol Res#44#4#20110400#^f303^l310#0100-879X#20110304#Co-cultur
e of chondrocytes and bone marrow mesenchymal stem cells in vitro enhances the e
xpression of cartilaginous extracellular matrix components^len#^rND^1A01^sQing^n
Chang#^rND^1A01^sWei-ding^nCui#^rND^1A01^sWei-min^nFan#Nanjing Medical Universit
y^iA01^1First Affiliated Hospital^2Department of Orthopedics^cNanjing^sJiangsu^p
China#^len^aChondrocytes and bone marrow mesenchymal stem cells (BMSCs) are freq
uently used as seed cells in cartilage tissue engineering. In the present study,
 we determined if the co-culture of rabbit articular chondrocytes and BMSCs in v
itro promotes the expression of cartilaginous extracellular matrix and, if so, w
hat is the optimal ratio of the two cell types. Cultures of rabbit articular cho
ndrocytes and BMSCs were expanded in vitro and then cultured individually or at 
a chondrocyte:BMSC ratio of 4:1, 2:1, 1:1, 1:2, 1:4 for 21 days and cultured in 
DMEM/F12. BMSCs were cultured in chondrogenic induction medium. Quantitative rea
l-time RT-PCR and Western blot were used to evaluate gene expression. In the co-
cultures, type II collagen and aggrecan expression increased on days 14 and 21. 
At the mRNA level, the expression of type II collagen and aggrecan on day 21 was
 much higher in the 4:1, 2:1, and 1:1 groups than in either the articular chondr
ocyte group or the induced BMSC group, and the best ratio of co-culture groups s
eems to be 2:1. Also on day 21, the expression of type II collagen and aggrecan 
proteins in the 2:1 group was much higher than in all other groups. The results 
demonstrate that the co-culture of rabbit chondrocytes and rabbit BMSCs at defin
ed ratios can promote the expression of cartilaginous extracellular matrix. The 
optimal cell ratio appears to be 2:1 (chondrocytes:BMSCs). This approach has pot
ential applications in cartilage tissue engineering since it provides a protocol
 for maintaining and promoting seed-cell differentiation and function.#^dnd^i1#^
tm^len^kCo-culture^i1#^tm^len^kBone mesenchymal stem cells^i1#^tm^len^kChondrocy
tes^i1#^tm^len^kTissue engineering^i1#other#39#20101022#October 22, 2010#2011021
0#February 10, 2011#S0100-879X2011007500026#804.htm##
02859000000000529000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400110014003500100015122400090016101201660
01700100023003360100025003590100024003840700111004080831599005190850008021180850
02302126085004002149085002502189085003102214117000602245072000302251112000902254
111002402263114000902287113002502296002000802321#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\804.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#06#BJMBR380#nd#Braz 
J Med Biol Res#44#4#20110400#^f303^l310#0100-879X#20110304#<b>Co-culture of chon
drocytes and bone marrow mesenchymal stem cells <i>in vitro</i> enhances the exp
ression of cartilaginous extracellular matrix components</b>^len#^rND^1A01^sQing
^nChang#^rND^1A01^sWei-ding^nCui#^rND^1A01^sWei-min^nFan#Nanjing Medical Univers
ity^iA01^1First Affiliated Hospital^2Department of Orthopedics^cNanjing^sJiangsu
^pChina#^len^aChondrocytes and bone marrow mesenchymal stem cells (BMSCs) are fr
equently used as seed cells in cartilage tissue engineering. In the present stud
y, we determined if the co-culture of rabbit articular chondrocytes and BMSCs <i
>in vitro</i> promotes the expression of cartilaginous extracellular matrix and,
 if so, what is the optimal ratio of the two cell types. Cultures of rabbit arti
cular chondrocytes and BMSCs were expanded <i>in vitro</i> and then cultured ind
ividually or at a chondrocyte:BMSC ratio of 4:1, 2:1, 1:1, 1:2, 1:4 for 21 days 
and cultured in DMEM/F12. BMSCs were cultured in chondrogenic induction medium. 
Quantitative real-time RT-PCR and Western blot were used to evaluate gene expres
sion. In the co-cultures, type II collagen and aggrecan expression increased on 
days 14 and 21. At the mRNA level, the expression of type II collagen and aggrec
an on day 21 was much higher in the 4:1, 2:1, and 1:1 groups than in either the 
articular chondrocyte group or the induced BMSC group, and the best ratio of co-
culture groups seems to be 2:1. Also on day 21, the expression of type II collag
en and aggrecan proteins in the 2:1 group was much higher than in all other grou
ps. The results demonstrate that the co-culture of rabbit chondrocytes and rabbi
t BMSCs at defined ratios can promote the expression of cartilaginous extracellu
lar matrix. The optimal cell ratio appears to be 2:1 (chondrocytes:BMSCs). This 
approach has potential applications in cartilage tissue engineering since it pro
vides a protocol for maintaining and promoting seed-cell differentiation and fun
ction.#^dnd^i1#^tm^len^kCo-culture^i1#^tm^len^kBone mesenchymal stem cells^i1#^t
m^len^kChondrocytes^i1#^tm^len^kTissue engineering^i1#other#39#20101022#<i>Octob
er 22, 2010</i>#20110210#<i>February 10, 2011</i>#804.htm##
02949000000000553000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099121000300104049000900107158000300116
03000240011903100030014303200020014606500090014801400110015703500100016822400090
01780120152001870100023003390100025003620100024003870700113004110831585005240850
00802109085002302117085004002140085002502180085003102205117000602236072000302242
112000902245111001702254114000902271113001802280002000802298008008902306#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#l#4#1#article#1#^mApr.^a2011#oa#en#
bjmbr#1#3.1#ilus#06#BJMBR380#nd#Braz. j. med. biol. res#44#4#20110400#^f303^l310
#0100-879X#20110304#Co-culture of chondrocytes and bone marrow mesenchymal stem 
cells in vitro enhances the expression of cartilaginous extracellular matrix com
ponents^len#^rND^1A01^sQing^nChang#^rND^1A01^sWei-ding^nCui#^rND^1A01^sWei-min^n
Fan#^iA01^1Nanjing Medical University^2First Affiliated Hospital^3Department of 
Orthopedics^cNanjing^sJiangsu^pChina#^len^aChondrocytes and bone marrow mesenchy
mal stem cells (BMSCs) are frequently used as seed cells in cartilage tissue eng
ineering. In the present study, we determined if the co-culture of rabbit articu
lar chondrocytes and BMSCs in vitro promotes the expression of cartilaginous ext
racellular matrix and, if so, what is the optimal ratio of the two cell types. C
ultures of rabbit articular chondrocytes and BMSCs were expanded in vitro and th
en cultured individually or at a chondrocyte:BMSC ratio of 4:1, 2:1, 1:1, 1:2, 1
:4 for 21 days and cultured in DMEM/F12. BMSCs were cultured in chondrogenic ind
uction medium. Quantitative real-time RT-PCR and Western blot were used to evalu
ate gene expression. In the co-cultures, type II collagen and aggrecan expressio
n increased on days 14 and 21. At the mRNA level, the expression of type II coll
agen and aggrecan on day 21 was much higher in the 4:1, 2:1, and 1:1 groups than
 in either the articular chondrocyte group or the induced BMSC group, and the be
st ratio of co-culture groups seems to be 2:1. Also on day 21, the expression of
 type II collagen and aggrecan proteins in the 2:1 group was much higher than in
 all other groups. The results demonstrate that the co-culture of rabbit chondro
cytes and rabbit BMSCs at defined ratios can promote the expression of cartilagi
nous extracellular matrix. The optimal cell ratio appears to be 2:1 (chondrocyte
s:BMSCs). This approach has potential applications in cartilage tissue engineeri
ng since it provides a protocol for maintaining and promoting seed-cell differen
tiation and function.#^dnd^i1#^tm^len^kCo-culture^i1#^tm^len^kBone mesenchymal s
tem cells^i1#^tm^len^kChondrocytes^i1#^tm^len^kTissue engineering^i1#other#39#20
101022#October 22, 2010#20110210#February 10, 2011#804.htm#Internet^ihttp://www.
scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000400006##
00373000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014900070002000800219#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#5#1#article#151#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 303-310  </B> </font></P>      ^cY#804.htm##
00483000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704025900070002000800329#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#6#2#article#151#<p ALIGN="LEFT"><font siz
e="5" face="Arial"><span lang="EN"><strong>Co-culture of chondrocytes and bone m
arrow mesenchymal stem cells <i>in vitro</i> enhances the expression of cartilag
inous extracellular matrix components</strong></span></font></p>      ^cY#804.ht
m##
00702000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704047800070002000800548#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#7#3#article#151#<p ALIGN="LEFT"><font fac
e="Arial"><span lang="EN">Qing Chang*, Wei-ding Cui* and <span lang="EN"><font f
ace="Arial, Helvetica, sans-serif"><sup><span lang="EN"><font face="Arial, Helve
tica, sans-serif"><b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v44
n4/recor.gif" border="0"></a></b> <a href="mailto:fanweimin@vip.sina.com"><img s
rc="/img/revistas/bjmbr/v44n4/email-ca.gif" border="0"></a></font></span></sup><
/font></span> Wei-min Fan</span></font></p>      ^cY#804.htm##
00443000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704021900070002000800289#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#8#4#article#151#<p ALIGN="LEFT"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Department of Ortho
pedics, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu,
 China</font></span></p>      ^cY#804.htm##
00414000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704019000070002000800260#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#9#5#article#151#<P> <font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#804.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#10#6#article#151#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#804.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#11#7#article#151#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#804.htm##
00397000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704017200071002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#12#8#article#151#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#804.htm##
00406000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018100071002000800252#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#13#9#article#151#<BR>   <A HREF="#Discuss
ion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#804
.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#14#10#article#151#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#804.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#15#11#article#151#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#804.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#16#12#article#151#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#804.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#17#13#article#151#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#804.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#18#14#article#151#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#804.htm##
02034000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704180800072002000801880#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#19#15#article#151#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial, Helvetica, sans-serif">Chondrocytes and bone marrow 
mesenchymal stem cells (BMSCs) are frequently used as seed cells in cartilage ti
ssue engineering. In the present study, we determined if the co-culture of rabbi
t articular chondrocytes and BMSCs <i>in vitro</i> promotes the expression of ca
rtilaginous extracellular matrix and, if so, what is the optimal ratio of the tw
o cell types. Cultures of rabbit articular chondrocytes and BMSCs were expanded 
<i>in vitro</i> and then cultured individually or at a chondrocyte:BMSC ratio of
 4:1, 2:1, 1:1, 1:2, 1:4 for 21 days and cultured in </font><font FACE="Arial, H
elvetica, sans-serif" COLOR="#0d0d0d">DMEM/F12</font><font FACE="Arial, Helvetic
a, sans-serif">. BMSCs were cultured in chondrogenic induction medium. Quantitat
ive real-time RT-PCR and Western blot were used to evaluate gene expression. In 
the co-cultures, type II collagen and aggrecan expression increased on days 14 a
nd 21. At the mRNA level, the expression of type II collagen and aggrecan on day
 21 was much higher in the 4:1, 2:1, and 1:1 groups than in either the articular
 chondrocyte group or the induced BMSC group, and the best ratio of co-culture g
roups seems to be 2:1. Also on day 21, the expression of type II collagen and ag
grecan proteins in the 2:1 group was much higher than in all other groups. The r
esults demonstrate that the co-culture of rabbit chondrocytes and rabbit BMSCs a
t defined ratios can promote the expression of cartilaginous extracellular matri
x. The optimal cell ratio appears to be 2:1 (chondrocytes:BMSCs). This approach 
has potential applications in cartilage tissue engineering since it provides a p
rotocol for maintaining and promoting seed-cell differentiation and function.</f
ont></span></p>      ^cY#804.htm##
00413000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018700072002000800259#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#20#16#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Key words: Co-culture; Bone mesenchymal stem cells; 
Chondrocytes; Tissue engineering</span></font></p>  <HR ALIGN=LEFT SIZE=2>      
^cY#804.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#21#17#article#151#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#804.htm##
01390000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704116400072002000801236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#22#18#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Chondrocytes and bone marrow mesenchymal stem cells 
(BMSCs) are frequently used as seed cells in cartilage tissue engineering (1-4).
 A satisfactory curative effect has been achieved in the clinical application of
 chondrocytes to the construction of tissue-engineered cartilage and the repair 
of defects of the articular cartilage (5-7). However, the clinical applications 
are hindered by the fact that: 1) chondrocytes are highly differentiated cells a
nd their availability is therefore limited and 2) under <i>in vitro</i> conditio
ns they tend to rapidly de-differentiate (8,9). BMSCs have been suggested as a s
ubstitute for chondrocytes in cartilage tissue engineering because of their sign
ificant proliferative and regenerative capacity (10,11). However, this strategy 
is problematic because of the low induction efficiency of single BMSC cultures, 
the potential risk for tumor formation by these cells (12), and the need for gro
wth factors and/or gene delivery systems to signal directed cell growth (13). Th
us, novel approaches are needed before BMSCs can be used therapeutically.</span>
</font></p>      ^cY#804.htm##
01068000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704084200072002000800914#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#23#19#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The co-culture of stem cells with other mature cells
 is being increasingly utilized to drive stem cells differentiation toward the n
eeded lineages (14). For example, the microenvironment formed by chondrocytes ca
n promote the differentiation of BMSCs into chondrocytes (15,16) and the cytokin
es secreted by BMSCs can encourage the proliferation of cartilage cells and the 
synthesis of cartilaginous extracellular matrix (ECM). Cartilage cells secrete g
rowth factors such as transforming growth factor-&beta; (TGF-&beta;) and insulin
-like growth factor-1 (IGF-1), which induce chondrocyte differentiation by BMSCs
 (17). Tsuchiya et al. (18) co-cultured human BMSCs and cow chondrocytes and fou
nd an increasing rate of propagation of chondrocytes and ECM synthesis.</span></
font></p>      ^cY#804.htm##
01217000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704099100072002000801063#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#24#20#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">However, the previous studies have not indicated whe
ther better results could be achieved with the co-culture of chondrocytes and BM
SCs than with pure cultures of either chondrocytes or chondrogenically induced B
MSCs. Furthermore, the optimal ratio of chondrocytes and BMSCs in co-cultures ha
s not been determined. The purpose of the present study was, firstly, to determi
ne whether co-culture of rabbit chondrocytes and BMSCs <i>in vitro</i> promotes 
the expression of cartilage ECM and, secondly, to define the optimal ratio of th
e two types of cells by measuring the production of extracellular matrix. Approx
imately 40-50% of total cartilage ECM is collagen, with 90% of total collagen be
ing type II. Proteoglycans, more than 50% of which are aggrecan, correspond to a
bout 25% of cartilage ECM. Thus, type II collagen and aggrecan were used to moni
tor the expression of cartilage ECM.</span></font></p>  <HR ALIGN=LEFT SIZE=2>  
    ^cY#804.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#25#21#article#151#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#804.htm##
00527000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704030100072002000800373#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#26#22#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">All experimental procedures involving animals confor
med with the NIH Guidelines for the Care and Use of Laboratory Animals and were 
approved by the Administration Committee of Experimental Animals, Jiangsu Provin
ce, China.</span></font></p>      ^cY#804.htm##
00383000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704015700072002000800229#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#27#23#article#151#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Isolation, culture, and expansion of bone marrow 
mesenchymal stem cells</span></font></b></p>      ^cY#804.htm##
01384000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704115800072002000801230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#28#24#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">BMSCs were isolated as described in Ref. 19. Briefly
, 6 mL BMSCs was harvested from the ileum of New Zealand white rabbits (N = 3) a
nd diluted with the same volume of phosphate-buffered saline (PBS) containing 50
00 U heparin. The mixture was separated by density centrifugation through lympho
cyte separation solution (1.073 g/mL) at 1000 <i>g</i> for 15 min at room temper
ature. The mononuclear fraction interphase was collected and washed twice in PBS
. The final pellet was resuspended in 3 mL Dulbecco&rsquo;s modified Eagle&rsquo
;s medium (DMEM)/F12 (Gibco, USA) supplemented with 10% fetal bovine serum (FBS;
 Gibco), 100 U/mL penicillin G (Gibco) and 100 &mu;g/mL streptomycin (Gibco), se
eded in a 25-cm<sup>2</sup> culture flask (Corning, USA), and cultured at 37&deg
;C under a 5% CO<sub>2</sub> atmosphere. The medium was changed every 48 h and n
onadherent hematopoietic cells were removed. After 14 days, the cells had grown 
to 90% confluence and were harvested by trypsinization. Two-passaged cells were 
used. Cell number and viability were assessed with a hemocytometer.</span></font
></p>      ^cY#804.htm##
00332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010600072002000800178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#29#25#article#151#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Chondrocyte cultures</span></font></b></p>      ^
cY#804.htm##
01068000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704084200072002000800914#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#30#26#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Chondrocytes were isolated from rabbit articular car
tilage as described previously (20). In brief, New Zealand white rabbits (N = 3)
 weighing about 250 g were euthanized by injection with a Nembutal overdose, and
 the knee cartilages were removed by sterile dissection. Pieces of cartilage wer
e finely minced and washed with PBS and were then digested with 0.2% (w/v) colla
genase (Sigma, USA) in PBS for 5 h at 37&deg;C. The isolated chondrocytes were r
esuspended in DMEM/F12 (Gibco) supplemented with 10% FBS (Gibco), 100 U/mL penic
illin G (Gibco), and 100 &mu;g/mL streptomycin (Gibco). The cells were then plat
ed at a density of 1 x 10<sup>5 </sup>cells/mL and placed in a 5% CO<sub>2</sub>
 incubator at 37&deg;C. The culture medium was changed every other day.</span></
font></p>      ^cY#804.htm##
00381000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704015500072002000800227#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#31#27#article#151#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Evaluation of the potential for multilineage diff
erentiation of BMSCs</span></font></b></p>      ^cY#804.htm##
00577000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704035100072002000800423#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#32#28#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">BMSCs at passage 2 were divided into 3 groups: the f
irst group was induced as described by Schilling et al. (21) so that the cells d
eveloped into an adipogenic lineage, the second group into an osteogenic lineage
 (21), and the third group into a chondrogenic lineage (22).</span></font></p>  
    ^cY#804.htm##
00828000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704060200072002000800674#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#33#29#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Intracellular lipid vesicles from the adipogenic mon
olayer cultures were stained with Oil Red O (Sigma) as described by Pittenger et
 al. (23). Cytoplasmic alkaline phosphatase (ALP) from differentiated or differe
ntiating osteoblasts was stained with ALP solution prepared using a mixture of 8
0 mL Naphthol AS-MX phosphate (Sigma) and 2 mL of fast violet B salt solution (p
repared according to manufacturer instructions). The cartilaginous phenotype of 
the induced cells was confirmed by Alcian blue and Safranin O staining.</span></
font></p>      ^cY#804.htm##
00369000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704014300072002000800215#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#34#30#article#151#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Chondrogenesis of mesenchymal stem cells and chon
drocytes</span></font></b></p>      ^cY#804.htm##
01585000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704135900072002000801431#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#35#31#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Chondrocytes and BMSCs of passage 2 were cultured to
 achieve chondrogenesis. Seven experimental groups were established as follows: 
in group 1, chondrocytes were cultured in DMEM/F12 (Gibco) supplemented with 10%
 FBS (Gibco), 100 U/mL penicillin G (Gibco), and 100 &mu;g/mL streptomycin (Gibc
o); in groups 2-6, chondrocytes and BMSCs were co-cultured at ratios of 4:1, 2:1
, 1:1, 1:2, and 1:4 in DMEM/F12 (Gibco) supplemented with 10% FBS (Gibco), 100 U
/mL penicillin G (Gibco) and 100 &mu;g/mL streptomycin (Gibco); in group 7, BMSC
s were cultured in chondrogenic induction medium (DMEM/F12 supplemented with 10%
 FBS, 100 U/mL penicillin G, 100 &mu;g/mL streptomycin, 1% ITS+ (Sigma), 10 ng/m
L TGF-&beta;1 (Invitrogen, USA), 0.1 &micro;M dexamethasone (Sigma), and 50 &mu;
g/mL ascorbate 2-phosphate (Sigma). In group 8, BMSCs were cultured in DMEM/F12 
(Gibco) supplemented with 10% FBS (Gibco), 100 U/mL penicillin G (Gibco) and 100
 &mu;g/mL streptomycin (Gibco). Groups 1, 7 and 8 served as the control groups, 
and groups 2-6 as the experimental groups. All groups initially contained 3 x 10
<sup>5</sup> cells plated at a density of 6 x 10<sup>3 </sup>cells per cm<sup>2<
/sup>. The medium was changed every 3 days, and the cells were harvested on days
 7, 14, and 21 for analysis.</span></font></p>      ^cY#804.htm##
00341000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011500072002000800187#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#36#32#article#151#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Quantitative real-time RT-PCR</span></font></b></
p>      ^cY#804.htm##
02667000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704244100072002000802513#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#37#33#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Total RNA was extracted from cell samples using Triz
ol (Invitrogen). cDNA was synthesized from total RNA using an Omniscript RT kit 
(Qiagen, USA) according to supplier instructions. Type II collagen and aggrecan 
mRNA levels were measured by real-time RT-PCR (Stepone real-time PCR Applied Bio
systems, USA) using the Fast EvaGreen<sup>&reg;</sup> master mix for quantitativ
e and high-resolution melting PCR (Biotium, USA). The 20-&mu;L reaction containe
d 1 &mu;L cDNA from each sample mixed with 10 &mu;L 2X Fast EvaGreen<sup>&reg;</
sup> qPCR Master Mix, 2 &mu;L 10X ROX of the assays-on-demand kit (Applied Biosy
stems), 1 &mu;L primer, and 6 &mu;L RNase/DNase-free water. The PCR conditions w
ere: incubation at 95&deg;C for 2 min followed by 45 cycles at 95&deg;C for 15 s
 and at 60&deg;C for 60 s. Data were analyzed using the ABI Stepone Sequence Det
ection Systems software, version 1.0, supplied by Applied Biosystems. The thresh
old cycle (Ct) value for each sample was defined as the cycle number at which th
e fluorescence intensity reached a certain threshold at which amplification of e
ach target gene was within the linear region of the reaction amplification curve
s. The relative expression level for each target gene was normalized by the Ct v
alue of the housekeeping gene GAPDH using the 2&Delta;Ct relative quantification
 method, as previously described (24), with the undetected levels treated as zer
o. In brief, the relative gene copy number was derived using the formula 2-&Delt
a;<sup>Ct</sup>, where &Delta;Ct is the difference in amplification cycles requi
red to detect the amplification products of the target genes (aggrecan and type 
II collagen) relative to the internal control, GAPDH; namely, relative copy numb
er = 2<sup>-[Ct(target) - Ct(GAPDH)]</sup>. Each sample was analyzed in triplica
te. PCR was performed using specific primers designed from the published sequenc
e of each cDNA as follows: GAPDH, sense: 5&prime;-CTGCCGCCTGGAGAAAG-3&prime;, an
tisense: 5&prime;-CGACCTGGTCCTCGGTGTA-3&prime;; type II collagen, sense: 5&prime
;-GCACCCATGGAC ATTGGAGGG-3&prime;, antisense: 5&prime;-GACACG GAGTAGCACCATCG-3&p
rime;; aggrecan, sense: 5&prime;-GGTCGTGGTGAAAGGTGTTG-3&prime;, antisense: 5&pri
me;-GGTGGAAGCCATCCTCGTA-3&prime;; type I collagen, sense: 5&prime;-AAGAGGAAACTG 
CAAGAAGGG-3&prime;, antisense: 5&prime;-CGTTGGG ACCATCATCACC-3&prime;.</span></f
ont></p>      ^cY#804.htm##
00333000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010700072002000800179#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#38#34#article#151#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Western blot analysis</span></font></b></p>      
^cY#804.htm##
01131000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704090500072002000800977#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#39#35#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Aliquots of cell lysates containing an equal amount 
of protein were submitted to SDS-PAGE and transferred onto PVDF membranes (Invit
rogen). After blocking in Tris-buffered saline (TBS, pH 7.6) containing 5% nonfa
t milk and 0.1% Tween-20, the membranes were probed with type II collagen antibo
dy (CP18, Calbiochem, Germany) and aggrecan antibody (AB-3773, Abcam, USA) at a 
1:200 dilution in the blocking buffer and incubated overnight at 4&deg;C, washed
 three times with TBST (TBS and 0.1% Tween-20), incubated with horseradish perox
idase (HRP)-conjugated secondary antibodies (Bio-Rad, USA), and then probed usin
g a SuperSignal West Pico chemiluminescent substrate kit (Pierce, USA). The memb
ranes were scanned using a GS800 Densitometer Scanner (Bio-Rad), followed by dat
a analysis using the PDQuest 7.2.0 software (Bio-Rad).</span></font></p>      ^c
Y#804.htm##
00332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010600072002000800178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#40#36#article#151#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Statistical analysis</span></font></b></p>      ^
cY#804.htm##
00639000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704041300072002000800485#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#41#37#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Data are reported as means &plusmn; SD and were anal
yzed statistically using the SPSS 10.0 software (LEAD Technologies, Inc., USA). 
The statistical significance of the differences between groups was determined by
 one-way analysis of variance (ANOVA). P &lt; 0.05 was considered to be statisti
cally significant.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#804.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#42#38#article#151#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#804.htm##
00379000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704015300072002000800225#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#43#39#article#151#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Analysis of the potential for multilineage differ
entiation of BMSCs</span></font></b></p>      ^cY#804.htm##
00925000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704069900072002000800771#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#44#40#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">To identify the cells isolated from rabbit bone marr
ow with undifferentiated BMSCs, multilineage differentiations were evaluated. Ad
ipogenesis was confirmed by the presence of neutral lipid vacuoles (lipid drople
ts) that were strongly positive to Oil Red O staining on day 14 (<a href="#Fig1"
>Figure 1A</a>). After 21 days of culture, the BMSCs exposed to osteogenic mediu
m were strongly positive to ALP staining (<a href="#Fig1">Figure 1B</a>). The ca
rtilaginous phenotype of the induced cells was confirmed by Alcian blue and Safr
anin O staining (<a href="#Fig1">Figure 1C</a> and <a href="#Fig1">D</a>, respec
tively).</span></font></p>      ^cY#804.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017300072002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#45#41#article#151#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Quantitative analysis of type II collagen, aggrec
an and type I collagen gene expression</span></font></b></p>      ^cY#804.htm##
02406000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704218000072002000802252#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#46#42#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Quantitative real-time RT-PCR of mRNA samples obtain
ed on days 7, 14, and 21 was performed to detect type II collagen gene expressio
n, aggrecan and type I collagen (<a href="#Fig2">Figure 2</a>). Expression of th
e type II collagen gene was lower in all co-culture groups and in the induced BM
SC group than in the chondrocyte group on day 7. On day 14, the gene expression 
of type II collagen in the 2:1 group was higher than in the chondrocyte group, w
hereas expression in the 1:2, 1:4, and induced BMSC groups was lower. On day 21,
 the gene expression of type II collagen was higher in the 4:1, 2:1, 1:1, and 1:
2 groups than in the chondrocyte group, whereas the difference between the 1:4 g
roup and the induced BMSC group or the chondrocyte group was not statistically s
ignificant. The expression of type II collagen was lower in the BMSC group than 
in the chondrocyte group on days 7, 14, 21 (<a href="#Fig2">Figure 2A</a>). On d
ay 7, the expression of the aggrecan gene in the 2:1 and 1:1 groups was higher t
han in the chondrocyte group but lower than in the other co-culture groups. Ther
e was no statistically significant difference between the induced BMSC group and
 the chondrocyte group. On day 14, the gene expression of aggrecan in the 4:1, 2
:1, and 1:1 groups was higher than in the chondrocyte group. The differences bet
ween the 1:2, 1:4, induced BMSC, and chondrocyte groups were not significant. On
 day 21, aggrecan gene expression was higher in all co-culture groups and in the
 induced BMSC group than in the chondrocyte group. The expression of aggrecan in
 the BMSC group was much lower than in the chondrocyte group on days 7, 14, and 
21 (<a href="#Fig2">Figure 2B</a>). Expression of type I collagen was lower in a
ll co-culture groups and in the induced BMSC group than in the chondrocyte group
 on days 7 and 14. On day 21, the expression of type I collagen in the 4:1, 1:1,
 1:2, 1:4, and induced BMSC groups was lower in the chondrocyte group, whereas t
here was no statistically significant difference between the 2:1 group and the c
hondrocyte group (<a href="#Fig2">Figure 2C</a>).</span></font></p>      ^cY#804
.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016400072002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#47#43#article#151#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Semi-quantitative analysis of type II collagen an
d aggrecan protein expression</span></font></b></p>      ^cY#804.htm##
01586000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704136000072002000801432#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#48#44#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Protein samples obtained on days 7, 14, and 21 were 
subjected to semi-quantitative Western blot analysis to detect the protein expre
ssion of type II collagen and aggrecan. There was no statistical difference in t
ype II collagen protein expression in all groups on day 7. On day 14, the expres
sion of type II collagen was higher in the 2:1 group than in the chondrocyte gro
up. On day 21, the expression of type II collagen in all co-culture groups and i
n the induced BMSC group was higher than in the chondrocyte group (<a href="#Fig
3">Figure 3A</a>). Aggrecan protein expression in the co-culture groups, the ind
uced BMSC group and the chondrocyte group on days 7 and 14 was not significantly
 different. On day 21, the expression of aggrecan in the 4:1, 2:1, and 1:1 group
s was higher than in the chondrocyte group, whereas there was no statistically s
ignificant difference between the 1:2, 1:4, induced BMSC groups, and the chondro
cyte group. The levels of type II collagen and aggrecan in the BMSC group were t
oo low to detect (<a href="#Fig3">Figure 3B</a>).</span></font></p>  <HR ALIGN=L
EFT SIZE=2>  <table  border="0">    <tr align="left" valign="top">      <td><a h
ref="/img/revistas/bjmbr/v44n4/html/804i01.htm"><img src="/img/revistas/bjmbr/v4
4n4/804i01peq.jpg" border="2"></a></td>      <td>    ^cY#804.htm##
01002000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704077600072002000800848#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#49#45#article#151#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. 
Analysis of the potential for multilineage differentiation of mesenchymal stem c
ells isolated from rabbit bone marrow. The bone marrow mesenchymal stem cells (B
MSCs) were shown to differentiate into mesenchymal lineages. Adipogenesis was co
nfirmed by neutral lipid vacuoles that stained with Oil Red O on day 14 (A, scal
e bar = 10 &mu;m). BMSCs exposed to osteogenic medium for 21 days were strongly 
positive to alkaline phosphatase staining (B, scale bar = 50 &mu;m). Cartilagino
us phenotype of the induced cells confirmed by Alcian blue (C, scale bar = 50 &m
u;m) and Safranin O staining (D, scale bar = 50 &mu;m).</font></span></p>      <
/td>    </tr>  </table>      ^cY#804.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033800072002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#50#46#article#151#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (320 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/804i02.htm"><img src="/img
/revistas/bjmbr/v44n4/804i02peq.jpg" border="2"></a></td>      <td>    ^cY#804.h
tm##
01026000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704080000072002000800872#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#51#47#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig2"></a>Figure 2. Quantitative analysis o
f type II collagen, aggrecan and type I collagen gene expression. The mixed cell
s at the five ratios of chondrocyte to bone marrow mesenchymal stem cells (4:1, 
2:1, 1:1, 1:2, 1:4) and of the single chondrocyte (C), bone marrow mesenchymal s
tem cell (M) and induced bone marrow mesenchymal stem cell (iM) groups are shown
. Type II collagen, aggrecan and type I collagen mRNA levels were measured by qu
antitative real-time RT-PCR in the co-culture groups or control groups. Data are
 reported as means &plusmn; SEM. The experiment was repeated in triplicate for e
ach sample. *P &lt; 0.05 <i>vs</i> chondrocyte control culture (one-way ANOVA).<
/span></font></p>      </td>    </tr>  </table>      ^cY#804.htm##
01385000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704115900072002000801231#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#52#48#article#151#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (217 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/804i03.htm"><img src="/img
/revistas/bjmbr/v44n4/804i03peq.jpg" border="2"></a></td>      <td><span lang="E
N"><font face="Arial"><span lang="EN"><a name="Fig3"></a>Figure 3. Western analy
sis of type II collagen and aggrecan protein expression. The mixed cells at the 
five ratios of chondrocyte to bone marrow mesenchymal stem cell (4:1, 2:1, 1:1, 
1:2, 1:4) and of the single chondrocyte (C), bone marrow mesenchymal stem cell (
M) and induced bone marrow mesenchymal stem cell (iM) groups are shown. Type II 
collagen and aggrecan protein levels were measured by Western blot analysis in c
o-cultures or control cultures. Representative blots are shown on the left; GAPD
H served as the internal control. Data are reported as means &plusmn; SEM. The e
xperiment was repeated in triplicate for each sample. *P &lt; 0.05 <i>vs</i> cho
ndrocyte control culture (one-way ANOVA).</span></font></span></td>    </tr>  </
table>      ^cY#804.htm##
00344000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011800072002000800190#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#53#49#article#151#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (147 K JPG file)]</font
></P>      ^cY#804.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#54#50#article#151#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#804.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#55#51#article#151#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#804.htm##
01110000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704088400072002000800956#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#56#52#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Cell co-culture provides a relatively new approach t
o overcome the deficits of single culture <i>in vitro</i>. Lin et al. (25) found
 that the bioactive factors excreted by pancreatic islets can enhance the migrat
ion of BMSCs and co-culture can improve islet survival and function. Rat mesench
ymal stem cells can be induced to nucleus pulposus-like cells <i>in vitro</i> un
der the direct influence of intact disc tissue. After 14 days of co-culture, the
se cells were able to express type II collagen, aggrecan, and sox-9 at the mRNA 
and protein levels (26). Rangappa et al. (27) co-cultured human mesenchymal stem
 cells and human cardiomyocytes with direct cell-to-cell contact. Their results 
indicated that human mesenchymal stem cells were plastic and could be reprogramm
ed into a cardiomyogenic lineage.</span></font></p>      ^cY#804.htm##
01796000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704157000072002000801642#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#57#53#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">To the best of our knowledge, there are only a few r
eports on the co-culture of chondrocytes and stem cells in cartilage tissue engi
neering. Human embryonic stem cells co-cultured with articular cartilage cells f
or 2 weeks significantly increased cartilage matrix production (28). BMSCs co-cu
ltured with human chondrocytes in an inert membrane system increasingly expresse
d aggrecan and type II collagen after 1 week (29). Mo et al. (30) reported that 
newly synthesized cartilaginous ECM and type II collagen gene expression were up
-regulated after human mesenchymal stem cells (hMSC) and rabbit articular chondr
ocytes (rAC) were encapsulated together in alginate hydrogels for 28 days. Altho
ugh the above cited studies found that stem cells could be induced into cartilag
e cell-like cells and that chondrocytes were supported by stem cells, they did n
ot determine whether the co-culture of chondrocytes and BMSCs was more effective
 than the single culture of each cell type. The present study showed that type I
I collagen and aggrecan mRNA levels were higher in the 4:1, 2:1, and 1:1 co-cult
ure groups than in either chondrocyte group or in the induced BMSC group on day 
21. Type II collagen and aggrecan protein levels in the 2:1 group were much high
er in the chondrocyte group or induced BMSC group on day 21. These findings indi
cated that the co-culture of rabbit articular chondrocytes and rabbit BMSCs with
in a defined range of ratios could promote the expression of cartilaginous ECM.<
/span></font></p>      ^cY#804.htm##
01473000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704124700072002000801319#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#58#54#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">To the best of our knowledge, the study of variation
s in the ratios of chondrocytes and BMSC co-cultures was only reported by Mo et 
al. (30). Rabbit articular chondrocytes and human mesenchymal stem cells were co
-cultured at different ratios. Their results showed that the GAG and type II col
lagen content of the 1:2 (rAC:hMSC) group was higher than that of the other co-c
ulture groups or of the BMSC group. However, the difference between the 1:2 (rAC
:hMSC) group and the chondrocyte group was not statistically significant. In ord
er to identify the origin of the newly synthesized type II collagen, in their ex
periment they used the two xenogeneic cell populations. Thus, the optimal ratio 
of two different cell populations obtained from the same species remains unknown
. In the present study, cells from the same species, i.e., rabbit, were mixed at
 different ratios. On day 21, the expression of type II collagen and aggrecan at
 the mRNA and protein levels in the 2:1 group were much higher than in all other
 groups. Thus, the optimal ratio of rabbit chondrocytes and rabbit BMSCs in mono
layer co-culture seems to be 2:1 for the expression of the proteins studied.</sp
an></font></p>      ^cY#804.htm##
00972000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704074600072002000800818#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#59#55#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Type I collagen can be detected in normal articular 
chondrocytes and was used to measure the osteogenic differentiation of BMSCs. In
 our study, the expression of type I collagen was reduced as shown by a decrease
d number of initial chondrocytes on day 7. The expression of type I collagen in 
the 4:1 and 2:1 groups was increased with increasing co-culture incubation time,
 indicating that co-culture generally enhanced gene expression. The expression l
evels of type II collagen and aggrecan were much higher than that of type I coll
agen, which is consistent with the results of Richardson et al. (31) who co-cult
ured human nucleus pulposus cells and human BMSCs (31).</span></font></p>      ^
cY#804.htm##
02019000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704179300072002000801865#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#60#56#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The reason why co-culture of chondrocytes and BMSCs 
can enhance the expression of cartilaginous ECM is unclear. The microenvironment
 formed by chondrocytes plays a crucial role in the chondrogeneic differentiatio
n of BMSCs (32). Morphogenetic factors from bovine articular chondrocytes are in
dispensable in multiple steps during chondrogenic differentiation <i>in vitro</i
> and <i>in vivo</i> (33). Chondrogenesis is an orchestrated molecular and cellu
lar process controlled by cellular interactions with growth and morphogenetic fa
ctors (34). Variations in the ratio of co-cultured chondrocytes and BMSCs could 
influence chondrocyte function and chondrogenic differentiation of BMSCs. Moreov
er, the cellular interactions between chondrocytes and BMSCs in monolayer co-cul
ture are likely to be bi-directional. Chondrocyte-secreted factors such as TGF-&
beta;, bone morphogenetic proteins and IGF-I may promote chondrogenesis of BMSCs
 <i>in vitro </i>(35-37). Yamamoto et al. (38) co-cultured nucleus pulposus cell
s with mesenchymal stem cells and found that mesenchymal stem cells can enhance 
secretion of TGF-&beta;, IGF-1 and epidermal growth factors from nucleus pulposu
s cells. A possible mode of action could be cross talk between cells via gap jun
ctions, which has been observed in co-culture of osteoprogenitor cells with endo
thelial cells where osteogenic differentiation was induced through the gap junct
ion protein connexin 43 (39). These data suggest that chondrocytes can enhance c
hondrogenesis of BMSCs and at same time BMSCs can improve chondrocyte function i
n the co-culture system. The neo-chondrocytes will further induce chondrogenic d
ifferentiation of BMSCs and ultimately form more chondrocytes.</span></font></p>
      ^cY#804.htm##
00765000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704053900072002000800611#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#61#57#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The 3-D scaffold has been frequently used in cartila
ge tissue engineering. It is well known that the 3-D scaffold closely mimics the
 environment of articular cartilage <i>in vivo</i>. We suppose that the co-cultu
re of chondrocytes and BMSCs promotes the expression of cartilaginous ECM not on
ly in the monolayer condition but also in the 3-D scaffold. However, the exact r
esults of co-culture of chondrocytes and BMSCs in a 3-D scaffold required furthe
r study.</span></font></p>      ^cY#804.htm##
00986000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704076000072002000800832#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#62#58#article#151#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Our study shows that the co-culture of rabbit articu
lar chondrocytes and rabbit BMSCs within a defined range of ratios promotes the 
expression of cartilaginous extracellular matrix. Under the present conditions d
escribed, the optimal ratio seems to be 2:1 (chondrocyte:BMSC). Our method has p
otential applications in cartilage tissue engineering since it provides a protoc
ol for maintaining and promoting seed-cell differentiation and function. However
, the optimal ratio of human articular chondrocytes and human BMSCs and the exac
t mechanisms mediating cell-to-cell interactions between chondrocytes and BMSCs 
in co-culture require further investigations.</span></font></p>  <HR ALIGN=LEFT 
SIZE=2>      ^cY#804.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#63#59#article#151#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#804.htm##
00481000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024100074002000800315#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#64#60#article#151#1#<p ALIGN=
"LEFT"><span lang="EN"><font face="Arial">1. Peterson L, Brittberg M, Kiviranta 
I, Akerlund EL, Lindahl A. Autologous chondrocyte transplantation. Biomechanics 
and long-term durability. <i>Am J Sports Med</i> 2002; 30: 2-12.    ^cY#804.htm#
#
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#65#61#article#151#</font></span></p>     
 ^cY#804.htm##
00596000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704035600074002000800430#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#66#62#article#151#2#<p align=
"LEFT"><span lang="EN"><font face="Arial">2. Wakitani S, Nawata M, Tensho K, Oka
be T, Machida H, Ohgushi H. Repair of articular cartilage defects in the patello
-femoral joint with autologous bone marrow mesenchymal cell transplantation: thr
ee case reports involving nine defects in five knees. <i>J Tissue Eng Regen Med<
/i> 2007; 1: 74-79.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#67#63#article#151#</font></span></p>     
 ^cY#804.htm##
00560000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704032000074002000800394#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#68#64#article#151#3#<p align=
"LEFT"><span lang="EN"><font face="Arial">3. Kuroda R, Ishida K, Matsumoto T, Ak
isue T, Fujioka H, Mizuno K, et al. Treatment of a full-thickness articular cart
ilage defect in the femoral condyle of an athlete with autologous bone-marrow st
romal cells. <i>Osteoarthritis Cartilage</i> 2007; 15: 226-231.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#69#65#article#151#</font></span></p>     
 ^cY#804.htm##
00508000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704026800074002000800342#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#70#66#article#151#4#<p align=
"LEFT"><span lang="EN"><font face="Arial">4. Rosenberger RE, Gomoll AH, Bryant T
, Minas T. Repair of large chondral defects of the knee with autologous chondroc
yte implantation in patients 45 years or older. <i>Am J Sports Med</i> 2008; 36:
 2336-2344.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#71#67#article#151#</font></span></p>     
 ^cY#804.htm##
00453000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704021300074002000800287#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#72#68#article#151#5#<p align=
"LEFT"><span lang="EN"><font face="Arial">5. Scapinelli R, Aglietti P, Baldovin 
M, Giron F, Teitge R. Biologic resurfacing of the patella: current status. <i>Cl
in Sports Med</i> 2002; 21: 547-573.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#73#69#article#151#</font></span></p>     
 ^cY#804.htm##
00575000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704034900072002000800421#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#74#70#article#151#<p align="LEFT"><span l
ang="EN"><font face="Arial">6. Gobbi A, Kon E, Berruto M, Filardo G, Delcogliano
 M, Boldrini L, et al. Patellofemoral full-thickness chondral defects treated wi
th second-generation autologous chondrocyte implantation: results at 5 years&rsq
uo; follow-up. <i>Am J Sports Med</i> 2009; 37: 1083-1092.</font></span></p>    
  ^cY#804.htm##
00449000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704020900074002000800283#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#75#71#article#151#7#<p align=
"LEFT"><span lang="EN"><font face="Arial">7. Steinwachs M. New technique for cel
l-seeded collagen-matrix-supported autologous chondrocyte transplantation. <i>Ar
throscopy</i> 2009; 25: 208-211.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#76#72#article#151#</font></span></p>     
 ^cY#804.htm##
00516000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027600074002000800350#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#77#73#article#151#8#<p align=
"LEFT"><span lang="EN"><font face="Arial">8. Marlovits S, Hombauer M, Truppe M, 
Vecsei V, Schlegel W. Changes in the ratio of type-I and type-II collagen expres
sion during monolayer culture of human chondrocytes. <i>J Bone Joint Surg Br</i>
 2004; 86: 286-295.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#78#74#article#151#</font></span></p>     
 ^cY#804.htm##
00462000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704022200074002000800296#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#79#75#article#151#9#<p align=
"LEFT"><span lang="EN"><font face="Arial">9. Kang SW, Yoo SP, Kim BS. Effect of 
chondrocyte passage number on histological aspects of tissue-engineered cartilag
e. <i>Biomed Mater Eng</i> 2007; 17: 269-276.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#80#76#article#151#</font></span></p>     
 ^cY#804.htm##
00431000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704019000075002000800265#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#81#77#article#151#10#<p align
="LEFT"><span lang="EN"><font face="Arial">10. Sharma B, Elisseeff JH. Engineeri
ng structurally organized cartilage and bone tissues. <i>Ann Biomed Eng</i> 2004
; 32: 148-159.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#82#78#article#151#</font></span></p>     
 ^cY#804.htm##
00554000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704031300075002000800388#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#83#79#article#151#11#<p align
="LEFT"><font face="Arial, Helvetica, sans-serif"><span LANG="EN">11. Tuan RS. S
temming cartilage degeneration: adult mesenchymal stem cells as a cell source fo
r articular cartilage tissue engineering. </span><i><span LANG="PT-BR">Arthritis
 Rheum</span></i><span LANG="PT-BR"> 2006; 54: 3075-3078.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#84#80#article#151#</span></font></p>     
 ^cY#804.htm##
00502000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704026100075002000800336#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#85#81#article#151#12#<p align
="LEFT"> <font face="Arial"><span LANG="PT-BR">12. Rubio D, Garcia-Castro J, Mar
tin MC, de la Fuente R, Cigudosa JC, Lloyd AC, et al. </span><span LANG="EN">Spo
ntaneous human adult stem cell transformation. <i>Cancer Res</i> 2005; 65: 3035-
3039.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#86#82#article#151#</span></font></p>     
 ^cY#804.htm##
00449000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704020800075002000800283#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#87#83#article#151#13#<p align
="LEFT"><span lang="EN"><font face="Arial">13. Heng BC, Cao T, Lee EH. Directing
 stem cell differentiation into the chondrogenic lineage <i>in vitro</i>. <i>Ste
m Cells</i> 2004; 22: 1152-1167.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#88#84#article#151#</font></span></p>     
 ^cY#804.htm##
00486000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704024500075002000800320#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#89#85#article#151#14#<p align
="LEFT"><span lang="EN"><font face="Arial">14. Sui Y, Clarke T, Khillan JS. Limb
 bud progenitor cells induce differentiation of pluripotent embryonic stem cells
 into chondrogenic lineage. <i>Differentiation</i> 2003; 71: 578-585.    ^cY#804
.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#90#86#article#151#</font></span></p>     
 ^cY#804.htm##
00484000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704024300075002000800318#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#91#87#article#151#15#<p align
="LEFT"><span lang="EN"><font face="Arial">15. Blunk T, Sieminski AL, Gooch KJ, 
Courter DL, Hollander AP, Nahir AM, et al. Differential effects of growth factor
s on tissue-engineered cartilage. <i>Tissue Eng</i> 2002; 8: 73-84.    ^cY#804.h
tm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#92#88#article#151#</font></span></p>     
 ^cY#804.htm##
00461000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704022000075002000800295#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#93#89#article#151#16#<p align
="LEFT"><span lang="EN"><font face="Arial">16. Ball SG, Shuttleworth AC, Kielty 
CM. Direct cell contact influences bone marrow mesenchymal stem cell fate. <i>In
t J Biochem Cell Biol</i> 2004; 36: 714-727.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#94#90#article#151#</font></span></p>     
 ^cY#804.htm##
00558000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704031700075002000800392#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#95#91#article#151#17#<p align
="LEFT"><span lang="EN"><font face="Arial">17. Pedrozo HA, Schwartz Z, Gomez R, 
Ornoy A, Xin-Sheng W, Dallas SL, et al. Growth plate chondrocytes store latent t
ransforming growth factor (TGF)-beta 1 in their matrix through latent TGF-beta 1
 binding protein-1. <i>J Cell Physiol</i> 1998; 177: 343-354.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#96#92#article#151#</font></span></p>     
 ^cY#804.htm##
00521000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704028000075002000800355#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#97#93#article#151#18#<p align
="LEFT"><span lang="EN"><font face="Arial">18. Tsuchiya K, Chen GP, Ushida T, Ma
tsuno T, Tateishi T. The effect of coculture of chondrocytes with mesenchymal st
em cells on their cartilaginous phenotype <i>in vitro</i>. <i>Mat Sci Eng C-Bio 
S</i> 2004; 24: 391-396.    ^cY#804.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#98#94#article#151#</font></span></p>     
 ^cY#804.htm##
00766000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704052500075002000800600#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#99#95#article#151#19#<p align
="LEFT"><span lang="EN"><font face="Arial">19. Fischer-Rasokat U, Assmus B, Seeg
er FH, Honold J, Leistner D, Fichtlscherer S, et al. A pilot trial to assess pot
ential effects of selective intracoronary bone marrow-derived progenitor cell in
fusion in patients with nonischemic dilated cardiomyopathy: final 1-year results
 of the transplantation of progenitor cells and functional regeneration enhancem
ent pilot trial in patients with nonischemic dilated cardiomyopathy. <i>Circ Hea
rt Fail</i> 2009; 2: 417-423.    ^cY#804.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#100#96#article#151#</font></span></p>    
  ^cY#804.htm##
00495000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704025300076002000800329#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#101#97#article#151#20#<p alig
n="LEFT"><span lang="EN"><font face="Arial">20. Ouyang HW, Goh JC, Mo XM, Teoh S
H, Lee EH. The efficacy of bone marrow stromal cell-seeded knitted PLGA fiber sc
affold for Achilles tendon repair. <i>Ann N Y Acad Sci</i> 2002; 961: 126-129.  
  ^cY#804.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#102#98#article#151#</font></span></p>    
  ^cY#804.htm##
00483000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704024100076002000800317#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#103#99#article#151#21#<p alig
n="LEFT"><span lang="EN"><font face="Arial">21. Schilling T, Noth U, Klein-Hitpa
ss L, Jakob F, Schutze N. Plasticity in adipogenesis and osteogenesis of human m
esenchymal stem cells. <i>Mol Cell Endocrinol</i> 2007; 271: 1-17.    ^cY#804.ht
m##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#104#100#article#151#</font></span></p>   
   ^cY#804.htm##
00485000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024200077002000800319#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#105#101#article#151#22#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">22. Johnstone B, Hering TM, Caplan 
AI, Goldberg VM, Yoo JU. <i>In vitro</i> chondrogenesis of bone marrow-derived m
esenchymal progenitor cells. <i>Exp Cell Res</i> 1998; 238: 265-272.    ^cY#804.
htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#106#102#article#151#</font></span></p>   
   ^cY#804.htm##
00476000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704023300077002000800310#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#107#103#article#151#23#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">23. Pittenger MF, Mackay AM, Beck S
C, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human
 mesenchymal stem cells. <i>Science</i> 1999; 284: 143-147.    ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#108#104#article#151#</font></span></p>   
   ^cY#804.htm##
00496000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704025300077002000800330#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#109#105#article#151#24#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">24. Schmittgen TD, Zakrajsek BA. Ef
fect of experimental treatment on housekeeping gene expression: validation by re
al-time, quantitative RT-PCR. <i>J Biochem Biophys Methods</i> 2000; 46: 69-81. 
   ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#110#106#article#151#</font></span></p>   
   ^cY#804.htm##
00603000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704036000077002000800437#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#111#107#article#151#25#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">25. Lin P, Chen L, Li D, Yang N, Su
n Y, Xu Y. Dynamic analysis of bone marrow mesenchymal stem cells migrating to p
ancreatic islets using coculture microfluidic chips: An accelerated migrating ra
te and better survival of pancreatic islets were revealed. <i>Neuro Endocrinol L
ett</i> 2009; 30: 204-208.    ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#112#108#article#151#</font></span></p>   
   ^cY#804.htm##
00546000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704030300077002000800380#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#113#109#article#151#26#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">26. Wei A, Chung SA, Tao H, Brisby 
H, Lin Z, Shen B, et al. Differentiation of rodent bone marrow mesenchymal stem 
cells into intervertebral disc-like cells following coculture with rat disc tiss
ue. <i>Tissue Eng Part A</i> 2009; 15: 2581-2595.    ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#114#110#article#151#</font></span></p>   
   ^cY#804.htm##
00509000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026600077002000800343#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#115#111#article#151#27#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">27. Rangappa S, Entwistle JW, Wechs
ler AS, Kresh JY. Cardiomyocyte-mediated contact programs human mesenchymal stem
 cells to express cardiogenic phenotype. <i>J Thorac Cardiovasc Surg</i> 2003; 1
26: 124-132.    ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#116#112#article#151#</font></span></p>   
   ^cY#804.htm##
00569000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704032600077002000800403#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#117#113#article#151#28#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">28. Bigdeli N, Karlsson C, Strehl R
, Concaro S, Hyllner J, Lindahl A. Coculture of human embryonic stem cells and h
uman articular chondrocytes results in significantly altered phenotype and impro
ved chondrogenic differentiation. <i>Stem Cells</i> 2009; 27: 1812-1821.    ^cY#
804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#118#114#article#151#</font></span></p>   
   ^cY#804.htm##
00505000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704026200077002000800339#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#119#115#article#151#29#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">29. Chen WH, Lai MT, Wu AT, Wu CC, 
Gelovani JG, Lin CT, et al. <i>In vitro</i> stage-specific chondrogenesis of mes
enchymal stem cells committed to chondrocytes. <i>Arthritis Rheum</i> 2009; 60: 
450-459.    ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#120#116#article#151#</font></span></p>   
   ^cY#804.htm##
00555000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704031200077002000800389#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#121#117#article#151#30#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">30. Mo XT, Guo SC, Xie HQ, Deng L, 
Zhi W, Xiang Z, et al. Variations in the ratios of co-cultured mesenchymal stem 
cells and chondrocytes regulate the expression of cartilaginous and osseous phen
otype in alginate constructs. <i>Bone</i> 2009; 45: 42-51.    ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#122#118#article#151#</font></span></p>   
   ^cY#804.htm##
00491000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704024800077002000800325#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#123#119#article#151#31#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">31. Richardson SM, Walker RV, Parke
r S, Rhodes NP, Hunt JA, Freemont AJ, et al. Intervertebral disc cell-mediated m
esenchymal stem cell differentiation. <i>Stem Cells</i> 2006; 24: 707-716.    ^c
Y#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#124#120#article#151#</font></span></p>   
   ^cY#804.htm##
00516000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027300077002000800350#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#125#121#article#151#32#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">32. Niyibizi C, Wang S, Mi Z, Robbi
ns PD. The fate of mesenchymal stem cells transplanted into immunocompetent neon
atal mice: implications for skeletal gene therapy via stem cells. <i>Mol Ther</i
> 2004; 9: 955-963.    ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#126#122#article#151#</font></span></p>   
   ^cY#804.htm##
00519000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027600077002000800353#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#127#123#article#151#33#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">33. Hwang NS, Varghese S, Puleo C, 
Zhang Z, Elisseeff J. Morphogenetic signals from chondrocytes promote chondrogen
ic and osteogenic differentiation of mesenchymal stem cells. <i>J Cell Physiol</
i> 2007; 212: 281-284.    ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#128#124#article#151#</font></span></p>   
   ^cY#804.htm##
00412000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704016900077002000800246#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#129#125#article#151#34#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">34. Goldring MB, Tsuchimochi K, Iji
ri K. The control of chondrogenesis. <i>J Cell Biochem</i> 2006; 97: 33-44.    ^
cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#130#126#article#151#</font></span></p>   
   ^cY#804.htm##
00557000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704031400077002000800391#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#131#127#article#151#35#<p ali
gn="LEFT"><font face="Arial"><span LANG="EN">35. Furumatsu T, Tsuda M, Taniguchi
 N, Tajima Y, Asahara H. Smad3 induces chondrogenesis through the activation of 
SOX9 via CREB-binding protein/p300 recruitment. </span><i><span LANG="PT-BR">J B
iol Chem</span></i><span LANG="PT-BR"> 2005; 280: 8343-8350.    ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#132#128#article#151#</span></font></p>   
   ^cY#804.htm##
00541000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029800077002000800375#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#133#129#article#151#36#<p ali
gn="LEFT"> <font face="Arial"><span LANG="PT-BR">36. Quintana L, zur Nieden NI, 
Semino CE. </span><span LANG="EN">Morphogenetic and regulatory mechanisms during
 developmental chondrogenesis: new paradigms for cartilage tissue engineering. <
i>Tissue Eng Part B Rev</i> 2009; 15: 29-41.    ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#134#130#article#151#</span></font></p>   
   ^cY#804.htm##
00535000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029200077002000800369#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#135#131#article#151#37#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">37. Zhang M, Zhou Q, Liang QQ, Li C
G, Holz JD, Tang D, et al. IGF-1 regulation of type II collagen and MMP-13 expre
ssion in rat endplate chondrocytes via distinct signaling pathways. <i>Osteoarth
ritis Cartilage</i> 2009; 17: 100-106.    ^cY#804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#136#132#article#151#</font></span></p>   
   ^cY#804.htm##
00569000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704032600077002000800403#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#137#133#article#151#38#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">38. Yamamoto Y, Mochida J, Sakai D,
 Nakai T, Nishimura K, Kawada H, et al. Upregulation of the viability of nucleus
 pulposus cells by bone marrow-derived stromal cells: significance of direct cel
l-to-cell contact in coculture system. <i>Spine</i> 2004; 29: 1508-1514.    ^cY#
804.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#138#134#article#151#</font></span></p>   
   ^cY#804.htm##
00521000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704027800077002000800355#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#p#139#135#article#151#39#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">39. Guillotin B, Bourget C, Remy-Zo
lgadri M, Bareille R, Fernandez P, Conrad V, et al. Human primary endothelial ce
lls stimulate human osteoprogenitor cell differentiation. <i>Cell Physiol Bioche
m</i> 2004; 14: 325-332.    ^cY#804.htm##
00280000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704005200074002000800126#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#140#136#article#151#</font></span></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#804.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033500074002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#141#137#article#151#<P><font face="Arial,
 Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE
=4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#804.ht
m##
00544000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704031600074002000800390#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#142#138#article#151#<p ALIGN="LEFT"><font
 face="Arial"><span lang="EN">Research supported by the National Natural Science
 Foundation of China (#30876338 and #81000800). Jiangsu Key Laboratory of Neuror
egeneration of Nantong University is gratefully acknowledged for technical suppo
rt.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#804.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033600074002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#143#139#article#151#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#804.h
tm##
00686000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704045800074002000800532#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#144#140#article#151#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/r
ecor.gif" border="0"></a> Address for correspondence:</b></font><font face="Aria
l"><span lang="EN"> Wei-min Fan, Department of Orthopedics, First Affiliated Hos
pital, Nanjing Medical University, Nanjing, Jiangsu 210029, China. Fax: +86-25-8
371-8836-6780. E-mail: <a href="mailto:fanweimin@vip.sina.com">fanweimin@vip.sin
a.com</a></span></font></p>      ^cY#804.htm##
00549000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704032100074002000800395#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#145#141#article#151#<p ALIGN="LEFT"><font
 face="Arial"><span lang="EN">*These authors contributed equally to this study. 
</span></font><i><font face="Arial"><span lang="EN">Received October 22, 2010. A
ccepted February 10, 2011. Available online March 4, 2011. Published April 11, 2
011.</span></font></i></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#804.htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#146#142#article#151#<div align="center"> 
       ^cY#804.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#147#143#article#151#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#804.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#148#144#article#151#<br>                ^
cY#804.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#149#145#article#151#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#804
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#150#146#article#151#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#804.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#151#147#article#151#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#804.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#152#148#article#151#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#804.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#153#149#article#151#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#804.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#154#150#article#151#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#804.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\804.htm#S#p#155#151#article#151#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#804.htm##
00642000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100019000910100
01900110010001900129010001700148012008200165030001600247065000900263064000500272
031000300277014000500280865000900285002000800294035001000302801001600312#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#156#1#article#39#1#^rND^sPeterson
^nL#^rND^sBrittberg^nM#^rND^sKiviranta^nI#^rND^sAkerlund^nEL#^rND^sLindahl^nA#Au
tologous chondrocyte transplantation: Biomechanics and long-term durability^len#
Am J Sports Med#20020000#2002#30#2-12#20110400#804.htm#0363-5465#Am J Sports Med
##
00739000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100016000910100
01600107010001500123010001700138010001700155012018900172030002300361710000200384
065000900386064000500395031000200400014000600402865000900408002000800417#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#157#2#article#39#2#^rND^sWakitani
^nS#^rND^sNawata^nM#^rND^sTensho^nK#^rND^sOkabe^nT#^rND^sMachida^nH#^rND^sOhgush
i^nH#Repair of articular cartilage defects in the patello-femoral joint with aut
ologous bone marrow mesenchymal cell transplantation: three case reports involvi
ng nine defects in five knees^len#J Tissue Eng Regen Med#2#20070000#2007#1#74-79
#20110400#804.htm##
00759000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100016000890100
01900105010001600124010001700140010001600157810000600173012014000179030002500319
06500090034406400050035303100030035801400080036186500090036900200080037803500100
0386801002500396#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#158#3#art
icle#39#3#^rND^sKuroda^nR#^rND^sIshida^nK#^rND^sMatsumoto^nT#^rND^sAkisue^nT#^rN
D^sFujioka^nH#^rND^sMizuno^nK#et al#Treatment of a full-thickness articular cart
ilage defect in the femoral condyle of an athlete with autologous bone-marrow st
romal cells^len#Osteoarthritis Cartilage#20070000#2007#15#226-231#20110400#804.h
tm#1063-4584#Osteoarthritis Cartilage##
00651000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100022000730100017000950100
01600112010001500128012012000143030001600263065000900279064000500288031000300293
014001000296865000900306002000800315035001000323801001600333#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\804.htm#S#c#159#4#article#39#4#^rND^sRosenberger^nRE#^rND
^sGomoll^nAH#^rND^sBryant^nT#^rND^sMinas^nT#Repair of large chondral defects of 
the knee with autologous chondrocyte implantation in patients 45 years or older^
len#Am J Sports Med#20080000#2008#36#2336-2344#20110400#804.htm#0363-5465#Am J S
ports Med##
00614000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100020000730100018000930100
01800111010001500129010001600144012005600160030001600216065000900232064000500241
031000300246014000800249865000900257002000800266035001000274801001600284#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#160#5#article#39#5#^rND^sScapinel
li^nR#^rND^sAglietti^nP#^rND^sBaldovin^nM#^rND^sGiron^nF#^rND^sTeitge^nR#Biologi
c resurfacing of the patella: current status^len#Clin Sports Med#20020000#2002#2
1#547-573#20110400#804.htm#0278-5919#Clin Sports Med##
00759000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100013000880100
01700101010001700118010002100135010001800156810000600174012015500180030001600335
06500090035106400050036003100030036501400100036886500090037800200080038703500100
0395801001600405#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#161#6#art
icle#39#6#^rND^sGobbi^nA#^rND^sKon^nE#^rND^sBerruto^nM#^rND^sFilardo^nG#^rND^sDe
lcogliano^nM#^rND^sBoldrini^nL#et al#Patellofemoral full-thickness chondral defe
cts treated with second-generation autologous chondrocyte implantation: results 
at 5 years&#8217; follow-up^len#Am J Sports Med#20090000#2009#37#1083-1092#20110
400#804.htm#0363-5465#Am J Sports Med##
00534000000000265000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100020000730120099000930300
01200192065000900204064000500213031000300218014000800221865000900229002000800238
035001000246801001200256#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#1
62#7#article#39#7#^rND^sSteinwachs^nM#New technique for cell-seeded collagen-mat
rix-supported autologous chondrocyte transplantation^len#Arthroscopy#20090000#20
09#25#208-211#20110400#804.htm#0749-8063#Arthroscopy##
00682000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100018000920100
01600110010001600126010001800142012011400160030002100274065000900295064000500304
031000300309014000800312865000900320002000800329035001000337801002100347#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#163#8#article#39#8#^rND^sMarlovit
s^nS#^rND^sHombauer^nM#^rND^sTruppe^nM#^rND^sVecsei^nV#^rND^sSchlegel^nW#Changes
 in the ratio of type-I and type-II collagen expression during monolayer culture
 of human chondrocytes^len#J Bone Joint Surg Br#20040000#2004#86#286-295#2011040
0#804.htm#0301-620X#J Bone Joint Surg Br##
00588000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100014000880100
01400102012009600116030001700212065000900229064000500238031000300243014000800246
865000900254002000800263035001000271801001700281#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\804.htm#S#c#164#9#article#39#9#^rND^sKang^nSW#^rND^sYoo^nSP#^rND^sKim
^nBS#Effect of chondrocyte passage number on histological aspects of tissue-engi
neered cartilage^len#Biomed Mater Eng#20070000#2007#17#269-276#20110400#804.htm#
0959-2989#Biomed Mater Eng##
00537000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100020000910120
06600111030001500177065000900192064000500201031000300206014000800209865000900217
002000800226035001000234801001500244#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
04.htm#S#c#165#10#article#39#10#^rND^sSharma^nB#^rND^sElisseeff^nJH#Engineering 
structurally organized cartilage and bone tissues^len#Ann Biomed Eng#20040000#20
04#32#148-159#20110400#804.htm#0090-6964#Ann Biomed Eng##
00568000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750120126000900300
01600216065000900232064000500241031000300246014001000249865000900259002000800268
035001000276801001600286#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#1
66#11#article#39#11#^rND^sTuan^nRS#Stemming cartilage degeneration: adult mesenc
hymal stem cells as a cell source for articular cartilage tissue engineering^len
#Arthritis Rheum#20060000#2006#54#3075-3078#20110400#804.htm#0004-3591#Arthritis
 rheum##
00660000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100023000900100
01700113010002200130010001900152010001600171810000600187012005300193030001100246
06500090025706400050026603100030027101400100027486500090028400200080029303500100
0301801001100311#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#167#12#ar
ticle#39#12#^rND^sRubio^nD#^rND^sGarcia-Castro^nJ#^rND^sMartin^nMC#^rND^sde^nla 
Fuente R#^rND^sCigudosa^nJC#^rND^sLloyd^nAC#et al#Spontaneous human adult stem c
ell transformation^len#Cancer Res#20050000#2005#65#3035-3039#20110400#804.htm#00
08-5472#Cancer res##
00562000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100013000900100
01400103012007900117030001100196065000900207064000500216031000300221014001000224
865000900234002000800243035001000251801001100261#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\804.htm#S#c#168#13#article#39#13#^rND^sHeng^nBC#^rND^sCao^nT#^rND^sLe
e^nEH#Directing stem cell differentiation into the chondrogenic lineage in vitro
^len#Stem Cells#20040000#2004#22#1152-1167#20110400#804.htm#0250-6793#STEM CELLS
##
00611000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100013000750100016000880100
01800104012011500122030001600237065000900253064000500262031000300267014000800270
865000900278002000800287035001000295801001600305#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\804.htm#S#c#169#14#article#39#14#^rND^sSui^nY#^rND^sClarke^nT#^rND^sK
hillan^nJS#Limb bud progenitor cells induce differentiation of pluripotent embry
onic stem cells into chondrogenic lineage^len#Differentiation#20030000#2003#71#5
78-585#20110400#804.htm#0301-4681#Differentiation##
00669000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100020000900100
01600110010001800126010002000144010001600164810000600180012007400186030001100260
06500090027106400050028003100020028501400060028786500090029300200080030203500100
0310801001100320#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#170#15#ar
ticle#39#15#^rND^sBlunk^nT#^rND^sSieminski^nAL#^rND^sGooch^nKJ#^rND^sCourter^nDL
#^rND^sHollander^nAP#^rND^sNahir^nAM#et al#Differential effects of growth factor
s on tissue-engineered cartilage^len#Tissue Eng#20020000#2002#8#73-84#20110400#8
04.htm#1076-3279#Tissue Eng##
00594000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100023000900100
01700113012007400130030002400204065000900228064000500237031000300242014000800245
865000900253002000800262035001000270801002400280#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\804.htm#S#c#171#16#article#39#16#^rND^sBall^nSG#^rND^sShuttleworth^nA
C#^rND^sKielty^nCM#Direct cell contact influences bone marrow mesenchymal stem c
ell fate^len#Int J Biochem Cell Biol#20040000#2004#36#714-727#20110400#804.htm#1
357-2725#Int J Biochem Cell Biol##
00747000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100018000930100
01500111010001500126010001900141010001700160810000600177012014300183030001500326
06500090034106400050035003100040035501400080035986500090036700200080037603500100
0384801001500394#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#172#17#ar
ticle#39#17#^rND^sPedrozo^nHA#^rND^sSchwartz^nZ#^rND^sGomez^nR#^rND^sOrnoy^nA#^r
ND^sXin-Sheng^nW#^rND^sDallas^nSL#et al#Growth plate chondrocytes store latent t
ransforming growth factor (TGF)-beta 1 in their matrix through latent TGF-beta 1
 binding protein-1^len#J Cell Physiol#19980000#1998#177#343-354#20110400#804.htm
#0021-9541#J Cell Physiol##
00639000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100015000930100
01600108010001700124010001800141012011400159030002000273710000200293065000900295
064000500304031000300309014000800312865000900320002000800329#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\804.htm#S#c#173#18#article#39#18#^rND^sTsuchiya^nK#^rND^s
Chen^nGP#^rND^sUshida^nT#^rND^sMatsuno^nT#^rND^sTateishi^nT#The effect of cocult
ure of chondrocytes with mesenchymal stem cells on their cartilaginous phenotype
 in vitro^len#Mat Sci Eng C-Bio S#2#20040000#2004#24#391-396#20110400#804.htm##
00920000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100025000750100016001000100
01700116010001600133010001800149010002300167810000600190012033900196030001600535
71000020055106500090055306400050056203100020056701400080056986500090057700200080
0586#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#174#19#article#39#19#
^rND^sFischer-Rasokat^nU#^rND^sAssmus^nB#^rND^sSeeger^nFH#^rND^sHonold^nJ#^rND^s
Leistner^nD#^rND^sFichtlscherer^nS#et al#A pilot trial to assess potential effec
ts of selective intracoronary bone marrow-derived progenitor cell infusion in pa
tients with nonischemic dilated cardiomyopathy: final 1-year results of the tran
splantation of progenitor cells and functional regeneration enhancement pilot tr
ial in patients with nonischemic dilated cardiomyopathy^len#Circ Heart Fail#2#20
090000#2009#2#417-423#20110400#804.htm##
00656000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100014000920100
01300106010001500119010001400134012010700148030001700255065000900272064000500281
031000400286014000800290865000900298002000800307035001000315801001700325#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#175#20#article#39#20#^rND^sOuyang
^nHW#^rND^sGoh^nJC#^rND^sMo^nXM#^rND^sTeoh^nSH#^rND^sLee^nEH#The efficacy of bon
e marrow stromal cell-seeded knitted PLGA fiber scaffold for Achilles tendon rep
air^len#Ann N Y Acad Sci#20020000#2002#961#126-129#20110400#804.htm#0077-8923#An
n N Y Acad Sci##
00647000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100014000940100
02300108010001500131010001700146012008000163030002000243065000900263064000500272
031000400277014000500281865000900286002000800295035001000303801002000313#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#176#21#article#39#21#^rND^sSchill
ing^nT#^rND^sNoth^nU#^rND^sKlein-Hitpass^nL#^rND^sJakob^nF#^rND^sSchutze^nN#Plas
ticity in adipogenesis and osteogenesis of human mesenchymal stem cells^len#Mol 
Cell Endocrinol#20070000#2007#271#1-17#20110400#804.htm#0303-7207#Mol Cell Endoc
rinol##
00634000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100017000940100
01700111010001900128010001400147012008000161030001300241065000900254064000500263
031000400268014000800272865000900280002000800289035001000297801001300307#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#177#22#article#39#22#^rND^sJohnst
one^nB#^rND^sHering^nTM#^rND^sCaplan^nAI#^rND^sGoldberg^nVM#^rND^sYoo^nJU#In vit
ro chondrogenesis of bone marrow-derived mesenchymal progenitor cells^len#Exp Ce
ll Res#19980000#1998#238#265-272#20110400#804.htm#0014-4827#Exp Cell Res##
00656000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100017000950100
01500112010001800127010001700145010001600162810000600178012006500184030000800249
06500090025706400050026603100040027101400080027586500090028300200080029203500100
0300801000800310#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#178#23#ar
ticle#39#23#^rND^sPittenger^nMF#^rND^sMackay^nAM#^rND^sBeck^nSC#^rND^sJaiswal^nR
K#^rND^sDouglas^nR#^rND^sMosca^nJD#et al#Multilineage potential of adult human m
esenchymal stem cells^len#Science#19990000#1999#284#143-147#20110400#804.htm#003
6-8075#Science##
00611000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100020000960120
11500116030002600231065000900257064000500266031000300271014000600274865000900280
002000800289035001000297801002600307#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
04.htm#S#c#179#24#article#39#24#^rND^sSchmittgen^nTD#^rND^sZakrajsek^nBA#Effect 
of experimental treatment on housekeeping gene expression: validation by real-ti
me, quantitative RT-PCR^len#J Biochem Biophys Methods#20000000#2000#46#69-81#201
10400#804.htm#0165-022X#J Biochem Biophys Methods##
00744000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100013000750100014000880100
01200102010001400114010001300128010001200141012021100153030002200364710000200386
065000900388064000500397031000300402014000800405865000900413002000800422#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#180#25#article#39#25#^rND^sLin^nP
#^rND^sChen^nL#^rND^sLi^nD#^rND^sYang^nN#^rND^sSun^nY#^rND^sXu^nY#Dynamic analys
is of bone marrow mesenchymal stem cells migrating to pancreatic islets using co
culture microfluidic chips: An accelerated migrating rate and better survival of
 pancreatic islets were revealed^len#Neuro Endocrinol Lett#2#20090000#2009#30#20
4-208#20110400#804.htm##
00698000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100013000750100016000880100
01300104010001600117010001300133010001400146810000600160012014200166030001800308
71000020032606500090032806400050033703100030034201400100034586500090035500200080
0364#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#181#26#article#39#26#
^rND^sWei^nA#^rND^sChung^nSA#^rND^sTao^nH#^rND^sBrisby^nH#^rND^sLin^nZ#^rND^sShe
n^nB#et al#Differentiation of rodent bone marrow mesenchymal stem cells into int
ervertebral disc-like cells following coculture with rat disc tissue^len#Tissue 
Eng Part A#2#20090000#2009#15#2581-2595#20110400#804.htm##
00659000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100020000930100
01900113010001600132012010600148030002500254065000900279064000500288031000400293
014000800297865000900305002000800314035001000322801002500332#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\804.htm#S#c#182#27#article#39#27#^rND^sRangappa^nS#^rND^s
Entwistle^nJW#^rND^sWechsler^nAS#^rND^sKresh^nJY#Cardiomyocyte-mediated contact 
programs human mesenchymal stem cells to express cardiogenic phenotype^len#J Tho
rac Cardiovasc Surg#20030000#2003#126#124-132#20110400#804.htm#0022-5223#J Thora
c Cardiovasc Surg##
00741000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100018000920100
01600110010001700126010001700143010001700160012016200177030001100339065000900350
06400050035903100030036401400100036786500090037700200080038603500100039480100110
0404#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#183#28#article#39#28#
^rND^sBigdeli^nN#^rND^sKarlsson^nC#^rND^sStrehl^nR#^rND^sConcaro^nS#^rND^sHyllne
r^nJ#^rND^sLindahl^nA#Coculture of human embryonic stem cells and human articula
r chondrocytes results in significantly altered phenotype and improved chondroge
nic differentiation^len#Stem Cells#20090000#2009#27#1812-1821#20110400#804.htm#0
250-6793#STEM CELLS##
00686000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100014000900100
01300104010001300117010001900130010001400149810000600163012009500169030001600264
06500090028006400050028903100030029401400080029786500090030500200080031403500100
0322801001600332#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#184#29#ar
ticle#39#29#^rND^sChen^nWH#^rND^sLai^nMT#^rND^sWu^nAT#^rND^sWu^nCC#^rND^sGelovan
i^nJG#^rND^sLin^nCT#et al#In vitro stage-specific chondrogenesis of mesenchymal 
stem cells committed to chondrocytes^len#Arthritis Rheum#20090000#2009#60#450-45
9#20110400#804.htm#0004-3591#Arthritis rheum##
00732000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100013000750100014000880100
01400102010001400116010001300130010001500143810000600158012017000164030000500334
06500090033906400050034803100030035301400060035686500090036200200080037103500100
0379801000500389#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#185#30#ar
ticle#39#30#^rND^sMo^nXT#^rND^sGuo^nSC#^rND^sXie^nHQ#^rND^sDeng^nL#^rND^sZhi^nW#
^rND^sXiang^nZ#et al#Variations in the ratios of co-cultured mesenchymal stem ce
lls and chondrocytes regulate the expression of cartilaginous and osseous phenot
ype in alginate constructs^len#Bone#20090000#2009#45#42-51#20110400#804.htm#8756
-3282#Bone##
00674000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100017000960100
01600113010001700129010001500146010001900161810000600180012007600186030001100262
06500090027306400050028203100030028701400080029086500090029800200080030703500100
0315801001100325#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#186#31#ar
ticle#39#31#^rND^sRichardson^nSM#^rND^sWalker^nRV#^rND^sParker^nS#^rND^sRhodes^n
NP#^rND^sHunt^nJA#^rND^sFreemont^nAJ#et al#Intervertebral disc cell-mediated mes
enchymal stem cell differentiation^len#Stem Cells#20060000#2006#24#707-716#20110
400#804.htm#0250-6793#STEM CELLS##
00621000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100014000930100
01200107010001800119012014200137030000900279710000200288065000900290064000500299
031000200304014000800306865000900314002000800323#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\804.htm#S#c#187#32#article#39#32#^rND^sNiyibizi^nC#^rND^sWang^nS#^rND
^sMi^nZ#^rND^sRobbins^nPD#The fate of mesenchymal stem cells transplanted into i
mmunocompetent neonatal mice: implications for skeletal gene therapy via stem ce
lls^len#Mol Ther#2#20040000#2004#9#955-963#20110400#804.htm##
00677000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100018000910100
01500109010001500124010001900139012012200158030001500280065000900295064000500304
031000400309014000800313865000900321002000800330035001000338801001500348#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#188#33#article#39#33#^rND^sHwang^
nNS#^rND^sVarghese^nS#^rND^sPuleo^nC#^rND^sZhang^nZ#^rND^sElisseeff^nJ#Morphogen
etic signals from chondrocytes promote chondrogenic and osteogenic differentiati
on of mesenchymal stem cells^len#J Cell Physiol#20070000#2007#212#281-284#201104
00#804.htm#0021-9541#J Cell Physiol##
00534000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100021000940100
01500115012003400130030001500164065000900179064000500188031000300193014000600196
865000900202002000800211035001000219801001500229#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\804.htm#S#c#189#34#article#39#34#^rND^sGoldring^nMB#^rND^sTsuchimochi
^nK#^rND^sIjiri^nK#The control of chondrogenesis^len#J Cell Biochem#20060000#200
6#97#33-44#20110400#804.htm#0730-2312#J Cell Biochem##
00660000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100015000940100
01900109010001600128010001700144012010600161030001200267065000900279064000500288
031000400293014001000297865000900307002000800316035001000324801001200334#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#190#35#article#39#35#^rND^sFuruma
tsu^nT#^rND^sTsuda^nM#^rND^sTaniguchi^nN#^rND^sTajima^nY#^rND^sAsahara^nH#Smad3 
induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p
300 recruitment^len#J Biol Chem#20050000#2005#280#8343-8350#20110400#804.htm#002
1-9258#J Biol Chem##
00601000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100021000930100
01700114012012800131030002200259710000200281065000900283064000500292031000300297
014000600300865000900306002000800315#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
04.htm#S#c#191#36#article#39#36#^rND^sQuintana^nL#^rND^szur^nNieden NI#^rND^sSem
ino^nCE#Morphogenetic and regulatory mechanisms during developmental chondrogene
sis: new paradigms for cartilage tissue engineering^len#Tissue Eng Part B Rev#2#
20090000#2009#15#29-41#20110400#804.htm##
00732000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100014000900100
01600104010001300120010001500133010001400148810000600162012012400168030002500292
06500090031706400050032603100030033101400080033486500090034200200080035103500100
0359801002500369#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#192#37#ar
ticle#39#37#^rND^sZhang^nM#^rND^sZhou^nQ#^rND^sLiang^nQQ#^rND^sLi^nCG#^rND^sHolz
^nJD#^rND^sTang^nD#et al#IGF-1 regulation of type II collagen and MMP-13 express
ion in rat endplate chondrocytes via distinct signaling pathways^len#Osteoarthri
tis Cartilage#20090000#2009#17#100-106#20110400#804.htm#1063-4584#Osteoarthritis
 Cartilage##
00747000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100017000930100
01500110010001500125010001900140010001600159810000600175012016200181030000600343
06500090034906400050035803100030036301400100036686500090037600200080038503500100
0393801000600403#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#193#38#ar
ticle#39#38#^rND^sYamamoto^nY#^rND^sMochida^nJ#^rND^sSakai^nD#^rND^sNakai^nT#^rN
D^sNishimura^nK#^rND^sKawada^nH#et al#Upregulation of the viability of nucleus p
ulposus cells by bone marrow-derived stromal cells: significance of direct cell-
to-cell contact in coculture system^len#Spine#20040000#2004#29#1508-1514#2011040
0#804.htm#0362-2436#SPINE##
00714000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100017000940100
02300111010001800134010001900152010001600171810000600187012008900193030002100282
06500090030306400050031203100030031701400080032086500090032800200080033703500100
0345801002100355#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\804.htm#S#c#194#39#ar
ticle#39#39#^rND^sGuillotin^nB#^rND^sBourget^nC#^rND^sRemy-Zolgadri^nM#^rND^sBar
eille^nR#^rND^sFernandez^nP#^rND^sConrad^nV#et al#Human primary endothelial cell
s stimulate human osteoprogenitor cell differentiation^len#Cell Physiol Biochem#
20040000#2004#14#325-332#20110400#804.htm#1015-8987#Cell Physiol Biochem##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#o#1#1#article#1#201
10411#094647#807.htm#151##
02970000000000589000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120091001780100025002690100027002940100028003210100026003490100029003750700
10200404070013700506083152600643085000802169085003602177085003002213085001902243
08500250226211700060228707200030229311200090229611100170230511400090232211300170
2331891002402348002000802372#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S
#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#03#BJMBR010#FAPESP#Braz J Med Biol R
es#44#4#20110400#^f283^l290#0100-879X#20110225#Overexpression of kermit/dGIPC is
 associated with lethality in Drosophila melanogaster^len#^rND^1A01^nG.B.^sPerei
ra#^rND^1A01 A02^nV.^sValente#^rND^1A01^nM.S.^sde Queiroz#^rND^1A01^nM.C.B.^sVia
nna#^rND^1A01^nM.L.^sPaçó-Larson#Universidade de São Paulo^iA01^1Departamento de
 Biologia Celular e Molecular e Bioagentes Patogênicos#Universidade de São Paulo
^iA02^1Faculdade de Medicina de Ribeirão Preto^2Departamento de Cirurgia e Anato
mia^cRibeirão Preto^sSP^pBrasil#^len^aInsertional mutagenesis is an important to
ol for functional genomics in Drosophila melanogaster. The insertion site in the
 KG00562 mutant fly line has been mapped to the CG8709 (herein named DmLpin) loc
us and to the 3&#8217; of kermit (also called dGIPC). This mutant line presents 
a high lethality rate resulting from a gain of function. To obtain some insight 
into the biological role of the mutated locus, we have characterized the mutatio
n and its relation to the high mortality of the KG00562 fly line. In this mutant
, we did not detect one of the DmLpin transcripts, namely DmLpinK, but we did de
tect an unusual 2.3-kb mRNA (LpinK-w). Further investigation revealed that the L
pinK-w transcript results from an aberrant splicing between the untranslated fir
st exon of DmLpinK and the mini-white marker gene. Lack of DmLpinK or LpinK-w ex
pression does not contribute to lethality, since heterozygous KG00562/Def7860 an
imals presented lethality rates comparable to those of the wild type. In contras
t, the overexpression of kermit was associated with lethality of the KG00562 fly
 line. Significantly higher levels of kermit were detected in the Malpighian tub
ules of KG00562/+ flies that presented higher lethality rates than wild-type or 
KG00562/Def7860 animals, in which the lethality was rescued. In agreement with a
 recently reported study, our data support the hypothesis that misexpression of 
kermit/dGIPC could interfere with Drosophila development, with further investiga
tions being needed in this direction.#^dnd^i1#^tm^len^kInsertional mutagenesis^i
1#^tm^len^kAberrant splicing^i1#^tm^len^kDmLpin^i1#^tm^len^kKermit/dGIPC^i1#othe
r#27#20101014#October 14, 2010#20110204#February 4, 2011#S0100-879X2011007500022
#807.htm##
03078000000000577000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120112001780100025002900100027003150100028003420100026003700100029003960700
10200425070013700527083162100664085000802285085003602293085003002329085002602359
08500320238511700060241707200030242311200090242611100240243511400090245911300240
2468002000802492#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#f#3#1#artic
le#1#oa#en#bjmbr#1#3.1#ILUS#TAB#03#BJMBR010#FAPESP#Braz J Med Biol Res#44#4#2011
0400#^f283^l290#0100-879X#20110225#<b>Overexpression of <i>kermit/dGIPC </i>is a
ssociated with lethality in<i> Drosophila melanogaster</i></b>^len#^rND^1A01^nG.
B.^sPereira#^rND^1A01 A02^nV.^sValente#^rND^1A01^nM.S.^sde Queiroz#^rND^1A01^nM.
C.B.^sVianna#^rND^1A01^nM.L.^sPaçó-Larson#Universidade de São Paulo^iA01^1Depart
amento de Biologia Celular e Molecular e Bioagentes Patogênicos#Universidade de 
São Paulo^iA02^1Faculdade de Medicina de Ribeirão Preto^2Departamento de Cirurgi
a e Anatomia^cRibeirão Preto^sSP^pBrasil#^len^aInsertional mutagenesis is an imp
ortant tool for functional genomics in <i>Drosophila melanogaster</i>. The inser
tion site in the KG00562 mutant fly line has been mapped to the CG8709 (herein n
amed <i>DmLpin</i>) <i>locus </i>and to the 3&#8217; of <i>kermit</i> (also call
ed <i>dGIPC</i>). This mutant line presents a high lethality rate resulting from
 a gain of function. To obtain some insight into the biological role of the muta
ted <i>locus</i>, we have characterized the mutation and its relation to the hig
h mortality of the KG00562 fly line. In this mutant, we did not detect one of th
e <i>DmLpin</i> transcripts, namely DmLpinK, but we did detect an unusual 2.3-kb
 mRNA (LpinK-w). Further investigation revealed that the LpinK-w transcript resu
lts from an aberrant splicing between the untranslated first exon of DmLpinK and
 the mini-white marker gene. Lack of DmLpinK or LpinK-w expression does not cont
ribute to lethality, since heterozygous KG00562/Def7860 animals presented lethal
ity rates comparable to those of the <em>wild type</em>. In contrast, the overex
pression of <i>kermit </i>was associated with lethality of the KG00562 fly line.
 Significantly higher levels of <i>kermit </i>were detected in the Malpighian tu
bules of KG00562/+ flies that presented higher lethality rates than <em>wild-typ
e</em> or KG00562/Def7860 animals, in which the lethality was rescued. In agreem
ent with a recently reported study, our data support the hypothesis that misexpr
ession of <i>kermit/dGIPC</i> could interfere with <i>Drosophila</i> development
, with further investigations being needed in this direction.#^dnd^i1#^tm^len^kI
nsertional mutagenesis^i1#^tm^len^kAberrant splicing^i1#^tm^len^k<i>DmLpin</i>^i
1#^tm^len^k<i>Kermit/dGIPC</i>^i1#other#27#20101014#<i>October 14, 2010</i>#2011
0204#<i>February 4, 2011</i>#807.htm##
03096000000000601000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762240009001860120091001950100025002860100026003110100028003370100027003650100
02900392070013200421070013900553083152600692085000802218085003602226085003002262
08500190229208500250231111700060233607200030234211200090234511100170235411400090
2371113001702380002000802397008008902405#v44n4#V:\SciELO\serial\bjmbr\v44n4\mark
up\807.htm#S#l#4#1#article#1#^mApr.^a2011#oa#en#bjmbr#1#3.1#ilus#tab#03#BJMBR010
#FAPESP#Braz. j. med. biol. res#44#4#20110400#^f283^l290#0100-879X#20110225#Over
expression of kermit/dGIPC is associated with lethality in Drosophila melanogast
er^len#^rND^1A01^nG. B^sPereira#^rND^1A01 A02^nV^sValente#^rND^1A01^nM. S^sde Qu
eiroz#^rND^1A01^nM. C. B^sVianna#^rND^1A01^nM. L^sPaçó-Larson#^iA01^1Universidad
e de São Paulo^2Departamento de Biologia Celular e Molecular e Bioagentes Patogê
nicos^cRibeirão Preto^sSP^pBrasil#^iA02^1Universidade de São Paulo^2Faculdade de
 Medicina de Ribeirão Preto^3Departamento de Cirurgia e Anatomia^cRibeirão Preto
^sSP^pBrasil#^len^aInsertional mutagenesis is an important tool for functional g
enomics in Drosophila melanogaster. The insertion site in the KG00562 mutant fly
 line has been mapped to the CG8709 (herein named DmLpin) locus and to the 3&#82
17; of kermit (also called dGIPC). This mutant line presents a high lethality ra
te resulting from a gain of function. To obtain some insight into the biological
 role of the mutated locus, we have characterized the mutation and its relation 
to the high mortality of the KG00562 fly line. In this mutant, we did not detect
 one of the DmLpin transcripts, namely DmLpinK, but we did detect an unusual 2.3
-kb mRNA (LpinK-w). Further investigation revealed that the LpinK-w transcript r
esults from an aberrant splicing between the untranslated first exon of DmLpinK 
and the mini-white marker gene. Lack of DmLpinK or LpinK-w expression does not c
ontribute to lethality, since heterozygous KG00562/Def7860 animals presented let
hality rates comparable to those of the wild type. In contrast, the overexpressi
on of kermit was associated with lethality of the KG00562 fly line. Significantl
y higher levels of kermit were detected in the Malpighian tubules of KG00562/+ f
lies that presented higher lethality rates than wild-type or KG00562/Def7860 ani
mals, in which the lethality was rescued. In agreement with a recently reported 
study, our data support the hypothesis that misexpression of kermit/dGIPC could 
interfere with Drosophila development, with further investigations being needed 
in this direction.#^dnd^i1#^tm^len^kInsertional mutagenesis^i1#^tm^len^kAberrant
 splicing^i1#^tm^len^kDmLpin^i1#^tm^len^kKermit/dGIPC^i1#other#27#20101014#Octob
er 14, 2010#20110204#February 4, 2011#807.htm#Internet^ihttp://www.scielo.br/sci
elo.php?script=sci_arttext&pid=S0100-879X2011000400003##
00373000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014900070002000800219#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#5#1#article#120#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 283-290  </B> </font></P>      ^cY#807.htm##
00501000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704027700070002000800347#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#6#2#article#120#<p ALIGN="LEFT"><strong><
font face="Arial"><span lang="EN"><font size="5">Overexpression of <i>kermit/dGI
PC </i>is associated </font></span></font><font size="5" face="Arial"><span lang
="EN">with lethality in<i> Drosophila melanogaster </i></span></font></strong></
p>      ^cY#807.htm##
00811000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704058700070002000800657#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#7#3#article#120#<p ALIGN="LEFT"><font fac
e="Arial"><span lang="EN">G.B. Pereira<sup>1</sup>, V. Valente<sup>1,2</sup>, M.
S. de Queiroz<sup>1</sup>, M.C.B. Vianna<sup>1</sup> and <span lang="EN"><font f
ace="Arial, Helvetica, sans-serif"><sup><span lang="EN"><font face="Arial, Helve
tica, sans-serif"><b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v44
n4/recor.gif" border="0"></a></b> <a href="mailto:mlplarso@fmrp.usp.br"><img src
="/img/revistas/bjmbr/v44n4/email-ca.gif" border="0"></a></font></span></sup></f
ont></span> M.L. Pa&ccedil;&oacute;-Larson<sup>1</sup></span></font></p>      ^c
Y#807.htm##
00677000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704045300070002000800523#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#8#4#article#120#<p ALIGN="LEFT"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Departamento de Bio
logia Celular e Molecular e Bioagentes Patog&ecirc;nicos, </font></span><font fa
ce="Arial"><span lang="EN"><sup>2</sup>Departamento de Cirurgia e Anatomia, Facu
ldade de Medicina de Ribeir&atilde;o Preto, </span></font><font face="Arial"><sp
an lang="EN">Universidade de S&atilde;o Paulo, Ribeir&atilde;o Preto, SP, Brasil
</span></font></p>      ^cY#807.htm##
00414000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704019000070002000800260#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#9#5#article#120#<P> <font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#807.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#10#6#article#120#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#807.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#11#7#article#120#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#807.htm##
00397000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704017200071002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#12#8#article#120#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#807.htm##
00406000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018100071002000800252#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#13#9#article#120#<BR>   <A HREF="#Discuss
ion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#807
.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#14#10#article#120#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#807.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#15#11#article#120#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#807.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#16#12#article#120#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#807.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#17#13#article#120#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#807.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#18#14#article#120#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#807.htm##
01919000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704169300072002000801765#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#19#15#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Insertional mutagenesis is an important tool for fun
ctional genomics in <i>Drosophila melanogaster</i>. The insertion site in the KG
00562 mutant fly line has been mapped to the CG8709 (herein named <i>DmLpin</i>)
 <i>locus </i>and to the 3&rsquo; of <i>kermit</i> (also called <i>dGIPC</i>). T
his mutant line presents a high lethality rate resulting from a gain of function
. To obtain some insight into the biological role of the mutated <i>locus</i>, w
e have characterized the mutation and its relation to the high mortality of the 
KG00562 fly line. In this mutant, we did not detect one of the <i>DmLpin</i> tra
nscripts, namely DmLpinK, but we did detect an unusual 2.3-kb mRNA (LpinK-w). Fu
rther investigation revealed that the LpinK-w transcript results from an aberran
t splicing between the untranslated first exon of DmLpinK and the mini-white mar
ker gene. Lack of DmLpinK or LpinK-w expression does not contribute to lethality
, since heterozygous KG00562/Def7860 animals presented lethality rates comparabl
e to those of the <em>wild type</em>. In contrast, the overexpression of <i>kerm
it </i>was associated with lethality of the KG00562 fly line. Significantly high
er levels of <i>kermit </i>were detected in the Malpighian tubules of KG00562/+ 
flies that presented higher lethality rates than <em>wild-type</em> or KG00562/D
ef7860 animals, in which the lethality was rescued. In agreement with a recently
 reported study, our data support the hypothesis that misexpression of <i>kermit
/dGIPC</i> could interfere with <i>Drosophila</i> development, with further inve
stigations being needed in this direction.</span></font></p>      ^cY#807.htm##
00418000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019200072002000800264#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#20#16#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Key words: Insertional mutagenesis; Aberrant splicin
g; <i>DmLpin</i>; <i>Kermit/dGIPC</i></span></font></p>  <HR ALIGN=LEFT SIZE=2> 
     ^cY#807.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#21#17#article#120#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#807.htm##
01438000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704121200072002000801284#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#22#18#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The <i>kermit</i> gene was first described in <i>Xen
opus</i> (1) and it was later shown that it shares 72% identity with mammalian G
IPC proteins (2). The PDZ-domain of GIPC proteins has been identified in several
 organisms through its interaction with a variety of binding partners, including
 many membrane proteins (3). Despite several reports on Xkermit/GIPC proteins, t
heir endogenous functions and the physiological roles of their interactions with
 several binding proteins are not well known. However, studies of loss of functi
on in<i> Xenopus </i>have shown that <i>kermit</i> is required for frizzled-3 in
duction in the neural crest of ectodermal explants (1,4) and for insulin-like gr
owth factor (IGF) signaling during the development of <i>Xenopus </i>eye (1,3). 
A recent report on <i>Drosophila</i> suggests that<i> kermit</i> (which was name
d <i>dGIPC)</i> might participate in the determination of the planar cell polari
ty of the wing epithelium by a mechanism independent of frizzled-3 (5). In addit
ion, <i>dGIPC</i> loss of function was reported to be associated with <i>Drosoph
ila</i> motor activity and longevity (6).</span></font></p>      ^cY#807.htm##
01629000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704140300072002000801475#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#23#19#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The KG00562 mutant contains the insertion of a trans
poson, with a P element-based construction P(SUPor-P) (7) in the first intron of
 a new isoform of the CG8709, named DmLpinK (8), and in the 3&rsquo; flanking re
gion of the <i>kermit</i> gene. Interestingly, the untranslated first exon of <i
>kermit</i> corresponds to the first exon of the DmLpinK isoform (<a href="#Fig1
">Figure 1A</a>). The isoforms encoded by <i>DmLpin</i> are homologous of lipins
 (8), which constitute a novel family of Mg<sup>2+</sup>-dependent phosphatidate
 phosphatase (PAP1) enzymes (9). These enzymes catalyze the dephosphorylation of
 phosphatidic acid to yield diacylglycerol. Lipins play important roles in sever
al cellular and physiological processes, as shown by studies performed on other 
organisms, including yeast, worms, and mammals (for a review, see Refs. 10,11). 
The yeast lipin homolog known as Pah1p controls the phospholipid biosynthesis re
quired for the nuclear and endoplasmic reticulum membranes (12,13). The <i>Caeno
rhabditis elegans</i> lipin is also needed for the maintenance of normal nuclear
 and endoplasmic reticulum morphology (14,15). In mammals, lipins are involved i
n the control of fatty acid metabolism (16) and in adipocyte differentiation (17
,18). Data on <i>Drosophila</i> lipin function are virtually inexistent.</span><
/font></p>      ^cY#807.htm##
01220000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704099400072002000801066#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#24#20#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">To gain some insights on the biological roles of <i>
DmLpin </i>and/or<i> Kermit</i> we have investigated the molecular bases of the 
semi-lethal mutation found in the KG00562 fly line. We show that the DmLpinK iso
form is not detected in the KG00562 fly line, whereas an unusual 2.3 kb mRNA is 
expressed instead. We also observed that this mutant presents a high lethality r
ate that was not rescued in the wild-type background, characterizing a gain of f
unction phenotype. Hence, we asked whether the lack of DmLpinK or the expression
 of this unusual mRNA was associated with this high lethality rate. We demonstra
ted that neither of these alterations is related to the lethality phenotype of t
he KG00562 fly line. Interestingly, we found that the overexpression of the <i>k
ermit</i> gene in Malpighian tubules seems to be associated with the gain of fun
ction observed in the KG00562 fly line.</span></font></p>  <HR ALIGN=LEFT SIZE=2
>      ^cY#807.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#25#21#article#120#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#807.htm##
00347000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704012100072002000800193#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#26#22#article#120#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN"><i>Drosophila</i> lines and culture</span></font>
</b></p>      ^cY#807.htm##
00972000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704074600072002000800818#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#27#23#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The flies were grown in standard cornmeal/agar media
 at 25&deg;C. CantonS (CS) and w<sup>1118</sup> flies were obtained from the lab
oratory of Dr. R.G.P. Ramos, FMRP, USP (Ribeir&atilde;o Preto, SP, Brazil). The 
KG00562 [y<sup>1</sup>w<sup>67c23</sup>; P(SUPor-P)KG00562], and Def7860 (w<sup>
1118</sup>; Df(2R)Exel7095/CyO) fly lines were obtained from the Bloomington Sto
ck Center (Bloomington, USA). The KG00562 mutant carries a P(PUPor-P) insertion 
in which the 3&rsquo; has been mapped to the 4,033,487 position on the 2R chromo
some (7,19). The Df(2R)Exel7095 has a ~100 kb deletion that extends from positio
n 4,012,164 to position 4,119,968 of the 2R chromosome.</span></font></p>      ^
cY#807.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704015800072002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#28#24#article#120#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">RNA extraction, Northern blot, 3&rsquo; end RACE 
cloning, and sequencing</span></font></b></p>      ^cY#807.htm##
02402000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704217600072002000802248#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#29#25#article#120#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Drosophila</i> total RNA was extracted using Tri
zol reagent (Invitrogen, New Zealand) according to manufacturer instructions. Po
lyA<sup>+</sup> RNA was purified with the OligoTex mRNA midi kit (Qiagen, German
y). In Northern blot hybridization experiments, RNA was fractionated on 1% agaro
se formaldehyde-denaturing gels and blotted to nylon membranes (Hybond N, Amersh
an, UK). Probe labeling, hybridization and post-hybridization washes were perfor
med essentially as described by Sambrook et al. (20). The final washes were perf
ormed at 65&deg;C in the presence of 0.1X SSC and 0.2% SDS. The cDNA of LpinB-w 
was cloned by rapid amplification of cDNA 3&rsquo;-end (RACE) using the 3&rsquo;
RACE System for Rapid Amplification of cDNA ends (Invitrogen, USA). A total of 5
00 ng KG00562 polyA<sup>+</sup> RNA in 20 &micro;L buffer containing 500 nM of t
he adaptor primer was incubated at 70&deg;C for 10 min and cooled on ice for 1 m
in. The reaction proceeded for 15 min at 70&deg;C in 20 mM Tris-HCl, pH 8, 50 mM
 KCl, 10 mM DTT, 0.5 mM dNTP, and 200 U Superscript II-RT (Invitrogen). PCR was 
performed with 3&rsquo;-RACE-Ready cDNAs (2 &micro;L) in a 50-&micro;L reaction 
mixture containing 0.2 mM dNTPs, 0.2 mM LpinB/Kermit first exon-specific primer 
(GSP-RACE-3&rsquo;; <a href="#Tab1">Table 1</a>), 0.2 mM Abridged Universal Ampl
ification Primer (AUAP), 20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.5 mM MgCl<sub>2</s
ub>, and 0.1 U Taq DNA polymerase (Fermentas, USA). The 3&rsquo;-end was obtaine
d with 37 cycles of denaturation (94&deg;C for 2 min), annealing (66&deg;C for 4
5 s), and extension (72&deg;C for 4 min). Finally, the 3&rsquo;-RACE-PCR product
 was gel-purified, cloned, and fully sequenced using the BigDye Terminator Cycle
 Sequencing Ready Reaction (PE Applied Biosystems, USA), M13 primers, and gene-s
pecific primers (<a href="#Tab1">Table 1</a>). Sequencing was performed with an 
ABI 3100 Genetic Analyzer (Applied Biosystems-HITACHI, USA). Sequence analysis a
nd clustering were performed using the STADEN software package and the amino aci
d sequence alignment was done using ClustalW.</span></font></p>      ^cY#807.htm
##
00341000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011500072002000800187#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#30#26#article#120#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Quantitative real-time RT-PCR</span></font></b></
p>      ^cY#807.htm##
01427000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704120100072002000801273#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#31#27#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">For quantitative real-time RT-PCR (qRT-PCR), 700 ng 
RNA was converted to cDNA with SuperScript II (Invitrogen). To amplify and detec
t the isoform-specific PCR products we used the SYBR Green PCR Master Mix (PE Ap
plied Biosystems) according to the manufacturer protocol. The primer sequences a
re shown in <a href="#Tab1">Table 1</a>. Reactions without template were run in 
parallel for all plates to verify purity of measurements within each experiment.
 Each run was completed with a melting curve analysis to confirm the specificity
 of the amplification and to confirm absence of primer dimers. The mean threshol
d cycle of a mixture of equal amounts of CS and KG00562 RNA was used as a refere
nce sample. The relative mRNA expression levels of target transcripts and the Rp
L32A gene (housekeeping) were quantified using a Gene Amp<sup>&reg;</sup> 7500 S
equence Detection System (PE Applied Biosystems). The qRT-PCR analyses were repe
ated three times and data were analyzed statistically by one-way analysis of var
iance (ANOVA) and by the Tukey multiple-comparison test (GraphPad Prism, version
 5.0).</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#807.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#32#28#article#120#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#807.htm##
00396000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017000072002000800242#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#33#29#article#120#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Characterization of the anomalous mRNA (LpinK-w) 
expressed in the KG00562 mutant fly</span></font></b></p>      ^cY#807.htm##
02005000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704177900072002000801851#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#34#30#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Northern blot of mRNA from both heterozygous and hom
ozygous KG00562 mutant flies probed with a fragment derived from the first exon 
of DmLpinK and <i>kermit</i> (probe B, <a href="#Fig1">Figure 1B</a>) revealed t
hat an mRNA of about 2.3 kb was not detected in CS wild-type flies. This unusual
 mRNA was not detected in the mutant when a DmLpinA-specific probe was used. Mor
eover, DmLpinK mRNA was not detected in the KG00562 flies, although the signal o
f <i>kermit</i> seemed to be unaffected (<a href="#Fig1">Figure 1C</a>). To dete
rmine the primary structure of the KG00562-specific transcript we performed 3&rs
quo;-RACE PCR using a gene-specific primer based on the sequence of probe B. The
 cloned cDNA revealed a sequence of 2305 bp (HM000003). The alignment of this se
quence with the <i>D. melanogaster</i> genome showed that this mRNA contains par
t of the untranslated first exon of DmLpinK and <i>kermit</i>, and the second, t
hird, fourth, fifth, and sixth exons of the white gene (<a href="#Fig2">Figure 2
A</a>). The presence of the DmLpinK/<i>kermit</i> first exon acceptor site and t
he donor splicing site of the second exon of white indicate that this new mRNA r
esulted from an aberrant splicing between the DmLpinK or <i>kermit</i> first exo
n and the second exon of the mini-white gene, present in the P(SUPor-P) transpos
on. The mRNA expressed in the KG00562 mutant was named LpinK-w (<a href="#Fig2">
Figure 2A</a>). The open reading frame of LpinK-w encodes a 770-amino acid seque
nce that corresponds to the white protein lacking the first 23 amino acids, whic
h maintains the ATP Binding Cassette (ABC) Transporter Complex domain required f
or its activity (<a href="#Fig2">Figure 2B</a>).</span></font></p>      ^cY#807.
htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#35#31#article#120#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Lethality of flies carrying the KG00562 insertion
 in different genetic backgrounds</span></font></b></p>      ^cY#807.htm##
01246000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704102000072002000801092#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#36#32#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Mutant flies homozygous for the KG00562 insertion pr
esented 48% lethality during development, which was significantly higher (P &lt;
 0.001) than the lethality observed for w- (w<sup>1118</sup>) or CS flies. The h
igh lethality rate of KG00562 was not rescued in the progeny obtained from cross
es of the mutant with w<sup>1118</sup> or CS flies, which presented an average l
ethality of 52 and 60%, respectively (<a href="#Tab2">Table 2</a>). These result
s suggest that the lethality associated with the KG00562 fly line is the result 
of a gain of function mutation. Additionally, the lethality of the progeny obtai
ned from crosses of the KG00562 line with flies carrying a ~100-kb deletion (Def
7860), which covers the mutated region, did not differ from the lethality of CS 
wild-type flies (<a href="#Tab2">Table 2</a>), indicating that the gain of funct
ion phenotype observed in KG00562 flies is related to alterations in this genomi
c region.</span></font></p>      ^cY#807.htm##
00414000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018800072002000800260#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#37#33#article#120#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Tissue expression of DmLpinK, <i>kermit</i>, and 
LpinK-w in animals with different genetic backgrounds</span></font></b></p>     
 ^cY#807.htm##
00865000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704063900072002000800711#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#38#34#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">To determine whether the chimeric mRNA LpinK-w expre
ssed in the KG00562 fly line results from an aberrant splicing of DmLpinK or <i>
kermit</i> mRNAs, we compared the expression profile of LpinK-w with that of DmL
pinK and <i>kermit</i> transcripts in the KG00562 mutant and wild-type tissues. 
These analyses were performed with total RNA extracted from the central nervous 
system (CNS), intestinal tract, and Malpighian tubules of 3rd-instar larvae, bec
ause of previous indications that <i>DmLpin</i> isoforms were differentially exp
ressed in these tissues (8).</span></font></p>      ^cY#807.htm##
01016000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704079000072002000800862#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#39#35#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Confirming our initial data, the DmLpinK transcripts
 were expressed in significantly higher levels (P &lt; 0.001) in the CNS of wild
-type animals than in the other tissues analyzed, but were not detected in the t
issues of the KG00562 mutant (<a href="#Fig3">Figure 3</a>). The chimeric LpinK-
w presented an expression pattern virtually identical to that of the wild-type D
mLpinK mRNA (<a href="#Fig3">Figure 3</a>). <i>Kermit</i> transcripts were detec
ted at low levels in all tissues of the wild-type CS larvae, while in the KG0056
2 mutant their levels were significantly higher (P &lt; 0.001) in the intestinal
 tract and in the Malpighian tubules when compared to the wild type (<a href="#F
ig3">Figure 3</a>).</span></font></p>      ^cY#807.htm##
01549000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704132300072002000801395#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#40#36#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The reduction of DmLpinK and/or the overexpression o
f <i>kermit</i> in the different larval tissues could be associated with the let
hality of KG00562 flies. To address this question we measured the levels of thes
e mRNAs in the progeny of crosses between KG00562 and CS or Def7860 animals, whe
re the lethality was approximately 60 and 17%, respectively (<a href="#Tab2">Tab
le 2</a>). DmLpinK levels were reduced in all tissues analyzed of animals carryi
ng the KG00562 insertion in both genetic backgrounds when compared to the wild-t
ype flies (<a href="#Fig4">Figure 4</a>). Similarly, <i>kermit</i> levels were a
lso reduced in the CNS and intestinal tract of larvae carrying the KG00562 inser
tion in both genetic backgrounds. Conversely, in the Malpighian tubules, the amo
unts of <i>kermit</i> transcripts in the KG00562/+ and KG00562/Def7860 flies dif
fered significantly, being increased in the former (~1.8-fold) and reduced in th
e latter (~0.6-fold) progenies compared to wild-type animals (<a href="#Fig4">Fi
gure 4</a>).</span></font></p>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <
tr align="left" valign="top">      <td><a href="/img/revistas/bjmbr/v44n4/html/8
07i01.htm"><img src="/img/revistas/bjmbr/v44n4/807i01peq.jpg" border="2"></a></t
d>      <td>    ^cY#807.htm##
01463000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704123700072002000801309#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#41#37#article#120#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. 
KG00562 expresses an anomalous mRNA detected by a probe for the 5&rsquo; UTR of 
DmLpinK and <i>kermit</i>. <i>A</i>, Map of CG8709 (<i>DmLpin</i>) and <i>kermit
 </i>gene span and the insertion site of the transposon P(SUPor-P) (7) in the ge
nome of the KG00562 <i>Drosophila</i> fly line. <i>B</i>, Schematic representati
on of the exon-intron organization of DmLpinA (CG8709-RA) and DmLpinK (GU327733)
 and predicted isoforms A, B, C, and D of the <i>kermit</i> gene. The exons are 
represented by bars and the introns by lines. Noncoding sequences are shown as n
arrower portions of the exon bars. The arrowheads on the intron lines indicate t
he transcription direction. <i>C</i>, Northern blots of polyA<sup>+</sup> RNA of
 CantonS, KG00562/Cy, and KG00562 flies probed with the last exon exclusive of D
mLpinA (probe A) or with a fragment of the first exon of the DmLpinK and <i>kerm
it</i> (probe B). Note that probe B, but not probe A, detected an mRNA of about 
2.5 kb (LpinB-w) in flies with the KG00562 background. The DmLpinK was not detec
ted in lines carrying the insertion.</font></span></p>      </td>    </tr>  </ta
ble>      ^cY#807.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033700072002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#42#38#article#120#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (99 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/807i02.htm"><img src="/img/
revistas/bjmbr/v44n4/807i02peq.jpg" border="2"></a></td>      <td>    ^cY#807.ht
m##
01340000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704111400072002000801186#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#43#39#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig2"></a>Figure 2. The anomalous mRNA expr
essed in the KG00562 fly is a chimera resulting from aberrant splicing. <i>A</i>
, Diagram of the exon-intron structure of the anomalous mRNA named LpinK-w. The 
first exon (grey box) corresponds to the 5&rsquo;UTR of the DmLpinK and <i>kermi
t</i> and the other five boxes (white) correspond to the second, third, fourth, 
fifth, and sixth exons of the mini-white marker gene. The nucleotide sequence of
 the mRNA 5&rsquo; region, including the first and second spliced exons, is show
n below. The DmLpinK and <i>kermit</i> first exon 3&rsquo; sequence is in black 
and the white second exon 5&rsquo; sequence is in grey. The donor and acceptor s
plice sites are underlined. <i>B</i>, Alignment between amino acid sequences of 
the white protein and the polypeptide deduced from the LpinK-w mRNA. Note that t
he ABC domain (ATP Binding Cassette Transporter Complex) highlighted by the grey
 box is maintained in a polypeptide encoded by the chimeric mRNA LpinK-w.</span>
</font></p>      </td>    </tr>  </table>      ^cY#807.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033800072002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#44#40#article#120#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (191 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/807i03.htm"><img src="/img
/revistas/bjmbr/v44n4/807i03peq.jpg" border="2"></a></td>      <td>    ^cY#807.h
tm##
00915000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704068900072002000800761#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#45#41#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig3"></a>Figure 3. The expression of DmLpi
nK and <i>kermit</i> is affected in the KG00562 line. qRT-PCR of DmLpinK, <i>ker
mit</i>, and LpinK-w are shown in different tissues (central nervous system, int
estinal tract, and Malpighian tubules) of the KG00562 mutant and CantonS (wild t
ype) 3rd-instar larvae. Data are reported as means &plusmn; SEM (N = 3). For DmL
pinK and LpinK-w, the asterisks denote significant differences between tissues (
*P &lt; 0.001, Tukey test). In the case of <i>Kermit</i>, the comparison was bet
ween CS and KG00562 (*P &lt; 0.001, Tukey test).</span></font></p>      </td>   
 </tr>  </table>      ^cY#807.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033700072002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#46#42#article#120#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (97 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/807i04.htm"><img src="/img/
revistas/bjmbr/v44n4/807i04peq.jpg" border="2"></a></td>      <td>    ^cY#807.ht
m##
00425000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019900072002000800271#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#47#43#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Fig4"></a>Figure 4. Overexpression of <i>ke
rmit</i> in the Malpighian tubules is maintained in animals carrying KG00562 mut
ation in    ^cY#807.htm##
00768000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704054200072002000800614#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#48#44#article#120#<br>   CantonS wild-typ
e background (CS). qRT-PCR of DmLpinK and <i>kermit</i> in different tissues (ce
ntral nervous system, intestinal tract, and Malpighian tubules) of 3rd-instar la
rvae. The tissues analyzed were from the progenies of crosses between KG00562 x 
CantonS (CS) and KG00562 x Def7860. Data are reported as means &plusmn; SEM (N =
 3) of each mRNA level in comparison to its level in CS. Asterisks denote signif
icant differences between groups (*P &lt; 0.001, Tukey test).</span></font></p> 
     </td>    </tr>  </table>      ^cY#807.htm##
00559000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033300072002000800405#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#49#45#article#120#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (60 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/807t01.htm"><img src="/img/
revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td>    ^cY#807.htm##
00406000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018000072002000800252#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#50#46#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN"><a name="Tab1"></a>Table 1. Primer sequences used in
 the present study.</span></font></p>      </td>    </tr>  </table>      ^cY#807
.htm##
00754000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704052800072002000800600#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#51#47#article#120#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (186 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/807t02.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td><span lang="EN"><
font face="Arial"><span lang="EN"><a name="Tab2"></a>Table 2. Lethality of the p
rogenies from crosses between different fly lines.</span></font></span></td>    
</tr>  </table>      ^cY#807.htm##
00344000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011800072002000800190#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#52#48#article#120#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (132 K JPG file)]</font
></P>      ^cY#807.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#53#49#article#120#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#807.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#54#50#article#120#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#807.htm##
03393000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704316700072002000803239#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#55#51#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">In this study we investigated the molecular bases of
 the semi-lethal mutation found in the KG00562 fly line. Our data show that the 
insertion of the P(SUPor-P) transposable element in KG00562 resulted in an aberr
ant splicing between DmLpinK and the mini-white marker gene (<a href="#Fig2">Fig
ure 2</a>). A similar mutagenic event has been reported for the PZ <i>lacZ rosy<
/i> transposon. The insertion of this transposon in the second intron of the <i>
pipsqueak</i> gene resulted in an aberrant splicing and in events of premature t
ranscription termination that produced an mRNA composed of 5&rsquo; sequences fr
om <i>pipsqueak</i> and 3&rsquo; sequences from the PZ element (21). Such a muta
tion could yield chimeric proteins with dominant effects. However, this is not t
he case for KG00562. We observed that, rather than a chimeric protein, the aberr
ant mRNA (LpinK-w) expressed in the KG00562 fly line encodes an aminoterminal de
leted white protein containing the ABC domain (ATP Binding Cassette; <a href="#F
ig2">Figure 2</a>). The ABC domain is required for the white function in transpo
rting molecules across membranes, such as the pigment precursors tryptophan and 
guanine (22-24), and the cGMP in Malpighian tubules (25). Lack of the white func
tion impairs pigment production in the light-screening cells of the compound eye
 resulting in flies with white eyes, which is the most prominent phenotype of <i
>w </i>mutants. The eye color provided by the <i>mini-white</i> expression in a 
<i>w-</i> (<i>w<sup>67c23</sup></i>) recipient line was used to identify P(SUPor
-P) transformants (5); thus the LpinK-w expression in the KG00562 fly line does 
not interfere with the white function. Ectopic overexpression of <i>white</i>, d
riven by a heat shock promoter, led to a marked change in the sexual behavior of
 mature adult males (26). Therefore, misexpression of the truncated white could 
contribute to the lethality of the KG00562 line. However, significantly higher r
ates of lethality (P &lt; 0.001) were still observed in heterozygous KG00562/w+ 
or KG00562/w- flies (<a href="#Tab2">Table 2</a>), while in heterozygous animals
 carrying the KG00562 insertion over a deletion that covers the mutated region (
<a href="#Tab2">Table 2</a>) the lethality phenotype was rescued. These data sug
gest that, rather than the expression of the chimeric LpinK-w mRNA, alterations 
in other genes covered by this deletion (Def7860) might be related to the lethal
ity. Lack of DmLpinK expression does not seem to contribute to lethality, since 
heterozygous KG00562/Def7860 animals, where DmLpinK expression does not occur (<
a href="#Fig4">Figure 4</a>), present lethality rates similar to those of the CS
 wild type (<a href="#Tab2">Table 2</a>). It is possible that the expression of 
the DmLpinA isoform, which seems to be normally expressed in the KG00562 fly lin
e (<a href="#Fig1">Figure 1</a>), compensates for the lack of the DmLpinK isofor
m. Accordingly, recent data showed that the increase of lipin-2 levels counterba
lance the PAP1 activity in the liver of mice deficient in <i>Lpin1 </i>(27).</sp
an></font></p>      ^cY#807.htm##
01597000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704137100072002000801443#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#56#52#article#120#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The overexpression of <i>kermit </i>was revealed to 
be associated with the lethality of the KG00562 fly, although we cannot rule out
 the involvement of other genes covered by the Def7860 deficiency. Significantly
 higher levels of <i>kermit</i> (1.8- to 3.0-fold) were observed in the Malpighi
an tubules of KG00562/+ flies in comparison to both CS line and KG00562/Def7860 
animals (<a href="#Fig4">Figure 4</a>). Since in the heterozygous KG00562/+ flie
s the lethality is highly elevated and in heterozygous KG00562/Def7860 the letha
lity phenotype is rescued to levels similar to those of CS wild type (<a href="#
Tab2">Table 2</a>), the overexpression of <i>kermit</i> is the only alteration o
bserved that can be associated with the KG00562 lethality. This agrees with a re
cent report showing that, although <i>kermit/dGIPC</i> is not essential for deve
lopment, increased doses of this gene can be deleterious. It was demonstrated th
at overexpression of <i>dGPIC</i> on the dorsal thorax interferes with the gener
ation of planar cell polarity in the wing (5). Further investigations on the eff
ect of <i>kermit/dGIPC </i>overexpression in specific tissues or developmental s
tages should contribute to understanding the role of this gene in <i>Drosophila 
</i>development.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#807.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#57#53#article#120#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#807.htm##
00514000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027400074002000800348#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#58#54#article#120#1#<p ALIGN=
"LEFT"><span lang="EN"><font face="Arial">1. Tan C, Deardorff MA, Saint-Jeannet 
JP, Yang J, Arzoumanian A, Klein PS. Kermit, a frizzled interacting protein, reg
ulates frizzled 3 signaling in neural crest development. <i>Development</i> 2001
; 128: 3665-3674.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#59#55#article#120#</font></span></p>     
 ^cY#807.htm##
00500000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704026000074002000800334#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#60#56#article#120#2#<p align=
"LEFT"><span lang="EN"><font face="Arial">2. De Vries L, Lou X, Zhao G, Zheng B,
 Farquhar MG. GIPC, a PDZ domain containing protein, interacts specifically with
 the C terminus of RGS-GAIP. <i>Proc Natl Acad Sci U S A</i> 1998; 95: 12340-123
45.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#61#57#article#120#</font></span></p>     
 ^cY#807.htm##
00513000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704028700072002000800359#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#62#58#article#120#<p align="LEFT"><span l
ang="EN"><font face="Arial">3. Wu J, O&rsquo;Donnell M, Gitler AD, Klein PS. Ker
mit 2/XGIPC, an IGF1 receptor interacting protein, is required for IGF signaling
 in <i>Xenopus </i>eye development. <i>Development</i> 2006; 133: 3651-3660.</fo
nt></span></p>      ^cY#807.htm##
00489000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024900074002000800323#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#63#59#article#120#4#<p align=
"LEFT"><span lang="EN"><font face="Arial">4. Rasmussen JT, Deardorff MA, Tan C, 
Rao MS, Klein PS, Vetter ML. Regulation of eye development by frizzled signaling
 in <i>Xenopus</i>. <i>Proc Natl Acad Sci U S A</i> 2001; 98: 3861-3866.    ^cY#
807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#64#60#article#120#</font></span></p>     
 ^cY#807.htm##
00491000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704025100074002000800325#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#65#61#article#120#5#<p align=
"LEFT"><span lang="EN"><font face="Arial">5. Djiane A, Mlodzik M. The <i>Drosoph
ila </i>GIPC homologue can modulate myosin based processes and planar cell polar
ity but is not essential for development. <i>PLoS One</i> 2010; 5: e11228.    ^c
Y#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#66#62#article#120#</font></span></p>     
 ^cY#807.htm##
00467000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704022700074002000800301#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#67#63#article#120#6#<p align=
"LEFT"><span lang="EN"><font face="Arial">6. Kim J, Lee S, Ko S, Kim-Ha J. dGIPC
 is required for the locomotive activity and longevity in <i>Drosophila</i>. <i>
Biochem Biophys Res Commun</i> 2010; 402: 565-570.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#68#64#article#120#</font></span></p>     
 ^cY#807.htm##
00618000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704037800074002000800452#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#69#65#article#120#7#<p align=
"LEFT"><font face="Arial, Helvetica, sans-serif"><span LANG="EN">7. Roseman RR, 
Johnson EA, Rodesch CK, Bjerke M, Nagoshi RN, Geyer PK. A P element containing s
uppressor of hairy-wing binding regions has novel properties for mutagenesis in 
<i>Drosophila melanogaster</i>. </span><i><span LANG="PT-BR">Genetics</span></i>
<span LANG="PT-BR"> 1995; 141: 1061-1074.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#70#66#article#120#</span></font></p>     
 ^cY#807.htm##
00571000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704033100074002000800405#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#71#67#article#120#8#<p align=
"LEFT"> <font face="Arial"><span LANG="PT-BR">8. Valente V, Maia RM, Vianna MC, 
Paco-Larson ML. </span><i><span LANG="EN">Drosophila melanogaster</span></i><spa
n LANG="EN"> lipins are tissue-regulated and developmentally regulated and prese
nt specific subcellular distributions. <i>FEBS J</i> 2010; 277: 4775-4788.    ^c
Y#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#72#68#article#120#</span></font></p>     
 ^cY#807.htm##
00483000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024300074002000800317#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#73#69#article#120#9#<p align=
"LEFT"><span lang="EN"><font face="Arial">9. Han GS, Wu WI, Carman GM. The <i>Sa
ccharomyces cerevisiae</i> Lipin homolog is a Mg<sup>2+</sup>-dependent phosphat
idate phosphatase enzyme. <i>J Biol Chem</i> 2006; 281: 9210-9218.    ^cY#807.ht
m##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#74#70#article#120#</font></span></p>     
 ^cY#807.htm##
00402000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704016100075002000800236#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#75#71#article#120#10#<p align
="LEFT"><span lang="EN"><font face="Arial">10. Siniossoglou S. Lipins, lipids an
d nuclear envelope structure. <i>Traffic</i> 2009; 10: 1181-1187.    ^cY#807.htm
##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#76#72#article#120#</font></span></p>     
 ^cY#807.htm##
00399000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704015800075002000800233#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#77#73#article#120#11#<p align
="LEFT"><span lang="EN"><font face="Arial">11. Reue K. The lipin family: mutatio
ns and metabolism. <i>Curr Opin Lipidol</i> 2009; 20: 165-170.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#78#74#article#120#</font></span></p>     
 ^cY#807.htm##
00485000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704024400075002000800319#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#79#75#article#120#12#<p align
="LEFT"><span lang="EN"><font face="Arial">12. Santos-Rosa H, Leung J, Grimsey N
, Peak-Chew S, Siniossoglou S. The yeast lipin Smp2 couples phospholipid biosynt
hesis to nuclear membrane growth. <i>EMBO J</i> 2005; 24: 1931-1941.    ^cY#807.
htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#80#76#article#120#</font></span></p>     
 ^cY#807.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033700072002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#81#77#article#120#<p align="LEFT"><span l
ang="EN"><font face="Arial">13. O&rsquo;Hara L, Han GS, Peak-Chew S, Grimsey N, 
Carman GM, Siniossoglou S. Control of phospholipid synthesis by phosphorylation 
of the yeast lipin Pah1p/Smp2p Mg<sup>2+</sup>-dependent phosphatidate phosphata
se. <i>J Biol Chem</i> 2006; 281: 34537-34548.</font></span></p>      ^cY#807.ht
m##
00525000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704028400075002000800359#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#82#78#article#120#14#<p align
="LEFT"><span lang="EN"><font face="Arial">14. Golden A, Liu J, Cohen-Fix O. Ina
ctivation of the <i>C. elegans</i> lipin homolog leads to ER disorganization and
 to defects in the breakdown and reassembly of the nuclear envelope. <i>J Cell S
ci</i> 2009; 122: 1970-1978.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#83#79#article#120#</font></span></p>     
 ^cY#807.htm##
00467000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704022600075002000800301#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#84#80#article#120#15#<p align
="LEFT"><span lang="EN"><font face="Arial">15. Gorjanacz M, Mattaj IW. Lipin is 
required for efficient breakdown of the nuclear envelope in <i>Caenorhabditis el
egans</i>. <i>J Cell Sci</i> 2009; 122: 1963-1969.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#85#81#article#120#</font></span></p>     
 ^cY#807.htm##
00435000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704019400075002000800269#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#86#82#article#120#16#<p align
="LEFT"><span lang="EN"><font face="Arial">16. Reue K, Zhang P. The lipin protei
n family: dual roles in lipid biosynthesis and gene expression. <i>FEBS Lett</i>
 2008; 582: 90-96.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#87#83#article#120#</font></span></p>     
 ^cY#807.htm##
00514000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704027300075002000800348#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#88#84#article#120#17#<p align
="LEFT"><span lang="EN"><font face="Arial">17. Phan J, Peterfy M, Reue K. Lipin 
expression preceding peroxisome proliferator-activated receptor-gamma is critica
l for adipogenesis <i>in vivo</i> and <i>in vitro</i>. <i>J Biol Chem</i> 2004; 
279: 29558-29564.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#89#85#article#120#</font></span></p>     
 ^cY#807.htm##
00499000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025800075002000800333#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#90#86#article#120#18#<p align
="LEFT"><span lang="EN"><font face="Arial">18. Peterfy M, Phan J, Reue K. Altern
atively spliced lipin isoforms exhibit distinct expression pattern, subcellular 
localization, and role in adipogenesis. <i>J Biol Chem</i> 2005; 280: 32883-3288
9.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#91#87#article#120#</font></span></p>     
 ^cY#807.htm##
00513000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704027200075002000800347#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#92#88#article#120#19#<p align
="LEFT"><span lang="EN"><font face="Arial">19. Bellen HJ, Levis RW, Liao G, He Y
, Carlson JW, Tsang G, et al. The BDGP gene disruption project: single transposo
n insertions associated with 40% of <i>Drosophila </i>genes. <i>Genetics</i> 200
4; 167: 761-781.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#93#89#article#120#</font></span></p>     
 ^cY#807.htm##
00437000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704019600075002000800271#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#94#90#article#120#20#<p align
="LEFT"><span lang="EN"><font face="Arial">20. Sambrook J, Fitsch EF, Maniatis T
. <i>Molecular cloning: A laboratory manual</i>. Cold Spring Harbor: Cold Spring
 Harbor Press; 1989.    ^cY#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#95#91#article#120#</font></span></p>     
 ^cY#807.htm##
00483000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704024200075002000800317#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#96#92#article#120#21#<p align
="LEFT"><span lang="EN"><font face="Arial">21. Horowitz H, Berg CA. Aberrant spl
icing and transcription termination caused by P element insertion into the intro
n of a <i>Drosophila </i>gene. <i>Genetics</i> 1995; 139: 327-335.    ^cY#807.ht
m##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#97#93#article#120#</font></span></p>     
 ^cY#807.htm##
00490000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704024900075002000800324#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#98#94#article#120#22#<p align
="LEFT"><span lang="EN"><font face="Arial">22. Sullivan DT, Bell LA, Paton DR, S
ullivan MC. Genetic and functional analysis of tryptophan transport in Malpighia
n tubules of <i>Drosophila</i>. <i>Biochem Genet</i> 1980; 18: 1109-1130.    ^cY
#807.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#99#95#article#120#</font></span></p>     
 ^cY#807.htm##
00423000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704018100076002000800257#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#100#96#article#120#23#<p alig
n="LEFT"><span lang="EN"><font face="Arial">23. Summers KM, Howells AJ, Pyliotis
 NA. Biology of eye pigmentation in insects. <i>Adv Insect Phys</i> 1982; 16: 11
9-166.    ^cY#807.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#101#97#article#120#</font></span></p>    
  ^cY#807.htm##
00579000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069888000300073704033700076002000800413#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#102#98#article#120#24#<p alig
n="LEFT"><span lang="EN"><font face="Arial">24. Shulenin S, Schriml LM, Remaley 
AT, Fojo S, Brewer B, Allikmets R, et al. An ATP-binding cassette gene (ABCG5) f
rom the ABCG (White) gene subfamily maps to human chromosome 2p21 in the region 
of the <i>Sitosterolemia locus</i>. <i>Cytogenet Cell Genet</i> 2001; 92: 204-20
8.    ^cY#807.htm##
00255000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704002800073002000800101#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#103#99#article#120#</font></span></p>    
  ^cY#807.htm##
00453000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704021000077002000800287#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#104#100#article#120#25#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">25. Evans JM, Day JP, Cabrero P, Do
w JA, Davies SA. A new role for a classical gene: white transports cyclic GMP. <
i>J Exp Biol</i> 2008; 211: 890-899.    ^cY#807.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#105#101#article#120#</font></span></p>   
   ^cY#807.htm##
00468000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704022500077002000800302#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#106#102#article#120#26#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">26. Zhang SD, Odenwald WF. Misexpre
ssion of the white (w) gene triggers male-male courtship in <i>Drosophila</i>. <
i>Proc Natl Acad Sci U S A</i> 1995; 92: 5525-5529.    ^cY#807.htm##
00256000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002800074002000800102#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#107#103#article#120#</font></span></p>   
   ^cY#807.htm##
00541000000000157000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070888000300074704029800077002000800375#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#p#108#104#article#120#27#<p ali
gn="LEFT"><span lang="EN"><font face="Arial">27. Gropler MC, Harris TE, Hall AM,
 Wolins NE, Gross RW, Han X, et al. Lipin 2 is a liver-enriched phosphatidate ph
osphohydrolase enzyme that is dynamically regulated by fasting and obesity in mi
ce. <i>J Biol Chem</i> 2009; 284: 6763-6772.    ^cY#807.htm##
00280000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704005200074002000800126#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#109#105#article#120#</font></span></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#807.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033500074002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#110#106#article#120#<P><font face="Arial,
 Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE
=4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#807.ht
m##
00995000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704076700074002000800841#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#111#107#article#120#<p ALIGN="LEFT"><font
 face="Arial"><span lang="EN">The KG00562 and Def7860 lines were provided by the
 Bloomington Stock Center at Indiana University (Bloomington, IN, USA). We thank
 Cirlei A.V. Saraiva and Benedita O. Souza for dedicated technical assistance, a
nd Tania Paula Aquino Defina for DNA sequencing assistance. Research supported b
y FAPESP (#2007/50173-8), CNPq (#479444/2008-0) and stipends from FAEPA-FMRP. G.
B. Pereira (#07/52871-4), V. Valente (#01/07696-3), and M.S. de Queiroz (#07/528
70-8) were supported by fellowships from FAPESP, and M.C.B. Vianna received a fe
llowship from CAPES. M.L. Pa&ccedil;&oacute;-Larson is the recipient of a Resear
ch Productivity fellowship from CNPq (#303197/2009-9).</span></font></p>  <HR AL
IGN=LEFT SIZE=2>      ^cY#807.htm##
00564000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704033600074002000800410#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#112#108#article#120#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#807.h
tm##
00889000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704066100074002000800735#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#113#109#article#120#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/r
ecor.gif" border="0"></a> Address for correspondence:</b></font><span lang="EN">
<font face="Arial, Helvetica, sans-serif"> </font></span><font face="Arial, Helv
etica, sans-serif"><span LANG="PT-BR">M.L. Pa&ccedil;&oacute;-Larson, Departamen
to de Biologia Celular e Molecular e Bioagentes Patog&ecirc;nicos, FMRP, USP, </
span></font><font face="Arial"><span lang="PT-BR">Av. Bandeirantes, 3900, 14049-
900 Ribeir&atilde;o Preto, SP, Brasil. Fax: +55-16-3633-1786. E-mail: <a href="m
ailto:mlplarso@fmrp.usp.br">mlplarso@fmrp.usp.br</a></span></font></p>      ^cY#
807.htm##
00453000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704022500074002000800299#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#114#110#article#120#<p ALIGN="LEFT"><i><s
pan lang="EN"><font face="Arial">Received October 14, 2010. Accepted February 4,
 2011. Available online February 25, 2011. Published April 11, 2011.</font></spa
n></i></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#807.htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#115#111#article#120#<div align="center"> 
       ^cY#807.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#116#112#article#120#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#807.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#117#113#article#120#<br>                ^
cY#807.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#118#114#article#120#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#807
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#119#115#article#120#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#807.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#120#116#article#120#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#807.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#121#117#article#120#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#807.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#122#118#article#120#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#807.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#123#119#article#120#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#807.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\807.htm#S#p#124#120#article#120#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#807.htm##
00689000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100013000730100020000860100
02400106010001400130010002100144010001600165012010300181030001200284065000900296
06400050030503100040031001400100031486500090032400200080033303500100034180100120
0351#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#125#1#article#27#1#^r
ND^sTan^nC#^rND^sDeardorff^nMA#^rND^sSaint-Jeannet^nJP#^rND^sYang^nJ#^rND^sArzou
manian^nA#^rND^sKlein^nPS#Kermit, a frizzled interacting protein, regulates friz
zled 3 signaling in neural crest development^len#Development#20010000#2001#128#3
665-3674#20110400#807.htm#0950-1991#Development##
00670000000000313000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100013000910100
01400104010001500118010001900133012009800152030002500250065000900275064000500284
031000300289014001200292865000900304002000800313035001000321801002500331#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#126#2#article#27#2#^rND^sDe^nVrie
s L#^rND^sLou^nX#^rND^sZhao^nG#^rND^sZheng^nB#^rND^sFarquhar^nMG#GIPC, a PDZ dom
ain containing protein, interacts specifically with the C terminus of RGS-GAIP^l
en#Proc Natl Acad Sci U S A#19980000#1998#95#12340-12345#20110400#807.htm#0027-8
424#Proc Natl Acad Sci U S A##
00639000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100012000730100025000850100
01700110010001600127012011500143030001200258065000900270064000500279031000400284
014001000288865000900298002000800307035001000315801001200325#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\807.htm#S#c#127#3#article#27#3#^rND^sWu^nJ#^rND^sO&#8217;
Donnell^nM#^rND^sGitler^nAD#^rND^sKlein^nPS#Kermit 2/XGIPC, an IGF1 receptor int
eracting protein, is required for IGF signaling in Xenopus eye development^len#D
evelopment#20060000#2006#133#3651-3660#20110400#807.htm#0950-1991#Development##
00670000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100020000730100020000930100
01300113010001400126010001600140010001700156012006700173030002500240065000900265
06400050027403100030027901400100028286500090029200200080030103500100030980100250
0319#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#128#4#article#27#4#^r
ND^sRasmussen^nJT#^rND^sDeardorff^nMA#^rND^sTan^nC#^rND^sRao^nMS#^rND^sKlein^nPS
#^rND^sVetter^nML#Regulation of eye development by frizzled signaling in Xenopus
^len#Proc Natl Acad Sci U S A#20010000#2001#98#3861-3866#20110400#807.htm#0027-8
424#Proc Natl Acad Sci U S A##
00555000000000265000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100017000890120
13200106030000900238710000200247065000900249064000500258031000200263014000700265
865000900272002000800281#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#1
29#5#article#27#5#^rND^sDjiane^nA#^rND^sMlodzik^nM#The Drosophila GIPC homologue
 can modulate myosin based processes and planar cell polarity but is not essenti
al for development^len#PLoS One#2#20100000#2010#5#e11228#20110400#807.htm##
00614000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100013000730100013000860100
01200099010001600111012007800127030002700205065000900232064000500241031000400246
014000800250865000900258002000800267035001000275801002700285#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\807.htm#S#c#130#6#article#27#6#^rND^sKim^nJ#^rND^sLee^nS#
^rND^sKo^nS#^rND^sKim-Ha^nJ#dGIPC is required for the locomotive activity and lo
ngevity in Drosophila^len#Biochem Biophys Res Commun#20100000#2010#402#565-570#2
0110400#807.htm#0006-291X#Biochem Biophys Res Commun##
00708000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100018000730100018000910100
01800109010001600127010001800143010001600161012013200177030000900309065000900318
06400050032703100040033201400100033686500090034600200080035503500100036380100090
0373#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#131#7#article#27#7#^r
ND^sRoseman^nRR#^rND^sJohnson^nEA#^rND^sRodesch^nCK#^rND^sBjerke^nM#^rND^sNagosh
i^nRN#^rND^sGeyer^nPK#A P element containing suppressor of hairy-wing binding re
gions has novel properties for mutagenesis in Drosophila melanogaster^len#Geneti
cs#19950000#1995#141#1061-1074#20110400#807.htm#0016-6731#Genetics##
00621000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100015000900100
01700105010002200122012013300144030000700277710000200284065000900286064000500295
031000400300014001000304865000900314002000800323#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\807.htm#S#c#132#8#article#27#8#^rND^sValente^nV#^rND^sMaia^nRM#^rND^s
Vianna^nMC#^rND^sPaco-Larson^nML#Drosophila melanogaster lipins are tissue-regul
ated and developmentally regulated and present specific subcellular distribution
s^len#FEBS J#2#20100000#2010#277#4775-4788#20110400#807.htm##
00586000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100014000730100013000870100
01700100012010000117030001200217065000900229064000500238031000400243014001000247
865000900257002000800266035001000274801001200284#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\807.htm#S#c#133#9#article#27#9#^rND^sHan^nGS#^rND^sWu^nWI#^rND^sCarma
n^nGM#The Saccharomyces cerevisiae Lipin homolog is a Mg2+-dependent phosphatida
te phosphatase enzyme^len#J Biol Chem#20060000#2006#281#9210-9218#20110400#807.h
tm#0021-9258#J Biol Chem##
00455000000000253000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100022000750120050000970300
00800147710000200155065000900157064000500166031000300171014001000174865000900184
002000800193#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#134#10#articl
e#27#10#^rND^sSiniossoglou^nS#Lipins, lipids and nuclear envelope structure^len#
Traffic#2#20090000#2009#10#1181-1187#20110400#807.htm##
00490000000000265000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750120047000890300
01800136065000900154064000500163031000300168014000800171865000900179002000800188
035001000196801001800206#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#1
35#11#article#27#11#^rND^sReue^nK#The lipin family: mutations and metabolism^len
#Curr Opin Lipidol#20090000#2009#20#165-170#20110400#807.htm#0957-9672#Curr Opin
 Lipidol##
00637000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100015000960100
01700111010001900128010002200147012008600169030000700255065000900262064000500271
031000300276014001000279865000900289002000800298035001000306801000700316#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#136#12#article#27#12#^rND^sSantos
-Rosa^nH#^rND^sLeung^nJ#^rND^sGrimsey^nN#^rND^sPeak-Chew^nS#^rND^sSiniossoglou^n
S#The yeast lipin Smp2 couples phospholipid biosynthesis to nuclear membrane gro
wth^len#EMBO J#20050000#2005#24#1931-1941#20110400#807.htm#0261-4189#Embo J##
00722000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100022000750100014000970100
01900111010001700130010001700147010002200164012012900186030001200315065000900327
06400050033603100040034101400120034586500090035700200080036603500100037480100120
0384#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#137#13#article#27#13#
^rND^sO&#8217;Hara^nL#^rND^sHan^nGS#^rND^sPeak-Chew^nS#^rND^sGrimsey^nN#^rND^sCa
rman^nGM#^rND^sSiniossoglou^nS#Control of phospholipid synthesis by phosphorylat
ion of the yeast lipin Pah1p/Smp2p Mg2+-dependent phosphatidate phosphatase^len#
J Biol Chem#20060000#2006#281#34537-34548#20110400#807.htm#0021-9258#J Biol Chem
##
00638000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100013000910100
01900104012014800123030001100271065000900282064000500291031000400296014001000300
865000900310002000800319035001000327801001100337#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\807.htm#S#c#138#14#article#27#14#^rND^sGolden^nA#^rND^sLiu^nJ#^rND^sC
ohen-Fix^nO#Inactivation of the C: elegans lipin homolog leads to ER disorganiza
tion and to defects in the breakdown and reassembly of the nuclear envelope^len#
J Cell Sci#20090000#2009#122#1970-1978#20110400#807.htm#0021-9533#J Cell Sci##
00562000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100017000940120
09600111030001100207065000900218064000500227031000400232014001000236865000900246
002000800255035001000263801001100273#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
07.htm#S#c#139#15#article#27#15#^rND^sGorjanacz^nM#^rND^sMattaj^nIW#Lipin is req
uired for efficient breakdown of the nuclear envelope in Caenorhabditis elegans^
len#J Cell Sci#20090000#2009#122#1963-1969#20110400#807.htm#0021-9533#J Cell Sci
##
00536000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100015000890120
08300104030001000187065000900197064000500206031000400211014000600215865000900221
002000800230035001000238801001000248#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
07.htm#S#c#140#16#article#27#16#^rND^sReue^nK#^rND^sZhang^nP#The lipin protein f
amily: dual roles in lipid biosynthesis and gene expression^len#FEBS Lett#200800
00#2008#582#90-96#20110400#807.htm#0014-5793#FEBS lett##
00621000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100017000890100
01400106012013000120030001200250065000900262064000500271031000400276014001200280
865000900292002000800301035001000309801001200319#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\807.htm#S#c#141#17#article#27#17#^rND^sPhan^nJ#^rND^sPeterfy^nM#^rND^
sReue^nK#Lipin expression preceding peroxisome proliferator-activated receptor-g
amma is critical for adipogenesis in vivo and in vitro^len#J Biol Chem#20040000#
2004#279#29558-29564#20110400#807.htm#0021-9258#J Biol Chem##
00620000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100014000920100
01400106012012900120030001200249065000900261064000500270031000400275014001200279
865000900291002000800300035001000308801001200318#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\807.htm#S#c#142#18#article#27#18#^rND^sPeterfy^nM#^rND^sPhan^nJ#^rND^
sReue^nK#Alternatively spliced lipin isoforms exhibit distinct expression patter
n, subcellular localization, and role in adipogenesis^len#J Biol Chem#20050000#2
005#280#32883-32889#20110400#807.htm#0021-9258#J Biol Chem##
00689000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
01400108010001200122010001800134010001500152810000600167012010700173030000900280
06500090028906400050029803100040030301400080030786500090031500200080032403500100
0332801000900342#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#143#19#ar
ticle#27#19#^rND^sBellen^nHJ#^rND^sLevis^nRW#^rND^sLiao^nG#^rND^sHe^nY#^rND^sCar
lson^nJW#^rND^sTsang^nG#et al#The BDGP gene disruption project: single transposo
n insertions associated with 40% of Drosophila genes^len#Genetics#20040000#2004#
167#761-781#20110400#807.htm#0016-6731#Genetics##
00500000000000253000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720160018000750160017000930160
01800110018004300128066001900171062002500190065000900215064000500224865000900229
002000800238#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#144#20#articl
e#27#20#^rND^sSambrook^nJ#^rND^sFitsch^nEF#^rND^sManiatis^nT#Molecular cloning: 
A laboratory manual^len#Cold Spring Harbor#Cold Spring Harbor Press#19890000#198
9#20110400#807.htm##
00576000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100015000930120
11900108030000900227065000900236064000500245031000400250014000800254865000900262
002000800271035001000279801000900289#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
07.htm#S#c#145#21#article#27#21#^rND^sHorowitz^nH#^rND^sBerg^nCA#Aberrant splici
ng and transcription termination caused by P element insertion into the intron o
f a Drosophila gene^len#Genetics#19950000#1995#139#327-335#20110400#807.htm#0016
-6731#Genetics##
00624000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100019000750100015000940100
01600109010001900125012009600144030001400240065000900254064000500263031000300268
014001000271865000900281002000800290035001000298801001400308#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\807.htm#S#c#146#22#article#27#22#^rND^sSullivan^nDT#^rND^
sBell^nLA#^rND^sPaton^nDR#^rND^sSullivan^nMC#Genetic and functional analysis of 
tryptophan transport in Malpighian tubules of Drosophila^len#Biochem Genet#19800
000#1980#18#1109-1130#20110400#807.htm#0006-2928#Biochem Genet##
00511000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100018000930100
01900111012004300130030001600173710000200189065000900191064000500200031000300205
014000800208865000900216002000800225#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
07.htm#S#c#147#23#article#27#23#^rND^sSummers^nKM#^rND^sHowells^nAJ#^rND^sPyliot
is^nNA#Biology of eye pigmentation in insects^len#Adv Insect Phys#2#19820000#198
2#16#119-166#20110400#807.htm##
00766000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100018000930100
01800111010001400129010001600143010001900159810000600178012015000184030002100334
06500090035506400050036403100030036901400080037286500090038000200080038903500100
0397801002100407#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#148#24#ar
ticle#27#24#^rND^sShulenin^nS#^rND^sSchriml^nLM#^rND^sRemaley^nAT#^rND^sFojo^nS#
^rND^sBrewer^nB#^rND^sAllikmets^nR#et al#An ATP-binding cassette gene (ABCG5) fr
om the ABCG (White) gene subfamily maps to human chromosome 2p21 in the region o
f the Sitosterolemia locus^len#Cytogenet Cell Genet#20010000#2001#92#204-208#201
10400#807.htm#0011-4529#Cytogenet Cell Genet##
00607000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100014000910100
01700105010001400122010001700136012006500153030001100218065000900229064000500238
031000400243014000800247865000900255002000800264035001000272801001100282#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#149#25#article#27#25#^rND^sEvans^
nJM#^rND^sDay^nJP#^rND^sCabrero^nP#^rND^sDow^nJA#^rND^sDavies^nSA#A new role for
 a classical gene: white transports cyclic GMP^len#J Exp Biol#20080000#2008#211#
890-899#20110400#807.htm#0022-0949#J Exp Biol##
00575000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910120
08300110030002500193065000900218064000500227031000300232014001000235865000900245
002000800254035001000262801002500272#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
07.htm#S#c#150#26#article#27#26#^rND^sZhang^nSD#^rND^sOdenwald^nWF#Misexpression
 of the white (w) gene triggers male-male courtship in Drosophila^len#Proc Natl 
Acad Sci U S A#19950000#1995#92#5525-5529#20110400#807.htm#0027-8424#Proc Natl A
cad Sci U S A##
00725000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100017000930100
01500110010001700125010001600142010001300158810000600171012013100177030001200308
06500090032006400050032903100040033401400100033886500090034800200080035703500100
0365801001200375#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\807.htm#S#c#151#27#ar
ticle#27#27#^rND^sGropler^nMC#^rND^sHarris^nTE#^rND^sHall^nAM#^rND^sWolins^nNE#^
rND^sGross^nRW#^rND^sHan^nX#et al#Lipin 2 is a liver-enriched phosphatidate phos
phohydrolase enzyme that is dynamically regulated by fasting and obesity in mice
^len#J Biol Chem#20090000#2009#284#6763-6772#20110400#807.htm#0021-9258#J Biol C
hem##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#o#1#1#article#1#201
10411#094651#812.htm#134##
03343000000000589000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000900094158000700103030002000110
03100030013003200020013306500090013501400110014403500100015522400090016501201130
01740100024002870100025003110100022003360100027003580100028003850700089004130700
13000502083188100632085000802513085003302521085002502554085002202579085002802601
08500310262911700060266007200030266611200090266911100160267811400090269411300180
2703891002402721002000802745#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S
#h#2#1#article#1#sc#en#bjmbr#1#3.1#ILUS#10#BJMBR060#FAPESP#Braz J Med Biol Res#4
4#4#20110400#^f332^l336#0100-879X#20110329#5-HT1A autoreceptor modulation of loc
omotor activity induced by nitric oxide in the rat dorsal raphe nucleus^len#^rND
^1A01^nL.B.^sGualda#^rND^1A01^nG.G.^sMartins#^rND^1A01^nB.^sMüller#^rND^1A02^nF.
S.^sGuimarães#^rND^1A01^nR.M.W.^sOliveira#Universidade Estadual de Maringá^iA01^
1Departamento de Farmacologia^cMaringá^sPR^pBrasil#Universidade de São Paulo^iA0
2^1Faculdade de Medicina de Ribeirão Preto^2Departamento de Farmacologia^cRibeir
ão Preto^sSP^pBrasil#^len^aThe dorsal raphe nucleus (DRN) is the origin of ascen
ding serotonergic projections and is considered to be an important component of 
the brain circuit that mediates anxiety- and depression-related behaviors. A lar
ge fraction of DRN serotonin-positive neurons contain nitric oxide (NO). Disrupt
ion of NO-mediated neurotransmission in the DRN by NO synthase inhibitors produc
es anxiolytic- and antidepressant-like effects in rats and also induces nonspeci
fic interference with locomotor activity. We investigated the involvement of the
 5-HT1A autoreceptor in the locomotor effects induced by NO in the DRN of male W
istar rats (280-310 g, N = 9-10 per group). The NO donor 3-morpholinosylnomine h
ydrochloride (SIN-1, 150, and 300 nmol) and the NO scavenger S-3-carboxy-4-hydro
xyphenylglycine (carboxy-PTIO, 0.1-3.0 nmol) were injected into the DRN of rats 
immediately before they were exposed to the open field for 10 min. To evaluate t
he involvement of the 5-HT1A receptor and the N-methyl-D-aspartate (NMDA) glutam
ate receptor in the locomotor effects of NO, animals were pretreated with the 5-
HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 8 nmol)
, the 5-HT1A receptor antagonist N-(2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl)-
N-2-pyridinyl-cyclohexanecarboxamide maleate (WAY-100635, 0.37 nmol), and the NM
DA receptor antagonist DL-2-amino-7-phosphonoheptanoic acid (AP7, 1 nmol), follo
wed by microinjection of SIN-1 into the DRN. SIN-1 increased the distance travel
ed (mean ± SEM) in the open-field test (4431 ± 306.1 cm; F7,63 = 2.44, P = 0.028
) and this effect was blocked by previous 8-OH-DPAT (2885 ± 490.4 cm) or AP7 (33
35 ± 283.5 cm) administration (P < 0.05, Duncan test). These results indicate th
at 5-HT1A receptor activation and/or facilitation of glutamate neurotransmission
 can modulate the locomotor effects induced by NO in the DRN.#^dnd^i1#^tm^len^kD
orsal raphe nucleus^i1#^tm^len^kNitric oxide^i1#^tm^len^kSerotonin^i1#^tm^len^k5
-HT1A receptor^i1#^tm^len^kLocomotor activity^i1#other#20#20101006#October 6, 20
10#20110223#February 23, 2011#S0100-879X2011007500033#812.htm##
03440000000000577000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000900094158000700103030002000110
03100030013003200020013306500090013501400110014403500100015522400090016501201310
01740100024003050100025003290100022003540100027003760100028004030700089004310700
13000520083197100650085000802621085003302629085002502662085002202687085003902709
08500310274811700060277907200030278511200090278811100230279711400090282011300250
2829002000802854#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#f#3#1#artic
le#1#sc#en#bjmbr#1#3.1#ILUS#10#BJMBR060#FAPESP#Braz J Med Biol Res#44#4#20110400
#^f332^l336#0100-879X#20110329#<b>5-HT<sub>1A</sub> autoreceptor modulation of l
ocomotor activity induced by nitric oxide in the rat dorsal raphe nucleus</b>^le
n#^rND^1A01^nL.B.^sGualda#^rND^1A01^nG.G.^sMartins#^rND^1A01^nB.^sMüller#^rND^1A
02^nF.S.^sGuimarães#^rND^1A01^nR.M.W.^sOliveira#Universidade Estadual de Maringá
^iA01^1Departamento de Farmacologia^cMaringá^sPR^pBrasil#Universidade de São Pau
lo^iA02^1Faculdade de Medicina de Ribeirão Preto^2Departamento de Farmacologia^c
Ribeirão Preto^sSP^pBrasil#^len^aThe dorsal raphe nucleus (DRN) is the origin of
 ascending serotonergic projections and is considered to be an important compone
nt of the brain circuit that mediates anxiety- and depression-related behaviors.
 A large fraction of DRN serotonin-positive neurons contain nitric oxide (NO). D
isruption of NO-mediated neurotransmission in the DRN by NO synthase inhibitors 
produces anxiolytic- and antidepressant-like effects in rats and also induces no
nspecific interference with locomotor activity. We investigated the involvement 
of the 5-HT<sub>1A</sub> autoreceptor in the locomotor effects induced by NO in 
the DRN of male Wistar rats (280-310 g, N = 9-10 per group). The NO donor 3-morp
holinosylnomine hydrochloride (SIN-1, 150, and 300 nmol) and the NO scavenger S-
3-carboxy-4-hydroxyphenylglycine (carboxy-PTIO, 0.1-3.0 nmol) were injected into
 the DRN of rats immediately before they were exposed to the open field for 10 m
in. To evaluate the involvement of the 5-HT<sub>1A</sub> receptor and the N-meth
yl-D-aspartate (NMDA) glutamate receptor in the locomotor effects of NO, animals
 were pretreated with the 5-HT<sub>1A</sub> receptor agonist 8-hydroxy-2-(di-<i>
n</i>-propylamino)tetralin (8-OH-DPAT, 8 nmol), the 5-HT<sub>1A</sub> receptor a
ntagonist <i>N</i>-(2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl)-<i>N</i>-2-pyrid
inyl-cyclohexanecarboxamide maleate (WAY-100635, 0.37 nmol), and the NMDA recept
or antagonist DL-2-amino-7-phosphonoheptanoic acid (AP7, 1 nmol), followed by mi
croinjection of SIN-1 into the DRN. SIN-1 increased the distance traveled (mean 
± SEM) in the open-field test (4431 ± 306.1 cm; F<sub>7,63</sub> = 2.44, P = 0.0
28) and this effect was blocked by previous 8-OH-DPAT (2885 ± 490.4 cm) or AP7 (
3335 ± 283.5 cm) administration (P &lt; 0.05, Duncan test). These results indica
te that 5-HT<sub>1A</sub> receptor activation and/or facilitation of glutamate n
eurotransmission can modulate the locomotor effects induced by NO in the DRN.#^d
nd^i1#^tm^len^kDorsal raphe nucleus^i1#^tm^len^kNitric oxide^i1#^tm^len^kSeroton
in^i1#^tm^len^k5-HT<sub>1A</sub> receptor^i1#^tm^len^kLocomotor activity^i1#othe
r#20#20101006#<i>October 6, 2010</i>#20110223#<i>February 23, 2011</i>#812.htm##
03441000000000601000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099121000300104049000900107158000700116
03000240012303100030014703200020015006500090015201400110016103500100017222400090
01820120113001910100024003040100025003280100021003530100027003740100029004010700
09100430070013200521083188100653085000802534085003302542085002502575085002202600
08500280262208500310265011700060268107200030268711200090269011100160269911400090
2715113001802724002000802742008008902750#v44n4#V:\SciELO\serial\bjmbr\v44n4\mark
up\812.htm#S#l#4#1#article#1#^mApr.^a2011#sc#en#bjmbr#1#3.1#ilus#10#BJMBR060#FAP
ESP#Braz. j. med. biol. res#44#4#20110400#^f332^l336#0100-879X#20110329#5-HT1A a
utoreceptor modulation of locomotor activity induced by nitric oxide in the rat 
dorsal raphe nucleus^len#^rND^1A01^nL. B^sGualda#^rND^1A01^nG. G^sMartins#^rND^1
A01^nB^sMüller#^rND^1A02^nF. S^sGuimarães#^rND^1A01^nR. M. W^sOliveira#^iA01^1Un
iversidade Estadual de Maringá^2Departamento de Farmacologia^cMaringá^sPR^pBrasi
l#^iA02^1Universidade de São Paulo^2Faculdade de Medicina de Ribeirão Preto^3Dep
artamento de Farmacologia^cRibeirão Preto^sSP^pBrasil#^len^aThe dorsal raphe nuc
leus (DRN) is the origin of ascending serotonergic projections and is considered
 to be an important component of the brain circuit that mediates anxiety- and de
pression-related behaviors. A large fraction of DRN serotonin-positive neurons c
ontain nitric oxide (NO). Disruption of NO-mediated neurotransmission in the DRN
 by NO synthase inhibitors produces anxiolytic- and antidepressant-like effects 
in rats and also induces nonspecific interference with locomotor activity. We in
vestigated the involvement of the 5-HT1A autoreceptor in the locomotor effects i
nduced by NO in the DRN of male Wistar rats (280-310 g, N = 9-10 per group). The
 NO donor 3-morpholinosylnomine hydrochloride (SIN-1, 150, and 300 nmol) and the
 NO scavenger S-3-carboxy-4-hydroxyphenylglycine (carboxy-PTIO, 0.1-3.0 nmol) we
re injected into the DRN of rats immediately before they were exposed to the ope
n field for 10 min. To evaluate the involvement of the 5-HT1A receptor and the N
-methyl-D-aspartate (NMDA) glutamate receptor in the locomotor effects of NO, an
imals were pretreated with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propyla
mino)tetralin (8-OH-DPAT, 8 nmol), the 5-HT1A receptor antagonist N-(2-[4-(2-met
hoxyphenyl)-1-piperazinyl]ethyl)-N-2-pyridinyl-cyclohexanecarboxamide maleate (W
AY-100635, 0.37 nmol), and the NMDA receptor antagonist DL-2-amino-7-phosphonohe
ptanoic acid (AP7, 1 nmol), followed by microinjection of SIN-1 into the DRN. SI
N-1 increased the distance traveled (mean ± SEM) in the open-field test (4431 ± 
306.1 cm; F7,63 = 2.44, P = 0.028) and this effect was blocked by previous 8-OH-
DPAT (2885 ± 490.4 cm) or AP7 (3335 ± 283.5 cm) administration (P < 0.05, Duncan
 test). These results indicate that 5-HT1A receptor activation and/or facilitati
on of glutamate neurotransmission can modulate the locomotor effects induced by 
NO in the DRN.#^dnd^i1#^tm^len^kDorsal raphe nucleus^i1#^tm^len^kNitric oxide^i1
#^tm^len^kSerotonin^i1#^tm^len^k5-HT1A receptor^i1#^tm^len^kLocomotor activity^i
1#other#20#20101006#October 6, 2010#20110223#February 23, 2011#812.htm#Internet^
ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000400010#
#
00372000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014800070002000800218#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#5#1#article#110#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 332-336  </B></font></P>      ^cY#812.htm##
00488000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704026400070002000800334#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#6#2#article#110#<p ALIGN="LEFT"><font siz
e="5" face="Arial"><span lang="EN"><strong>5-HT<sub>1A</sub> autoreceptor modula
tion of locomotor </strong></span><strong><span lang="EN">activity induced by ni
tric oxide in the rat dorsal raphe nucleus</span></strong></font></p>      ^cY#8
12.htm##
00801000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704057700070002000800647#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#7#3#article#110#<p ALIGN="LEFT"><font fac
e="Arial"><span lang="EN">L.B. Gualda<sup>1</sup>, G.G. Martins<sup>1</sup>, B. 
M&uuml;ller<sup>1</sup>, F.S. Guimar&atilde;es<sup>2</sup> and <span lang="EN"><
font face="Arial, Helvetica, sans-serif"><sup><span lang="EN"><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Correspondence"><img src="/img/revistas/bjm
br/v44n4/recor.gif" border="0"></a></b> <a href="mailto:rmmwoliveira@uem.br"><im
g src="/img/revistas/bjmbr/v44n4/email-ca.gif" border="0"></a></font></span></su
p></font></span> R.M.W. Oliveira<sup>1</sup></span></font></p>      ^cY#812.htm#
#
00418000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704019400070002000800264#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#8#4#article#110#<p ALIGN="LEFT"><span lan
g="EN"><sup><font FACE="Arial">1</font></sup><font FACE="Arial">Departamento de 
Farmacologia, Universidade Estadual de Maring&aacute;, Maring&aacute;, PR, Brasi
l    ^cY#812.htm##
00513000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704028900070002000800359#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#9#5#article#110#<br>  </font></span><font
 face="Arial"><span lang="EN"><sup>2</sup>Departamento de Farmacologia, Faculdad
e de Medicina de Ribeir&atilde;o Preto, </span></font><font face="Arial"><span l
ang="EN">Universidade de S&atilde;o Paulo, Ribeir&atilde;o Preto, SP, Brasil</sp
an></font></p>      ^cY#812.htm##
00415000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704019000071002000800261#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#10#6#article#110#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#812.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#11#7#article#110#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#812.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#12#8#article#110#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#812.htm##
00397000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704017200071002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#13#9#article#110#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#812.htm##
00407000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018100072002000800253#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#14#10#article#110#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#81
2.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#15#11#article#110#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#812.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#16#12#article#110#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#812.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#17#13#article#110#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#812.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#18#14#article#110#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#812.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#19#15#article#110#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#812.htm##
02297000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704207100072002000802143#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#20#16#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The dorsal raphe nucleus (DRN) is the origin of asce
nding serotonergic projections and is considered to be an important component of
 the brain circuit that mediates anxiety- and depression-related behaviors. A la
rge fraction of DRN serotonin-positive neurons contain nitric oxide (NO). Disrup
tion of NO-mediated neurotransmission in the DRN by NO synthase inhibitors produ
ces anxiolytic- and antidepressant-like effects in rats and also induces nonspec
ific interference with locomotor activity. We investigated the involvement of th
e 5-HT<sub>1A</sub> autoreceptor in the locomotor effects induced by NO in the D
RN of male Wistar rats (280-310 g, N = 9-10 per group). The NO donor 3-morpholin
osylnomine hydrochloride (SIN-1, 150, and 300 nmol) and the NO scavenger S-3-car
boxy-4-hydroxyphenylglycine (carboxy-PTIO, 0.1-3.0 nmol) were injected into the 
DRN of rats immediately before they were exposed to the open field for 10 min. T
o evaluate the involvement of the 5-HT<sub>1A</sub> receptor and the N-methyl-D-
aspartate (NMDA) glutamate receptor in the locomotor effects of NO, animals were
 pretreated with the 5-HT<sub>1A</sub> receptor agonist 8-hydroxy-2-(di-<i>n</i>
-propylamino)tetralin (8-OH-DPAT, 8 nmol), the 5-HT<sub>1A</sub> receptor antago
nist <i>N</i>-(2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl)-<i>N</i>-2-pyridinyl-
cyclohexanecarboxamide maleate (WAY-100635, 0.37 nmol), and the NMDA receptor an
tagonist DL-2-amino-7-phosphonoheptanoic acid (AP7, 1 nmol), followed by microin
jection of SIN-1 into the DRN. SIN-1 increased the distance traveled (mean &plus
mn; SEM) in the open-field test (4431 &plusmn; 306.1 cm; F<sub>7,63</sub> = 2.44
, P = 0.028) and this effect was blocked by previous 8-OH-DPAT (2885 &plusmn; 49
0.4 cm) or AP7 (3335 &plusmn; 283.5 cm) administration (P &lt; 0.05, Duncan test
). These results indicate that 5-HT<sub>1A</sub> receptor activation and/or faci
litation of glutamate neurotransmission can modulate the locomotor effects induc
ed by NO in the DRN.</span></font></p>      ^cY#812.htm##
00433000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020700072002000800279#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#21#17#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Key words: Dorsal raphe nucleus; Nitric oxide; Serot
onin; 5-HT<sub>1A</sub> receptor; Locomotor activity</span></font></p>  <HR ALIG
N=LEFT SIZE=2>      ^cY#812.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#22#18#article#110#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#812.htm##
00936000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704071000072002000800782#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#23#19#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Inhibition of the nitric oxide (NO) signaling pathwa
y in the brain has been reported to induce anxiolytic- and antidepressant-like e
ffects in animal models. Systemic administration of the NO synthase (NOS) inhibi
tor <i>N</i>-methyl-L-arginine ester (L-NAME) (1,2) or the more selective neuron
al NOS (nNOS) inhibitor 7-nitroindazole (2) produces anxiolytic-like effects in 
the elevated plus maze. The same compounds and the soluble guanylyl cyclase inhi
bitors methylene blue (3) dose-dependently reduce immobility time in the forced 
swimming test, a preclinical behavioral method for detecting antidepressant-like
 activity of drugs.</span></font></p>      ^cY#812.htm##
01452000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704122600072002000801298#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#24#20#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The behavioral effects of NOS inhibitors appear to d
epend on endogenous serotonin (5-hydroxytryptamine, 5-HT). Low doses of L-NAME t
hat are ineffective at 3 mg/kg potentiate the behavioral effects of imipramine a
nd fluoxetine but not reboxetine, a norepinephrine reuptake inhibitor, in the fo
rced swimming test (4). A functional interaction between 5-HT receptor subtypes 
and NO has been recently proposed. Ulak et al. (5) have shown that depletion of 
endogenous 5-HT or the antagonism of 5-HT<sub>2</sub> receptor prevented the ant
idepressant-like effect of 1-(2-trifluoromethylphenyl)-imidazole (TRIM), an nNOS
 inhibitor, implying that the antidepressant effects of TRIM might be mediated b
y an interaction with 5-HT<sub>2</sub> receptors. 5-HT<sub>2</sub> receptors hav
e been shown to mediate an increase in the hippocampal NOS activity induced by i
mipramine withdrawal in rats (6). Furthermore, hippocampal NOS is required for t
he functional activity of 5-HT<sub>1A</sub> receptors in modulating anxiety-rela
ted behaviors (7). These findings suggest that nNOS may serve as a downstream si
gnaling enzyme of the 5-HT neurotransmitter system (7).</span></font></p>      ^
cY#812.htm##
00903000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704067700072002000800749#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#25#21#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Nitric oxide has been involved in the release of sev
eral neurotransmitters. In the hippocampus and dorsal raphe nucleus (DRN), NO pr
ovides a tonic stimulus to maintain elevated levels of 5-HT release. Thus, nNOS 
inhibitors have been reported to cause an increase in hippocampal 5-HT efflux in
 the rat ventral hippocampus after local or systemic administration, whereas the
 NO precursor L-arginine had the opposite effect (8). These effects, however, ma
y be region-dependent. When infused into the DRN, nNOS inhibitors decrease local
 extracellular 5-HT while increasing it in the frontal cortex (9).</span></font>
</p>      ^cY#812.htm##
01224000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704099800072002000801070#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#26#22#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The DRN is the origin of ascending serotonergic proj
ections and is considered to be an important component of the brain circuit that
 mediates anxiety- and depression-related behaviors (10). 5-HT<sub>1A</sub> rece
ptors are expressed presynaptically in the DRN and act as inhibitory somatodendr
itic autoreceptors. A large fraction of DRN 5-HT-positive neurons also contain n
NOS (11), suggesting that NO could interfere with DRN function. We recently show
ed that disruption of NO-mediated neurotransmission by the NOS inhibitors L-NAME
 and 7-nitroindazole in the DRN produced anxiolytic- and antidepressant-like eff
ects in rats (2). However, the effects occurred within a limited dose range, wit
h low doses causing anxiolytic-like effects and high doses decreasing locomotor 
activity. These results suggest that NO-related drugs administered into the DRN 
may also induce the nonspecific interference of locomotor activity.</span></font
></p>      ^cY#812.htm##
00890000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704066400072002000800736#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#27#23#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">In the present study, we investigated the involvemen
t of 5-HT<sub>1A</sub> receptors in the locomotor effects of NO administered int
o the DRN. Nitric oxide may increase glutamate release in the central nervous sy
stem, and 5-HT neurons in the DRN receive excitatory glutamatergic inputs from f
orebrain areas, hypothalamic nuclei and the lateral habenula (12). Therefore, we
 also tested the effects of pretreatment with DL-2-amino-7-phosphonoheptanoic ac
id (AP7), a glutamate <i>N</i>-methyl-D-aspartate (NMDA) receptor inhibitor, on 
the effects of NO in the DRN.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY
#812.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#28#24#article#110#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#812.htm##
00319000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009300072002000800165#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#29#25#article#110#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Animals</span></font></b></p>      ^cY#812.htm##
00598000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704037200072002000800444#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#30#26#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Male Wistar rats (N = 127) weighing 280-310 g (77-91
 days) were transported to a colony room adjacent to the test laboratory 48 h be
fore surgery. They were housed 5 per cage under a 12/12-h light/dark cycle (ligh
ts on at 7:00 am) at 23 &plusmn; 1&deg;C and given free access to food and water
.</span></font></p>      ^cY#812.htm##
00701000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704047500072002000800547#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#31#27#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The experimental procedures used here were conducted
 in accordance with the Brazilian Society of Neuroscience and Behavior Guideline
s for the Care and Use of Laboratory Animals, which comply with international gu
idelines and were approved by the Animal Ethics Committee of Universidade Estadu
al de Maring&aacute;, Paran&aacute; (CEEA/037/2007). All efforts were made to mi
nimize animal suffering.</span></font></p>      ^cY#812.htm##
00334000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010800072002000800180#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#32#28#article#110#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Experimental procedure</span></font></b></p>     
 ^cY#812.htm##
00914000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704068800072002000800760#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#33#29#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The animals were anesthetized with sodium pentobarbi
tal (45 mg/kg, <i>ip</i>) and fixed in a stereotaxic frame. A stainless steel gu
ide cannula (outer diameter: 0.7 mm) was implanted in the DRN using to the follo
wing coordinates: anterior/posterior: &plusmn;1.4 mm from lambda, lateral: 3.7 m
m, ventral: 6.2 mm (13). The guide cannula was inserted into the right hemispher
e of the brain at a 36&deg; angle to the vertical plane to avoid the sagittal si
nus. The tip of the guide cannula was positioned 1 mm above the DRN. After the s
urgical procedures, animals were housed 5 to a cage until behavioral testing.</s
pan></font></p>      ^cY#812.htm##
00525000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704029900072002000800371#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#34#30#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Six to 7 days after surgery, the animals were transp
orted to the test laboratory and were not disturbed for at least 1 h prior to te
sting. They were then randomly assigned to one of the treatment groups (N = 9-10
/group).</span></font></p>      ^cY#812.htm##
01439000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704121300072002000801285#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#35#31#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">For the microinjection procedure, a thin dental need
le (outer diameter: 0.3 mm) was introduced through the guide cannula using a mic
rosyringe (Hamilton, USA) controlled by an infusion pump (Kd Scientific, USA). A
 PE10 polyethylene catheter was interposed between the upper end of the dental n
eedle and the microsyringe. The displacement of an air bubble inside the polyeth
ylene tubing was used to monitor the microinjection process. The needle was held
 in place for an additional 1 min to maximize diffusion away from the injector t
ip. The animals received injections of saline or drugs into the DRN and were imm
ediately placed in the center of an open-field apparatus (70 x 70 x 40 cm) for 1
0 min. Their behavior was videotaped and the distance traveled by them was deter
mined by the Ethovision XT<sup>&reg;</sup> software (Noldus Inc., Netherlands). 
For combined treatments, the animals received injections of saline or drugs, fol
lowed 10 min later by saline or the NO donor 3-morpholinosydnonimine (SIN-1). Fo
r all microinjections, including the first and second injections, the infused vo
lume was 0.3 &micro;L delivered over 30 s.</span></font></p>      ^cY#812.htm##
00317000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009100072002000800163#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#36#32#article#110#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Drugs</span></font></b></p>      ^cY#812.htm##
01259000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704103300072002000801105#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#37#33#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The NO donor SIN-1 (150 and 300 nmol), the NO scaven
ger S-3-carboxy-4-hydroxyphenylglycine (carboxy-PTIO, 0.1-3.0 nmol), the 5-HT<su
b>1A</sub> agonist 8-hydroxy-2-(di-<i>n</i>-propylamino)tetralin (8-OH-DPAT, 8 n
mol), the 5-HT<sub>1A</sub> receptor antagonist <i>N</i>-(2-[4-(2-methoxyphenyl)
-1-piperazinyl]ethyl)-<i>N</i>-2-pyridinyl-cyclohexanecarboxamide maleate (WAY-1
00635, 0.37 nmol), and the glutamate NMDA receptor antagonist AP7 (1 nmol) were 
dissolved in sterile isotonic saline. The drugs were purchased from Sigma Chemic
als (USA). The solutions were prepared immediately before use. The doses of 8-OH
-DPAT and WAY-100635 were chosen on the basis of studies showing no locomotor ef
fects induced by these compounds when injected into the DRN (14,15). The doses o
f SIN-1 (2,16), carboxy-PTIO (17) and AP7 (16) were based on previous studies us
ing direct administration of these compounds into the dorsolateral periaqueducta
l gray matter (DLPAG).</span></font></p>      ^cY#812.htm##
00321000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009500072002000800167#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#38#34#article#110#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Histology</span></font></b></p>      ^cY#812.htm#
#
01095000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704086900072002000800941#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#39#35#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">After behavioral analysis, the rats were sacrificed 
by deep urethane anesthesia and were perfused through the left ventricle of the 
heart with isotonic saline followed by a 10% formalin. A dental needle was then 
inserted through the guide cannula, and 0.3 &micro;L methylene blue was injected
. The brains were removed and immersed in a 10% formalin for a minimum of 3 days
. Coronal brain sections (50 &micro;m) were then obtained with a cryostat (Cryoc
ut 1800, Leica, Germany) and stained with cresyl violet. The injection sites wer
e identified using diagrams from the atlas of Paxinos and Watson (13). Animals w
ith injection sites located outside the DRN were excluded from the main statisti
cal analysis but were combined in a group denoted &quot;OUT&quot; in <a href="#F
ig1">Figure 1</a>.</span></font></p>      ^cY#812.htm##
00332000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704010600072002000800178#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#40#36#article#110#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Statistical analysis</span></font></b></p>      ^
cY#812.htm##
01032000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704080600072002000800878#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#41#37#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Data regarding the distance traveled by the rats wer
e analyzed by one-way analysis of variance (ANOVA; <a href="#Fig1">Figure 1</a>)
. For combined treatments (<a href="#Fig2">Figure 2</a>), data were analyzed by 
a two-way ANOVA, with the main factors being the first and second injections. In
 case of a significant interaction, the groups were compared by one-way ANOVA. <
i>Post-hoc</i> comparisons were performed by the Duncan test. For ethical reason
s, to minimize the number of animals used in this experiment, the same control (
saline/saline) and SIN-1 (saline/SIN-1) groups were included in the experiment p
resented in <a href="#Fig2">Figure 2</a>. The level of significance was set at P
 &lt; 0.05.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#812.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#42#38#article#110#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#812.htm##
00396000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017000072002000800242#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#43#39#article#110#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Effects of SIN-1 and carboxy-PTIO on the distance
 traveled by rats in the open field</span></font></b></p>      ^cY#812.htm##
00837000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704061100072002000800683#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#44#40#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">SIN-1, an NO donor, at 150 or 300 nmol significantly
 increased the distance traveled by the rats in the open field (<i>F</i><sub>2,3
1</sub> = 11.28, P = 0.002; <a href="#Fig1">Figure 1</a>). No significant effect
 on distance traveled was detected after carboxy-PTIO administration into the DR
N (<i>F</i><sub>2,35</sub> = 2.06; P = 0.13; <a href="#Fig1">Figure 1</a>). Anim
als that received SIN-1 or carboxy-PTIO outside the DRN (OUT) did not differ fro
m controls (F<sub>6,70</sub> = 3.51, P &gt; 0.05; <a href="#Fig1">Figure 1</a>).
</span></font></p>      ^cY#812.htm##
00461000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704023500072002000800307#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#45#41#article#110#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Pretreatment with 8-OH-DPAT or AP7 blocked the </
span></font></b><b><font face="Arial"><span lang="EN">effects of SIN-1 on locomo
tor activity in rats</span></font></b></p>      ^cY#812.htm##
01549000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704132300072002000801395#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#46#42#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">As expected, SIN-1 increased the distance traveled c
ompared to all groups of the combined treatment (<a href="#Fig2">Figure 2</a>), 
except for the WAY-100635 + saline and WAY-100635 + SIN-1 groups (F<sub>7,63</su
b> = 2.47, P &lt; 0.028; P &lt; 0.05, Duncan test). ANOVA detected a significant
 interaction between the first and the second injection (F<sub>3,63</sub> = 2.76
, P = 0.049). The effects of SIN-1 were prevented by pretreatment with the selec
tive 5-HT<sub>1A</sub> receptor agonist 8-OH-DPAT or the glutamate NMDA receptor
 antagonist AP7 before SIN-1 administration (P &lt; 0.05, Duncan test). These re
sults suggest that 5-HT<sub>1A</sub> receptors in the DRN may mediate the effect
s of NO on locomotor activity. The effects of SIN-1 were also prevented by pretr
eatment with AP7 (P &lt; 0.05, Duncan test). Since AP7 is a glutamate NMDA recep
tor antagonist, SIN-1 may also act by facilitating glutamate release in the DRN.
 No significant effect was detected with WAY-100635 pretreatment (P &gt; 0.05, D
uncan test).</span></font></p>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <
tr align="left" valign="top">      <td><a href="/img/revistas/bjmbr/v44n4/html/8
12i01.htm"><img src="/img/revistas/bjmbr/v44n4/812i01peq.jpg" border="2"></a></t
d>      <td>    ^cY#812.htm##
01016000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704079000072002000800862#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#47#43#article#110#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial"><a name="Fig1"></a>Figure 1. Effects of intra-DRN in
jection of the NO donor SIN-1 (150 and 300 nmol) or carboxy-PTIO (0.1-3.0 nmol) 
on the distance traveled by rats in the open field for 10 min. The drugs were ad
ministered immediately before testing. Rats whose injections of SIN-1 or carboxy
-PTIO were outside the DRN (N = 15) are reported in the OUT group. The height of
 the columns indicate the means, and the bars represent the SEM (N = 9-10/group)
. DRN = dorsal raphe nucleus; NO = nitric oxide; SIN-1 = 3-morpholinosylnomine h
ydrochloride; carboxy-PTIO = S-3-carboxy-4-hydroxyphenylglycine. *P &lt; 0.05 co
mpared to the saline (Sal) group (ANOVA followed by the Duncan test).</font></sp
an></p>      </td>    </tr>  </table>      ^cY#812.htm##
01615000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704138900072002000801461#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#48#44#article#110#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (79 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/812i02.htm"><img src="/img/
revistas/bjmbr/v44n4/812i02peq.jpg" border="2"></a></td>      <td><span lang="EN
"><font face="Arial"><span lang="EN"><a name="Fig2"></a>Figure 2. Effects of pre
treatment with the 5-HT<sub>1A</sub> receptor agonist 8-OH-DPAT (DPAT, 8 nmol), 
the 5-HT<sub>1A</sub> receptor antagonist WAY-100635 (WAY, 0.37 nmol) and the gl
utamate NMDA receptor antagonist AP7 (1 nmol) 10 min before SIN-1 (150 nmol) adm
inistration into the DRN in rats tested in the open field for 10 min. The height
 of the columns indicate the means, and the bars indicate the SEM (N = 9-10/grou
p). 8-OH-DPAT = 8-hydroxy-2-(di-<i>n</i>-propylamino)tetralin; WAY-100635 = <i>N
</i>-(2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl)-<i>N</i>-2-pyridinyl-cyclohexa
necarboxamide maleate; AP7 = DL-2-amino-7-phosphonoheptanoic acid; SIN-1 = 3-mor
pholinosylnomine hydrochloride; DRN = dorsal raphe nucleus. *P &lt; 0.05 compare
d to the saline + saline (Sal + Sal) group (ANOVA followed by the Duncan test); 
<sup>#</sup>P &lt; 0.05 compared to the saline + SIN-1 (Sal + SIN-1) group (ANOV
A followed by the Duncan test).</span></font></span></td>    </tr>  </table>    
  ^cY#812.htm##
00343000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011700072002000800189#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#49#45#article#110#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (99 K JPG file)]</font>
</P>      ^cY#812.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#50#46#article#110#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#812.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#51#47#article#110#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#812.htm##
01040000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704081400072002000800886#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#52#48#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Nonspecific suppression of rat locomotor activity by
 NO-related drugs has been reported previously. NOS inhibitors, such as L-NAME (
2) and methylene blue (3), reduce spontaneous locomotor activity in a dose-depen
dent way and may induce catalepsy in rodents (18). The latter effect involves NO
S inhibition in the striatum. However, other brain areas have been shown to be i
nvolved in the systemic effects of NOS inhibitors on locomotor activity. Spiacci
 Jr. et al. (2) showed that NOS inhibitors injected into the DRN decreased, wher
eas the cyclic guanosine monophosphate (cGMP) analog 8-Br-cGMP dose-dependently 
increased, locomotor activity in rats, implicating NO neurotransmission in the D
RN in the modulation of locomotor behavior.</span></font></p>      ^cY#812.htm##
00797000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704057100072002000800643#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#53#49#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">In the present study, administration of SIN-1, an NO
 donor, into the DRN increased the distance traveled by rats in the open field. 
Pretreatment with the 5-HT<sub>1A</sub> receptor agonist 8-OH-DPAT or the NMDA r
eceptor antagonist AP7 blocked the effects of SIN-1 on the locomotor activity of
 rats. Although a slight increase in locomotor activity was detected with WAY-10
0635 administration into the DRN, this effect was not statistically significant 
and did not modify the effects of SIN-1.</span></font></p>      ^cY#812.htm##
01038000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704081200072002000800884#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#54#50#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The activity of DRN neurons is under complex regulat
ory control mediated by the medial prefrontal cortex and lateral habenula, a pro
cess that involves excitatory glutamate inputs to serotonergic and &gamma;-amino
butyric acid (GABA) neurons (19). The glutamatergic inputs are mediated, at leas
t in part, by NMDA receptors, resulting in NO formation. Nitric oxide thus modul
ates the local release of glutamate, GABA, and 5-HT, having complex effects on D
RN neuronal activity and implying interference of motor and emotion-related proc
esses. The DRN innervates emotion-related areas such as the amygdala, hippocampu
s and DLPAG (19). It also sends 5-HT fibers to the striatum, a motor-related are
a where they can modulate motor function.</span></font></p>      ^cY#812.htm##
00973000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704074700072002000800819#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#55#51#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">We showed that NO neurotransmission in the DRN media
tes anxiolytic- and antidepressant-like effects in rats, which were followed by 
significant locomotor changes (2). The fact that the locomotor effects of SIN-1 
were prevented by AP7, a glutamate NMDA receptor antagonist, suggests that SIN-1
 may act by facilitating glutamate release in the DRN. Similar mechanisms have b
een implicated in the escape responses produced by SIN-1 administration into the
 DLPAG. In this region, escape responses appear to be modulated also by 5-HT bec
ause these effects were inhibited by the 5-HT<sub>2A/2C</sub> receptor agonist 1
-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) (20).</span></font></p>      
^cY#812.htm##
01619000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704139300072002000801465#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#56#52#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The present study demonstrated that the increased lo
comotor activity induced by SIN-1 administration into the DRN was prevented by p
retreatment with the 5-HT<sub>1A</sub> receptor agonist 8-OH-DPAT. Considering t
his evidence, it is possible that 5-HT<sub>1A</sub> receptors in the DRN mediate
 the effects of NO on locomotor activity. Recently, it was demonstrated that adm
inistration of the 5-HT<sub>1A</sub> receptor agonist 8-OH-DPAT into the DRN fav
ored the expression of the escape, which was chemically induced by SIN-1 adminis
tration into the DLPAG while intra-DRN injection of the WAY-100635 did not chang
e this defensive behavior (14). These findings support the view that DRN 5-HT<su
b>1A</sub> autoreceptors are under the tonic inhibitory influence of 5-HT. In th
is respect, an interesting interaction between NO and 5-HT has been demonstrated
 in the regulation of anxiety- and depressive-related behaviors. Zhang et al. (7
) have shown that nNOS is required not only for the anxiolytic-like effects of t
he 5-HT<sub>1A</sub> receptor agonist 8-OH-DPAT but also for the anxiogenic-like
 effects of the 5-HT<sub>1A</sub> receptor antagonist 1-(methoxyphenyl)-4-[4-(2-
phthalimido)butyl]piperazine (NAN-190), indicating that NO may serve as a downst
ream signaling enzyme of 5-HT<sub>1A</sub> receptor functions.</span></font></p>
      ^cY#812.htm##
01372000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704114600072002000801218#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#57#53#article#110#<p ALIGN="LEFT"><span l
ang="EN"><font FACE="Arial">Contrary to expectations, however, administration of
 carboxy-PTIO failed to change the locomotor activity when injected into the DRN
. It is possible that exogenous NO, delivered</font> <font FACE="Arial">by SIN-1
 was more effective in interfering with locomotion than the effect of the NO sca
venger, carboxy-PTIO. The results of our study also revealed that pretreatment o
f rats with WAY-100635 did not affect locomotor activity or increase the effects
 of SIN-1. WAY-100635 slightly increased the distance traveled in the open field
, but this effect was not statistically significant. The failure of WAY-100635 t
o modify the increased locomotor activity produced by SIN-1, however, is consist
ent with reports showing that WAY-100635 injected into the DRN at the same dose 
(0.37 nmol) presented a panicolytic-like effect without affecting locomotion (12
) and did not change defensive behaviors induced by DLPAG stimulation (14). To b
etter clarify the interaction between NO and 5-HT<sub>1A</sub> receptors in the 
DRN, however, further experiments need to be conducted.</font></span></p>      ^
cY#812.htm##
00617000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704039100072002000800463#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#58#54#article#110#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The present results indicate that exogenous NO admin
istration into the DRN increases locomotor activity in rats, and this effect is 
mediated at least in part by 5-HT<sub>1A</sub> receptor activation and/or facili
tation of glutamate NMDA receptor-mediated neurotransmission in this region.</sp
an></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#812.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#59#55#article#110#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#812.htm##
00510000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027000074002000800344#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#60#56#article#110#1#<p ALIGN=
"LEFT"><font face="Arial"><span lang="EN">1. Faria MS, Muscara MN, Moreno Junior
 H, Teixeira SA, Dias HB, De Oliveira B, et al. Acute inhibition of nitric oxide
 synthesis induces anxiolysis in the plus maze test. <i>Eur J Pharmacol</i> 1997
; 323: 37-43.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#61#57#article#110#</span></font></p>     
 ^cY#812.htm##
00518000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027800074002000800352#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#62#58#article#110#2#<p ALIGN=
"LEFT"><font face="Arial"><span lang="EN">2. Spiacci A Jr, Kanamaru F, Guimaraes
 FS, Oliveira RM. Nitric oxide-mediated anxiolytic-like and antidepressant-like 
effects in animal models of anxiety and depression. <i>Pharmacol Biochem Behav</
i> 2008; 88: 247-255.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#63#59#article#110#</span></font></p>     
 ^cY#812.htm##
00590000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704035000074002000800424#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#64#60#article#110#3#<p align=
"LEFT"><font face="Arial"><span lang="EN">3. Harvey BH, Duvenhage I, Viljoen F, 
Scheepers N, Malan SF, Wegener G, et al. Role of monoamine oxidase, nitric oxide
 synthase and regional brain monoamines in the antidepressant-like effects of me
thylene blue and selected structural analogues. <i>Biochem Pharmacol</i> 2010; 8
0: 1580-1591.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#65#61#article#110#</span></font></p>     
 ^cY#812.htm##
00510000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027000074002000800344#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#66#62#article#110#4#<p align=
"LEFT"><font face="Arial"><span lang="EN">4. Harkin A, Connor TJ, Burns MP, Kell
y JP. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptak
e inhibitors in the forced swimming test. <i>Eur Neuropsycho-pharmacol</i> 2004;
 14: 274-281.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#67#63#article#110#</span></font></p>     
 ^cY#812.htm##
00530000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704029000074002000800364#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#68#64#article#110#5#<p align=
"LEFT"><font face="Arial"><span lang="EN">5. Ulak G, Mutlu O, Tanyeri P, Komsuog
lu FI, Akar FY, Erden BF. Involvement of serotonin receptor subtypes in the anti
depressant-like effect of TRIM in the rat forced swimming test. <i>Pharmacol Bio
chem Behav</i> 2010; 95: 308-314.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#69#65#article#110#</span></font></p>     
 ^cY#812.htm##
00525000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704028500074002000800359#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#70#66#article#110#6#<p align=
"LEFT"><font face="Arial"><span lang="EN">6. Harvey BH, Retief R, Korff A, Wegen
er G. Increased hippocampal nitric oxide synthase activity and stress responsive
ness after imipramine discontinuation: role of 5HT 2A/C-receptors. <i>Metab Brai
n Dis</i> 2006; 21: 211-220.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#71#67#article#110#</span></font></p>     
 ^cY#812.htm##
00518000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027800074002000800352#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#72#68#article#110#7#<p align=
"LEFT"><font face="Arial"><span lang="EN">7. Zhang J, Huang XY, Ye ML, Luo CX, W
u HY, Hu Y, et al. Neuronal nitric oxide synthase alteration accounts for the ro
le of 5-HT1A receptor in modulating anxiety-related behaviors. <i>J Neurosci</i>
 2010; 30: 2433-2441.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#73#69#article#110#</span></font></p>     
 ^cY#812.htm##
00471000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704023100074002000800305#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#74#70#article#110#8#<p align=
"LEFT"><font face="Arial"><span lang="EN">8. Wegener G, Volke V, Rosenberg R. En
dogenous nitric oxide decreases hippocampal levels of serotonin and dopamine <i>
in vivo</i>. <i>Br J Pharmacol</i> 2000; 130: 575-580.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#75#71#article#110#</span></font></p>     
 ^cY#812.htm##
00486000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704024600074002000800320#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#76#72#article#110#9#<p align=
"LEFT"><font face="Arial"><span lang="EN">9. Smith JC, Whitton PS. The regulatio
n of NMDA-evoked dopamine release by nitric oxide in the frontal cortex and raph
e nuclei of the freely moving rat. <i>Brain Res</i> 2001; 889: 57-62.    ^cY#812
.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#77#73#article#110#</span></font></p>     
 ^cY#812.htm##
00453000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704021200075002000800287#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#78#74#article#110#10#<p align
="LEFT"><font face="Arial"><span lang="EN">10. Graeff FG, Guimaraes FS, De Andra
de TG, Deakin JF. Role of 5-HT in stress, anxiety, and depression. <i>Pharmacol 
Biochem Behav</i> 1996; 54: 129-141.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#79#75#article#110#</span></font></p>     
 ^cY#812.htm##
00481000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704024000075002000800315#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#80#76#article#110#11#<p align
="LEFT"><font face="Arial"><span lang="EN">11. Wang QP, Guan JL, Nakai Y. Distri
bution and synaptic relations of NOS neurons in the dorsal raphe nucleus: a comp
arison to 5-HT neurons. <i>Brain Res Bull</i> 1995; 37: 177-187.    ^cY#812.htm#
#
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#81#77#article#110#</span></font></p>     
 ^cY#812.htm##
00458000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704021700075002000800292#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#82#78#article#110#12#<p align
="LEFT"><font face="Arial"><span lang="EN">12. Lee HS, Kim MA, Valentino RJ, Wat
erhouse BD. Glutamatergic afferent projections to the dorsal raphe nucleus of th
e rat. <i>Brain Res</i> 2003; 963: 57-71.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#83#79#article#110#</span></font></p>     
 ^cY#812.htm##
00415000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704017400075002000800249#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#84#80#article#110#13#<p align
="LEFT"><font face="Arial"><span lang="EN">13. Paxinos G, Watson C. <i>The rat b
rain in stereotaxic coordinates</i>. 3rd edn. San Diego: Academic Press; 1997.  
  ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#85#81#article#110#</span></font></p>     
 ^cY#812.htm##
00537000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704029600075002000800371#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#86#82#article#110#14#<p align
="LEFT"><font face="Arial"><span lang="EN">14. Miguel TL, Pobbe RL, Spiacci JA, 
Zangrossi JH. Dorsal raphe nucleus regulation of a panic-like defensive behavior
 evoked by chemical stimulation of the rat dorsal periaqueductal gray matter. <i
>Behav Brain Res</i> 2010; 213: 195-200.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#87#83#article#110#</span></font></p>     
 ^cY#812.htm##
00559000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704031800075002000800393#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#88#84#article#110#15#<p align
="LEFT"><font face="Arial"><span lang="EN">15. Pobbe RL, Zangrossi H Jr. 5-HT(1A
) and 5-HT(2A) receptors in the rat dorsal periaqueductal gray mediate the antip
anic-like effect induced by the stimulation of serotonergic neurons in the dorsa
l raphe nucleus. <i>Psychopharmacology </i>2005; 183: 314-321.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#89#85#article#110#</span></font></p>     
 ^cY#812.htm##
00515000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704027400075002000800349#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#90#86#article#110#16#<p align
="LEFT"><font face="Arial"><span lang="EN">16. De Oliveira RM, Del Bel EA, Guima
raes FS. Effects of excitatory amino acids and nitric oxide on flight behavior e
licited from the dorsolateral periaqueductal gray. <i>Neurosci Biobehav Rev</i> 
2001; 25: 679-685.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#91#87#article#110#</span></font></p>     
 ^cY#812.htm##
00571000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704033000075002000800405#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#92#88#article#110#17#<p align
="LEFT"><font face="Arial"><span lang="EN">17. Aguiar DC, Moreira FA, Guimaraes 
FS. Flight reactions induced by injection of glutamate N-methyl-D-aspartate rece
ptor agonist into the rat dorsolateral periaqueductal gray are not dependent on 
endogenous nitric oxide. <i>Pharmacol Biochem Behav</i> 2006; 83: 296-301.    ^c
Y#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#93#89#article#110#</span></font></p>     
 ^cY#812.htm##
00492000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025100075002000800326#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#94#90#article#110#18#<p align
="LEFT"><font face="Arial"><span lang="EN">18. Del Bel EA, Guimaraes FS, Bermude
z-Echeverry M, Gomes MZ, Schiaveto-de-Souza A, Padovan-Neto FE, et al. Role of n
itric oxide on motor behavior. <i>Cell Mol Neurobiol</i> 2005; 25: 371-392.    ^
cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#95#91#article#110#</span></font></p>     
 ^cY#812.htm##
00539000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704029800075002000800373#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#96#92#article#110#19#<p align
="LEFT"><font face="Arial"><span lang="EN">19. Celada P, Puig MV, Casanovas JM, 
Guillazo G, Artigas F. Control of dorsal raphe serotonergic neurons by the media
l prefrontal cortex: Involvement of serotonin-1A, GABA(A), and glutamate recepto
rs. <i>J Neurosci</i> 2001; 21: 9917-9929.    ^cY#812.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#97#93#article#110#</span></font></p>     
 ^cY#812.htm##
00529000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704028800075002000800363#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#p#98#94#article#110#20#<p align
="LEFT"><font face="Arial"><span lang="EN">20. Moreira FA, Guimaraes FS. Role of
 serotonin receptors in panic-like behavior induced by nitric oxide in the rat d
orsolateral periaqueductal gray: effects of chronic clomipramine treatment. <i>L
ife Sci</i> 2005; 77: 1972-1982.    ^cY#812.htm##
00278000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704005200072002000800124#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#99#95#article#110#</span></font></p>  <HR
 ALIGN=LEFT SIZE=2>      ^cY#812.htm##
00562000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704033500073002000800408#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#100#96#article#110#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE=
4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, sa
ns-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN
=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#812.htm
##
00518000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704029100073002000800364#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#101#97#article#110#<p ALIGN="LEFT"><font 
face="Arial"><span lang="EN">We thank M.A. Trombelli (Universidade Estadual de M
aring&aacute;, Maring&aacute;, PR, Brazil) for technical support. Research suppo
rted by Funda&ccedil;&atilde;o Arauc&aacute;ria and CNPq.</span></font></p>  <HR
 ALIGN=LEFT SIZE=2>      ^cY#812.htm##
00563000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704033600073002000800409#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#102#98#article#110#<P><FONT SIZE=4 face="
Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><
B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, Hel
vetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.
gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#812.ht
m##
00692000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704046500073002000800538#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#103#99#article#110#<p><font face="Arial, 
Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/re
cor.gif" border="0"></a> Address for correspondence:</b></font> <font face="Aria
l"><span lang="EN">R.M.W. Oliveira, Departamento de Farmacologia, Universidade E
stadual de Maring&aacute;, Av. Colombo, 5790, 87020-900 Maring&aacute;, PR, Bras
il. Fax: +55-44-3261-4999. E-mail: <a href="mailto:rmmwoliveira@uem.br">rmmwoliv
eira@uem.br</a></span></font></p>      ^cY#812.htm##
00450000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704022200074002000800296#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#104#100#article#110#<p ALIGN="LEFT"><i><f
ont face="Arial"><span lang="EN">Received October 6, 2010. Accepted February 23,
 2011. Available online March 25, 2011. Published April 11, 2011.</span></font><
/i></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#812.htm##
00260000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704003200074002000800106#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#105#101#article#110#<div align="center"> 
       ^cY#812.htm##
00426000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704019800074002000800272#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#106#102#article#110#<p><font color="#0000
00" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilia
n Journal of Medical and Biological Research is partially financed by</font></em
><strong>    ^cY#812.htm##
00252000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704002400074002000800098#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#107#103#article#110#<br>                ^
cY#812.htm##
00326000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704009800074002000800172#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#108#104#article#110#<br>    </strong></fo
nt></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#812
.htm##
00384000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015600074002000800230#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#109#105#article#110#<div align="center"><
a target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4
/cnpq.jpg" border="0"></a></div></td>      <td>    ^cY#812.htm##
00386000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704015800074002000800232#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#110#106#article#110#<div align="center"><
a target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#812.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016200074002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#111#107#article#110#<div align="center"><
a target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#812.htm##
00401000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017300074002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#112#108#article#110#<div align="center"><
a target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/r
evistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#812.htm#
#
00392000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704016400074002000800238#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#113#109#article#110#<div align="center"><
a target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr
/v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#812.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\812.htm#S#p#114#110#article#110#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#812.htm##
00700000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100018000890100
02300107010001900130010001500149010002100164810000600185012008800191030001600279
06500090029506400050030403100040030901400060031386500090031900200080032803500100
0336801001600346#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#c#115#1#art
icle#20#1#^rND^sFaria^nMS#^rND^sMuscara^nMN#^rND^sMoreno^nJunior H#^rND^sTeixeir
a^nSA#^rND^sDias^nHB#^rND^sDe^nOliveira B#et al#Acute inhibition of nitric oxide
 synthesis induces anxiolysis in the plus maze test^len#Eur J Pharmacol#19970000
#1997#323#37-43#20110400#812.htm#0014-2999#Eur J Pharmacol##
00669000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100020000730100018000930100
02000111010001900131012011700150030002400267065000900291064000500300031000300305
014000800308865000900316002000800325035001000333801002400343#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\812.htm#S#c#116#2#article#20#2#^rND^sSpiacci^nA Jr#^rND^s
Kanamaru^nF#^rND^sGuimaraes^nFS#^rND^sOliveira^nRM#Nitric oxide-mediated anxioly
tic-like and antidepressant-like effects in animal models of anxiety and depress
ion^len#Pharmacol Biochem Behav#20080000#2008#88#247-255#20110400#812.htm#0091-3
057#Pharmacol Biochem Behav##
00782000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100019000900100
01700109010001900126010001600145010001700161810000600178012017000184030001800354
06500090037206400050038103100030038601400100038986500090039900200080040803500100
0416801001800426#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#c#117#3#art
icle#20#3#^rND^sHarvey^nBH#^rND^sDuvenhage^nI#^rND^sViljoen^nF#^rND^sScheepers^n
N#^rND^sMalan^nSF#^rND^sWegener^nG#et al#Role of monoamine oxidase, nitric oxide
 synthase and regional brain monoamines in the antidepressant-like effects of me
thylene blue and selected structural analogues^len#Biochem Pharmacol#20100000#20
10#80#1580-1591#20110400#812.htm#0006-2952#Biochem Pharmacol##
00617000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100017000890100
01600106010001600122012011900138030002600257710000200283065000900285064000500294
031000300299014000800302865000900310002000800319#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\812.htm#S#c#118#4#article#20#4#^rND^sHarkin^nA#^rND^sConnor^nTJ#^rND^
sBurns^nMP#^rND^sKelly^nJP#Nitric oxide synthase inhibitors augment the effects 
of serotonin re-uptake inhibitors in the forced swimming test^len#Eur Neuropsych
o-pharmacol#2#20040000#2004#14#274-281#20110400#812.htm##
00717000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100014000730100015000870100
01700102010002000119010001500139010001600154012012100170030002400291065000900315
06400050032403100030032901400080033286500090034000200080034903500100035780100240
0367#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#c#119#5#article#20#5#^r
ND^sUlak^nG#^rND^sMutlu^nO#^rND^sTanyeri^nP#^rND^sKomsuoglu^nFI#^rND^sAkar^nFY#^
rND^sErden^nBF#Involvement of serotonin receptor subtypes in the antidepressant-
like effect of TRIM in the rat forced swimming test^len#Pharmacol Biochem Behav#
20100000#2010#95#308-314#20110400#812.htm#0091-3057#Pharmacol Biochem Behav##
00668000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100016000900100
01500106010001700121012014400138030001600282065000900298064000500307031000300312
014000800315865000900323002000800332035001000340801001600350#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\812.htm#S#c#120#6#article#20#6#^rND^sHarvey^nBH#^rND^sRet
ief^nR#^rND^sKorff^nA#^rND^sWegener^nG#Increased hippocampal nitric oxide syntha
se activity and stress responsiveness after imipramine discontinuation: role of 
5HT 2A/C-receptors^len#Metab Brain Dis#20060000#2006#21#211-220#20110400#812.htm
#0885-7490#Metab Brain Dis##
00703000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100016000880100
01300104010001400117010001300131010001200144810000600156012012700162030001100289
06500090030006400050030903100030031401400100031786500090032700200080033603500100
0344801001100354#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#c#121#7#art
icle#20#7#^rND^sZhang^nJ#^rND^sHuang^nXY#^rND^sYe^nML#^rND^sLuo^nCX#^rND^sWu^nHY
#^rND^sHu^nY#et al#Neuronal nitric oxide synthase alteration accounts for the ro
le of 5-HT1A receptor in modulating anxiety-related behaviors^len#J Neurosci#201
00000#2010#30#2433-2441#20110400#812.htm#0270-6474#J Neurosci##
00588000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100015000900100
01900105012009100124030001500215065000900230064000500239031000400244014000800248
865000900256002000800265035001000273801001500283#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\812.htm#S#c#122#8#article#20#8#^rND^sWegener^nG#^rND^sVolke^nV#^rND^s
Rosenberg^nR#Endogenous nitric oxide decreases hippocampal levels of serotonin a
nd dopamine in vivo^len#Br J Pharmacol#20000000#2000#130#575-580#20110400#812.ht
m#0007-1188#Br J Pharmacol##
00587000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100018000890120
13100107030001000238065000900248064000500257031000400262014000600266865000900272
002000800281035001000289801001000299#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
12.htm#S#c#123#9#article#20#9#^rND^sSmith^nJC#^rND^sWhitton^nPS#The regulation o
f NMDA-evoked dopamine release by nitric oxide in the frontal cortex and raphe n
uclei of the freely moving rat^len#Brain Res#20010000#2001#889#57-62#20110400#81
2.htm#0006-8993#Brain res##
00604000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100020000920100
02100112010001700133012005200150030002400202065000900226064000500235031000300240
014000800243865000900251002000800260035001000268801002400278#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\812.htm#S#c#124#10#article#20#10#^rND^sGraeff^nFG#^rND^sG
uimaraes^nFS#^rND^sDe^nAndrade TG#^rND^sDeakin^nJF#Role of 5-HT in stress, anxie
ty, and depression^len#Pharmacol Biochem Behav#19960000#1996#54#129-141#20110400
#812.htm#0091-3057#Pharmacol Biochem Behav##
00605000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100015000900100
01500105012011300120030001500233065000900248064000500257031000300262014000800265
865000900273002000800282035001000290801001500300#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\812.htm#S#c#125#11#article#20#11#^rND^sWang^nQP#^rND^sGuan^nJL#^rND^s
Nakai^nY#Distribution and synaptic relations of NOS neurons in the dorsal raphe 
nucleus: a comparison to 5-HT neurons^len#Brain Res Bull#19950000#1995#37#177-18
7#20110400#812.htm#0361-9230#Brain Res Bull##
00595000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100014000890100
02000103010002100123012007800144030001000222065000900232064000500241031000400246
014000600250865000900256002000800265035001000273801001000283#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\812.htm#S#c#126#12#article#20#12#^rND^sLee^nHS#^rND^sKim^
nMA#^rND^sValentino^nRJ#^rND^sWaterhouse^nBD#Glutamatergic afferent projections 
to the dorsal raphe nucleus of the rat^len#Brain Res#20030000#2003#963#57-71#201
10400#812.htm#0006-8993#Brain res##
00465000000000253000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720160017000750160016000920180
04500108063000200153066001000155062001500165065000900180064000500189865000900194
002000800203#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#c#127#13#articl
e#20#13#^rND^sPaxinos^nG#^rND^sWatson^nC#The rat brain in stereotaxic coordinate
s^len#3#San Diego#Academic Press#19970000#1997#20110400#812.htm##
00680000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
01800108010002000126012014700146030001600293065000900309064000500318031000400323
014000800327865000900335002000800344035001000352801001600362#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\812.htm#S#c#128#14#article#20#14#^rND^sMiguel^nTL#^rND^sP
obbe^nRL#^rND^sSpiacci^nJA#^rND^sZangrossi^nJH#Dorsal raphe nucleus regulation o
f a panic-like defensive behavior evoked by chemical stimulation of the rat dors
al periaqueductal gray matter^len#Behav Brain Res#20100000#2010#213#195-200#2011
0400#812.htm#0166-4328#Behav Brain Res##
00669000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100022000910120
18700113030001900300065000900319064000500328031000400333014000800337865000900345
002000800354035001000362801001900372#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
12.htm#S#c#129#15#article#20#15#^rND^sPobbe^nRL#^rND^sZangrossi^nH Jr#5-HT(1A) a
nd 5-HT(2A) receptors in the rat dorsal periaqueductal gray mediate the antipani
c-like effect induced by the stimulation of serotonergic neurons in the dorsal r
aphe nucleus^len#Psychopharmacology#20050000#2005#183#314-321#20110400#812.htm#0
033-3158#Psychopharmacology##
00646000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100022000750100018000970100
02000115012012500135030002200260065000900282064000500291031000300296014000800299
865000900307002000800316035001000324801002200334#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\812.htm#S#c#130#16#article#20#16#^rND^sDe^nOliveira RM#^rND^sDel^nBel
 EA#^rND^sGuimaraes^nFS#Effects of excitatory amino acids and nitric oxide on fl
ight behavior elicited from the dorsolateral periaqueductal gray^len#Neurosci Bi
obehav Rev#20010000#2001#25#679-685#20110400#812.htm#0149-7634#Neurosci Biobehav
 Rev##
00704000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100018000920100
02000110012018400130030002400314065000900338064000500347031000300352014000800355
865000900363002000800372035001000380801002400390#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\812.htm#S#c#131#17#article#20#17#^rND^sAguiar^nDC#^rND^sMoreira^nFA#^
rND^sGuimaraes^nFS#Flight reactions induced by injection of glutamate N-methyl-D
-aspartate receptor agonist into the rat dorsolateral periaqueductal gray are no
t dependent on endogenous nitric oxide^len#Pharmacol Biochem Behav#20060000#2006
#83#296-301#20110400#812.htm#0091-3057#Pharmacol Biochem Behav##
00692000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100020000930100
02800113010001600141010002800157010002300185010001300208012004300221030001900264
06500090028306400050029203100030029701400080030086500090030800200080031703500100
0325801001900335#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#c#132#18#ar
ticle#20#18#^rND^sDel^nBel EA#^rND^sGuimaraes^nFS#^rND^sBermudez-Echeverry^nM#^r
ND^sGomes^nMZ#^rND^sSchiaveto-de-Souza^nA#^rND^sPadovan-Neto^nFE#^rND^set^nal#Ro
le of nitric oxide on motor behavior^len#Cell Mol Neurobiol#20050000#2005#25#371
-392#20110400#812.htm#0272-4340#Cell Mol Neurobiol##
00695000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100015000910100
02000106010001800126010001700144012014400161030001100305065000900316064000500325
031000300330014001000333865000900343002000800352035001000360801001100370#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\812.htm#S#c#133#19#article#20#19#^rND^sCelada
^nP#^rND^sPuig^nMV#^rND^sCasanovas^nJM#^rND^sGuillazo^nG#^rND^sArtigas^nF#Contro
l of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvem
ent of serotonin-1A, GABA(A), and glutamate receptors^len#J Neurosci#20010000#20
01#21#9917-9929#20110400#812.htm#0270-6474#J Neurosci##
00629000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100020000930120
16600113030000900279065000900288064000500297031000300302014001000305865000900315
002000800324035001000332801000900342#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
12.htm#S#c#134#20#article#20#20#^rND^sMoreira^nFA#^rND^sGuimaraes^nFS#Role of se
rotonin receptors in panic-like behavior induced by nitric oxide in the rat dors
olateral periaqueductal gray: effects of chronic clomipramine treatment^len#Life
 Sci#20050000#2005#77#1972-1982#20110400#812.htm#0024-3205#Life sci##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#o#1#1#article#1#201
10411#094654#817.htm#125##
03332000000000673000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000900094158000700103030002000110
03100030013003200020013306500090013501400110014403500100015522400090016501201160
01740100023002900100024003130100026003370100028003630100027003910100033004180100
03500451010003000486070011300516070011500629070011400744070006600858070012500924
08313400104908500080238908500310239708500200242808500300244808500290247808500260
25070850033025331170006025660720003025721120009025751110016025841140009026001130
01702609891002402626002000802650#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.h
tm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#14#BJMBR400#FAPESP#Braz J Med Biol R
es#44#4#20110400#^f361^l365#0100-879X#20110211#The novel p.E89K mutation in the 
SRY gene inhibits DNA binding and causes the 46,XY disorder of sex development^l
en#^rND^1A01^nJ.L.^sCunha#^rND^1A01^nF.C.^sSoardi#^rND^1A01^nR.D.^sBernardi#^rND
^1A01^nL.E.C.^sOliveira#^rND^1A02^nC.E.^sBenedetti#^rND^1A03 A04^nG.^sGuerra-Jun
ior#^rND^1A03 A05^nA.T.^sMaciel-Guerra#^rND^1A01 A03^nM.P.^sde Mello#Universidad
e Estadual de Campinas^iA01^1Centro de Biologia Molecular e Engenharia Genética^
cCampinas^sSP^pBrasil#Centro Nacional de Pesquisa em Energia e Materiais^iA02^1L
aboratório Nacional de Biociências^cCampinas^sSP^pBrasil#Universidade Estadual d
e Campinas^iA03^1Grupo Interdisciplinar de Estudos da Determinação e Diferenciaç
ão do Sexo#Universidade Estadual de Campinas^iA04^1Departamento de Pediatria#Uni
versidade Estadual de Campinas^iA05^1Faculdade de Ciências Médicas^2Departamento
 de Genética Médica^cCampinas^sSP^pBrasil#^len^aMale sex determination in humans
 is controlled by the SRY gene, which encodes a transcriptional regulator contai
ning a conserved high mobility group box domain (HMG-box) required for DNA bindi
ng. Mutations in the SRY HMG-box affect protein function, causing sex reversal p
henotypes. In the present study, we describe a 19-year-old female presenting 46,
XY karyotype with hypogonadism and primary amenorrhea that led to the diagnosis 
of 46,XY complete gonadal dysgenesis. The novel p.E89K missense mutation in the 
SRY HMG-box was identified as a de novo mutation. Electrophoretic mobility shift
 assays showed that p.E89K almost completely abolished SRY DNA-binding activity,
 suggesting that it is the cause of SRY function impairment. In addition, we rep
ort the occurrence of the p.G95R mutation in a 46,XY female with complete gonada
l dysgenesis. According to the three-dimensional structure of the human SRY HMG-
box, the substitution of the conserved glutamic acid residue by the basic lysine
 at position 89 introduces an extra positive charge adjacent to and between the 
positively charged residues R86 and K92, important for stabilizing the HMG-box h
elix 2 with DNA. Thus, we propose that an electrostatic repulsion caused by the 
proximity of these positive charges could destabilize the tip of helix 2, abroga
ting DNA interaction.#^dnd^i1#^tm^len^kGonadal dysgenesis^i1#^tm^len^kHMG-box^i1
#^tm^len^kMissense mutation^i1#^tm^len^kSex reversal SRY^i1#^tm^len^kStreak gona
ds^i1#^tm^len^kTestis determination^i1#other#22#20101007#October 7, 2010#2011013
1#January 31, 2011#S0100-879X2011007500017#817.htm##
03324000000000661000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086121000300091049000900094158000700103030002000110
03100030013003200020013306500090013501400110014403500100015522400090016501201300
01740100023003040100024003270100026003510100028003770100027004050100033004320100
03500465010003000500070011300530070011500643070011400758070006600872070012500938
08313540106308500080241708500310242508500200245608500300247608500290250608500260
25350850033025611170006025940720003026001120009026031110016026121140009026281130
01702637002000802654#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#f#3#1#a
rticle#1#oa#en#bjmbr#1#3.1#ILUS#14#BJMBR400#FAPESP#Braz J Med Biol Res#44#4#2011
0400#^f361^l365#0100-879X#20110211#<b>The novel p.E89K mutation in the<i> SRY</i
> gene inhibits DNA binding and causes the 46,XY disorder of sex development</b>
^len#^rND^1A01^nJ.L.^sCunha#^rND^1A01^nF.C.^sSoardi#^rND^1A01^nR.D.^sBernardi#^r
ND^1A01^nL.E.C.^sOliveira#^rND^1A02^nC.E.^sBenedetti#^rND^1A03 A04^nG.^sGuerra-J
unior#^rND^1A03 A05^nA.T.^sMaciel-Guerra#^rND^1A01 A03^nM.P.^sde Mello#Universid
ade Estadual de Campinas^iA01^1Centro de Biologia Molecular e Engenharia Genétic
a^cCampinas^sSP^pBrasil#Centro Nacional de Pesquisa em Energia e Materiais^iA02^
1Laboratório Nacional de Biociências^cCampinas^sSP^pBrasil#Universidade Estadual
 de Campinas^iA03^1Grupo Interdisciplinar de Estudos da Determinação e Diferenci
ação do Sexo#Universidade Estadual de Campinas^iA04^1Departamento de Pediatria#U
niversidade Estadual de Campinas^iA05^1Faculdade de Ciências Médicas^2Departamen
to de Genética Médica^cCampinas^sSP^pBrasil#^len^aMale sex determination in huma
ns is controlled by the <i>SRY</i> gene, which encodes a transcriptional regulat
or containing a conserved high mobility group box domain (HMG-box) required for 
DNA binding. Mutations in the SRY HMG-box affect protein function, causing sex r
eversal phenotypes. In the present study, we describe a 19-year-old female prese
nting 46,XY karyotype with hypogonadism and primary amenorrhea that led to the d
iagnosis of 46,XY complete gonadal dysgenesis. The novel p.E89K missense mutatio
n in the SRY HMG-box was identified as a<i> de novo </i>mutation. Electrophoreti
c mobility shift assays showed that p.E89K almost completely abolished SRY DNA-b
inding activity, suggesting that it is the cause of SRY function impairment. In 
addition, we report the occurrence of the p.G95R mutation in a 46,XY female with
 complete gonadal dysgenesis. According to the three-dimensional structure of th
e human SRY HMG-box, the substitution of the conserved glutamic acid residue by 
the basic lysine at position 89 introduces an extra positive charge adjacent to 
and between the positively charged residues R86 and K92, important for stabilizi
ng the HMG-box helix 2 with DNA. Thus, we propose that an electrostatic repulsio
n caused by the proximity of these positive charges could destabilize the tip of
 helix 2, abrogating DNA interaction.#^dnd^i1#^tm^len^kGonadal dysgenesis^i1#^tm
^len^kHMG-box^i1#^tm^len^kMissense mutation^i1#^tm^len^kSex reversal SRY^i1#^tm^
len^kStreak gonads^i1#^tm^len^kTestis determination^i1#other#22#20101007#October
 7, 2010#20110131#January 31, 2011#817.htm##
03480000000000685000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099121000300104049000900107158000700116
03000240012303100030014703200020015006500090015201400110016103500100017222400090
01820120116001910100023003070100024003300100026003540100029003800100027004090100
03200436010003500468010003000503070011500533070011700648070013800765070009000903
07001270099308313400112008500080246008500310246808500200249908500300251908500290
25490850026025780850033026041170006026370720003026431120009026461110016026551140
00902671113001702680002000802697008008902705#v44n4#V:\SciELO\serial\bjmbr\v44n4\
markup\817.htm#S#l#4#1#article#1#^mApr.^a2011#oa#en#bjmbr#1#3.1#ilus#14#BJMBR400
#FAPESP#Braz. j. med. biol. res#44#4#20110400#^f361^l365#0100-879X#20110211#The 
novel p.E89K mutation in the SRY gene inhibits DNA binding and causes the 46,XY 
disorder of sex development^len#^rND^1A01^nJ. L^sCunha#^rND^1A01^nF. C^sSoardi#^
rND^1A01^nR. D^sBernardi#^rND^1A01^nL. E. C^sOliveira#^rND^1A02^nC. E^sBenedetti
#^rND^1A03 A04^nG^sGuerra-Junior#^rND^1A03 A05^nA. T^sMaciel-Guerra#^rND^1A01 A0
3^nM. P^sde Mello#^iA01^1Universidade Estadual de Campinas^2Centro de Biologia M
olecular e Engenharia Genética^cCampinas^sSP^pBrasil#^iA02^1Centro Nacional de P
esquisa em Energia e Materiais^2Laboratório Nacional de Biociências^cCampinas^sS
P^pBrasil#^iA03^1Universidade Estadual de Campinas^2Grupo Interdisciplinar de Es
tudos da Determinação e Diferenciação do Sexo^cCampinas^sSP^pBrasil#^iA04^1Unive
rsidade Estadual de Campinas^2Departamento de Pediatria^cCampinas^sSP^pBrasil#^i
A05^1Universidade Estadual de Campinas^2Faculdade de Ciências Médicas^3Departame
nto de Genética Médica^cCampinas^sSP^pBrasil#^len^aMale sex determination in hum
ans is controlled by the SRY gene, which encodes a transcriptional regulator con
taining a conserved high mobility group box domain (HMG-box) required for DNA bi
nding. Mutations in the SRY HMG-box affect protein function, causing sex reversa
l phenotypes. In the present study, we describe a 19-year-old female presenting 
46,XY karyotype with hypogonadism and primary amenorrhea that led to the diagnos
is of 46,XY complete gonadal dysgenesis. The novel p.E89K missense mutation in t
he SRY HMG-box was identified as a de novo mutation. Electrophoretic mobility sh
ift assays showed that p.E89K almost completely abolished SRY DNA-binding activi
ty, suggesting that it is the cause of SRY function impairment. In addition, we 
report the occurrence of the p.G95R mutation in a 46,XY female with complete gon
adal dysgenesis. According to the three-dimensional structure of the human SRY H
MG-box, the substitution of the conserved glutamic acid residue by the basic lys
ine at position 89 introduces an extra positive charge adjacent to and between t
he positively charged residues R86 and K92, important for stabilizing the HMG-bo
x helix 2 with DNA. Thus, we propose that an electrostatic repulsion caused by t
he proximity of these positive charges could destabilize the tip of helix 2, abr
ogating DNA interaction.#^dnd^i1#^tm^len^kGonadal dysgenesis^i1#^tm^len^kHMG-box
^i1#^tm^len^kMissense mutation^i1#^tm^len^kSex reversal SRY^i1#^tm^len^kStreak g
onads^i1#^tm^len^kTestis determination^i1#other#22#20101007#October 7, 2010#2011
0131#January 31, 2011#817.htm#Internet^ihttp://www.scielo.br/scielo.php?script=s
ci_arttext&pid=S0100-879X2011000400014##
00372000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000300066704014900069002000800218#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#5#1#article#99#<P> <font face="Arial, Hel
vetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volum
e 44(4) 361-365  </B> </font></P>      ^cY#817.htm##
00459000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000300066704023600069002000800305#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#6#2#article#99#<p ALIGN="LEFT"><span lang
="EN"><font size="5" face="Arial, Helvetica, sans-serif"><b>The novel p.E89K mut
ation in the<i> SRY</i> gene inhibits DNA binding and causes the 46,XY disorder 
of sex development</b></font></span></p>      ^cY#817.htm##
00978000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000300066704075500069002000800824#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#7#3#article#99#<p ALIGN="LEFT"><span lang
="EN"><font face="Arial, Helvetica, sans-serif">J.L. Cunha<sup>1</sup>, F.C. Soa
rdi<sup>1</sup>, R.D. Bernardi<sup>1</sup>, L.E.C. Oliveira<sup>1</sup>, C.E. Be
nedetti<sup>2</sup>, </font></span><span lang="EN"><font face="Arial, Helvetica,
 sans-serif">G. Guerra-Junior<sup>3,4</sup>, A.T. Maciel-Guerra<sup>3,5</sup> an
d <span lang="EN"><font face="Arial, Helvetica, sans-serif"><sup><span lang="EN"
><font face="Arial, Helvetica, sans-serif"><b><a href="#Correspondence"><img src
="/img/revistas/bjmbr/v44n4/recor.gif" border="0"></a></b> <a href="mailto:mmell
o@unicamp.br"><img src="/img/revistas/bjmbr/v44n4/email-ca.gif" border="0"></a><
/font></span></sup></font></span> M.P. de Mello<sup>1,3</sup></font></span></p> 
     ^cY#817.htm##
00432000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000300066704020900069002000800278#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#8#4#article#99#<p ALIGN="LEFT"><span lang
="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Centro de Biologia M
olecular e Engenharia Gen&eacute;tica, Universidade Estadual de Campinas, Campin
as, SP, Brasil     ^cY#817.htm##
00445000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000300066704022200069002000800291#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#9#5#article#99#<br>    </font></span><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif"><sup>2</sup>Laborat&oacute
;rio Nacional de Bioci&ecirc;ncias, Centro Nacional de Pesquisa em Energia e Mat
eriais, Campinas, SP, Brasil    ^cY#817.htm##
00786000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000300067704056200070002000800632#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#10#6#article#99#<br>  </font></span><span
 lang="EN"><font face="Arial, Helvetica, sans-serif"><sup>3</sup>Grupo Interdisc
iplinar de Estudos da Determina&ccedil;&atilde;o e Diferencia&ccedil;&atilde;o d
o Sexo, </font></span><span lang="EN"><font face="Arial, Helvetica, sans-serif">
<sup>4</sup>Departamento de Pediatria, <sup>5</sup>Departamento de Gen&eacute;ti
ca M&eacute;dica, Faculdade de Ci&ecirc;ncias M&eacute;dicas, </font></span><spa
n lang="EN"><font face="Arial, Helvetica, sans-serif">Universidade Estadual de C
ampinas, Campinas, SP, Brasil</font></span></p>      ^cY#817.htm##
00414000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000300067704019000070002000800260#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#11#7#article#99#<P> <font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#817.htm##
00411000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000300067704018700070002000800257#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#12#8#article#99#<BR>   <A HREF="#Introduc
tion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^c
Y#817.htm##
00411000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000300067704018700070002000800257#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#13#9#article#99#<BR>   <A HREF="#Material
"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Material"><strong>Patients and Methods</strong></A>    ^c
Y#817.htm##
00397000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704017200071002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#14#10#article#99#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#817.htm##
00406000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704018100071002000800252#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#15#11#article#99#<BR>   <A HREF="#Discuss
ion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#817
.htm##
00393000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704016800071002000800239#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#16#12#article#99#<BR>   <A HREF="#Referen
ces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#817.htm##
00434000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704020900071002000800280#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#17#13#article#99#<br>   </strong></A><A H
REF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledgm
ents</strong></A>    ^cY#817.htm##
00443000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704021800071002000800289#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#18#14#article#99#<BR>   <A HREF="#Corresp
ondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSP
ACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footnot
es</strong></A>  </font>      ^cY#817.htm##
00262000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704003700071002000800108#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#19#15#article#99#<P>  <HR ALIGN=LEFT SIZE
=2>      ^cY#817.htm##
00491000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704026600071002000800337#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#20#16#article#99#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><B
>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^c
Y#817.htm##
01674000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704144900071002000801520#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#21#17#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">Male sex determination in huma
ns is controlled by the <i>SRY</i> gene, which encodes a transcriptional regulat
or containing a conserved high mobility group box domain (HMG-box) required for 
DNA binding. Mutations in the SRY HMG-box affect protein function, causing sex r
eversal phenotypes. In the present study, we describe a 19-year-old female prese
nting 46,XY karyotype with hypogonadism and primary amenorrhea that led to the d
iagnosis of 46,XY complete gonadal dysgenesis. The novel p.E89K missense mutatio
n in the SRY HMG-box was identified as a<i> de novo </i>mutation. Electrophoreti
c mobility shift assays showed that p.E89K almost completely abolished SRY DNA-b
inding activity, suggesting that it is the cause of SRY function impairment. In 
addition, we report the occurrence of the p.G95R mutation in a 46,XY female with
 complete gonadal dysgenesis. According to the three-dimensional structure of th
e human SRY HMG-box, the substitution of the conserved glutamic acid residue by 
the basic lysine at position 89 introduces an extra positive charge adjacent to 
and between the positively charged residues R86 and K92, important for stabilizi
ng the HMG-box helix 2 with DNA. Thus, we propose that an electrostatic repulsio
n caused by the proximity of these positive charges could destabilize the tip of
 helix 2, abrogating DNA interaction.</font></span></p>      ^cY#817.htm##
00463000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704023800071002000800309#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#22#18#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">Key words: Gonadal dysgenesis;
 HMG-box; Missense mutation; Sex reversal SRY; Streak gonads; Testis determinati
on</font></span></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#817.htm##
00547000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704032200071002000800393#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#23#19#article#99#<P><font face="Arial, He
lvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B>
Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif
"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM 
BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#817.htm##
01360000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704113500071002000801206#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#24#20#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">In humans, as in other mammals
, sex determination is controlled by a dominant switch located on the Y-chromoso
me, the <i>SRY</i> gene, also referred to as the sex-determining region on the Y
 (1,2). The human single copy monoexonic <i>SRY</i> gene encodes a 204-amino aci
d protein that contains a conserved domain formed by 79 residues known as the hi
gh mobility group box (HMG-box), which is flanked by two nuclear localization si
gnals (3). The HMG-box characterizes the SRY as a transcription regulator with D
NA-binding and bending abilities (4-6). Mutations within the <i>SRY</i> gene seq
uence cause male-to-female sex reversal in XY individuals as a result of failure
 of indifferent gonads to develop into testes, leading to complete XY gonadal dy
sgenesis (46,XY CGD) (7), included among the 46,XY disorders of sex development 
(8). Patients with 46,XY CGD present a normal female phenotype and streak gonads
 at birth, whereas they will present primary amenorrhea and failure to develop f
emale secondary characteristics at puberty.</font></span></p>      ^cY#817.htm##
01263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704103800071002000801109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#25#21#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">The importance of SRY function
 has been indicated by a number of studies describing amino acid changes within 
this protein in patients with 46,XY CGD (9). To date, up to 68 mutations have be
en identified within the open reading frame of the <i>SRY</i> gene (10). The maj
ority of these mutations are located within the HMG-box, highlighting the critic
al role of this domain in DNA binding and transcriptional activation (11). Altho
ugh mutations outside the <i>SRY</i> HMG-box domain are rare, they can also caus
e 46,XY CGD (12,13). Furthermore, a small subset of reports describe familial mu
tations (13,14), whereas the majority are <i>de novo</i> mutations affecting onl
y one individual in a family. In summary, a large spectrum of phenotypic variati
on is observed among patients carrying different <i>SRY</i> gene mutations; ther
efore, phenotype and genotype correlations in patients with XY gonadal dysgenesi
s are not straightforward.</font></span></p>      ^cY#817.htm##
00944000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704071900071002000800790#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#26#22#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">In the present study, the nove
l p.E89K and p.G95R mutations within the SRY HMG-box were identified in patients
 with 46,XY CGD. The E89 residue is conserved among the SRY proteins and the p.E
89K mutation significantly affects the protein DNA-binding activity <i>in vitro<
/i>. Interestingly, both mutations introduce an extra positive charge adjacent t
o and between the positively charged residues R86 and K92 important for stabiliz
ing the HMG-box helix 2 and DNA complex. The role of the electrostatic repulsion
 caused by the proximity of those positive charges on DNA interaction is discuss
ed.</font></span></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#817.htm##
00549000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704032400071002000800395#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#27#23#article#99#<P><font face="Arial, He
lvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Pati
ents and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-s
erif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#817.htm##
00342000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704011700071002000800188#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#28#24#article#99#<p ALIGN="LEFT"><b><span
 lang="EN"><font face="Arial, Helvetica, sans-serif">Patients</font></span></b><
/p>      ^cY#817.htm##
01188000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704096300071002000801034#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#29#25#article#99#<p ALIGN="LEFT"> <span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><i>Patient 1</i>. A 19-year-o
ld female was referred to us due to hypogonadism and primary amenorrhea. She was
 born at term by normal delivery, but her birth weight is unknown. She was the f
irst child of non-consanguineous parents in a sibship of 8 (6 sisters and 1 brot
her) with unremarkable family history. Upon physical examination, her weight was
 42.4 kg and height 158 cm. She had female external genitalia with pubertal deve
lopment in Tanner stage M1P2, and there was no dysmorphic picture. Cytogenetic a
nalysis revealed a 46,XY karyotype. There were high levels of FSH (164 mIU/mL; n
ormal range (NR): 1.5-12.4 mIU/mL) and LH (31.1 mIU/mL; NR: 1.7-8.6 mIU/mL), and
 ultrasonography revealed infantile uterus, but no female gonads were visualized
. Both dysgenetic gonads were removed and a microscopic gonadoblastoma (2 x 2 mm
) was found in the right gonad.</font></span></p>      ^cY#817.htm##
01315000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704109000071002000801161#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#30#26#article#99#<p ALIGN="LEFT"> <span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><i>Patient 2</i>. A 17-year-o
ld female was referred to us due to hypogonadism and primary amenorrhea. She was
 born at term by normal delivery to nonconsanguineous parents, with 2.6 kg and 4
6 cm of birth weight and length, respectively. Her mother had a stillborn girl a
nd a first-trimester miscarriage, followed by an 18-year-old girl and the propos
ita; family history was unremarkable. On physical examination, her weight was 67
.8 kg and height 174.3 cm. She had female external genitalia with pubertal devel
opment in Tanner stage M1P3, and no dysmorphic characteristics. Cytogenetic anal
ysis revealed a 46,XY karyotype. There were high levels of FSH (80.1 mIU/mL; NR:
 1.5-12.4 mIU/mL) and LH (21.4 mIU/mL; NR: 1.7-8.6 mIU/mL), and ultrasonography 
revealed infantile uterus, but no female gonads were visualized. The patient was
 informed about the risk of malignant development of gonadal tissue and was refe
rred to other services in order to perform prophylactic bilateral gonadectomy.</
font></span></p>      ^cY#817.htm##
00481000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704025600071002000800327#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#31#27#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">The study was approved by the 
Ethics Committee of the Universidade Estadual de Campinas, and informed consent 
was obtained from the patients and controls.</font></span></p>      ^cY#817.htm#
#
00341000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704011600071002000800187#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#32#28#article#99#<p ALIGN="LEFT"><b><span
 lang="EN"><font face="Arial, Helvetica, sans-serif">Methods</font></span></b></
p>      ^cY#817.htm##
02367000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704214200071002000802213#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#33#29#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">Genomic DNA was extracted from
 peripheral blood by standard techniques (15). PCR was performed with 0.5 &micro
;g genomic DNA, 10% DMSO, 200 &micro;M each deoxyribonucleoside triphosphates, 0
.5 &micro;M each primer, 1X Taq DNA polymerase buffer solution (Amersham-GE, USA
), and 1.5 U Taq DNA polymerase (Invitrogen, USA). Each PCR contained normal fem
ale and male control DNA. The <i>SRY</i> open reading frame was amplified as des
cribed before (13) and sequenced twice with products from different PCR assays. 
Both sense and antisense primers were used to confirm sequence results. Amplifie
d<i> SRY</i> fragments were purified with Wizard SV Gel and PCR Clean-UP System 
(Promega, USA) and directly sequenced with the Big Dye Terminator Cycle Sequenci
ng Kit V3.1 Ready Reaction (Applied Biosystems, USA). Wild-type and mutant <i>SR
Y</i> gene samples were amplified by PCR to be cloned into pET28A bacterial expr
ession vector (Novagen, USA) to produce N-terminal His-tagged fusion proteins as
 described elsewhere (13). Resulting constructs were used to transform BL21 (DE3
) competent <i>Escherichia coli</i> cells, and the expression of wild-type and m
utant SRY proteins was induced with 0.1 mM isopropyl-1-thio-beta-D-galactopyrano
side (IPTG). Cells were collected and lysed and protein was purified with an Ni-
NTA agarose column (Qiagen, Germany). SRY proteins were eluted and stored at -70
&deg;C. Specific oligonucleotides containing the SRY-target DNA sequence were sy
nthesized and subsequently annealed to generate a double-stranded probe (oligoA)
 as previously described (13,16). The ds-oligonucleotide was labeled with (&alph
a;-<sup>32</sup>P) dCTP (Amersham-GE) using the standard Klenow fill-in reaction
. The mixtures were incubated in the presence of increasing concentrations of ei
ther normal or mutant SRY proteins. Electrophoretic mobility shift assays (EMSAs
) were carried out on non-denaturing 6% polyacrylamide gels and the shifted band
s were visualized on Hiperfilm MP autoradiographies (Amersham-GE).</font></span>
</p>  <HR ALIGN=LEFT SIZE=2>      ^cY#817.htm##
00535000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704031000071002000800381#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#34#30#article#99#<P><font face="Arial, He
lvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resul
ts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF=
"#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0></B></A></font></P>      ^cY#817.htm##
01152000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704092700071002000800998#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#35#31#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">The 380-bp amplified fragment 
encoding the <i>SRY</i> conserved domain was sequenced with 46,XY CGD in both fe
male patients. A hemizygous transition of a guanine (GAG) to an adenine (AAG) in
 codon 89 was observed in patient 1 (<a href="#Fig1">Figure 1A</a>). This novel 
mutation causes the substitution of a glutamic acid by a lysine (p.E89K) within 
the HMG-box of the <i>SRY</i> gene. Sequencing the whole <i>SRY</i> coding regio
n did not show any other nucleotide variation. The patient&rsquo;s father and br
other did not present the nucleotide change, suggesting that this mutation had o
ccurred as a <i>de novo </i>event. The p.G95R mutation was identified in patient
 2 as a result of the GGA&gt;CGA nucleotide change (<span lang="EN"><font face="
Arial, Helvetica, sans-serif"><a href="#Fig1">Figure 1B</a></font></span>).</fon
t></span></p>      ^cY#817.htm##
01066000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704084100071002000800912#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#36#32#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">To investigate the effect of t
he p.E89K mutation on the SRY DNA-binding activity, EMSAs were performed with th
e purified wild-type and mutant proteins. The assay with increasing protein conc
entrations showed that the mutant protein was unable to bind to the DNA probe ev
en at high concentrations, as compared to the wild-type protein, indicating that
 the mutation drastically decreased the SRY DNA-binding activity (<span lang="EN
"><font face="Arial, Helvetica, sans-serif"><a href="#Fig1">Figure 1C</a></font>
</span>).</font></span></p>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr 
align="left" valign="top">      <td><a href="/img/revistas/bjmbr/v44n4/html/817i
01.htm"><img src="/img/revistas/bjmbr/v44n4/817i01peq.jpg" border="2"></a></td> 
     <td>    ^cY#817.htm##
01590000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704136500071002000801436#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#37#33#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. P
artial electropherograms of <i>SRY</i> gene DNA sequences of normal control and 
patients with 46,XY complete gonadal dysgenesis are shown. <i>A</i>, Patient 1 s
howing the G&gt;A substitution that leads to a change in the amino acid E89 to K
, within the highly conserved DNA-binding motif (HMG-box) of the SRY protein. <i
>B</i>, Patient 2 showing the G&gt;C substitution that leads to a change in the 
amino acid G95 to R, within the highly conserved DNA-binding motif (HMG-box) of 
the SRY protein. <i>C</i>, Effect of the p.E89K mutation on the DNA-binding acti
vity of the SRY protein. Electrophoretic mobility shift assays (EMSA) were perfo
rmed using the purified wild-type and mutant SRY proteins. <i>Lane 1</i> corresp
onds to the <sup>32</sup>P-labeled free probe. <i>Lanes 2</i>, <i>4</i>, <i>6</i
>, and <i>8</i> correspond to reactions comprising the probe + wild-type SRY pro
tein at increasing concentrations (0.5, 1, 2.5, and 5 &micro;g, respectively). T
he arrow indicates the SRY-DNA complex. <i>Lanes 3</i>, <i>5</i>, <i>7</i>, and 
<i>9</i> correspond to reactions containing the probe + mutant SRY<sup>E89K</sup
> protein at increasing concentrations (0.5, 1, 2.5, and 5 &micro;g, respectivel
y).</font></span></p>      </td>    </tr>  </table>      ^cY#817.htm##
01045000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704082000071002000800891#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#38#34#article#99#<P><font face="Arial, He
lvetica, sans-serif">[View larger version of this image (151 K JPG file)]</font>
</P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="to
p">      <td><a href="/img/revistas/bjmbr/v44n4/html/817i02.htm"><img src="/img/
revistas/bjmbr/v44n4/817i02peq.jpg" border="2"></a></td>      <td><span lang="EN
"><span lang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig2"></a>F
igure 2. Representation of the SRY-DNA complex depicting the tip of helix 2 invo
lved in the DNA interaction. The electrostatic surface of SRY shows that the sid
e chain of E89 sits between R86 and K92. The picture was created with the progra
m PyMOL using the 3-D coordinates of the SRY protein (PDB code 1J46) published b
y Murphy et al. (21).</font></span></span></td>    </tr>  </table>      ^cY#817.
htm##
00343000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704011800071002000800189#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#39#35#article#99#<P><font face="Arial, He
lvetica, sans-serif">[View larger version of this image (214 K JPG file)]</font>
</P>      ^cY#817.htm##
00262000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704003700071002000800108#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#40#36#article#99#<P>  <HR ALIGN=LEFT SIZE
=2>      ^cY#817.htm##
00495000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704027000071002000800341#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#41#37#article#99#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/
back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>    
  ^cY#817.htm##
00695000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704047000071002000800541#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#42#38#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">In the present study, we repor
t a case of p.G95R substitution associated with sex reversal and describe a nove
l mutation (p.E89K) within the SRY HMG-box in patients with 46,XY pure gonadal d
ysgenesis. The p.G95R mutation has already been described in cases of complete X
Y gonadal dysgenesis and has been shown to affect the DNA-binding activity of th
e protein (17-19).</font></span></p>      ^cY#817.htm##
02463000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704223800071002000802309#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#43#39#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">The majority of the SRY mutati
ons reported in patients with diseases of sex differentiation occur within the H
MG-box domain (20). Not surprisingly, we found that the p.E89K mutation also imp
aired significantly the <i>in vitro</i> DNA-binding activity of the SRY protein.
 Although the E89 residue does not make contacts with DNA (21), its replacement 
by a positively charged residue is likely to have caused alterations in the elec
trostatic net charge of the protein surface, since E89 is located outside the HM
G-box helix 2 (21). In addition, it is worth noting that in the 3-D structure of
 SRY (Protein Data Bank - PDB code 1J46), the side chain of E89 is located adjac
ent to and between the side chains of residues R86 and K92, both of which stabil
ize helix 2 through hydrogen bonds with the phosphate groups of DNA (see Ref. 21
 and <a href="#Fig2">Figure 2</a>). Since in the protein-DNA complex the atomic 
distances between E89 and the adjacent R86 and K92 side chains are outside the n
ormal range for a strong electrostatic interaction (&gt;4 &Aring;), E89 may play
 a critical role to hold both R86 and K92 side chains in position to interact wi
th DNA when the protein is not bound to its target sequence. Therefore, it is re
asonable to suggest that the insertion of an extra positive charge between R86 a
nd K92 would cause strong electrostatic repulsion among the side chains leading 
to the destabilization of the tip of helix 2, precluding DNA interaction. The fa
ct that E89 is conserved in SRY protein in various mammalian species (22) is a s
trong indication that an acidic side chain in this position is important to main
tain the protein function. Mutations in the same region of the SRY protein invol
ving residues 90, 91, 94, and 95 also produced proteins with reduced binding act
ivity (18). Accordingly, the G to R change at position 95 reported here also pla
ces a strong positive charge in the region adjacently to the K92 side chain. How
ever, in this case, the insertion of an R residue might favor an inadvertent con
tact with the phosphate group, breaking hydrogen bonds formed by the R86 and K92
 side chains with the DNA.</font></span></p>      ^cY#817.htm##
00515000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704029000071002000800361#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#44#40#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">In conclusion, there is a good
 correlation between <i>in vitro</i> and <i>in</i> <i>vivo</i> effects involving
 mutant SRY proteins identified in the present report.</font></span></p>  <HR AL
IGN=LEFT SIZE=2>      ^cY#817.htm##
00541000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704031600071002000800387#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#45#41#article#99#<P><font face="Arial, He
lvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>Re
ferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A
 HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORD
ER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#817.htm##
00502000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000200071704026300073002000800336#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#46#42#article#99#1#<p ALIGN="
LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">1. Berta P, Hawk
ins JR, Sinclair AH, Taylor A, Griffiths BL, Goodfellow PN, et al. Genetic evide
nce equating SRY and the testis-determining factor. <i>Nature</i> 1990; 348: 448
-450.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#47#43#article#99#</font></span></p>      
^cY#817.htm##
00544000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000200071704030500073002000800378#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#48#44#article#99#2#<p align="
LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">2. Sinclair AH, 
Berta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, et al. A gene from the h
uman sex-determining region encodes a protein with homology to a conserved DNA-b
inding motif. <i>Nature</i> 1990; 346: 240-244.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#49#45#article#99#</font></span></p>      
^cY#817.htm##
00488000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000200071704024900073002000800322#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#50#46#article#99#3#<p align="
LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">3. Behlke MA, Bo
gan JS, Beer-Romero P, Page DC. Evidence that the SRY protein is encoded by a si
ngle exon on the human Y chromosome. <i>Genomics</i> 1993; 17: 736-739.    ^cY#8
17.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#51#47#article#99#</font></span></p>      
^cY#817.htm##
00515000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000200071704027600073002000800349#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#52#48#article#99#4#<p align="
LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">4. Harley VR, Ja
ckson DI, Hextall PJ, Hawkins JR, Berkovitz GD, Sockanathan S, et al. DNA bindin
g activity of recombinant SRY from normal males and XY females. <i>Science</i> 1
992; 255: 453-456.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#53#49#article#99#</font></span></p>      
^cY#817.htm##
00505000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000200071704026600073002000800339#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#54#50#article#99#5#<p align="
LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">5. Pontiggia A, 
Rimini R, Harley VR, Goodfellow PN, Lovell-Badge R, Bianchi ME. Sex-reversing mu
tations affect the architecture of SRY-DNA complexes. <i>EMBO J</i> 1994; 13: 61
15-6124.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#55#51#article#99#</font></span></p>      
^cY#817.htm##
00523000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000200071704028400073002000800357#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#56#52#article#99#6#<p align="
LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">6. Giese K, Page
l J, Grosschedl R. Distinct DNA-binding properties of the high mobility group do
main of murine and human SRY sex-determining factors. <i>Proc Natl Acad Sci U S 
A</i> 1994; 91: 3368-3372.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#57#53#article#99#</font></span></p>      
^cY#817.htm##
00569000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000200071704033000073002000800403#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#58#54#article#99#7#<p align="
LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">7. Gimelli G, Gi
melli S, Dimasi N, Bocciardi R, Di Battista E, Pramparo T, et al. Identification
 and molecular modelling of a novel familial mutation in the SRY gene implicated
 in the pure gonadal dysgenesis. <i>Eur J Hum Genet</i> 2007; 15: 76-80.    ^cY#
817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#59#55#article#99#</font></span></p>      
^cY#817.htm##
00458000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000200071704021900073002000800292#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#60#56#article#99#8#<p align="
LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">8. Hughes IA, Ho
uk C, Ahmed SF, Lee PA. Consensus statement on management of intersex disorders.
 <i>Arch Dis Child</i> 2006; 91: 554-563.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#61#57#article#99#</font></span></p>      
^cY#817.htm##
00468000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000200071704022900073002000800302#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#62#58#article#99#9#<p align="
LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">9. Knower KC, Ke
lly S, Harley VR. Turning on the male - SRY, SOX9 and sex determination in mamma
ls. <i>Cytogenet Genome Res</i> 2003; 101: 185-198.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#63#59#article#99#</font></span></p>      
^cY#817.htm##
00474000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000300071704023400074002000800308#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#64#60#article#99#10#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">10. Stenson PD,
 Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, et al. The Human Gene Mutat
ion Database: 2008 update. <i>Genome Med</i> 2009; 1: 13.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#65#61#article#99#</font></span></p>      
^cY#817.htm##
00361000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704013600071002000800207#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#66#62#article#99#<p align="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">11. Shahid M, Dhillion VS, Jai
n N, Hedau S, Diwakar S,    ^cY#817.htm##
00499000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704027400071002000800345#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#67#63#article#99#<br>   Sachdeva P, et al
. Two new novel point mutations localized upstream and downstream of the HMG box
 region of the SRY gene in three Indian 46,XY females with sex reversal and gona
dal tumour formation. <i>Mol Hum Reprod</i> 2004; 10: 521-526.</font></span></p>
      ^cY#817.htm##
00525000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000300071704028500074002000800359#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#68#64#article#99#12#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">12. Marchina E,
 Gambera A, Spinelli E, Clerici P, Scagliola P, Sartori E, et al. Identification
 of a new mutation in the SRY gene in a 46,XY woman with Swyer syndrome. <i>Fert
il Steril</i> 2009; 91: 932.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#69#65#article#99#</font></span></p>      
^cY#817.htm##
00639000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000300071704039900074002000800473#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#70#66#article#99#13#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">13. Assumpcao J
G, Benedetti CE, Maciel-Guerra AT, Guerra G Jr, Baptista MT, Scolfaro MR, et al.
 Novel mutations affecting SRY DNA-binding activity: the HMG box N65H associated
 with 46,XY pure gonadal dysgenesis and the familial non-HMG box R30I associated
 with variable phenotypes. <i>J Mol Med</i> 2002; 80: 782-790.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#71#67#article#99#</font></span></p>      
^cY#817.htm##
00492000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000300071704025200074002000800326#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#72#68#article#99#14#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">14. Plaseska-Ka
ranfilska D, Noveski P, Kuzevska K, Basheska N, Kocova M, Efremov GD. A new fami
lial mutation (R133G) in the SRY gene. <i>Clin Genet</i> 2007; 71: 480-482.    ^
cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#73#69#article#99#</font></span></p>      
^cY#817.htm##
00468000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000300071704022800074002000800302#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#74#70#article#99#15#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">15. Sambrook J,
 Russell DW. <i>Molecular cloning: a laboratory manual</i>. 3rd edn. Cold Spring
 Harbor: Cold Spring Harbor Laboratory Press; 2001.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#75#71#article#99#</font></span></p>      
^cY#817.htm##
00546000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000300071704030600074002000800380#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#76#72#article#99#16#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">16. Schmitt-Ney
 M, Thiele H, Kaltwasser P, Bardoni B, Cisternino M, Scherer G. Two novel SRY mi
ssense mutations reducing DNA binding identified in XY females and their mosaic 
fathers. <i>Am J Hum Genet</i> 1995; 56: 862-869.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#77#73#article#99#</font></span></p>      
^cY#817.htm##
00557000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000300071704031700074002000800391#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#78#74#article#99#17#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">17. Hawkins JR,
 Taylor A, Goodfellow PN, Migeon CJ, Smith KD, Berkovitz GD. Evidence for increa
sed prevalence of SRY mutations in XY females with complete rather than partial 
gonadal dysgenesis. <i>Am J Hum Genet</i> 1992; 51: 979-984.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#79#75#article#99#</font></span></p>      
^cY#817.htm##
00519000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000300071704027900074002000800353#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#80#76#article#99#18#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">18. Rimini R, P
ontiggia A, Spada F, Ferrari S, Harley VR, Goodfellow PN, et al. Interaction of 
normal and mutant SRY proteins with DNA. <i>Philos Trans R Soc Lond B Biol Sci</
i> 1995; 350: 215-220.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#81#77#article#99#</font></span></p>      
^cY#817.htm##
00495000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704027000071002000800341#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#82#78#article#99#<p align="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">19. Copelli SB, Pasqualini T. 
Association of Turner&rsquo;s syndrome and Swyer&rsquo;s syndrome in the same fa
mily. <i>J Pediatr Endocrinol Metab</i> 2000; 13: 557-559.</font></span></p>    
  ^cY#817.htm##
00575000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000300071704033500074002000800409#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#83#79#article#99#20#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">20. Harley VR, 
Clarkson MJ, Argentaro A. The molecular action and regulation of the testis-dete
rmining factors, SRY (sex-determining region on the Y chromosome) and SOX9 [SRY-
related high-mobility group (HMG) box 9]. <i>Endocr Rev</i> 2003; 24: 466-487.  
  ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#84#80#article#99#</font></span></p>      
^cY#817.htm##
00543000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000300071704030300074002000800377#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#85#81#article#99#21#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">21. Murphy EC, 
Zhurkin VB, Louis JM, Cornilescu G, Clore GM. Structural basis for SRY-dependent
 46-X,Y sex reversal: modulation of DNA bending by a naturally occurring point m
utation. <i>J Mol Biol</i> 2001; 312: 481-499.    ^cY#817.htm##
00253000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002800071002000800099#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#86#82#article#99#</font></span></p>      
^cY#817.htm##
00570000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068888000300071704033000074002000800404#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#p#87#83#article#99#22#<p align=
"LEFT"><span lang="EN"><font face="Arial, Helvetica, sans-serif">22. Shahid M, D
hillon VS, Hussain Z, Masa JF, Aslam M, Raish M, et al. Analysis of the SRY gene
 in two sex-reversed XY sisters identifies two new novel point mutations in the 
high mobility group box domain. <i>Fertil Steril</i> 2008; 90: 1199.e1-8.    ^cY
#817.htm##
00277000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704005200071002000800123#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#88#84#article#99#</font></span></p>  <HR 
ALIGN=LEFT SIZE=2>      ^cY#817.htm##
00560000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704033500071002000800406#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#89#85#article#99#<P><font face="Arial, He
lvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE=4>
<B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, sans
-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#817.htm##
00561000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704033600071002000800407#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#90#86#article#99#<p ALIGN="LEFT"><span la
ng="EN"><font face="Arial, Helvetica, sans-serif">Research supported by FAPESP (
#08/54776-1 to M.P. de Mello, and scholarships #02/13237-4, #07/00900-0, and #08
/03168-1 to L.E.C. Oliveira, J.L. Cunha and F.C. Soardi, respectively. We also t
hank CAPES and CNPq.</font></span></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#817.htm#
#
00561000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704033600071002000800407#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#91#87#article#99#<P><FONT SIZE=4 face="Ar
ial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B>
Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, Helve
tica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gi
f" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#817.htm#
#
00645000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704042000071002000800491#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#92#88#article#99#<p><font face="Arial, He
lvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/reco
r.gif" border="0"></a> Address for correspondence:</b></font><span lang="EN"><fo
nt face="Arial, Helvetica, sans-serif"> M.P. de Mello, CBMEG-UNICAMP, Caixa Post
al 6010, 13083-875 Campinas, SP, Brasil. Fax: +55-19-3521-1089. E-mail: <a href=
"mailto:mmello@unicamp.br">mmello@unicamp.br</a></font></span></p>      ^cY#817.
htm##
00380000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704015500071002000800226#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#93#89#article#99#<p>Received October 7, 2
010. Accepted January 31, 2011. Available online February 11, 2011. Published Ap
ril 11, 2011.</p>  <HR ALIGN=LEFT SIZE=2>      ^cY#817.htm##
00257000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704003200071002000800103#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#94#90#article#99#<div align="center">    
    ^cY#817.htm##
00423000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704019800071002000800269#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#95#91#article#99#<p><font color="#000000"
 face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilian J
ournal of Medical and Biological Research is partially financed by</font></em><s
trong>    ^cY#817.htm##
00249000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704002400071002000800095#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#96#92#article#99#<br>                ^cY#
817.htm##
00323000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704009800071002000800169#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#97#93#article#99#<br>    </strong></font>
</p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#817.ht
m##
00381000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704015600071002000800227#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#98#94#article#99#<div align="center"><a t
arget="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4/cn
pq.jpg" border="0"></a></div></td>      <td>    ^cY#817.htm##
00383000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000300068704015800071002000800229#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#99#95#article#99#<div align="center"><a t
arget="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v44n4
/mct.jpg" border="0"></a></div></td>      <td>    ^cY#817.htm##
00388000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000300069704016200072002000800234#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#100#96#article#99#<div align="center"><a 
target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/v4
4n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#817.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000300069704017300072002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#101#97#article#99#<div align="center"><a 
target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/rev
istas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#817.htm##
00390000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000300069704016400072002000800236#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#102#98#article#99#<div align="center"><a 
target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr/v
44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#817.htm##
00397000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000300069704017100072002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\817.htm#S#p#103#99#article#99#<div align="center"><a 
target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44n4
/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#817.htm##
00661000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100018000880100
01900106010001600125010002000141010002100161810000600182012006800188030000700256
06500090026306400050027203100040027701400080028186500090028900200080029803500100
0306801000700316#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#104#1#art
icle#22#1#^rND^sBerta^nP#^rND^sHawkins^nJR#^rND^sSinclair^nAH#^rND^sTaylor^nA#^r
ND^sGriffiths^nBL#^rND^sGoodfellow^nPN#et al#Genetic evidence equating SRY and t
he testis-determining factor^len#Nature#19900000#1990#348#448-450#20110400#817.h
tm#0028-0836#Nature##
00703000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100015000920100
01700107010001800124010002000142010001600162810000600178012011400184030000700298
06500090030506400050031403100040031901400080032386500090033100200080034003500100
0348801000700358#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#105#2#art
icle#22#2#^rND^sSinclair^nAH#^rND^sBerta^nP#^rND^sPalmer^nMS#^rND^sHawkins^nJR#^
rND^sGriffiths^nBL#^rND^sSmith^nMJ#et al#A gene from the human sex-determining r
egion encodes a protein with homology to a conserved DNA-binding motif^len#Natur
e#19900000#1990#346#240-244#20110400#817.htm#0028-0836#Nature##
00602000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100016000900100
02100106010001500127012008800142030000900230065000900239064000500248031000300253
014000800256865000900264002000800273035001000281801000900291#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\817.htm#S#c#106#3#article#22#3#^rND^sBehlke^nMA#^rND^sBog
an^nJS#^rND^sBeer-Romero^nP#^rND^sPage^nDC#Evidence that the SRY protein is enco
ded by a single exon on the human Y chromosome^len#Genomics#19930000#1993#17#736
-739#20110400#817.htm#0888-7543#Genomics##
00675000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100018000900100
01800108010001800126010002000144010002100164810000600185012007700191030000800268
06500090027606400050028503100040029001400080029486500090030200200080031103500100
0319801000800329#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#107#4#art
icle#22#4#^rND^sHarley^nVR#^rND^sJackson^nDI#^rND^sHextall^nPJ#^rND^sHawkins^nJR
#^rND^sBerkovitz^nGD#^rND^sSockanathan^nS#et al#DNA binding activity of recombin
ant SRY from normal males and XY females^len#Science#19920000#1992#255#453-456#2
0110400#817.htm#0036-8075#Science##
00653000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100016000920100
01700108010002100125010002200146010001800168012007300186030000700259065000900266
06400050027503100030028001400100028386500090029300200080030203500100031080100070
0320#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#108#5#article#22#5#^r
ND^sPontiggia^nA#^rND^sRimini^nR#^rND^sHarley^nVR#^rND^sGoodfellow^nPN#^rND^sLov
ell-Badge^nR#^rND^sBianchi^nME#Sex-reversing mutations affect the architecture o
f SRY-DNA complexes^len#EMBO J#19940000#1994#13#6115-6124#20110400#817.htm#0261-
4189#Embo J##
00635000000000289000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100015000880100
02000103012011800123030002500241065000900266064000500275031000300280014001000283
865000900293002000800302035001000310801002500320#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\817.htm#S#c#109#6#article#22#6#^rND^sGiese^nK#^rND^sPagel^nJ#^rND^sGr
osschedl^nR#Distinct DNA-binding properties of the high mobility group domain of
 murine and human SRY sex-determining factors^len#Proc Natl Acad Sci U S A#19940
000#1994#91#3368-3372#20110400#817.htm#0027-8424#Proc Natl Acad Sci U S A##
00737000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100017000900100
01600107010001900123010002100142010001800163810000600181012013000187030001600317
06500090033306400050034203100030034701400060035086500090035600200080036503500100
0373801001600383#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#110#7#art
icle#22#7#^rND^sGimelli^nG#^rND^sGimelli^nS#^rND^sDimasi^nN#^rND^sBocciardi^nR#^
rND^sDi^nBattista E#^rND^sPramparo^nT#et al#Identification and molecular modelli
ng of a novel familial mutation in the SRY gene implicated in the pure gonadal d
ysgenesis^len#Eur J Hum Genet#20070000#2007#15#76-80#20110400#817.htm#1018-4813#
Eur J Hum Genet##
00578000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100014000900100
01600104010001400120012006000134030001500194065000900209064000500218031000300223
014000800226865000900234002000800243035001000251801001500261#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\817.htm#S#c#111#8#article#22#8#^rND^sHughes^nIA#^rND^sHou
k^nC#^rND^sAhmed^nSF#^rND^sLee^nPA#Consensus statement on management of intersex
 disorders^len#Arch Dis Child#20060000#2006#91#554-563#20110400#817.htm#0003-988
8#Arch Dis Child##
00535000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100015000900100
01700105012006900122030002100191710000200212065000900214064000500223031000400228
014000800232865000900240002000800249#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
17.htm#S#c#112#9#article#22#9#^rND^sKnower^nKC#^rND^sKelly^nS#^rND^sHarley^nVR#T
urning on the male - SRY, SOX9 and sex determination in mammals^len#Cytogenet Ge
nome Res#2#20030000#2003#101#185-198#20110400#817.htm##
00606000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100014000930100
01500107010001700122010001900139010001700158810000600175012005000181030001100231
71000020024206500090024406400050025303100020025801400030026086500090026300200080
0272#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#113#10#article#22#10#
^rND^sStenson^nPD#^rND^sMort^nM#^rND^sBall^nEV#^rND^sHowells^nK#^rND^sPhillips^n
AD#^rND^sThomas^nNS#et al#The Human Gene Mutation Database: 2008 update^len#Geno
me Med#2#20090000#2009#1#13#20110400#817.htm##
00783000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910100
01400110010001500124010001700139010001800156810000600174012018300180030001500363
06500090037806400050038703100030039201400080039586500090040300200080041203500100
0420801001500430#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#114#11#ar
ticle#22#11#^rND^sShahid^nM#^rND^sDhillion^nVS#^rND^sJain^nN#^rND^sHedau^nS#^rND
^sDiwakar^nS#^rND^sSachdeva^nP#et al#Two new novel point mutations localized ups
tream and downstream of the HMG box region of the SRY gene in three Indian 46,XY
 females with sex reversal and gonadal tumour formation^len#Mol Hum Reprod#20040
000#2004#10#521-526#20110400#817.htm#1360-9947#Mol Hum Reprod##
00691000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100017000930100
01800110010001700128010001900145010001700164810000600181012009000187030001400277
06500090029106400050030003100030030501400040030886500090031200200080032103500100
0329801001400339#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#115#12#ar
ticle#22#12#^rND^sMarchina^nE#^rND^sGambera^nA#^rND^sSpinelli^nE#^rND^sClerici^n
P#^rND^sScagliola^nP#^rND^sSartori^nE#et al#Identification of a new mutation in 
the SRY gene in a 46,XY woman with Swyer syndrome^len#Fertil Steril#20090000#200
9#91#932#20110400#817.htm#0015-0282#Fertil Steril##
00801000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100020000750100020000950100
02400115010001900139010001900158010001900177810000600196012018900202030001000391
06500090040106400050041003100030041501400080041886500090042600200080043503500100
0443801001000453#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#116#13#ar
ticle#22#13#^rND^sAssumpcao^nJG#^rND^sBenedetti^nCE#^rND^sMaciel-Guerra^nAT#^rND
^sGuerra^nG Jr#^rND^sBaptista^nMT#^rND^sScolfaro^nMR#et al#Novel mutations affec
ting SRY DNA-binding activity: the HMG box N65H associated with 46,XY pure gonad
al dysgenesis and the familial non-HMG box R30I associated with variable phenoty
pes^len#J Mol Med#20020000#2002#80#782-790#20110400#817.htm#0377-046X#J Mol Med#
#
00644000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100030000750100017001050100
01800122010001800140010001600158010001800174012005200192030001100244065000900255
06400050026403100030026901400080027286500090028000200080028903500100029780100110
0307#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#117#14#article#22#14#
^rND^sPlaseska-Karanfilska^nD#^rND^sNoveski^nP#^rND^sKuzevska^nK#^rND^sBasheska^
nN#^rND^sKocova^nM#^rND^sEfremov^nGD#A new familial mutation (R133G) in the SRY 
gene^len#Clin Genet#20070000#2007#71#480-482#20110400#817.htm#0009-9163#Clin Gen
et##
00458000000000229000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720160018000750160018000930180
04300111063000200154066001900156062003600175865000900211002000800220#v44n4#V:\Sc
iELO\serial\bjmbr\v44n4\markup\817.htm#S#c#118#15#article#22#15#^rND^sSambrook^n
J#^rND^sRussell^nDW#Molecular cloning: a laboratory manual^len#3#Cold Spring Har
bor#Cold Spring Harbor Laboratory Press#20110400#817.htm##
00702000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100016000960100
02000112010001700132010002000149010001700169012010800186030001500294065000900309
06400050031803100030032301400080032686500090033400200080034303500100035180100150
0361#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#119#16#article#22#16#
^rND^sSchmitt-Ney^nM#^rND^sThiele^nH#^rND^sKaltwasser^nP#^rND^sBardoni^nB#^rND^s
Cisternino^nM#^rND^sScherer^nG#Two novel SRY missense mutations reducing DNA bin
ding identified in XY females and their mosaic fathers^len#Am J Hum Genet#199500
00#1995#56#862-869#20110400#817.htm#0002-9297#Am J Hum Genet##
00713000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100016000930100
02100109010001700130010001600147010002000163012012200183030001500305065000900320
06400050032903100030033401400080033786500090034500200080035403500100036280100150
0372#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#120#17#article#22#17#
^rND^sHawkins^nJR#^rND^sTaylor^nA#^rND^sGoodfellow^nPN#^rND^sMigeon^nCJ#^rND^sSm
ith^nKD#^rND^sBerkovitz^nGD#Evidence for increased prevalence of SRY mutations i
n XY females with complete rather than partial gonadal dysgenesis^len#Am J Hum G
enet#19920000#1992#51#979-984#20110400#817.htm#0002-9297#Am J Hum Genet##
00706000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100019000910100
01500110010001700125010001700142010002100159810000600180012005900186030003500245
06500090028006400050028903100040029401400080029886500090030600200080031503500100
0323801003500333#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#121#18#ar
ticle#22#18#^rND^sRimini^nR#^rND^sPontiggia^nA#^rND^sSpada^nF#^rND^sFerrari^nS#^
rND^sHarley^nVR#^rND^sGoodfellow^nPN#et al#Interaction of normal and mutant SRY 
proteins with DNA^len#Philos Trans R Soc Lond B Biol Sci#19950000#1995#350#215-2
20#20110400#817.htm#0962-8436#Philos Trans R Soc Lond B Biol Sci##
00586000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100020000930120
08900113030002700202065000900229064000500238031000300243014000800246865000900254
002000800263035001000271801002700281#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
17.htm#S#c#122#19#article#22#19#^rND^sCopelli^nSB#^rND^sPasqualini^nT#Associatio
n of Turner&#8217;s syndrome and Swyer&#8217;s syndrome in the same family^len#J
 Pediatr Endocrinol Metab#20000000#2000#13#557-559#20110400#817.htm#0334-018X#J 
Pediatr Endocrinol Metab##
00673000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100019000920100
01900111012017900130030001100309065000900320064000500329031000300334014000800337
865000900345002000800354035001000362801001100372#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\817.htm#S#c#123#20#article#22#20#^rND^sHarley^nVR#^rND^sClarkson^nMJ#
^rND^sArgentaro^nA#The molecular action and regulation of the testis-determining
 factors, SRY (sex-determining region on the Y chromosome) and SOX9 [SRY-related
 high-mobility group (HMG) box 9]^len#Endocr Rev#20030000#2003#24#466-487#201104
00#817.htm#0163-769X#Endocr Rev##
00677000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100018000920100
01600110010002000126010001600146012012600162030001100288065000900299064000500308
031000400313014000800317865000900325002000800334035001000342801001100352#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#124#21#article#22#21#^rND^sMurphy
^nEC#^rND^sZhurkin^nVB#^rND^sLouis^nJM#^rND^sCornilescu^nG#^rND^sClore^nGM#Struc
tural basis for SRY-dependent 46-X,Y sex reversal: modulation of DNA bending by 
a naturally occurring point mutation^len#J Mol Biol#20010000#2001#312#481-499#20
110400#817.htm#0022-2836#J Mol Biol##
00738000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100018000910100
01700109010001500126010001500141010001500156810000600171012013900177030001400316
06500090033006400050033903100030034401400120034786500090035900200080036803500100
0376801001400386#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\817.htm#S#c#125#22#ar
ticle#22#22#^rND^sShahid^nM#^rND^sDhillon^nVS#^rND^sHussain^nZ#^rND^sMasa^nJF#^r
ND^sAslam^nM#^rND^sRaish^nM#et al#Analysis of the SRY gene in two sex-reversed X
Y sisters identifies two new novel point mutations in the high mobility group bo
x domain^len#Fertil Steril#20080000#2008#90#1199 - e1-8#20110400#817.htm#0015-02
82#Fertil Steril##
00266000000000169000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660910009000680920007000770020008000847030
00400092#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#o#1#1#article#1#201
10411#094657#891.htm#124##
02855000000000589000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120082001780100024002600100024002840100024003080700072003320700120004040831
48000524085000802004085002002012085001902032085003402051085004402085085002202129
08500200215111700060217107200030217711200090218011100170218911400090220611300180
2215891002402233002000802257#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S
#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#05#BJMBR010#FAPESP#Braz J Med Biol R
es#44#4#20110400#^f297^l302#0100-879X#20110304#Expression and purification of th
e non-tagged LipL32 of pathogenic Leptospira^len#^rND^1A01 A02^nP.^sHauk#^rND^1A
01^nE.^sCarvalho#^rND^1A01 A02^nP.L.^sHo#Instituto Butantan^iA01^1Centro de Biot
ecnologia^cSão Paulo^sSP^pBrasil#Universidade de São Paulo^iA02^1Instituto de Ci
ências Biomédicas^2Interunidades em Biotecnologia^cSão Paulo^sSP^pBrasil#^len^aL
eptospirosis is a reemerging infectious disease and the most disseminated zoonos
is worldwide. A leptospiral surface protein, LipL32, only occurs in pathogenic L
eptospira, and is the most abundant protein on the bacterial surface, being desc
ribed as an important factor in host immunogenic response and also in bacterial 
infection. We describe here an alternative and simple purification protocol for 
non-tagged recombinant LipL32. The recombinant LipL32(21-272) was expressed in E
scherichia coli without His-tag or any other tag used to facilitate recombinant 
protein purification. The recombinant protein was expressed in the soluble form,
 and the purification was based on ion exchange (anionic and cationic) and hydro
phobic interactions. The final purification yielded 3 mg soluble LipL32(21-272) 
per liter of the induced culture. Antiserum produced against the recombinant pro
tein was effective to detect native LipL32 from cell extracts of several Leptosp
ira serovars. The purified recombinant LipL32(21-272) produced by this protocol 
can be used for structural, biochemical and functional studies and avoids the ri
sk of possible interactions and interferences of the tags commonly used as well 
as the time consuming and almost always inefficient methods to cleave these tags
 when a tag-free LipL32 is needed. Non-tagged LipL32 may represent an alternativ
e antigen for biochemical studies, for serodiagnosis and for the development of 
a vaccine against leptospirosis.#^dnd^i1#^tm^len^kAntigen^i1#^tm^len^kLipL32^i1#
^tm^len^kPathogenic Leptospira^i1#^tm^len^kNon-tagged protein purification^i1#^t
m^len^kDiagnosis^i1#^tm^len^kVaccine^i1#other#20#20101107#November 7, 2010#20110
216#February 16, 2011#S0100-879X2011007500025#891.htm##
02902000000000577000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660710003000680400003000710010006000740420
00200080120000400082038000500086038000400091121000300095049000900098158000700107
03000200011403100030013403200020013706500090013901400110014803500100015922400090
01690120096001780100024002740100024002980100024003220700072003460700120004180831
52800538085000802066085002002074085001902094085004102113085004402154085002202198
08500200222011700060224007200030224611200090224911100240225811400090228211300250
2291002000802316#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#f#3#1#artic
le#1#oa#en#bjmbr#1#3.1#ILUS#TAB#05#BJMBR010#FAPESP#Braz J Med Biol Res#44#4#2011
0400#^f297^l302#0100-879X#20110304#<b>Expression and purification of the non-tag
ged LipL32 of pathogenic <i>Leptospira</i></b>^len#^rND^1A01 A02^nP.^sHauk#^rND^
1A01^nE.^sCarvalho#^rND^1A01 A02^nP.L.^sHo#Instituto Butantan^iA01^1Centro de Bi
otecnologia^cSão Paulo^sSP^pBrasil#Universidade de São Paulo^iA02^1Instituto de 
Ciências Biomédicas^2Interunidades em Biotecnologia^cSão Paulo^sSP^pBrasil#^len^
aLeptospirosis is a reemerging infectious disease and the most disseminated zoon
osis worldwide. A leptospiral surface protein, LipL32, only occurs in pathogenic
 <i>Leptospira</i>, and is the most abundant protein on the bacterial surface, b
eing described as an important factor in host immunogenic response and also in b
acterial infection. We describe here an alternative and simple purification prot
ocol for non-tagged recombinant LipL32. The recombinant LipL32<sub>21-272</sub> 
was expressed in <i>Escherichia coli</i> without His-tag or any other tag used t
o facilitate recombinant protein purification. The recombinant protein was expre
ssed in the soluble form, and the purification was based on ion exchange (anioni
c and cationic) and hydrophobic interactions. The final purification yielded 3 m
g soluble LipL32<sub>21-272</sub> per liter of the induced culture. Antiserum pr
oduced against the recombinant protein was effective to detect native LipL32 fro
m cell extracts of several <i>Leptospira</i> serovars. The purified recombinant 
LipL32<sub>21-272</sub> produced by this protocol can be used for structural, bi
ochemical and functional studies and avoids the risk of possible interactions an
d interferences of the tags commonly used as well as the time consuming and almo
st always inefficient methods to cleave these tags when a tag-free LipL32 is nee
ded. Non-tagged LipL32 may represent an alternative antigen for biochemical stud
ies, for serodiagnosis and for the development of a vaccine against leptospirosi
s.#^dnd^i1#^tm^len^kAntigen^i1#^tm^len^kLipL32^i1#^tm^len^kPathogenic <i>Leptosp
ira</i>^i1#^tm^len^kNon-tagged protein purification^i1#^tm^len^kDiagnosis^i1#^tm
^len^kVaccine^i1#other#20#20101107#<i>November 7, 2010</i>#20110216#<i>February 
16, 2011</i>#891.htm##
02951000000000601000450000400060000070200440000670500020005070600020005270000020
00547010002000567090008000587080002000660640013000680710003000810400003000840010
00600087042000200093120000400095038000500099038000400104121000300108049000900111
15800070012003000240012703100030015103200020015406500090015601400110016503500100
01762240009001860120082001950100023002770100023003000100024003230700074003470700
12200421083148000543085000802023085002002031085001902051085003402070085004402104
08500220214808500200217011700060219007200030219611200090219911100170220811400090
2225113001802234002000802252008008902260#v44n4#V:\SciELO\serial\bjmbr\v44n4\mark
up\891.htm#S#l#4#1#article#1#^mApr.^a2011#oa#en#bjmbr#1#3.1#ilus#tab#05#BJMBR010
#FAPESP#Braz. j. med. biol. res#44#4#20110400#^f297^l302#0100-879X#20110304#Expr
ession and purification of the non-tagged LipL32 of pathogenic Leptospira^len#^r
ND^1A01 A02^nP^sHauk#^rND^1A01^nE^sCarvalho#^rND^1A01 A02^nP. L^sHo#^iA01^1Insti
tuto Butantan^2Centro de Biotecnologia^cSão Paulo^sSP^pBrasil#^iA02^1Universidad
e de São Paulo^2Instituto de Ciências Biomédicas^3Interunidades em Biotecnologia
^cSão Paulo^sSP^pBrasil#^len^aLeptospirosis is a reemerging infectious disease a
nd the most disseminated zoonosis worldwide. A leptospiral surface protein, LipL
32, only occurs in pathogenic Leptospira, and is the most abundant protein on th
e bacterial surface, being described as an important factor in host immunogenic 
response and also in bacterial infection. We describe here an alternative and si
mple purification protocol for non-tagged recombinant LipL32. The recombinant Li
pL32(21-272) was expressed in Escherichia coli without His-tag or any other tag 
used to facilitate recombinant protein purification. The recombinant protein was
 expressed in the soluble form, and the purification was based on ion exchange (
anionic and cationic) and hydrophobic interactions. The final purification yield
ed 3 mg soluble LipL32(21-272) per liter of the induced culture. Antiserum produ
ced against the recombinant protein was effective to detect native LipL32 from c
ell extracts of several Leptospira serovars. The purified recombinant LipL32(21-
272) produced by this protocol can be used for structural, biochemical and funct
ional studies and avoids the risk of possible interactions and interferences of 
the tags commonly used as well as the time consuming and almost always inefficie
nt methods to cleave these tags when a tag-free LipL32 is needed. Non-tagged Lip
L32 may represent an alternative antigen for biochemical studies, for serodiagno
sis and for the development of a vaccine against leptospirosis.#^dnd^i1#^tm^len^
kAntigen^i1#^tm^len^kLipL32^i1#^tm^len^kPathogenic Leptospira^i1#^tm^len^kNon-ta
gged protein purification^i1#^tm^len^kDiagnosis^i1#^tm^len^kVaccine^i1#other#20#
20101107#November 7, 2010#20110216#February 16, 2011#891.htm#Internet^ihttp://ww
w.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000400005##
00372000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704014800070002000800218#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#5#1#article#100#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, April 2011, Volu
me 44(4) 297-302 </B> </font></P>      ^cY#891.htm##
00413000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704018900070002000800259#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#6#2#article#100#<p ALIGN="LEFT"><font siz
e="5" face="Arial"><span lang="EN"><strong>Expression and purification of the no
n-tagged LipL32 of pathogenic <i>Leptospira</i></strong></span></font></p>      
^cY#891.htm##
00732000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704050800070002000800578#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#7#3#article#100#<p ALIGN="LEFT"><font fac
e="Arial"><span lang="EN">P. Hauk<sup>1,2</sup>, E. Carvalho<sup>1</sup> and <sp
an lang="EN"><font face="Arial, Helvetica, sans-serif"><sup><span lang="EN"><fon
t face="Arial, Helvetica, sans-serif"><b><a href="#Correspondence"><img src="/im
g/revistas/bjmbr/v44n4/recor.gif" border="0"></a></b> <a href="mailto:hoplee@but
antan.gov.br"><img src="/img/revistas/bjmbr/v44n4/email-ca.gif" border="0"></a><
/font></span></sup></font></span> P.L. Ho<sup>1,2</sup></span></font></p>      ^
cY#891.htm##
00391000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704016700070002000800237#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#8#4#article#100#<p ALIGN="LEFT"><span lan
g="EN"><font face="Arial, Helvetica, sans-serif"><sup>1</sup>Centro de Biotecnol
ogia, Instituto Butantan, S&atilde;o Paulo, SP, Brasil    ^cY#891.htm##
00509000000000145000450000400060000070200440000670500020005070600020005270000020
0054701000200056709000800058708000400066704028500070002000800355#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#9#5#article#100#<br>  </font></span><font
 face="Arial"><span lang="EN"><sup>2</sup>Interunidades em Biotecnologia, Instit
uto de Ci&ecirc;ncias Biom&eacute;dicas, Universidade de S&atilde;o Paulo, </spa
n></font><font face="Arial"><span lang="EN">S&atilde;o Paulo, SP, Brasil</span><
/font></p>      ^cY#891.htm##
00415000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704019000071002000800261#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#10#6#article#100#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v44n4/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#891.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#11#7#article#100#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#891.htm##
00412000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704018700071002000800258#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#12#8#article#100#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#891.htm##
00397000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000200057709000800059708000400067704017200071002000800243#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#13#9#article#100#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#891.htm##
00407000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704018100072002000800253#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#14#10#article#100#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#89
1.htm##
00394000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704016800072002000800240#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#15#11#article#100#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#891.htm##
00435000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704020900072002000800281#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#16#12#article#100#<br>   </strong></A><A 
HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTT
OM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowledg
ments</strong></A>    ^cY#891.htm##
00444000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021800072002000800290#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#17#13#article#100#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v44n4/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footno
tes</strong></A>  </font>      ^cY#891.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#18#14#article#100#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#891.htm##
00492000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704026600072002000800338#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#19#15#article#100#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>      ^
cY#891.htm##
01826000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704160000072002000801672#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#20#16#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Leptospirosis is a reemerging infectious disease and
 the most disseminated zoonosis worldwide. A leptospiral surface protein, LipL32
, only occurs in pathogenic <i>Leptospira</i>, and is the most abundant protein 
on the bacterial surface, being described as an important factor in host immunog
enic response and also in bacterial infection. We describe here an alternative a
nd simple purification protocol for non-tagged recombinant LipL32. The recombina
nt LipL32<sub>21-272</sub> was expressed in <i>Escherichia coli</i> without His-
tag or any other tag used to facilitate recombinant protein purification. The re
combinant protein was expressed in the soluble form, and the purification was ba
sed on ion exchange (anionic and cationic) and hydrophobic interactions. The fin
al purification yielded 3 mg soluble LipL32<sub>21-272</sub> per liter of the in
duced culture. Antiserum produced against the recombinant protein was effective 
to detect native LipL32 from cell extracts of several <i>Leptospira</i> serovars
. The purified recombinant LipL32<sub>21-272</sub> produced by this protocol can
 be used for structural, biochemical and functional studies and avoids the risk 
of possible interactions and interferences of the tags commonly used as well as 
the time consuming and almost always inefficient methods to cleave these tags wh
en a tag-free LipL32 is needed. Non-tagged LipL32 may represent an alternative a
ntigen for biochemical studies, for serodiagnosis and for the development of a v
accine against leptospirosis.</span></font></p>      ^cY#891.htm##
00438000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704021200072002000800284#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#21#17#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Key words: Antigen; LipL32; Pathogenic <i>Leptospira
</i>; Non-tagged protein purification; Diagnosis; Vaccine</span></font></p>  <HR
 ALIGN=LEFT SIZE=2>      ^cY#891.htm##
00548000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032200072002000800394#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#22#18#article#100#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>        ^cY#891.htm##
02920000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704269400072002000802766#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#23#19#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Leptospirosis is a zoonosis caused by the genus <i>L
eptospira.</i> Humans and domestic animals are most commonly infected through co
ntact with the urine of carrier animals, either directly or via contaminated wat
er or soil. In humans, this disease is characterized by fever, renal and hepatic
 insufficiency and pulmonary manifestations (1). The most abundant antigen found
 in the leptospiral total protein profile is LipL32, displaying around 40,000 co
pies/cell (2). This lipoprotein is highly conserved among pathogenic <i>Leptospi
ra</i> species (3), but no orthologs were observed in the saprophytic non-pathog
enic <i>Leptospira biflexa</i> (4). Expressed at high levels both during cultiva
tion and natural infection, LipL32 was shown to be surface exposed and highly im
munogenic (3). This lipoprotein is also involved in the pathogenesis of tubuloin
terstitial nephritis that is the main renal manifestation. Pathogenic leptospire
s accumulate mostly in the proximal tubules and induce the expression of inflamm
atory molecules, part of this response being mediated by LipL32 (5). Considering
 these remarkable findings, many strategies have used LipL32 as a target for vac
cine development and diagnosis (for a review, see Ref. 6). Studies performed wit
h the C-terminal and intermediate domains of LipL32 have shown that they are rec
ognized by sera of patients. For instance, an IgM response was detected exclusiv
ely against the LipL32 C-terminus in both the acute and convalescent phases of i
llness (7). Moreover, the capacity of LipL32 to interact with extracellular matr
ix components such as laminin (8), collagen type IV and plasma fibronectin (7) w
as also described. A dose-dependent and specific binding of LipL32 to collagen I
V and plasma fibronectin was observed, and interestingly, the binding capacity c
ould be attributed to the C-terminal portion of this molecule. Both heparin and 
gelatin could inhibit LipL32 binding to fibronectin in a concentration-dependent
 manner, indicating that the 30-kDa heparin- and the 45-kDa gelatin-binding doma
ins of fibronectin are involved in this interaction (7,8). Surprisingly, studies
 using the <i>lip</i>L32 mutant have shown that it does not play a role in eithe
r the acute or chronic models of infection (9). While these data do not suggest 
a role in pathogenesis, a function for LipL32 has not been demonstrated. In the 
present study, we describe the cloning and purification of LipL32<sub>21-272</su
b> (LipL32 containing amino acids 21 to 272) without His-tag or any other tag co
mmonly used to facilitate recombinant protein purification.</span></font></p>  <
HR ALIGN=LEFT SIZE=2>      ^cY#891.htm##
00550000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704032400072002000800396#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#24#20#article#100#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#891.htm##
00363000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013700072002000800209#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#25#21#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Bacterial strains, plasmids, and culture conditio
ns</span></font></b></p>      ^cY#891.htm##
00860000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704063400072002000800706#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#26#22#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Leptospiral strains were obtained from the Faculdade
 de Medicina Veterin&aacute;ria e Zootecnia, Universidade de S&atilde;o Paulo (U
SP), Brazil.<i> E.</i> <i>coli</i> DH5&alpha; was used as the cloning host strai
n and <i>E</i>. <i>coli</i> BL21 (SI; Gibco/BRL, USA) as the host strain for eff
icient overproduction of cloned gene products using NaCl as the inducer (10). Re
combinant <i>E</i>. <i>coli</i> BL21 (SI) cells were grown on 2YT ON (16 g/L try
ptone and 10 g/L yeast extract) medium supplemented with ampicillin (100 &micro;
g/mL) before induction.</span></font></p>      ^cY#891.htm##
00367000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704014100072002000800213#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#27#23#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Cloning steps and screening of the recombinant pl
asmids</span></font></b></p>      ^cY#891.htm##
01514000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704128800072002000801360#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#28#24#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">To avoid misfolding and aggregation of the recombina
nt protein, the region coding for the hydrophobic signal peptide (amino acids 1 
to 20) was not included in the cloned fragment. PCR was used to amplify the gene
 fragment coding for LipL32<sub>21-272</sub> using a genomic DNA purified from <
i>L</i>. <i>interrogans</i> serovar Copenhageni strain Fiocruz L1-130 isolated f
rom a patient in Salvador, Brazil (ATCC No. BAA-1198) (11), as template, with th
e forward primer (5&rsquo;-CTCGAGCATATGGGTGCTTTCGGTGGTCTG-3&rsquo;) containing <
i>Xho</i>I and <i>Nde</i>I restriction endonuclease sites (underlined) and the r
everse primer (5&rsquo;-AAGCTTACTTAGTCGCGTCAGAAGC-3&rsquo;) containing a <i>Hin<
/i>dIII (underlined) restriction site. Plasmid pGEM-T easy (Promega, USA) was us
ed to clone the amplified gene. The resulting 759-bp fragment was cloned into <i
>Nde</i>I/<i>Hin</i>dIII sites in the T7 promoter-based expression plasmid pAE (
12). <i>E.</i> <i>coli </i>DH5&alpha; competent cells were transformed with the 
ligation product. Recombinant colonies were analyzed by a protocol based on the 
size of the plasmid (13). Positive clones were investigated for the presence of 
the correct insert by DNA sequencing.</span></font></p>      ^cY#891.htm##
00340000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011400072002000800186#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#29#25#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Expression in <i>E. coli</i></span></font></b></p
>      ^cY#891.htm##
01147000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704092100072002000800993#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#30#26#article#100#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>E</i>. <i>coli</i> BL21 (SI) competent cells (Gi
bco/BRL) were transformed with the pAE-<i>lip</i>L32 and grown overnight at 30&d
eg;C. In this strain, the expression of T7 RNA polymerase is under the control o
f the <i>E</i>. <i>coli</i> osmotically inducible promoter <i>proU</i> (10). The
 transformed <i>E</i>. <i>coli</i> BL21 (SI) was cultured in 1 L 2YT ON medium c
ontaining ampicillin and grown until the optical density reached 0.6 at 600 nm. 
The expression of the recombinant protein was induced with 0.3 M NaCl, followed 
by culture for an additional 3 h at 30&deg;C. The cells were collected by centri
fugation and resuspended in 100 mL 20 mM triethanolamine, pH 7.8, and lysed in a
 French press (Thermo Spectronic, USA) at 30,000 psi. The soluble and insoluble 
fractions were isolated by centrifugation at 8400 <i>g</i> for 10 min.</span></f
ont></p>      ^cY#891.htm##
00350000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704012400072002000800196#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#31#27#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Purification of the recombinant LipL32</span></fo
nt></b></p>      ^cY#891.htm##
01917000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704169100072002000801763#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#32#28#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The soluble fraction recovered from the centrifugati
on step described above was applied to a column (1 cm in diameter) containing 5 
mL Q-Sepharose Fast Flow resin (GE HealthCare, USA) previously equilibrated with
 20 mM triethanolamine, pH 7.8. The unbound fraction containing LipL32<sub>21-27
2</sub> was harvested and then applied to a column of similar dimension containi
ng SP-Sepharose Fast Flow resin (GE Healthcare). After adsorption of LipL32 prot
ein to the cationic resin, the preparation was washed with 10 column volumes of 
20 mM triethanolamine, pH 7.8, containing 0.1, 0.3, 0.5, 0.7, 1.0, 1.5, and 2.0 
M NaCl, respectively. Fractions were analyzed by 15% SDS-PAGE to detect the pres
ence of LipL32<sub>21-272</sub>. Samples containing LipL32<sub>21-272</sub> were
 pooled, NaCl was added to a final concentration of 3.0 M and this mixture was t
hen adsorbed to a Phenyl-Sepharose Fast Flow column (GE HealthCare) previously e
quilibrated with 20 mM triethanolamine, pH 7.8, and 3.0 M NaCl. After the adsorp
tion of the recombinant protein, the resin was washed with 10 column volumes of 
20 mM triethanolamine, pH 7.8, containing 2.5, 2.0, 1.5, 1.0, 0.7, 0.5, 0.3, and
 0.1 M NaCl, respectively, and finally, 20 mM triethanolamine, pH 7.8, and H<sub
>2</sub>O. The chromatographic steps were carried out with a peristaltic pump (P
-1, GE HealthCare). The eluted fractions were analyzed by 15% SDS-PAGE. Proteins
 were pooled from selected fractions, dialyzed with three changes, each consisti
ng of 2 L 20 mM triethanolamine, pH 7.8, every 18 h, and considered to be the fi
nal LipL32<sub>21-272</sub> preparation.</span></font></p>      ^cY#891.htm##
00359000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013300072002000800205#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#33#29#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Production of LipL32<sub>21-272</sub> antiserum</
span></font></b></p>      ^cY#891.htm##
00778000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704055200072002000800624#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#34#30#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Five to eight-week-old female BALB/c mice were immun
ized intraperitoneally with 10 &micro;g purified LipL32<sub>21-272</sub> and 100
 &micro;g aluminum ion (added in the form of Al(OH)<sub>3</sub>). The immunizati
ons were performed over a period of 4 weeks, with booster doses at every week. M
ice were bled by the retrorbital plexus and blood was incubated for 30 min at 37
&deg;C. The clot was then removed by centrifugation and the serum was collected 
from the supernatant.</span></font></p>      ^cY#891.htm##
00324000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009800072002000800170#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#35#31#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Western blot</span></font></b></p>      ^cY#891.h
tm##
00979000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704075300072002000800825#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#36#32#article#100#<p ALIGN="LEFT"> <font 
face="Arial"><span lang="EN"><i>Leptospira</i> extracts were fractionated by 15%
 SDS-PAGE and electro-transferred to a nitrocellulose membrane. The membrane was
 incubated with 10% (w/v) non-fat dried milk in 0.05% Tween 20/phosphate-buffere
d saline (PBS-T) and after three washes with PBS-T for 10 min, it was further in
cubated with mouse anti-recombinant LipL32<sub>21-272</sub> serum in 5% non-fat 
dried milk-PBS-T for 1 h. Following the repetition of the PBS-T wash as describe
d above, the membrane was incubated with a proper dilution of goat anti-mouse Ig
G peroxidase conjugate (Sigma) in 5% non-fat dried milk-PBS-T, washed, and devel
oped with ECL reagent (GE HealthCare).</span></font></p>  <HR ALIGN=LEFT SIZE=2>
      ^cY#891.htm##
00536000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031000072002000800382#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#37#33#article#100#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#891.htm##
00370000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704014400072002000800216#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#38#34#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Cloning, expression and purification of recombina
nt LipL32</span></font></b></p>      ^cY#891.htm##
02473000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704224700072002000802319#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#39#35#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The gene fragment coding for LipL32<sub>21-272</sub>
 (3,14) was amplified by PCR and cloned in the <i>E. coli</i> expression vector 
pAE (12). The resulting plasmid pAE-<i>lip</i>L32 codes for the expression of Li
pL32<sub>21-272</sub> with an additional Met at the N-terminus of the molecule (
we will refer to this molecule as LipL32<sub>21-272</sub>). Recombinant LipL32<s
ub>21-272</sub> was expressed in <i>E. coli</i> BL21 (SI) after induction by 0.3
 M NaCl. The protein was expressed both in the soluble and in the insoluble frac
tions (data not shown). We found equal levels of LipL32 in the inclusion bodies 
and in the soluble fraction. We preferred to purify LipL32<sub>21-272</sub> from
 the soluble fraction, since this material is likely to be in the native and cor
rect conformation. The soluble LipL32<sub>21-272</sub> was purified in three chr
omatographic steps (<a href="#Fig1">Figure 1A</a>). In the first step, the solub
le fraction was adsorbed onto a Q-Sepharose column. The flow through containing 
LipL32<sub>21-272</sub> (<a href="#Fig1">Figure 1B</a>) was further purified by 
SP-Sepharose and the protein eluted in 0.1 M NaCl, 20 mM triethanolamine, pH 7.8
 (fraction P1, <a href="#Fig1">Figure 1B</a>). In the third step, the sample con
taining LipL32<sub>21-272</sub> eluted from the cationic chromatography was adju
sted to 3 M NaCl and finally purified by Phenyl-Sepharose (fraction P2, <a href=
"#Fig1">Figure 1C</a>). The recombinant LipL32<sub>21-272</sub> was eluted in 0.
5, 0.3, 0.1 M NaCl in 20 mM triethanolamine, pH 7.8, and 20 mM triethanolamine, 
pH 7.8, and H<sub>2</sub>O. The samples enriched with LipL32<sub>21-272</sub> we
re those eluted with 0.5, 0.3, and 0.1 M NaCl (fraction P2, <a href="#Fig1">Figu
re 1C</a>). These fractions were dialyzed in three steps with 2 L 20 mM triethan
olamine, pH 7.8, and concentrated to 10 mL using an Amicon ultrafiltration syste
m with a 10-kDa cut-off membrane (<a href="#Fig1">Figure 1D</a>). The final puri
fication yield considering fraction P2 was approximately 3 mg/L culture and more
 than 95% pure (<a href="#Tab1">Table 1</a>), suitable for crystallographic and 
tertiary structural studies (15,16).</span></font></p>      ^cY#891.htm##
00359000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704013300072002000800205#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#40#36#article#100#<p ALIGN="LEFT"><b><fon
t face="Arial"><span lang="EN">Production of LipL32<sub>21-272</sub> antiserum</
span></font></b></p>      ^cY#891.htm##
01374000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704114800072002000801220#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#41#37#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">The purified LipL32<sub>21-272</sub> was inoculated 
in female BALB/c mice for the production of antiserum against LipL32. The antise
rum obtained was able to recognize the recombinant LipL32<sub>21-272</sub> in We
stern blot (<a href="#Fig1">Figure 1E</a>, lane 11). Moreover, a conserved 32-kD
a band corresponding to the expected size of LipL32 was also recognized in the e
xtracts of a large panel of pathogenic<i> Leptospira</i> (<i>L</i>. <i>interroga
ns </i>serovars Canicola, Pyrogenes, Pomona, Autumnalis, Hardjo, Brastilava, Cop
enhageni, and Icterohaemorrhagiae, and <i>L</i>. <i>kirschneri</i> serovar Gripp
otyphosa), whereas no reaction was observed in the extract of the non-pathogenic
 saprophytic <i>L</i>. <i>biflexa</i> serovar Patoc (<a href="#Fig1">Figure 1E</
a>).</span></font><span lang="EN"><font face="Arial, Helvetica, sans-serif"> </f
ont></span></p>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left"
 valign="top">      <td><a href="/img/revistas/bjmbr/v44n4/html/891i01.htm"><img
 src="/img/revistas/bjmbr/v44n4/891i01peq.jpg" border="2"></a></td>      <td>   
 ^cY#891.htm##
02375000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704214900072002000802221#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#42#38#article#100#<p ALIGN="LEFT"><span l
ang="EN"><font face="Arial, Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. 
Expression and purification of LipL32<sub>21-272</sub> and antiserum recognition
 of native LipL32.</font> <font face="Arial, Helvetica, sans-serif"><i>Panel</i>
 <i>A</i>, Flowchart showing the three main steps of LipL32<sub>21-272</sub> pur
ification. SI = <i>Escherichia</i> <i>coli</i> BL21; S = supernatant; Q = anion 
exchange; FT = flow through - unbound proteins; SP = cation exchange; P1 = 0.1 M
 NaCl - fraction containing LipL32<sub>21-272</sub> eluted with 0.1 M NaCl; P2 =
 purified LipL32<sub>21-272</sub>. <i>Panel</i> <i>B</i>, SDS-PAGE of LipL32<sub
>21-272</sub> purification shown in <i>Panel A</i>. M = Molecular marker; NI = n
on-induced <i>E</i>. <i>coli</i> BL21 (SI); I = <i>E</i>. <i>coli</i> BL21 (SI) 
induced with NaCl; S = supernatant; FT = flow through - unbound proteins; P1 = 0
.1 M NaCl &ndash; fraction containing LipL32<sub>21-272</sub> eluted with 0.1 M 
NaCl. <i>Panel</i> <i>C</i>, SDS-PAGE of LipL32<sub>21-272</sub> purified from P
henyl-Sepharose. M = Molecular marker; P2 = purified LipL32<sub>21-272</sub> aft
er elution with 0.5, 0.3, and 0.1 M NaCl using phenyl-sepharose. <i>Panel</i> <i
>D</i>, SDS-PAGE showing the purified LipL32<sub>21-272</sub>. M = Molecular mar
ker; L = LipL32<sub>21-272</sub> after membrane concentration (cut off 10 kDa). 
<i>Panel</i> <i>E</i>, Western-blot showing that anti-non-tagged LipL32<sub>21-2
72</sub> antiserum recognizes native LipL32 from cell extracts of different <i>L
eptospira</i> serovars. <i>Lane 1</i>, Whole-cell extracts of <i>L</i>. <i>inter
rogans </i>serovars Icterohaemorrhagiae; <i>lane 2</i>, Copenhageni; <i>lane 3</
i>, Bratislava; <i>lane 4</i>, Hardjo; <i>lane 5</i>, Autumnalis; <i>lane 6</i>,
 Pomona; <i>lane 7</i>, Pyrogenes; <i>lane 8</i>, Canicola, and <i>lane 10</i>,<
i> L</i>. <i>kirschneri </i>serovar Grippotyphosa. Serum also recognized the rec
ombinant protein (lane 11) but failed to react with the whole-cell extract of no
n-pathogenic <i>L</i>. <i>biflexa </i>serovar Patoc (<i>lane </i>9).</font></spa
n></p>      </td>    </tr>  </table>      ^cY#891.htm##
00732000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704050600072002000800578#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#43#39#article#100#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (104 K JPG file)]</font
></P>  <HR ALIGN=LEFT SIZE=2>  <table  border="0">    <tr align="left" valign="t
op">      <td><a href="/img/revistas/bjmbr/v44n4/html/891t01.htm"><img src="/img
/revistas/bjmbr/v44n4/table.jpg" border="2"></a></td>      <td><span lang="EN"><
font face="Arial"><span lang="EN"><a name="Tab1"></a>Table 1. Purification yield
 of LipL32<sub>21-272</sub>.</span></font></span></td>    </tr>  </table>      ^
cY#891.htm##
00344000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704011800072002000800190#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#44#40#article#100#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (139 K JPG file)]</font
></P>      ^cY#891.htm##
00263000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003700072002000800109#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#45#41#article#100#<P>  <HR ALIGN=LEFT SIZ
E=2>      ^cY#891.htm##
00496000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704027000072002000800342#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#46#42#article#100#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#891.htm##
02529000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704230300072002000802375#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#47#43#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Affinity tags are efficient tools for protein purifi
cation since they facilitate the derivation of large amounts of highly homogenou
s proteins from heterologous expression systems (17). His-tags are the most wide
ly used affinity tags, but several others are also widely used such as the malto
se-binding protein, glutathione-<i>S</i>-transferase, chitin-binding domain, and
 elastin-like polypeptide tag. His-tag binding to metal is not affected by urea 
solutions used to solubilize proteins expressed in inclusion bodies in contrast 
to the other tags that require non-denaturing conditions to be functional. Affin
ity tags may have a positive or negative effect on the biochemical properties of
 the target protein (17). Examples of positive effects are protein yield improve
ment, protein refolding facilitation, proteolysis prevention, preservation of fu
sion protein antigenicity and increased solubility. Most of the negative effects
 are related to changes in protein conformation, lower protein yields, inhibitio
n of enzyme activity, alteration of biological activity, undesired flexibility i
n structural analysis, and toxicity (17). Due to unpredictable changes that addi
ng a tag would introduce in a protein, we obtained LipL32<sub>21-272</sub> witho
ut any tags. The purification of LipL32<sub>21-272</sub> was based on ion exchan
ge (both anionic and cationic) and hydrophobic interaction chromatography. For s
tructural studies, an additional concentration step is necessary. LipL32 is cons
idered to be an important antigen in leptospirosis (3,16,18). It is highly immun
ogenic and expressed on the surface of pathogenic <i>Leptospira </i>sp (2,3,7,8)
. However, the exact biological role of this protein in leptospirosis or in <i>L
eptospira </i>biology is unknown. Since LipL32 is well conserved in all pathogen
ic species tested to date, but absent in free-living <i>L. biflexa </i>serovar P
atoc (3,4) (<a href="#Fig1">Figure 1E</a>), it was suggested that LipL32 could b
e involved in leptospiral pathogenicity. However, an <i>L. interrogans</i> mutan
t lacking functional LipL32 did not show any detectable loss in the ability to i
nfect and colonize hosts or even to survive in water, making this a paradoxical 
protein (9).</span></font></p>      ^cY#891.htm##
02457000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704223100072002000802303#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#48#44#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Structural studies have shown a tertiary structure r
elated to jelly roll fold proteins (16,18). Indeed, in both structural studies, 
LipL32 was crystallized without His-tag. In the first attempt to crystallize Lip
L32, the protein was obtained with a His-tag that was further cleaved out using 
the V8 staphylococcus protease. The removal of the His-tag was necessary to obta
in suitable LipL32 for high-quality structural studies. The purification method 
used by Vivian et al. (18) included several steps: Nickel-Sepharose followed by 
gel-filtration chromatography (S75 16/60), a Mono Q50/50 anion-exchange column a
nd the unbound fraction containing pure LipL32 was proteolyzed to the V8 proteas
e and finally reapplied to the S75 16/60 column. However, problems may be encoun
tered during the cleavage step, including low yield, precipitation of the target
 protein, tedious optimization of cleavage conditions, high cost of proteases or
 failure to recover the active or structurally intact protein (19). In addition,
 some biochemical features of LipL32 may be better explored using a non-tagged p
rotein to avoid possible interferences. We proposed here a simple method to puri
fy homogenous non-tagged LipL32. A partial but not detailed description of this 
protocol has been published (15,16). Studies performed by our group using this n
on-tagged LipL32 purified by ion exchange (anionic and cationic) and hydrophobic
 interactions showed that LipL32 binds to calcium in a specific manner but not t
o zinc or copper ions. This kind of study would not be possible with a His-tagge
d LipL32. Besides, the purified non-tagged LipL32 yielded high-quality crystals 
suitable for diffraction data and three-dimensional structure determination (16)
 and may also represent an alternative antigen for serodiagnosis and vaccine dev
elopment for leptospirosis, although His-tagged LipL32 have proved so far to be 
highly immunogenic as well (20). Overall, we believe that a description of a met
hod for obtaining purified non-tagged LipL32 may be useful for researchers in th
e field, since this is the most abundant protein on the leptospiral surface.</sp
an></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#891.htm##
00542000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704031600072002000800388#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#49#45#article#100#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#891.htm##
00403000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704016300074002000800237#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#50#46#article#100#1#<p ALIGN=
"LEFT"><font face="Arial"><span lang="EN">1. Adler B, de la Pena MA. <i>Leptospi
ra </i>and leptospirosis. <i>Vet Microbiol</i> 2010; 140: 287-296.    ^cY#891.ht
m##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#51#47#article#100#</span></font></p>     
 ^cY#891.htm##
00500000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704026000074002000800334#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#52#48#article#100#2#<p align=
"LEFT"><font face="Arial"><span lang="EN">2. Malmstrom J, Beck M, Schmidt A, Lan
ge V, Deutsch EW, Aebersold R. Proteome-wide cellular protein concentrations of 
the human pathogen <i>Leptospira interrogans</i>. <i>Nature</i> 2009; 460: 762-7
65.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#53#49#article#100#</span></font></p>     
 ^cY#891.htm##
00518000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704027800074002000800352#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#54#50#article#100#3#<p align=
"LEFT"><font face="Arial"><span lang="EN">3. Haake DA, Chao G, Zuerner RL, Barne
tt JK, Barnett D, Mazel M, et al. The leptospiral major outer membrane protein L
ipL32 is a lipoprotein expressed during mammalian infection. <i>Infect Immun</i>
 2000; 68: 2276-2285.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#55#51#article#100#</span></font></p>     
 ^cY#891.htm##
00566000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704032600074002000800400#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#56#52#article#100#4#<p align=
"LEFT"><font face="Arial"><span lang="EN">4. Picardeau M, Bulach DM, Bouchier C,
 Zuerner RL, Zidane N, Wilson PJ, et al. Genome sequence of the saprophyte<i> Le
ptospira biflexa</i> provides insights into the evolution of <i>Leptospira </i>a
nd the pathogenesis of leptospirosis. <i>PLoS One</i> 2008; 3: e1607.    ^cY#891
.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#57#53#article#100#</span></font></p>     
 ^cY#891.htm##
00550000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704031000074002000800384#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#58#54#article#100#5#<p align=
"LEFT"><font face="Arial"><span lang="EN">5. Yang CW, Wu MS, Pan MJ, Hsieh WJ, V
andewalle A, Huang CC. The <i>Leptospira </i>outer membrane protein LipL32 induc
es tubulointerstitial nephritis-mediated gene expression in mouse proximal tubul
e cells. <i>J Am Soc Nephrol</i> 2002; 13: 2037-2045.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#59#55#article#100#</span></font></p>     
 ^cY#891.htm##
00441000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704020100074002000800275#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#60#56#article#100#6#<p align=
"LEFT"><font face="Arial"><span lang="EN">6. Palaniappan RU, Ramanujam S, Chang 
YF. Leptospirosis: pathogenesis, immunity, and diagnosis. <i>Curr Opin Infect Di
s</i> 2007; 20: 284-292.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#61#57#article#100#</span></font></p>     
 ^cY#891.htm##
00582000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704034200074002000800416#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#62#58#article#100#7#<p align=
"LEFT"><font face="Arial"><span lang="EN">7. Hauk P, Macedo F, Romero EC, Vascon
cellos SA, de Morais ZM, Barbosa AS, et al. In LipL32, the major leptospiral lip
oprotein, the C terminus is the primary immunogenic domain and mediates interact
ion with collagen IV and plasma fibronectin. <i>Infect Immun</i> 2008; 76: 2642-
2650.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#63#59#article#100#</span></font></p>     
 ^cY#891.htm##
00497000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704025700074002000800331#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#64#60#article#100#8#<p align=
"LEFT"><font face="Arial"><span lang="EN">8. Hoke DE, Egan S, Cullen PA, Adler B
. LipL32 is an extracellular matrix-interacting protein of <i>Leptospira </i>spp
 and <i>Pseudoalteromonas tunicata</i>. <i>Infect Immun</i> 2008; 76: 2063-2069.
    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#65#61#article#100#</span></font></p>     
 ^cY#891.htm##
00526000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000200072704028600074002000800360#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#66#62#article#100#9#<p align=
"LEFT"><font face="Arial"><span lang="EN">9. Murray GL, Srikram A, Hoke DE, Wund
er EA Jr, Henry R, Lo M, et al. Major surface protein LipL32 is not required for
 either acute or chronic infection with <i>Leptospira interrogans</i>. <i>Infect
 Immun</i> 2009; 77: 952-958.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#67#63#article#100#</span></font></p>     
 ^cY#891.htm##
00497000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025600075002000800331#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#68#64#article#100#10#<p align
="LEFT"><font face="Arial"><span lang="EN">10. Bhandari P, Gowrishankar J. An <i
>Escherichia coli </i>host strain useful for efficient overproduction of cloned 
gene products with NaCl as the inducer. <i>J Bacteriol</i> 1997; 179: 4403-4406.
    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#69#65#article#100#</span></font></p>     
 ^cY#891.htm##
00528000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704028700075002000800362#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#70#66#article#100#11#<p align
="LEFT"><font face="Arial"><span lang="EN">11. Nascimento AL, Verjovski-Almeida 
S, Van Sluys MA, Monteiro-Vitorello CB, Camargo LE, Digiampietri LA, et al. Geno
me features of <i>Leptospira interrogans</i> serovar Copenhageni. <i>Braz J Med 
Biol Res</i> 2004; 37: 459-477.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#71#67#article#100#</span></font></p>     
 ^cY#891.htm##
00546000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704030500075002000800380#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#72#68#article#100#12#<p align
="LEFT"><font face="Arial"><span lang="EN">12. Ramos CR, Abreu PA, Nascimento AL
, Ho PL. A high-copy T7<i> Escherichia coli</i> expression vector for the produc
tion of recombinant proteins with a minimal N-terminal His-tagged fusion peptide
. <i>Braz J Med Biol Res</i> 2004; 37: 1103-1109.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#73#69#article#100#</span></font></p>     
 ^cY#891.htm##
00438000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704019700075002000800272#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#74#70#article#100#13#<p align
="LEFT"><font face="Arial"><span lang="EN">13. Beuken E, Vink C, Bruggeman CA. O
ne-step procedure for screening recombinant plasmids by size. <i>Biotechniques</
i> 1998; 24: 748-750.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#75#71#article#100#</span></font></p>     
 ^cY#891.htm##
00497000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025600075002000800331#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#76#72#article#100#14#<p align
="LEFT"><font face="Arial"><span lang="EN">14. Lee SH, Kim KA, Park YG, Seong IW
, Kim MJ, Lee YJ. Identification and partial characterization of a novel hemolys
in from <i>Leptospira interrogans</i> serovar lai. <i>Gene</i> 2000; 254: 19-28.
    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#77#73#article#100#</span></font></p>     
 ^cY#891.htm##
00526000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704028500075002000800360#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#78#74#article#100#15#<p align
="LEFT"><font face="Arial"><span lang="EN">15. Hauk P, Guzzo CR, Ho PL, Farah CS
. Crystallization and preliminary X-ray analysis of LipL32 from<i> Leptospira in
terrogans</i> serovar Copenhageni. <i>Acta Crystallogr Sect F Struct Biol Cryst 
Commun</i> 2009; 65: 307-309.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#79#75#article#100#</span></font></p>     
 ^cY#891.htm##
00498000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704025700075002000800332#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#80#76#article#100#16#<p align
="LEFT"><font face="Arial"><span lang="EN">16. Hauk P, Guzzo CR, Roman RH, Ho PL
, Farah CS. Structure and calcium-binding activity of LipL32, the major surface 
antigen of pathogenic <i>Leptospira </i>sp. <i>J Mol Biol</i> 2009; 390: 722-736
.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#81#77#article#100#</span></font></p>     
 ^cY#891.htm##
00502000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704026100075002000800336#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#82#78#article#100#17#<p align
="LEFT"><font face="Arial"><span lang="EN">17. Arnau J, Lauritzen C, Petersen GE
, Pedersen J. Current strategies for the use of affinity tags and tag removal fo
r the purification of recombinant proteins. <i>Protein Expr Purif</i> 2006; 48: 
1-13.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#83#79#article#100#</span></font></p>     
 ^cY#891.htm##
00520000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704027900075002000800354#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#84#80#article#100#18#<p align
="LEFT"><font face="Arial"><span lang="EN">18. Vivian JP, Beddoe T, McAlister AD
, Wilce MC, Zaker-Tabrizi L, Troy S, et al. Crystal structure of LipL32, the mos
t abundant surface protein of pathogenic <i>Leptospira </i>spp. <i>J Mol Biol</i
> 2009; 387: 1229-1238.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#85#81#article#100#</span></font></p>     
 ^cY#891.htm##
00438000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704019700075002000800272#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#86#82#article#100#19#<p align
="LEFT"><font face="Arial"><span lang="EN">19. Baneyx F, Mujacic M. Recombinant 
protein folding and misfolding in<i> Escherichia coli</i>. <i>Nat Biotechnol</i>
 2004; 22: 1399-1408.    ^cY#891.htm##
00254000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002800072002000800100#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#87#83#article#100#</span></font></p>     
 ^cY#891.htm##
00535000000000157000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068888000300072704029400075002000800369#v44
n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#p#88#84#article#100#20#<p align
="LEFT"><font face="Arial"><span lang="EN">20. Luo D, Xue F, Ojcius DM, Zhao J, 
Mao Y, Li L, et al. Protein typing of major outer membrane lipoproteins from Chi
nese pathogenic <i>Leptospira </i>spp. and characterization of their immunogenic
ity. <i>Vaccine</i> 2009; 28: 243-255.    ^cY#891.htm##
00278000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704005200072002000800124#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#89#85#article#100#</span></font></p>  <HR
 ALIGN=LEFT SIZE=2>      ^cY#891.htm##
00561000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033500072002000800407#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#90#86#article#100#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE=4
><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, san
s-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.gif" ALIGN=
BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#891.htm#
#
00401000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704017500072002000800247#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#91#87#article#100#<p ALIGN="LEFT"><font f
ace="Arial"><span lang="EN">Research supported by FAPESP, CNPq, and Funda&ccedil
;&atilde;o Butantan.</span></font></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#891.htm#
#
00562000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704033600072002000800408#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#92#88#article#100#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, Helv
etica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v44n4/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#891.htm
##
00721000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704049500072002000800567#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#93#89#article#100#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v44n4/rec
or.gif" border="0"></a> Address for correspondence:</b></font><font face="Arial"
><span lang="EN"> P.L. Ho, Centro de Biotecnologia, Instituto Butantan, Av. Vita
l Brasil, 1500, 05503-900 S&atilde;o Paulo, SP, Brasil.   </span></font><font fa
ce="Arial"><span lang="EN">Fax: +55-11-3726-1505. E-mail: <a href="mailto:hoplee
@butantan.gov.br">hoplee@butantan.gov.br</a></span></font></p>      ^cY#891.htm#
#
00448000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704022200072002000800294#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#94#90#article#100#<p ALIGN="LEFT"><i><fon
t face="Arial"><span lang="EN">Received November 7, 2010. Accepted February 16, 
2011. Available online March 4, 2011. Published April 11, 2011.</span></font></i
></p>  <HR ALIGN=LEFT SIZE=2>      ^cY#891.htm##
00258000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704003200072002000800104#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#95#91#article#100#<div align="center">   
     ^cY#891.htm##
00424000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704019800072002000800270#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#96#92#article#100#<p><font color="#000000
" face="Verdana, Arial, Helvetica, sans-serif"><em><font size="2">The Brazilian 
Journal of Medical and Biological Research is partially financed by</font></em><
strong>    ^cY#891.htm##
00250000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704002400072002000800096#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#97#93#article#100#<br>                ^cY
#891.htm##
00324000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704009800072002000800170#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#98#94#article#100#<br>    </strong></font
></p>  </div>  <table  border="0" align="center">    <tr>      <td>    ^cY#891.h
tm##
00382000000000145000450000400060000070200440000670500020005070600020005270000030
0054701000300057709000800060708000400068704015600072002000800228#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#99#95#article#100#<div align="center"><a 
target="_blank" href="http://www.cnpq.br/"><img src="/img/revistas/bjmbr/v44n4/c
npq.jpg" border="0"></a></div></td>      <td>    ^cY#891.htm##
00385000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704015800073002000800231#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#100#96#article#100#<div align="center"><a
 target="_blank" href="http://www.mct.gov.br/"><img src="/img/revistas/bjmbr/v44
n4/mct.jpg" border="0"></a></div></td>      <td>    ^cY#891.htm##
00389000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704016200073002000800235#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#101#97#article#100#<div align="center"><a
 target="_blank" href="http://www.capes.gov.br/"><img src="/img/revistas/bjmbr/v
44n4/capes.jpg" border="0"></a></div></td>      <td>    ^cY#891.htm##
00400000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704017300073002000800246#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#102#98#article#100#<div align="center"><a
 target="_blank" href="http://portal.mec.gov.br/mec/index.php"><img src="/img/re
vistas/bjmbr/v44n4/me.jpg" border="0"></a></div></td>      <td>    ^cY#891.htm##
00391000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000300058709000800061708000400069704016400073002000800237#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#103#99#article#100#<div align="center"><a
 target="_blank" href="http://www.brasil.gov.br/"><img src="/img/revistas/bjmbr/
v44n4/brasil.jpg" border="0"></a></div></td>      <td>    ^cY#891.htm##
00399000000000145000450000400060000070200440000670500020005070600020005270000040
0054701000400058709000800062708000400070704017100074002000800245#v44n4#V:\SciELO
\serial\bjmbr\v44n4\markup\891.htm#S#p#104#100#article#100#<div align="center"><
a target="_blank" href="http://www.fapesp.br/"><img src="/img/revistas/bjmbr/v44
n4/fapesp.jpg" border="0"></a></div></td>    </tr>  </table>      ^cY#891.htm##
00501000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100021000880120
03300109030001400142065000900156064000500165031000400170014000800174865000900182
002000800191035001000199801001400209#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
91.htm#S#c#105#1#article#20#1#^rND^sAdler^nB#^rND^sde^nla Pena MA#Leptospira and
 leptospirosis^len#Vet Microbiol#20100000#2010#140#287-296#20110400#891.htm#0378
-1135#Vet Microbiol##
00663000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100014000920100
01700106010001500123010001800138010001900156012009500175030000700270065000900277
06400050028603100040029101400080029586500090030300200080031203500100032080100070
0330#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#c#106#2#article#20#2#^r
ND^sMalmstrom^nJ#^rND^sBeck^nM#^rND^sSchmidt^nA#^rND^sLange^nV#^rND^sDeutsch^nEW
#^rND^sAebersold^nR#Proteome-wide cellular protein concentrations of the human p
athogen Leptospira interrogans^len#Nature#20090000#2009#460#762-765#20110400#891
.htm#0028-0836#Nature##
00705000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100016000730100014000890100
01800103010001800121010001700139010001500156810000600171012011000177030001300287
06500090030006400050030903100030031401400100031786500090032700200080033603500100
0344801001300354#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#c#107#3#art
icle#20#3#^rND^sHaake^nDA#^rND^sChao^nG#^rND^sZuerner^nRL#^rND^sBarnett^nJK#^rND
^sBarnett^nD#^rND^sMazel^nM#et al#The leptospiral major outer membrane protein L
ipL32 is a lipoprotein expressed during mammalian infection^len#Infect Immun#200
00000#2000#68#2276-2285#20110400#891.htm#0019-9567#Infect Immun##
00706000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100019000730100017000920100
01800109010001800127010001600145010001700161810000600178012014600184030000900330
71000020033906500090034106400050035003100020035501400060035786500090036300200080
0372#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#c#108#4#article#20#4#^r
ND^sPicardeau^nM#^rND^sBulach^nDM#^rND^sBouchier^nC#^rND^sZuerner^nRL#^rND^sZida
ne^nN#^rND^sWilson^nPJ#et al#Genome sequence of the saprophyte Leptospira biflex
a provides insights into the evolution of Leptospira and the pathogenesis of lep
tospirosis^len#PLoS One#2#20080000#2008#3#e1607#20110400#891.htm##
00723000000000325000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100013000880100
01400101010001600115010002000131010001600151012014200167030001700309065000900326
06400050033503100030034001400100034386500090035300200080036203500100037080100170
0380#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#c#109#5#article#20#5#^r
ND^sYang^nCW#^rND^sWu^nMS#^rND^sPan^nMJ#^rND^sHsieh^nWJ#^rND^sVandewalle^nA#^rND
^sHuang^nCC#The Leptospira outer membrane protein LipL32 induces tubulointerstit
ial nephritis-mediated gene expression in mouse proximal tubule cells^len#J Am S
oc Nephrol#20020000#2002#13#2037-2045#20110400#891.htm#1046-6673#J Am Soc Nephro
l##
00530000000000277000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100022000730100019000950100
01600114012005700130030002100187710000200208065000900210064000500219031000300224
014000800227865000900235002000800244#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
91.htm#S#c#110#6#article#20#6#^rND^sPalaniappan^nRU#^rND^sRamanujam^nS#^rND^sCha
ng^nYF#Leptospirosis: pathogenesis, immunity, and diagnosis^len#Curr Opin Infect
 Dis#2#20070000#2007#20#284-292#20110400#891.htm##
00769000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100014000730100016000870100
01700103010002300120010002000143010001800163810000600181012016400187030001300351
06500090036406400050037303100030037801400100038186500090039100200080040003500100
0408801001300418#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#c#111#7#art
icle#20#7#^rND^sHauk^nP#^rND^sMacedo^nF#^rND^sRomero^nEC#^rND^sVasconcellos^nSA#
^rND^sde^nMorais ZM#^rND^sBarbosa^nAS#et al#In LipL32, the major leptospiral lip
oprotein, the C terminus is the primary immunogenic domain and mediates interact
ion with collagen IV and plasma fibronectin^len#Infect Immun#20080000#2008#76#26
42-2650#20110400#891.htm#0019-9567#Infect Immun##
00623000000000301000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100015000730100014000880100
01700102010001500119012010700134030001300241065000900254064000500263031000300268
014001000271865000900281002000800290035001000298801001300308#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\891.htm#S#c#112#8#article#20#8#^rND^sHoke^nDE#^rND^sEgan^
nS#^rND^sCullen^nPA#^rND^sAdler^nB#LipL32 is an extracellular matrix-interacting
 protein of Leptospira spp and Pseudoalteromonas tunicata^len#Infect Immun#20080
000#2008#76#2063-2069#20110400#891.htm#0019-9567#Infect Immun##
00706000000000337000450000400060000070200440000670500020005070600020005270000040
00547010002000587090008000607080003000681180002000710100017000730100017000900100
01500107010002000122010001500142010001200157810000600169012011500175030001300290
06500090030306400050031203100030031701400080032086500090032800200080033703500100
0345801001300355#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#c#113#9#art
icle#20#9#^rND^sMurray^nGL#^rND^sSrikram^nA#^rND^sHoke^nDE#^rND^sWunder^nEA Jr#^
rND^sHenry^nR#^rND^sLo^nM#et al#Major surface protein LipL32 is not required for
 either acute or chronic infection with Leptospira interrogans^len#Infect Immun#
20090000#2009#77#952-958#20110400#891.htm#0019-9567#Infect Immun##
00593000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100018000750100022000930120
12100115030001200236065000900248064000500257031000400262014001000266865000900276
002000800285035001000293801001200303#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
91.htm#S#c#114#10#article#20#10#^rND^sBhandari^nP#^rND^sGowrishankar^nJ#An Esche
richia coli host strain useful for efficient overproduction of cloned gene produ
cts with NaCl as the inducer^len#J Bacteriol#19970000#1997#179#4403-4406#2011040
0#891.htm#0021-9193#J Bacteriol##
00715000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100021000750100027000960100
02000123010002900143010001800172010002300190810000600213012006600219030002000285
06500090030506400050031403100030031901400080032286500090033000200080033903500100
0347801002000357#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#c#115#11#ar
ticle#20#11#^rND^sNascimento^nAL#^rND^sVerjovski-Almeida^nS#^rND^sVan^nSluys MA#
^rND^sMonteiro-Vitorello^nCB#^rND^sCamargo^nLE#^rND^sDigiampietri^nLA#et al#Geno
me features of Leptospira interrogans serovar Copenhageni^len#Braz J Med Biol Re
s#20040000#2004#37#459-477#20110400#891.htm#0100-879X#Braz J Med Biol Res##
00686000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100016000910100
02100107010001300128012014900141030002000290065000900310064000500319031000300324
014001000327865000900337002000800346035001000354801002000364#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\891.htm#S#c#116#12#article#20#12#^rND^sRamos^nCR#^rND^sAb
reu^nPA#^rND^sNascimento^nAL#^rND^sHo^nPL#A high-copy T7 Escherichia coli expres
sion vector for the production of recombinant proteins with a minimal N-terminal
 His-tagged fusion peptide^len#Braz J Med Biol Res#20040000#2004#37#1103-1109#20
110400#891.htm#0100-879X#Braz J Med Biol Res##
00561000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100014000910100
02000105012006600125030001400191065000900205064000500214031000300219014000800222
865000900230002000800239035001000247801001400257#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\891.htm#S#c#117#13#article#20#13#^rND^sBeuken^nE#^rND^sVink^nC#^rND^s
Bruggeman^nCA#One-step procedure for screening recombinant plasmids by size^len#
Biotechniques#19980000#1998#24#748-750#20110400#891.htm#0736-6205#Biotechniques#
#
00658000000000325000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100014000890100
01500103010001600118010001400134010001400148012010900162030000500271065000900276
06400050028503100040029001400060029486500090030000200080030903500100031780100050
0327#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#c#118#14#article#20#14#
^rND^sLee^nSH#^rND^sKim^nKA#^rND^sPark^nYG#^rND^sSeong^nIW#^rND^sKim^nMJ#^rND^sL
ee^nYJ#Identification and partial characterization of a novel hemolysin from Lep
tospira interrogans serovar lai^len#Gene#20000000#2000#254#19-28#20110400#891.ht
m#0378-1119#Gene##
00626000000000289000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100016000890100
01300105010001600118012010900134030004900243710000200292065000900294064000500303
031000300308014000800311865000900319002000800328#v44n4#V:\SciELO\serial\bjmbr\v4
4n4\markup\891.htm#S#c#119#15#article#20#15#^rND^sHauk^nP#^rND^sGuzzo^nCR#^rND^s
Ho^nPL#^rND^sFarah^nCS#Crystallization and preliminary X-ray analysis of LipL32 
from Leptospira interrogans serovar Copenhageni^len#Acta Crystallogr Sect F Stru
ct Biol Cryst Commun#2#20090000#2009#65#307-309#20110400#891.htm##
00647000000000313000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100014000750100016000890100
01600105010001300121010001600134012010800150030001100258065000900269064000500278
031000400283014000800287865000900295002000800304035001000312801001100322#v44n4#V
:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#c#120#16#article#20#16#^rND^sHauk^n
P#^rND^sGuzzo^nCR#^rND^sRoman^nRH#^rND^sHo^nPL#^rND^sFarah^nCS#Structure and cal
cium-binding activity of LipL32, the major surface antigen of pathogenic Leptosp
ira sp^len#J Mol Biol#20090000#2009#390#722-736#20110400#891.htm#0022-2836#J Mol
 Biol##
00648000000000301000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100015000750100019000900100
01900109010001800128012011300146030001900259065000900278064000500287031000300292
014000500295865000900300002000800309035001000317801001900327#v44n4#V:\SciELO\ser
ial\bjmbr\v44n4\markup\891.htm#S#c#121#17#article#20#17#^rND^sArnau^nJ#^rND^sLau
ritzen^nC#^rND^sPetersen^nGE#^rND^sPedersen^nJ#Current strategies for the use of
 affinity tags and tag removal for the purification of recombinant proteins^len#
Protein Expr Purif#20060000#2006#48#1-13#20110400#891.htm#1046-5928#Protein Expr
 Purif##
00698000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100017000750100016000920100
02000108010001600128010002300144010001400167810000600181012009600187030001100283
06500090029406400050030303100040030801400100031286500090032200200080033103500100
0339801001100349#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#c#122#18#ar
ticle#20#18#^rND^sVivian^nJP#^rND^sBeddoe^nT#^rND^sMcAlister^nAD#^rND^sWilce^nMC
#^rND^sZaker-Tabrizi^nL#^rND^sTroy^nS#et al#Crystal structure of LipL32, the mos
t abundant surface protein of pathogenic Leptospira spp^len#J Mol Biol#20090000#
2009#387#1229-1238#20110400#891.htm#0022-2836#J Mol Biol##
00537000000000277000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100016000750100017000910120
06700108030001500175065000900190064000500199031000300204014001000207865000900217
002000800226035001000234801001500244#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\8
91.htm#S#c#123#19#article#20#19#^rND^sBaneyx^nF#^rND^sMujacic^nM#Recombinant pro
tein folding and misfolding in Escherichia coli^len#Nat Biotechnol#20040000#2004
#22#1399-1408#20110400#891.htm#1087-0156#Nat Biotechnol##
00710000000000337000450000400060000070200440000670500020005070600020005270000040
00547010003000587090008000617080003000691180003000720100013000750100013000880100
01700101010001400118010001300132010001200145810000600157012014100163030000800304
06500090031206400050032103100030032601400080032986500090033700200080034603500100
0354801000800364#v44n4#V:\SciELO\serial\bjmbr\v44n4\markup\891.htm#S#c#124#20#ar
ticle#20#20#^rND^sLuo^nD#^rND^sXue^nF#^rND^sOjcius^nDM#^rND^sZhao^nJ#^rND^sMao^n
Y#^rND^sLi^nL#et al#Protein typing of major outer membrane lipoproteins from Chi
nese pathogenic Leptospira spp: and characterization of their immunogenicity^len
#Vaccine#20090000#2009#28#243-255#20110400#891.htm#0264-410X#Vaccine##
